NCT.ID,Title,Recruitment,Study.Results,Conditions,Interventions,Sponsors,Gender,Age.Groups,Phases,Enrollment,Funded.Bys,Study.Types,Study.Designs,Other.IDs,First.Received,Start.Date,Completion.Date,Last.Updated,Last.Verified,Acronym,Primary.Completion.Date,Outcome.Measures,URL,study.location,Drug,FDA_app,Number_ints,Brand_name_in_trial
NCT00001151,Studies With Vitamin D,Completed,No Results Available,Hypocalcemia|Rickets,"Drug: 1,25-Dihydroxycholecalciferol",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Both,Child|Adult|Senior,Phase II,200,NIH,Interventional,Primary Purpose: Treatment,760081|76-DK-0081,11/03/1999,01/03/1976,01/10/2009,7/29/2010,01/10/2009,,01/10/2009,Normal serum calcium concentration.,http://ClinicalTrials.gov/show/NCT00001151,United States,1,0,1,NA
NCT00001563,EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma,Completed,No Results Available,AIDS Related Lymphoma|Non Hodgkin's Lymphoma,Biological: filgrastim|Biological: rituximab|Drug: EPOCH regimen|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,39,NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,970040|97-C-0040,11/03/1999,01/12/1996,01/06/2009,9/17/2010,01/03/2010,,01/06/2009,Toxicity and activity of EPOCH during and at the completion of study treatment|Molecular markers of drug resistance and lymphomagenesis in tumor tissue at the beginning of study treatment,http://ClinicalTrials.gov/show/NCT00001563,United States,1,1,10,0
NCT00002514,Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission,Completed,No Results Available,Leukemia,Biological: filgrastim|Biological: sargramostim|Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: imatinib mesylate|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Medical Research Council,Both,Child|Adult,Phase III,590,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,CDR0000078099|ECOG-2993|MRC-LEUK-UKALL-XII|EST-4491,11/01/1999,01/04/1993,NA,4/22/2010,01/08/2007,,01/03/2009,Complete remission,http://ClinicalTrials.gov/show/NCT00002514,United States,1,1,20,0
NCT00002546,Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus,Completed,No Results Available,Sarcoma,Drug: cisplatin|Drug: ifosfamide|Procedure: adjuvant therapy|Radiation: radiation therapy,Gynecologic Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group,Female,Adult|Senior,Phase III,216,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000063303|GOG-0150|ECOG-G150,11/01/1999,01/12/1993,NA,2/13/2009,01/11/2005,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00002546,"United States, &nbsp; South Africa",1,1,4,0
NCT00002556,Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Previously Untreated Multiple Myeloma,Completed,No Results Available,Multiple Myeloma and Plasma Cell Neoplasm,Biological: filgrastim|Biological: recombinant interferon alfa|Drug: carmustine|Drug: cyclophosphamide|Drug: melphalan|Drug: prednisone|Drug: vincristine sulfate,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase III,289,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000063435|E-5A93,11/01/1999,01/04/1994,NA,5/29/2009,01/06/2002,,01/05/2009,,http://ClinicalTrials.gov/show/NCT00002556,United States,1,1,7,0
NCT00002570,Immediate Compared With Delayed Chemotherapy in Treating Patients With Advanced Colorectal Cancer Without Signs or Symptoms of Disease,Completed,No Results Available,Colorectal Cancer,Drug: fluorouracil|Drug: leucovorin calcium,NCIC Clinical Trials Group|North Central Cancer Treatment Group,Both,Adult|Senior,Phase III,144,Other,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CO10|CAN-NCIC-CO10|NCCTG-JCO10|NCCTG-JCO.10|NCI-V94-0463|CDR0000063607,11/01/1999,01/07/1994,01/02/2009,11/07/2010,01/11/2010,,01/02/2009,,http://ClinicalTrials.gov/show/NCT00002570,United States,1,1,2,0
NCT00002583,Vinorelbine Plus Cisplatin or No Further Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Surgically Removed,Completed,No Results Available,Lung Cancer,Drug: cisplatin|Drug: vinorelbine ditartrate,NCIC Clinical Trials Group|National Cancer Institute (NCI)|Southwest Oncology Group|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B,Both,Adult|Senior,Phase III,450,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,BR10|CAN-NCIC-BR10|CLB-9795|E-JBR10|SWOG-JBR10|GW-565/040|NCI-V94-0492|CDR0000063698,11/01/1999,01/07/1994,01/12/2009,11/07/2010,01/11/2010,,01/12/2009,,http://ClinicalTrials.gov/show/NCT00002583,"United States, &nbsp; Canada",1,1,2,0
NCT00002678,Combination Chemotherapy in Treating Patients With Multiple Myeloma,Completed,No Results Available,Multiple Myeloma and Plasma Cell Neoplasm,Drug: dexamethasone|Drug: melphalan|Drug: prednisone,NCIC Clinical Trials Group,Both,Adult|Senior,Phase III,600,Other,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,MY7|CAN-NCIC-MY7|NCI-V95-0713|CDR0000064328,11/01/1999,01/05/1995,01/12/2009,11/07/2010,01/11/2010,,01/12/2009,,http://ClinicalTrials.gov/show/NCT00002678,"United States, &nbsp; Canada",1,1,3,0
NCT00002760,Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer,Completed,No Results Available,Prostate Cancer,Drug: ketoconazole|Drug: therapeutic hydrocortisone,Cancer and Leukemia Group B|National Cancer Institute (NCI),Male,Child|Adult|Senior,Phase III,250,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000064708|CLB-9583,11/01/1999,01/08/1996,NA,8/27/2009,01/08/2009,,01/08/2009,,http://ClinicalTrials.gov/show/NCT00002760,United States,1,1,2,0
NCT00002868,Interferon-Alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia,Completed,No Results Available,Leukemia,Biological: filgrastim|Biological: recombinant interferon alfa|Drug: busulfan|Drug: cytarabine|Drug: etoposide|Drug: hydroxyurea|Drug: idarubicin|Procedure: peripheral blood stem cell transplantation,Medical Research Council|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group,Both,Child|Adult,Phase III,744,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000065146|MRC-LEUK-CML-2000|ECOG-E7995|MRC-LEUK-CML-IV|MRC-LEUK-CML-IVa|EU-96029,11/01/1999,01/01/1996,NA,02/04/2009,01/06/2005,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00002868,"United States, &nbsp; United Kingdom",1,1,8,0
NCT00002975,Photodynamic Therapy in Treating Patients With Skin Cancer,Completed,No Results Available,Non-melanomatous Skin Cancer|Precancerous Condition,Drug: aminolevulinic acid,Roswell Park Cancer Institute|National Cancer Institute (NCI),Both,Child|Adult|Senior,Phase II,175,Other|NIH,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000065494|RPCI-DS-96-55|NCI-G97-1224,11/01/1999,01/02/1997,01/04/2010,9/15/2010,01/09/2010,,01/04/2009,Efficacy|Range of biological variations in PpIX levels and distributions within lesions and skin|Range of biological variations in the rate and extent of treatment-induced photobleaching of the PpIX and recovery from photobleaching|Range of biological variations in photodynamic therapy (PDT)-induced clinical epidermal toxicity|Range of biological variations in PDT-induced tissue damage and host responses on a microscopic level|Range of biological variations in the rate and extent of treatment-induced photobleaching within lesions and skin,http://ClinicalTrials.gov/show/NCT00002975,United States,1,1,1,1
NCT00003078,Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix,Completed,No Results Available,Cervical Cancer,Drug: cisplatin|Drug: fluorouracil|Radiation: brachytherapy|Radiation: radiation therapy,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Child|Adult|Senior,Phase III,870,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000065771|GOG-0165,11/01/1999,01/10/1997,NA,2/27/2010,01/02/2010,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00003078,"United States, &nbsp; Canada",1,1,4,0
NCT00003128,"Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus",Completed,No Results Available,Sarcoma,Biological: filgrastim|Drug: ifosfamide|Drug: paclitaxel,Gynecologic Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group,Female,Adult|Senior,Phase III,166,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000065891|GOG-0161|ECOG-G0161,11/01/1999,01/11/1997,NA,2/13/2009,01/05/2004,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00003128,United States,1,1,3,0
NCT00003134,Irinotecan in Treating Patients With Recurrent Glioma,Completed,No Results Available,Brain and Central Nervous System Tumors,Drug: irinotecan hydrochloride,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,60,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000065900|NCCTG-967251,11/01/1999,01/01/1998,NA,1/27/2009,01/01/2009,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00003134,United States,1,1,1,0
NCT00003199,Combination Chemotherapy and Peripheral Stem Cell Transplantation Followed by Interleukin-2 and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer,Completed,No Results Available,Breast Cancer,Biological: aldesleukin|Biological: sargramostim|Drug: busulfan|Drug: melphalan|Drug: tamoxifen citrate|Drug: thiotepa|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,Adult,Phase II,70,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,1229.00|FHCRC-1229.00|PSOC-1605|NCI-G98-1399|CDR0000066035|IR-4559,11/01/1999,01/11/1997,NA,10/01/2010,01/10/2010,,01/12/2009,,http://ClinicalTrials.gov/show/NCT00003199,United States,1,1,9,1
NCT00003377,"Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix",Completed,No Results Available,Cervical Cancer,Drug: cisplatin|Drug: paclitaxel|Radiation: brachytherapy|Radiation: radiation therapy,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Adult|Senior,Phase I|Phase II,40,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000066371|GOG-9804,11/01/1999,01/11/1999,NA,10/15/2009,01/05/2006,,01/07/2009,Maximum tolerated dose (MTD) as assessed by CTC 3.0 after 6 weeks of treatment|Toxicity of the MTD as assessed by CTC 3.0 after 6 weeks of treatment|Disease-free survival at 2 years|Overall survival at 2 years,http://ClinicalTrials.gov/show/NCT00003377,United States,1,1,4,0
NCT00003417,Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme,Completed,No Results Available,Brain and Central Nervous System Tumors,Drug: carmustine|Radiation: radiation therapy,Radiation Therapy Oncology Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase I|Phase II,40,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000066432|RTOG-9803,11/01/1999,01/09/1998,NA,12/26/2009,01/09/2003,,01/03/2009,,http://ClinicalTrials.gov/show/NCT00003417,"United States, &nbsp; Canada",1,1,2,0
NCT00003659,"Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia",Completed,No Results Available,Leukemia,Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate,Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,30,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000066752|MSKCC-98080|NCI-G98-1483,11/01/1999,01/09/1998,NA,06/06/2009,01/06/2009,,01/05/2009,,http://ClinicalTrials.gov/show/NCT00003659,United States,1,1,4,0
NCT00003691,"Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer",Completed,No Results Available,Endometrial Cancer,Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: paclitaxel,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Adult|Senior,Phase III,240,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000066794|GOG-0177,11/01/1999,01/12/1998,NA,09/10/2010,01/09/2010,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00003691,"United States, &nbsp; Canada",1,1,4,0
NCT00003892,ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer,Completed,No Results Available,Ovarian Cancer,Drug: ISIS 5132,NCIC Clinical Trials Group,Female,Adult|Senior,Phase II,30,Other,Interventional,Primary Purpose: Treatment,I116|CAN-NCIC-IND116|CDR0000067061,11/01/1999,01/02/1999,01/12/2009,11/07/2010,01/03/2010,,01/12/2009,,http://ClinicalTrials.gov/show/NCT00003892,"United States, &nbsp; Canada, &nbsp; United Kingdom",1,0,1,NA
NCT00003896,"Combination Chemotherapy in Treating Women With Stage III Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",Completed,No Results Available,Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer,Drug: cisplatin|Drug: paclitaxel|Drug: pegylated liposomal doxorubicin hydrochloride|Procedure: adjuvant therapy,Southwest Oncology Group|National Cancer Institute (NCI),Female,Child|Adult|Senior,Phase II,62,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000067066|SWOG-S9912,11/01/1999,01/09/1999,NA,06/10/2009,01/09/2005,,01/01/2009,Progression-free survival,http://ClinicalTrials.gov/show/NCT00003896,United States,1,0,4,NA
NCT00004547,"Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy",Completed,No Results Available,Abdominal Neoplasm|Colonic Neoplasm|Mesothelioma|Peritoneal Neoplasm,Procedure: Adjuvant therapy|Procedure: Conventional therapy|Drug: Cisplatin|Drug: fluorouracil|Drug: Paclitaxel|Procedure: Hyperthermia treatment,National Cancer Institute (NCI),Both,Child|Adult,Phase II,188,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,000069|00-C-0069,02/03/2000,01/01/2000,01/08/2009,9/17/2010,01/05/2010,,01/08/2009,Disease-free survival at 6 or 12 months.,http://ClinicalTrials.gov/show/NCT00004547,United States,1,1,6,0
NCT00004888,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer,Completed,No Results Available,Breast Cancer,Biological: trastuzumab|Drug: docetaxel|Drug: pegylated liposomal doxorubicin hydrochloride,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),Female,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067564|ECOG-3198,03/07/2000,01/10/2000,NA,5/29/2009,01/04/2004,,01/05/2009,,http://ClinicalTrials.gov/show/NCT00004888,"United States, &nbsp; South Africa",1,0,3,NA
NCT00005036,Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Completed,No Results Available,Colorectal Cancer,Drug: FOLFOX regimen|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin,North Central Cancer Treatment Group|National Cancer Institute (NCI)|Southwest Oncology Group|Eastern Cooperative Oncology Group,Both,Adult|Senior,Phase III,NA,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,CDR0000067623|NCCTG-N9841|ECOG-N9841|SWOG-N9841,04/06/2000,01/11/1999,NA,10/15/2009,01/02/2004,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00005036,"United States, &nbsp; Canada, &nbsp; South Africa",1,1,5,0
NCT00005811,Topotecan in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment,Completed,No Results Available,"Brain and Central Nervous System Tumors|Leukemia|Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific",Drug: topotecan hydrochloride,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult,Phase II,77,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000067813|COG-P9962|POG-9962|CCG-P9962|NCI-01-C-0123,06/02/2000,01/04/2000,NA,11/20/2010,01/11/2010,,01/02/2009,Therapeutic activity|Safety and toxicity|Concentration of matrix metalloproteinases in the CSF,http://ClinicalTrials.gov/show/NCT00005811,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Switzerland",1,1,1,0
NCT00005850,Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer,Completed,No Results Available,Anxiety Disorder|Depression|Fatigue|Lung Cancer,Drug: cisplatin|Drug: fluoxetine|Drug: gemcitabine hydrochloride,Cancer and Leukemia Group B|National Cancer Institute (NCI),Both,Child|Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067871|CLB-119802,06/02/2000,01/08/2001,NA,09/10/2009,01/08/2003,,01/08/2009,,http://ClinicalTrials.gov/show/NCT00005850,"United States, &nbsp; Puerto Rico",1,1,3,0
NCT00005963,Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: carboplatin|Drug: docetaxel,North Central Cancer Treatment Group|National Cancer Institute (NCI),Female,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067945|NCCTG-N9932,07/05/2000,01/11/2000,NA,1/31/2009,01/05/2006,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00005963,United States,1,1,2,0
NCT00006001,SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer,Completed,No Results Available,Colorectal Cancer,Drug: semaxanib,University of Chicago|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068009|UCCRC-NCI-52|NCI-52,07/05/2000,01/08/2000,NA,2/26/2009,01/02/2009,,01/02/2009,,http://ClinicalTrials.gov/show/NCT00006001,United States,1,0,1,NA
NCT00006014,SU5416 in Treating Patients With Malignant Mesothelioma,Completed,No Results Available,Malignant Mesothelioma,Drug: semaxanib,University of Chicago|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068023|UCCRC-10409|UCCRC-NCI-44|NCI-44,07/05/2000,01/08/2000,NA,2/26/2009,01/02/2009,,01/02/2009,,http://ClinicalTrials.gov/show/NCT00006014,United States,1,0,1,NA
NCT00006015,"Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer",Completed,No Results Available,Colorectal Cancer,Biological: trastuzumab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin,Cancer and Leukemia Group B|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068024|CALGB-89902,07/05/2000,01/05/2000,NA,4/26/2009,01/04/2009,,01/01/2009,Response rate after treatment with study regimen|Time to progression|Overall toxicity,http://ClinicalTrials.gov/show/NCT00006015,United States,1,1,4,0
NCT00006228,Trastuzumab Plus Interleukin-2 in Treating Patients With Metastatic Breast Cancer,Completed,No Results Available,Breast Cancer,Biological: aldesleukin|Biological: trastuzumab,Arthur G. James Cancer Hospital & Richard J. Solove Research Institute|National Cancer Institute (NCI),Both,Child|Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068150|OSU-99H0192|OSU-9945|NCI-195,09/11/2000,01/01/2001,NA,02/06/2010,01/12/2003,,01/07/2009,,http://ClinicalTrials.gov/show/NCT00006228,United States,0,NA,2,1
NCT00006229,Paclitaxel and Carboplatin With or Without BMS-275291 in Treating Patients With Advanced or Metastatic Non-small Cell Lung Cancer,Completed,No Results Available,Lung Cancer,Drug: carboplatin|Drug: paclitaxel|Drug: rebimastat,NCIC Clinical Trials Group,Both,Adult|Senior,Phase II|Phase III,NA,Other,Interventional,Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Treatment,BR18|CAN-NCIC-BR18|BMS-CA161-003|CDR0000068153,09/11/2000,01/04/2000,01/02/2009,11/07/2010,01/03/2010,,01/02/2009,,http://ClinicalTrials.gov/show/NCT00006229,"United States, &nbsp; Austria, &nbsp; Belgium, &nbsp; Canada, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Portugal, &nbsp; Spain, &nbsp; Switzerland, &nbsp; United Kingdom",1,0,3,NA
NCT00006461,Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor,Completed,No Results Available,Brain and Central Nervous System Tumors,Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy,Children's Oncology Group|National Cancer Institute (NCI),Both,Child,Phase III,65,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068269|COG-P9934|POG-P9934,11/06/2000,01/10/2000,NA,11/20/2010,01/11/2010,,01/01/2009,Event-free survival rate at 1 year|Feasibility and safety|Toxicity|Neuropsychological and neuroendocrine effects|Incidence of atypical teratoid and/or rhabdoid tumor,http://ClinicalTrials.gov/show/NCT00006461,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Netherlands, &nbsp; New Zealand, &nbsp; Switzerland",1,1,6,0
NCT00006734,Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor,Completed,No Results Available,Sarcoma,Biological: filgrastim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: brachytherapy|Radiation: radiation therapy,Children's Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group,Both,Child|Adult,Phase III,NA,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,CDR0000068323|COG-AEWS0031|CCG-A7983|SWOG-COG-AEWS0031,12/06/2000,01/05/2001,NA,12/16/2010,01/11/2010,,01/08/2009,Event-free survival,http://ClinicalTrials.gov/show/NCT00006734,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Netherlands, &nbsp; New Zealand, &nbsp; Puerto Rico, &nbsp; Switzerland",1,1,11,0
NCT00009867,Arsenic Trioxide in Treating Patients With Recurrent Bladder or Urinary Tract Cancer,Completed,No Results Available,Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer,Drug: arsenic trioxide,Cancer and Leukemia Group B|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068419|CLB-99903,02/02/2001,01/02/2001,NA,10/15/2009,01/10/2009,,01/07/2009,,http://ClinicalTrials.gov/show/NCT00009867,United States,1,1,1,0
NCT00009893,Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer,Completed,No Results Available,Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer,Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068421|NCCTG-N0042,02/02/2001,01/05/2001,NA,10/16/2009,01/10/2009,,01/10/2009,,http://ClinicalTrials.gov/show/NCT00009893,United States,1,1,3,0
NCT00014495,Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer,Completed,No Results Available,Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,Biological: filgrastim|Drug: cytarabine|Radiation: bismuth Bi213 monoclonal antibody M195,Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI),Both,Child|Adult|Senior,Phase I|Phase II,39,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068549|MSKCC-00117|NCI-H01-0071,04/10/2001,01/11/2000,NA,04/10/2010,01/10/2008,,01/12/2009,"Maximum tolerated dose|Antileukemic effects|Toxicity|Pharmacology, biodistribution, and dosimetry",http://ClinicalTrials.gov/show/NCT00014495,United States,1,0,3,NA
NCT00015457,Amlodipine Plus Botulinum Toxin for Focal Dystonia,Completed,No Results Available,Focal Dystonia,Drug: Amlodipine plus Botulinum toxin,National Institute of Neurological Disorders and Stroke (NINDS),Both,Adult|Senior,Phase II,80,NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",010147|01-N-0147,4/18/2001,01/04/2001,NA,1/28/2010,01/04/2009,,01/04/2009,Change in response to botulinum toxin injection.|Change in duration of response to bolulinum toxin injection.,http://ClinicalTrials.gov/show/NCT00015457,United States,1,1,1,0
NCT00015886,Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery,Completed,No Results Available,Breast Cancer,Drug: docetaxel|Drug: fluorouracil|Drug: leucovorin calcium,Wake Forest University|National Cancer Institute (NCI),Female,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068567|CCCWFU-74896|NCI-3137,05/06/2001,01/05/2001,NA,9/18/2009,01/09/2009,,01/07/2009,,http://ClinicalTrials.gov/show/NCT00015886,United States,1,1,3,0
NCT00016120,Vaccine Therapy Plus Biological Therapy in Treating Patients With Relapsed Prostate Cancer,Completed,No Results Available,Prostate Cancer,Biological: Globo H-GM2-Lewis-y-MUC1-32-mer-TF(c)-Tn(c)-KLH conjugate vaccine|Biological: QS21,Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI),Male,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068596|MSKCC-00064|NCI-G01-1940,05/06/2001,01/06/2000,NA,12/13/2009,01/12/2003,,01/03/2009,,http://ClinicalTrials.gov/show/NCT00016120,United States,0,NA,2,NA
NCT00016718,"Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs",Completed,No Results Available,HIV Infections,Drug: Didanosine|Drug: Efavirenz|Drug: Emtricitabine,National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Both,Child|Adult,Phase I|Phase II,53,NIH,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ACTG P1021|PACTG P1021|IMPAACT P1021|10038,5/31/2001,01/06/2005,NA,4/23/2010,01/09/2008,,01/01/2009,Development of Grade 3 or 4 adverse events attributed to the study treatment|Suppression of HIV viral load to less than 400 copies/ml and 50 copies/ml at Week 16|Time to virologic failure at or after Week 16,http://ClinicalTrials.gov/show/NCT00016718,"United States, &nbsp; Puerto Rico",1,1,3,0
NCT00018031,Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients,Completed,No Results Available,Hepatitis C|HIV Infections,Drug: Peginterferon alpha-2b|Drug: Ribavirin,National Institute of Allergy and Infectious Diseases (NIAID),Both,Adult|Senior,Phase II,180,NIH,Interventional,Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,010194|01-I-0194,6/27/2001,01/06/2001,01/04/2009,11/12/2010,01/11/2010,,01/04/2009,Correlation of HCV viral kinetics to treatment response rates.|Gene an proteomics expression in PBMC and liver and their relationship to the treatment response rates.,http://ClinicalTrials.gov/show/NCT00018031,United States,1,1,2,0
NCT00020683,COL-3 in Treating Patients With HIV-Related Kaposi's Sarcoma,Completed,No Results Available,Sarcoma,Drug: incyclinide,AIDS Malignancy Clinical Trials Consortium|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment,CDR0000068703|U01CA070019|AMC-027,07/11/2001,01/04/2001,NA,11/03/2010,01/11/2010,,01/11/2009,,http://ClinicalTrials.gov/show/NCT00020683,United States,1,0,1,NA
NCT00020943,Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma,Completed,No Results Available,Lymphoma,Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation,Cancer and Leukemia Group B|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000068732|CALGB-59909,07/11/2001,01/06/2001,NA,11/19/2009,01/09/2004,,01/07/2009,,http://ClinicalTrials.gov/show/NCT00020943,"United States, &nbsp; Puerto Rico",1,1,13,0
NCT00021320,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer,Completed,No Results Available,Esophageal Cancer,Drug: cisplatin|Drug: fluorouracil|Drug: paclitaxel|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy,Fox Chase Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068769|P30CA006927|FCCC-00003|NCI-G01-1982,07/11/2001,01/05/2000,01/04/2009,02/11/2010,01/02/2010,,01/04/2009,,http://ClinicalTrials.gov/show/NCT00021320,United States,1,1,6,0
NCT00022139,"Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction",Completed,No Results Available,Esophageal Cancer|Gastric Cancer,Drug: carboplatin|Drug: fluorouracil|Drug: paclitaxel|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000068789|NCCTG-N0044,08/10/2001,01/01/2002,NA,02/04/2009,01/09/2007,,01/01/2009,Proportion of successes|Toxicity-free rate|Clinical tumor response|Pathologic tumor response|Time to disease progression|Surgical outcome|Survival|Time to treatment failure|Quality of life,http://ClinicalTrials.gov/show/NCT00022139,United States,1,1,6,0
NCT00022737,Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia,Completed,No Results Available,Leukemia,Biological: filgrastim|Drug: asparaginase|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: ifosfamide|Drug: imatinib mesylate|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult,Phase II,220,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068859|COG-AALL0031,08/10/2001,01/10/2002,NA,11/20/2010,01/11/2010,,01/07/2009,"Feasibility, in terms of toxicity and patient accrual|Safety|Event-free survival|Feasibility of administering hematopoietic stem cell transplantation after the second consolidation block of chemotherapy|Prognostic effect of minimal residual disease assays",http://ClinicalTrials.gov/show/NCT00022737,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; New Zealand",1,1,19,0
NCT00023764,Bortezomib in Treating Patients With Lymphoproliferative Disorders,Completed,No Results Available,Lymphoma,Drug: bortezomib,Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,105,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000068860|MSKCC-01049|NCI-2795|CWRU-MSKCC-1Y02|UNMC-03903,9/13/2001,01/06/2001,NA,2/26/2010,01/12/2009,,01/03/2009,"Frequency and duration of complete and partial response rates|Mean and median duration of response, progression-free survival, and overall survival|Probability of polymerase chain reaction (PCR) negativity after completion of study treatment",http://ClinicalTrials.gov/show/NCT00023764,United States,1,1,1,1
NCT00023946,BMS-247550 in Treating Patients With Liver or Gallbladder Cancer,Completed,No Results Available,Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer,Drug: ixabepilone,University of Chicago|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068878|UCCRC-11045|NCI-3656,9/13/2001,01/10/2001,NA,12/02/2009,01/06/2005,,01/11/2009,,http://ClinicalTrials.gov/show/NCT00023946,United States,1,1,1,1
NCT00024102,Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: CMF regimen|Drug: capecitabine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Procedure: adjuvant therapy,Cancer and Leukemia Group B|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Southwest Oncology Group|NCIC Clinical Trials Group,Female,Adult|Senior,Phase III,1800,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,CDR0000068891|CALGB-49907|ECOG-CALGB-49907|CAN-NCIC-MAC1|SWOG-CALGB-49907,9/13/2001,01/09/2001,NA,04/10/2010,01/01/2007,,01/05/2009,Duration of disease-free survival|Overall survival|Toxicity,http://ClinicalTrials.gov/show/NCT00024102,"United States, &nbsp; Canada, &nbsp; Peru",1,1,7,0
NCT00024258,Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors,Completed,No Results Available,Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Kidney Cancer|Liver Cancer|Neuroblastoma|Ovarian Cancer|Retinoblastoma|Sarcoma,Drug: arsenic trioxide,Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI),Both,Child|Adult,Phase II,120,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068906|MSKCC-01042|CTI-1059|NCI-G01-2014,9/13/2001,01/03/2001,NA,7/22/2009,01/07/2009,,01/05/2009,Response rate after every 3 courses during treatment and then every 2-3 months for 1 year after completion of treatment|Toxicity after every course during treatment,http://ClinicalTrials.gov/show/NCT00024258,United States,1,1,1,0
NCT00025233,Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix,Completed,No Results Available,Cervical Cancer,Biological: bevacizumab,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Adult|Senior,Phase II,51,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000068940|GOG-0227C,10/11/2001,01/04/2002,NA,08/08/2009,01/10/2006,,01/07/2009,"Progression-free survival at 6 months|Frequency and severity of adverse effects as assessed by CTC|Duration of progression-free survival and overall survival|Frequency of clinical response (partial and complete response) as assessed by RECIST criteria|Prognostic factors, including initial performance status and age",http://ClinicalTrials.gov/show/NCT00025233,United States,0,NA,1,0
NCT00025675,Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors,Completed,No Results Available,Brain and Central Nervous System Tumors,Drug: gefitinib,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,NABTC-0001 CDR0000068984|U01CA062399|ABTC-0001|NABTC-0001,10/11/2001,01/01/2002,NA,10/01/2010,01/10/2010,,01/06/2009,Progression-free survival at 6 months,http://ClinicalTrials.gov/show/NCT00025675,United States,1,1,1,1
NCT00026338,Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Drug: erlotinib hydrochloride|Drug: gemcitabine hydrochloride,NCIC Clinical Trials Group,Both,Adult|Senior,Phase III,NA,Other,Interventional,Primary Purpose: Treatment,PA3|CAN-NCIC-PA3|OSI-CAN-NCIC-PA3|CDR0000069020,11/09/2001,01/08/2001,01/02/2009,11/07/2010,01/03/2010,,01/02/2009,,http://ClinicalTrials.gov/show/NCT00026338,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; China, &nbsp; Germany, &nbsp; Greece, &nbsp; Hong Kong, &nbsp; Israel, &nbsp; Italy, &nbsp; Mexico, &nbsp; New Zealand, &nbsp; Poland, &nbsp; Romania, &nbsp; Singapore, &nbsp; United Kingdom",1,1,2,0
NCT00026403,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Drug: cisplatin|Drug: gemcitabine hydrochloride|Radiation: radiation therapy,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000069026|NCCTG-N9942,11/09/2001,01/09/2001,NA,08/04/2009,01/07/2009,,01/07/2009,,http://ClinicalTrials.gov/show/NCT00026403,"United States, &nbsp; Canada",1,1,3,0
NCT00027560,"Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer",Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,Biological: alemtuzumab|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation,Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI),Both,Child|Adult|Senior,Phase II,50,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000069043|MSKCC-01092|NCI-G01-2028,12/07/2001,01/07/2001,NA,04/10/2010,01/12/2009,,01/04/2009,"Durable hematopoietic reconstitution|Incidence and characteristics of peritransplantation morbidity and mortality|Incidence and severity of acute and chronic graft-versus-host disease|Overall and disease-free survival at 1, 3, 6, 12, and 24 months after transplantation|Quality of bone marrow and peripheral blood chimerism at 1, 3, 6, 12, and 24 months after transplantation|Kinetics of immune reconstitution",http://ClinicalTrials.gov/show/NCT00027560,United States,1,1,6,0
NCT00027872,Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,Completed,No Results Available,Leukemia,Drug: tipifarnib,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,"CDR0000069089, J0255|U01CA069854|P30CA006973|JHOC-J0255|MSGCC-U5400|MSGCC-0116|NCI-1754",12/07/2001,01/12/2001,NA,03/09/2010,01/03/2010,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00027872,United States,1,0,1,NA
NCT00028002,Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor,Completed,No Results Available,Gastrointestinal Stromal Tumor,Drug: imatinib mesylate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy,Radiation Therapy Oncology Group|National Cancer Institute (NCI)|American College of Radiology Imaging Network|Eastern Cooperative Oncology Group,Both,Adult|Senior,Phase II,63,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000069111|RTOG-S-0132|ACRIN-6665|RTOG-DEV-1055|ECOG-RTOG-R0132,12/07/2001,01/02/2002,NA,7/31/2010,01/01/2009,,01/01/2009,"Biological effects of imatinib mesylate|Rate of disease recurrence at 2 years|Rates of objective response (complete, partial, and stable)|Major toxicity (i.e., grade ??­ 3)|Correlation of glucose transported expression and positron emission tomography (PET) interpretations|Tumor changes observed on PET and correlation with size changes observed on conventional cross-sectional imaging|Diagnostic accuracy of PET to predict disease recurrence",http://ClinicalTrials.gov/show/NCT00028002,United States,1,1,4,0
NCT00028574,Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer,Completed,No Results Available,Hot Flashes|Prostate Cancer,Drug: gabapentin,North Central Cancer Treatment Group|National Cancer Institute (NCI),Male,Adult|Senior,Phase III,220,Other|NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care,CDR0000069107|NCCTG-N00CB|NCI-P01-0199,01/04/2002,01/12/2001,NA,7/20/2010,01/12/2006,,01/11/2009,Hot flash reduction by diary scores at 4 weeks|Toxicity by questionnaires at 4 weeks,http://ClinicalTrials.gov/show/NCT00028574,United States,1,1,1,0
NCT00028951,Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva,Completed,No Results Available,Lymphedema|Perioperative/Postoperative Complications|Vulvar Cancer,Drug: fibrin sealant|Procedure: surgical wound closure,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Adult|Senior,Phase III,NA,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Supportive Care,CDR0000069149|GOG-0195|NCI-P01-0201,01/04/2002,01/01/2003,NA,05/09/2009,01/12/2005,,01/01/2009,"Incidence of lymphedema of the lower extremity at 1 week, 6 weeks, 3 months, and 6 months postoperatively|Frequency of surgical complications at 1 week, 6 weeks, 3 months, and 6 months postoperatively",http://ClinicalTrials.gov/show/NCT00028951,United States,1,0,2,NA
NCT00030407,Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer,Completed,No Results Available,Lung Cancer,Drug: celecoxib|Drug: docetaxel,Barbara Ann Karmanos Cancer Institute,Both,Adult|Senior,Phase II,NA,Other,Interventional,Primary Purpose: Treatment,CDR0000069163|WSU-C-2305|AVENTIS-WSU-C-2305|WSU-06-15-01-M01-FB|NCI-V01-1687,2/14/2002,01/10/2001,NA,4/13/2010,01/01/2005,,01/04/2009,,http://ClinicalTrials.gov/show/NCT00030407,United States,1,1,2,0
NCT00031629,Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus,Completed,No Results Available,Sarcoma,Biological: filgrastim|Biological: pegfilgrastim|Drug: docetaxel|Drug: gemcitabine hydrochloride,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Adult|Senior,Phase II,51,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000069206|GOG-0131G,03/08/2002,01/01/2002,NA,02/05/2009,01/12/2006,,01/01/2009,Antitumor activity|Toxicity,http://ClinicalTrials.gov/show/NCT00031629,United States,1,1,4,0
NCT00033748,Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver,Completed,No Results Available,Colorectal Cancer|Metastatic Cancer,Biological: monoclonal antibody 11D10 anti-idiotype vaccine|Biological: monoclonal antibody 3H1 anti-idiotype vaccine|Procedure: adjuvant therapy,Cancer and Leukemia Group B|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000069324|CALGB-89903,04/09/2002,01/12/2001,NA,8/27/2009,01/07/2004,,01/08/2009,,http://ClinicalTrials.gov/show/NCT00033748,United States,0,NA,3,NA
NCT00036933,Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer,Completed,No Results Available,Prostate Cancer,Biological: MUC-2-Globo H-KLH conjugate vaccine|Biological: QS21,Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI),Male,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000069342|MSKCC-01140|NCI-G02-2064,5/13/2002,01/03/2002,NA,12/03/2009,01/03/2003,,01/03/2009,,http://ClinicalTrials.gov/show/NCT00036933,United States,0,NA,2,NA
NCT00039442,Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer,Completed,No Results Available,Cervical Cancer,Drug: capecitabine,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Child|Adult|Senior,Phase II,NA,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000069384|GOG-0128G,06/06/2002,01/06/2002,NA,2/13/2009,01/07/2005,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00039442,United States,1,1,1,1
NCT00039741,Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children,Completed,No Results Available,HIV Infections,Drug: Highly active antiretroviral therapy,National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|PENTA Foundation,Both,Child|Adult,Phase II|Phase III,256,NIH|Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment,PENTA 9/PACTG 390|PENPACT-1B,06/07/2002,01/10/2005,01/04/2010,8/17/2010,01/06/2008,,01/08/2009,"Change in viral load measured in log10 HIV-1 RNA copies/ml|Number of Grade 3 or higher signs, symptoms, or laboratory abnormalities experienced|Change in immunologic outcome, defined as the change in CD4% from baseline to 4 years|Time to a significant HIV-related clinical event, defined as the time to first new CDC Category diagnosis (except for recurrent bacterial infections)|Whether or not a child switched regimens|Time to HIV-1 RNA of 400 copies/ml or greater during first-line therapy or permanent discontinuation of first-line therapy|Time to HIV-1 RNA of 30,000 copies/ml or greater during second-line therapy or permanent discontinuation of second-line therapy|Whether or not a child has an HIV-1 RNA level of less than 400 copies/ml at Week 24 and has not permanently discontinued first-line therapy prior to that week|Whether or not a child has a HIV-1 RNA level less than 400 copies/ml regardless of therapy at that time",http://ClinicalTrials.gov/show/NCT00039741,"United States, &nbsp; Bahamas, &nbsp; Brazil, &nbsp; Puerto Rico",1,1,1,0
NCT00041041,Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer,Completed,No Results Available,Ovarian Cancer|Peritoneal Cavity Cancer,Drug: imatinib mesylate,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000069438|GOG-0170E,07/08/2002,01/06/2002,NA,02/05/2009,01/09/2004,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00041041,United States,1,1,1,0
NCT00041106,Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer,Completed,No Results Available,Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer,Drug: cisplatin|Drug: gefitinib|Drug: gemcitabine hydrochloride,Cancer and Leukemia Group B|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000069443|CALGB-90102,07/08/2002,01/07/2002,NA,5/20/2009,01/11/2004,,01/05/2009,,http://ClinicalTrials.gov/show/NCT00041106,United States,1,1,3,0
NCT00045435,Peripheral Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia,Completed,No Results Available,Leukemia,Biological: therapeutic allogeneic lymphocytes|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,40,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,1654.00|FHCRC-1654.00|CDR0000256466,09/06/2002,01/04/2002,NA,9/20/2010,01/09/2010,,01/06/2009,Disease-free survival 1 year post-transplant|Nonrelapse mortality on day 200 post-transplant,http://ClinicalTrials.gov/show/NCT00045435,United States,1,0,6,NA
NCT00045630,Combination Chemotherapy Followed By Observation or Surgery in Treating Patients With Stage II or Stage III Cancer of the Urothelium,Completed,No Results Available,Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer,Drug: carboplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Procedure: conventional surgery|Procedure: neoadjuvant therapy,Southwest Oncology Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,95,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000256921|SWOG-S0219,09/06/2002,01/01/2003,NA,4/21/2009,01/12/2006,,01/01/2009,Pathologic complete response rate by transurethral resection of bladder tumor (TURBT) and imaging studies after chemotherapy,http://ClinicalTrials.gov/show/NCT00045630,United States,1,1,5,0
NCT00045695,Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia,Completed,No Results Available,Lymphoma,Drug: bortezomib,NCIC Clinical Trials Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group,Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,I152|CAN-NCIC-IND152|ECOG-JI152|NCI-NCIC-152|CDR0000257042,09/06/2002,01/08/2002,01/12/2009,11/07/2010,01/03/2010,,01/12/2009,,http://ClinicalTrials.gov/show/NCT00045695,"United States, &nbsp; Canada",1,1,1,1
NCT00046930,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Completed,Has Results,Leukemia|Myelodysplastic Syndromes,Biological: filgrastim|Biological: sargramostim|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: zosuquidar trihydrochloride|Drug: Placebo,Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Eli Lilly and Company|Kanisa Pharmaceuticals,Both,Adult|Senior,Phase III,449,Other|NIH|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CDR0000257122|E3999|U10CA021115,10/03/2002,01/07/2002,NA,8/17/2010,01/08/2010,,01/06/2009,Overall Survival|Progression-free Survival|Response,http://ClinicalTrials.gov/show/NCT00046930,"United States, &nbsp; Israel",1,0,6,NA
NCT00047320,Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors,Completed,No Results Available,Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor,Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Drug: thiotepa|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult,Phase II,100,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000257664|COG-ACNS0122,10/03/2002,01/01/2004,NA,12/17/2010,01/11/2010,,01/05/2009,Response (complete and partial response)|Toxic death|Occurrence of nonhematological grade 4 toxicity during chemotherapy|Event-free survival|Progression-free survival|Overall survival,http://ClinicalTrials.gov/show/NCT00047320,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; New Zealand, &nbsp; Switzerland",1,0,11,NA
NCT00047879,Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas,Completed,No Results Available,Glioma,Biological: PEG-interferon alfa-2b|Drug: Thalidomide|Procedure: Adjuvant Therapy,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,7,NIH,Interventional,Control: Active Control|Primary Purpose: Treatment,030002|03-C-0002,6/19/2006,01/10/2002,01/06/2009,12/03/2010,01/11/2010,,01/06/2009,Progression-free survival at 6-months|Response (complete and partial response),http://ClinicalTrials.gov/show/NCT00047879,United States,1,1,3,1
NCT00048568,A Phase III Study of BMS-188667 in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate,Completed,No Results Available,Rheumatoid Arthritis,Drug: BMS-188667|Drug: Methotrexate|Drug: Placebo|Drug: BMS-188667|Drug: Methotrexate,Bristol-Myers Squibb,Both,Adult|Senior,Phase III,656,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",IM101-102,11/02/2002,01/12/2002,01/10/2009,11/30/2009,01/11/2009,,01/10/2009,"Compare the clinical efficacy of BMS-188667 used in combination with methotrexate versus methotrexate alone on: Symptomatic relief as measured by ACR20 following 6 months of treatment|Compare the clinical efficacy of BMS-188667 used in combination with methotrexate versus methotrexate alone on: Physical function as measured by the disability index of the HAQ at 12 months|Compare the clinical efficacy of BMS-188667 used in combination with methotrexate versus methotrexate alone on: Structural damage as assessed by erosion scores using a Genant-modified method at 12 months of treatment|The primary objective of long term extension is to assess the safety and long term tolerability of BMS-188667 in subjects who have completed the initial 12-month double-blind treatment period|Determine the effect of BMS-188667 in combination with methotrexate on structural damage as assessed by total and joint space narrowing score using a Genant-modified Sharp method at 12 months of treatment|Compare ACR 50 and ACR 70|Assessed ACR 20, ACR 50, and ACR 70|Determine the proportion of subjects receiving BMS-188667 in combination with methotrexate who achieve a major clinical response (continuous ACR 70)|Assess disease activity as measured by Disease Activity Score-28 (DAS-28)|Assess the safety of chronic use of BMS-188667 in combination with methotrexate|Assess the discontinuation rate in subjects receiving BMS-188667 in combination with methotrexate|Assess the incidence of new tender and swollen joints and 100% reduction in joint counts|Assess the immunogenicity of BMS-188667 in combination with methotrexate|Assess changes of surrogate markers (RF, CRP, ESR, IL2-r) in subjects receiving BMS-188667 in combination with methotrexate|Assess the changes of functional status as measured by the disability index and individual components of the HAQ in subjects receiving BMS-188667 in combination with methotrexate|Assess the change of subject's health-related quality of life, as measured by the SF-36 questionnaire in subjects receiving BMS-188667 in combination with methotrexate|Assess the pharmacokinetics of BMS-188667|Determine the effect of BMS-188667 in combination with methotrexate on structural damage as assessed by x-ray evaluation in subjects with RA after two years of treatment|Assess chx of functional status measured by disability index & individual components of HAQ in subjects receiving BMS-188667 in combination with methotrexate to determine if any improvement in HAQ associated with BMS-188667 treatment - long-term adm|Assess ACR 20, ACR 50, and ACR 70|Determine the proportion of subjects receiving BMS-188667 in combination with methotrexate who achieve a major clinical response (continuous ACR 70 for six months)|Assess disease activity as measured by Disease Activity Score-28 (DAS-28), at each quarterly visit|Assess the immunogenicity of BMS-188667 in combination with methotrexate|Assess changes of surrogate markers (RF, CRP, ESR, IL-6, MMP-3) in subjects receiving BMS-188667 in combination with methotrexate|Assess the change of subject's health-related quality of life, as measured by the SF-36 questionnaire in subjects receiving BMS-188667 in combination with methotrexate",http://ClinicalTrials.gov/show/NCT00048568,United States,1,1,5,0
NCT00048581,Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.,Completed,No Results Available,Rheumatoid Arthritis,Drug: Abatacept|Drug: Placebo|Drug: Abatacept,Bristol-Myers Squibb,Both,Adult|Senior,Phase III,393,Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,IM101-029,11/02/2002,01/12/2002,01/09/2009,7/28/2010,01/09/2009,,01/09/2009,"The clinical efficacy of a fixed dose of abatacept with placebo as assessed by the ACR 20 response rate in subjects with active RA on a background of DMARDs who have failed any anti-TNF therapy|Compare ACR 50 and ACR 70 response rates|compare ACR 20, ACR 50 and ACR 70 response rates|Assess the long-term safety and tolerability of abatacept|Assess the efficacy, pharmacodynamic marker activity and immunogenicity of abatacept in combination with background non-biologic DMARDs",http://ClinicalTrials.gov/show/NCT00048581,United States,1,1,3,1
NCT00048932,A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis,Completed,No Results Available,Rheumatoid Arthritis,Drug: Abatacept|Drug: Placebo|Drug: Abatacept,Bristol-Myers Squibb,Both,Adult|Senior,Phase III,1795,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",IM101-031,11/11/2002,01/12/2002,01/10/2009,10/06/2009,01/10/2009,,01/10/2009,"incidence of AE, SAE, discontinuation due to AE",http://ClinicalTrials.gov/show/NCT00048932,United States,1,1,3,1
NCT00049036,"Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",Completed,No Results Available,Lymphoma,Biological: rituximab,AIDS Malignancy Clinical Trials Consortium|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group,Both,Adult|Senior,Phase II,70,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment,CDR0000257660|U01CA070019|AMC-034|ECOG-AMC34,11/12/2002,01/01/2003,NA,11/03/2010,01/11/2010,,01/05/2009,Complete response as measured by tumor response after completion of study treatment,http://ClinicalTrials.gov/show/NCT00049036,United States,0,NA,1,0
NCT00050011,Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy,Completed,No Results Available,Breast Neoplasms|Osteoporosis,Drug: Zoledronic Acid and Letrozole,Novartis Pharmaceuticals,Female,Adult|Senior,Phase III,602,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,CZOL446EUS32,11/18/2002,01/09/2002,NA,5/28/2010,01/05/2010,,01/01/2009,"Percent change in lumbar spine (L1-L4) bone mineral density (BMD) at 2 years, 3 years and 5 years|Percent change in lumbar spine and total hip BMD over 5 years|Changes in biochemical markers of bone turnover over 5 years|Incidence of fractures at 3 years|Time to disease recurrence/relapse",http://ClinicalTrials.gov/show/NCT00050011,"United States, &nbsp; Puerto Rico",1,1,1,0
NCT00051168,A Long-term Safety Study of Once-daily Travatan,Completed,Has Results,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: Travatan,Alcon Research,Both,Adult|Senior,Phase III,502,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,C-02-20,01/03/2003,01/01/2006,NA,04/09/2010,01/04/2010,,01/03/2009,Mean Intraocular Pressure,http://ClinicalTrials.gov/show/NCT00051168,United States,1,1,1,1
NCT00052442,10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma,Completed,No Results Available,Lymphoma,Drug: pralatrexate,Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000258425|MSKCC-02078|NCI-H02-0100,1/24/2003,01/08/2002,NA,12/13/2009,01/12/2009,,01/03/2009,,http://ClinicalTrials.gov/show/NCT00052442,United States,1,1,1,1
NCT00052845,"Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",Completed,No Results Available,Prostate Cancer,Drug: docetaxel|Drug: estramustine phosphate sodium|Drug: exisulind,Cancer and Leukemia Group B|National Cancer Institute (NCI),Male,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000258766|CALGB-90004,1/24/2003,01/11/2002,NA,11/16/2009,01/12/2003,,01/08/2009,,http://ClinicalTrials.gov/show/NCT00052845,"United States, &nbsp; Canada, &nbsp; Puerto Rico",1,0,3,NA
NCT00053209,Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium,Completed,No Results Available,Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer,Drug: gemcitabine hydrochloride|Drug: pemetrexed disodium,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000269302|ECOG-E4802,1/27/2003,01/04/2004,NA,5/29/2009,01/10/2005,,01/05/2009,Response as measured by RECIST criteria|Time to disease progression|Overall survival,http://ClinicalTrials.gov/show/NCT00053209,United States,1,1,2,0
NCT00054418,Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer,Completed,No Results Available,Breast Cancer|Osteoporosis,Dietary Supplement: calcium carbonate|Dietary Supplement: cholecalciferol|Drug: risedronate sodium,North Central Cancer Treatment Group|National Cancer Institute (NCI),Female,Adult|Senior,Phase III,NA,Other|NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care,CDR0000270449|NCCTG-N02C1,02/05/2003,01/03/2003,NA,05/12/2009,01/05/2006,,01/03/2009,"Average intra-patient change in lumbar spine (L2-L4, PA) bone mineral density (BMD) from baseline to one year after study entry|Average intra-patient change in femoral neck and total hip BMD from baseline to one year after study entry|Incidence of osteopenia in the risedronate vs placebo groups at one year after study entry|Incidence of osteoporosis in the risedronate vs placebo groups at one year after study entry|Incidence of a 5% difference in intra-patient BMD scores at baseline|Serum and urine N-telopeptide and serum alkaline phosphatase at baseline and 6 months|Frequency and severity of toxicity as measured by NCI CTC version 2.0|Menopausal symptoms as measured by the Greene Climacteric Scale (GCS) at baseline, monthly during chemotherapy, at 6 months, 1 year, and 2 years after study entry|Association of baseline serum estradiol levels with permanent cessation of menses|Relationship between the subscales of the GCS (psychological, vasomotor, somatic and sexual) with type of chemotherapy, duration of chemotherapy, and menstrual cycle changes",http://ClinicalTrials.gov/show/NCT00054418,"United States, &nbsp; Canada",1,1,3,1
NCT00055770,"Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer",Completed,No Results Available,Head and Neck Cancer,Drug: docetaxel|Drug: erlotinib hydrochloride,Arthur G. James Cancer Hospital & Richard J. Solove Research Institute|National Cancer Institute (NCI),Both,Adult|Senior,Phase I|Phase II,45,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000271197|OSU-02H0084|OSU-0213|NCI-5393,03/06/2003,01/02/2003,NA,02/06/2010,01/12/2006,,01/02/2009,Maximum tolerated dose of erlotinib and docetaxel (Phase I)|Objective response (Phase II)|Response rate as measured by RECIST criteria (Phase II)|Time to tumor progression (Phase II)|Median survival (Phase II),http://ClinicalTrials.gov/show/NCT00055770,United States,1,1,2,1
NCT00056004,Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia,Completed,No Results Available,Head and Neck Cancer|Lung Cancer,Drug: zileuton,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,134,Other|NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Prevention,CDR0000271915|WSU-D-2405|WSU-093201MP4F,03/06/2003,01/09/2002,NA,4/13/2010,01/04/2010,,01/03/2009,"Bronchial dysplasia number and grade at 6 months|Biomarkers (Ki-67, Cyclin D1, bcl-2, bax, caspase-3) by immunohistochemistry at 6 and 12 months|Biomarkers (5-HETE, LTB-4) by blood and BAL levels at 6 and 12 months|Adverse events as measured by number and severity monthly",http://ClinicalTrials.gov/show/NCT00056004,United States,1,1,1,0
NCT00056407,"\REDUCE\"" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk""",Completed,Has Results,"Neoplasms, Prostate|Prostate Cancer",Drug: Dutasteride|Drug: Placebo,GlaxoSmithKline,Male,Adult|Senior,Phase III,8231,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ARI40006,03/11/2003,01/03/2003,01/05/2009,01/06/2011,01/01/2011,REDUCE,01/01/2009,"Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Crude Rate Approach)|Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Modified Crude Rate Approach)|Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Restricted Crude Rate Approach)|Number of Participants With the Indicated Gleason Score at Diagnosis|Number of Participants With HGPIN, ASAP, and Prostate Cancer at Biopsy|Volume of HGPIN at Biopsy|Percentage of Core Involved at Diagnosis|Number of Cancer-positive Cores|Treatment Alteration Score|Number of Participants Undergoing Intervention (Surgical and Non-surgical) for Prostate Cancer Treatment|Adjusted Mean Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 48|Adjusted Mean Percentage Change From Baseline in Prostate Volume at Months 24 and 48|Adjusted Mean Change From Baseline in Maximum Urinary Flow (Qmax) at Months 12, 24, 36, and 48|Number of Participants Starting Alpha Blockers to Control Benign Prostatic Hyperplasia (BPH) Symptoms|Number of Participants With at Least One Event of Acute Urinary Retention (AUR)|Number of Participants With at Least One Urinary Tract Infection (UTI)|Number of Participants With Post-biopsy Macroscopic Hematuria|Number of Participants With Post-biopsy Macroscopic Hematospermia|Overall Survival|Adjusted Mean Change From Baseline in the Benign Prostatic Hypertrohpy (BPH) Impact Index (BII) at Month 48|Adjusted Mean Change From Baseline in The Medical Outcomes Study Sleep Problems Index 6-item Standard Version (MOS Sleep-6S) at Month 48|Adjusted Mean Change From Baseline in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH CPSI) at Month 48|Adjusted Mean Change From Baseline in Quality of Life Question 8 (QOL Q8) at Month 48|Adjusted Mean Change From Baseline in the Problem Assessment Scale of the Sexual Function Index (PASSFI) at Month 48|Number of Participants With the Indicated Serum Dihydrotestosterone (DHT) Concentration at Month 48|Mean Change From Baseline in Testosterone at Month 48",http://ClinicalTrials.gov/show/NCT00056407,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Austria, &nbsp; Belarus, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Chile, &nbsp; Croatia, &nbsp; Denmark, &nbsp; Estonia, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Hungary, &nbsp; Ireland, &nbsp; Italy, &nbsp; Japan, &nbsp; Latvia, &nbsp; Lithuania, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; New Zealand, &nbsp; Norway, &nbsp; Poland, &nbsp; Portugal, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; Slovenia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; Tunisia, &nbsp; Turkey, &nbsp; Ukraine, &nbsp; United Kingdom",1,1,2,0
NCT00056966,Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases,Completed,No Results Available,Hematologic Malignancy,Drug: ANTI-CD45|Drug: CAMPATH-1H|Drug: FK506|Drug: Fludarabine|Radiation: Total Body Irradiation|Procedure: Stem cell infusion,"Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine",Both,Child|Adult|Senior,Phase I|Phase II,40,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,12472|ACHE,3/26/2003,01/11/2002,01/10/2009,12/02/2009,01/10/2009,,01/10/2009,"Assess safety and feasibility of monoclonal abs directed to CD45 and CD52 antigens, Fludarabine and low dose TBI, as a non-myeloablative preparatory regimen for allo HSCT. This will be determined by 100d Non-relapse mortality and 100d Graft rejection|To obtain a preliminary estimate of the efficacy of this therapy as defined by: Complete remission at day 100 and One-year disease free survival.",http://ClinicalTrials.gov/show/NCT00056966,United States,1,0,6,NA
NCT00057811,"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma",Completed,No Results Available,Drug/Agent Toxicity by Tissue/Organ|Leukemia|Lymphoma,Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: methylprednisolone|Drug: prednisone|Drug: rasburicase|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult,Phase II,90,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000271941|COG-ANHL01P1,04/07/2003,01/06/2004,NA,11/20/2010,01/11/2010,,01/10/2009,Toxicity|Incidence of tumor lysis syndrome|Response rate|Minimal residual disease,http://ClinicalTrials.gov/show/NCT00057811,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Puerto Rico, &nbsp; Switzerland",1,1,13,0
NCT00057876,Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Drug: gemcitabine hydrochloride|Radiation: radiation therapy,Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Radiation Therapy Oncology Group,Both,Adult|Senior,Phase III,NA,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,CDR0000278947|ECOG-E4201|RTOG-ECOG-E4201,04/07/2003,01/04/2003,NA,5/29/2009,01/01/2006,,01/05/2009,"Overall survival at 13, 20, 26, and 36 months|Objective response rate|Progression-free survival|Toxicity as measured by NCI CTC v2.0|Quality of life as measured by Functional Assessment of Cancer Treatment-Hepatobiliary Symptom Index at baseline, 6, 15, and 16 weeks, and at 9 months",http://ClinicalTrials.gov/show/NCT00057876,"United States, &nbsp; South Africa",1,1,2,1
NCT00058097,Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Completed,No Results Available,Brain and Central Nervous System Tumors,Drug: tipifarnib|Radiation: radiation therapy,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000285732|NABTT-2200|JHOC-NABTT-2200,04/07/2003,01/08/2003,NA,4/24/2009,01/04/2004,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00058097,United States,1,0,2,NA
NCT00058214,Perifosine in Treating Patients With Recurrent Prostate Cancer,Completed,No Results Available,Prostate Cancer,Drug: perifosine,California Cancer Consortium|National Cancer Institute (NCI),Male,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000287195|CCC-PHII-44|CHNMC-PHII-44-02166|NCI-5978,04/07/2003,01/03/2003,NA,10/04/2010,01/10/2010,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00058214,United States,1,0,1,NA
NCT00058357,Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery,Completed,No Results Available,"Pain|Unspecified Adult Solid Tumor, Protocol Specific",Drug: lidocaine,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase III,100,Other|NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care,CDR0000288824|NCCTG-N01CB,04/07/2003,01/05/2004,NA,11/24/2009,01/06/2006,,01/02/2009,"Pain intensity rating (NRS)|Pain as assessed by the Brief Pain Inventory-Short Form, Neuropathy Pain Scale, Subject Global Impression of Change, Pain Catastrophizing Scale, Profile of Mood States Short Form, and NCCTG Quality of Life|Incidence of each toxicity reported in each treatment period|Maximum severity reported of each toxicity|Distribution of the overall toxicity score|Proportion of patients who report a preference for lidocaine patch or placebo at study completion|Proportion of patients who terminate treatment prematurely",http://ClinicalTrials.gov/show/NCT00058357,United States,1,1,1,0
NCT00059839,Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma,Completed,No Results Available,Lymphoma,Drug: doxorubicin hydrochloride|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: vinblastine sulfate|Drug: vincristine sulfate,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult,Phase III,200,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,CDR0000298777|COG-ANHL0131,05/06/2003,01/11/2003,NA,11/20/2010,01/11/2010,,01/12/2009,Event-free survival|Toxicity|Overall survival|Disease response,http://ClinicalTrials.gov/show/NCT00059839,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Puerto Rico, &nbsp; Switzerland",1,1,6,0
NCT00059852,Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane,Completed,No Results Available,Breast Cancer,Drug: erlotinib hydrochloride|Drug: gemcitabine hydrochloride,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000298778|NCCTG-N0234,05/06/2003,01/06/2003,NA,02/04/2009,01/09/2004,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00059852,United States,1,1,2,0
NCT00060528,Sequential Vaccinations in Prostate Cancer Patients,Completed,No Results Available,Prostatic Neoplasms,Drug: Recombinant Vaccinia-PSA(L155)-TRICOM (PROSTVAC-V/TRICOM)|Drug: Recombinant Fowlpox-PSA(L155)-TRICOM (PRSTVAC-F/TRICOM)|Drug: Recombinant Fowlpox-GM-CSF,National Cancer Institute (NCI),Male,Adult|Senior,Phase II,47,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,030176|03-C-0176,05/07/2003,01/05/2003,01/10/2009,9/17/2010,01/07/2010,,01/10/2009,T cell precursor frequency as measured by Enzyme-linked ImmunoSpot Assay (ELISPOT) assay.|Clinical response,http://ClinicalTrials.gov/show/NCT00060528,United States,1,0,3,NA
NCT00061373,Adjunctive Drug Treatment for Ischemic Stroke Patients,Completed,No Results Available,Cerebrovascular Accident,"Drug: Eptifibatide in combination w Aspirin, Tinzaparin sodium",National Institute of Neurological Disorders and Stroke (NINDS),Both,Adult|Senior,Phase II,18,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,030171|03-N-0171,5/23/2003,01/05/2003,01/12/2009,9/17/2010,01/12/2009,,01/12/2009,"Symptomatic ICH, major systemic hemorrhage, or other serious adverse event related to study drug administration, including death, occurring after study drug initiation and prior to the 72-hour safety head CT.|Secondary safety outcomes will be all ICH types (fatal, symptomatic, asymptomatic), all bleeding (major, minor, insignificant), deaths, serious adverse events at 72 hrs, 5 days, and 30 days. Reperfusion on MRI and clinical improvements are also ...",http://ClinicalTrials.gov/show/NCT00061373,United States,1,1,1,0
NCT00061893,"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors",Completed,No Results Available,Sarcoma,Drug: celecoxib|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vinblastine sulfate|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult,Phase II,36,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000302409|COG-AEWS02P1,06/05/2003,01/04/2004,NA,11/20/2010,01/11/2010,,01/05/2009,Feasibility as measured by toxicity at study completion|Event-free survival at 1 to 2 years following study completion,http://ClinicalTrials.gov/show/NCT00061893,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Puerto Rico",1,1,9,0
NCT00062738,Treatment of Depression in Parkinson's Disease Trial,Completed,No Results Available,Parkinson Disease|Depression,Drug: paroxetine|Drug: nortirptyline,University of Medicine and Dentistry New Jersey|GlaxoSmithKline,Both,Adult|Senior,Phase II,52,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",4381,06/12/2003,01/06/2003,01/01/2009,09/09/2009,01/04/2009,,01/01/2009,Hamilton Depression Scale|Percent responders,http://ClinicalTrials.gov/show/NCT00062738,United States,1,1,2,1
NCT00062764,Treating Nonalcoholic Steatohepatitis With Pioglitazone,Completed,No Results Available,Hepatitis,Drug: Actos (Pioglitazone),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Both,Adult|Senior,Phase II,30,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,030212|03-DK-0212,06/12/2003,01/06/2003,NA,1/28/2010,01/02/2009,,01/02/2009,"Improvement in liver histology|Insulin sensitivity, reduction in visceral fat, liver volune and liver tests.",http://ClinicalTrials.gov/show/NCT00062764,United States,1,1,1,1
NCT00063622,Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS),Completed,No Results Available,Liver Diseases,Drug: Pioglitazone|Dietary Supplement: Vitamin E|Drug: Matching placebo,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Both,Adult|Senior,Phase III,247,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",NASH - ADULT (IND),07/01/2003,01/11/2004,01/09/2009,01/12/2010,01/01/2010,,01/06/2009,Improvement in NASH activity defined by change in standardized scoring of liver biopsies at baseline and after 96 weeks of treatment.|Liver fibrosis,http://ClinicalTrials.gov/show/NCT00063622,United States,1,1,3,1
NCT00064701,Comparative Study of Modified Release (MR) Tacrolimus/MMF in de Novo Kidney Transplant Recipients,Completed,No Results Available,Kidney Transplantation,Drug: Tacrolimus Modified Release (MR)|Drug: Tacrolimus|Drug: cyclosporine microemulsion|Drug: mycophenolate mofetil,Astellas Pharma Inc,Both,Child|Adult|Senior,Phase III,668,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,02-0-158,07/10/2003,01/06/2003,01/04/2009,5/17/2010,01/05/2009,,01/04/2009,"1 yr Efficacy Failure (composite endpoint defined as death, graft loss, having biopsy confirmed acute rejection or lost-to follow up)|1 year patient and graft survival rates|Incidence of biopsy confirmed acute rejection (Banff Grade ??­ 1) at 6 and 12 months, time to first acute rejection episode,|Requirement of anti-lymphocyte antibody therapy for treatment of rejection|Severity of acute rejection|Number of patients experiencing multiple rejection episodes|Number of clinically treated acute rejection episodes|Incidence of crossover for treatment failure,Evaluation of renal function.",http://ClinicalTrials.gov/show/NCT00064701,"United States, &nbsp; Brazil, &nbsp; Canada",1,0,4,NA
NCT00065442,Provenge?ó (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy,Completed,Has Results,Prostate Cancer,Biological: Sipuleucel-T|Biological: APC-Placebo,Dendreon,Male,Adult|Senior,Phase III,512,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",D9902B,7/23/2003,01/07/2003,01/01/2009,09/02/2010,01/09/2010,,01/01/2009,Overall Survival|Time to Objective Disease Progression,http://ClinicalTrials.gov/show/NCT00065442,"United States, &nbsp; Canada",0,NA,2,NA
NCT00066066,Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers,Completed,No Results Available,Periodontitis|Periodontal Diseases,Drug: Group 1: metronidazole|Drug: Group 2: metronidazole + amoxicillin + locally delivered|Drug: Tetracycline|Drug: Metronidazole,The Forsyth Institute|National Institute of Dental and Craniofacial Research (NIDCR),Both,Adult|Senior,Phase II,216,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NIDCR-14242|R01DE014242,08/01/2003,01/07/2003,01/07/2009,11/08/2010,01/11/2010,,01/07/2009,Change in mean attachment level,http://ClinicalTrials.gov/show/NCT00066066,United States,1,1,4,0
NCT00066469,"Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation",Completed,No Results Available,Lymphoproliferative Disorder,Biological: rituximab|Drug: cyclophosphamide|Drug: methylprednisolone|Drug: prednisone,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult,Phase II,60,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000316241|COG-ANHL0221,08/06/2003,01/04/2004,NA,11/20/2010,01/11/2010,,01/10/2009,Event-free survival at 2 years,http://ClinicalTrials.gov/show/NCT00066469,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; New Zealand",1,1,4,0
NCT00066742,Tirapazamine Combined With Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer,Completed,No Results Available,Lung Cancer,Drug: cisplatin|Drug: etoposide|Drug: tirapazamine|Radiation: radiation therapy,Southwest Oncology Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,85,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000318805|SWOG-S0222,08/06/2003,01/09/2003,NA,4/18/2009,01/08/2006,,01/01/2009,Measurability of lesions|Objective response|Best response|Performance status|Time to treatment failure|Survival,http://ClinicalTrials.gov/show/NCT00066742,United States,1,0,4,NA
NCT00066781,Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary,Completed,No Results Available,Carcinoma of Unknown Primary,Drug: gemcitabine hydrochloride|Drug: irinotecan hydrochloride,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,42,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000318830|NCCTG-N004E,08/06/2003,01/02/2004,NA,4/14/2009,01/03/2009,,01/03/2009,"Confirmed response rate (partial or complete response for 2 consecutive evaluations at least 4 weeks apart) as measured by RECIST criteria|Overall survival periodically for up to 2 years from registration|Time to disease progression periodically for up to 2 years from registration|Adverse event rates assessed by NCI common toxicity criteria for adverse events (CTCAE v3.0) at all courses|Relationship between genetic variations and the clinical outcomes of response, adverse events, survival, and time to progression at baseline",http://ClinicalTrials.gov/show/NCT00066781,United States,1,1,2,0
NCT00068770,Celecoxib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Who Are Receiving Anticonvulsant Drugs and Undergoing Radiation Therapy,Completed,No Results Available,Brain and Central Nervous System Tumors,Drug: celecoxib|Radiation: radiation therapy,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,NABTT-2100 CDR0000328117|U01CA062475|NABTT-2100|JHOC-NABTT-2100,09/10/2003,01/10/2003,NA,10/01/2010,01/10/2010,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00068770,United States,1,1,2,0
NCT00069095,A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer,Completed,No Results Available,Colorectal Cancer,Drug: capecitabine [Xeloda]|Drug: Oxaliplatin|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5 FU|Drug: Avastin|Drug: Avastin,Hoffmann-La Roche,Both,Adult|Senior,Phase III,2035,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment,NO16966,9/15/2003,,01/11/2009,2/15/2010,01/02/2010,,01/11/2009,"Non-inferiority of XELOX vs FOLFOX, with respect to time to progression or death, and superiority of Avastin vs placebo.|Overall survival, overall response rate, time to response, duration of response, time to treatment failure.|AEs, laboratory tests.",http://ClinicalTrials.gov/show/NCT00069095,"United States, &nbsp; Australia, &nbsp; Austria, &nbsp; Brazil, &nbsp; Canada, &nbsp; China, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Guatemala, &nbsp; Hong Kong, &nbsp; Hungary, &nbsp; Ireland, &nbsp; Israel, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; New Zealand, &nbsp; Norway, &nbsp; Panama, &nbsp; Portugal, &nbsp; Puerto Rico, &nbsp; Russian Federation, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; Taiwan, &nbsp; Thailand, &nbsp; Turkey, &nbsp; United Kingdom",1,1,7,1
NCT00069160,"Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer",Completed,No Results Available,Lung Neoplasms|Ovarian Neoplasms|Cervix Neoplasms|Renal Neoplasms,Drug: docetaxel|Drug: tariquidar,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,48,NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,030284|03-C-0284,9/15/2003,01/09/2003,01/12/2009,01/11/2011,01/09/2010,,01/12/2009,Pharmacokinetics|Safety|Clinical response|Impact of tariquidar on technietium Tc 99m sestamibi uptake,http://ClinicalTrials.gov/show/NCT00069160,United States,1,0,2,NA
NCT00071721,Valproate in Dementia (VALID),Completed,Has Results,Alzheimer Disease,Drug: Valproate|Drug: Placebo,Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA),Both,Adult|Senior,Phase III,313,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IA0043|1RC2AG036535|IND 67,222|ADCS Protocol ADC-022-VN",10/29/2003,01/10/2003,01/12/2009,9/24/2010,01/09/2010,,01/02/2009,"Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change Rated by the Study Clinician|Cognitive Performance Assessed by the Alzheimer's Disease Assessment Scale-cognitive Subtest (ADAS-cog)|Functional Performance Assessed by the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory|Global Severity of Dementia Using the CDR Sum of Boxes|Agitation Measured by the Cohen-Mansfield Agitation Inventory (CMAI), Community Version|Participant's Clinical Condition or Endpoint Assessed With the ADCS-Clinical Global Impression of Change (ADCS-CGIC)",http://ClinicalTrials.gov/show/NCT00071721,United States,1,1,2,1
NCT00071981,Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: incomplete Freund's adjuvant|Biological: melanoma helper peptide vaccine|Biological: multi-epitope melanoma peptide vaccine|Biological: sargramostim|Biological: tetanus peptide melanoma vaccine,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,169,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,CDR0000335055|ECOG-E1602,11/04/2003,01/03/2005,NA,7/29/2009,01/03/2009,,01/03/2009,Immune response as measured by amount of peripheral blood T-cell lymphocytes present over the first 6 weeks|Clinical response as measured by amount of helper T-cells present at week 8,http://ClinicalTrials.gov/show/NCT00071981,United States,0,NA,5,NA
NCT00072150,Bortezomib in Treating Patients With Advanced Transitional Cell Carcinoma of the Urothelium,Completed,No Results Available,Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer,Drug: bortezomib,Cancer and Leukemia Group B|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000335517|CALGB-90207,11/04/2003,01/10/2003,NA,10/01/2009,01/11/2004,,01/08/2009,,http://ClinicalTrials.gov/show/NCT00072150,United States,1,1,1,1
NCT00072306,Neoadjuvant and Adjuvant Pamidronate With Induction and Maintenance Chemotherapy in Treating Patients With Osteosarcoma,Completed,No Results Available,Sarcoma,Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: pamidronate disodium|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy,Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI),Both,Child|Adult|Senior,Phase II,75,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000339591|MSKCC-03074,11/04/2003,01/07/2003,NA,12/16/2009,01/12/2009,,01/02/2009,"Event-free survival 3 years after completion of study treatment|Prosthesis survival as assessed by prosthesis failure when surgery is required|Safety and toxicity as assessed by creatinine and creatinine clearance monthly prior to each course and for 1 year after completion of study treatment|Tumor necrosis as assessed by the Huvos grading system 12 weeks after beginning treatment, at time of definitive surgery after induction chemotherapy|Radiographic response as assessed by RECIST criteria 10 weeks after beginning treatment, after induction chemotherapy, and before definitive surgery|Correlate biological studies with clinical outcome as assessed by protocol 97-094 \Chemotherapy Resistance in Osteogenic Sarcoma) at diagnosis""",http://ClinicalTrials.gov/show/NCT00072306,United States,1,1,7,0
NCT00072449,Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma,Completed,No Results Available,Lymphoma,Biological: rituximab,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,25,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,NABTT-2201 CDR0000339737|U01CA062475|NABTT-2201,11/04/2003,01/05/2004,NA,10/01/2010,01/10/2010,,01/03/2009,Radiographic response|Progression-free survival|Overall survival|Toxicity,http://ClinicalTrials.gov/show/NCT00072449,United States,0,NA,1,1
NCT00072631,"Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer",Completed,No Results Available,Advanced Non Small Cell Lung Cancer|Failed Prior Chemotherapy,"Drug: Tarceva (Trademark) (erlotinib HCl, OSI-774)",OSI Pharmaceuticals,Both,Adult|Senior,Phase II,50,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,OSI-774-202|Dose to Rash,11/05/2003,01/08/2003,01/10/2009,11/03/2009,01/10/2009,,01/10/2009,"Feasibility of intrapatient dose escalation of erlotinib HCI to introduce a characteristic, target rash, and evaluate the effect on objective response rate|Feasibility of correlating objective response rate and duration of response to grade of rash",http://ClinicalTrials.gov/show/NCT00072631,United States,1,1,1,1
NCT00073996,"Tariquidar, Mitotane, Doxorubicin, Vincristine, and Etoposide Plus Surgery in Treating Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer",Completed,No Results Available,Adrenocortical Carcinoma,Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: mitotane|Drug: tariquidar|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,50,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000341556|NCI-04-C-0011,12/10/2003,01/12/2004,NA,11/26/2009,01/04/2008,,01/11/2009,Response rate (partial or complete)|Progression-free survival|Assessment of the extent of in vivo P-glycoprotein (Pgp) inhibition in CD56-positive cells as measured by CD56-positive cell assay with rhodamine|In vivo imaging with 99mTc-sestamibi and assessment of Pgp inhibition|Correlation of the pattern of gene expression found with the cDNA microarray with response and survival|Correlation of Pgp expression as measured by quantitative polymerase chain reaction and immunohistochemistry with response,http://ClinicalTrials.gov/show/NCT00073996,United States,1,0,8,NA
NCT00074126,CC-5013 in Treating Patients With Red Blood Cell Transfusion-Dependent Myelodysplastic Syndromes and a Cytogenetic Abnormality,Completed,No Results Available,Myelodysplastic Syndromes,Drug: lenalidomide,Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000343384|MSKCC-03085|CELGENE-CC-5013-MDS-003,12/10/2003,01/07/2003,NA,08/06/2009,01/08/2009,,01/05/2009,,http://ClinicalTrials.gov/show/NCT00074126,United States,1,1,1,0
NCT00074308,Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers,Completed,No Results Available,"Melanoma (Skin)|Unspecified Adult Solid Tumor, Protocol Specific",Biological: bevacizumab|Drug: imatinib mesylate,Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI),Both,Adult|Senior,Phase I|Phase II,64,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000343804|UPCC-03903|NCI-6006,12/10/2003,01/10/2003,NA,10/15/2009,01/11/2008,,01/10/2009,Toxicity (phase I)|Progression-free survival at 8 weeks (phase II)|Response rate at 8 weeks (phase II)|Overall survival (phase II),http://ClinicalTrials.gov/show/NCT00074308,United States,1,1,2,0
NCT00076336,Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis,Completed,No Results Available,"Hepatitis|Hepatitis B, Chronic|Cirrhosis",Drug: telbivudine|Drug: lamivudine,Novartis Pharmaceuticals,Both,Child|Adult|Senior,Phase III,232,Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLDT600A2301,1/20/2004,01/12/2003,NA,3/24/2010,01/03/2010,,01/12/2009,"Primary Outcome is a composite endpoint termed Clinical Response, defined as achievement of the following three efficacy criteria: Serum HBV DNA < 4 log10 copies/mL, Normal ALT level, Improvement or stabilization in CTP score|Time to Clinical Response; Duration of Clinical Response; Improvement, Stabilization, and Worsening in CTP score; Improvement, Stabilization, and Worsening in a modified (3-component) CTP score",http://ClinicalTrials.gov/show/NCT00076336,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; China, &nbsp; France, &nbsp; Germany, &nbsp; India, &nbsp; Israel, &nbsp; Korea, Republic of, &nbsp; Latvia, &nbsp; Malaysia, &nbsp; New Zealand, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Singapore, &nbsp; Spain, &nbsp; Taiwan, &nbsp; Thailand, &nbsp; Turkey, &nbsp; United Kingdom, &nbsp; Vietnam",1,1,2,0
NCT00077545,3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction,Completed,No Results Available,Esophageal Cancer,Drug: cisplatin|Drug: triapine,University of Chicago|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000352307|UCCRC-12765A|NCI-6285,02/10/2004,01/01/2004,NA,7/21/2009,01/12/2005,,01/07/2009,Objective response rate (complete and partial)|Duration of response|Progression-free survival|Overall survival|Toxicity|Improvement in dysphagia,http://ClinicalTrials.gov/show/NCT00077545,United States,1,0,2,NA
NCT00078403,Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV),Completed,No Results Available,HIV Infections|Hepatitis C|Liver Disease,Drug: Peginterferon alfa-2a|Drug: Ribavirin,National Institute of Allergy and Infectious Diseases (NIAID),Both,Adult|Senior,Phase II,300,NIH,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,ACTG A5178|SLAM-C|10008,2/24/2004,01/07/2004,01/02/2009,1/20/2010,01/07/2008,,01/02/2009,"Liver fibrosis (Metavir) score|HCV viral loads|Liver inflammation (Metavir) score|Safety, defined as rates and grades of anemia, neutropenia, thrombocytopenia, depression, and other psychological events, and all other high-grade signs and symptoms and laboratory values|Regimen tolerability, defined as dose modification and temporary and permanent drug discontinuation, increased symptom distress, or decreased quality of life|Adherence to study medication|HCV polymorphisms|HCV-specific immune response in intrahepatic lymphocytes|Noninvasive measures of liver fibrosis, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, albumin, and protein measurements|HIV viral load|Weight|Insulin resistance, defined as fasting glucose|Step 3 end of treatment virologic response and sustained virologic response|Use of antianorexia agents, such as megestrol and dronabinol|Use of hematologic adjuvant therapies, such as erythropoietin, granulocyte colony-stimulating factor, and granulocyte-monocyte colony-stimulating factor",http://ClinicalTrials.gov/show/NCT00078403,"United States, &nbsp; Puerto Rico",1,1,2,1
NCT00079040,"Cisplatin, Etoposide & Bevacizumab in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer",Completed,Has Results,Lung Cancer,Biological: bevacizumab|Drug: cisplatin|Drug: etoposide,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,65,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000353484|ECOG-E3501,03/08/2004,01/06/2004,01/01/2009,02/03/2010,01/02/2010,,01/01/2009,Percentage of Participants Alive and Progression-free (PF) at 6 Months|Overall Survival|Best Objective Response,http://ClinicalTrials.gov/show/NCT00079040,United States,1,1,3,0
NCT00079235,CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer,Completed,No Results Available,Lung Cancer,Drug: temsirolimus,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,55,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000355117|NCCTG-N0323,03/08/2004,01/02/2004,NA,12/03/2009,01/11/2009,,01/11/2009,Confirmed response|Progression-free survival at 24 weeks|Survival time|Time to disease progression|Effects of CCI-779 on mTOR,http://ClinicalTrials.gov/show/NCT00079235,United States,1,1,1,0
NCT00079456,CCI-779 in Treating Patients With Relapsed or Refractory Multiple Myeloma,Completed,No Results Available,Multiple Myeloma and Plasma Cell Neoplasm,Drug: temsirolimus,Arthur G. James Cancer Hospital & Richard J. Solove Research Institute|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,25,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000355767|OSU-0347|NCI-6186|OSU-2003C0090,03/08/2004,01/02/2004,NA,2/20/2010,01/08/2006,,01/03/2009,Overall response rate|Progression-free survival|Toxicity|Incidence of PTEN mutation|Pharmacodynamics,http://ClinicalTrials.gov/show/NCT00079456,United States,1,1,1,1
NCT00079482,Study of CEP-701 in Patients With Acute Myeloid Leukemia (AML),Completed,No Results Available,Acute Myeloid Leukemia,Drug: lestaurtinib|Drug: lestaurtinib,Cephalon,Both,Adult|Senior,Phase II,224,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,C701a/204/ON/US,03/08/2004,01/10/2003,01/01/2010,4/29/2010,01/04/2010,,01/03/2009,Determine whether CEP-701 given in sequence with induction chemotherapy increases the proportion of patients with relapsed AML who achieve a second complete remission or a complete remission with incomplete platelet count recovery.|- overall survival - event-free survival - remission duration - safety and tolerability of CEP-701 - pharmacokinetics of CEP-701 - CEP-701 inhibitory activity,http://ClinicalTrials.gov/show/NCT00079482,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Germany, &nbsp; Israel, &nbsp; Italy, &nbsp; New Zealand, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Sweden, &nbsp; Ukraine",1,0,2,NA
NCT00080899,Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Na??ve Prostate Cancer,Completed,No Results Available,Prostate Cancer,Drug: fenretinide,California Cancer Consortium|National Cancer Institute (NCI),Male,Child|Adult|Senior,Phase II,37,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000357312|CCC-PHII-47|NCI-6168,04/07/2004,01/06/2004,NA,10/11/2010,01/10/2010,,01/01/2009,Prostate-specific antigen response|Time to clinical progression|Toxicity,http://ClinicalTrials.gov/show/NCT00080899,United States,1,0,1,NA
NCT00082342,Transcranial Electrical Polarization to Treat Symptoms of Parkinson's Disease,Completed,No Results Available,Parkinson Disease,Device: Phoressor II (IOMED),National Institute of Neurological Disorders and Stroke (NINDS),Both,Adult|Senior,Phase II,46,NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment",030116|03-N-0116,05/06/2004,01/03/2003,NA,1/28/2010,01/02/2009,,01/02/2009,Gait speed before and after real and placebo TEP course.|UPDRS total scores before and after real TEP course and after sham TEP course. UPDRS motor scores before and after real TEP course and after sham TEP course. Rigidity scores before and after real TEP course and after placebo TEP course.,http://ClinicalTrials.gov/show/NCT00082342,United States,0,NA,1,NA
NCT00084409,Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease,Completed,No Results Available,Lung Cancer|Precancerous Condition,Drug: iloprost|Other: placebo,"University of Colorado, Denver|National Cancer Institute (NCI)",Both,Adult|Senior,Phase II,152,Other|NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Prevention,CDR0000362053|UCHSC-01279,06/10/2004,01/11/2001,NA,02/01/2010,01/04/2008,,01/01/2009,"Measures of improvement in histologic response at baseline and 6 months after completion of treatment|Change in mean, dysplastic index, and worst histologic score|Change in the proliferative intermediate marker Ki-67",http://ClinicalTrials.gov/show/NCT00084409,United States,1,1,2,0
NCT00084656,Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma,Completed,No Results Available,Intraocular Melanoma|Melanoma (Skin),Biological: ipilimumab|Biological: Tyrosinase/gp100/MART-1 Peptides,Bristol-Myers Squibb|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,75,Industry|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000365467|P30CA076292|P30CA014089|MCC-15241|MDX010-16|NCI-6446|CA184-016,06/10/2004,01/05/2004,NA,4/23/2010,01/04/2010,,01/10/2009,"First part of study: To achieve at least a 40% immune-related adverse event rate defined by the induction of Grade 1, grade 2, or acceptable grade 3 drug-related immune-related adverse events|Second part of study: To determine the time to disease relapse and to determine the rate of acceptable immune-related Grade 1, grade 2, or acceptable grade 3 drug-related immune-related adverse events|Determine incidence of drug-related irAEs (1st & 2nd part) through clinical and laboratory assessment of immune-related adverse events|Determine time to disease relapse (1st part) through diagnostic imaging assessments, including brain MRI|Determine immunologic response (1st & 2nd part) through assay of peripheral blood samples|Evaluate toxicity profile (1st & 2nd part) through clinical and laboratory assessment of adverse events",http://ClinicalTrials.gov/show/NCT00084656,United States,0,NA,2,NA
NCT00084890,Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix,Completed,No Results Available,Cervical Cancer,Drug: carboplatin|Drug: docetaxel,Wake Forest University|National Cancer Institute (NCI),Female,Adult|Senior,Phase I|Phase II,64,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000366942|CCCWFU-30102B|NCI-6949,06/10/2004,01/05/2004,NA,6/26/2009,01/04/2007,,01/06/2009,Maximum tolerated dose of docetaxel|Response rate|Time to progression|Toxicity|Quality of life,http://ClinicalTrials.gov/show/NCT00084890,United States,1,1,2,0
NCT00085098,Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary CNS Germ Cell Tumor,Completed,No Results Available,Brain and Central Nervous System Tumors,Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Radiation: radiation therapy,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult,Phase III,225,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment,CDR0000367294|COG-ACNS0232,06/10/2004,01/01/2007,NA,11/20/2010,01/11/2010,,01/08/2009,Event-free survival|Response|Toxicity|Quality of life,http://ClinicalTrials.gov/show/NCT00085098,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Puerto Rico",1,1,6,0
NCT00085124,Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,Completed,No Results Available,Leukemia,Biological: oblimersen sodium|Drug: cytarabine|Drug: daunorubicin hydrochloride,Cancer and Leukemia Group B|National Cancer Institute (NCI),Both,Adult|Senior,Phase III,500,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,CDR0000367323|CALGB-10201,06/10/2004,01/12/2003,NA,02/06/2010,01/10/2006,,01/12/2009,Overall survival|Complete remission during remission induction therapy|Disease-free survival|Event-free survival,http://ClinicalTrials.gov/show/NCT00085124,United States,1,0,3,NA
NCT00085332,Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer),Completed,No Results Available,Endometrial Cancer,Drug: docetaxel,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Child|Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000368634|GOG-0129N,06/10/2004,01/07/2004,NA,02/05/2009,01/09/2004,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00085332,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Japan, &nbsp; Norway",1,1,1,0
NCT00087113,Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix,Completed,No Results Available,Cervical Cancer,Drug: pemetrexed disodium,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Child|Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000372923|GOG-0127T|LILLY-H3E-US-JMGS,07/08/2004,01/08/2004,NA,02/05/2009,01/04/2006,,01/01/2009,Antitumor activity|Toxicity,http://ClinicalTrials.gov/show/NCT00087113,United States,1,1,1,1
NCT00087373,Vaccine Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: recombinant fowlpox-TRICOM vaccine,University of Chicago|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,28,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000374979|UCCRC-12759A|NCI-6038,07/08/2004,01/06/2004,NA,3/13/2010,01/08/2006,,01/06/2009,"Safety and tolerability|Local response rate (complete or partial response, stable or progressive disease)|Overall clinical response as measured by RECIST criteria|Change in mRNA expression of B7-1, LFA-3, and/or ICAM-1in the tumor microenvironment and correlate with response|Change in tumor-associated T cells and correlate with response|Time to tumor progression",http://ClinicalTrials.gov/show/NCT00087373,United States,0,NA,1,NA
NCT00087672,A Phase II Study of CC-5013 in Myelofibrosis,Completed,No Results Available,Myelofibrosis,Drug: CC-5013,M.D. Anderson Cancer Center|Celgene Corporation,Both,Child|Adult|Senior,Phase II,41,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2003-0648,07/12/2004,01/07/2004,01/02/2009,8/31/2009,01/08/2009,,01/02/2009,Efficacy of CC-5013 in myelofibrosis.,http://ClinicalTrials.gov/show/NCT00087672,United States,1,1,1,1
NCT00088010,Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer,Completed,No Results Available,"Osteoporosis, Postmenopausal",Drug: Arzoxifene|Drug: Placebo,Eli Lilly and Company,Female,Adult|Senior,Phase III,9369,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",8536|H4Z-MC-GJAD,7/19/2004,01/06/2004,01/11/2009,5/27/2010,01/05/2010,,01/06/2009,Effects of arzoxifene on bone fractures and bone mass|Effects of arzoxifene on getting breast cancer|The safety of arzoxifene and any side effects|Effects of arzoxifene on certain types of cardiovascular events|Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health|Effects of arzoxifene on the uterus|Effects of arzoxifene on cognition|Effects of arzoxifene on back pain,http://ClinicalTrials.gov/show/NCT00088010,United States,1,0,2,NA
NCT00088374,17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease,Completed,No Results Available,Hippel-Lindau Disease|Kidney Cancer,Drug: 17 allylamino-17-demethoxygeldanamycin|Drug: 18 FDG|Drug: [15-O] H2O|Drug: EPL diluent,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,9,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,040238|04-C-0238,7/23/2004,01/07/2004,01/01/2009,12/23/2010,01/12/2010,,01/01/2009,Response of renal tumors after 3 courses of study therapy.|Effect of 17-N-allylamino-17-demethoxygeldanamycin (17AAG) on nonrenal tumors.,http://ClinicalTrials.gov/show/NCT00088374,United States,1,0,4,NA
NCT00088556,"Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer",Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: TLK286|Drug: carboplatin|Drug: paclitaxel,Telik,Both,Adult|Senior,Phase I|Phase II,100,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Masking: Open Label|Primary Purpose: Treatment,TLK286.2023,7/29/2004,01/08/2004,01/05/2009,5/27/2009,01/05/2009,,01/05/2009,,http://ClinicalTrials.gov/show/NCT00088556,United States,1,0,3,NA
NCT00088985,"Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer",Completed,No Results Available,Breast Cancer,Biological: therapeutic autologous dendritic cells|Biological: trastuzumab|Drug: vinorelbine ditartrate,UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI),Female,Adult|Senior,Phase II,37,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000377732|UNC-LCCC-0310|UNC-GCRC-2102-ORC,08/04/2004,01/01/2004,NA,4/18/2009,01/04/2009,,01/04/2009,Response rate by RECIST criteria at 6 months following treatment|Immune response by ELISPOT tetramer at 3 months following treatment,http://ClinicalTrials.gov/show/NCT00088985,United States,1,0,3,NA
NCT00089154,Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,Completed,No Results Available,Leukemia|Lymphoma,Biological: apolizumab,Chronic Lymphocytic Leukemia Research Consortium|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000378072|CLLRC-OSU-0410|NCI-6257|OSU-0410,08/04/2004,01/08/2004,NA,02/06/2010,01/09/2005,,01/09/2009,"Overall response rate (compete and partial response)|Safety and toxicity as assessed by NCI CTCAE v3.0|Time to progression|Disease-free survival|Correlation of pharmacokinetic clearance and 1D10 antigen density with leukemic or lymphoma cells, clinical response, and frequency and severity of observed toxicities|Correlation of presence of reactive oxygen species and specific signaling pathways' promotion of drug-mediated apoptosis in vitro and in vivo in primary leukemic or lymphoma cells with clinical response|Cellular properties that convey resistance in vivo|Spontaneous and apolizumab-induced apoptosis|Bcl-2 and superoxide dismutase|Lysis sensitivity",http://ClinicalTrials.gov/show/NCT00089154,United States,0,NA,1,NA
NCT00090103,Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: dutasteride|Drug: tamsulosin,GlaxoSmithKline,Male,Adult|Senior,Phase III,4844,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",ARI40005,8/24/2004,01/11/2003,01/09/2009,6/17/2010,01/06/2010,,01/09/2009,"Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.|Number of Participants With AUR or BPH-related Surgery|Number of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4|The Number of Participants With Each of the Five Components of BPH Clinical Progression|Number of Events of Symptom Deterioration at the Indicated Time Periods|Number of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria|Number of Participants With an Event of Post-baseline BPH-related Hematospermia|Adjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12, 24, 36, and 48|Adjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12, 24, 36, and 48|Adjusted Mean Percent Change From Baseline in Prostate Volume at Months 12, 24, 36, and 48|Adjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12, 24, 36, and 48|Number of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit|Number of \Yes\"" Responses to the Question: \""Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned\""?.|Number of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit|Number of \""Yes\"" Responses to the Question: \""Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?\""|Number of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI",http://ClinicalTrials.gov/show/NCT00090103,"United States, &nbsp; Argentina, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Estonia, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Hungary, &nbsp; Iceland, &nbsp; Israel, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Lithuania, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Philippines, &nbsp; Poland, &nbsp; Portugal, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Taiwan, &nbsp; Thailand, &nbsp; Tunisia, &nbsp; Turkey, &nbsp; United Kingdom",1,1,2,0
NCT00090987,Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma,Completed,No Results Available,Sarcoma,Drug: imatinib mesylate,AIDS Associated Malignancies Clinical Trials Consortium|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,30,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000380955|AMC-042,09/07/2004,01/06/2005,NA,12/05/2009,01/10/2007,,01/12/2009,Clinical response|Inhibition of platelet-derived growth factor-receptor as assessed by immunohistochemistry|Cytokine profiles before and after imatinib therapy|Pharmacokinetic profile of imatinib and antiretrovirals|Mechanisms of primary and secondary resistance to imatinib therapy|Viral transcription profile of Kaposi's sarcoma-associated herpesvirus,http://ClinicalTrials.gov/show/NCT00090987,United States,1,1,1,1
NCT00091897,Rituximab to Treat Stiff Person Syndrome,Completed,No Results Available,Stiff Person Syndrome,Drug: Rituximab,National Institute of Neurological Disorders and Stroke (NINDS),Both,Adult|Senior,Phase II,24,NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",040287|04-N-0287,9/18/2004,01/09/2004,NA,1/28/2010,01/05/2009,,01/05/2009,"To evaluate the efficacy, safety of the chimeric monoclonal antibody Rituximab to deplete B lymphocytes in patients with Stiff Person Syndrome with high anti-GAD antibodies.|The Heightened Sensitivity Scale will be used as a secondary outcome measure.",http://ClinicalTrials.gov/show/NCT00091897,United States,1,1,1,1
NCT00093431,Sorafenib in Treating Patients With Metastatic Prostate Cancer,Completed,No Results Available,Prostate Cancer,Drug: sorafenib tosylate,National Cancer Institute (NCI),Male,Adult|Senior,Phase II,46,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000387958|NCI-04-C-0262|NCI-6594,10/06/2004,01/09/2004,NA,12/05/2009,01/01/2009,,01/04/2009,"Progression-free survival at 4 months by clinical, radiographic, and prostate-specific antigen (PSA) criteria|Proteomics|PSA|Pharmacokinetics|Molecular effects",http://ClinicalTrials.gov/show/NCT00093431,United States,1,1,1,0
NCT00093847,Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression,Completed,No Results Available,Depression,Drug: S-adenosyl methione (SAMe)|Drug: Placebo,National Institute of Mental Health (NIMH),Both,Adult|Senior,Phase III,80,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment",K23 MH069629|DATR AK-TNET1,10/06/2004,01/05/2004,01/02/2009,03/10/2009,01/03/2009,,01/02/2009,Depressive scales|Self-report depression questionnaires,http://ClinicalTrials.gov/show/NCT00093847,United States,1,0,2,NA
NCT00094055,Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer,Completed,No Results Available,Thyroid Neoplasms,Drug: AG013736,Pfizer,Both,Adult|Senior,Phase II,60,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,A4061014,10/08/2004,01/09/2004,01/01/2009,9/24/2009,01/09/2009,,01/01/2009,"Response rate of AG 013736 in patients with 131 I cancer|As measured by the overall response rate|As measured by the complete response (CR)|And as by partial response (PR) by RECIST|Time to completion is estimated at 12 months|Determine progression-free survival (PFS)|Determine duration of response|Determine overall survival, population pharmacokinetic analyses|Determine the safety profile of AG 013736|Explore relationships between clinical response and plasma soluble proteins",http://ClinicalTrials.gov/show/NCT00094055,United States,1,0,1,NA
NCT00094172,Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis,Completed,No Results Available,Multiple Sclerosis,Drug: Atorvastatin|Drug: Placebo,National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network,Both,Adult,Phase II,83,NIH|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",DAIT ITN020AI,10/14/2004,01/05/2005,01/05/2009,8/23/2010,01/01/2008,STAYCIS,01/05/2009,"The proportion of participants who develop at least three new T2 lesions with or without Gd+ enhancement (in any combination), or one clinical exacerbation, at anytime during the 12-month treatment phase compared to baseline|Incidence of adverse events|Proportion of participants who are diagnosed with MS according to the McDonald criteria during treatment phase|Proportion of participants who are diagnosed with MS according to the McDonald criteria through end of follow-up phase",http://ClinicalTrials.gov/show/NCT00094172,"United States, &nbsp; Canada",1,1,2,1
NCT00094653,"MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma",Completed,No Results Available,Melanoma|Metastases,Drug: MDX-010 (anti-CTLA4) monoclonal antibody|Biological: MDX-1379 Melanoma Peptide Vaccine,Bristol-Myers Squibb,Both,Adult|Senior,Phase III,676,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",MDX010-20|CA184-002,10/21/2004,01/09/2004,01/10/2009,09/10/2010,01/04/2010,,01/08/2009,Comparison of overall survival of patients administered MDX-010 in combination with gp 100 melanoma peptide vaccine versus those administered gp 100 melanoma peptide vaccine alone|Determination of Best overall response rate (BORR)|Major durable response rate|duration of response|progression free survival|time to progression|health-related Quality of Life|Comparison of overall survial of patients administered MDX-010 in combination with gp100 melanoma vaccine vs MDX-010 monotherapy and patients administered vaccine monotherapy vs MDX-010 monotherpay,http://ClinicalTrials.gov/show/NCT00094653,"United States, &nbsp; Argentina, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; Netherlands, &nbsp; South Africa, &nbsp; Switzerland, &nbsp; United Kingdom",1,0,2,NA
NCT00095147,Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis,Completed,No Results Available,Rheumatoid Arthritis,Drug: Abatacept + Methotrexate|Drug: Infliximab + Methotrexate|Drug: Placebo + Methotrexate|Drug: Abatacept,Bristol-Myers Squibb,Both,Adult|Senior,Phase III,400,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IM101-043,11/01/2004,01/02/2005,01/07/2009,6/17/2010,01/06/2010,,01/07/2009,To demonstrate that the Abatacept in combination with Methotraexate will demonstrate a greater reduction in disease activity than placebo in combination with methotrexate as measured by the Disease Activity Score (das28)|Assess the safety and long-term tolerability of Abatacept in subjects who will continue in the long-term extention|To demonstrate that infliximab in combination with methotrexate will demonstrate a greater reduction in disease activity than placebo in combination with methotrexate (mtx) as measured by the disease activity score (DASE28)|Assess the immunogenicity of abatacept in combionation with methotrexate,http://ClinicalTrials.gov/show/NCT00095147,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Brazil, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Peru, &nbsp; Poland, &nbsp; Puerto Rico, &nbsp; Russian Federation, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland",1,1,4,0
NCT00095563,Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers,Completed,No Results Available,Head and Neck Cancer,Drug: lapatinib ditosylate,"Princess Margaret Hospital, Canada|National Cancer Institute (NCI)",Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000394174|PMH-PHL-028|NCI-6701,11/05/2004,01/11/2004,NA,12/01/2009,01/01/2006,,01/06/2009,Objective response rate (complete response and partial response)|Objective response duration|Stable disease rate|Stable disease duration|Progression-free survival at 6 months and 1 year|Overall survival at 6 months and 1 year|Median survival|Safety and tolerability,http://ClinicalTrials.gov/show/NCT00095563,"United States, &nbsp; Canada",1,1,1,1
NCT00095979,Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer,Completed,No Results Available,Endometrial Cancer,Drug: ixabepilone,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Child|Adult|Senior,Phase II,51,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000391849|GOG-0129P,11/09/2004,01/05/2005,NA,08/08/2009,01/12/2007,,01/07/2009,Frequency and duration of objective response|Frequency and severity of observed adverse effects|Survival time|Duration of progression-free survival,http://ClinicalTrials.gov/show/NCT00095979,United States,1,1,1,1
NCT00096070,"Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer",Completed,No Results Available,Pancreatic Cancer,Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: oxaliplatin|Radiation: radiation therapy,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,50,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000391191|NCCTG-N0349,11/09/2004,01/12/2004,NA,03/10/2009,01/03/2009,,01/03/2009,Overall survival at 6 and 12 months|Survival time|Confirmed tumor response (complete and partial response)|Time to disease progression|Duration of response|Time to treatment failure,http://ClinicalTrials.gov/show/NCT00096070,United States,1,1,4,0
NCT00096109,17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: tanespimycin,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Female,Adult|Senior,Phase II,37,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000391198|WSU-C-2803|NCI-6552,11/09/2004,01/09/2004,NA,4/13/2010,01/04/2010,,01/11/2009,Response rate|Progression-free survival|Correlation of HER2/neu status with response,http://ClinicalTrials.gov/show/NCT00096109,United States,1,0,1,NA
NCT00096382,"Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma",Completed,No Results Available,Melanoma (Skin),Biological: aldesleukin|Biological: filgrastim|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,116,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000393480|NCI-04-C-0288|NCI-7025|NCI-PRMC-P6273,11/09/2004,01/09/2004,NA,02/06/2009,01/01/2007,,01/01/2009,Complete clinical tumor regression|Safety|Survival,http://ClinicalTrials.gov/show/NCT00096382,United States,1,0,7,NA
NCT00096434,Sorafenib in Treating Patients With Metastatic Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: sorafenib tosylate,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000393224|NCCTG-N0336,11/09/2004,01/09/2004,NA,2/21/2009,01/02/2009,,01/02/2009,,http://ClinicalTrials.gov/show/NCT00096434,United States,1,1,1,0
NCT00097786,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: nateglinide|Drug: valsartan,Novartis Pharmaceuticals,Both,Adult|Senior,Phase III,9518,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",CDJN608B2302,11/30/2004,01/01/2002,01/10/2009,6/23/2010,01/06/2010,Navigator,01/10/2009,"Time to having a cardiovascular or neurologic event, including: death from a cardiovascular event, heart attack, stroke, hospitalization for chest pain or heart failure, or procedure to open a blockage in an arterial blood vessel.|Risk of developing diabetes|Time to having a cardiovascular or neurologic event, including: death from a cardiovascular event, heart attack, stroke, or hospitalization for heart failure.",http://ClinicalTrials.gov/show/NCT00097786,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; China, &nbsp; Colombia, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Ecuador, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Guatemala, &nbsp; Hong Kong, &nbsp; Hungary, &nbsp; Italy, &nbsp; Malaysia, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Peru, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Singapore, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; Taiwan, &nbsp; Turkey, &nbsp; United Kingdom, &nbsp; Uruguay",1,1,2,0
NCT00100815,"Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer",Completed,No Results Available,Pancreatic Cancer,Biological: bevacizumab|Drug: capecitabine|Drug: gemcitabine hydrochloride,Roswell Park Cancer Institute,Both,Adult|Senior,Phase II,35,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000409556|RPCI-I-19903|GENENTECH-RPCI-I-19903,01/06/2005,01/08/2004,NA,11/17/2009,01/11/2009,,01/02/2009,Progression-free survival|Toxicity|Quality of life|Clinical response,http://ClinicalTrials.gov/show/NCT00100815,United States,1,1,3,0
NCT00100945,Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer,Completed,No Results Available,Esophageal Cancer,Drug: gefitinib|Procedure: adjuvant therapy,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,72,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000407534|NCCTG-N0342,01/07/2005,01/07/2005,NA,10/13/2009,01/10/2009,,01/10/2009,1-year overall survival rate|Survival time|Disease-free survival|Time to disease recurrence|Time to treatment failure|Quality of life|Toxicity,http://ClinicalTrials.gov/show/NCT00100945,United States,1,1,2,1
NCT00101036,Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery,Completed,No Results Available,Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer,Drug: lapatinib ditosylate,California Cancer Consortium|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000406604|CCC-PHII-53|NCI-6674|PCI-04091,01/07/2005,01/01/2005,01/01/2009,10/11/2010,01/10/2010,,01/01/2009,Anti-tumor activity by response rate based on tumor measurements every 8 weeks|Overall survival every 4 weeks during study treatment|Time to progression every 4 weeks during study treatment|Disease control rate every 4 weeks during study treatment,http://ClinicalTrials.gov/show/NCT00101036,United States,1,1,1,0
NCT00101127,"Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma",Completed,No Results Available,Sarcoma,Biological: filgrastim|Biological: pegfilgrastim|Drug: docetaxel|Drug: gemcitabine hydrochloride,Gynecologic Oncology Group|National Cancer Institute (NCI),Female,Adult|Senior,Phase II,NA,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000405892|GOG-0087L,01/07/2005,01/12/2003,NA,2/13/2009,01/06/2006,,01/01/2009,Antitumor activity|Toxicity,http://ClinicalTrials.gov/show/NCT00101127,United States,1,1,4,0
NCT00102596,Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor,Completed,No Results Available,Essential Tremor,Drug: 1-Octanol,National Institute of Neurological Disorders and Stroke (NINDS),Both,Adult|Senior,Phase II,50,NIH,Interventional,Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,050092|05-N-0092,1/30/2005,01/01/2005,01/09/2009,5/29/2010,01/09/2009,,01/09/2009,1-octanol concentration-time data to determine pharmacokinetic. Assess bioequivalence between the two formulations based on the ratio of the peak concentrations and the ratio of the areas under the concentration-time curves for the 2 formulation...|Tremor severity based on accelerometric data will be assessed along with safety based on intoxication ratings and EKG monitoring.,http://ClinicalTrials.gov/show/NCT00102596,United States,1,0,1,NA
NCT00103727,Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: Talnetant,GlaxoSmithKline,Both,Adult,Phase II,NA,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",SB-223412/093,2/14/2005,01/12/2004,01/01/2009,01/06/2011,01/01/2011,,01/01/2009,"The primary outcome measure is change in the Positive and Negative Syndrome Scale (PANSS) at Week 6 compared to baseline values.|The secondary measures assess both efficacy (cognition, depression) as well as a variety of safety/tolerability endpoints (adverse events, motor function, laboratory measures).",http://ClinicalTrials.gov/show/NCT00103727,United States,1,0,1,NA
NCT00105027,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,Completed,Has Results,"Macular Edema, Cystoid|Retinal Vein Occlusion",Other: Standard Care|Drug: intravitreal triamcinolone injection|Drug: intravitreal triamcinolone injection,Allergan|National Eye Institute (NEI),Both,Adult|Senior,Phase III,682,Industry|NIH,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NEI-99|5U10EY014351-05|5U10EY014404|5U10EY014352,03/03/2005,01/10/2004,01/02/2009,12/16/2010,01/12/2010,SCORE,01/02/2009,The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit|Changes From Baseline in Best-corrected ETDRS Visual Acuity Score|Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography|Adverse Ocular Outcomes,http://ClinicalTrials.gov/show/NCT00105027,United States,1,1,3,0
NCT00107783,Long-Term Study of Nitisinone to Treat Alkaptonuria,Completed,Has Results,Alkaptonuria,Drug: Nitisinone (NTBC),National Human Genome Research Institute (NHGRI),Both,Adult|Senior,Phase II,40,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,050076|05-HG-0076,04/07/2005,01/01/2005,01/04/2009,12/20/2010,01/12/2010,,01/04/2009,Change in Total ROM Worse Hip.|Change in Schober's Test|Change in Functional Reach Assessment|Change in Timed Get up and go|Change in 6 Minute Walk Test (6MWT),http://ClinicalTrials.gov/show/NCT00107783,United States,1,1,1,1
NCT00108550,Chronic Low Back Pain Research Project,Completed,No Results Available,Chronic Low Back Pain,Drug: gabapentin|Drug: Inert placebo,Department of Veterans Affairs,Both,Adult|Senior,Phase II,115,U.S. Fed,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLNA-013-04S,4/15/2005,01/10/2004,01/09/2009,12/08/2010,01/12/2010,,01/07/2009,Mean pain intensity (Descriptor Differential Scale) at exit|Oswestry Disability Index|SF-36|Quality of Well-Being,http://ClinicalTrials.gov/show/NCT00108550,United States,1,1,2,1
NCT00109473,Trial of Growth Hormone Therapy in Pediatric Crohn's Disease,Completed,No Results Available,Crohn's Disease,"Drug: Somatropin, E-coli Derived","Children's Hospital Medical Center, Cincinnati|Genentech",Both,Child|Adult|Senior,Phase II,22,Other|Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CCHMC IRB #: 04-12-06|FDA IND#: 71344,4/28/2005,01/04/2005,01/08/2009,08/10/2010,01/08/2010,,01/07/2009,The primary endpoint will be the CD histologic index of severity (CDHIS)|Serum IGF-1|Colon crypt epithelial cell (CEC) proliferation labeling index|IMPACT III|Pediatric Crohn's disease Activity Index|Total corticosteroid use|Intra-abdominal fat|Height velocity|Fecal Calprotectin,http://ClinicalTrials.gov/show/NCT00109473,United States,1,1,1,0
NCT00111657,Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout,Completed,No Results Available,Gout,Biological: Pegloticase,Duke University|Savient Pharmaceuticals,Both,Adult|Senior,Phase II,30,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,FD-R-02537,5/24/2005,01/12/2004,01/07/2009,10/07/2010,01/10/2010,,01/07/2009,"Reduction in plasma uric acid to less than 6 mg/dL|Clinical response will be evaluated, including the frequency of gout flares, number and distribution of swollen/tender joints, change in size of tophi, change in functional status|In a subset of subjects who volunteer separately, change in uric acid pool size will be assessed by a method that involves infusion of uric acid labeled with N15, a stable (nonradioactive) isotope of nitrogen.|Reduction of the ratio of uric acid:creatinine in urine|Development of antibodies to PEG-uricase|Pharmacokinetics of PEG-uricase",http://ClinicalTrials.gov/show/NCT00111657,United States,0,NA,1,1
NCT00111917,Beryllium Infliximab Study: Clinical Interventional Trial,Completed,No Results Available,Berylliosis|Beryllium Disease,Drug: Infliximab,"Maier, Lisa, M.D.|Centocor, Inc.",Both,Adult|Senior,Phase I|Phase II,13,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NJ202|HS1862,5/26/2005,01/02/2005,01/01/2009,02/06/2009,01/02/2009,BISCIT,01/01/2009,arterial alveolar oxygen gradient (A-adO2) at end exercise|airflow|lung volume|diffusing capacity (DLCO)|profusion of small opacities on chest x-ray|dyspnea score|quality of life (QOL) questionnaires,http://ClinicalTrials.gov/show/NCT00111917,United States,1,1,1,1
NCT00112580,MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery,Completed,No Results Available,Pancreatic Cancer,Biological: ipilimumab,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,82,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000430666|NCI-05-C-0141|NCI-P6557|MDX-010-24,06/02/2005,01/07/2005,NA,9/21/2010,01/08/2009,,01/08/2009,Clinical response (complete and partial)|Incidence of autoimmunity,http://ClinicalTrials.gov/show/NCT00112580,United States,0,NA,1,NA
NCT00112606,Lenalidomide in Treating Patients With Stage IV Eye Melanoma,Completed,No Results Available,Intraocular Melanoma,Drug: lenalidomide,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,38,NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000430670|NCI-05-C-0095|NCI-P6501,06/02/2005,01/04/2005,NA,4/21/2009,01/04/2008,,01/04/2009,Clinical response rate (complete and partial response)|Toxicity,http://ClinicalTrials.gov/show/NCT00112606,United States,1,1,1,1
NCT00112749,Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer,Completed,No Results Available,Breast Cancer|Fatigue,Biological: infliximab|Other: Clinical Assessment|Other: Self-report questionnaires|Other: Immune Assessment,"University of California, Los Angeles|National Cancer Institute (NCI)|American Cancer Society",Female,Adult,Phase II,6,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care,CDR0000428460|P30CA016042|UCLA-0410033-01,06/02/2005,01/02/2005,01/01/2009,11/05/2010,01/11/2010,,01/01/2009,"Fatigue as measured by the fatigue symptom inventory (FSI) at baseline and after completion of study treatment|Fatigue as measured by multidimensional fatigue symptom inventory (MFSI) at baseline and after completion of study|Proinflammatory cytokines as measured by interleukin-1 receptor antagonist, interleukin 6, and tumor necrosis factor at baseline and after completion of study treatment",http://ClinicalTrials.gov/show/NCT00112749,United States,0,NA,4,1
NCT00113230,Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer,Completed,Has Results,Rectal Cancer,"Drug: Avastin (Bevacizumab, RHUMAB VEGF)|Drug: Capecitabine|Radiation: Radiation Therapy",M.D. Anderson Cancer Center|Genentech,Both,Adult|Senior,Phase II,25,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2003-0832,06/06/2005,01/02/2005,01/01/2009,10/13/2009,01/10/2009,,01/01/2009,Pathologic Local Tumor Response,http://ClinicalTrials.gov/show/NCT00113230,United States,1,1,3,1
NCT00113269,"Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients",Completed,No Results Available,Kidney Transplantation,Drug: basiliximab|Drug: rabbit anti-thymocyte globulin|Drug: tacrolimus|Drug: alemtuzumab,Astellas Pharma Inc,Both,Adult|Senior,Phase IV,502,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,20-04-003,06/07/2005,01/05/2005,01/03/2009,4/17/2009,01/04/2009,INTAC,01/03/2009,The incidence of biopsy-confirmed acute rejection|Patient and graft survival rates,http://ClinicalTrials.gov/show/NCT00113269,United States,1,0,4,NA
NCT00113360,RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma,Completed,Has Results,Neuroendocrine Carcinoma|Islet Cell Carcinoma,Drug: RAD001|Drug: Octreotide Depot,M.D. Anderson Cancer Center|Novartis Pharmaceuticals,Both,Adult|Senior,Phase II,67,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2004-0597,06/07/2005,01/01/2005,01/07/2009,11/08/2010,01/11/2010,,01/07/2009,Progression Free Survival (PFS),http://ClinicalTrials.gov/show/NCT00113360,United States,1,1,2,1
NCT00113386,Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer,Completed,No Results Available,Lung Cancer,Biological: filgrastim|Biological: pegfilgrastim|Drug: cisplatin|Drug: docetaxel|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy,Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group,Both,Adult|Senior,Phase III,574,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,CDR0000429479|RTOG-0412|SWOG-S0332|CALGB-RTOG-0412|ECOG-RTOG-0412|NCCTG-RTOG-0412,06/07/2005,01/04/2005,NA,12/26/2009,01/02/2009,,01/02/2009,"Comparison of overall survival|Comparison of progression-free survival|Comparison of median survival time|Comparison of treatment toxicity rates|Comparison of clinical and pathologic response rates|Comparison of overall survival and progression-free survival between patients with and without pathologic complete response|Association of molecular markers and overall survival, progression-free survival and response|Change in patient-reported functional status",http://ClinicalTrials.gov/show/NCT00113386,United States,1,1,8,0
NCT00113399,Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery,Completed,No Results Available,Head and Neck Cancer,Biological: filgrastim|Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Drug: paclitaxel|Radiation: radiation therapy,Radiation Therapy Oncology Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase III,240,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment,CDR0000429480|RTOG-0421|ECOG-R0421,06/07/2005,01/04/2005,NA,2/24/2009,01/02/2009,,01/02/2009,"Survival|Progression-free survival|Grade 5 toxicity rate|Quality of life as assessed by the immediate (acute) side effects of treatment at 3 months|Quality of life as assessed by the late side effects of treatment at 6, 12, 24, and 36 months|Quality-adjusted survival",http://ClinicalTrials.gov/show/NCT00113399,United States,1,1,6,0
NCT00113516,A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer,Completed,Has Results,Non-small Cell Lung Cancer,Drug: carboplatin|Drug: paclitaxel|Drug: sunitinib,Pfizer,Both,Adult|Senior,Phase II,84,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,A6181057,06/08/2005,01/09/2005,01/03/2009,5/14/2010,01/05/2010,,01/03/2009,"Proportion of Subjects Surviving at One Year|Progression-free Survival (PFS)|Time to Tumor Progression (TTP)|Duration of Response (DR)|Number of Subjects With Overall Confirmed Objective Disease Response|Overall Survival (OS)|Trough Plasma Concentration (Ctrough) of Sunitinib|Ctrough of SU-012662 (Sunitinib's Metabolite)|Ctrough of Total Drug (Sunitinib + SU-012662)|Dose-Corrected Ctrough of Sunitinib|Dose-Corrected Ctrough of SU-012662 (Sunitinib's Metabolite)|Dose-Corrected Ctrough of Total Drug (Sunitinib + SU-012662)|Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Concentration at Baseline|VEGFR3 Ratio to Baseline at Each Time Point|VEGF-C Concentration at Baseline|VEGF-C Ratio to Baseline at Each Time Point|Soluble E-Selectin at Baseline|Soluble E-Selectin Ratio to Baseline at Each Time Point|VEGFR3 at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|VEGFR3 Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|VEGF-C at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|VEGF-C Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|Soluble E-Selectin at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|Soluble E-Selectin Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD)|Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline|Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline|Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline|Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline|Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline|Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline Changes From Baseline|Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline Changes From Baseline|Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline|Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline|Immunohistochemical Staining of Paraffin Embedded Tumor Tissue|Correlation of Polymorphisms in c-Kit, Flt-3 and c-Fms to Safety of Sunitinib|Change From Baseline in Health Related Quality of Life (HRQOL) and Lung Cancer Related Symptoms as Assessed With the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)|Change From Baseline in HRQOL and Lung Cancer Related Symptoms as Assessed With the EORTC QLQ Lung Cancer Module (QLQ-LC13)",http://ClinicalTrials.gov/show/NCT00113516,"United States, &nbsp; Canada, &nbsp; France",1,1,3,1
NCT00113568,Safety Study of XP12B in Women With Menorrhagia,Completed,Has Results,Menorrhagia|Heavy Menstrual Bleeding,Drug: Tranexamic acid tablets (XP12B),Ferring Pharmaceuticals,Female,Adult,Phase III,784,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,XP12B-MR-302,06/08/2005,01/06/2005,01/05/2009,06/09/2010,01/06/2010,,01/05/2009,Number of Subjects With at Least One Adverse Event During the Study|Number of Subjects With at Least One Possibly Treatment-Related Adverse Event During the Study|Number of Subjects With at Least One Probably Treatment-Related Adverse Event During the Study|Number of Subjects With at Least One Definitely Treatment-Related Adverse Event During the Study|Number of Subjects With at Least One Serious Adverse Event During the Study|Number of Subjects With at Least One Life-Threatening Adverse Event During the Study|Number of Subjects With Adverse Events That Led to Discontinuation From the Study|Number of Subjects With Any Thrombotic or Thromboembolic Adverse Event During the Study|Number of Subjects Who Died During the Study,http://ClinicalTrials.gov/show/NCT00113568,United States,1,1,1,1
NCT00113919,UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex?ó) in Multiple Myeloma Patients,Completed,No Results Available,Multiple Myeloma,Drug: Busulfex?ó,University of Arkansas,Both,Adult|Senior,Phase I|Phase II,14,Other,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2003-25,06/10/2005,01/06/2004,01/10/2009,6/29/2010,01/06/2010,,01/10/2009,"To determine the maximal dose of Busulfex?ó that can be given in a two, three, or four day periods with acceptable toxicity|To perform pharmacokinetic (PK) studies to evaluate inter-individual variability and relationship to toxicities.",http://ClinicalTrials.gov/show/NCT00113919,United States,1,1,1,1
NCT00114634,Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome,Completed,No Results Available,Smith-Lemli-Opitz Syndrome,Drug: Cholesterol Suspension,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Both,Child,Phase II,13,NIH,Interventional,Primary Purpose: Treatment,050168|05-CH-0168,6/15/2005,01/06/2005,01/02/2009,11/25/2009,01/11/2009,,01/02/2009,"Hyperactivity subscale of the Abberrant Behavior Checklist (ABC).|ABC subscales - inappropriate speech, lethargy, stereotypy, and irritability; Time of caretake tolerance.",http://ClinicalTrials.gov/show/NCT00114634,United States,1,0,1,NA
NCT00116207,An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes,Completed,No Results Available,Diabetic Autonomic Neuropathy,"Drug: allopurinal, alpha lipoic acid (ALA), nicotinamide",University of Michigan|Juvenile Diabetes Research Foundation,Both,Adult,Phase III,50,Other,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,IRB:2002-0460,6/27/2005,01/01/2000,01/12/2009,7/27/2010,01/07/2010,,01/09/2009,Retention Index (RI)|Endothelial function|8-epi prostaglandin F2alpha|CRP|Adverse events,http://ClinicalTrials.gov/show/NCT00116207,United States,1,0,1,NA
NCT00116857,Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors,Completed,No Results Available,"Cardiovascular Diseases|Depression|Heart Diseases|Myocardial Infarction|Angina, Unstable",Drug: Sertraline/omega-3|Drug: Sertraline/Corn Oil,"National Heart, Lung, and Blood Institute (NHLBI)",Both,Adult|Senior,Phase III,122,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",186|R01 HL76808,6/30/2005,01/02/2005,01/11/2009,11/05/2010,01/02/2009,,01/06/2009,Depression interview and self-report inventory|Procoagulant and proinflammatory markers and plasma levels of sertraline and omega-3 from blood draws,http://ClinicalTrials.gov/show/NCT00116857,United States,1,1,2,0
NCT00117286,Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Degarelix,Ferring Pharmaceuticals,Male,Adult|Senior,Phase II|Phase III,57,Industry,Interventional,Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,FE200486 CS14A,6/30/2005,01/03/2005,01/11/2009,9/29/2010,01/09/2010,,01/09/2009,Participants With Markedly Abnormal Change in Vital Signs and Body Weight|Liver Function Tests,http://ClinicalTrials.gov/show/NCT00117286,"United States, &nbsp; Canada",1,1,1,1
NCT00118898,Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults,Completed,Has Results,HIV Infections,Drug: Abacavir/Lamivudine|Drug: Atazanavir|Drug: Efavirenz|Drug: Emtricitabine/Tenofovir disoproxil fumarate|Drug: Ritonavir|Drug: Abacavir/Lamivudine placebo|Drug: Emtricitabine/Tenofovir disoproxil fumarate placebo,AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID),Both,Child|Adult|Senior,Phase III,1864,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ACTG A5202|1U01AI068636|ACTG 5224s,07/07/2005,01/09/2005,01/11/2009,01/10/2011,01/01/2011,,01/11/2009,"Time From Randomization to Virologic Failure|Time From Treatment Dispensation to a Grade 3/4 Safety Event|Time From Treatment Dispensation to Treatment Modification|Time From Treatment Dispensation to Regimen Failure (First Occurrence of Virologic Failure or Treatment Modification)|The Number of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL|Number of Participants With HIV-1 RNA Levels Less Than 200 Copies/mL|Change in CD4 Count (Cells/mm3) From Baseline|Number of Participants With Virologic Failure and Emergence of Major Resistance|Number of Participants Experiencing Certain Targeted Clinical Events, Including Death, AIDS-defining Illness, and HIV-1 Related Events.|Change in Fasting Total Cholesterol Level From Baseline|Change in Fasting High-density Lipoprotein (HDL) Cholesterol Level From Baseline|Change in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Level From Baseline|Change in Fasting Triglyceride Level From Baseline",http://ClinicalTrials.gov/show/NCT00118898,"United States, &nbsp; Puerto Rico",1,1,7,0
NCT00121836,A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: capecitabine [Xeloda]|Drug: Avastin,Hoffmann-La Roche,Female,Adult|Senior,Phase IV,108,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ML18527,7/18/2005,,01/07/2009,10/15/2009,01/10/2009,,01/07/2009,"Overall survival, defined as the time from date of first study medication to death, across the study phases|Safety profile, using NCI CTCAE version 3.0 (AEs, laboratory parameters, vital signs, premature withdrawals)",http://ClinicalTrials.gov/show/NCT00121836,United States,1,1,2,1
NCT00122681,Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18,Completed,Has Results,Human Papillomavirus (HPV) Infection|Papillomavirus Vaccines|Cervical Neoplasia,Biological: Cervarix?ºÑ|Biological: Havrix?ºÑ-based investigational formulation,GlaxoSmithKline,Female,Child|Adult,Phase III,18729,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",580299/008,7/20/2005,01/05/2004,01/11/2009,01/06/2011,01/01/2011,,01/11/2009,"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection|Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection|Number of Subjects Reporting Solicited Local and General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events|Number of Subjects Reporting Serious Adverse Events (SAEs)|Number of Subjects Reporting New Onset of Chronic Disease (NOCDs)|Number of Subjects Reporting Medically Significant Conditions|Number of Subjects With Outcome of Pregnancies, Overall and Stratified by Initial (Month 0) HPV-16/18 DNA Status and According to HPV-16 or -18 Serostatus|Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18|Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18|Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types|Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types|Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Subjects Reporting Persistent Infection (12-month Definition) With HPV-16 or HPV-18|Number of Subjects Reporting Persistent Infection (12-month Definition) With HPV-16 or HPV-18|Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Subjects With Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen|Number of Seropositive Subjects for Anti-HPV-16 and Anti-HPV-18 Antibody Titers by ELISA in the Immunogenicity Subset, According to Initial (Month 0) HPV-16 or HPV-18 Serostatus|Anti-HPV-16 and Anti-HPV-18 ELISA Titers in the Immunogenicity Subset|HPV-16 and HPV-18 Seroconversion (V5/J4 Monoclonal Inhibition Test)|HPV-16 and HPV-18 Geometric Mean Titers (GMT) (V5/J4 Monoclonal Inhibition Test)|Number of Subjects Seropositive for Anti-HPV-16 and Anti-HPV-18 Antibodies Using Pseudovirion Based Neutralizing Assay (PBNA)|Titers for Anti-HPV-16 and Anti-HPV-18 Antibodies Using Pseudovirion Based Neutralizing Assay (PBNA)",http://ClinicalTrials.gov/show/NCT00122681,"United States, &nbsp; Australia, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Finland, &nbsp; Germany, &nbsp; Italy, &nbsp; Mexico, &nbsp; Philippines, &nbsp; Spain, &nbsp; Taiwan, &nbsp; Thailand, &nbsp; United Kingdom",0,NA,2,NA
NCT00124982,Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy,Completed,No Results Available,Rheumatoid Arthritis,Drug: Abatacept,Bristol-Myers Squibb,Both,Adult|Senior,Phase III,535,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IM101-064,6/30/2005,01/10/2005,01/08/2009,7/28/2010,01/06/2010,,01/08/2009,Assess the long term safety and tolerability of abatacept in subjects who have completed the initial 6 month open label treatment period|Assess efficacy and immunogenicity of abatacept in combination with non-biologic DMARDs|Assess maintenance of response in subjects who eliminate or reduce their dose of concomitant non-biologic background DMARD therapy,http://ClinicalTrials.gov/show/NCT00124982,"United States, &nbsp; Belgium, &nbsp; Czech Republic, &nbsp; France, &nbsp; Germany, &nbsp; Ireland, &nbsp; Italy, &nbsp; Mexico, &nbsp; Spain, &nbsp; United Kingdom",1,1,1,0
NCT00125190,Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency,Completed,Has Results,Insulin-Like Growth Factor-1 Deficiency|Growth Disorders,Drug: rhIGF-1 (mecasermin) for a period of 86 weeks,Ipsen,Both,Child|Adult|Senior,Phase II|Phase III,45,Industry,Interventional,Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MS308,7/27/2005,01/07/2005,01/01/2009,9/14/2010,01/09/2010,,01/01/2009,Height Velocity Over the Study Period 0 - 34 Weeks [Intent to Treat Population]|Height Velocity Over the Study Period 34 - 86 Weeks [Intent to Treat Population]|Changes in Height Standard Deviation (SD) Score Over the Study Period 0 - 34 Weeks [Intent to Treat Population]|Changes in Height Standard Deviation (SD) Score Over the Study Period 34 - 86 Weeks|Bone Age - Change From Pretreatment Minus Change in Chronological Age Over the Study Period 0 - 86 Weeks [Intent to Treat Population]|Percent Changes in Serum Concentration of Insulin-like Growth Factor Binding-1 (IGFBP-1) From Baseline to Week 86|Percent Changes in Serum Concentration of Insulin-like Growth Factor Binding-2 (IGFBP-2) From Baseline to Week 86|Percent Changes in Serum Concentration of Insulin-like Growth Factor Binding-3 (IGFBP-3) From Baseline to Week 86|Percent Changes in Serum Concentration of Acid Labile Subunit (ALS) From Baseline to Week 86|rhIGF-1 Doses Required to Achieve the Serum IGF-1 Targets With Measures Taken at Each Study Visit,http://ClinicalTrials.gov/show/NCT00125190,United States,1,1,1,1
NCT00127933,XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: capecitabine [Xeloda]|Drug: Taxotere|Drug: Herceptin,Hoffmann-La Roche,Female,Adult|Senior,Phase IV,157,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ML18530,08/05/2005,,01/07/2009,11/16/2009,01/11/2009,,01/07/2009,"Pathological complete response in primary breast tumor at time of definitive surgery|Complete pathological response, overall clinical response, local recurrence, disease-free and overall survival.|AEs, laboratory parameters",http://ClinicalTrials.gov/show/NCT00127933,United States,1,1,3,1
NCT00128193,Leprosy Skin Test Antigens Trial,Completed,Has Results,Leprosy,"Drug: MLSA-LAM|Drug: MLCwA|Drug: RT-23|Drug: Placebo|Drug: Tuberculin, Purified Protein Derivative (Tubersol?ó)",National Institute of Allergy and Infectious Diseases (NIAID),Both,Adult,Phase II,260,NIH,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic",00-002,08/05/2005,01/04/2002,01/10/2009,12/02/2010,01/08/2010,,01/10/2009,Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram|Number of Participants With the Reaction of Itching to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram|Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Microgram|Number of Participants With the Reaction of Itching to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Microgram|Number of Participants With Reactions to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Microgram|Number of Participants With Reaction of Itching to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Microgram|Number of Participants With Reactions to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Microgram|Number of Participants With the Reaction of Itching to the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Microgram|Number of Participants With Reactions to the Antigen Purified Protein Derivative (PPD)|Number of Participants With the Reaction of Itching to the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms|Mean Diameter of Erythema at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Erythema at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 0.1 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen M. Leprae Cell Wall Antigen (MLCwA) at Doses of 1.0 Micrograms|Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Mean Diameter of Induration at Site of Injection With the Antigen Purified Protein Derivative (PPD)|Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 0.1 Microgram.|Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 1.0 Microgram.|Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 0.1 Microgram.|Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 1.0 Microgram.|Number of Participants With QuantiFERON Responses Based on the Presence or Absence of Induration at the Injection Site for the Antigen PPD.|Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 0.1 Microgram|Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLSA-LAM at Doses of 1.0 Microgram|Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 0.1 Microgram|Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen MLCwA at Doses of 1.0 Microgram|Number of Participants Positive for Phenolic Glycolipid-1 (PGL-1) by QuantiFERON Results and the Presence or Absence of Induration at the Injection Site for the Antigen PPD,http://ClinicalTrials.gov/show/NCT00128193,"United States, &nbsp; Nepal",1,0,5,NA
NCT00130923,Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder,Completed,No Results Available,Schizophrenia|Psychotic Disorders|Substance Abuse|Alcohol Abuse,Drug: risperidone long-acting|Drug: oral risperidone,"Dartmouth-Hitchcock Medical Center|Janssen, LP",Both,Adult,Phase IV,95,Other|Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,17359|RIS-EMR-4032,8/15/2005,01/09/2005,01/07/2010,11/02/2010,01/11/2010,,01/06/2009,"Alcohol use assessed by the Timeline Followback scale|Other substance use as assessed by the Timeline Followback scale|Clinical symptoms, global functioning, cognition, and extrapyramidal system effects",http://ClinicalTrials.gov/show/NCT00130923,United States,1,1,2,1
NCT00132314,Long-Acting Injectable Risperidone in the Treatment of Schizophrenia,Completed,No Results Available,Schizoaffective Disorder|Schizophrenia,Drug: IM risperidone|Drug: oral antipsychotic medication,Department of Veterans Affairs,Both,Adult|Senior,Phase III,382,U.S. Fed,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,555,8/17/2005,01/09/2006,01/09/2009,12/11/2009,01/12/2009,,01/09/2009,Time to re-hospitalization,http://ClinicalTrials.gov/show/NCT00132314,United States,1,1,2,0
NCT00134043,Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer,Completed,No Results Available,Head and Neck Cancer,Drug: vorinostat,Arthur G. James Cancer Hospital & Richard J. Solove Research Institute|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,25,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000439450|OSU-04110|NCI-6902,8/22/2005,01/12/2005,NA,02/06/2010,01/01/2007,,01/03/2009,Objective response rate|Toxicity,http://ClinicalTrials.gov/show/NCT00134043,United States,1,1,1,1
NCT00136760,Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia,Completed,No Results Available,Schizophrenia and Disorders With Psychotic Features|Tobacco Use Disorder,Drug: Bupropion|Drug: Contingent reinforcement plus placebo|Drug: non-contingent reinforcement plus bupropion|Drug: Non-contingent reinforcement plus placebo,National Institute on Drug Abuse (NIDA)|Brown University,Both,Adult|Senior,Phase II,57,NIH|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment",NIDA-17566-1|R01-17566-1,8/25/2005,01/09/2003,01/03/2009,10/01/2010,01/10/2010,,01/03/2009,Urinary cotinine|Cigarettes smoked per day|Withdrawal severity|Craving|Adverse events,http://ClinicalTrials.gov/show/NCT00136760,United States,1,1,4,1
NCT00138125,Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: Faslodex|Biological: Herceptin,"Translational Oncology Research International|University of California, Los Angeles|Genentech|AstraZeneca",Female,Adult|Senior,Phase II,3,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000439421|UCLA-0502057-01|TORI-B-04|441350-RI-78322,8/29/2005,01/04/2005,01/12/2009,09/01/2010,01/09/2010,,01/09/2009,Progression-free survival|overall objective response rate|time to tumor progression|duration of response|overall survival|clinical benefit (CR + PR + SD > 6 months),http://ClinicalTrials.gov/show/NCT00138125,United States,1,1,2,1
NCT00139841,Safety and Efficacy of Treanda?ºÑ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: Bendamustine HCl,Cephalon,Both,Adult|Senior,Phase III,103,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SDX-105-03,8/18/2005,01/10/2005,01/10/2009,5/31/2010,01/05/2010,,01/05/2009,Assess the overall response rate (ORR = CR + CRu + PR) and duration of response (DR) to a regimen of bendamustine in patients who are refractory to rituximab therapy.|??Ñ assess the safety profile of Treanda in this patient population. ??Ñ assess the duration of progression-free survival (PFS). ??Ñ estimate the basic pharmacokinetic parameters ??Ñ assess the effects of plasma concentrations,http://ClinicalTrials.gov/show/NCT00139841,"United States, &nbsp; Canada, &nbsp; Puerto Rico",1,0,1,NA
NCT00145418,Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Oxaliplatin + Docetaxel,"Oncology Specialists, S.C.|Sanofi-Synthelabo",Both,Adult|Senior,Phase II,15,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,OX-03-137 (0409),09/01/2005,01/02/2005,01/03/2010,03/03/2010,01/04/2008,,01/08/2009,Response rate|Time to progression|Duration of response|Toxicity,http://ClinicalTrials.gov/show/NCT00145418,United States,1,1,1,0
NCT00145535,SOLX Titanium Sapphire Laser for Trabeculoplasty,Completed,No Results Available,"Glaucoma|Glaucoma, Open Angle",Device: SOLX Titanium Sapphire Laser (TiSaLT)|Device: Argon Laser Trabeculoplasty (ALT),"SOLX, Inc.",Both,Adult|Senior,Phase III,120,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SLX41,09/01/2005,01/05/2004,01/06/2009,1/28/2010,01/07/2009,,01/06/2009,Intraocular Pressure (IOP)|Adverse event frequency,http://ClinicalTrials.gov/show/NCT00145535,"United States, &nbsp; Canada, &nbsp; Israel, &nbsp; Spain",0,NA,2,NA
NCT00146848,PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy,Completed,Has Results,Heart Failure,Device: Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices,Boston Scientific Corporation,Both,Adult|Senior,Phase IV,1742,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,CR-CA-100604-H|PEGASUS,09/02/2005,01/12/2004,01/02/2009,9/21/2010,01/09/2010,PEGASUS CRT,01/01/2009,Clinical Composite Score|Change in Quality of Life|Change in Self Assessed Physical Activity,http://ClinicalTrials.gov/show/NCT00146848,United States,0,NA,1,NA
NCT00147966,Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study),Completed,Has Results,Rheumatoid Arthritis,Drug: rituximab,"University of California, San Diego|Genentech",Both,Adult|Senior,Phase II,24,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,41569,09/02/2005,01/06/2008,01/12/2009,3/22/2010,01/06/2008,,01/12/2009,American College of Rheumatology (ACR) 20 at Week 12,http://ClinicalTrials.gov/show/NCT00147966,United States,1,1,1,1
NCT00148954,RIGHT: Rhythm ID Going Head-to-Head Trial,Completed,No Results Available,Tachycardia,Device: Implantable Cardioverter Defibrillator,Boston Scientific Corporation,Both,Adult|Senior,Phase IV,2000,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,CR-CA-032105-T|RIGHT,09/06/2005,01/07/2005,01/07/2010,8/17/2010,01/08/2010,,01/03/2009,Time to first inappropriate ventricular tachycardia (VT)/ventricular fibrillation (VF) therapy (shock or antitachycardia pacing [ATP]) after the Pre-Discharge visit|Time to first inappropriate shock using Guidant and competitive ICDs|Positive predictive value (PPV) of VT/VF discrimination algorithms found in Guidant and competitive ICDs|Time to first inappropriate therapy for which the discrimination algorithm found in Guidant and competitive ICDs inappropriately classified the episode,http://ClinicalTrials.gov/show/NCT00148954,United States,0,NA,1,NA
NCT00151892,Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis,Completed,Has Results,"Colitis, Ulcerative",Drug: SPD476|Drug: Asacol,Shire Pharmaceutical Development,Both,Adult|Senior,Phase III,829,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SPD476-304,09/07/2005,01/11/2007,01/10/2009,9/24/2010,01/09/2010,,01/09/2009,Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months|Withdrawal Due to Relapse of UC|Endoscopic Remission of UC With No or Mild Symptoms at 6 Months|Change From Baseline in Modified Ulcerative Colitis Disease Activity Index (UCDAI) Score at 6 Months|Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Total Score,http://ClinicalTrials.gov/show/NCT00151892,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; New Zealand, &nbsp; Peru, &nbsp; Poland, &nbsp; Portugal, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Singapore, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Taiwan, &nbsp; United Kingdom",1,0,2,NA
NCT00157157,Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients,Completed,No Results Available,Hemophilia A,"Drug: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM)|Drug: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM)|Drug: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM)",Baxter Healthcare Corporation,Both,Child,Phase III,50,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,60103,09/09/2005,01/04/2004,01/09/2009,9/16/2009,01/09/2009,,01/09/2009,"To assess the immunogenicity of rAHF PFM by determining the risk of factor VIII inhibitor development|To assess in vivo incremental recovery of rAHF PFM|To evaluate the hemostatic efficacy of rAHF PFM in the management of acute bleeding events|To evaluate the hemostatic efficacy of rAHF PFM during surgical prophylaxis, if surgery is required|To assess the safety of rAHF-PFM",http://ClinicalTrials.gov/show/NCT00157157,"United States, &nbsp; Austria, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Puerto Rico, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",0,NA,3,NA
NCT00158184,Prescription Opioid Effects in Abusers Versus Non-Abusers,Completed,No Results Available,Opioid-Related Disorders|Substance-Related Disorders,Drug: oxycodone,National Institute on Drug Abuse (NIDA),Both,Adult,Phase II,96,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Basic Science",NIDA-16759-1|R01 DA16759-01|DPMC,09/08/2005,01/06/2004,01/06/2009,7/15/2009,01/07/2009,,01/06/2009,Progressive ratio breakpoint value,http://ClinicalTrials.gov/show/NCT00158184,United States,1,1,1,0
NCT00159432,"Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer",Completed,No Results Available,Colorectal Cancer,"Drug: bevacizumab, capecitabine, oxaliplatin",USC/Norris Comprehensive Cancer Center|Hoffmann-La Roche|Genentech,Both,Adult|Senior,Phase II,53,Other|Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,3C-04-10,09/07/2005,01/02/2005,NA,7/23/2010,01/07/2010,,01/06/2009,"To determine the median time for progression free survival in patients with advanced colorectal cancer treated with a combination of capecitabine, oxaliplatin and bevacizumab.|To assess the toxicity of this regimen.|To confirm the association of TS, TP, DPD, and ERCC1 expression levels in tumor tissue with clinical outcome.|To identify other molecular predictors of response, survival, and toxicity to this combination of chemotherapy.|Confirm the association between TS, TP, DPD, and ERCC1 mRNA expression levels in tumor tissue and progression free survival, time to progression on this regimen, response, and overall survival",http://ClinicalTrials.gov/show/NCT00159432,United States,1,1,1,0
NCT00160199,Safety and Efficacy of PROMETRIUM?ó Capsules in Induction of Secretory Conversion,Completed,Has Results,Secondary Amenorrhea,Drug: PROMETRIUM?ó 300 mg|Drug: PROMETRIUM?ó 400 mg,Solvay Pharmaceuticals,Female,Adult,Phase IV,240,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,S168.4.002,09/08/2005,01/11/2004,01/02/2009,6/30/2010,01/06/2010,,01/02/2009,Secretory Conversion of the Endometrium|Number of Subjects With Withdrawal Bleeding|Maximum Intensity of Withdrawal Bleeding After Any Cycle|The Duration of Withdrawal Bleeding After the First Treatment Cycle|The Duration of Withdrawal Bleeding After Second Treatment Cycle|Time to Withdrawal Bleeding After First Treatment Cycle|Time to Withdrawal Bleeding After Second Treatment Cycle,http://ClinicalTrials.gov/show/NCT00160199,United States,1,1,2,1
NCT00161213,Gemcitabine and Imatinib Mesylate as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Drug: gemcitabine hydrochloride|Drug: imatinib mesylate,University of Medicine and Dentistry New Jersey|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,42,Other|NIH,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Masking: Open Label|Primary Purpose: Treatment,CDR0000539409|P30CA072720|CINJ-070501|CINJ-5324|CINJ-NJ1205,09/08/2005,01/09/2005,01/07/2009,11/12/2009,01/11/2009,,01/07/2009,Time to disease progression|Response rate|Percentage of patients who survive 1 year or more,http://ClinicalTrials.gov/show/NCT00161213,United States,1,1,2,0
NCT00162266,CTLA4IG With Methotrexate- Phase IIB - Long Term,Completed,No Results Available,Rheumatoid Arthritis,Drug: Abatacept|Drug: Abatacept|Drug: Placebo,Bristol-Myers Squibb,Both,Adult|Senior,Phase II,219,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",IM101-100,09/09/2005,01/10/2000,01/09/2009,5/26/2010,01/05/2010,,01/09/2009,Abatacept combined with methotrexate will have greater clinical efficacy than the use of methotrexate alone in subjects with active rheumatoid arthritis|ACR 50 and 70 will be evaluated,http://ClinicalTrials.gov/show/NCT00162266,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Belgium, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Ireland, &nbsp; Netherlands, &nbsp; South Africa, &nbsp; United Kingdom",1,1,3,1
NCT00163020,17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies,Completed,No Results Available,Preterm Birth,Drug: 17-alpha-hydroxyprogesterone caproate injectable|Drug: Placebo,Obstetrix Medical Group,Female,Adult,Phase II|Phase III,321,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OBX0003|IND # 59-536,09/09/2005,01/11/2004,01/08/2009,10/06/2010,01/10/2010,170HP,01/08/2009,"Respiratory distress syndrome|Use of oxygen therapy at 28 days of newborn life|Neonatal sepsis|Pneumonia|Intraventricular hemorrhage grade 3 or 4|Periventricular leukomalacia|Necrotizing enterocolitis requiring surgery|Retinopathy of prematurity|Newborn asphyxia with ischemic injury of brain, heart, kidneys, or liver|Individual components of neonatal morbidity enumerated above|Twins: Delivery prior to 28 weeks (wks), 32 wks, 37 wks|Triplets: Delivery prior to 28 wks, 32 wks, 35 wks|Gestational age at delivery|Birthweight|Drop-out rates|Side effects requiring cessation of therapy|Specific side effects (such as: nausea, vomiting, injection site soreness, vaginal bleeding, vaginal discharge, decreased fetal movement, rash, pruritis)",http://ClinicalTrials.gov/show/NCT00163020,United States,1,1,2,0
NCT00166114,"Depression, Epinephrine, and Platelet Function",Completed,No Results Available,Major Depressive Disorder,Drug: escitalopram or desipramine,"Emory University|National Heart, Lung, and Blood Institute (NHLBI)",Both,Adult,Phase IV,90,Other|NIH,Interventional,"Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1 RO1 HL65523-01A2,9/13/2005,01/02/2002,01/01/2009,1/14/2009,01/01/2009,,01/01/2009,"Study endpoints will include measures of psychiatric function|biologic parameters|Measurement of psychiatric function before and after treatment will include:|Measurement of early life abuse: Early Trauma Inventory, Childhood Trauma Questionnaire|Measurements of mood and anxiety symptoms: Hamilton Depression Rating Scale,|Zung Depression Rating Scale|Measurements of HPA axis activity: adrenocorticotropin and cortisol.|Measurements of immunoinflammatory mediators and lipid metabolism|Measurement of oxidative stress|Measurements of platelet function:|platelet autocrine stimulation release of platelet serotonin (whole blood concentrations) and platelet 5HT2 receptor binding,|adenosine disphosphate (ADP) release, and|thromboxane A2 production (as detected by serum and urine thromboxane B2|increased platelet-surface epitopes, as detected by flow cytometric analysis of:|platelet expression of the GPIIb/IIIa receptor, as detected by the monoclonal antibody (mAb), anti-LIBS binding- measurement taken at pre-treatment, post week 1 treatment, and post-treatment.|platelet aggregation [as detected by diminished half-maximal aggregation concentration (AC50) of platelet agonists - taken at pre-treatment, week 1 of treatment, and post-treatment.|A Holter monitor will be utilized to determine Heart Rate variability- measurement taken pre-treatment and post-treatment.",http://ClinicalTrials.gov/show/NCT00166114,United States,1,1,1,0
NCT00167492,Enteric Coated Myfortic for Liver Transplant Recipients,Completed,No Results Available,Liver Transplantation,Drug: Myfortic,"The University of Texas Health Science Center, Houston|Novartis",Both,Adult|Senior,Phase IV,50,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HSC-MS-05-0197|Novartis Pharmaceuticals|CERL080A-US11,09/09/2005,01/09/2005,01/02/2009,5/14/2009,01/05/2009,,01/02/2009,Rate of rejection|Rate of gastrointestinal side-effects|Levels of calcineurin inhibitors|Renal function|Relationship of dose to biologic monitoring of immunosuppression,http://ClinicalTrials.gov/show/NCT00167492,United States,1,1,1,1
NCT00167544,Randomized Trial of Hydrocortisone in Very Preterm High-Risk Infants,Completed,No Results Available,Bronchopulmonary Dysplasia|Encephalomalacia|Premature Birth,Drug: Hydrocortisone|Drug: Placebo,"The University of Texas Health Science Center, Houston|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)",Both,Child,Phase II,64,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",K23NS048152-2|1 K23NS 048152-01A1|HSC-MS-05-0218,09/09/2005,01/11/2005,01/04/2009,4/29/2009,01/04/2009,,01/01/2009,Total cerebral volume as measured by volumetric brain MRI|Regional brain volumes|Duration of mechanical ventilation|Duration of oxygen requirement|Diagnosis of BPD,http://ClinicalTrials.gov/show/NCT00167544,United States,1,1,2,0
NCT00171197,"A 1-year Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Liver Iron Concentration of Deferasirox and Deferoxamine in Children and Adults With Sickle Cell Disease and Transfusional Hemosiderosis",Completed,No Results Available,Sickle Cell Disease,Drug: Deferasirox,Novartis Pharmaceuticals,Both,Child|Adult|Senior,Phase II,170,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CICL670A109E1,09/12/2005,01/05/2004,NA,12/09/2010,01/12/2010,,01/07/2009,Evaluate the long-term safety and tolerability profile of ICL670|Allow patients to continue iron chelation therapy|Estimate the absolute and relative change of liver iron content (LIC) and total body iron excretion (TBIE)|Evaluate the relationship between hepatic iron and potential surrogate markers,http://ClinicalTrials.gov/show/NCT00171197,"United States, &nbsp; Canada, &nbsp; France, &nbsp; Italy, &nbsp; United Kingdom",1,1,1,1
NCT00176644,Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer,Completed,No Results Available,Prostate Cancer,Drug: Transdermal Estradiol,University of Medicine and Dentistry New Jersey,Male,Adult|Senior,Phase II,33,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,5247|CINJ 080419,9/13/2005,01/05/2005,01/10/2009,12/10/2009,01/12/2009,,01/10/2009,"To evaluate the antitumor activity, as measured by PSA response rate in patients with hormone and chemotherapy refractory prostate cancer.|To evaluate the toxicities of the use of transdermal estradiol in patients with HRPC after initial chemotherapy. To measure quality of life of patients receiving therapy with the Functional Assessment of Cancer Therapy-Prostate scale (FACT-P).|To evaluate measurable disease response in patients with hormone and chemotherapy refractory prostate cancer.|To evaluate time to progression.|To assess the plateau level of estradiol that is attained with the dose of 0.4mg/day given via transdermal estradiol patch and in addition, assess the response on testosterone in the androgen resistant population.",http://ClinicalTrials.gov/show/NCT00176644,United States,1,1,1,1
NCT00176878,Stem Cell Transplant for Bone Marrow Failure Syndromes,Completed,Has Results,Diamond-Blackfan Anemia|Kostmann's Neutropenia|Shwachman-Diamond Syndrome,Procedure: Stem cell transplant|Drug: Fludarabine monophosphate|Procedure: Total lymphoid irradiation|Drug: Busulfan|Biological: anti-thymocyte globulin,"Masonic Cancer Center, University of Minnesota",Both,Child|Adult,Phase II|Phase III,10,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MT2000-18|9504M09637,09/12/2005,01/06/2000,01/03/2009,9/30/2010,01/09/2010,,01/03/2009,Number of Patients Alive (Survival) at 2 Years|Number of Patients Alive at Three Years (Survival)|Number of Patients With Succcessful Engraftment After Transplantation|Number of Patients With Grade 2-4 Acute Graft Versus Host Disease|Number of Patients With Chronic Graft Versus Host Disease|Number of Patients With Disease Recurrence,http://ClinicalTrials.gov/show/NCT00176878,United States,1,0,5,NA
NCT00183274,Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR,Completed,No Results Available,Anxiety Disorders,Drug: Venlafaxine XR|Drug: Placebo,National Institute of Mental Health (NIMH),Both,Adult|Senior,Phase IV,330,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01 MH65963|DSIR 83-ATAS,09/12/2005,01/01/2004,01/09/2009,10/12/2010,01/09/2008,,01/09/2009,"Relapse of GAD|Anxiety, depression, and GAD symptoms",http://ClinicalTrials.gov/show/NCT00183274,United States,1,1,2,1
NCT00183469,Maintenance Treatment of Bipolar Depression,Completed,No Results Available,Bipolar Disorder|Depression,Drug: Lamotrigine (LAM)|Drug: Divalproex (DIV)|Drug: Placebo,National Institute of Mental Health (NIMH),Both,Adult|Senior,Phase IV,170,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P20 MH68662|DSIR 83-ATSO,9/13/2005,01/12/2004,01/04/2009,6/30/2009,01/06/2009,,01/02/2009,Rates of response to treatment regimen,http://ClinicalTrials.gov/show/NCT00183469,United States,1,1,3,1
NCT00183794,Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma,Completed,No Results Available,Ovarian Carcinoma|Peritoneal Neoplasms,Drug: Docetaxel and Gemcitabine,USC/Norris Comprehensive Cancer Center,Female,Adult|Senior,Phase II,20,Other,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,5GYN-02-2,09/09/2005,01/11/2002,01/05/2009,11/03/2010,01/11/2010,,01/05/2009,The percent of patients who experience a response to docetaxel + gemcitabine,http://ClinicalTrials.gov/show/NCT00183794,United States,1,1,1,0
NCT00185588,Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Drug: PTK787/ZK 222584|Drug: Gemcitabine,Stanford University|Novartis,Both,Adult|Senior,Phase I|Phase II,32,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PANC0002|95533|CPTK787AUS08|PANC0002,09/12/2005,01/10/2004,01/12/2009,6/18/2010,01/06/2010,,01/01/2009,"Optimal safe and tolerable dose (MTD) of gemcitabine in combination with the 1250 mg continuous once daily dose of PTK/ZK.|Efficacy, as reflected in objective response rate, of the PTK/ZK and gemcitabine combination in patients with advanced pancreatic cancer.|Efficacy, as reflected in time to progression, of the PTK/ZK and gemcitabine combination in patients with advanced pancreatic cancer.|Efficacy, as reflected in overall survival, of the PTK/ZK and gemcitabine combination in patients with advanced pancreatic cancer.|Effect of the PTK/ZK and gemcitabine combination on DCE-MRI determinants of tumor perfusion.",http://ClinicalTrials.gov/show/NCT00185588,United States,1,0,2,NA
NCT00187889,"EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia",Completed,No Results Available,Ischemic Heart Disease,Drug: eplerenone,"University of Florida|National Heart, Lung, and Blood Institute (NHLBI)|Pfizer",Female,Adult|Senior,Phase IV,53,Other|NIH|Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,EWISE|R01 H267173-01,09/10/2005,01/08/2004,01/02/2009,8/26/2010,01/08/2010,,01/02/2009,Epicardial coronary artery endothelial function (adjusted) at Week 16 comparing the eplerenone group to the placebo group|Microvascular coronary endothelial function (adjusted) at Week 16 comparing the eplerenone group to the placebo group,http://ClinicalTrials.gov/show/NCT00187889,United States,1,1,1,0
NCT00189436,Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children,Completed,No Results Available,Asthma,Drug: Nebulized Budesonide|Drug: Usual care (albuterol with or without oral steroid),West Penn Allegheny Health System|AstraZeneca,Both,Child,Phase IV,61,Other|Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,BUD ER 3425|RC - 3425,09/12/2005,01/03/2003,01/01/2009,5/28/2009,01/05/2009,BudER,01/01/2009,Wheezing/Asthma/Bronchospasm relapse rate|Urinary Cortisol|Spirometry readings,http://ClinicalTrials.gov/show/NCT00189436,United States,1,1,2,0
NCT00190684,"Long-Term, Open Label Atomoxetine Study",Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: atomoxetine,Eli Lilly and Company,Both,Child|Adult,Phase III,1553,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,4331|B4Z-MC-LYAI,09/12/2005,01/08/2000,01/10/2009,12/15/2010,01/12/2010,,01/10/2009,"Categorical Changes in Vital Signs (Blood Pressure [BP], Pulse, Weight, Temperature) During the Study|Change From Baseline to 5 Year Endpoint in BP|Change From Baseline to 5 Year Endpoint in Pulse|Change From Baseline to 5 Year Endpoint in Body Weight|Change From Baseline to 5 Year Endpoint in Height|Change From Baseline to 5 Year Endpoint in Weight, Height, and Body Mass Index (BMI) Percentile Stratified by Baseline Quartile|Change From Baseline to 5 Year Endpoint in Electrocardiogram (ECG)|Change From Baseline to 5 Year Endpoint in Heart Rate|Number of Patients Meeting Committee for Proprietary Medicinal Products (CPMP) Categorical QTc Interval Criteria Part I (Numerical Increase)|Number of Patients Meeting CPMP Categorical QTc Interval Criteria Part II (Interpretation at Baseline and Endpoint)|Number of Participants With Abnormal Laboratory Analytes During the Study|Number of Participants in Each Tanner Stage (Pubic Hair) by Age Group|Change From Baseline to 5 Year Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score and Subscale Scores|Change From Baseline to 5 Year Endpoint in Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity (CGI-ADHD-S) Score|Change From Baseline to 5 Year Endpoint in Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S) Subscale Scores|Change From Baseline to 5 Year Endpoint in the Stroop Word Color Test",http://ClinicalTrials.gov/show/NCT00190684,"United States, &nbsp; Australia, &nbsp; Belgium, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Israel, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Puerto Rico, &nbsp; South Africa, &nbsp; Sweden, &nbsp; United Kingdom",1,1,1,1
NCT00190775,"A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)",Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Atomoxetine Hydrochloride|Drug: Placebo,Eli Lilly and Company,Both,Adult|Senior,Phase IV,502,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",9043|B4Z-US-LYCW,09/12/2005,01/09/2004,01/10/2009,10/04/2010,01/10/2010,,01/07/2009,Change From Baseline to 24 Weeks in the Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scale - Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptoms Score|Change From Baseline to 12 Weeks in the Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scale - Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptoms Score|Change From Baseline to 8 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Participant|Change From Baseline to 24 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Participant|Change From Baseline to 8 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Spouse/Significant Other|Change From Baseline to 24 Weeks in the Family Assessment Measure Version III (FAM) Dyadic Relationship Scale (DRS) - Spouse/Significant Other|Change From Baseline to 8 Weeks in the Dyadic Adjustment Scale (DAS) - Participant|Change From Baseline to 24 Weeks in the Dyadic Adjustment Scale (DAS) - Participant|Change From Baseline to 8 Weeks in the Dyadic Adjustment Scale (DAS) - Spouse/Significant Other|Change From Baseline to 24 Weeks in the Dyadic Adjustment Scale (DAS) - Spouse/Significant Other|Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Total Stress and Life Stress|Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Parent Domains|Change From Baseline to 8 Weeks in the Parenting Stress Index (PSI) Score - Child Domains|Change From Baseline to 24 Weeks in the Parenting Stress Index (PSI) Score - Total Stress and Life Stress|Change From Baseline to 24 Weeks in the Parenting Stress Index (PSI) Score - Parent Domains|Change From Baseline to 24 Weeks in the Parenting Stress Index (PSI) Score - Child Domains|Change From Baseline to 12 Weeks in the Alabama Parenting Questionnaire (APQ) Parent Form|Change From Baseline to 24 Weeks in the Alabama Parenting Questionnaire (APQ) Parent Form|Change From Baseline to 12 Weeks in the Alabama Parenting Questionnaire (APQ) Child Form|Change From Baseline to 24 Weeks in the Alabama Parenting Questionnaire (APQ) Child Form|Mean Change From Baseline to 24 Weeks in the Child Disruptive Behavior Rating Scale (CDBRS) Parent Form|Mean Change From Baseline to 24 Weeks in the Child Disruptive Behavior Rating Scale (CDBRS) Parent Form Oppositional Defiant Disorder (ODD) and Conduct Disorder Flags|Change From Baseline to 8 Weeks in the Parenting Sense of Competence (PSOC) Scale|Change From Baseline to 24 Weeks in the Parenting Sense of Competence (PSOC) Scale|Change From Baseline to 12 and 24 Weeks in the Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale Total and Subscale Scores|Change From Baseline to 8 and 24 Weeks in the Clinical Global Improvement Attention Deficit Hyperactivity Disorder Severity (CGI-ADHD-S)|Change From Baseline to 12 and 24 Weeks in the Montgomery-Asberg Depression Rating Scale Total Score (MADRS)|Change From Baseline to 12 and 24 Weeks in the State-Trait Anxiety Inventories (STAI)|Change From Baseline to 1 Week of Titration in the CAARS-Inv:SV Total Attention Deficit Hyperactivity Disorder (ADHD) Symptoms and Subscale Scores|Change From Baseline to 2 Weeks of Titration in the CAARS-Inv:SV Total Attention Deficit Hyperactivity Disorder (ADHD) Symptoms and Subscale Scores|Change From Baseline to After a 2-Week Titration Period Beginning at Week 24 and Ending at Week 26 in the CAARS-Inv:SV Total Attention Deficit Hyperactivity Disorder (ADHD) Symptoms and Subscale Scores: Dosing Titration Strategy After Placebo,http://ClinicalTrials.gov/show/NCT00190775,"United States, &nbsp; Puerto Rico",1,1,2,1
NCT00191646,"An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy",Completed,Has Results,"Genital Neoplasms, Female|Fallopian Tube Neoplasms|Ovarian Neoplasms|Pelvic Neoplasms|Peritoneal Neoplasms",Drug: Gemcitabine|Drug: Paclitaxel|Drug: Carboplatin,Eli Lilly and Company,Female,Adult|Senior,Phase III,919,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,6891|B9E-US-S302,09/12/2005,01/10/2002,01/08/2009,10/13/2010,01/10/2010,,01/08/2009,Progression Free Survival (PFS)|Proportion of Participants With Response (Response Rate)|Time to Treatment Failure|Overall Survival,http://ClinicalTrials.gov/show/NCT00191646,"United States, &nbsp; Puerto Rico",1,1,3,0
NCT00193453,"Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer",Completed,No Results Available,Lung Cancer,Drug: Gemcitabine|Drug: Docetaxel|Drug: Cetuximab,Sarah Cannon Research Institute|Bristol-Myers Squibb,Both,Adult|Senior,Phase II,69,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SCRI LUN 92|CA225 117,09/12/2005,01/07/2005,01/12/2009,11/02/2010,01/11/2010,,01/02/2009,Overall clinical response rate|Progression free survival|Toxicity of drug combination,http://ClinicalTrials.gov/show/NCT00193453,United States,1,1,3,0
NCT00195676,Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis,Completed,Has Results,Psoriasis,Drug: adalimumab,Abbott,Both,Adult|Senior,Phase III,1469,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,M03-658|2005-000095-41,9/13/2005,01/05/2004,01/10/2009,12/13/2010,01/12/2010,,01/10/2009,Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R,http://ClinicalTrials.gov/show/NCT00195676,"United States, &nbsp; Austria, &nbsp; Belgium, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Poland, &nbsp; Puerto Rico, &nbsp; Spain, &nbsp; Switzerland",1,1,1,1
NCT00197015,Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children,Completed,Has Results,Hepatitis A Vaccine|Hepatitis A,Biological: Havrix?ó|Biological: M-M-R?óII|Biological: VARIVAX?ó,GlaxoSmithKline,Both,Child,Phase III,1474,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,208109/231,9/13/2005,01/10/2003,01/06/2009,11/30/2010,01/11/2010,,01/01/2009,"Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups.|Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups|Number of Subjects Seroconverted for Anti-measle, Anti-mumps and Anti-varicella Antibodies in HAV+MMR+V and MMR+V??ÊHAV Groups|Number of Subjects With Vaccine Response for Anti-rubella Antibodies in HAV+MMR+V and MMR+V??ÊHAV Groups|Anti-measles, Anti-mumps, Anti-rubella and Anti-varicella Antibody Titers in HAV+MMR+V and MMR+V??ÊHAV Groups|Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups|Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups|Anti-hepatitis A Virus (HAV) Antibody Concentrations in MMR+V??ÊHAV Group|Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value in MMR+V??ÊHAV Group|Number of Subjects With Vaccine Response to Havrix?ó|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Measles, Mumps, Rubella and Varicella Specific Solicited General Adverse Events|Number of Subjects Reporting Unsolicited Adverse Events (AEs)|Number of Subjects Reporting Serious Adverse Events (SAEs)|Number of Subjects Reporting New Chronic Illnesses|Number of Subjects Reporting Medically Significant Events",http://ClinicalTrials.gov/show/NCT00197015,United States,0,NA,3,NA
NCT00197392,Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System,Completed,No Results Available,Intraventricular Hemorrhage|Subarachnoid Hemorrhage,Device: Bactiseal TM EVD,Codman & Shurtleff,Both,Adult|Senior,Phase IV,515,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,BAC-IN02-002,9/13/2005,01/11/2004,01/01/2010,12/06/2010,01/12/2010,,01/12/2009,The rate of infection for the Codman B-EVD in comparison to the conventional EVD catheter (ventriculostomy-related infections) throughout the duration of the implanted EVD systems and for a 2-week period post-explant.|The time to infection|The class of bacteria|The rate and extent of intraluminal bacterial colonization in EVD catheter systems|Device related adverse events|Influence of number of days with indwelling catheter|Subject age and diagnosis (reasons for catheter placement) on infection rates|Procedural differences and techniques|The influence of concurrent systemic antibiotics on infection rates|Health economic inferences.,http://ClinicalTrials.gov/show/NCT00197392,"United States, &nbsp; Canada, &nbsp; China, &nbsp; France, &nbsp; Hong Kong, &nbsp; Norway, &nbsp; Singapore, &nbsp; United Kingdom",0,NA,1,NA
NCT00201409,A Randomized Trial of GM-CSF in Patients With ALI/ARDS,Completed,No Results Available,"Respiratory Distress Syndrome, Adult",Drug: Placebo|Drug: GM-CSF,"National Heart, Lung, and Blood Institute (NHLBI)|University of Michigan|Emory University|University of Colorado, Denver",Both,Adult|Senior,Phase II,132,NIH|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",258|P50 HL074024,09/12/2005,01/07/2004,01/06/2009,7/14/2009,01/07/2009,,01/05/2009,Ventilator-free days during Days 1-28|Lung epithelial cell integrity|Alveolar macrophage function|Changes in severity of physiologic derangements of respiratory gas exchange|Non-respiratory organ failure|Incidence of ventilator-associated pneumonia,http://ClinicalTrials.gov/show/NCT00201409,United States,1,0,2,NA
NCT00205179,Alzheimer's Disease: Potential Benefit of Isoflavones,Completed,No Results Available,Alzheimer's Disease,Drug: Novasoy|Drug: Placebo,"University of Wisconsin, Madison|National Institutes of Health (NIH)",Both,Adult|Senior,Phase II,60,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2003-0048|5K23AG024302-03,9/13/2005,01/01/2005,01/12/2009,9/27/2010,01/09/2010,,01/12/2009,Cognitive Data|biological assays of isoflavones and hormones,http://ClinicalTrials.gov/show/NCT00205179,United States,1,0,2,NA
NCT00205660,"Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole",Completed,No Results Available,Schizophrenia|Type 2 Diabetes Mellitus,Drug: ziprasidone|Drug: risperidone|Drug: olanzapine|Drug: quetiapine|Drug: aripiprazole|Drug: aripiprazole|Drug: aripiprazole|Drug: aripiprazole,Washington University School of Medicine|Bristol-Myers Squibb,Both,Adult,Phase IV,78,Other|Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,BMS #942370,09/12/2005,01/02/2005,01/08/2009,7/30/2010,01/07/2010,,01/08/2009,Improvement in Total Body Adiposity at 12 weeks|Improvement in high sensitivity C-reactive protein @ 12 wks|Improvement in glucose metabolism @ 12 wks|Improvement in lipid metabolism @ 12 wks,http://ClinicalTrials.gov/show/NCT00205660,United States,1,1,8,1
NCT00211237,CAFE Study - Cancer Patient Fracture Evaluation,Completed,Has Results,Cancer|Spinal Fractures,Device: Balloon Kyphoplasty|Other: Non Surgical Management,Medtronic Spine LLC,Both,Adult|Senior,Phase IV,134,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,SP0401 - CAFE Study,9/13/2005,01/05/2005,01/12/2009,5/18/2010,01/05/2010,CAFE,01/04/2009,"The Functional Status, as Measured by the Roland-Morris Disability Questionnaire (RDQ) at 1 Month|Study Treatment-related Adverse Events and Change in Neurological Status|Clinical: Change in Functional Status (as Assessed With the Roland-Morris Disability Questionnaire and the Karnofsky Performance Scale)|Change in Quality of Life (as Assessed by the SF-36v2?ºÑ Health Survey)|Change in Back Pain (as Measured by a 10-point Numerical Rating Scale)|Radiographic: Change in Spinal Deformity, Defined as the Degree of Spine Angulation (as Assessed by an Independent Radiologist at the Core Laboratory)|Radiographic: Rate of Subsequent Vertebral Body Fractures (as Assessed by Independent Radiologists at the Core Laboratory)",http://ClinicalTrials.gov/show/NCT00211237,"United States, &nbsp; Australia, &nbsp; Belgium, &nbsp; Canada, &nbsp; Germany, &nbsp; Hungary, &nbsp; Sweden, &nbsp; United Kingdom",0,NA,2,NA
NCT00213928,Horse Chestnut Seed Extract for Lymphedema,Completed,No Results Available,#NAME?,Drug: horse chestnut seed extract,"University of Wisconsin, Madison",Female,Child|Adult|Senior,Phase II,48,Other,Interventional,Allocation: Randomized|Control: Active Control|Intervention Model: Factorial Assignment|Masking: Single Blind,2004-050|CC 01106,9/13/2005,01/05/2002,01/12/2005,12/21/2007,01/09/2005,,01/12/2009,Reduction of arm lymphedema|- comparison of bioelectric impedance to measure lymphedema changes|- validation of bioelectric impedance to measure lymphedema changes|- validation of lymphedema questionnaire,http://ClinicalTrials.gov/show/NCT00213928,United States,1,0,1,NA
NCT00215930,The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Vinorelbine|Drug: Docetaxel|Drug: Gemcitabine|Drug: Carboplatin,H. Lee Moffitt Cancer Center and Research Institute|Eli Lilly and Company|Aventis Pharmaceuticals,Both,Adult|Senior,Phase II,72,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-13208,9/15/2005,01/02/2004,01/10/2009,9/17/2010,01/09/2010,,01/10/2009,response rates(RR)|progression free survival (PFS)|median survival(MS)|1-yr survival(1-yr S),http://ClinicalTrials.gov/show/NCT00215930,United States,1,1,4,1
NCT00216099,Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer,Completed,No Results Available,Prostate Cancer,Drug: Pemetrexed|Dietary Supplement: Folic Acid|Dietary Supplement: Vitamin B12,Hoosier Oncology Group|Eli Lilly and Company|Walther Cancer Institute,Male,Adult|Senior,Phase II,43,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,HOG GU03-67,09/12/2005,01/02/2005,01/03/2009,4/29/2009,01/04/2009,,01/03/2009,"?? To determine the rates of best overall PSA response (??­ 50% decline in PSA) at any time during the study with single agent pemetrexed in subjects with HRPC whose disease has progressed following one prior taxane based chemotherapy regimen for HRPC??|To determine time to disease progression, overall survival and duration of response (PSA criteria)|To determine OBJECTIVE response per RECIST|To determine the rate of clinical benefit (decreased pain, improved performance status)|To determine the safety and tolerability of pemetrexed in subjects with HRPC whose disease has progressed following one prior taxane-based chemotherapy regimen for HRPC|To explore whether polymorphisms of enzymes involved in pemetrexed metabolism impact its toxicity or efficacy profile",http://ClinicalTrials.gov/show/NCT00216099,United States,1,1,3,1
NCT00218296,Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use,Completed,No Results Available,Tobacco Use Disorder,Drug: Smokeless Tobacco Reduction Treatment|Drug: Standard Tobacco Cessation Treatment,National Institute on Drug Abuse (NIDA),Both,Adult|Senior,Phase II,300,NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NIDA-14404-4|R01-DA14404-4|DPMCDA,9/16/2005,01/11/2006,01/01/2009,10/21/2009,01/10/2009,,01/01/2009,Abstinence from tobacco|Duration of treatment|Reduction in ST use (measured at Month 6),http://ClinicalTrials.gov/show/NCT00218296,United States,1,0,2,NA
NCT00218465,"Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking",Completed,Has Results,Nicotine Dependence,Drug: GW468816|Drug: Placebo Comparator,Massachusetts General Hospital|National Institute on Drug Abuse (NIDA)|Mclean Hospital|GlaxoSmithKline,Female,Adult,Phase II,264,Other|NIH|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",NIDA-19378-2|U01DA019378|IND 74964,9/16/2005,01/08/2006,01/06/2009,11/23/2010,01/11/2010,,01/06/2009,Time to Relapse to Smoking in the 5-week Relapse Prevention Phase.|Number of Abstinent and Nonabstinent Participants at End of 5 Week Placebo-controlled Relapse Prevention Trial|Days to Relapse Within the 60 Days Following Randomization,http://ClinicalTrials.gov/show/NCT00218465,United States,1,0,2,NA
NCT00221039,"Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A",Completed,No Results Available,Cutaneous T Cell Lymphoma|Mycosis Fungoides,Drug: UVADEX (methoxsalen) Solution with UVAR XTS Photopheresis,Therakos|Departments of Dermatology University of Texas M D Anderson Cancer Center|Boston Medical Center|University of Pittsburgh|Case Western Reserve University|Vanderbilt University|University of Minnesota - Clinical and Translational Science Institute|Rush Medical Center,Both,Adult|Senior,Phase IV,19,Industry|Other,Interventional,Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ECTCL1,9/13/2005,01/09/2004,01/02/2009,3/31/2010,01/03/2010,,01/02/2009,The primary endpoint will be the overall response based on skin-weighted assessment.|Time to response|Duration of response|Quality of life,http://ClinicalTrials.gov/show/NCT00221039,United States,1,1,1,1
NCT00221299,Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use,Completed,No Results Available,Glucocorticoid Induced Osteoporosis,Drug: Risedronate|Drug: Parathyroid Hormone,"University of California, Davis|University of California, San Francisco",Both,Adult|Senior,Phase IV,60,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",200513216|RA-015865,9/14/2005,01/09/2005,01/05/2009,5/22/2009,01/05/2009,,01/03/2009,Bone Mineral Density (BMD): Examine the pattern and effect of BMD changes at hip and spine measured by DXA every 6 months.|Bone Turnover Markers : Evaluate the levels of bone biochemical markers serum total calcium and urinary excretion of calcium.|Incident Vertebral and non-Vertebral Fractures: Evaluate using Instant Vertebral Assessment (IVA) obtained at baseline and annually thereafter.,http://ClinicalTrials.gov/show/NCT00221299,United States,1,1,2,0
NCT00222729,Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer,Completed,No Results Available,Cancer,Drug: Pemetrexed|Drug: Bevacizumab,University of Pittsburgh|Eli Lilly and Company|Genentech,Both,Adult|Senior,Phase II,20,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,"05-002|12,158",9/16/2005,01/11/2005,01/09/2009,4/30/2010,01/04/2010,,01/09/2009,"To evaluate the time to progression (primary endpoint) with the combination of pemetrexed and bevacizumab in recurrent or metastatic head and neck cancer.|To evaluate the objective response rate, duration of response, overall survival, and toxicities associated with the above therapy.|A secondary endpoint will be the objective response rate.A secondary endpoint will be the objective response rate. The target response rate for the combination is 40%, and if the target is in fact observed, its 95% confidence interval will be 30%.",http://ClinicalTrials.gov/show/NCT00222729,United States,1,1,2,1
NCT00225147,Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema,Completed,No Results Available,Hereditary Angioedema|Angioneurotic Edema,Drug: Recombinant Human C1 Inhibitor,Pharming Technologies B.V.|FDA Office of Orphan Products Development,Both,Child|Adult|Senior,Phase II,77,Industry|U.S. Fed,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C1 1205-01|3086,9/20/2005,01/07/2005,01/01/2010,8/30/2010,01/08/2010,,01/10/2009,Relief of angioedema symptoms|Safety and tolerability; pharmacokinetics/pharmacodynamics,http://ClinicalTrials.gov/show/NCT00225147,United States,1,0,1,NA
NCT00226655,"An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies",Completed,No Results Available,Brain Edema|Brain Tumor,Drug: hCRF [XERECEPT (corticorelin acetate injection)],Celtic Pharma Development Services|Neurobiological Technologies,Both,Adult|Senior,Phase III,340,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NTI 0501,9/23/2005,01/07/2005,01/04/2009,4/28/2009,01/04/2009,,01/03/2009,"The study will evaluate the overall long-term safety and tolerability of hCRF and steroid toxicities by monitoring dexamethasone dosing, laboratory values, adverse events,electrocardiograms and neurological and clinical status.",http://ClinicalTrials.gov/show/NCT00226655,"United States, &nbsp; Canada",1,0,1,NA
NCT00227565,Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Completed,No Results Available,Lung Cancer,Drug: carboplatin|Drug: pemetrexed disodium,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,77,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000442866|NCCTG-N0423,9/26/2005,01/02/2006,NA,7/28/2010,01/10/2009,,01/10/2009,Proportion of confirmed-tumor response,http://ClinicalTrials.gov/show/NCT00227565,United States,1,1,2,0
NCT00228826,GVH 0313: Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies at High Risk for Transplant Related Mortality With Standard Transplantation,Completed,No Results Available,Graft vs Host Disease,Drug: Pentostatin,Emory University,Both,Child|Adult,Phase II,NA,Other,Interventional,Allocation: Non-Randomized|Control: Active Control|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,045-2004,9/27/2005,01/02/2004,01/06/2009,6/29/2009,01/09/2005,,01/06/2009,,http://ClinicalTrials.gov/show/NCT00228826,United States,1,1,1,1
NCT00232557,Telecommunications System in Asthma,Completed,No Results Available,Asthma,Device: Telephone,Department of Veterans Affairs,Both,Adult|Senior,Phase III,170,U.S. Fed,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label,IIR 01-054,9/30/2005,01/08/2004,01/12/2009,05/11/2010,01/05/2010,,01/07/2009,Unscheduled Asthma-related Visits|Oral Corticosteroid Use; Quality of Life; Medication Adherence,http://ClinicalTrials.gov/show/NCT00232557,United States,0,NA,1,NA
NCT00234000,Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes,Completed,No Results Available,Leukemia|Myelodysplastic Syndromes,Drug: arsenic trioxide|Drug: azacitidine,"University of California, Los Angeles|National Cancer Institute (NCI)|Cell Therapeutics|Celgene Corporation",Both,Adult|Senior,Phase I|Phase II,78,Other|NIH|Industry,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000442931|P30CA016042|UCLA-0408087,10/05/2005,01/02/2007,01/02/2009,9/24/2010,01/09/2010,,01/02/2009,Safety and tolerability as assessed by NCI CTCAE v3.0 (Phase I)|Transfusion independence (Phase II)|Improvement in peripheral blood counts (Phase II)|Complete or partial remission (Phase II)|Hematologic-platelet and hematologic-neutrophil response|Time to disease progression|Overall and progression-free survival|Cytogenetic response,http://ClinicalTrials.gov/show/NCT00234000,United States,1,1,2,0
NCT00234832,A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients,Completed,Has Results,Obesity,Drug: Sibutramine hydrochloride|Drug: Placebo|Drug: Sibutramine hydrochloride,Abbott,Both,Adult|Senior,Phase III,10777,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",M01-392,9/13/2005,01/01/2003,01/11/2009,05/06/2010,01/05/2010,SCOUT,01/03/2009,"Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)|Risk of Death From Any Cause (All-cause Mortality)|Risk of Experiencing a POE or a Revascularization Procedure|Risk of Experiencing a Nonfatal MI Included in the POE|Risk of Experiencing a Nonfatal Stroke Included in the POE|Risk of Experiencing a Resuscitated Cardiac Arrest Included in the POE|Risk of Experiencing Cardiovascular Death Included in the POE",http://ClinicalTrials.gov/show/NCT00234832,United States,1,1,3,0
NCT00238316,Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density,Completed,No Results Available,Breast Cancer,Drug: letrozole,NCIC Clinical Trials Group,Female,Child|Adult|Senior,Phase II,120,Other,Interventional,Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Prevention,MAP1|CAN-NCIC-MAP1|CDR0000445442,10/12/2005,01/12/2000,01/02/2009,11/07/2010,01/03/2010,,01/02/2009,Percentage change of the BMD parameters from baseline BMD values|Percentage change of bone biomarker measurements (serum bone alkaline phosphatase and urine N-telopeptide) from baseline values,http://ClinicalTrials.gov/show/NCT00238316,"United States, &nbsp; Canada",1,1,1,0
NCT00238368,Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant,Completed,No Results Available,Lymphoma,Biological: filgrastim|Biological: rituximab|Drug: busulfan|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: methylprednisolone|Drug: prednisone|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: positron emission tomography|Radiation: fludeoxyglucose F 18|Radiation: radiation therapy,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,55,Other|NIH,Interventional,Primary Purpose: Diagnostic,CDR0000445618|P30CA006973|JHOC-J0348|JHOC-03082605,10/12/2005,01/02/2004,NA,3/16/2010,01/03/2010,,01/02/2009,2-year event free survival|Overall survival|Predictive value of early negative fludeoxyglucose F 18 positron emission tomography (FDG-PET)|Correlation of International Prognostic Index risk category with FDG-PET results and overall outcome,http://ClinicalTrials.gov/show/NCT00238368,United States,1,1,16,0
NCT00239642,Safety Efficacy of Iron Sucrose in Children,Completed,No Results Available,Anemia|Chronic Kidney Disease,Drug: iron sucrose injection,Luitpold Pharmaceuticals,Both,Child|Adult,Phase IV,120,Industry,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic,1VEN03017,10/13/2005,01/07/2005,01/04/2010,8/24/2010,01/08/2010,,01/01/2009,Safety - incidence of adverse advents|Clinical success,http://ClinicalTrials.gov/show/NCT00239642,United States,1,1,1,1
NCT00240981,TOM: Testosterone in Older Men With Sarcopenia,Completed,No Results Available,Sarcopenia|Hypogonadism|Muscular Diseases,Drug: Topical testosterone gel 1% (active formulation)|Drug: Topical gel (placebo formulation),Boston Medical Center|National Institute on Aging (NIA),Male,Adult|Senior,Phase IV,210,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AG0057|U01AG014369|2U01AG14369-06,10/14/2005,01/01/2005,01/12/2009,04/02/2010,01/03/2010,,01/12/2009,"Changes in physical performance measured by an exercise testing regimen|Changes in disability, fatigue, affect, and sense of well being assessed by validated questionnaires",http://ClinicalTrials.gov/show/NCT00240981,United States,1,1,2,1
NCT00243503,Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer,Completed,Has Results,Breast Neoplasms,Drug: SU011248/Trastuzumab,Pfizer,Both,Adult|Senior,Phase II,61,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,A6181067,10/20/2005,01/02/2006,01/07/2010,08/05/2010,01/08/2010,,01/04/2009,Number of Subjects With Overall Confirmed Objective Disease Response|Clinical Benefit Rate|Progression Free Survival (PFS)|Duration of Response|Overall Survival|Time to Progression (TTP)|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)|Probability of Survival at One Year|EORTC QLQ Breast Cancer Module (BR23)|Trough Plasma Concentrations (Ctrough) of Sunitinib|Ctrough of SU-012662 (Sunitinib's Metabolite)|Ctrough of Total Drug (Sunitinib + SU-012662),http://ClinicalTrials.gov/show/NCT00243503,"United States, &nbsp; Belgium, &nbsp; Canada, &nbsp; France, &nbsp; Spain",1,1,1,0
NCT00244933,Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer,Completed,No Results Available,Breast Cancer,Dietary Supplement: genistein|Drug: gemcitabine hydrochloride|Procedure: complementary or alternative medicine procedure,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Female,Adult|Senior,Phase II,36,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000446089|WSU-C-2597,10/25/2005,01/02/2004,NA,4/13/2010,01/04/2010,,01/10/2009,"Objective response rate by RECIST criteria following every 2 courses until disease progression or death|Duration of response|Overall survival|Time to disease progression|Duration of survival at 1 year following study treatment|Qualitative and quantitative toxicities from treatment initiation until 30 days following treatment|Correlate responses with plasma genistein levels at course 1 day -7, course 1 day -1 (before and 4 hours after dose), course 2 day 1 (before and 4 hours after dose)|In vivo effects of genistein in breast cancer tissue biomarkers (Ki67, TUNEL assay, p-Akt, NF-kB, immunohistochemistry and cDNA microarray analysis) at baseline (pre-genistein treatment) and 7 days following genistein treatment",http://ClinicalTrials.gov/show/NCT00244933,United States,1,0,3,NA
NCT00246324,Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis,Completed,No Results Available,Multiple Sclerosis,Drug: Doxycycline,Louisiana State University - Shreveport|Biogen Idec,Both,Adult,Phase IV,NA,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H04-090,10/27/2005,01/12/2003,01/08/2009,07/01/2010,01/12/2004,,01/08/2009,"to determine whether the combination of doxycycline with Avonex will reduce the mean number of new GD+ lesions|to determine pre- and on-treatment relapse rate,proportion relapse free, %free of new MRI activity, and % experencing greater than 25% reduction in new MRI activity|determine safety and tolerability of combination therapy with Avonex plus doxycycline|determine pre- and on-treatment cytokine ELISA, MMP ELISA and bioassay",http://ClinicalTrials.gov/show/NCT00246324,United States,1,1,1,0
NCT00247416,Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer,Completed,No Results Available,Stage IV Non-small Cell Lung Cancer|Stage IIIB-pleural Effusion,Drug: Gemcitabine|Drug: Dexamethasone|Drug: Carboplatin,University of Kentucky|Kentucky Lung Cancer Research Program,Both,Adult|Senior,Phase II,124,Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CTN-0501,10/28/2005,01/08/2005,01/07/2009,1/27/2010,01/06/2008,,01/07/2009,"Determine the effect of dexamethasone pre-treatment on response rates, and survival.|Evaluate the effect of dexamethasone on clinically relevant parameters of hematologic, non-hematologic toxicity and quality of life parameters.",http://ClinicalTrials.gov/show/NCT00247416,United States,1,1,3,0
NCT00248781,Home-based Exercise Via a Telecommunications System,Completed,No Results Available,Functional Limitation,Device: Telecommunications system,Department of Veterans Affairs,Both,Adult|Senior,Phase III,398,U.S. Fed,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label,E2777R,11/02/2005,01/09/2003,01/11/2009,11/13/2009,01/11/2009,,01/04/2009,Muscle strength and physical performance|Durability of benefits,http://ClinicalTrials.gov/show/NCT00248781,United States,0,NA,1,NA
NCT00249795,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I),Completed,Has Results,Atrial Fibrillation|Cardiovascular Disease,Drug: Irbesartan|Drug: placebo,Sanofi-Aventis|Bristol-Myers Squibb,Both,Adult|Senior,Phase III,9016,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",EFC4912 I|Clopidogrel (SR25990),11/04/2005,01/06/2003,01/08/2009,9/29/2010,01/09/2010,ACTIVE I,01/08/2009,"First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke or Vascular Death as Per Adjudication|First Occurence of Any Component of the Composite of Myocardial Infarction, Stroke, Vascular Death or Hospitalization for Heart Failure as Per Adjudication|First Occurrence of Stroke|Death From Any Cause|First Occurrence of Any Heart Failure (HF) Episode|First Hospitalisation for Heart Failure (HF)|First Hospitalisation for Other Cardiovascular (CV) Cause",http://ClinicalTrials.gov/show/NCT00249795,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Hong Kong, &nbsp; Hungary, &nbsp; Italy, &nbsp; Malaysia, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Poland, &nbsp; Portugal, &nbsp; Singapore, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; Taiwan, &nbsp; United Kingdom",1,1,2,1
NCT00249873,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A),Completed,Has Results,Atrial Fibrillation|Vascular Risk,Drug: clopidogrel (SR25990C)|Drug: placebo,Sanofi-Aventis|Bristol-Myers Squibb,Both,Adult|Senior,Phase III,7554,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",EFC4912 A,11/04/2005,01/06/2003,01/03/2009,3/31/2010,01/03/2010,,01/03/2009,"First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication|Occurrence of Stroke|Death From Any Cause (Cardiovascular and Noncardiovascular)|Adjudicated Major Bleedings",http://ClinicalTrials.gov/show/NCT00249873,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Hong Kong, &nbsp; Hungary, &nbsp; Italy, &nbsp; Malaysia, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Poland, &nbsp; Portugal, &nbsp; Singapore, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; Taiwan, &nbsp; United Kingdom",1,1,2,1
NCT00250705,Trial of Aripiprazole in the Treatment of CD in Adolescents,Completed,No Results Available,Conduct Disorder,Drug: Aripiprazole,University of Iowa|Bristol-Myers Squibb,Male,Child,Phase IV,12,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,200306035|B042700,11/04/2005,01/05/2004,01/03/2009,1/14/2010,01/01/2010,,01/03/2009,"The primary outcome efficacy measures will be the Rating of Aggression Against People and/or Property Scale (RAAPP) (Kemph et al 1993), Overt Aggression Scale-Modified (OAS-M) (Kay et al 1988), and Children's Aggression Scale-Parent Version (CAS-P)|The secondary outcome measure will be the CGI severity and improvement scale (NIMH, 1985a).",http://ClinicalTrials.gov/show/NCT00250705,United States,1,1,1,0
NCT00251004,Efficacy and Safety Study of Everolimus Plus Cyclosporine and Mycophenolic Acid Plus Cyclosporine in Kidney Transplants,Completed,No Results Available,Kidney Transplantation|Graft Rejection,Drug: everolimus|Drug: mycophenolate,Novartis,Both,Adult|Senior,Phase III,832,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CRAD001A2309,11/07/2005,01/09/2005,01/10/2009,09/02/2010,01/09/2010,,01/08/2009,"treated biopsy acute rejection, graft loss, and survival|graft loss, survival, and renal function",http://ClinicalTrials.gov/show/NCT00251004,United States,1,1,2,0
NCT00251277,Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura,Completed,No Results Available,Thrombotic Thrombocytopenic Purpura,Drug: Rituximab,Weill Medical College of Cornell University|Genentech,Both,Child|Adult|Senior,Phase I|Phase II,12,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,409007463,11/07/2005,01/11/2005,01/04/2009,9/28/2010,01/09/2010,,01/04/2009,"Failure to maintain the complete response until day 120; Non-protocol treatment for TTP, such as other immunosuppressive agents or splenectomy, reinstitution of plasma exchange within the first 90 days",http://ClinicalTrials.gov/show/NCT00251277,United States,1,1,1,1
NCT00251524,A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC,Completed,No Results Available,Non-small Cell Lung Cancer,"Drug: Bevacizumab, Oxaliplatin, Pemetrexed",Veeda Oncology|Sanofi-Aventis|Eli Lilly and Company|Genentech,Both,Adult|Senior,Phase II,69,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,I-04-015,11/08/2005,01/11/2005,01/05/2009,11/30/2010,01/08/2008,,01/05/2009,To determine the median progression-free survival in patients with advanced non-squamous non-small cell lung cancer (NSCLC) receiving Eloxatin and Alimta in combination with Bevacizumab as first-line treatment|To evaluate the median and the 1-year and 2-year survival in patients with advanced NSCLC receiving Eloxatin and Alimta in combination with Bevacizumab as first-line treatment.|To determine the overall objective response and the duration of response in patients with advanced NSCLC receiving Eloxatin and Alimta in combination with Bevacizumab as first-line treatment.|To evaluate the safety of Eloxatin and Alimta in combination with Bevacizumab in patients with advanced NSCLC as first-line treatment.,http://ClinicalTrials.gov/show/NCT00251524,United States,1,1,1,1
NCT00253513,"Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",Completed,No Results Available,Leukemia|Myelodysplastic Syndromes,Drug: fludarabine|Drug: treosulfan|Procedure: allogeneic blood or bone marrow transplantation,OHSU Knight Cancer Institute|medac GmbH|National Cancer Institute (NCI),Both,Child|Adult,Phase II,62,Other|Industry|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000445306|FHCRC-1931.00|MEDAC-FHCRC-1931.00|OHSU-HEM-05107-LM,11/11/2005,01/06/2005,01/10/2009,10/05/2010,01/10/2010,,01/10/2009,"Incidence of severe to fatal regimen-related toxicity to major organ systems (cardiac, bladder/renal, pulmonary, hepatic, neurologic and gastrointestinal) between days -6 and 28|Incidence of graft failure|Incidence of nonrelapse mortality by day 200 (second phase only)|Disease-free survival",http://ClinicalTrials.gov/show/NCT00253513,United States,1,1,3,0
NCT00254579,"Study of CP-675,206 in Refractory Melanoma",Completed,No Results Available,Refractory Melanoma,"Drug: CP-675,206",Pfizer,Both,Adult|Senior,Phase II,251,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,A3671008,11/14/2005,01/12/2005,01/12/2009,10/21/2010,01/10/2010,,01/12/2009,"To assess the anti-tumor efficacy, as determined by objective response rate, of intravenous CP-675,206 administered at a dose of 15 mg/kg every 90 days to patients with relapsed or refractory advanced melanoma|Safety, PK, Survival, health-related QoL",http://ClinicalTrials.gov/show/NCT00254579,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Spain, &nbsp; United Kingdom",1,0,1,NA
NCT00255086,The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,Completed,No Results Available,Alzheimer Disease,Drug: Memantine,"Stanford University|Palo Alto Institute for Research and Education, Inc|Forest Laboratories",Both,Adult|Senior,Phase III,17,Other|Industry,Interventional,"Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",95722,11/15/2005,01/05/2005,01/02/2010,10/14/2010,01/10/2010,,01/06/2009,NAA/Cr ratio|Progression as measured by performance on the ADAS-Cog and caregiver and clinician ratings.,http://ClinicalTrials.gov/show/NCT00255086,United States,1,1,1,0
NCT00255125,Role of Soy Supplementation in Prostate Cancer Development,Completed,No Results Available,Prostate Neoplasm,Drug: Soy Supplement|Drug: Placebo,Department of Veterans Affairs,Male,Adult|Senior,Phase III,87,U.S. Fed,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CLIN-006-05S,11/15/2005,01/09/2005,01/10/2009,10/02/2009,01/10/2009,,01/04/2009,1.Effect of Soy Isoflavones on serum hormonal serum levels.|2.Effect of Soy Isoflavones on estrogen receptor status.|Molecular Effects of Soy Isoflavones.,http://ClinicalTrials.gov/show/NCT00255125,United States,1,0,2,NA
NCT00255632,Transdermal Estradiol in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy and Chemotherapy,Completed,No Results Available,Prostate Cancer,Biological: therapeutic estradiol,University of Medicine and Dentistry New Jersey|National Cancer Institute (NCI),Male,Adult|Senior,Phase II,33,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,080419; CDR0000445280|P30CA072720|CINJ-080419-5247,11/18/2005,01/05/2005,01/11/2009,03/08/2010,01/03/2010,,01/11/2009,Decrease of 50% in PSA,http://ClinicalTrials.gov/show/NCT00255632,United States,0,NA,1,1
NCT00258180,Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy,Completed,No Results Available,"Diarrhea|Gastrointestinal Complications|Unspecified Childhood Solid Tumor, Protocol Specific",Biological: filgrastim|Drug: cyclophosphamide,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Both,Child|Adult,Phase II,11,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Supportive Care,"J0326, CDR0000441133|P30CA006973|JHOC-J0326|JHOC-03070804",11/22/2005,01/06/2005,01/01/2009,9/21/2010,01/09/2010,,01/01/2009,Treatment-free remission at 1 year after study completion|Toxicities during study treatment|Effect of treatment on anti-enterocyte antibody titers at 1 year after study completion,http://ClinicalTrials.gov/show/NCT00258180,United States,1,1,2,0
NCT00258362,"Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer",Completed,Has Results,Endometrial Cancer,Drug: carboplatin|Drug: docetaxel|Radiation: radiation therapy,"Masonic Cancer Center, University of Minnesota|Sanofi-Aventis",Female,Adult|Senior,Phase II,41,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2004LS021|UMN-WCC-38|13062,11/22/2005,01/07/2005,01/12/2009,11/10/2010,01/11/2010,,01/12/2009,Percent of Patients Estimated to be Progression-Free and Alive|Percent of Patients Estimated to be Alive,http://ClinicalTrials.gov/show/NCT00258362,United States,1,1,3,0
NCT00259610,Treatment of Early Aggressive Rheumatoid Arthritis (TEAR),Completed,No Results Available,Rheumatoid Arthritis,Drug: methotrexate|Drug: sulfasalazine|Drug: hydroxychloroquine|Drug: etanercept|Drug: MTX + Etanercept|Drug: MTX + SSZ/HCQ|Drug: MTX + Etanercept|Drug: MTX or MTX + SSZ/HCQ|Drug: MTX or MTX + Etanercept,University of Alabama at Birmingham|Amgen|Barr Laboratories|Pfizer,Both,Adult|Senior,Phase IV,750,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",X031030004|20040391,11/28/2005,01/05/2004,01/06/2009,09/02/2009,01/09/2009,TEAR,01/06/2009,Disease Activity,http://ClinicalTrials.gov/show/NCT00259610,United States,1,1,9,0
NCT00260078,Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children,Completed,No Results Available,HIV Infections,Drug: Atazanavir|Drug: Darunavir|Drug: Efavirenz|Drug: Nevirapine|Drug: Ritonavir|Drug: Tenofovir disoproxil fumarate|Procedure: Pharmacokinetic Study,National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Both,Child,Phase I|Phase II,64,NIH,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,IMPAACT P1058|PACTG 1058,11/29/2005,01/02/2006,01/04/2009,10/19/2010,01/04/2009,,01/04/2009,Predosage concentration (C0 and C12) and area under the concentration-time curve (AUC),http://ClinicalTrials.gov/show/NCT00260078,"United States, &nbsp; Puerto Rico",1,1,7,1
NCT00261443,A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania,Completed,No Results Available,Bipolar Disorder,Drug: Lithium or Valproate with PBO|Drug: Lithium or Valproate with Aripiprazole,Bristol-Myers Squibb|Otsuka America Pharmaceutical,Both,Adult|Senior,Phase IV,1300,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CN138-189,12/01/2005,01/09/2005,01/10/2009,4/27/2010,01/04/2010,,01/06/2009,Any mood episode|Mean change in the Clinical Global Impression Scale for Bipolar Disorder (CGI-BP) Severity of Illness Score (mania),http://ClinicalTrials.gov/show/NCT00261443,"United States, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Croatia, &nbsp; Czech Republic, &nbsp; France, &nbsp; India, &nbsp; Russian Federation, &nbsp; South Africa",1,1,2,0
NCT00262600,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Completed,No Results Available,Atrial Fibrillation|Cerebrovascular Accident,Drug: Dabigatran etex|Drug: Warfarin,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase III,18115,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention,1160.26|2005-003894-26,12/06/2005,01/11/2005,NA,09/01/2010,01/09/2010,,01/04/2009,"Incidence of stroke (including hemorrhagic) and systemic embolism|Incidence of stroke (including hemorrhagic), systemic embolism, all death Incidence of stroke (including hemorrhagic), systemic embolism, pulmonary embolism, acute myocardial infarction, or vascular deaths (including deaths from bleeding)",http://ClinicalTrials.gov/show/NCT00262600,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; China, &nbsp; Colombia, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Hong Kong, &nbsp; Hungary, &nbsp; India, &nbsp; Italy, &nbsp; Japan, &nbsp; Korea, Republic of, &nbsp; Malaysia, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Peru, &nbsp; Philippines, &nbsp; Poland, &nbsp; Portugal, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Singapore, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; Taiwan, &nbsp; Thailand, &nbsp; Turkey, &nbsp; Ukraine, &nbsp; United Kingdom",1,1,2,0
NCT00262730,Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,Completed,No Results Available,Brain and Central Nervous System Tumors,Drug: poly ICLC|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,96,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000454915|NABTT-0501,12/06/2005,01/01/2006,NA,7/15/2010,01/01/2007,,01/08/2009,Survival,http://ClinicalTrials.gov/show/NCT00262730,United States,1,0,4,NA
NCT00265200,Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer,Completed,No Results Available,"Carcinoma, Non-Small Cell Lung|Carcinoma, Small Cell Lung|Metastases",Drug: zoledronic acid,James Graham Brown Cancer Center|University of Louisville|Novartis Pharmaceuticals,Both,Adult|Senior,Phase II,28,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,565.04|BCC-LUN-04-002,12/12/2005,01/02/2005,01/06/2009,01/11/2010,01/01/2010,,01/06/2009,"Blood specimens to measure TRAP level|Brief Pain Questionnaire to evaluate subject's pain|Bone imaging tests (bone scan, PET scan, MRI, and/or x-ray) will be done to measure progression of bone metastasis",http://ClinicalTrials.gov/show/NCT00265200,United States,1,1,1,1
NCT00266279,Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies,Completed,No Results Available,Head & Neck Cancer,"Drug: Oxaliplatin, Capecitabine",James Graham Brown Cancer Center|University of Louisville,Both,Adult|Senior,Phase II,13,Other,Interventional,Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,153.05,12/15/2005,01/04/2005,01/10/2009,11/02/2009,01/11/2009,,01/10/2009,,http://ClinicalTrials.gov/show/NCT00266279,United States,1,1,1,0
NCT00266877,Study Evaluating the Safety of HKI-272 in Subjects With Advanced Non-Small Cell Lung Cancer,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung|Lung Neoplasms",Drug: HKI-272,Wyeth,Both,Adult|Senior,Phase II,167,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,3144A1-200,12/16/2005,01/11/2005,01/01/2009,6/17/2010,01/06/2010,,01/01/2009,Radiographic tumor assessments will be used to assess outcome.,http://ClinicalTrials.gov/show/NCT00266877,"United States, &nbsp; France, &nbsp; Hungary, &nbsp; Poland, &nbsp; Spain",1,0,1,NA
NCT00267059,Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL),Completed,No Results Available,Chronic Lymphocytic Leukemia|Leukemia,Drug: Lenalidomide,M.D. Anderson Cancer Center|Celgene Corporation,Both,Adult|Senior,Phase II,45,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2005-0175,12/19/2005,01/12/2005,01/08/2009,09/04/2009,01/09/2009,,01/08/2009,Overall response (OR),http://ClinicalTrials.gov/show/NCT00267059,United States,1,1,1,1
NCT00270205,"Safety and Tolerability of and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving Anti-HIV Treatment",Completed,No Results Available,HIV Infections,Biological: LC002 standard vaccination|Biological: LC002 high-dose vaccination|Biological: LC002 placebo vaccination,National Institute of Allergy and Infectious Diseases (NIAID),Both,Adult,Phase I|Phase II,24,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment",ACTG A5176,12/21/2005,01/02/2006,NA,3/24/2010,01/01/2010,,01/02/2009,"Occurrence of at least one Grade 3 or higher adverse event, including signs/symptoms, lab toxicities, and/or clinical events possibly or definitely related to study treatment|CD4+ T-cell count/ml in PBMCs|CD8+ T-cell count/ml in PBMCs|T-cell count and percent of HIV-1-specific CD4+ and CD8+ T-cell subsets, based on flow cytometry with CFSE staining to detect antigen-specific lymphocyte proliferation responding to whole HIV-1 antigen, p24 protein, and various HIV-1 peptide antigens|T-cell count and percent of HIV-1-specific CD4+ and CD8+ T-cell subsets, based on flow cytometry to detect antigen-specific IFN-gamma- and IL-2-producing cells responding to whole Zn-finger inactivated virus stimulation and various HIV-1 peptide antigens|Magnitude of HIV-specific immune response, as determined by summing the number of spot-forming cells/10^5 PBMCs observed in each ELISPOT assay for IFN-gamma production for whole HIV-1 antigen, p24 protein, and HIV-1 peptide antigen pools|Breadth of HIV-1-specific immune response, as determined by the number of overlapping HIV-1 peptides for which the ELISPOT assay for IFN-gamma production is observed to have five or more spot-forming cells/ 10^5 PBMCs|Lymphocyte proliferation stimulation Index (SI) in response to whole HIV-1 antigen, p24 antigen, and pooled HIV-1 peptide antigens|Anti-dsDNA antibody response",http://ClinicalTrials.gov/show/NCT00270205,United States,0,NA,3,NA
NCT00270504,Memokath?ó 044TW Stent for Treatment of Urethral Stricture,Completed,No Results Available,Urethral Stricture,Device: Memokath stenting,Engineers & Doctors Wallsten Medical Group,Male,Adult|Senior,Phase III,92,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,1-044TWUS,12/23/2005,01/12/2002,01/11/2009,11/17/2009,01/12/2008,,01/10/2009,"Stent/control effectiveness - urethral patency|Peak urinary flow rate|Re-intervention|Standard survey instruments (QOL, IPSS etc.)|Stent placement success|Stent removal success",http://ClinicalTrials.gov/show/NCT00270504,United States,0,NA,1,NA
NCT00270634,Study of ISA247 in De Novo Renal Transplantation,Completed,No Results Available,Kidney Diseases,Drug: Voclosporin|Drug: tacrolimus,Isotechnika,Both,Adult,Phase II,334,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ISA05-01,12/23/2005,01/01/2006,01/07/2009,7/29/2009,01/07/2009,PROMISE,01/07/2009,"Biopsy proven acute rejection (BPAR)|To demonstrate a 5% improvement in renal function as measured by Iothalamate glomerular filtration rate (GFR)|To determine the pharmacokinetic-pharmacodynamic relationship between ISA247 and calcineurin inhibition, or tacrolimus and calcineurin inhibition|To determine patient survival|To determine graft survival|To determine the proportion of patients with hypertension, hyperlipidemia, or hyperglycemia|A composite of biopsy-proven chronic rejection graft loss, death, or lost to follow up.|A composite of biopsy-proven acute rejections, graft loss or death|To establish the safety of voclosporin",http://ClinicalTrials.gov/show/NCT00270634,"United States, &nbsp; Canada",1,0,2,NA
NCT00272311,Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome,Completed,No Results Available,Cardiovascular Diseases|Metabolic Syndrome X|Atherosclerosis,Drug: Aspirin,Florida Atlantic University|Bayer,Both,Adult|Senior,Phase IV,100,Other|Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",H07-28,01/03/2006,01/10/2006,01/01/2009,04/01/2009,01/04/2009,PAD,01/01/2009,"inflammatory markers, measured at baseline and 3 months|platelet biomarkers, measured at baseline and 3 months|nitric oxide formation, measured at baseline and 3 months",http://ClinicalTrials.gov/show/NCT00272311,United States,1,1,1,0
NCT00272337,Aspirin Dose and Atherosclerosis in Patients With Heart Disease,Completed,No Results Available,Cardiovascular Diseases|Atherosclerosis|Myocardial Infarction,Drug: Aspirin,Florida Atlantic University|Bayer,Both,Adult|Senior,Phase IV,70,Other|Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H07-29,01/03/2006,01/10/2006,01/01/2009,04/01/2009,01/04/2009,TAD,01/01/2009,"inflammatory markers, at baseline and 3 months.|platelet biomarkers, at baseline and 3 months.|nitric oxide formation, at baseline and 3 months.|endothelial function, at baseline and 3 months",http://ClinicalTrials.gov/show/NCT00272337,United States,1,1,1,0
NCT00273650,Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism,Completed,No Results Available,Autistic Disorder,Drug: methylcobalamin|Other: saline placebo,"University of California, Davis",Both,Child,Phase II|Phase III,35,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",MB12-AUT,01/06/2006,01/07/2005,01/08/2009,1/19/2010,01/01/2010,,01/06/2009,"Primary measure is the Clinical Global Impression Scale -Improvement supplemented by videos taken at all visits and rated blindly to measure executive function, speech, and language, and socio-economic development.|Secondary measures:NEPSY, ABC, PPVT, SB:V, PDRF, MCDI, PIA-CV, and CARS.",http://ClinicalTrials.gov/show/NCT00273650,United States,1,0,2,NA
NCT00273884,Amonafide in Combination With Cytarabine in Secondary AML,Completed,No Results Available,Acute Myeloid Leukemia,Drug: Amonafide L-Malate|Drug: Cytarabine,"Xanthus Pharmaceuticals, Inc.",Both,Adult|Senior,Phase II,80,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,0001A3-200-GL,01/05/2006,01/08/2005,01/04/2009,2/16/2007,01/02/2007,,01/04/2009,- To determine the rate of complete remission with or without complete hematopoietic recovery (CR + CRi).|Determine the median duration of complete remission with or without complete hematopoietic recovery (CR or CRi)|Determine the proportion of subjects,http://ClinicalTrials.gov/show/NCT00273884,"United States, &nbsp; Canada",1,0,2,NA
NCT00274768,Capecitabine in Treating Patients With Metastatic Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: capecitabine,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,45,Other|NIH,Interventional,Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,J0425 CDR0000446286|P30CA006973|JHOC-J0425|JHOC-SKCCC-J0425|JHOC-IRB-04032502,01/10/2006,01/04/2004,NA,08/06/2010,01/08/2010,,01/12/2009,"Response rate|Clinical benefit, time to treatment failure, safety and toxicity|Pharmacokinetic and pharmacodynamic effects|Patient adherence and compliance to oral treatment",http://ClinicalTrials.gov/show/NCT00274768,United States,1,1,1,1
NCT00275548,Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C,Completed,No Results Available,Liver Transplant|Hepatitis C,Drug: Pagssys and Copegus,Mayo Clinic|Roche Pharma AG,Both,Adult|Senior,Phase IV,12,Other|Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,1404-04,01/10/2006,01/07/2004,01/04/2009,1/19/2010,01/01/2010,,01/04/2009,"The proportion of patients in each group who experienced histologically confirmed recurrence of HCV at 120 weeks post randomization.|The proportion of patients who have non-detectable serum HCV-RNA measured by Quanta Sure plus HCV test and HCV RNA negative by quantative PCR at week 12, 24, and 48 following initiation of treatment or on observation.|Virological response rate to antiviral therapy at week 12, week 24, and week 48 of therapy among patients who received antiviral therapy in either study arm.|Sustained virological response rate: the virological response at the conclusion of the 24 weeks treatment free follow-up period or 72 weeks on observation (for patients who received no treatment).|The virological response at the conclusion of the 24 weeks treatment-free follow-up period among patients who received antiviral therapy in either arm of the study.|Patient death or graft failure (as indicated by retransplantation).",http://ClinicalTrials.gov/show/NCT00275548,United States,1,0,1,NA
NCT00276419,Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin,Completed,No Results Available,Breast Pain|Non-cyclical Mastalgia|Surgical Scar-Related Breast Pain,Drug: Compounded topical formulation of diclofenac|Drug: Placebo,Mayo Clinic,Female,Adult|Senior,Phase II|Phase III,27,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",92-05,01/11/2006,01/06/2005,01/05/2009,12/04/2009,01/12/2009,,01/05/2009,Frequency of breast pain|Severity of breast pain|Side effects|Adherence|Level of anxiety generated by breast symptoms,http://ClinicalTrials.gov/show/NCT00276419,United States,1,1,2,0
NCT00276614,Bortezomib in Treating Patients With Metastatic Kidney Cancer,Completed,No Results Available,Kidney Cancer,Drug: bortezomib,"University of California, Los Angeles|National Cancer Institute (NCI)",Both,Adult|Senior,Phase II,3,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000453541|P30CA016042|UCLA-0412011-01|MILLENNIUM-X05145,01/12/2006,01/04/2006,01/07/2009,06/03/2010,01/06/2010,,01/05/2009,Objective response rate as measured by RECIST criteria after every 2 courses of treatment for up to 6 courses,http://ClinicalTrials.gov/show/NCT00276614,United States,1,1,1,1
NCT00276861,Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer,Completed,No Results Available,Colorectal Cancer,Drug: gemcitabine hydrochloride|Drug: oxaliplatin,University of Miami Sylvester Comprehensive Cancer Center,Both,Adult|Senior,Phase II,27,Other,Interventional,Allocation: Non-Randomized|Primary Purpose: Treatment,EPROST-20030655|SCCC-2003110|WIRB-20050993,01/12/2006,01/09/2005,NA,01/11/2010,01/01/2010,,01/06/2009,Response rate as measured by RECIST criteria|Time to progression as measured by the Kaplan Meyer curve at completion of study treatment,http://ClinicalTrials.gov/show/NCT00276861,United States,1,1,2,0
NCT00277212,A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode,Completed,Has Results,Bipolar Disorder,Drug: Lamotrigine + Aripiprazole|Drug: Lamotrigine + Placebo,Bristol-Myers Squibb|Otsuka America Pharmaceutical,Both,Adult|Senior,Phase IV,1169,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CN138-392 ST,1/13/2006,01/12/2005,01/07/2009,11/16/2010,01/11/2010,,01/07/2009,"Proportion of Participants Not Experiencing Relapse Through Week 52 in the Double-Blind Relapse Assessment Phase (Phase 2)|Proportion of Participants Not Experiencing Relapse (Manic, Mixed, Depressive) in the Double-blind Relapse Assessment Phase Phase 2|Proportion of Participants Not Experiencing a Depressive Relapse in the Double-blind Relapse Assessment Phase (Phase 2)|Proportion of Participants Without Discontinuation for Any Reason in the Double-blind Relapse Assessment Phase (Phase 2)|Deaths, Treatment-Emergent Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation of Study Medication, Treatment-Emergent AEs and Treatment-Emergent Extrapyramidal Syndrome (EPS)-Related AEs|Adjusted Mean Change From Baseline in Body Weight, Phase 2|Number of Participants Showing Clinically Relevant Weight Loss by Study Week|Number of Participants Showing Clinically Relevant Weight Gain by Study Week|Adjusted Mean Change From Baseline in BMI by Study Week|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities Occurring During Double-Blind Treatment|Number of Participants With Potentially Clinically Relevant Vital Sign Abnormalities Occurring During Double-Blind Treatment|Number of Participants With Potentially Clinically Relevant Laboratory Abnormalities Occurring During Double-Blind Treatment (Phase 2)|Summary of Concomitant Medications, Phase 1|Summary of Concomitant Medications, Phase 2|Adjusted Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score|Adjusted Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score|Adjusted Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment,",http://ClinicalTrials.gov/show/NCT00277212,"United States, &nbsp; Puerto Rico",1,1,2,0
NCT00277641,Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity,Completed,No Results Available,Binge Eating Disorder|Obesity,Drug: Lamotrigine|Drug: placebo,Lindner Center of HOPE|GlaxoSmithKline|University of Cincinnati,Both,Adult,Phase III,70,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",106531,01/12/2006,01/03/2006,01/01/2009,03/12/2009,01/03/2009,,01/01/2009,The specific aims of this study are to examine the efficacy and safety of lamotrigine compared with placebo in outpatients with binge eating disorder associated with obesity.,http://ClinicalTrials.gov/show/NCT00277641,United States,1,1,2,0
NCT00279201,The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV),Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Insulin glargine|Drug: Lispro LM|Drug: Lispro Mid Mix|Drug: Lispro,Eli Lilly and Company,Both,Adult|Senior,Phase IV,2133,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,10455|F3Z-US-IOOV,12/15/2005,01/12/2005,01/11/2009,1/15/2010,01/01/2010,IOOV,01/11/2009,"INITIATION: Endpoint Hemoglobin A1c (HbA1c) after 6 months of starter insulin therapy with either insulin lispro low mixture [LM] twice-daily or insulin glargine.|MAINTENANCE: Duration of time that each starter insulin regimen is able to maintain HbA1c at goal.|ADDENDUM: Endpoint HbA1c after 6 months of second step intensification regimens in patients who have not achieved control during 6 months of starter insulin therapy.|INITIATION: Change in HbA1c from baseline to 24 weeks (or endpoint)|INITIATION: Percentage of patients with HbA1c < or = 7.0% and HbA1c < or = 6.5%|INITIATION: HbA1c at each visit|INITIATION: 7-point self-monitored plasma glucose (SMPG) profiles and postprandial excursions from these profiles|INITIATION: 1,5 Anhydroglucitol|INITIATION: Body weight|INITIATION: Incidence of self-reported hypoglycemic episodes|INITIATION: Insulin dose|INITIATION: Baseline and endpoint characteristics of patients who did vs. did not achieve HbA1c goal|MAINTENANCE: HbA1c at specified visits and endpoint|MAINTENANCE: 7-point SMPG profiles and postprandial excursions|MAINTENANCE: Rate of increase in HbA1c|MAINTENANCE: Percentage of patients with HbA1c < or = 7.0% and HbA1c < or = 6.5%|MAINTENANCE: Body weight|MAINTENANCE: Insulin dose|MAINTENANCE: Incidence of self-reported hypoglycemic episodes|MAINTENANCE: 1,5-Anhydroglucitol|MAINTENANCE: Change in HbA1c|MAINTENANCE: Baseline and endpoint characteristics of patients who did vs. did not achieve HbA1c goal|ADDENDUM: Change in HbA1c from point of second randomization to endpoint|ADDENDUM: Percentage of patients with HbA1c < or = 7.0% and < or = 6.5%|ADDENDUM: 7-point SMPG profiles|ADDENDUM: Body weight|ADDENDUM: Insulin dose|ADDENDUM: Incidence of self-reported hypoglycemic episodes|ADDENDUM: 1,5-Anhydroglucitol|ADDENDUM: HbA1c at specified visits and endpoint|INITIATION: Rate of self-reported hypoglycemic episodes|MAINTENANCE: Rate of self-reported hypoglycemic episodes|ADDENDUM: Rate of self-reported hypoglycemic episodes|INITIATION: Incremental weight change|MAINTENANCE: Incremental weight change|ADDENDUM: Incremental weight change",http://ClinicalTrials.gov/show/NCT00279201,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Brazil, &nbsp; Canada, &nbsp; Greece, &nbsp; Hungary, &nbsp; India, &nbsp; Netherlands, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Spain",1,1,4,1
NCT00280748,Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer,Completed,No Results Available,Lung Cancer|Metastatic Cancer,Drug: pemetrexed disodium|Radiation: radiation therapy,UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,30,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000551069|UNC-LCCC-0409,1/19/2006,01/05/2005,NA,8/29/2009,01/06/2009,,01/06/2009,Response of intracranial metastases (complete and partial response),http://ClinicalTrials.gov/show/NCT00280748,United States,1,1,2,1
NCT00282048,Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer,Completed,No Results Available,"Kidney Neoplasms|Carcinoma, Renal Cell",Drug: AG-013736 (axitinib),Pfizer,Both,Adult|Senior,Phase II,62,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,A4061023,1/23/2006,01/03/2006,01/08/2009,11/13/2009,01/11/2009,,01/02/2009,"Measured by overall objective response rate, CR and PR, by RECIST.|To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer|Progression-free survival|Duration of response|Explore effects of treatment on patient reported outcomes|Cancer related symptoms (FKSI)|Overall survival|Explore PK correlates with response or adverse events.|Safety profile of AG-013736",http://ClinicalTrials.gov/show/NCT00282048,United States,1,0,1,NA
NCT00282282,Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation,Completed,No Results Available,Graft Versus Host Disease|GVHD,Drug: tacrolimus|Drug: sirolimus|Drug: fludarabine|Drug: busulfex,Dana-Farber Cancer Institute|Brigham and Women's Hospital,Both,Adult|Senior,Phase II,30,Other,Interventional,Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,05-362,1/24/2006,01/01/2006,01/07/2009,01/04/2010,01/01/2010,,01/01/2009,"To assess the incidence and severity of grade II-IV acute GvHD developing by day 100 following non-myeloablative PBSC transplantation using tacrolimus and sirolimus.|To assess donor stem cell engraftment, including donor-host hematopoietic chimerism studies post transplant|to assess disease response.",http://ClinicalTrials.gov/show/NCT00282282,United States,1,1,4,0
NCT00283504,A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy,Completed,No Results Available,Allergic Asthma,Drug: ANTI-IGE THERAPY (XOLAIR),Children's Hospital of The King's Daughters|Novartis|Genentech,Both,Child|Adult,Phase IV,40,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,IRB# 05-08-EX-0247,1/26/2006,01/01/2006,01/01/2009,5/25/2010,01/01/2006,,01/01/2009,description of sputum inflammatory markers|improvement in lung functions and symptoms scores,http://ClinicalTrials.gov/show/NCT00283504,United States,1,1,1,1
NCT00283595,Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa,Completed,No Results Available,Anorexia Nervosa|Osteopenia|Osteoporosis|Eating Disorders,Drug: Recombinant Human Growth Hormone|Drug: Placebo for Recombinant Human Growth Hormone,Massachusetts General Hospital|Genentech,Female,Child|Adult,Phase II,21,Other|Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,2005-P-001443/3; MGH,1/27/2006,01/01/2006,01/02/2009,4/13/2009,01/04/2009,,01/02/2009,Bone Metabolism|IGF-1,http://ClinicalTrials.gov/show/NCT00283595,United States,1,1,2,1
NCT00284154,Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer,Completed,No Results Available,"Carcinoma, Small Cell|Lung Cancer",Drug: Vinflunine,Sarah Cannon Research Institute|Bristol-Myers Squibb,Both,Adult|Senior,Phase II,41,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SCRI LUN 122|CA183017,1/27/2006,01/01/2006,01/11/2009,11/01/2010,01/11/2010,,01/05/2009,Overall response rate|Duration of response|Overall survival|Progression free survival,http://ClinicalTrials.gov/show/NCT00284154,United States,1,0,1,NA
NCT00285259,Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT),Completed,No Results Available,Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Myelodysplastic Syndrome,Biological: VCL-CB01|Other: PBS,Vical,Both,Adult,Phase II,240,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CB01-202,1/30/2006,01/01/2006,01/11/2010,12/15/2010,01/07/2010,,01/11/2009,Safety of CMV immunotherapeutic vaccine in donors and recipients undergoing HCT|occurrence rate of clinically significant CMV viremia in recipients receiving CMV immunotherapeutic vaccine.,http://ClinicalTrials.gov/show/NCT00285259,United States,0,NA,2,NA
NCT00286793,Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer,Completed,No Results Available,Prostate Cancer,Drug: AT-101|Drug: Docetaxel|Drug: Prednisone,Ascenta Therapeutics,Male,Adult|Senior,Phase I|Phase II,75,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AT-101-CS-202,02/03/2006,01/02/2006,01/11/2009,02/02/2010,01/02/2010,,01/11/2009,Safety of AT-101 in combination with docetaxel and prednisone|Preliminary efficacy of AT-101 in combination with docetaxel and prednisone,http://ClinicalTrials.gov/show/NCT00286793,United States,1,0,3,NA
NCT00289549,"Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)",Completed,No Results Available,"Leukemia, Lymphocytic, Chronic",Drug: forodesine hydrochloride (BCX-1777),BioCryst Pharmaceuticals,Both,Adult|Senior,Phase II,30,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BCX1777-Bo-05-204,02/08/2006,01/06/2005,01/01/2009,12/02/2009,01/12/2009,,01/01/2009,,http://ClinicalTrials.gov/show/NCT00289549,United States,1,0,1,NA
NCT00291226,Glycine vs Placebo for the Schizophrenia Prodrome,Completed,No Results Available,Schizophrenia Prodrome,Drug: Glycine|Drug: Placebo,"Yale University|Glytech, Inc|National Alliance for Research on Schizophrenia and Depression",Both,Child|Adult,Phase II|Phase III,8,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Glytech|NARSAD Distinguished 2005,02/10/2006,01/03/2006,01/07/2009,1/13/2010,01/01/2010,,01/07/2009,Scale of Prodromal Symptoms total score,http://ClinicalTrials.gov/show/NCT00291226,United States,1,1,2,0
NCT00291330,Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism,Completed,No Results Available,Thromboembolism,Drug: Dabigatran etexilate|Drug: Warfarin,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase III,2564,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,1160.53|2005-001999-12,2/13/2006,01/02/2006,NA,5/27/2009,01/05/2009,,01/05/2009,"Composite of recurrent symptomatic venous thromboembolism (VTE) and deaths related to VTE within 6 months. VTE is defined as the composite incidence of deep vein thrombosis (DVT) of the leg and pulmonary embolism (PE).|Composite of recurrent symptomatic VTE and all deaths, symptomatic DVT, symptomatic PE, deaths related to VTE and all deaths. Bleeds, adverse events (AEs), discontinuation due to AEs, laboratory measures, Acute Coronary Syndromes, ECG and vital signs.",http://ClinicalTrials.gov/show/NCT00291330,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Hungary, &nbsp; India, &nbsp; Israel, &nbsp; Italy, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; New Zealand, &nbsp; Norway, &nbsp; Portugal, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Turkey, &nbsp; Ukraine, &nbsp; United Kingdom",1,1,2,0
NCT00294762,Tarceva as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Tarceva|Drug: Tarceva + carboplatin/paclitaxel,OSI Pharmaceuticals,Both,Adult|Senior,Phase II,140,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,OSI-774-203,2/17/2006,01/01/2006,01/04/2009,6/29/2010,01/05/2009,,01/04/2009,"Progression Free Survival|Estimates, overall survival, tumor response, Safety",http://ClinicalTrials.gov/show/NCT00294762,"United States, &nbsp; United Kingdom",1,1,2,0
NCT00296374,Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease,Completed,Has Results,Diabetes Mellitus,Drug: Rosuvastatin|Drug: Rosuvastatin|Drug: Atorvastatin,AstraZeneca,Both,Adult|Senior,Phase II,353,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D3569C00007|PLANET 1,2/23/2006,01/02/2006,01/03/2009,11/30/2010,01/11/2010,PLANET 1,01/03/2009,Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes.|Urinary Protein/Creatinine Ratio at Week 26.|Urinary Albumin/Creatinine Ratio at Week 26|Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]|Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26|Change From Baseline in eGFR at Week 52 [LOCF]|Correlation Coefficient Urinary Protein/Creatinine Ratio and Total Cholesterol [TC] Indicating the Relationship Between Renal Effects and Lipid Changes|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio TC|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Low Density Lipoprotein Cholesterol [LDL-C]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and High Density Lipoprotein Cholesterol [HDL-C]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and HDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Non-high Density Lipoprotein Cholesterol [nonHDL-C]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Triglyceride [TG]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TG|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein A-1 [ApoA-1]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoA-1|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and Apolipoprotein B [ApoB]|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Protein/Creatinine Ratio and ApoB/ApoA-1 Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and HDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TG|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoA-1|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio|Relationship Between Renal Effects and Lipid Changes: Urinary Albumin/Creatinine Ratio and ApoB/ApoA-1 Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and TC|Relationship Between Renal Effects and Lipid Changes: eGFR and TC|Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and HDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C|Relationship Between Renal Effects and Lipid Changes: eGFR and TG|Relationship Between Renal Effects and Lipid Changes: eGFR and TG|Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and TC/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and LDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and nonHDL-C/HDL-C Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoA1|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio|Relationship Between Renal Effects and Lipid Changes: eGFR and ApoB/ApoA-1 Ratio,http://ClinicalTrials.gov/show/NCT00296374,"United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Denmark, &nbsp; France, &nbsp; Hungary, &nbsp; Italy, &nbsp; Mexico, &nbsp; Romania",1,1,3,1
NCT00296400,Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease,Completed,Has Results,Hyperlipidemia,Drug: Rosuvastatin|Drug: Atorvastatin,AstraZeneca,Both,Adult|Senior,Phase II,237,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,D3569C00011|PLANET II,2/23/2006,01/02/2006,01/06/2009,11/30/2010,01/11/2010,PLANET II,01/06/2009,Urinary Protein/Creatinine Ratio at Week 52 [LOCF]|Urinary Protein/Creatinine Ratio at Week 26.|Urinary Albumin/Creatinine Ratio at Week 26|Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]|Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26|Change From Baseline in eGFR at Week 52 [LOCF]|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26|Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26|Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26|Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26|Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26|Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52,http://ClinicalTrials.gov/show/NCT00296400,"United States, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Denmark, &nbsp; Germany, &nbsp; Hungary, &nbsp; Italy, &nbsp; Mexico, &nbsp; Romania, &nbsp; South Africa",1,1,2,0
NCT00297037,Pimecrolimus Cream for Oral Lichen Planus,Completed,No Results Available,Oral Lichen Planus,Drug: Pimecrolimus cream,University of Utah|Novartis,Both,Adult|Senior,Phase II,22,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",12589,2/23/2006,01/08/2005,01/02/2009,02/09/2009,01/02/2009,,01/02/2009,"The primary efficacy variable will be change in the Investigator's Global Assessment of the overall severity of disease from baseline to week 6.|The secondary efficacy variables will be changes in the size of the target erosion in millimeters, erythema and assessment of spontaneous pain on a visual analog scale (0-10).",http://ClinicalTrials.gov/show/NCT00297037,United States,1,1,1,1
NCT00297089,A Phase 2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer,Completed,No Results Available,Non-Small-Cell Lung Cancer|Lung Cancer|NSCLC,Drug: ABT-751|Drug: pemetrexed|Drug: placebo,Abbott,Both,Adult|Senior,Phase I|Phase II,165,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M05-780,2/27/2006,01/11/2006,NA,11/10/2010,01/09/2010,,01/01/2009,Progression-free Survival|Overall Survival|Response Rate|Time-to-Progression (TTP),http://ClinicalTrials.gov/show/NCT00297089,"United States, &nbsp; Czech Republic, &nbsp; Greece, &nbsp; Netherlands, &nbsp; Slovakia",1,0,3,NA
NCT00297947,High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder,Drug: quetiapine|Drug: quetiapine,Manhattan Psychiatric Center|Nathan Kline Institute for Psychiatric Research,Both,Adult,Phase II|Phase III,60,Other,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRUSQUET0348,2/27/2006,01/12/2004,NA,08/09/2010,01/08/2010,HDQ,01/10/2009,To see if mean extrapyramidal symptoms measure will change significantly from baseline to endpoint for the whole group and if the mean change in EPS measure is significantly different between quetiapine 1200mg daily group and quetiapine 600mg daily group|To see if treatment with quetiapine 1200 mg per day will improve total PANSS more robustly than quetiapine 600 mg per day,http://ClinicalTrials.gov/show/NCT00297947,United States,1,1,2,1
NCT00298766,Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis,Completed,Has Results,Amyloidosis,Drug: VELCADE,"Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Both,Adult|Senior,Phase I|Phase II,70,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,26866138-CAN-2007,03/01/2006,01/06/2005,01/09/2009,9/24/2010,01/09/2010,,01/07/2009,Maximum Tolerated Dose|Subjects With Treatment Emergent Adverse Events|Subjects With Serious Treatment Emergent Adverse Events|Subjects Grade 3/4/5 Treatment Emergent Adverse Events|Subjects With Treatment Emergent Adverse Events Leading to Treatment Termination|Best Confirmed Hematologic Responders,http://ClinicalTrials.gov/show/NCT00298766,United States,1,1,1,1
NCT00299000,A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI,Completed,Has Results,Mucopolysaccharidosis VI|Maroteaux-Lamy Syndrome,Drug: Naglazyme,BioMarin Pharmaceutical,Both,Child,Phase IV,4,Industry,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,ASB-008,03/02/2006,01/05/2006,01/04/2009,9/28/2010,01/09/2010,,01/04/2009,Change in Height|Change in Weight|Change in Haed Circumference|Change in Urinary Glycosaminoglycan Levels,http://ClinicalTrials.gov/show/NCT00299000,"United States, &nbsp; France, &nbsp; Portugal",1,1,1,1
NCT00299416,Caffeinol Hypothermia Protocol,Completed,No Results Available,Acute Ischemic Stroke,Drug: Caffeinol|Procedure: hypothermia,"The University of Texas Health Science Center, Houston",Both,Adult|Senior,Phase I|Phase II,30,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HSC- MS-02-188|P50NS44277 project #1,03/02/2006,01/02/2003,01/08/2009,07/12/2010,01/07/2010,,01/01/2009,"Safety: symptomatic hemorrhage, catheter-related complications, infections, cardiorespiratory failure, arrhythmias|Feasibility: time required to reach the target core temperature or lowest tolerated temperature, stability of patient temperature, control of rewarming,|achievement of therapeutic serum ethanol and caffeine levels, and amount of sedation needed to suppress shivering.|Efficacy: NIHSS < 2 at 24 hours, mRS < 2 at 3 months, NIHSS < 2 at 3 months, and length of hospital and ICU stay.",http://ClinicalTrials.gov/show/NCT00299416,United States,1,0,2,NA
NCT00299988,Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: Intravenous Immunoglobulin,Weill Medical College of Cornell University|Baxter BioScience|National Institutes of Health (NIH),Both,Adult|Senior,Phase II,24,Other|Industry|NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,512008265,03/03/2006,01/02/2006,01/04/2010,11/08/2010,01/11/2010,,01/01/2009,ADAS-Cog|ADCS-CGIC|3MS|ADCS-ADL|NPI|GDS|QOL|ADCS Pharmacoeconomic Assessment|Plasma and CSF anti-amyloid antibody titers|Plasma and CSF beta amyloid levels|FDG Cerebral Glucose Utilization|PIB Cerebral Amyloid Distribution (PET)|PK11195 Microglial Activation (PET)|Adverse Event Frequency and Severity,http://ClinicalTrials.gov/show/NCT00299988,United States,1,0,1,NA
NCT00303251,Safety of TKI258 in Advanced/Metastatic Melanoma Subjects,Completed,No Results Available,Melanoma,Drug: TKI258,Novartis Pharmaceuticals,Both,Adult|Senior,Phase I|Phase II,47,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CTKI258A2105,3/14/2006,01/04/2006,NA,11/20/2009,01/11/2009,,01/09/2009,"Dose Expansion: Determine the maximum tolerated dose based on dose limiting toxicity of TKI258|Dose Expansion: Determine the plasma and whole blood pharmacokinetics of orally administered TKI258|Dose Escalation: Assess tumor response according to RECIST as measured by response rate and lack of early progressive disease (<=2 months)|Assess the safety profile of TKI258 in this patient population|Assess the effect of TKI258 on biomarkers in the blood|Assess biomarker changes in tumor/nevi biopsies and archival tumor tissues where accessible, pre- and post-treatment|Assess changes in tumor glucose metabolism/cell viability between pre- and post-treatment using [18F]-FDG-PET|Assess anti-angiogenic effects of TKI258 using DCE-MRI pre- and post-treatment",http://ClinicalTrials.gov/show/NCT00303251,United States,1,0,1,NA
NCT00303446,Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA),Completed,Has Results,Kennedy's Disease|Spinal and Bulbar Muscular Atrophy,Drug: Dutasteride|Drug: Placebo,National Institute of Neurological Disorders and Stroke (NINDS),Male,Adult|Senior,Phase II,57,NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",060113|06-N-0113,3/15/2006,01/03/2006,01/12/2009,6/21/2010,01/06/2010,,01/12/2009,"Muscle Strength Change From Baseline|Creatine Kinase, Change From Baseline|Manual Muscle Testing, Change From Baseline.|Adult Myopathy Assessment Tool, Change From Baseline|Timed 2-minute Walk, Change From Baseline|Swallow Score Average, Change From Baseline|Bulbar Rating Scale, Change From Baseline|Sensory Nerve Action Potential Average, Change From Baseline|Median Compound Muscle Action Potential, Change From Baseline|Peroneal Compound Muscle Action Potential, Change From Baseline|Motor Unit Nerve Estimation, Change From Baseline|Activities of Daily Living, Change From Baseline|Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Physical Component Summary, Change From Baseline|Medical Outcomes Study 36-item Short Form Version 2 (SF-36v2) Mental Component Summary, Percent Change From Baseline|International Index for Erectile Function (IIEF), Change From Baseline",http://ClinicalTrials.gov/show/NCT00303446,United States,1,1,2,1
NCT00305188,Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.,Completed,No Results Available,Metastases|Colorectal Neoplasms|Colorectal Carcinoma,Drug: xaliproden (SR57746A)|Drug: Placebo|Drug: oxaliplatin,Sanofi-Aventis,Both,Adult|Senior,Phase III,879,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Prevention",EFC5505|EUDRACT : 2005-002570-30,3/20/2006,01/12/2005,01/10/2009,12/16/2010,01/12/2010,,01/10/2009,Clinical evaluation of peripheral sensory neuropathy using the Oxaliplatin specific scale for dose adjustment|Main: response rate using RECIST criteria|Other: nerve conduction studies|Other: progression free survival and survival,http://ClinicalTrials.gov/show/NCT00305188,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; Germany, &nbsp; Hungary, &nbsp; Italy, &nbsp; Poland, &nbsp; Portugal, &nbsp; Spain, &nbsp; United Kingdom",1,0,3,NA
NCT00305942,Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer,Completed,No Results Available,"Carcinoma, Small Cell",Drug: Topotecan|Drug: carboplatin,Sarah Cannon Research Institute|GlaxoSmithKline,Both,Adult|Senior,Phase II,60,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SCRI LUN 117|105118,3/20/2006,01/03/2006,01/11/2009,11/01/2010,01/11/2010,,01/04/2009,Overall response rate,http://ClinicalTrials.gov/show/NCT00305942,United States,1,1,2,0
NCT00307398,Anecortave Acetate Risk-Reduction Trial (AART),Completed,No Results Available,Dry AMD,Drug: Anecortave Acetate,Alcon Research,Both,Adult|Senior,Phase III,2500,Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Treatment,C-02-60,3/24/2006,01/03/2004,NA,05/07/2009,01/05/2009,,01/01/2009,To demonstrate that anecortave acetate is safe and effective in arresting the progression of dry AMD to wet AMD in at-risk patients|Time to development of sight threatening CNV,http://ClinicalTrials.gov/show/NCT00307398,United States,1,0,1,NA
NCT00308750,First Line Chemotherapy Treatment of Advanced NSCLC,Completed,No Results Available,Non-small Cell Lung Cancer,Drug: enzastaurin|Drug: pemetrexed|Drug: docetaxel|Drug: carboplatin,Eli Lilly and Company,Both,Adult|Senior,Phase II,217,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,10651|H6Q-US-S004,3/28/2006,01/03/2006,01/07/2009,5/27/2010,01/05/2010,,01/07/2009,"Time to progressive disease|Assessment of biomarkers relevant to pemetrexed, carboplatin, enzastaurin, and disease state, and their correlation to clinical outcome|Assessment of smoking history and hormone replacement therapy and the correlation to clinical outcome|Comparisons of safety between each treatment arm|Comparisons of patient reported outcomes using the FACT-Lung and FACT-Taxane|Overall survival|Duration of response|Time to treatment failure",http://ClinicalTrials.gov/show/NCT00308750,United States,1,0,4,NA
NCT00309140,An Open Label Study of Oral Enzastaurin in Patients With Cancer,Completed,No Results Available,Neoplasms|Cancer,Drug: enzastaurin,Eli Lilly and Company,Both,Adult|Senior,Phase II,23,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,10287|H6Q-MC-S001,3/29/2006,01/03/2006,01/07/2009,5/27/2010,01/05/2010,,01/07/2009,This study will collect basic safety data on patients cancer treated with enzastaurin.|This study will document antitumor activity that may be observed with enzastaurin.,http://ClinicalTrials.gov/show/NCT00309140,United States,1,0,1,NA
NCT00310011,"Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium",Completed,No Results Available,Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter,Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Procedure: conventional surgery,Wake Forest University|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,71,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000466059|CCCWFU-88197|CCCWFU-BG98-217|AMGEN-CCCWFU-88197,3/29/2006,01/06/1998,NA,9/18/2009,01/12/2006,,01/07/2009,Response|Response duration|Freedom from progression|Overall survival|Toxicity,http://ClinicalTrials.gov/show/NCT00310011,United States,1,1,4,1
NCT00311584,Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma,Completed,No Results Available,Neuroblastoma,Drug: irinotecan hydrochloride|Drug: temozolomide,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult,Phase II,50,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000465487|COG-ANBL0421,04/05/2006,01/04/2006,NA,1/15/2011,01/11/2010,,01/04/2009,Overall response (complete and partial response),http://ClinicalTrials.gov/show/NCT00311584,"United States, &nbsp; Australia, &nbsp; Canada",1,1,2,0
NCT00312052,Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease,Completed,No Results Available,Coronary Artery Disease,Drug: E5555|Drug: E5555|Drug: E5555|Drug: Placebo,Eisai Inc.,Both,Adult|Senior,Phase II,600,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",E5555-G000-201,04/05/2006,01/09/2007,01/09/2009,09/01/2009,01/09/2009,,01/02/2009,Safety and tolerability - especially the risk of bleeding|Incidence of major adverse cardiovascular events; the effect on platelet aggregation inhibition. Exploratory Outcome Measure: effects on endovascular inflammatory processes,http://ClinicalTrials.gov/show/NCT00312052,United States,1,0,4,NA
NCT00315640,Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation,Completed,No Results Available,Eye Diseases,Drug: Anecortave Acetate,Alcon Research,Both,Adult|Senior,Phase II,60,Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,C-05-03|2005-001598-93,4/17/2006,01/12/2005,NA,1/27/2010,01/01/2010,,01/08/2009,Mean IOP,http://ClinicalTrials.gov/show/NCT00315640,"United States, &nbsp; Brazil, &nbsp; Hungary, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Puerto Rico, &nbsp; Spain, &nbsp; United Kingdom",1,0,1,NA
NCT00316173,Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer,Completed,Has Results,Ovarian Cancer,Drug: topotecan|Drug: CARBOPLATIN,GlaxoSmithKline,Female,Adult|Senior,Phase II,77,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,104864/902,4/19/2006,01/03/2005,01/03/2009,12/17/2009,01/12/2009,,01/01/2009,Number of Participants With the Indicated Response|Time to Response|Duration of Response|Progression-free Survival|Number of Participants Who Died From the Start of Treatment to Follow-up|The Number of Participants Classified as Responders in Cancer Antigen 125 (CA-125)|Time to Disease Progression,http://ClinicalTrials.gov/show/NCT00316173,"United States, &nbsp; Canada",1,1,2,0
NCT00316589,Safety and Immunogenicity of IMVAMUNE?ó (MVA-BN?ó) Smallpox Vaccine in HIV Infected Patients,Completed,No Results Available,HIV Infections,Biological: IMVAMUNE (MVA-BN)|Biological: IMVAMUNE|Biological: IMVAMUNE,Bavarian Nordic|National Institutes of Health (NIH),Both,Adult,Phase II,581,Industry|NIH,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,POX-MVA-011,4/19/2006,01/06/2006,01/10/2009,5/21/2010,01/05/2010,,01/03/2009,"Occurrence, relationship and intensity of any serious and/or unexpected adverse reaction at any time during the study|Neutralisation assay specific seroconversion rates and geometric mean titres (at all blood sampling time points);|ELISA specific seroconversion rates and geometric mean titres (at all blood sampling time points)",http://ClinicalTrials.gov/show/NCT00316589,"United States, &nbsp; Puerto Rico",0,NA,3,NA
NCT00316602,A Phase II Study on Immunogenicity and Safety of MVA-BN?ó (IMVAMUNE?ºÑ) Smallpox Vaccine in Subjects With Atopic Dermatitis,Completed,No Results Available,Atopic Dermatitis,Biological: MVA-BN?ó (IMVAMUNE)|Biological: IMVAMUNE,Bavarian Nordic|National Institute of Allergy and Infectious Diseases (NIAID),Both,Adult,Phase II,632,Industry|NIH,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,POX-MVA-008|DMID 05-0133,4/20/2006,01/07/2006,01/04/2010,5/19/2010,01/05/2010,,01/11/2009,"Seroconversion rate at visit 4 assessed by MVA-BN ELISA|Neutralisation assay specific seroconversion rates and geometric mean titres (at all blood sampling time points)|ELISA specific seroconversion rates and geometric mean titres (at all blood sampling time points)|Occurrence, relationship and intensity of any serious and/or unexpected adverse reaction at any time during the study",http://ClinicalTrials.gov/show/NCT00316602,"United States, &nbsp; Mexico",0,NA,2,NA
NCT00316914,"Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery",Completed,No Results Available,Colorectal Cancer|Neurotoxicity,Drug: calcium gluconate|Drug: magnesium sulfate|Other: placebo,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase III,300,Other|NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care,CDR0000471238|NCCTG-N04C7,4/19/2006,01/01/2006,NA,1/13/2011,01/07/2009,,01/07/2009,Percentage of patients with oxaliplatin-induced neurotoxicity as assessed by CTCAE v3.0|Time to onset of grade 2+ chronic neurotoxicity as assessed by CTCAE v3.0|Time to onset of grade 3+ chronic neurotoxicity as assessed by CTCAE v3.0|Average duration of chronic neuropathic toxicity as assessed by CTCAE v3.0|Percentage of patients discontinuing therapy as assessed by CTCAE v3.0|Average cumulative oxaliplatin dose|Average duration of treatment|Percentage of patients with acute neuropathic toxicity|Incidence of calcium magnesium (CaMg)-induced toxicity|Percentage of patients experiencing impact on activities of daily living (ADL)|Average fatigue from baseline to 1 month|Average quality of life from baseline to 1 month|Percentage of patients with grade 2+ chronic neuropathic toxicity who express the GSTP1 1105V polymorphism|Time to onset of grade 2+ chronic neuropathic toxicity comparison between patients who either express or don't express the GSTP1 1105V polymorphism,http://ClinicalTrials.gov/show/NCT00316914,United States,1,1,3,0
NCT00318591,Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections,Completed,No Results Available,Urinary Tract Infections,Device: Intermittent catheter|Device: intermittent catheter,Coloplast A/S,Both,Adult|Senior,Phase IV,226,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,DK046CC,4/26/2006,01/04/2006,01/10/2009,1/19/2010,01/01/2010,,01/10/2009,"Occurrence of symptomatic urinary tract infections (UTIs)|Symptomatic UTIs where antibiotic treatment has been prescribed|Symptomatic UTIs that meet protocol definition and antibiotic treatment has been prescribed|Bacteriuria, urine leucocytes and erythrocytes|Nurse evaluation of catheters ans overall satisfaction|Patient or caregiver's evaluation of catheters and overall satisfaction|Nurse time spent on catheterization procedure|Health economic measures|Adverse events",http://ClinicalTrials.gov/show/NCT00318591,"United States, &nbsp; Canada",0,NA,2,NA
NCT00318708,Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA),Completed,No Results Available,Asthma,Drug: Clarithromycin|Drug: Fluticasone propionate,"National Heart, Lung, and Blood Institute (NHLBI)",Both,Adult,Phase III,92,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",377|5U10 HL074231|7U10 HL074206|5U10 HL074208|5U10 HL074073|5U10 HL074227|5U10 HL074225|5U10 HL074204|5U10 HL074218|5U10 HL074212,4/25/2006,01/06/2006,01/04/2009,6/23/2009,01/06/2009,MIA,01/04/2009,Asthma control questionnaire (ACQ) results|Asthma symptoms|Asthma rescue medication use|AM and PM peak expiratory flow (PEF)|Forced expiratory volume in one second (FEV1)|Asthma-specific quality of life|Methacholine provocative concentration (PC20)|Exhaled nitric oxide (eNO)|Blood cell counts|AM cortisol|Adverse events,http://ClinicalTrials.gov/show/NCT00318708,United States,1,1,2,1
NCT00319111,Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH),Completed,No Results Available,Pulmonary Hypertension,Drug: bosentan,Actelion,Both,Adult|Senior,Phase III,148,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AC-052-370|BENEFIT OL,4/26/2006,01/01/2006,01/04/2009,02/11/2010,01/02/2010,BENEFIT,01/02/2009,Change from baseline to all assessed time points in 6-minute walk test distance|Change from baseline to all assessed time points in Borg dyspnea index|Change from baseline to all assessed time points in New York Heart Association (NYHA) class|Time to clinical worsening up to end-of-study|Adverse event(s) leading to premature discontinuation of study medication|Serious adverse events up to 28 days after study medication discontinuation|Occurrence of liver function test (ALT and/or AST) abnormality and hemoglobin abnormality,http://ClinicalTrials.gov/show/NCT00319111,"United States, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Spain, &nbsp; United Kingdom",1,1,1,0
NCT00319254,Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer,Completed,No Results Available,Breast Neoplasms|Neoplasm Metastasis,Drug: SKI-606 (Bosutinib),Wyeth,Female,Adult|Senior,Phase II,75,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,3160A2-201|B1871014,4/24/2006,01/04/2006,01/02/2009,11/29/2010,01/11/2010,,01/02/2009,Rate of progression free survival (PFS) at 16 weeks.|Safety profile of 400mg/day|Rate of objective response within 1 year after beginning treatment.|Survival rate at 3 years after beginning treatment.|Pharmacokinetics (PK) of SKI-606 (Bosutinib) in this patient population.,http://ClinicalTrials.gov/show/NCT00319254,"United States, &nbsp; Australia, &nbsp; France, &nbsp; Hong Kong, &nbsp; Malta, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Ukraine",1,0,1,NA
NCT00320242,Laser Light Cues for Gait Freezing in Parkinson's Disease,Completed,No Results Available,Parkinson's Disease,Device: Laser Cane and U-Step Walker with Laser Accessory,Beth Israel Deaconess Medical Center,Both,Adult|Senior,Phase III,26,Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,2006-P-000085,4/28/2006,01/04/2006,01/06/2009,7/31/2009,01/07/2009,,01/06/2009,Mean change from baseline (visit 1 until visit 2) to endpoint (after visit 2 until visit 3) in the freezing of gait questionnaire score.|Mean change in time to perform the timed gait test with versus without the laser feature from visit 1 to visit 3.|Mean change in falls per month for the period between visit 1 and visit 2 (without laser) compared to the period between visit 2 and visit 3 (with the laser).|Comparison of the changes in falls and the Freezing of Gait Questionnaire scores for group 1 versus group 2 based on the change from the first month after baseline visit to the second month after the baseline visit.,http://ClinicalTrials.gov/show/NCT00320242,United States,0,NA,1,NA
NCT00320255,A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer,Completed,No Results Available,Thrombosis|Cancer|Pulmonary Embolism,Drug: Apixaban|Drug: Placebo,Bristol-Myers Squibb|Ontario Clinical Oncology Group,Both,Adult|Senior,Phase II,129,Industry|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",CV185-027,4/28/2006,01/06/2006,01/01/2009,01/06/2011,01/05/2009,,01/01/2009,The occurrence of either a major bleeding (fatal or non-fatal) event or a clinically relevant non-major bleeding event|Symptoms compatible with venous thromboembolism,http://ClinicalTrials.gov/show/NCT00320255,"United States, &nbsp; Canada",1,0,2,NA
NCT00320489,Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: olanzapine|Drug: olanzapine pamoate depot,Eli Lilly and Company,Both,Adult,Phase III,524,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,6390|F1D-MC-HGLQ,4/28/2006,01/04/2006,01/09/2009,10/25/2010,01/10/2010,,01/09/2009,"Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision)|Change From Baseline in Heinrich-Carpenter Quality of Life in Schizophrenia Scale (QLS) Total Score at 104 Weeks|Change From Baseline in 36-Item Short Form Health Survey (SF-36) at 104 Weeks, All Domains and Summary Scores|Change From Baseline in Overall Health Status Assessment Using the EuroQol: 5 Dimensions Questionnaire (EQ-5D) at 104 Weeks|Change From Baseline in Burden Assessment Scale (BAS) Total Score at 104 Weeks|Resource Utilization: Number of Outpatient Physician Visits During the Study|Resource Utilization: Days of Unpaid Care, Days of Workdays Missed, Days of Paid Care Per Week During the Study|Number of Hospitalization Days|Change From Baseline in Scale to Assess Unawareness of Mental Disorder (SUMD) Total Score at 104 Weeks|Change From Baseline in Working Alliance Inventory (WAI) Total Score at 104 Weeks|Change From Baseline in Schizophrenia Objective Functioning Instrument (SOFI) Global Score at 104 Weeks|Patient Satisfaction With Medication Questionnaire-Modified (PSMQ) at 104 Weeks (All Items)|Patient Attitude Toward Treatment Using the Drug Attitude Inventory (DAI) Scale Total Score at 104 Weeks|Number of Participants With All-Cause Discontinuations (Excluding Sponsor Decision)|Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Scale Scores at 104 Weeks|Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total and Subscale Scores at 104 Weeks|Median Time to Relapse|Number of Participants Experiencing Relapse|Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Score at 104 Weeks|Resource Utilization: Number of Outpatient Surgeries During the Study, 24 Months After Randomization|Change From Baseline in Weight at 104 Weeks|Participants With Potentially Clinically Significant (PCS) Weight Gain at 104 Weeks|Participants With Normal to High Fasting Glucose, Fasting Total Cholesterol, and Fasting Triglycerides|Participants With Treatment-Emergent Abnormal High Prolactin at 104 Weeks|Participants With Treatment-Emergent High Alanine Transaminase (ALT), Aspartate Transaminase (AST), and Total Bilirubin|Participants Discontinuing Because of an Adverse Event (AE) or Death",http://ClinicalTrials.gov/show/NCT00320489,"United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Canada, &nbsp; France, &nbsp; Greece, &nbsp; Portugal, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Slovakia, &nbsp; Spain, &nbsp; Taiwan",1,1,2,1
NCT00321854,Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease,Completed,Has Results,Parkinson Disease,Drug: pramipexole,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase IV,535,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,248.595,05/03/2006,01/05/2006,NA,09/01/2010,01/09/2010,,01/04/2009,Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Total Score at Month 9|Change From Baseline in the Investigator Rated UPDRS Total Score at Month 6|Change From Baseline in the Investigator Rated UPDRS Total Score at Month 3|Change From Baseline in the Blinded Rater UPDRS Parts II+III Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 9|Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 6|Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 3|Change From Baseline in the Blinded Rater UPDRS Part III Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 9|Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 6|Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 3|Change From Baseline in the Blinded Rater UPDRS Part II Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 9|Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 6|Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 3|Change From Baseline in the Blinded Rater UPDRS Part I Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 15|Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 9|Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 6|Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 3|Number of Responders Using the Blinded Rater Assessment of Clinical Global Impressions of Global Improvement (CGI-I) Score at Month 15|Change From Baseline in Blinded Rater Assessment of Clinical Global Impressions of Severity of Illness (CGI-S) Category at Month 15|Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 15|Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 9|Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 6|Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 3|Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 15|Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 9|Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 15|Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 9|Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 15|Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 9|Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 1|Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 6|Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 9|Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 12|Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 15|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 1|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 6|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 9|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 12|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 15|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 1|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 6|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 9|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 12|Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 15|Percentage Change From Baseline in the Striatum Uptake at Month 15,http://ClinicalTrials.gov/show/NCT00321854,"United States, &nbsp; Austria, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Japan, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",1,1,1,1
NCT00322465,NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole),Completed,No Results Available,C Trachomatis|M Genitalium|Non-Gonococcal Urethritis|Urethritis|T Vaginalis,Drug: Azithromycin|Drug: Placebo|Drug: Tinidazole|Drug: Doxycycline,National Institute of Allergy and Infectious Diseases (NIAID),Male,Child|Adult,Phase II,305,NIH,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",05-0120,05/04/2006,01/11/2006,01/04/2009,02/04/2010,01/11/2009,,01/04/2009,"Evaluate the safety and tolerability of doxycycline/tinidazole and azithromycin/tinidazole in the treatment of NGU.|For the treatment of NGU, compare the clinical cure rates of doxycycline versus doxycycline with tinidazole; and azithromycin versus azithromycin with tinidazole.|Clinical cure rates, analysis will also include: (doxycycline plus doxycycline/tinidazole) versus (azithromycin plus azithromycin/tinidazole).|Collect specimens for future studies to determine the role of unique and novel pathogens in the etiology of non-gonococcal urethritis.|Evaluate microbiological cure of C. trachomatis, T. vaginalis, and M. genitalium in men treated with doxycycline versus doxycycline with tinidazole; and azithromycin versus azithromycin with tinidazole.|Prevalence of C. trachomatis, T. vaginalis, and M. genitalium in men with non-gonococcal urethritis; clinical, behavioral, and demographic predictors of C. trachomatis, T. vaginalis, and M. genitalium in men with non-gonococcal urethritis.",http://ClinicalTrials.gov/show/NCT00322465,United States,1,1,4,0
NCT00323882,Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer,Completed,No Results Available,Prostate Cancer|Neoplasm Metastasis,Drug: MDX-010,Bristol-Myers Squibb,Male,Adult|Senior,Phase I|Phase II,66,Industry,Interventional,Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MDX010-21|CA184-017,05/08/2006,01/02/2005,01/09/2009,4/23/2010,01/04/2010,MDX010-21,01/09/2009,"The primary objective of the study is to determine the safety profile|Provide a preliminary assessment of clinical antitumor activity, including an assessment of prostate-specific antigen (PSA) responses and metabolic bone activity.",http://ClinicalTrials.gov/show/NCT00323882,United States,1,0,1,NA
NCT00327444,Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites,Completed,No Results Available,Ovarian Neoplasms|Ascites,Drug: aflibercept (AVE0005 / VEGF Trap)|Drug: placebo,Sanofi-Aventis|Regeneron Pharmaceuticals,Female,Adult|Senior,Phase II|Phase III,58,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",EFC6125|EudraCT : 2005-005026-31|AVE0005A /3001,5/16/2006,01/07/2006,01/10/2009,08/03/2010,01/08/2010,,01/10/2009,Time to repeat paracentesis|Ascites Impact Measure (patient questionnaire)|60-Day frequency of paracentesis,http://ClinicalTrials.gov/show/NCT00327444,"United States, &nbsp; Austria, &nbsp; Belgium, &nbsp; Canada, &nbsp; Hungary, &nbsp; India, &nbsp; Israel, &nbsp; Spain, &nbsp; United Kingdom",1,0,2,NA
NCT00327743,Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer,Completed,No Results Available,Breast Cancer|Cancer,Drug: larotaxel (XRP9881)|Drug: capecitabine,Sanofi-Aventis,Female,Adult|Senior,Phase I|Phase II,34,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TCD6511|EudraCT:2006-006474-21,05/04/2006,01/08/2006,01/03/2009,08/03/2010,01/08/2010,,01/03/2009,"Safety, tolerability, and maximum tolerated dose (MTD) of XRP9881 when given in combination with capecitabine|Response in patients with measurable disease",http://ClinicalTrials.gov/show/NCT00327743,"United States, &nbsp; France",1,0,2,NA
NCT00330369,DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension,Completed,No Results Available,Hypertension,Drug: darusentan (LU 135252) and placebo,Gilead Sciences,Both,Adult|Senior,Phase III,352,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DAR-311,5/24/2006,01/06/2006,01/01/2009,10/02/2009,01/10/2009,,01/01/2009,"The co-primary efficacy measures are change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry|Secondary efficacy measurements are (i) change from baseline in mean 24-hour systolic and diastolic ambulatory blood pressure, (ii) percent of subjects to reach systolic blood pressure goal, and (iii) change from baseline in eGFR",http://ClinicalTrials.gov/show/NCT00330369,"United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Canada, &nbsp; Denmark, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",1,0,1,NA
NCT00331643,Ixabepilone in Treating Young Patients With Refractory Solid Tumors,Completed,No Results Available,Kidney Cancer|Neuroblastoma|Sarcoma,Drug: ixabepilone,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult,Phase II,120,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000472912|COG-ADVL0524|NCI-06-C-0146|NCI-P6451,5/30/2006,01/04/2006,NA,11/20/2010,01/11/2010,,01/01/2009,"Time to progression as measured by the product-limit method of Kaplan-Meier|Progression-free survival at 6 months|Response rates (complete response and partial response)|Toxicity|Correlate tumor burden and change in tumor burden by RECIST, WHO, and volumetric analysis",http://ClinicalTrials.gov/show/NCT00331643,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; New Zealand",1,1,1,1
NCT00332189,Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006,Completed,No Results Available,Phenylketonuria,Drug: sapropterin dihydrochloride,BioMarin Pharmaceutical,Both,Child|Adult|Senior,Phase III,128,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PKU-008,5/30/2006,01/07/2006,01/08/2009,06/02/2010,01/06/2010,,01/08/2009,Tabulating the incidence and frequency of all AEs and SAEs that occur throughout the study.|Following blood Phe levels.,http://ClinicalTrials.gov/show/NCT00332189,United States,1,1,1,1
NCT00332605,N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence,Completed,No Results Available,Methamphetamine Dependence,Drug: Naltrexone|Drug: Placebo|Drug: N-Acetyl Cysteine,University of Minnesota - Clinical and Translational Science Institute,Both,Adult,Phase II,47,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",0601M80486,5/30/2006,01/06/2006,01/01/2010,3/23/2010,01/03/2010,,01/12/2009,Penn Craving Scale|Urine toxicology screens,http://ClinicalTrials.gov/show/NCT00332605,United States,1,1,3,0
NCT00334542,"Simvastatin in Preventing a New Breast Cancer in Women Who Are at High Risk for a New Breast Cancer After Undergoing Surgery for Ductal Carcinoma in Situ or Stage I, Stage II, or Stage III Breast Cancer",Completed,No Results Available,Breast Cancer,Drug: simvastatin|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: radiomammography,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Female,Adult|Senior,Phase II,50,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,"JHOC-J0485, CDR0000477214|P50CA088843|P30CA006973|JHOC-J0485|JHOC-SKCCC-J0485|JHOC-04100404",06/07/2006,01/03/2006,NA,08/09/2010,01/08/2010,,01/06/2009,"Change in a panel of biomarkers (high-sensitivity C-reactive protein [hsCRP], lipid profile, circulating estrogens, and contralateral breast density) from baseline|Prevalence of breast gene (estrogen receptor [ER]-?? and ER-??, cyclin D2, RAR-??, Twist, RASSF1A, and HIN-1) hypermethylation|Prevalence of Akt and p-Akt activation by contralateral core breast biopsies",http://ClinicalTrials.gov/show/NCT00334542,United States,1,1,4,0
NCT00334633,Treatment of BV With Tinidazole,Completed,No Results Available,Bacterial Vaginosis,Drug: tinidazole,University of Alabama at Birmingham|National Institute of Allergy and Infectious Diseases (NIAID),Female,Adult,Phase IV,500,Other|NIH,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",F040329003|R01AI058033,06/07/2006,01/11/2004,01/12/2009,7/28/2010,01/07/2010,,01/12/2009,cure of BV|recurrence of BV,http://ClinicalTrials.gov/show/NCT00334633,United States,1,1,1,1
NCT00335127,"Chemotherapy and Total-Body Irradiation Followed By Autologous Lymphocyte Infusion, Aldesleukin, and Autologous Stem Cell Transplant in Treating Patients With Metastatic Melanoma",Completed,No Results Available,Melanoma (Skin)|Non-Melanomatous Skin Cancer,Biological: aldesleukin|Biological: filgrastim|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: autologous bone marrow transplantation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,108,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000480141|NCI-06-C-0136|NCI-P6763,06/07/2006,01/04/2006,NA,3/24/2009,01/11/2008,,01/03/2009,Complete tumor regression|Safety|Cell survival,http://ClinicalTrials.gov/show/NCT00335127,United States,1,1,9,0
NCT00335244,Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery,Completed,No Results Available,"Heart Defects, Congenital|Hypertension, Pulmonary",Drug: L-citrulline|Drug: Placebo of intravenous L-citrulline,"Asklepion Pharmaceuticals, LLC|Vanderbilt University",Both,Child,Phase III,77,Industry|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",409|R01 HL73317-01|IRB# 060197,06/07/2006,01/05/2006,01/12/2009,1/19/2010,01/01/2010,,01/12/2009,"Duration of postoperative mechanical ventilation in hours compared between treatment groups.|Incidence of increased PVT (defined as a sustained mean pulmonary artery pressure greater than 20 mm Hg for at least 2 hours, measured during the first 48 hours|Postoperative intravenous inotrope score|Length and volume of chest tube drainage|Length of ICU stay|Length of hospitalization|Survival",http://ClinicalTrials.gov/show/NCT00335244,United States,1,0,2,NA
NCT00335452,Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS,Completed,Has Results,Acute Coronary Disease|Angina Unstable,Drug: Clopidogrel|Drug: acetylsalicyclic acid (ASA),Sanofi-Aventis|Bristol-Myers Squibb,Both,Adult|Senior,Phase III,25086,Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC5965|EUDRACT: 2006-000313-38,06/08/2006,01/06/2006,01/09/2009,11/09/2010,01/11/2010,CURRENT/OASIS7,01/09/2009,First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison|First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison|First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level|First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup|Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison|Occurrence of Major Bleeding - ASA Dose Level Comparison,http://ClinicalTrials.gov/show/NCT00335452,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Chile, &nbsp; China, &nbsp; Croatia, &nbsp; Czech Republic, &nbsp; Estonia, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; India, &nbsp; Ireland, &nbsp; Israel, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Latvia, &nbsp; Lithuania, &nbsp; Malaysia, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Singapore, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; Turkey, &nbsp; United Kingdom",1,0,2,NA
NCT00335504,"Atorvastatin, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia",Completed,No Results Available,Colorectal Cancer|Precancerous Condition,Dietary Supplement: oligofructose-enriched inulin|Drug: atorvastatin calcium|Drug: sulindac|Other: placebo,Mayo Clinic|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,112,Other|NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Prevention,CDR0000467755|MAYO-030103|MAYO-1395-05,06/08/2006,01/03/2006,NA,02/01/2010,01/01/2009,,01/04/2009,Percent change in number of rectal aberrant cryptic foci (ACF) as measured by magnification chromoendoscopy|Screening for possible phase III testing|Effects on proliferation (Ki67 expression) and apoptosis (caspase-3 expression) as measured by biopsy samples obtained from normal-appearing rectal mucosa at baseline and after completion of study treatment|Correlation of endoscopic features with histologic characteristics of rectal ACF|Observation of the natural history of rectal ACF in patients receiving placebo|Adverse events|Utilization of a biospecimen repository archive,http://ClinicalTrials.gov/show/NCT00335504,"United States, &nbsp; Canada",1,1,4,0
NCT00336141,Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer,Completed,No Results Available,Colorectal Cancer,Drug: Suberoylanilide hydroxamic acid,USC/Norris Comprehensive Cancer Center|Merck,Both,Adult|Senior,Phase I|Phase II,77,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,3C-05-3,06/09/2006,01/06/2006,01/04/2009,9/23/2010,01/09/2010,,01/04/2009,Toxicity|Response,http://ClinicalTrials.gov/show/NCT00336141,United States,1,0,1,NA
NCT00338988,Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma,Completed,Has Results,Cancer of the Gallbladder|Cancer of the Biliary Tract,Drug: Capecitabine|Drug: Oxaliplatin,M.D. Anderson Cancer Center|Sanofi-Synthelabo,Both,Adult|Senior,Phase II,44,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2003-0340,6/16/2006,01/08/2003,01/05/2009,11/03/2010,01/11/2010,,01/05/2009,Number of Patients With Objective Response|Patient Toxicity,http://ClinicalTrials.gov/show/NCT00338988,United States,1,1,2,1
NCT00339040,Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children,Completed,No Results Available,HIV Infections|Sexually Transmitted Diseases,"Biological: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP)|Other: Placebo",National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Both,Child,Phase II,120,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",PACTG P1047,6/19/2006,01/10/2006,NA,8/31/2010,01/05/2008,,01/08/2009,"Safety, as determined by development of Grade 3 or 4 adverse events (AEs)|safety, as determined by development of Grade 3 or 4 AEs attributed to study treatment|immunogenicity, as determined by anti-HPV 6, 11, 16, 18 responses measured by Clinical Laboratory Improvement Act (CLIA)|serum antibody titers|Change in CD4 count and percent|change in viral load (HIV-1 RNA copies/ml)",http://ClinicalTrials.gov/show/NCT00339040,"United States, &nbsp; Puerto Rico",0,NA,2,NA
NCT00340704,"PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder",Completed,No Results Available,"Bladder, Neurogenic",Drug: tamsulosin hydrochloride,Astellas Pharma Inc|Boehringer Ingelheim Pharmaceuticals,Both,Child,Phase II,143,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,527.66,6/19/2006,01/04/2006,01/06/2009,7/22/2009,01/07/2009,,01/06/2009,Responder rate who achieves a decrease in their detrusor leak point pressure to less than 40cm H2O|Improvement or stabilization of hydronephrosis and/or hydroureter base|Assessment of pharmacokinetics parameters,http://ClinicalTrials.gov/show/NCT00340704,"United States, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Germany, &nbsp; India, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Philippines, &nbsp; Russian Federation, &nbsp; South Africa, &nbsp; Spain, &nbsp; Ukraine",1,1,1,0
NCT00343252,Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis,Completed,Has Results,"Osteoporosis, Postmenopausal|Back Pain|Spinal Fracture",Drug: teriparatide|Drug: risedronate|Drug: placebo|Drug: placebo,Eli Lilly and Company,Female,Adult|Senior,Phase III,712,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",9041|B3D-MC-GHCY,6/20/2006,01/06/2006,01/06/2010,08/12/2010,01/08/2010,,01/06/2009,"Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 6-Month Endpoint|Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 12-Month Endpoint|Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 6-Month Endpoint|Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 12-Month Endpoint|Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 6 Months|Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 12 Months|Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 6 Months|Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 12 Months|Change From Baseline to 3-Month Endpoint in the Roland-Morris Disability Questionnaire.|Change From Baseline to 6-Month Endpoint in the Roland-Morris Disability Questionnaire.|Change From Baseline to 12-Month Endpoint in the Roland-Morris Disability Questionnaire.|Change From Baseline to 6-Month Endpoint, European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO)|Change From Baseline to 12-Month Endpoint, European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO)|Safety|Safety|Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 18-Month Endpoint|Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 18-Month Endpoint|Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 18 Months|Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 18 Months|Change From Baseline to 18-Month Endpoint in the Roland-Morris Disability Questionnaire.|Change From Baseline to 18-Month Endpoint in European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO)",http://ClinicalTrials.gov/show/NCT00343252,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Mexico, &nbsp; Puerto Rico, &nbsp; Spain, &nbsp; Sweden",1,1,4,1
NCT00344448,Raptiva to Treat Sjogren's Syndrome,Completed,No Results Available,Sjogren's Syndrome,Drug: Raptiva,National Institute of Dental and Craniofacial Research (NIDCR),Both,Adult|Senior,Phase II,10,NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",060181|06-D-0181,6/23/2006,01/06/2006,01/01/2009,2/20/2010,01/12/2009,,01/01/2009,Improvement in exocrine function|Response defined by a composite criteria,http://ClinicalTrials.gov/show/NCT00344448,United States,1,0,1,NA
NCT00348140,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: Rosiglitazone Extended Release 2mg|Drug: Rosiglitazone Extended Release 8mg|Other: Placebo,GlaxoSmithKline,Both,Adult|Senior,Phase III,1450,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AVA102670,6/30/2006,01/07/2006,01/03/2009,4/22/2010,01/04/2010,REFLECT-3,01/03/2009,"Change from baseline in ADAS-Cog total score and CDR-Sum of Boxes score at Week 48, as a function of APOE e4 status.|At visits between Week 4 and 24: Assessments of changes in behavior, activities of daily living, healthcare resource utilization, subject and caregiver quality of life, pharmacokinetics, exploratory pharmacogenetics, proteomics, and transcriptomics.|Assessments of changes in behavior, activities of daily living, healthcare resource utilization, subject and caregiver quality of life, pharmacokinetics, exploratory pharmacogenetics, proteomics, and transcriptomics.|Secondary endpoints include measures of: Cognition and function: MMSE, Neuropsychiatric Inventory (NPI), DAD.|Health Outcomes: Resource Utilization in Dementia (RUD), European Quality of Life -5 Dimensions (EQ-5D), Alzheimer's Carer's Quality of Life Instrument (ACQLI).",http://ClinicalTrials.gov/show/NCT00348140,"United States, &nbsp; Australia, &nbsp; Belgium, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Hong Kong, &nbsp; Korea, Republic of, &nbsp; Malaysia, &nbsp; Netherlands, &nbsp; Philippines, &nbsp; Poland, &nbsp; Singapore, &nbsp; Slovakia, &nbsp; Slovenia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",1,0,3,NA
NCT00348309,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: Rosiglitazone Extended Release 8mg|Drug: Rosiglitazone Extended Release 2mg|Other: Placebo,GlaxoSmithKline,Both,Adult|Senior,Phase III,1496,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AVA102672,6/30/2006,01/07/2006,01/01/2009,4/22/2010,01/04/2010,REFLECT-2,01/01/2009,"Change from baseline in ADAS-Cog total score and CDR-Sum of Boxes score at Week 48, as a function of APOE e4 status.|Assessments of changes in behaviorActivities of daily livingHealthcare resource utilizationSubject and caregiver quality of lifeExploratory pharmacogeneticsProteomicsTranscriptomics|Secondary endpoints include measures of:Cognition and function: MMSE, Neuropsychiatric Inventory (NPI), DAD.|Health Outcomes: Resource Utilization in Dementia (RUD), European Quality of Life -5 Dimensions (EQ-5D), Alzheimer's Carer's Quality of Life Instrument (ACQLI).",http://ClinicalTrials.gov/show/NCT00348309,"United States, &nbsp; Argentina, &nbsp; Austria, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; Czech Republic, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Hungary, &nbsp; India, &nbsp; Italy, &nbsp; Japan, &nbsp; Poland, &nbsp; Portugal, &nbsp; Spain, &nbsp; Switzerland",1,1,3,0
NCT00349778,High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma,Completed,No Results Available,Multiple Myeloma,Drug: cyclophosphamide|Drug: etoposide|Drug: BCNU Melphalan,Stanford University,Both,Adult|Senior,Phase I|Phase II,49,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BMT183|97115|BMT183,07/05/2006,01/08/2006,01/04/2010,10/07/2010,01/10/2010,,01/04/2009,"Evaluate the risk of interstitial pneumonitis with the current dosing of BCNU and melphalan|Remission rate, event-free survival, overall survival and relapse",http://ClinicalTrials.gov/show/NCT00349778,United States,1,1,3,0
NCT00350272,"Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects",Completed,No Results Available,HIV Infections,Drug: elvucitabine,Achillion Pharmaceuticals,Both,Adult,Phase II,60,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,ACH443-015,07/06/2006,01/04/2006,01/07/2009,8/18/2009,01/08/2009,,01/07/2009,"Primary:|Determination of the proportion of subjects having achieved a virologic response for 10 mg/day elvucitabine in combination with efavirenz and tenofovir in human immunodeficiency virus type 1 (HIV-1)-infected subjects by 12 weeks compared with the propor|Determination of the safety profile of elvucitabine.|Secondary:|Determination of the pharmacokinetics (PK) of 10-mg/day elvucitabine over 12 weeks as measured by concentrations of elvucitabine in plasma and of elvucitabine triphosphate in peripheral blood mononuclear cells|Determination of the efficacy of the study treatment regimen compared with the standard regimen, as measured by the change in HIV 1?? RNA and helper T cell (CD4) count.",http://ClinicalTrials.gov/show/NCT00350272,"United States, &nbsp; Puerto Rico",1,0,1,NA
NCT00350727,Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma,Completed,No Results Available,Glioma|Malignant Disease,Drug: lapatinib|Drug: pazopanib,GlaxoSmithKline,Both,Adult|Senior,Phase II,75,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,VEG102857,07/10/2006,01/12/2006,01/12/2009,07/01/2010,01/07/2010,VEG102857,01/12/2009,"Adverse events. Changes in vital signs. Changes in laboratory values.|Phase I: Pharmacokinetic parameters including AUC(0-24), [AUC(0-12) for patients on twice daily administration], Cmax, the time to maximum observed concentration (tmax) and C24 of pazopanib and lapatinib when administered in combination with EIAC.|Phase II: Pharmacokinetic parameters including AUC(0-24), [AUC(0-12) for patients on twice daily administration], Cmax, tmax, and C24 of pazopanib and lapatinib, as appropriate, when administered together in combination with non-EIAC.|Phase II: Plasma concentrations of the circulating biomarkers VEGF, sVEGFR-1, and sVEGFR-2.",http://ClinicalTrials.gov/show/NCT00350727,"United States, &nbsp; United Kingdom",1,1,2,0
NCT00352612,Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections,Completed,No Results Available,Staphylococcal Infection|Abscess|Staphylococcal Skin Infection|Folliculitis,Drug: clindamycin|Drug: cephalexin,Johns Hopkins University|Thrasher Research Fund,Both,Child|Adult,Phase IV,200,Other,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment",NA_00003301,7/13/2006,01/09/2006,01/08/2009,08/10/2009,01/08/2009,,01/05/2009,Clinical improvement at the 48-72 hour clinical follow-up|Clinical improvement at 7 days|Time to clinical improvement|Time to resolution of disease|Treatment failures|Need for subsequent hospitalization|Need for subsequent procedure,http://ClinicalTrials.gov/show/NCT00352612,United States,1,1,2,0
NCT00353015,Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract,Completed,No Results Available,"Gastrointestinal Cancer|Carcinoma, Neuroendocrine",Drug: Cisplatin|Drug: Irinotecan,M.D. Anderson Cancer Center|Pharmacia,Both,Child|Adult|Senior,Phase II,21,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ID02-523,7/13/2006,01/03/2003,01/07/2009,08/12/2009,01/08/2009,,01/07/2009,"Complete blood count (CBC). If platelet count is < 50,000/mm3, frequent platelet counts until the platelet count is > 50,000/mm3 or clearly rising|Prior to each course of chemotherapy (every 3 weeks), CBC, serum chemistries, lactate dehydrogenase (LDH), SGPT, electrolytes|At time of response evaluation, in addition to above. Carcinoembryonic antigen (CEA), chromogranin A|Following the completion of 3 course = 9 weeks of treatment, assess all measurable or evaluable lesions|Chest x-ray will be obtained at the time of response evaluation.",http://ClinicalTrials.gov/show/NCT00353015,United States,1,1,2,0
NCT00354055,Chemotherapy Followed By Autologous Natural Killer Cells and Aldesleukin in Treating Patients With Metastatic Melanoma or Kidney Cancer,Completed,No Results Available,Kidney Cancer|Melanoma (Skin),Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,58,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000486918|NCI-06-C-0169|NCI-P6950,7/19/2006,01/05/2006,NA,4/18/2009,01/11/2008,,01/03/2009,Tumor regression|Clinical response|Natural killer (NK) cell repopulation in the immune system|Toxicity,http://ClinicalTrials.gov/show/NCT00354055,United States,1,1,4,0
NCT00354887,Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater,Completed,No Results Available,Gastrointestinal Cancer,Drug: Capecitabine|Drug: Oxaliplatin,M.D. Anderson Cancer Center|Sanofi-Synthelabo,Both,Adult|Senior,Phase II,31,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2003-0827,7/18/2006,01/11/2004,01/11/2009,11/03/2010,01/11/2010,,01/11/2009,Number of Patients with Response (Complete Response or Partial Response),http://ClinicalTrials.gov/show/NCT00354887,United States,1,1,2,1
NCT00354926,Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma,Completed,No Results Available,Non-Hodgkin's Lymphoma,Biological: AME-133v (LY2469298),Applied Molecular Evolution,Both,Adult|Senior,Phase I|Phase II,80,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AME 06.133v.A,7/18/2006,01/07/2006,01/01/2009,08/11/2010,01/08/2010,,01/01/2009,Adverse events and laboratory evaluations|Pharmacokinetic analysis and tumor evaluation by International Workshop criteria,http://ClinicalTrials.gov/show/NCT00354926,United States,0,NA,1,NA
NCT00355121,Study of Menactra?ó in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL?ó,Completed,No Results Available,Meningococcal Meningitis|Tetanus|Diphtheria|Pertussis|Poliomyelitis,Biological: Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Biological: Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Biological: Polysaccharide Diphtheria Toxoid Conjugate Vaccine,Sanofi-Aventis,Both,Child,Phase II,882,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",MTA43,7/20/2006,01/10/2006,01/07/2009,09/02/2010,01/09/2010,,01/06/2009,To provide information concerning the immune response of DAPTACEL?ó.|To provide information concerning the safety after concomitant administration of DAPTACEL?ó and Menactra?ó vaccines.,http://ClinicalTrials.gov/show/NCT00355121,United States,0,NA,3,NA
NCT00355264,Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency,Completed,No Results Available,"Tetrahydrobiopterin Deficiencies|Hyperphenylalaninemia, Non-Phenylketonuric",Drug: Phenoptin,BioMarin Pharmaceutical,Both,Child|Adult|Senior,Phase II,12,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PKU-007,7/19/2006,01/08/2006,01/06/2009,06/07/2010,01/06/2010,,01/06/2009,"control of blood phenylalanine levels, as measured by the proportion of subjects|whose blood Phe level at Week 10 is < 360 mmol/L;|the mean blood Phe level at Week 10 among all subjects.",http://ClinicalTrials.gov/show/NCT00355264,United States,1,0,1,NA
NCT00357396,"Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors",Completed,No Results Available,Sarcoma,Biological: graft versus host disease prophylaxis/therapy|Drug: busulfan|Drug: melphalan|Drug: thiotepa|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation,Memorial Sloan-Kettering Cancer Center,Both,Child|Adult,Phase II,30,Other,Interventional,Primary Purpose: Treatment,CDR0000487592|MSKCC-05059,7/26/2006,01/06/2005,NA,11/10/2009,01/11/2009,,01/10/2009,Disease-free survival at 1 year|Overall survival|Morbidity and mortality|Incidence of acute and chronic graft-vs-host disease (GVHD)|Biologic response of minimal residual disease,http://ClinicalTrials.gov/show/NCT00357396,United States,1,1,7,0
NCT00359385,The Effects of Alendronate After Cure of Primary Hyperparathyroidism,Completed,No Results Available,Hyperparathyroidism,Drug: Alendronate 70mg weekly,Columbia University|Merck,Both,Adult|Senior,Phase IV,40,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",AAAB8202,08/01/2006,01/07/2006,01/09/2009,08/10/2010,01/08/2010,AlenPostPara,01/09/2009,"To investigate the effects of alendronate on bone mineral density using data on changes at the lumbar spine, the hip and distal 1/3 radius. The rate of change in BMD at these sites will also be determined by BMD.|We also intend to determine whether alendronate alters bone turnover to maximize the augmented window defined by a rapid fall in bone resorption and a slower fall in bone formation.",http://ClinicalTrials.gov/show/NCT00359385,United States,1,1,1,1
NCT00359619,Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine,Completed,No Results Available,Prophylaxis for HPV Infections and Cervical Neoplasia,"Biological: CervarixTM|Biological: HPV investigational vaccine GSK568893A, different formulations",GlaxoSmithKline,Female,Adult,Phase II,166,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,108052 (FU month 18)|107919 (FU month 24)|107921 (FU month 36)|107918 (FU month 48),7/18/2006,01/09/2006,01/08/2009,10/15/2009,01/10/2009,,01/08/2009,HPV-16 and -18 seroconversion rates and GMTs|Seroconversion rates and GMTs to other defined HPV serotypes|Occurrence of SAEs|Occurrence of AEs related to NOCDs and other medically significant conditions|Occurrence of pregnancy and pregnancy outcomes,http://ClinicalTrials.gov/show/NCT00359619,"United States, &nbsp; Belgium",0,NA,2,NA
NCT00360776,Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia,Completed,No Results Available,Anemia|Leukemia|Neutropenia,Drug: tipifarnib|Genetic: mutation analysis|Other: laboratory biomarker analysis,The Cleveland Clinic|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,56,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CASE-4202|P30CA043703|CASE-4202|NCI-6823|CASE-RDN-5402,08/03/2006,01/06/2006,NA,05/12/2010,01/06/2009,,01/06/2009,"Complete response rate, partial response rate, and overall response rate|Toxicity of treatment|Mechanism of treatment response as measured by biomarkers in peripheral blood at baseline and at the end of 4 and 8 courses of treatment",http://ClinicalTrials.gov/show/NCT00360776,United States,1,0,3,NA
NCT00361972,Elucidation of Acid-Induced Pulmonary Inflammation,Completed,No Results Available,Gastroesophageal Reflux|Asthma,Drug: lansoprazole|Drug: placebo,University of Utah,Both,Adult,Phase II|Phase III,36,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",15444|IRB #15444,08/08/2006,01/08/2006,01/04/2009,4/22/2009,01/04/2009,,01/04/2009,To determine whether treatment of asthmatics with gastric acid suppressing medication will decrease bronchial inflammation and bronchoreactivity in asthmatics. We will demonstrate a decrease in specific cytokine expression and inflammatory infiltrate in|To determine whether reduction in inflammation in pulmonary biopsies (as defined by reduction in specific cytokines or cellular infiltrate) correlates with improvement in pulmonary symptoms as defined by use of rescue inhalers or validated asthma quality,http://ClinicalTrials.gov/show/NCT00361972,United States,1,1,2,0
NCT00362986,Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer,Completed,No Results Available,"Dermatologic Complications|Unspecified Adult Solid Tumor, Protocol Specific",Biological: cetuximab|Biological: matuzumab|Biological: panitumumab|Drug: canertinib dihydrochloride|Drug: erlotinib hydrochloride|Drug: gefitinib|Drug: titanium dioxide/zinc oxide sunscreen cream SPF 60,North Central Cancer Treatment Group|National Cancer Institute (NCI),Both,Adult|Senior,Phase III,110,Other|NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care,CDR0000492254|NCCTG-N05C4,08/10/2006,01/10/2006,NA,09/01/2010,01/10/2009,,01/10/2009,Incidence and severity of rash development by Skindex questionnaire|Toxicity by NCI CTCAE v3.0|Rash incidence at 4 and 8 weeks,http://ClinicalTrials.gov/show/NCT00362986,United States,1,0,7,NA
NCT00363974,Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML,Completed,No Results Available,"Leukemia, Myelomonocytic, Acute",Drug: XIAP antisense,Aegera Therapeutics,Both,Adult|Senior,Phase I|Phase II,54,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AEG35156-103|MDA 2005-0384|PMH 05-0452-C,08/10/2006,01/10/2005,01/03/2009,11/30/2009,01/11/2009,,01/03/2009,"Dose at which AEG35156 when combined with fixed doses of ara-C and idarubicin, produces acceptable CR and toxicity rates as defined and observed at 30 days post-last dose|Effects of AEG35156 on XIAP mRNA and protein expression and plasma pharmacokinetic profile of AEG35156.",http://ClinicalTrials.gov/show/NCT00363974,"United States, &nbsp; Canada",1,0,1,NA
NCT00365053,PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery,Completed,No Results Available,Malignant Mesothelioma,Drug: belinostat|Genetic: reverse transcriptase-polymerase chain reaction|Other: laboratory biomarker analysis,California Cancer Consortium|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,37,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000489194|U01CA062505|CCC-PHII-67|NCI-7255,8/16/2006,01/06/2006,NA,10/11/2010,01/10/2010,,01/03/2009,"Objective tumor response rate as measured by RECIST criteria|Overall survival by Kaplan-Meier|Time to progression by Kaplan-Meier|Toxicity profile|Effect of PXD101 on apoptosis and histone acetylation as measured by TUNEL assay, immunohistochemistry, and western blot",http://ClinicalTrials.gov/show/NCT00365053,United States,1,0,3,NA
NCT00365261,Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer,Completed,No Results Available,Sleep Initiation and Maintenance Disorders,Drug: eszopiclone,"University of California, San Diego",Both,Adult|Senior,Phase IV,50,Other,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,UCSD 060340|ESRC 054,8/15/2006,01/09/2006,01/12/2009,6/24/2010,01/06/2010,,01/12/2009,"Patient Self-report data on sleep, pain, and fatigue|Opiate dosing from patient controlled analgesia",http://ClinicalTrials.gov/show/NCT00365261,United States,1,1,1,0
NCT00365508,Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking,Completed,No Results Available,Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Leukemia|Liver Cancer|Lung Cancer|Pancreatic Cancer|Tobacco Use Disorder,Drug: nicotine,Fox Chase Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase III,700,Other|NIH,Interventional,Allocation: Randomized|Masking: Open Label,CDR0000491296|FCCC-FCRB-04-003-P,8/16/2006,01/02/2006,NA,11/05/2009,01/11/2009,,01/08/2009,Continuous abstinence assessed by the time-line follow-back method (quit day to 6-month follow up)|Rate of compliance at 24 hours and 30 days,http://ClinicalTrials.gov/show/NCT00365508,United States,1,1,1,0
NCT00365859,Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD),Completed,Has Results,Autistic Disorder|Behavioral Symptoms,Drug: Aripiprazole,Bristol-Myers Squibb|Otsuka America Pharmaceutical,Both,Child,Phase III,330,Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CN138-180,8/15/2006,01/09/2006,01/06/2009,6/28/2010,01/06/2010,,01/06/2009,"Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome (EPS)-Related AEs|Mean Change From Baseline in Total Simpson-Angus Scale (SAS) At Week 8, Week 26, and Week 52|Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) At Week 8, Week 26, and Week 52|Mean Change From Baseline in Barnes Akathisia Global Clinical Assessment at Week 8, Week 26, Week 52, and Endpoint|Number of Participants With Potentially Clinically Relevant Laboratory Metabolic Abnormalities|Number of Participants With Potentially Clinically Relevant Laboratory Hematology Abnormalities|Number of Participants With Potentially Clinically Relevant Laboratory Chemistry Abnormalities|Number of Participants With Potentially Clinically Relevant Eletrocardiograph (ECG) Abnormalities|Number of Potentially Clinically Relevant Vital Sign Abnormalities|Mean Change From Baseline in Patient Weight|Mean Change From Baseline by Time Period in Body Weight Z-Score|Mean Change From Baseline in Patient Body Mass Index (BMI)|Mean Change From Baseline By Time Period in BMI Z-Score|Mean Change From Baseline in Clinical Global Impression (CGI)-Severity Score at Week 52 (Endpoint, LOCF)|CGI-Improvement Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Hyperactivity Subscale Score at Week 52 (Endpoint, LOCF)|Change From Baseline in ABC Stereotypy Subscale Score at Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Social Withdrawal Scale At Week 52 (Endpoint, LOCF)|Mean Change From Baseline in ABC Inappropriate Speech Subscale Score at Week 52 (Endpoint, LOCF)|Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Score at Week 52 (Endpoint, LOCF)",http://ClinicalTrials.gov/show/NCT00365859,United States,1,1,1,1
NCT00366145,Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Patients Who Have Failed to Respond to Steroid Treatment for Acute Graft Versus Host Disease (GVHD),Completed,No Results Available,Graft Versus Host Disease,Biological: Mesenchymal Stem Cells|Biological: placebo,Osiris Therapeutics,Both,Child|Adult|Senior,Phase III,240,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",280,8/17/2006,01/07/2006,01/05/2009,8/26/2009,01/08/2009,,01/05/2009,Complete Response of greater than or equal to 28 days duration|Survival at 180 days post first infusion,http://ClinicalTrials.gov/show/NCT00366145,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Italy, &nbsp; Switzerland, &nbsp; United Kingdom",0,NA,2,NA
NCT00366249,Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.,Completed,Has Results,Bacterial Infections|Diabetic Foot|Osteomyelitis,Drug: Tigecycline|Drug: Ertapenem,Wyeth,Both,Adult|Senior,Phase III,1061,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",3074K5-319,8/17/2006,01/01/2007,01/03/2009,4/22/2010,01/04/2010,,01/03/2009,Number of Patients With Clinical Response of Cure Vs. Failure.|Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.|Number of Patients With Clinical Response of Cure Vs. Failure Assessed at Least 25 - 27 Weeks Post Last Dose.|Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate Assessed at Least 25 - 27 Weeks Post Last Dose.|Number of Patients With Microbiologic Response of Eradication.,http://ClinicalTrials.gov/show/NCT00366249,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; China, &nbsp; Colombia, &nbsp; Croatia, &nbsp; Denmark, &nbsp; Estonia, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Hungary, &nbsp; India, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Latvia, &nbsp; Lithuania, &nbsp; Mexico, &nbsp; Panama, &nbsp; Peru, &nbsp; Poland, &nbsp; Portugal, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; Taiwan, &nbsp; Turkey, &nbsp; Ukraine, &nbsp; United Kingdom",1,1,2,1
NCT00368550,Sertraline Pharmacotherapy for Alcoholism Subtypes,Completed,Has Results,Alcoholism,Drug: Sertraline|Drug: Placebo,University of Connecticut Health Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Both,Adult,Phase IV,134,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",03-225-2|R01AA013631,8/22/2006,01/02/2004,01/12/2009,01/03/2011,01/01/2011,,01/06/2009,Number of Days on Which Subjects Drank|Number of Days of Heavy Drinking (Defined as Days on Which Women Drank >= 4 Drinks and Men Drank >= 5 Drinks)|Change in the Level of Alcohol-related Problems,http://ClinicalTrials.gov/show/NCT00368550,United States,1,1,2,1
NCT00369746,STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse,Completed,No Results Available,Non-Psychotic Major Depressive Disorder|Alcohol Use Disorder,Drug: citalopram,National Institute on Alcohol Abuse and Alcoholism (NIAAA),Both,Adult,Phase IV,60,NIH,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NIAAA-GRE-13303-01|NIH Grant RO1 AA13303-01,8/24/2006,01/09/2006,01/02/2009,2/23/2009,01/02/2009,,01/02/2009,Quick Inventory of Depression - Clinician 16 (QIDS-C 16)|Quick Inventory of Depression- Self Report 16 (QIDS-SR 16)|Hamilton Depression Scale 17 (HAM-D 17)|Timeline Follow Back (TLFB)|Quantitative Substance Use Inventory ((SUI)|Treatment Services Review (TSR),http://ClinicalTrials.gov/show/NCT00369746,United States,1,1,1,0
NCT00370552,A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer,Completed,No Results Available,Metastatic Breast Cancer,Drug: Ixabepilone|Drug: Ixabepilone|Drug: Bevacizumab|Drug: Bevacizumab|Drug: Paclitaxel|Drug: Bevacizumab,Bristol-Myers Squibb,Both,Adult|Senior,Phase II,123,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CA163-115,8/30/2006,01/03/2007,01/11/2009,7/26/2010,01/12/2009,,01/11/2009,Response Rate|duration of response|time to response|week 24 PFS (progression free survival)|PFS and OS (overall survival),http://ClinicalTrials.gov/show/NCT00370552,"United States, &nbsp; France, &nbsp; Italy, &nbsp; Spain, &nbsp; United Kingdom",1,1,6,1
NCT00371345,Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer,Completed,Has Results,Breast Cancer|Metastasis,Drug: Dasatinib|Drug: Dasatinib 100 mg,Bristol-Myers Squibb,Female,Adult|Senior,Phase II,92,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA180-088,09/01/2006,01/12/2006,01/05/2009,10/07/2010,01/10/2010,,01/03/2009,"Number of Participants With Objective Response|Percentage of Participants With Objective Response|Best Overall Response|Number of Response-evaluable Participants With Disease Control (DCR)|Percentage of Response-evaluable Participants With Disease Control (DCR)|Number of Participants Who Progressed|Median Progression Free Survival (PFS)|Percentage of Participants With Progression-free Survival (PFS) at Weeks 9, 17, and 25|Duration Of Objective Response|Number of Participants With Death, Adverse Events (AEs), and AEs Leading to Discontinuation|Number of Participants With On-study CTCAE Version 3.0 Grade 3-4 Laboratory Abnormalities|Number of Participants With Serious AEs (SAEs), Drug-related AEs, Drug-related SAEs, and Drug-Related Grade 3 AEs|Number Of Participants With Notable Drug-related AEs|Pharmacokinetics (PK): Plasma Concentration of Dasatinib at Week 3|PK: Plasma Concentration of Dasatinib at Week 7 or Week 9|Pharmacodynamics: Percent Change From Baseline In Plasma Level of Collagen Type IV at Week 3 in Participants With and Without DCR|Pharmacodynamics: Percent Change From Baseline In Plasma Level of Collagen Type IV at Week 5 in Participants With and Without DCR|Pharmacodynamics: Percent Change From Baseline In Plasma Level of VEGFR2 at Week 3 in Participants With and Without DCR|Pharmacodynamics: Percent Change From Baseline In Plasma Level of VEGFR2 at Week 5 in Participants With and Without DCR",http://ClinicalTrials.gov/show/NCT00371345,"United States, &nbsp; Argentina, &nbsp; Belgium, &nbsp; France, &nbsp; Italy, &nbsp; Peru, &nbsp; Spain",1,1,2,1
NCT00372411,Robotic Assisted Upper-Limb Neurorehabilitation in Stroke Patients,Completed,No Results Available,Stroke,Device: Robot-Assisted Therapy - MIT-MANUS System|Other: Intensive Comparison Therapy,Department of Veterans Affairs|Burke Medical Research Institute,Both,Adult|Senior,Phase II,127,U.S. Fed|Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,558,09/05/2006,01/12/2005,01/08/2009,11/10/2010,01/11/2010,VA ROBOTICS,01/07/2009,Fugl-Meyer Assessment for Motor Recovery (FM) Scale,http://ClinicalTrials.gov/show/NCT00372411,United States,0,NA,2,NA
NCT00372775,Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases,Completed,No Results Available,Non-small Cell Lung Cancer,Drug: Sunitinib,Pfizer,Both,Adult|Senior,Phase II,66,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,A6181092,09/05/2006,01/03/2007,01/12/2009,8/13/2010,01/08/2010,,01/12/2009,"Radiographic progression of disease|Radiographic progression of intracranial disease, overall objective disease response, safety evaluated by adverse events and standard laboratory assessments, survival at 1 year, pharmacokinetics, biomarkers and patient reported outcomes.",http://ClinicalTrials.gov/show/NCT00372775,"United States, &nbsp; France, &nbsp; Italy, &nbsp; Spain",1,1,1,1
NCT00376168,A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease,Completed,No Results Available,Gaucher Disease,Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)|Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD),Protalix,Both,Adult|Senior,Phase III,32,Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PB-06-001,09/12/2006,01/08/2007,01/10/2009,10/06/2009,01/10/2009,,01/09/2009,"Change from baseline in spleen volume measured by MRI.|Change from baseline in: Liver volume, Hemoglobin measurement, Platelet count, Biomarkers (chitotriosidase and pulmonary and activation-regulated chemokine (PARC/ CCL18)",http://ClinicalTrials.gov/show/NCT00376168,"United States, &nbsp; Canada, &nbsp; Chile, &nbsp; Israel, &nbsp; Italy, &nbsp; South Africa, &nbsp; Spain, &nbsp; United Kingdom",1,0,2,NA
NCT00377260,Acute Otitis Media (AOM) Therapy Trial in Young Children,Completed,Has Results,Acute Otitis Media,Drug: Amoxicillin-clavulanate|Drug: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Both,Child,Phase IV,291,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",05-0142,9/14/2006,01/11/2006,01/04/2009,01/06/2011,01/04/2010,,01/04/2009,"The Time to Resolution of Symptoms, Defined as Acute Otitis Media-Severity of Symptoms (AOM-SOS) Score of 0 or 1, According to Treatment Assignment|The Time to Resolution of Symptoms, Defined as Acute Otitis Media-Severity of Symptoms (AOM-SOS) Score of 0 or 1 on Two Consecutive Occasions, According to Treatment Assignment|The Distribution of Clinical Failures by the On-therapy Visit According to Treatment Assignment|The Distribution of Clinical Failures by the End-of-therapy Visit According to Treatment Assignment|The Mean Acute Otitis Media - Severity of Symptom (AOM-SOS) Score, Post-enrollment, Over the First 7 Days of Therapy According to Treatment Assignment|The Distribution of Children Developing Worsening Symptoms Prior to Receiving 72 Hours of Study Medication According to Treatment Assignment|The Mean Number of Times Analgesic Medication Was Administered to the Child According to Treatment Assignment|The Distribution of Children With Observed or Parent Reported Adverse Events or Complications According to Treatment Assignment|The Distribution of Children With Nasopharyngeal (NP) Colonization With AOM Pathogens at the End-of-therapy Visit According to Treatment Assignment|The Distribution of Children With Nasopharyngeal (NP) Colonization With Penicillin-susceptible Streptococcus Pneumoniae (S. pn) at the End-of-therapy Visit According to Treatment Assignment|The Distribution of Children With Nasopharyngeal (NP) Colonization With AOM Pathogens at the Follow-up Visit According to Treatment Assignment|The Distribution of Children With Nasopharyngeal (NP) Colonization With Penicillin-susceptible Streptococcus Pneumoniae (S. pn) at the Follow-up Visit|The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the On-therapy Visit According to Treatment Assignment|The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the End-of-therapy Visit According to Treatment Assignment|The Probability of Middle Ear Effusion, Based on an Algorithm That Estimates the Probability of Middle Ear Effusion From an Interpretable Tympanographic Configuration, at the Follow-up Visit According to Treatment Assignment|The Mean Number of Visits to a Primary Care Provider (PCP) According to Treatment Assignment|The Mean Number of Emergency Room Visits According to Treatment Assignment|The Mean Number of Antibiotic Prescriptions, Exclusive of Study Medication, According to Treatment Assignment|The Total Number of Visits, Summed Across All Participants, at Which a Family Member Reported Having Missed Work According to Treatment Assignment|The Total Number of Visits, Summed Across All Participants, at Which a Family Member Reported Making Special Daycare Arrangements According to Treatment Assignment|The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the On-therapy Visit According to Treatment Assignment|The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the End-of-therapy Visit According to Treatment Assignment|The Mean Score Representing Parental Satisfaction With the Study Medication As Recorded at the Follow-up Visit According to Treatment Assignment",http://ClinicalTrials.gov/show/NCT00377260,United States,1,1,2,1
NCT00377403,Treatment of Acute Sinusitis,Completed,No Results Available,Acute Respiratory Infections|Acute Rhinosinusitis,Drug: Acetaminophen|Drug: Amoxicillin|Drug: Dextromethorphan hydrobromide (10mg/5ml) with guaifenesin (100mg/5ml)|Drug: Mucinex OTC (guaifenesin)|Drug: Pseudoephedrine Sustained Action|Drug: Saline spray (0.65%),Washington University School of Medicine|National Institute of Allergy and Infectious Diseases (NIAID),Both,Adult|Senior,Phase IV,172,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",05-0140,9/14/2006,01/10/2006,01/08/2010,9/27/2010,01/09/2010,,01/05/2009,SNOT-16 to measure disease-specific quality of life,http://ClinicalTrials.gov/show/NCT00377403,United States,1,1,6,0
NCT00378898,Feasibility of Placing Bravo PH Capsule in Proximal Esophagus,Completed,No Results Available,Gastroesophageal Reflux Disease,Device: Bravo PH capsule|Procedure: Fluoroscopy,Vanderbilt University,Both,Adult|Senior,Phase III,25,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic",60724,9/20/2006,01/09/2006,01/07/2009,01/11/2010,01/01/2010,bravo,01/03/2009,Patient tolerance to a Bravo PH monitor in the proximal esophagus after 48 hours|Collection of and comparison of data between distal and proximal Bravo capsule,http://ClinicalTrials.gov/show/NCT00378898,United States,0,NA,2,NA
NCT00380861,Does Implant Design Improve Postoperative Flexion?,Completed,No Results Available,Arthritis,Device: Total Knee Arthroplasty,DePuy Orthopaedics,Both,Adult|Senior,Phase IV,186,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,4092,9/26/2006,01/03/2006,01/12/2009,1/19/2010,01/01/2010,,01/12/2009,Flexion at 6 and 12 months after total knee arthroplasty in a series of simultaneous bilateral knees where 1 implant design is in the left knee and a 2nd design is in the right knee.|Range of motion (ROM) over time|Effect of subject demographics and anthropometrics on ROM|AKS Score|KOOS score|Knee pain|Ability to perform activities|Crepitus|Subject satisfaction|Rate of adverse events,http://ClinicalTrials.gov/show/NCT00380861,United States,0,NA,1,NA
NCT00381238,Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: rosiglitazone maleate,GlaxoSmithKline,Both,Adult|Senior,Phase II,33,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AVA104617,9/26/2006,01/06/2006,01/02/2009,09/03/2010,01/09/2010,,01/02/2009,"Long term safety and tolerability of rosiglitazone (RSG) XR.|Long-term efficacy of RSG XR in terms of orientation, memory (recent and immediate), concentration, language and praxis.|Frequency of serious adverse events.|Percentage of subjects with adverse event of edema|Change from baseline in vital signs. Frequency of vital signs of clinical concern.|Change from baseline in weight.|Frequency of clinical chemistry (including lipids) and hematology parameters of clinical concern.",http://ClinicalTrials.gov/show/NCT00381238,"United States, &nbsp; Canada",1,1,1,0
NCT00381888,Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer,Completed,Has Results,Cervical Cancer|Endometrial Cancer|Fallopian Tube Cancer|Ovarian Cancer|Sarcoma|Thromboembolism|Vaginal Cancer|Vulvar Cancer,Drug: fondaparinux sodium,"Masonic Cancer Center, University of Minnesota",Female,Adult|Senior,Phase II,44,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000503985|UMN-2006LS009|UMN-0603M82707,9/26/2006,01/01/2007,01/01/2009,1/26/2010,01/01/2010,,01/01/2009,Number of Patients With Venous Thromboembolism at Week 4|Number of Patients Who Achieved Thromboembolism Prophylaxis at Week 4.,http://ClinicalTrials.gov/show/NCT00381888,United States,1,1,1,1
NCT00381940,"Bortezomib, Ifosfamide, and Vinorelbine in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy",Completed,No Results Available,Lymphoma,Biological: filgrastim|Drug: bortezomib|Drug: ifosfamide|Drug: vinorelbine ditartrate,Children's Oncology Group|National Cancer Institute (NCI),Both,Child|Adult,Phase II,48,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000500142|COG-AHOD0521,9/26/2006,01/01/2007,NA,12/14/2010,01/11/2010,,01/10/2009,Toxicity|Complete response after 2 or 4 courses of treatment|Overall tumor response|Proportion of patients able to mobilize sufficient hematopoietic stem cells|Overall response rate after 2 or 4 courses of treatment|Induction success rate,http://ClinicalTrials.gov/show/NCT00381940,"United States, &nbsp; Australia, &nbsp; Canada",1,1,4,0
NCT00383149,"A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer",Completed,Has Results,Metastatic Pancreatic Cancer,Drug: Ixabepilone + Cetuximab,Bristol-Myers Squibb,Both,Adult|Senior,Phase II,58,Industry,Interventional,Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA163-116,9/28/2006,01/01/2007,01/06/2009,9/24/2010,01/09/2010,,01/06/2009,"Percentage of Participants Surviving at 6 Months|Best Overall Tumor Response|Percentage of Participants With Objective Tumor Response|Median Progression Free Survival Time|Median Overall Survival Time|Median Duration of Response|Median Time to Response|Number of Participants With Death Within 30 Days of Last Dose, Any Serious Adverse Event (SAE), Any Adverse Event (AE) Leading to Discontinuation (DC), or Any Treatment-related AEs By Common Terminology Criteria Version 3.0 (CTC v3) Grade (Gr)|Most Common Treatment-related Nonhematologic AE (>25%) By CTC v3 Grade (Gr)|Number of Participants With Hematology, Liver Function, and Renal Laboratory Abnormalities By CTC v3 Grade (Gr)|Number of Participants With Dose Reduction, Dose Delay, or Dose Interruption|Percentage of Participants With Baseline Epidermal Growth Factor Receptor (EGFR) Tumor Expression|Change From Baseline in FHSI-8 Total Score by Time-point",http://ClinicalTrials.gov/show/NCT00383149,United States,1,1,1,1
NCT00383786,Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder,Completed,No Results Available,PTSD,Drug: NK1 Antagoist (GR205171)|Procedure: Psychophysiology (Trauma Script)|Procedure: Psychophysiology (Verbal Threat)|Procedure: Psychophysiology (Fear Conditioning)|Procedure: Psychophysiology (Affective Modulation)|Procedure: Psychophysiology (Heart rate variability)|Procedure: Lumbar Puncture|Procedure: 24-hour plasma sampling|Procedure: MRI|Device: GR205171,National Institute of Mental Health (NIMH),Both,Adult,Phase II,52,NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Treatment,060253|06-M-0253,10/03/2006,01/09/2006,01/06/2009,9/16/2009,01/09/2009,,01/06/2009,Changes in CAPS scores.|Able to identify biological markers that predict response to treatment.,http://ClinicalTrials.gov/show/NCT00383786,United States,1,0,10,NA
NCT00384358,Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures,Completed,No Results Available,Fractures,Drug: rhBMP-2/CPM|Drug: rhBMP-2/CPM|Other: surgical intervention alone,Wyeth,Both,Adult|Senior,Phase II,108,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,3100N7-211|B1921004,10/03/2006,01/01/2007,01/06/2010,9/14/2010,01/09/2010,,01/02/2009,The safety outcome is the incidence of secondary fracture displacement among subjects treated with rhBMP-2/CPM compared to those receiving standard surgical treatment (internal fixation) alone.|To establish a satisfactory method of administering rhBMP-2/CPM to implement in a phase 3 efficacy trial in this clinical indication.|To estimate the success and failure rates associated with key fracture outcomes.,http://ClinicalTrials.gov/show/NCT00384358,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; Norway, &nbsp; Sweden, &nbsp; United Kingdom",1,0,3,NA
NCT00384449,Lucentis (Ranibizumab) for Eales' Disease,Completed,No Results Available,Eales' Disease,Drug: Ranibizumab,Oregon Health and Science University|Genentech,Both,Adult|Senior,Phase II|Phase III,5,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,FVF3849s,10/05/2006,01/10/2006,01/04/2009,04/02/2009,01/04/2009,,01/04/2009,"Change in OCT thickness.|Incidence and severity of ocular adverse events, as identified by eye examination (including visual acuity testing)|Incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs|BCVA, as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters.|Incidence of ocular and non-ocular adverse events evaluated through month 6.",http://ClinicalTrials.gov/show/NCT00384449,United States,1,1,1,1
NCT00384839,Vidaza to Restore Hormone Thx Prostate,Completed,No Results Available,Prostate Cancer,Drug: azacitidine for injectable suspension,US Oncology Research|Celgene Corporation|USC/Norris Comprehensive Cancer Center,Male,Adult|Senior,Phase II,36,Industry|Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,5015,10/04/2006,01/04/2006,01/11/2009,04/05/2010,01/04/2010,,01/11/2009,To determine if Vidaza can convert hormone-refractory prostate cancer to a hormone-responsive state,http://ClinicalTrials.gov/show/NCT00384839,United States,1,1,1,1
NCT00384852,A Study of rhBMP-2/CPM in Closed Fractures of the Humerus,Completed,No Results Available,Fractures,Drug: rhBMP-2/CPM,Wyeth,Both,Adult|Senior,Phase II,139,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",3100N7-212,10/03/2006,01/11/2006,01/02/2010,04/12/2010,01/04/2010,,01/02/2009,The primary efficacy variable in this study is radiographic union.,http://ClinicalTrials.gov/show/NCT00384852,"United States, &nbsp; Australia, &nbsp; Brazil, &nbsp; Canada, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Mexico, &nbsp; Norway, &nbsp; Romania, &nbsp; Sweden",1,0,1,NA
NCT00385216,Nicotine as an Adjuvant Analgesic for Third Molar Surgery,Completed,Has Results,Dental Crowding,Drug: Nicotine|Other: Placebo,Columbia University,Both,Adult,Phase IV,20,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAA6273,10/05/2006,01/07/2004,01/06/2009,12/01/2010,01/12/2010,,01/05/2009,Pain Reported by Patient|Nausea|hydrocodone5 mg/Acetaminopgen 325 mg Use|Heart Rate|Systolic Blood Pressure|Diastolic Blood Pressure,http://ClinicalTrials.gov/show/NCT00385216,United States,1,1,2,0
NCT00385671,An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain,Completed,Has Results,"Diabetic Neuropathy, Painful",Drug: duloxetine hydrochloride|Drug: pregabalin|Drug: gabapentin,Eli Lilly and Company|Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase IV,407,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,10822|F1J-US-HMEZ,10/06/2006,01/09/2006,01/11/2009,10/01/2010,01/10/2010,,01/08/2009,"Mean Change From Baseline to 12 Weeks in Weekly Mean of Daily 24 Hour Average Pain Score, Pregabalin Compared With Duloxetine|Mean Change From Baseline to 12 Weeks in Weekly Mean of Daily 24 Hour Average Pain Score, Duloxetine Compared With Duloxetine+Gabapentin|Mean Change From Baseline to 12 Weeks in Weekly Mean of Nighttime Pain Severity|Mean Change From Baseline to 12 Weeks in Weekly Mean of the Daily Worst Pain Severity Score|Mean Change From Baseline to 12 Weeks in Clinical Global Impression of Severity Scale (CGI Severity)|Patient's Global Impression of Improvement Scale (PGI - Improvement) at 12 Weeks|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: 24-hour Average Pain|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: Worst Pain|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: Least Pain|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Severity: Pain Right Now|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference: With General Activity|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Mood|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Walking Ability|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Normal Work|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Relations With Other People|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Sleep|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Interference With Enjoyment of Life|Mean Change From Baseline to 12 Weeks in Brief Pain Inventory (BPI) - Mean Interference Score|Number of Participants With ??­ 30% Reduction in the Weekly Mean 24 Hour Average Pain Score at 12 Weeks|Number of Patients With a Reduction of ??­ 50% in Weekly Mean of 24 Hour Average Pain Score|Number of Participants With a ??­ 2-points Reduction on the Weekly Average of the Daily 24-hour Average Pain Scale at 12 Weeks|Mean Change From Baseline to 12 Weeks in Leeds Sleep Evaluation Questionnaire (LSEQ) Subscales of Ease of Going to Sleep (GTS), Awakening (AFS), and Behaviour Following Wakefulness (BFW), Quality of Sleep (QOS)|Mean Change From Baseline to 12 Weeks in Sheehan Disability Scale (SDS) - Total Score and Scores for Items 1 to 3|Summary of Adverse Events and Serious Adverse Events Leading to Discontinuation|Mean Change From Baseline to 12 Weeks in Sexual Functioning Questionnaire (CSFQ) Total Score and Subscale Scores|Categorical Change From Baseline to 12 Weeks in Sexual Functioning Questionnaire (CSFQ) Total Score and Subscale Scores|Mean Change From Baseline to 12 Weeks in Portland Neurotoxicity Scale - Total Score and Subscale Scores|Categorial Change From Baseline to 12 Weeks in Portland Neurotoxicity Scale - Total Score and Subscale Scores|Path Analysis of Improvement in Pain Through Improvement in Depressive Symptoms|Mean Change From Baseline to 12 Weeks in Beck Depression Inventory II (BDI-II) Total Score|Categorical Change From Baseline to 12 Weeks in Number of Patients Using Health Care as Measured by the Resource Utilization Scale|Summary of Number of Participants Who Discontinued|Time to First ??­ 30% Reduction in Weekly Mean 24 Hour Average Pain Score|Time to First ??­ 50 % Reduction in Weekly Mean 24 Hour Average Pain Score|Time to First Sustained Response in Weekly Mean 24 Hour Average Pain Score|Time to First ??­ 2 Points Reduction in Weekly Mean 24 Hour Average Pain Score|Weekly Mean Change in 24 Hour Average Pain Severity +/- Generalized Anxiety Disorer (GAD)|Weekly Mean Change From Baseline to 12 Weeks in 24 Hour Average Pain Severity - Only Participants Who Adhered to Key Protocol Requirements (Per-Protocol Population)|Weekly Mean Change in 24 Hour Average Pain Severity by Week by Gabapentin Exposure Subgroup (de Novo Versus Prior Use)|Discontinuations for Abnormal Laboratory Analytes, Vital Signs, Overall and for Each Measure|Mean Change From Baseline to 12 Weeks in Blood Pressure|Mean Change From Baseline to 12 Weeks in Heart Rate|Mean Change From Baseline to 12 Weeks in Body Weight|Number of Participants With Treatment-emergent Elevated Blood Pressure|Number of Participants With Treatment-Emergent Elevated Heart Rate|Number of Participants With Treatment-Emergent Changes in Body Weight|Mean Change From Baseline to 12 Weeks in Hepatic Enzyme Serum Levels|Mean Change From Baseline to 12 Weeks in Total Bilirubin|Mean Change From Baseline to 12 Weeks in Fasting Plasma Glucose|Mean Change From Baseline to 12 Weeks in Hemoglobin A1C|Number of Patients With Treatment-Emergent Elevated Laboratory Analytes",http://ClinicalTrials.gov/show/NCT00385671,"United States, &nbsp; Germany",1,0,3,NA
NCT00385736,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Biological: adalimumab|Biological: adalimumab|Biological: placebo,Abbott,Both,Adult|Senior,Phase III,576,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M06-826|2006-002781-20,10/09/2006,01/11/2006,01/03/2010,6/17/2010,01/06/2010,,01/04/2009,Proportion of Participants With Remission Per Mayo Score at Week 8|Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 80/40 Versus Placebo).|Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 80/40 Versus Placebo).|Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).|Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).|Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).|Proportion of IBDQ Responders at Week 8 (Adalimumab 160/80/40 Versus Placebo).|Proportion of IBDQ Responders at Week 8 (Adalimumab 80/40 Versus Placebo).,http://ClinicalTrials.gov/show/NCT00385736,"United States, &nbsp; Austria, &nbsp; Belgium, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; Germany, &nbsp; Hungary, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Puerto Rico, &nbsp; Slovakia, &nbsp; Sweden",0,NA,3,1
NCT00386100,A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Metformin 2000 mg (ttd)|Drug: Metformin 500 mg (ttd)|Drug: Avandamet 2 mg/500 mg (ttd)|Drug: Avandamet 8 mg/ 2000 mg (ttd)|Drug: Avandamet 6 mg/1500 mg (ttd)|Drug: Avandamet 4 mg/1000 mg (ttd)|Drug: Metformin 1000 mg (ttd)|Drug: Metformin 1500 mg (ttd),GlaxoSmithKline,Both,Adult|Senior,Phase IV,688,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AVT105913,10/09/2006,01/10/2006,01/09/2009,06/03/2010,01/06/2010,,01/09/2009,"Percentage change in BMD, as measured by DXA, from baseline to 80 weeks at the lumbar spine (L1-L4) (Bone sub-study)|Mean change in HbA1c from baseline to week 80|Change in adiponectin and C-reactive protein from baseline to week 56 and week 80. Change in total cholesterol, LDL-cholesterol, non-HDL-cholesterol, HDL-cholesterol and triglycerides from baseline to week 80.|Percentage change in BMD at the total hip, femoral neck, trochanter, distal radius, and total body after 80 weeks of treatment (Bone sub-study)|Percentage change in BMD at the lumbar spine (L1-L4), total hip, femoral neck, trochanter, distal radius, and total body over time (Bone sub-study)|Change in biochemical markers of bone turnover at weeks 20, 56 and 80 (Bone sub-study)|Change in estradiol at weeks 20, 56 and 80 (Bone sub-study)|Changes in markers of calcium homeostasis markers at week 80 (Bone sub-study)|Mean change in FPG from baseline to week 80.Change from baseline in HbA1c and FPG by visit (over time).Proportion of subjects achieving recommended glycemic targets.Evaluation of adverse events/safety and tolerability over 80 weeks of treatment.|Change in HbA1c from baseline to week 80 based on last observation carried forward (LOCF) from week 32. Proportion of subjects achieving HbA1c 6.5% and <7% at week 80.|Change in FPG from baseline to week 80. Proportion of subjects achieving FPG 100 mg/dL (5.56 mmol/L), <110mg/dL (6.1 mmol/L) and 126 mg/dL (7 mmol/L) at week 80. Change from baseline in HbA1c and FPG at each visit.|Time from randomization to treatment failure (i.e., HbA1c 7% after week 32 or withdrawal due to ITE). Change in FFA, fasting insulin, C-peptide, HOMA-S and HOMA-B from baseline to week 80 (subset of subjects).|Rate of change (i.e. slope) in -cell function as estimated by the ratio I/G over 80 weeks of treatment (subset of subjects). Proportion of subjects with HbA1c 6.5% and >6.5%, and <7% and 7% at week 32 and at week 80.",http://ClinicalTrials.gov/show/NCT00386100,"United States, &nbsp; Brazil, &nbsp; Canada, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Philippines, &nbsp; Taiwan",1,1,8,0
NCT00386425,Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated),Completed,Has Results,Severe Sepsis,Drug: Drotrecogin alfa (activated),Eli Lilly and Company,Both,Adult|Senior,Phase II,486,Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",10553|F1K-MC-EVDK,10/06/2006,01/11/2006,01/08/2009,11/18/2010,01/11/2010,,01/08/2009,Mean Change in Protein C Levels From Day 1 to Day 7|Mean Change in Protein C Level From Study Day 1 to Study Day 7 in Patients With Moderate and Severe Protein C Deficiency|Day 28 All-Cause Mortality|Hospital Mortality (up to Day 90)|28-Day Time Averaged Sequential Organ Failure (SOFA) Score|Number of Participants With Serious Adverse Events (SAE) and Serious Bleeding Events (SBE) by Time Period|Mortality by Protein C Normalized Versus Not-normalized,http://ClinicalTrials.gov/show/NCT00386425,"United States, &nbsp; Belgium, &nbsp; Canada, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Puerto Rico, &nbsp; Spain, &nbsp; United Kingdom",1,1,1,1
NCT00387088,Tiotropium / Respimat One Year Study in COPD.,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Device: Respimat|Drug: Tiotropium,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase III,3991,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,205.372|2006-001009-27,10/11/2006,01/09/2006,NA,09/01/2010,01/09/2010,,01/01/2009,Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337|Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation|Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29|Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 169|Number of COPD Exacerbations Per Patient - Exposure Adjusted|Number of COPD Exacerbations Per Patient - na??ve Estimate|Number of Patients With at Least One COPD Exacerbation|Time to First Hospitalisation for COPD Exacerbation|Number of Hospitalisations for COPD Exacerbations Per Patient - Exposure Adjusted|Number of Hospitalisations for COPD Exacerbations Per Patient - na??ve Estimate|Number of Patients With at Least One Hospitalisation for a COPD Exacerbation|Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 337|Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 169|Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 29|Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 169|Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 337,http://ClinicalTrials.gov/show/NCT00387088,"United States, &nbsp; Australia, &nbsp; Brazil, &nbsp; Canada, &nbsp; China, &nbsp; Denmark, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Hong Kong, &nbsp; Hungary, &nbsp; India, &nbsp; Ireland, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Lithuania, &nbsp; Malaysia, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Portugal, &nbsp; Singapore, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; Taiwan, &nbsp; Turkey, &nbsp; United Kingdom",1,1,2,1
NCT00388505,Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis,Completed,No Results Available,Cystic Fibrosis,Drug: Tobramycin Inhalation Powder|Drug: Tobramycin Solution,Novartis,Both,Child|Adult|Senior,Phase III,517,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CTBM100C2302,10/16/2006,01/02/2006,01/03/2009,6/23/2009,01/06/2009,EAGER,01/03/2009,"Safety assessed by incidence of treatment-emergent adverse events and clinical laboratory results|Serum tobramycin concentrations|Audiology test results (at select CF centers)|Change in forced expiratory volume in one second (FEV1) at baseline and after Week 24|Patient satisfaction, assessed using the Treatment Satisfaction Questionnaire for Medication",http://ClinicalTrials.gov/show/NCT00388505,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Chile, &nbsp; Colombia, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; Israel, &nbsp; Italy, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Spain, &nbsp; United Kingdom",1,0,2,NA
NCT00388999,Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant,Completed,No Results Available,Multiple Myeloma,Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL),"Enzon Pharmaceuticals, Inc.",Both,Adult|Senior,Phase I|Phase II,50,Industry,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EZN-2232-01,10/13/2006,01/09/2006,01/05/2009,10/19/2009,01/10/2009,,01/02/2009,"Safety and tolerability of rhMBL|Pharmacokinetic (PK) of rhMBL|Pharmacodynamics (PD) of rhMBL|Immunogenicity of rhMBL, incidence of infectious complications",http://ClinicalTrials.gov/show/NCT00388999,United States,1,0,3,NA
NCT00389285,Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma,Completed,No Results Available,"Carcinoma, Renal Cell",Drug: rIL-21 only|Drug: rIL-21 + sorafenib,ZymoGenetics,Both,Adult|Senior,Phase I|Phase II,52,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,494F01,10/16/2006,01/10/2006,01/05/2009,5/26/2009,01/05/2009,,01/05/2009,"Safety profile, including incidence and severity of adverse events|Objective response rate at recommended dose of rIL-21|Progression-free survival at recommended dose of rIL-21|Pharmacokinetic profiles of rIL-21 and sorafenib",http://ClinicalTrials.gov/show/NCT00389285,United States,1,0,2,NA
NCT00389779,DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension,Completed,No Results Available,Hypertension,"Drug: darusentan (LU 135252), guanfacine, and placebo",Gilead Sciences,Both,Adult|Senior,Phase III,849,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Protocol DAR-312,10/17/2006,01/09/2006,01/08/2009,10/02/2009,01/10/2009,Darusentan,01/08/2009,Co-primary efficacy measures: changes from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry|Secondary efficacy measures: 1) change from baseline in mean 24-hour systolic and diastolic blood pressure measured by ABPM; 2) percent of subjects reaching systolic blood pressure goal after 14 weeks of treatment; 3) change from baseline in eGFR.,http://ClinicalTrials.gov/show/NCT00389779,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Denmark, &nbsp; France, &nbsp; Germany, &nbsp; New Zealand, &nbsp; Spain",1,0,1,NA
NCT00390468,Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases,Completed,No Results Available,Metastatic Cancer|Pain|Prostate Cancer,Drug: Tandutinib,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Male,Adult|Senior,Phase II,18,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2005-0717|P30CA016672|MDA-2005-0717|NCI-7409|CDR0000504104,10/18/2006,01/10/2006,01/11/2009,9/23/2010,01/09/2010,,01/11/2009,Time to Progression,http://ClinicalTrials.gov/show/NCT00390468,United States,1,0,1,NA
NCT00391872,A Comparison of AZD6140 and Clopidogrel in Patients With Acute Coronary Syndrome,Completed,No Results Available,Acute Coronary Syndrome,Drug: AZD6140|Drug: Clopidogrel,AstraZeneca,Both,Adult|Senior,Phase III,18000,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D5130C05262|PLATO,10/23/2006,01/10/2006,01/03/2009,4/21/2009,01/04/2009,PLATO,01/03/2009,"The primary outcome measure will be the reduction in the relative risk of vascular death, nonfatal myocardial infarction, or nonfatal stroke (composite primary endpoint), comparing AZD6140 to clopidogrel in patients with non-ST or ST elevation ACS.|Secondary outcomes will include the individual event categories from the primary composite endpoint, a variety of other important clinical outcomes related to ACS, and assessment of the overall safety and tolerability of AZD6140 compared to clopidogrel.",http://ClinicalTrials.gov/show/NCT00391872,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; China, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Finland, &nbsp; France, &nbsp; Georgia, &nbsp; Germany, &nbsp; Greece, &nbsp; Hong Kong, &nbsp; Hungary, &nbsp; India, &nbsp; Indonesia, &nbsp; Israel, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Malaysia, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Philippines, &nbsp; Poland, &nbsp; Portugal, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; Taiwan, &nbsp; Thailand, &nbsp; Turkey, &nbsp; Ukraine, &nbsp; United Kingdom",1,0,2,NA
NCT00392041,Eszopiclone in the Treatment of Insomnia and Fibromyalgia,Completed,No Results Available,Fibromyalgia|Insomnia,Drug: Eszopiclone|Drug: placebo,University of Medicine and Dentistry New Jersey|Sunovion,Both,Adult,Phase IV,95,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",220060122,10/24/2006,01/08/2006,01/03/2009,02/03/2010,01/02/2010,,01/03/2009,Total sleep time (TST) as recorded in patient diaries|Wake time after sleep onset (WASO)|Sleep quality|Clinician-rated overall severity of fibromyalgia|Fibromyalgia Impact Questionnaire,http://ClinicalTrials.gov/show/NCT00392041,United States,1,1,2,1
NCT00392379,Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction,Completed,Has Results,Smokeless Tobacco Use,Drug: Nicotine Lozenges|Drug: Placebo lozenge,Mayo Clinic|National Cancer Institute (NCI),Both,Adult|Senior,Phase III,270,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",06-003091|R01 CA121165,10/24/2006,01/01/2007,01/03/2009,08/09/2010,01/08/2010,,01/03/2009,Prolonged Smokeless Tobacco Abstinence at 3 Months|Self-reported Point Prevalence All Tobacco Abstinence at 3 Months|Prolonged Smokeless Tobacco Abstinence at 6 Months,http://ClinicalTrials.gov/show/NCT00392379,United States,1,1,2,1
NCT00393042,Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR,Completed,No Results Available,Attention Deficit Hyperactivity Disorder,"Drug: Dexmethylphenidate XR|Drug: Mixed Amphetamine Salts, ER|Drug: placebo",University of Illinois|Novartis,Both,Child,Phase III,77,Other|Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment",CRIT124E US15|2006-0423|2006-04,10/25/2006,01/01/2006,01/02/2009,9/27/2010,01/09/2010,,01/02/2009,"Number of minutes to sleep onset as determined by actigraph and sleep diary over 8 weeks.Ratings of side effects, mood.|Ratings of ADHD symptoms along with parent, self report and clinician ratings of mood, tolerability, stimulant side effects, functional outcomes (e.g. family conflicts), and vital signs over a period of 8 weeks.|The number of 10 repeat alleles of DAT1 as correlated with ADHD symptoms and CGI-S ratings.|Family Conflicts|ADHD Symptoms",http://ClinicalTrials.gov/show/NCT00393042,United States,1,1,3,0
NCT00394095,Pilot Study of Topiramate and Olanzapine in the Prevention of Weight Gain in Children and Adolescents With Bipolar Disorder,Completed,No Results Available,Bipolar Disorder|Weight Gain,Drug: olanzapine/topiramate|Drug: olanzapine/placebo,University of Cincinnati,Both,Child|Adult,Phase IV,30,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",F1D-MC-X304,10/27/2006,01/12/2006,01/09/2009,10/09/2009,01/10/2009,,01/08/2009,To examine the efficacy of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder.|To examine the tolerability of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder.,http://ClinicalTrials.gov/show/NCT00394095,United States,1,1,2,0
NCT00394277,A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C,Completed,Has Results,"Hepatitis C, Chronic",Drug: peginterferon alfa-2a|Drug: Ribavirin|Drug: peginterferon alfa-2a|Drug: Ribavirin,Hoffmann-La Roche,Both,Adult|Senior,Phase IV,1175,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NV18210,10/30/2006,01/02/2007,01/04/2009,7/30/2010,01/07/2010,,01/04/2009,Sustained Virological Response (SVR)-24 (Scheduled Treatment Period)|SVR-24 (Actual Treatment Period)|SVR-12 (Scheduled Treatment Period)|SVR-12 (Actual Treatment Period),http://ClinicalTrials.gov/show/NCT00394277,"United States, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Denmark, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Sweden, &nbsp; United Kingdom",1,1,4,1
NCT00395135,BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management,Completed,No Results Available,Obesity,Drug: lorcaserin|Drug: matching placebo,Arena Pharmaceuticals,Both,Adult,Phase III,3182,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",APD356-009,10/31/2006,01/11/2006,01/02/2009,7/27/2009,01/07/2009,,01/02/2009,"Year 1: Proportion (%) of patients achieving > or = 5% weight reduction at the end of the first year of treatment (Week 52)|Year 2: Proportion of patients maintaining > or = 5% weight reduction at the end of Year 2 (Week 104)|Change in body weight at the end of Year 1|Additional body weight change during Year 2|Change in waist and hip measurements|Change in cardiovascular risk factors|Change in use of concomitant medications for comorbidities (i.e., hypertension, dyslipidemia)|Change in Quality of Life measures",http://ClinicalTrials.gov/show/NCT00395135,United States,1,0,2,NA
NCT00395304,Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER),Completed,Has Results,Asthma,Drug: fluticasone propionate + montelukast|Drug: fluticasone propionate|Drug: fluticasone propionate + salmeterol,"National Heart, Lung, and Blood Institute (NHLBI)",Both,Child|Adult,Phase III,182,NIH,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",444|5U10HL064313|5U10HL064288|5U10HL064305|5U10HL064295|5U10HL064287|5U10HL064307,10/31/2006,01/03/2007,01/06/2009,9/17/2010,01/05/2010,BADGER,01/06/2009,"The Number of Participants With a Differential Response to the Three Step-up Therapies Based on Fixed Threshold Criteria for the Following Three Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations, Asthma Control Days and FEV1.|Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1)|Post-bronchodilator Forced FEV1|Forced Vital Capacity (FVC)|FEV1/FVC|Morning Peak Expiratory Flow Rate (PEFR)|Evening PEFR|PEFR Variability|Impulse Oscillometry|Methacholine PC20|Exhaled Nitric Oxide|Asthma Control Test|Asthma Quality of Life|Time Until First Asthma Exacerbation|Adverse Events",http://ClinicalTrials.gov/show/NCT00395304,United States,1,1,3,1
NCT00395447,REPLACE: Implantable Cardiac Pulse Generator Replacement Registry,Completed,Has Results,Device Replacement|Elective Replacement (ERI)|Device Advisory|Device Upgrade|Postoperative Complications,"Procedure: Pulse generator replacement or upgrade|Device: Pacemaker, ICD or CRT system","Biotronik, Inc.",Both,Adult|Senior,Phase IV,1744,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research,REPLACE,11/01/2006,01/07/2007,01/06/2009,11/29/2010,01/11/2010,REPLACE,01/06/2009,Percentage of Subjects Experiencing a Complication During Generator Replacement Without a Planned Lead Revision or Addition (Straight-forward Device Replacment) or With a Planned Lead Revision or Addition (Planned System Modification)|Baseline Variables for Subjects Undergoing Generator Replacement Without a Planned Lead Revision or Addition (Straight-forward Device Replacment) or With a Planned Lead Revision or Addition (Planned System Modification),http://ClinicalTrials.gov/show/NCT00395447,United States,0,NA,2,NA
NCT00395629,Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis,Completed,No Results Available,Iron Overload in Hereditary Hemochromatosis,Drug: deferasirox,Novartis Pharmaceuticals,Both,Adult|Senior,Phase II,49,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CICL670A2202|EudraCT no. 2006-002102-57,11/01/2006,01/08/2006,NA,1/20/2010,01/01/2010,,01/03/2009,"To explore the safety of ICL670 (dose range 5 to 20 mg/kg PO per day) in adult hemochromatosis patients homozygous for the C282Y mutation, with iron overload|To explore the effect of ICL670 on serum ferritin|To characterize the pharmacokinetics of ICL670 in patients with hereditary hemochromatosis",http://ClinicalTrials.gov/show/NCT00395629,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Italy",1,1,1,1
NCT00396331,AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts,Completed,Has Results,Autologous Stem Cell Transplantation,Drug: G-CSF plus plerixafor,Genzyme,Both,Adult|Senior,Phase II,100,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AMD31002112,11/02/2006,01/10/2005,01/12/2009,12/01/2010,01/12/2010,,01/12/2009,Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment Period|Proportion of Participants Who Achieved ??­2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF|Proportion of Participants Who Achieved ??­5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF|Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment|Median Number of Days to Platelet (PLT) Engraftment|Number of Participants With Durable Engraftment 12 Months After Autologous Transplantation|Number of Participants With Non-Hodgkin's Lymphoma (NHL) Who Had Evidence of Tumor Cell Mobilization After G-CSF or Plerixafor Administration|Number of Participants Who Achieved ??­2*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF|Number of Participants Who Achieved ??­5*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF|Maximum Observed Plasma Concentration (Cmax) on Day 4|Maximum Observed Plasma Concentration (Cmax) on Day 7|Time to Maximum Plasma Concentration (Tmax) on Day 4|Time to Maximum Plasma Concentration (Tmax) on Day 7|Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 4|Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 7,http://ClinicalTrials.gov/show/NCT00396331,United States,1,0,1,NA
NCT00397345,TroVax Renal Immunotherapy Survival Trial,Completed,No Results Available,Clear Cell Renal Carcinoma,Biological: Trovax,Oxford BioMedica,Both,Adult|Senior,Phase III,700,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",TV3/001/06,11/08/2006,01/09/2006,01/12/2009,06/04/2010,01/06/2010,,01/12/2009,overall survival,http://ClinicalTrials.gov/show/NCT00397345,"United States, &nbsp; France, &nbsp; Germany, &nbsp; Israel, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Ukraine, &nbsp; United Kingdom",0,NA,1,NA
NCT00402116,Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients,Completed,No Results Available,Glioblastoma|Glioblastoma Multiforme|Gliosarcoma,Drug: enzastaurin|Drug: temozolomide|Radiation: radiation,"Eli Lilly and Company|University of California, San Francisco",Both,Adult|Senior,Phase I|Phase II,72,Industry|Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,9815|H6Q-MC-S008,11/17/2006,01/09/2006,01/12/2009,10/25/2010,01/10/2010,,01/12/2009,"Phase 1 - To determine the maximum tolerated dose (MTD) of enzastaurin in patients with newly diagnosed GBM or GS|Phase 2 - To determine the efficacy of enzastaurin in combination with radiation therapy and temozolomide in patients with newly diagnosed GBM or GS as measured by overall survival (OS)|Phase 1 - To characterize the safety of enzastaurin when combined with temozolomide and radiation therapy in this setting|Phase 1 - To characterize the pharmacokinetics of enzastaurin when administered in combination with temozolomide and radiation therapy|Phase 1 - To assess biomarkers relevant to enzastaurin and disease state, and their correlation to clinical outcome|Phase 1 - To assess for evidence of antitumor activity in this patient population|Phase 2 - To evaluate progression free survival (PFS)|Phase 2 - To evaluate the safety profile of enzastaurin in combination with temozolomide and radiation therapy in this patient population|Phase 2 - To assess biomarkers relevant to enzastaurin and disease state and their correlation to clinical outcome|Phase 2 - To explore the utility of magnetic resonance perfusion techniques to assess treatment with enzastaurin when possible|Phase 2 - To assess changes in health-related quality of life and symptoms in this patient population",http://ClinicalTrials.gov/show/NCT00402116,United States,1,0,3,NA
NCT00402428,Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients,Completed,No Results Available,Chronic Hepatitis C,Drug: albumin interferon alfa-2b|Drug: peginterferon alfa-2a|Drug: Ribavirin,Human Genome Sciences|Novartis,Both,Adult|Senior,Phase III,1331,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HGS1008-C1060|ACHIEVE-1,11/20/2006,01/12/2006,01/02/2009,9/17/2009,01/09/2009,,01/02/2009,"Sustained virologic response (SVR)|Rapid virologic response|Early virologic response|Undetectable HCV RNA|Normalization of ALT (a liver enzyme)|Quality of life evaluation|Safety assessments (physical exams, AE reporting, lab testing/analysis, HADS and Immunogenicity testing)",http://ClinicalTrials.gov/show/NCT00402428,"United States, &nbsp; Australia, &nbsp; Austria, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; France, &nbsp; Germany, &nbsp; India, &nbsp; Israel, &nbsp; Italy, &nbsp; Poland, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Spain, &nbsp; United Kingdom",1,1,3,0
NCT00402883,"Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer",Completed,No Results Available,Lung Cancer,Drug: Bevacizumab|Drug: Pemetrexed|Procedure: Radiation therapy,Sarah Cannon Research Institute|Genentech|Eli Lilly and Company,Both,Adult|Senior,Phase II,50,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SCRI LUN 134|AVF3793s|H3E-US-1019,11/21/2006,01/11/2006,01/01/2009,11/01/2010,01/11/2010,,01/01/2009,Time to progression|To evaluate the objective response rates|Overall survival,http://ClinicalTrials.gov/show/NCT00402883,United States,1,1,3,0
NCT00403273,Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Joint,Completed,No Results Available,"Arthroplasty, Replacement, Knee",Drug: Botulinum toxin A|Drug: Normal Saline,Minneapolis Veterans Affairs Medical Center|University of Minnesota - Clinical and Translational Science Institute|Arthritis Foundation,Both,Child|Adult|Senior,Phase II,50,U.S. Fed|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1-singh,11/21/2006,01/07/2006,01/01/2009,04/06/2009,01/04/2009,,01/01/2009,"proportion with clinically meaningful Change in Pain Severity (0-10)|Patient global assessment of response to treatment|Physician global assessment of response to treatment|Improvement in Physical Function subscale of the WOMAC and WOMAC total|Time to Onset of Pain Relief and duration of pain relief|Change in joint function as measured by active and passive range of motion, and Time to perform sit to stand 10 times without using arms to push up (Timed Stands Test) and Timed up-and-go (TUG) tests|QOL: SF-36 scores, a generic health status measure|Clinical assessment of joint erythema, warmth, swelling and tenderness|Manual muscle strength testing of flexion and extension.|Proportion with Minimal Clinically Important Improvement (MCII) on VAS pain, WOMAC pain, physical function, stiffness subscales and total scores|correlation of Baseline Serum and Joint Fluid Cytokine Levels with baseline pain and function|Correlation of Change in Serum and Joint Fluid Cytokine Levels with improvement in pain and function|McGill Sensory pain, affective pain and total score",http://ClinicalTrials.gov/show/NCT00403273,United States,1,1,2,1
NCT00403390,Generic vs. Name-Brand Levothyroxine,Completed,No Results Available,Congenital Hypothyroidism|Hypothyroidism,Drug: Levothyroxine versus Levothyroxine,Children's Hospital Boston,Both,Child|Adult,Phase III,34,Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,###############################################################################################################################################################################################################################################################,11/21/2006,01/11/2006,01/03/2010,12/02/2010,01/12/2010,,01/12/2009,Thyroid Stimulating Hormone Measure,http://ClinicalTrials.gov/show/NCT00403390,United States,1,1,1,0
NCT00403559,A 4 Week Study of Elidel for the Treatment of Seborrheic Dermatitis,Completed,No Results Available,Seborrheic Dermatitis,Drug: Elidel,Dermatology Specialists Research|Novartis,Both,Adult|Senior,Phase II,110,Other|Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,"CASM981CUS37|SAIRB # 06-4893|IND 75,225",11/21/2006,01/01/2007,01/01/2009,3/31/2009,01/10/2007,,01/01/2009,The change of IGA from BL to wk 1 will be the primary efficacy variable|Key secondary efficacy will be the % of patients with facial clearance,http://ClinicalTrials.gov/show/NCT00403559,United States,1,1,1,1
NCT00404248,Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma,Completed,No Results Available,Brain and Central Nervous System Tumors,Drug: terameprocol|Other: pharmacological study,National Cancer Institute (NCI),Both,Adult|Senior,Phase I|Phase II,50,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000515952|NABTT-0503,11/27/2006,01/01/2007,NA,6/23/2009,01/06/2009,,01/06/2009,Maximum tolerated dose (Phase I)|Response rate (Phase II)|Pharmacokinetics (Phase I)|Toxicity (Phase I)|Effects of hepatic enzyme-inducing anticonvulsants on the pharmacokinetic profile (Phase I)|Safety (Phase II)|Tolerability (Phase I and II)|Overall survival (Phase I and II)|Treatment response (complete and partial remission and stable disease) (Phase II),http://ClinicalTrials.gov/show/NCT00404248,United States,1,0,2,NA
NCT00405743,A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies,Completed,No Results Available,Hematologic Malignancies|AML,Drug: CP-4055|Drug: CP-4055,Clavis Pharma,Both,Adult|Senior,Phase I|Phase II,153,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CP4055-106,11/29/2006,01/05/2006,01/05/2010,09/03/2010,01/09/2010,,01/05/2009,Phase I: Determine the MTD and PK properties of CP-4055 single agent.|Phase II: Determine the efficacy of CP-4055 single agent in AML|Phase I: Evaluate the safety profile of CP-4055 single agent.|Determine the MTD and PK of CP-4055 in combination with idarubicin.|Phase II: Extended evaluation of the safety profile of CP-4055 single agent in AML,http://ClinicalTrials.gov/show/NCT00405743,"United States, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Norway, &nbsp; United Kingdom",1,0,2,NA
NCT00406848,A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients,Completed,Has Results,Major Depressive Disorder,Drug: duloxetine hydrochloride|Drug: placebo,Eli Lilly and Company|Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase IV,370,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10815|F1J-US-HMFA,11/29/2006,01/11/2006,01/11/2009,9/13/2010,01/09/2010,,01/07/2009,"Change From Baseline to 13 Weeks in Hamilton Depression Rating Scale (HAMD-17) Maier Subscale|Change From Baseline on the 30-item Geriatric Depression Scale (GDS)|Change From Baseline in the HAMD-17 Total Score, Subscales, and Individual Items|Change From Baseline in the Brief Pain Inventory (BPI) Severity and Interference Scores|Change From Baseline in the Numeric Rating Scales (NRS) for Pain Item Scores|Patient's Global Impression of Improvement (PGI-I) at 13 Weeks and 25 Weeks|Change From Baseline in the Clinical Global Impression-Severity (CGI-S)|Change From Baseline in the Mini-Mental State Exam (MMSE)|Change From Baseline in the Quality of Life, Enjoyment, and Satisfaction Questionnaire (Q-LES-Q-SF)|Probability of Remission as Measured by the HAMD-17 Total Score ???7 and ???10|Probability of Response at Endpoint as Measured by ??­50% Improvement in the HAMD-17 Total Score|Probability of Remission as Measured by the HAMD-17 Total Score ???7 and ???10 by Medical Comorbidity Severity as Assessed by the Cumulative Illness Rating Scale-Geriatric Version (CIRS-G)|Probability of Efficacy Onset as Measured by at Least 20% Sustained Reduction From Baseline in the HAMD-17 Maier Subscale at Week 3|Change From Baseline in Supine Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Pulse Rate|Change From Baseline in Weight|Number of Participants With Abnormal Vital Signs and Weight at Any Time During the Study|Number of Participants Experiencing Sustained Hypertension (SH) or Orthostatic Hypotension (OH)|Summary of Adverse Events and Serious Adverse Events Leading to Discontinuation|Change From Baseline in Laboratory Values - Platelet Count|Change From Baseline in Laboratory Values - Uric Acid|Change From Baseline in Laboratory Values - Erythrocyte Count|Change From Baseline in Laboratory Values - Hemoglobin, Mean Cell Hemoglobin Concentration (MCHC)|Change From Baseline in Laboratory Values - Chloride and Fasting Glucose|Number of Participants With Abnormal Laboratory Values - Low Leukocyte Count|Change From Baseline in Electrocardiograms|Number of Participants With Successful Treatment Outcome|Change From Baseline on Cognitive Test Scores: Verbal Learning and Recall Test (VLRT), Symbol Digit Substitution Test (SDST), Trail Making Test (Part B), 2-Digit Cancellation Test (2DCT), and the Composite Cognitive Score Derived From the Above Scores",http://ClinicalTrials.gov/show/NCT00406848,"United States, &nbsp; France, &nbsp; Mexico, &nbsp; Puerto Rico",1,1,2,1
NCT00407095,An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.,Completed,No Results Available,Advanced Stage Parkinson's Disease,Drug: Pardoprunox,Solvay Pharmaceuticals,Both,Adult|Senior,Phase III,140,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,S308.3.007|2006-005183-91|00407095,11/30/2006,01/08/2007,01/05/2009,09/10/2010,01/09/2010,,01/05/2009,"Safety: laboratory data, adverse events, vital signs, ECG|On' and 'off' time recording, UPDRS parts 1-4, CGI-improvement, PDQ-39 total score: all change from baseline",http://ClinicalTrials.gov/show/NCT00407095,"United States, &nbsp; Albania, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Chile, &nbsp; Colombia, &nbsp; Latvia, &nbsp; Lithuania, &nbsp; Peru, &nbsp; Russian Federation, &nbsp; Ukraine",1,0,1,NA
NCT00407303,Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL),Completed,No Results Available,Mantle-Cell Lymphoma,Drug: Obatoclax mesylate (GX15-070MS)|Drug: Obatoclax,Gemin X,Both,Adult|Senior,Phase I|Phase II,24,Industry,Interventional,Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,GEM012,12/01/2006,01/10/2006,01/11/2009,9/13/2010,01/09/2010,,01/03/2009,Determine the response rate to obatoclax in combination with Bortezomib and characterize the safety profile|Peripheral blood counts; Bone marrow aspirates and biopsies; Transfusion and growth factor requirements,http://ClinicalTrials.gov/show/NCT00407303,United States,1,0,2,NA
NCT00407966,"Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",Completed,No Results Available,Leukemia,Drug: alvocidib|Drug: cytarabine|Drug: mitoxantrone hydrochloride,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,25,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000518322|U01CA070095|P30CA006973|JHOC-J0669,12/04/2006,01/10/2006,NA,3/18/2010,01/03/2010,,01/11/2009,Complete response|Toxicity,http://ClinicalTrials.gov/show/NCT00407966,United States,1,0,3,NA
NCT00409175,Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis,Completed,No Results Available,Familial Amyloid Polyneuropathy,Drug: Fx-1006A,FoldRx Pharmaceuticals|FDA Office of Orphan Products Development,Both,Adult|Senior,Phase II|Phase III,127,Industry|U.S. Fed,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Fx-005,12/06/2006,01/12/2006,01/06/2009,03/09/2010,01/03/2010,,01/05/2009,"Response to treatment at Month 18 as measured by the Neurologic Impairment Score - Lower Limb (NIS-LL)|Change from Baseline to 18 months in the Total Quality of Life (TQOL) score, as measured by the Norfolk QOL-DN.|Change from Baseline through Month 18 in \+7 composite score\"" as measured by nerve conduction studies (NCS)",http://ClinicalTrials.gov/show/NCT00409175,"United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; France, &nbsp; Germany, &nbsp; Portugal, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",1,0,1,NA
NCT00409292,RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Drug: RAD001,Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Novartis,Both,Adult|Senior,Phase II,35,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,06-197,12/06/2006,01/01/2007,01/05/2009,10/30/2009,01/10/2009,,01/01/2009,To assess progression-free survival of RAD001 at two months in patients with metastatic pancreatic cancer whose disease has progressed on gemcitabine chemotherapy.|To assess the safety of RAD001 in patients with metastatic pancreatic cancer|to assess response rate and overall survival associated with RAD001 in this patient population.,http://ClinicalTrials.gov/show/NCT00409292,United States,1,1,1,1
NCT00409578,Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome,Completed,No Results Available,Post Acute Coronary Syndrome|Myocardial Ischemia,Drug: Aliskiren/Valsartan|Drug: Aliskiren/Valsartan|Drug: Placebo,Novartis|The TIMI Study Group,Both,Adult|Senior,Phase II,1100,Industry|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CSPP100A2347,12/07/2006,01/04/2007,NA,8/31/2009,01/08/2009,,01/05/2009,"Reduction of the NT-proBNP levels for valsartan and aliskiren compared to placebo|Reduction of NT-proBNP levels for valsartan/aliskiren combination compared to each individual monotherapy and placebo|Reduction of adverse cardiac events rate (death, recurrent myocardial infarction, or hospitalization for congestive heart failure) as compared to placebo|Explore if the combination of aliskiren or valsartan reduces the rate of adverse cardiac events (death, recurrent myocardial infarction, or hospitalization for congestive heart failure) as compared to each individual monotherapy and placebo|Reduction of NT-proBNP levels for valsartan or aliskiren compared to placebo|Reduction of NT-proBNP levels for aliskiren or valsartan compared to placebo|Reduction of levels of key biomarkers of cardiovascular risk (e.g, hsCRP, PRA) for aliskiren and valsartan combination or individual monotherapies",http://ClinicalTrials.gov/show/NCT00409578,"United States, &nbsp; Belgium, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; Germany, &nbsp; Hungary, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Sweden",1,1,3,1
NCT00410384,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE),Completed,No Results Available,Systemic Lupus Erythematosus,Drug: belimumab|Drug: belimumab|Drug: Placebo,Human Genome Sciences|GlaxoSmithKline,Both,Adult|Senior,Phase III,819,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",HGS1006-C1056|BLISS-76,12/08/2006,01/12/2006,01/10/2010,10/21/2010,01/10/2010,,01/09/2009,"At Wk 52 the % of subjects with great than or equal to 4 point reduction from baseline in SELENA SLEDAI score & no worsening in PGA & no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline at the time of assessment.|At Wk 76, % of subjects with great than or equal to 4 point reduction from baseline in SELENA SLEDAI score & no worsening in (PGA) and no new BILAG organ domain score or 2 new BILAG organ domain scores compared with baseline at the time of assessment.|Percent of subjects with great than or equal to 4 point reduction from baseline in SELENA SLEDAI score at Wk 52.|Mean change in PGA at Wk 24.|Mean change in SF-36 Health Survey physical component summary score (PCS) at Wk 24.|Percent of subjects whose average prednisone dose has been reduced by greater than or equal to 25% from baseline to less than or equal to 7.5 mg/day during Weeks 40 through 52",http://ClinicalTrials.gov/show/NCT00410384,"United States, &nbsp; Austria, &nbsp; Belgium, &nbsp; Canada, &nbsp; Costa Rica, &nbsp; Czech Republic, &nbsp; France, &nbsp; Germany, &nbsp; Israel, &nbsp; Italy, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Slovakia, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",1,0,3,NA
NCT00410410,A Study of Abatacept in Patients With Active Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: abatacept (ABA)|Drug: placebo|Drug: abatacept,Bristol-Myers Squibb,Both,Adult|Senior,Phase III,591,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",IM101-108,12/11/2006,01/12/2006,01/11/2009,11/04/2010,01/11/2010,,01/06/2009,"Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)|Maintenance Period (MP); Number of Participants With Clinical Response (Per Mayo Score) at Month 12|Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation|OL; Number of Participants With AEs of Special Interest|OL; Number of Participants With Physical Examination Findings|OL; Number of Participants With Marked Hematology Laboratory Abnormalities|OL; Number of Participants With Liver and Kidney Function and Electrolyte Laboratory Abnormalities|OL; Number of Participants With Chemistry and Urinalysis Laboratory Abnormalities|IP; Baseline Mayo Score: IP1C|IP; Number of Participants in Clinical Remission (Per Mayo Score) at Week 12: IP1C|IP; Number of Participants in Mucosal Healing (Per Mayo Score) at Week 12: IP1C|IP; Number of Participants With Clinical Response (Per Mayo Score) at Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C|IP; Baseline Inflammatory Bowel Disease Questionnaire (IBDQ) Score: IP1C|IP; Mean Change From Baseline To Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ): IP1C|IP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (???1 Point) at Week 12: IP1C|IP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (???1 Point) at Week 12: IP1C|IP; Number of Participants With Mayo Physician Global Assessment (PGA) Subscores Indicating Mild Disease (???1 Point) at Week 12: IP1C|IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With Clinical Response At Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C|IP; Number of Participants With Clinical Response At Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C|IP; Number of Participants in Clinical Remission at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C|IP; Number of Participants in Mucosal Healing at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C|IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation: IP1C + IP2C|IP; Number of Participants With AEs Of Special Interest: IP1C + IP2C|IP; Number of Participants With Physical Examination Findings: IP1C + IP2C|IP; Number of Participants With Marked Hematology Laboratory Abnormalities: IP1C|IP; Number of Participants With Marked Liver and Kidney Function and Electrolyte Laboratory Abnormalities: IP1C|IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP1C|IP; Number of Participants With Marked Hematology, Liver and Kidney Function, and Electrolyte Laboratory Abnormalities: IP2C|IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP2C|IP; Number of Participants With Abatacept-Induced Antibodies: IP1C + IP2C|MP; Number of Participants in Clinical Remission at Month 12|MP; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (???1 Point) at Month 12|MP; Number of Participants in Clinical Remission at Both Month 6 and Month 12|MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids and Achieved Clinical Remission by Month 12|MP; Mean Change From Baseline to Month 12 in IBDQ|MP; Mean Change From Baseline to Month 12 in Short Form-36 (SF-36)|MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids for 90 Consecutive Days and Achieved Clinical Remission by Month 12|MP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (???1 Point) at Month 12|MP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (???1 Point) at Month 12|MP; Number of Participants With Mayo PGA Subscores Indicating Mild Disease (???1 Point) at Month 12|MP; Number of Participants With Clinical Response at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)|MP; Number of Participants With Clinical Remission at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)|MP; Number of Participants With Clinical Mucosal Healing at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)|MP; Number of Participants With Abatacept-Induced Antibodies|MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation|MP; Number of Participants With AEs of Special Interest|MP; Number of Participants With Physical Examination Findings|MP; Number of Participants With Marked Hematology Laboratory Abnormalities|MP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities|OL; Number of Participants With Clinical Response Over Time|OL; Number of Participants With Clinical Remission Over Time|OL; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (???1 Point) During OL|OL; Number of Participants With Clinical Response or Clinical Remission Upon Retreatment With Abatacept Among Those Who Received Abatacept in the IP or MP Period|OL; Number of Participants With Abatacept-Induced Antibodies|OL; Number of Participants Using Corticosteroids During OL",http://ClinicalTrials.gov/show/NCT00410410,"United States, &nbsp; Australia, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; France, &nbsp; Germany, &nbsp; India, &nbsp; Ireland, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Puerto Rico, &nbsp; South Africa, &nbsp; Switzerland, &nbsp; United Kingdom",1,1,3,1
NCT00412425,Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting,Completed,No Results Available,Melanoma,Drug: Palonosetron,M.D. Anderson Cancer Center|Eisai Inc.,Both,Adult,Phase I|Phase II,30,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2005-0506,12/14/2006,01/11/2006,01/05/2009,10/22/2009,01/10/2009,,01/05/2009,Patient Response to Palonosetron,http://ClinicalTrials.gov/show/NCT00412425,United States,1,1,1,0
NCT00412542,Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas,Completed,No Results Available,Glioblastoma Multiforme|Glioma,Drug: Thalidomide|Drug: CPT-11|Procedure: MRI Scan|Procedure: Quantitative Sensory Tests (QST),M.D. Anderson Cancer Center|Celgene Corporation,Both,Child|Adult|Senior,Phase II,78,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DM02-595,12/15/2006,01/10/2003,01/10/2009,10/08/2009,01/10/2009,,01/10/2009,To study if the drug Thalomid (thalidomide) when combined with CPT-11 is effective in the treatment of brain cancer.|To learn if a special MRI technique is useful in observing the effect of treatment on the tumor,http://ClinicalTrials.gov/show/NCT00412542,United States,1,1,4,0
NCT00413114,Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS),Completed,No Results Available,Myelodysplastic Syndromes,Drug: Obatoclax mesylate (GX15-070MS),Gemin X,Both,Adult|Senior,Phase II,24,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GEM013,12/18/2006,01/12/2006,01/11/2009,9/14/2010,01/09/2010,,01/02/2009,Determine the response rate to obatoclax and characterize the safety profile.|Peripheral blood counts; Bone marrow aspirates and biopsies; Transfusions and growth factor requirements,http://ClinicalTrials.gov/show/NCT00413114,"United States, &nbsp; Canada",1,0,1,NA
NCT00414609,Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE),Completed,No Results Available,Myocardial Infarction,Drug: Aliskiren|Drug: placebo,Novartis,Both,Adult|Senior,Phase III,800,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CSPP100A2340,12/19/2006,01/12/2006,NA,10/27/2009,01/10/2009,,01/09/2009,"Change in left ventricular end systolic volume (LVESD) as measured by echocardiography|Cardiovascular-related deaths, hospitalization for heart failure, recurrent myocardial infarction, stroke, and resuscitated sudden deaths|Change in left ventricular end diastolic volume|Change in left ventricular ejection fraction|Overall safety and tolerability",http://ClinicalTrials.gov/show/NCT00414609,"United States, &nbsp; Argentina, &nbsp; Belgium, &nbsp; Canada, &nbsp; Colombia, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Israel, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; Spain, &nbsp; Sweden, &nbsp; Turkey, &nbsp; United Kingdom, &nbsp; Venezuela",1,1,2,0
NCT00415532,AMG 531 Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura,Completed,No Results Available,Thrombocytopenic Purpura|Idiopathic Thrombocytopenic Purpura|Thrombocytopenia|Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP),Biological: AMG531|Drug: Medical Standard of Care for ITP,Amgen,Both,Adult|Senior,Phase III,131,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,20060131,12/21/2006,01/11/2006,01/07/2009,9/23/2010,01/09/2010,,01/05/2009,Number of subjects undergoing a splenectomy by treatment group during the 52-week treatment period.|Number of subjects with a treatment failure during the 52-week treatment period.|Time to splenectomy.|Platelet response.|Change in the ITP-PAQ (Patient reported outcome scale) Physical Health domains.,http://ClinicalTrials.gov/show/NCT00415532,"United States, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Spain, &nbsp; Switzerland, &nbsp; United Kingdom",1,1,2,0
NCT00416793,Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Drug: Bortezomib|Drug: Carboplatin,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,9,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MDA-2006-0079|P30CA016672|MDA-2006-0079|CDR0000522739,12/27/2006,01/12/2006,01/10/2009,09/07/2010,01/09/2010,,01/10/2009,Overall survival at 6 months|Overall response rate|Overall survival,http://ClinicalTrials.gov/show/NCT00416793,United States,1,1,2,0
NCT00417079,XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer,Completed,Has Results,Neoplasms|Prostatic Neoplasms,Drug: cabazitaxel (XRP6258) (RPR116258)|Drug: mitoxantrone|Drug: prednisone,Sanofi-Aventis,Male,Adult|Senior,Phase III,755,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EFC6193,12/28/2006,01/01/2007,01/09/2009,12/22/2010,01/12/2010,TROPIC,01/09/2009,Overall Survival|Time to Progression Free Survival (PFS)|Overall Tumor Response|Time to Tumor Progression|Time to Prostatic Specific Antigen (PSA) Progression|PSA (Prostate-Specific Antigen) Response|Time to Pain Progression|Pain Response,http://ClinicalTrials.gov/show/NCT00417079,"United States, &nbsp; Argentina, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Netherlands, &nbsp; Russian Federation, &nbsp; Singapore, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Taiwan, &nbsp; Turkey, &nbsp; United Kingdom",1,1,3,0
NCT00417209,Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen,Completed,No Results Available,Pancreatic Neoplasms,Drug: larotaxel (XRP9881)|Drug: 5-Fluorouracil,Sanofi-Aventis,Both,Adult|Senior,Phase III,408,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EFC6596|EUDRACT: 2006-003086-14,12/28/2006,01/12/2006,01/11/2009,08/03/2010,01/08/2010,PAPRIKA,01/07/2009,overall survival (OS) defined as the time interval from the date of randomization to the date of death due to any cause|Progression free survival (PFS); Overall Response Rate (proportion of patients with confirmed RECIST-defined complete response (CR) or partial response (PR); clinical benefit based on the measurement of tumor related symptoms;,http://ClinicalTrials.gov/show/NCT00417209,"United States, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; Colombia, &nbsp; Czech Republic, &nbsp; Finland, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Italy, &nbsp; Mexico, &nbsp; Norway, &nbsp; Peru, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; Spain, &nbsp; Turkey, &nbsp; United Kingdom",1,0,2,NA
NCT00417287,Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer,Completed,No Results Available,Pancreatic Neoplasms,Drug: PX-12,"Oncothyreon Inc.|National Cancer Institute (NCI)|Translational Genomics Research Institute, Phoenix, Arizona.",Both,Adult|Senior,Phase II,80,Industry|NIH|Other,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PX-12-II-01|P01 CA109552,12/29/2006,01/12/2006,01/04/2009,02/03/2010,01/02/2010,,01/04/2009,Progression free survival and overall survival (percentage of patients alive at 6 months)|Determine if there is a difference in effect on circulating Trx-1 protein levels between two dose levels of PX-12|Determine which of two dose levels of PX-12 causes the greatest effect on three surrogate markers of clinical activity|Determine effects of two different dose levels on overall clinical response|Further evaluate safety profile of PX-12|Assess the effects of metabolic excretion of PX-12,http://ClinicalTrials.gov/show/NCT00417287,United States,1,0,1,NA
NCT00418691,Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning,Completed,No Results Available,Brain Tumor,Drug: IR Methylphenidate|Drug: Modafinil|Drug: SR Methylphenidate,M.D. Anderson Cancer Center,Both,Adult|Senior,Phase III,34,Other,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2003-0925,01/03/2007,01/02/2004,01/11/2009,12/28/2009,01/12/2009,,01/11/2009,Patient Cognitive Test Scores at End of Treatment Period,http://ClinicalTrials.gov/show/NCT00418691,United States,1,1,3,0
NCT00418951,Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections,Completed,No Results Available,Acute Myelogenous Leukemia|Myelodysplastic Syndrome,Drug: Voriconazole|Drug: Liposomal amphotericin B|Drug: Liposomal amphotericin B,M.D. Anderson Cancer Center,Both,Adult|Senior,Phase II,120,Other,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,2006-0536,01/03/2007,01/11/2006,01/10/2009,12/14/2009,01/12/2009,,01/10/2009,Infection Rate|Toxicity Rate,http://ClinicalTrials.gov/show/NCT00418951,United States,1,1,3,1
NCT00419094,Conversion to Monotherapy Study With Keppra XR for Partial Seizures,Completed,Has Results,Epilepsy,Drug: Keppra XR|Drug: Keppra XR,"UCB, Inc.",Both,Child|Adult|Senior,Phase III,228,Industry,Interventional,"Allocation: Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",N01280,01/04/2007,01/08/2007,01/09/2009,01/04/2011,01/01/2011,,01/09/2009,"The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase|The Cumulative Rate of Exit Events, Which Include Discontinuation Due to Exit Criteria, Withdrawal Due to Adverse Events (AE) and Withdrawal Due to Lack of Efficacy, at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase|The Cumulative Rate of Exit Events Due to Any Reasons at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase|The Cumulative Exit Rate at 112 Days for the Keppra XR 1000 mg Group After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase",http://ClinicalTrials.gov/show/NCT00419094,"United States, &nbsp; Mexico, &nbsp; Poland, &nbsp; Russian Federation",1,1,2,1
NCT00419159,Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Chemotherapy,Completed,No Results Available,Colorectal Cancer,Drug: everolimus,Novartis Pharmaceuticals,Both,Adult|Senior,Phase II|Phase III,199,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CRAD001C2241,01/04/2007,01/12/2006,NA,02/05/2010,01/02/2010,,01/03/2009,Disease control rate (DCR) and objective response rate (ORR) according to the response evaluation criteria in solid tumors (RECIST)|Progression-free survival|Overall survival|Safety profile of RAD001,http://ClinicalTrials.gov/show/NCT00419159,United States,1,1,1,1
NCT00419666,A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis,Completed,No Results Available,Chronic Plaque Psoriasis,Drug: Calcitriol,Galderma,Both,Child,Phase II,25,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RD.06.SPR.18102,01/05/2007,01/08/2006,01/11/2009,4/19/2010,01/04/2010,,01/09/2009,PK|PD,http://ClinicalTrials.gov/show/NCT00419666,"United States, &nbsp; Canada",1,1,1,0
NCT00419744,A Comparison of SYMBICORT?ó pMDI With Formoterol Turbuhaler?ó in Subjects With COPD,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Budesonide/formoterol (SYMBICORT) pMDI|Drug: Formoterol Turbuhaler,AstraZeneca,Both,Adult|Senior,Phase III,1200,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,D589CC00003,01/05/2007,01/01/2007,01/08/2009,8/18/2010,01/08/2010,,01/08/2009,Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year|Rate of Exacerbations Per Subject-year|Pre-dose Forced Expiratory Volume in 1 Second (FEV1)|Morning Peak Expiratory Flow (PEF)|Evening PEF|Dyspnea Symptom Scores|Use of Rescue Medication|St. George's Respiratory Questionnaire (SGRQ) Score,http://ClinicalTrials.gov/show/NCT00419744,"United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Chile, &nbsp; Colombia, &nbsp; Mexico, &nbsp; Peru, &nbsp; South Africa, &nbsp; Venezuela",1,1,2,1
NCT00419952,A Comparison of SYMBICORT pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.,Completed,No Results Available,Asthma,Drug: Budesonide/formoterol (SYMBICORT) pMDI|Drug: Budesonide HFA pMDI,AstraZeneca,Both,Child|Adult|Senior,Phase III,720,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,D5896C00022,01/05/2007,01/02/2007,01/11/2009,4/23/2010,01/04/2010,,01/11/2009,"To assess the long-term safety profile of SYMBICORT pMDI 160/4.5 ??g x 2 actuations twice daily compared to budesonide HFA pMDI 160 ??g x 2 actuations twice daily, in African American subjects with moderate to severe asthma, over a 52-week treatment perio|Patient reported outcome variables over a 52-week treatment period collected using Onset of Effect Questionnaire to assess pre-dose FEV1 and morning peak expiratory flow (AM PEF)|To collect a blood sample for pharmacogenetic analyses in all subjects",http://ClinicalTrials.gov/show/NCT00419952,United States,1,1,2,0
NCT00420628,Pediatric Zylet Safety and Efficacy Study,Completed,Has Results,Chalazion|Hordeolum,Drug: loteprednol etabonate/tobramycin opthalmic suspension|Drug: vehicle,"Bausch & Lomb, Inc.",Both,Child,Phase IV,108,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",459,01/08/2007,01/11/2006,01/06/2009,8/27/2010,01/08/2010,,01/01/2009,Treatment Emergent Adverse Events|Investigators Global Assessment of the Clinical Condition|Assessment of Ocular Signs in the Study Eye - Visit 1|Assessment of Ocular Signs in the Study Eye - Visit 2|Assessment of Ocular Signs in the Study Eye - Visit 3,http://ClinicalTrials.gov/show/NCT00420628,United States,1,1,2,1
NCT00420784,"A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C",Completed,No Results Available,Hepatitis C,Drug: Telaprevir|Drug: Ribavirin|Drug: Peg-interferon Alfa-2a,Vertex Pharmaceuticals Incorporated,Both,Adult|Senior,Phase II,440,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VX06-950-106,01/08/2007,01/01/2007,01/04/2009,05/08/2009,01/05/2009,,01/04/2009,"Undetectable HCV RNA|Undetectable HCV RNA|Undetectable HCV RNA|Adverse events and clinical laboratory assessments, including ALT and other liver function tests.|Genotypic and phenotypic analyses of the NS3??Ñ4A HCV region.|Pharmacokinetic assessments of telaprevir, Peg-IFN-a-2a, and RBV.",http://ClinicalTrials.gov/show/NCT00420784,"United States, &nbsp; Canada, &nbsp; Germany, &nbsp; Netherlands, &nbsp; Puerto Rico",1,0,3,NA
NCT00421525,Phase I/II Study of hLL1 in Multiple Myeloma,Completed,No Results Available,"Multiple Myeloma|Myeloma, Plasma-Cell|Plasmacytoma",Biological: milatuzumab,"Immunomedics, Inc.",Both,Adult|Senior,Phase I|Phase II,66,Industry,Interventional,Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PROTOCOL: IMMU-115-01,01/11/2007,01/01/2007,NA,12/01/2009,01/12/2009,,01/08/2009,"safety and tolerability of hLL1 administered twice weekly for 4 consecutive weeks|The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.",http://ClinicalTrials.gov/show/NCT00421525,United States,0,NA,1,NA
NCT00421733,The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors,Completed,Has Results,Diabetic Nephropathy|Chronic Kidney Disease,Drug: Zemplar (paricalcitol ) capsules|Drug: Zemplar (paricalcitol) capsules|Drug: Placebo,Abbott,Both,Adult|Senior,Phase II,281,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M05-741|2006-001363-31,01/10/2007,01/12/2006,01/06/2009,9/27/2010,01/09/2010,VITAL,01/06/2009,Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine Collections Comparing Placebo to the Combined Paricalcitol Treatment Groups (1 Mcg and 2 Mcg).|Number of Participants Achieving a 15% or Greater Reduction From Baseline to Last On-treatment Urine Albumin to Creatinine Ratio (UACR) Levels.|Change From Baseline to the Last On-treatment Measurement in Albumin Levels Determined From 24-hour Urine Collection.|Change From Baseline to the Last On-treatment Observation in Intact Parathyroid Hormone (iPTH) Levels.,http://ClinicalTrials.gov/show/NCT00421733,"United States, &nbsp; Germany, &nbsp; Greece, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Portugal, &nbsp; Puerto Rico, &nbsp; Spain, &nbsp; Taiwan",1,1,3,1
NCT00421811,A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan,Completed,No Results Available,Neoplasms,Drug: ADH-1|Drug: melphalan,"Adherex Technologies, Inc.",Both,Adult|Senior,Phase I|Phase II,56,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AHX-01-007,01/10/2007,01/04/2007,01/03/2009,12/27/2010,01/12/2010,,01/03/2009,"To tabulate the Best Overall Response according to unconfirmed RECIST, modified for cutaneous lesions",http://ClinicalTrials.gov/show/NCT00421811,United States,1,0,2,NA
NCT00422292,Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra?ó in Healthy Toddlers,Completed,No Results Available,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,"Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|Biological: Measles, Mumps, Rubella and Varicella",Sanofi-Aventis,Both,Child,Phase III,1664,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention,MTA37,01/12/2007,01/12/2006,01/04/2009,3/31/2010,01/03/2010,,01/01/2009,"To provide information concerning the immune response of MMRV, Hib, and PCV after vaccination.",http://ClinicalTrials.gov/show/NCT00422292,"United States, &nbsp; Puerto Rico",0,NA,4,NA
NCT00423319,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery,Completed,No Results Available,Deep Vein Thrombosis|Pulmonary Embolism,Drug: Enoxaparin + Placebo|Drug: Apixaban + Placebo,Bristol-Myers Squibb,Both,Adult|Senior,Phase III,5406,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",CV185-035,1/17/2007,01/03/2007,01/09/2009,9/17/2009,01/09/2009,,01/09/2009,"A combination of asymptomatic and symptomatic DVT, non-fatal PE and all-cause death|Combined endpoints: Proximal DVT, non-fatal PE, and VTE-related death|Major & non-major bleeding events",http://ClinicalTrials.gov/show/NCT00423319,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Belgium, &nbsp; Canada, &nbsp; China, &nbsp; Denmark, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Israel, &nbsp; Mexico, &nbsp; Norway, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Sweden, &nbsp; Ukraine, &nbsp; United Kingdom",1,0,2,NA
NCT00423813,A Safety and Efficacy Study of Xyrem?ó (Sodium Oxybate) to Treat Fibromyalgia.,Completed,No Results Available,Fibromyalgia,Drug: placebo|Drug: Xyrem?ó,Jazz Pharmaceuticals,Both,Adult|Senior,Phase III,573,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",06-009,1/16/2007,01/12/2006,01/06/2009,12/18/2009,01/12/2009,,01/04/2009,Pain Severity accessby VAS; Fibromyalgia Impact Questionnaire; Patient Global Impression of Change.,http://ClinicalTrials.gov/show/NCT00423813,"United States, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Spain, &nbsp; United Kingdom",1,1,2,1
NCT00423878,Comparison of Antipsychotics for Metabolic Problems in the Treatment of People With Schizophrenia or Schizoaffective Disorder,Completed,No Results Available,Schizophrenia|Schizoaffective Disorder,Drug: Risperidone|Drug: Olanzapine|Drug: Quetiapine|Drug: Aripiprazole|Behavioral: Intervention used to control diet and modify activity level,National Institute of Mental Health (NIMH),Both,Adult,Phase IV,215,NIH,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,STROUP06STN0|DSIR AT-AP,1/16/2007,01/01/2007,01/03/2010,11/12/2010,01/11/2010,CAMP,01/10/2009,"Mean difference in non-HDL cholesterol level changes between patients assigned to stay compared to patients assigned to switch at the last observation|Efficacy failure, defined as psychiatric hospitalization, a 25 percent increase from baseline on the Positive and Negative Syndrome Scale or substantial clinical deterioration on the Clinical Global Impressions-Change (CGI-C)",http://ClinicalTrials.gov/show/NCT00423878,United States,1,1,5,1
NCT00424151,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy,Completed,No Results Available,Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy,Drug: Rituximab,"Silkiss, Rona Z., M.D., FACS|Lauer, Simeon, M.D.|Reier, Alice M.D.|Coleman, Morton M.D.",Both,Adult|Senior,Phase I|Phase II,12,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,U4126s,1/17/2007,01/12/2006,01/03/2009,10/04/2010,01/10/2010,,01/03/2009,"Clinical response to treatment, alteration in immunoglobulin levels|To assess the safety and tolerability of Rituximab in Graves' dysthyroid disease up to 24 weeks. Adverse and serious adverse events during the study period, reasonably or probably related to Rituximab, will be assessed at each study visit up to 12 month|Efficacy:|A significant (25%) reduction in progression of Thyroid Associated Ophthalmopathy or disease activity as measured by the thyroid associated ophthalmopathy scale (University of British Columbia Thyroid Orbitopathy Inflammatory Score) up to 24 weeks.|To evaluate for a reduction in disease activity as measured by:|Reduction (25%) of elevated antibody levels- serum thyroid stimulating immunoglobulin (TSI), antithyroidperoxidase antibody (TPO) or antithyroglobulin levels at 24 weeks.|MRI of the orbit with coronal and axial views to evaluate evidence of optic nerve crowding, muscle size reduction or decreased proptosis during treatment and follow up interval at 24 weeks.",http://ClinicalTrials.gov/show/NCT00424151,United States,1,1,1,1
NCT00425750,Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,Completed,No Results Available,Head and Neck Cancer,Drug: bortezomib|Drug: docetaxel|Other: laboratory biomarker analysis|Other: pharmacological study,Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,25,Other|NIH,Interventional,Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment,CDR0000525999|P30CA068485|VU-VICC-HN-0501|MILLENIUM-X05170|VU-VICC-IRB-050183,1/19/2007,01/08/2005,01/06/2009,11/25/2010,01/11/2010,,01/06/2009,Response data by RECIST criteria|Overall survival|Progression-free survival,http://ClinicalTrials.gov/show/NCT00425750,United States,1,1,4,1
NCT00427791,Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia,Completed,No Results Available,Leukemia,Drug: Etoposide|Radiation: Total Body Irradiation|Drug: Rituximab,M.D. Anderson Cancer Center,Both,Child|Adult,Phase II,23,Other,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2004-0989,1/25/2007,01/07/2005,01/10/2009,10/29/2009,01/10/2009,,01/10/2009,To find out if giving rituximab with etoposide and total body irradiation (TBI) will help to control ALL in patients scheduled to receive an allogeneic hematopoietic stem cell transplantation (SCT).|To find the effect of this treatment on the occurrence of graft versus host disease (GVHD) in study participants.,http://ClinicalTrials.gov/show/NCT00427791,United States,1,1,3,0
NCT00427856,Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL),Completed,No Results Available,"Lymphoma, Follicular",Drug: Obatoclax mesylate (GX15-070MS),Gemin X,Both,Adult|Senior,Phase II,7,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GEM014,1/25/2007,01/03/2007,01/07/2009,9/14/2010,01/09/2010,,01/02/2009,Determine the response rate to obatoclax in combination with rituximab and characterize the safety profile.|Time to Tumor Progression.,http://ClinicalTrials.gov/show/NCT00427856,United States,1,0,1,NA
NCT00429104,Herceptin and GM-CSF for Metastatic Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: Herceptin|Drug: GM-CSF,M.D. Anderson Cancer Center|Bayer,Female,Child|Adult|Senior,Phase II,18,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DM01-0100,1/29/2007,01/08/2002,01/11/2009,9/30/2010,01/09/2010,,01/11/2009,"To see if Herceptin (trastuzumab) and GM-CSF can help to shrink or slow the growth of breast cancer that has spread outside the breast, which did not respond to earlier treatment with Herceptin.|To study the safety of this treatment.",http://ClinicalTrials.gov/show/NCT00429104,United States,1,1,2,1
NCT00429312,A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma,Completed,No Results Available,Melanoma,Biological: JX-594,Jennerex Biotherapeutics,Both,Adult|Senior,Phase I|Phase II,15,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,JX594-IT-MEL005,1/29/2007,01/02/2007,01/12/2009,3/31/2010,01/03/2010,,01/12/2009,"Response rate for injected tumor(s)|Safety, as determined by incidence of treatment-related adverse events, serious adverse events (SAEs), and clinically-significant changes from baseline in routine laboratory parameters|Best overall response for entire disease burden (RECIST criteria)|Progression-free survival (PFS)|Response rate of non-injected tumor(s)",http://ClinicalTrials.gov/show/NCT00429312,United States,0,NA,1,NA
NCT00429416,"Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation",Completed,No Results Available,Hematological Malignancies,Drug: L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells,Thomas Jefferson University,Both,Adult|Senior,Phase I|Phase II,22,Other,Interventional,Allocation: Non-Randomized|Control: Historical Control|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,04U.115|2003-68,1/29/2007,01/03/2004,01/05/2009,8/24/2010,01/08/2010,,01/05/2009,,http://ClinicalTrials.gov/show/NCT00429416,United States,1,0,1,NA
NCT00429702,"Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy in Young Patients With Newly Diagnosed Cancer",Completed,No Results Available,"Nausea and Vomiting|Unspecified Childhood Solid Tumor, Protocol Specific",Drug: dexamethasone|Drug: diphenhydramine hydrochloride|Drug: lorazepam|Drug: ondansetron hydrochloride,SunCoast CCOP Research Base at the University of South Florida|National Cancer Institute (NCI),Both,Child|Adult,Phase II,180,Other|NIH,Interventional,Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Supportive Care,CDR0000527333|SCUSF-0503|HLMCC-0503,1/31/2007,01/10/2007,NA,9/18/2010,01/09/2010,,01/08/2009,"Efficacy of diphenhydramine hydrochloride, lorazepam, & dexamethasone in preventing chemo-induced nausea & vomiting (CINV) as measured by proportion of patients requiring rescue medication for breakthrough nausea or emesis during inpatient chemotherapy|Efficacy of diphenhydramine hydrochloride, lorazepam, and dexamethasone in preventing CINV for 3 days after completion of the first course of emetogenic chemotherapy|Severity of CINV as measured by the Adapted Rhodes Index of Nausea, Vomiting, and Retching--Measured by Child/Parent questionnaire",http://ClinicalTrials.gov/show/NCT00429702,"United States, &nbsp; Puerto Rico",1,0,4,NA
NCT00430495,A Phase II Dose-finding Study of Atacicept in Rheumatoid Arthritis (RA),Completed,No Results Available,Rheumatoid Arthritis,Drug: Atacicept,EMD Serono|ZymoGenetics,Both,Adult|Senior,Phase II,288,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",27298,1/30/2007,01/12/2006,NA,11/16/2010,01/12/2009,August I,01/09/2009,"Primary is functional status or ACR 20 at week 26. Interval measurments are performed at monthly visits.|Proportions of subjects achieving: ACR50 and ACR70 responses, a DAS 28 of 3.2 or less, or subjects with an improvement in the HAQ Disability Index of at least 0.3 from baseline",http://ClinicalTrials.gov/show/NCT00430495,"United States, &nbsp; Canada",1,0,1,NA
NCT00431067,Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy,Completed,No Results Available,Breast Neoplasms,Drug: BIBW 2992,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase II,41,Industry,Interventional,Primary Purpose: Treatment,1200.11|EUDRACT 2007-004805-80,02/02/2007,01/09/2006,NA,8/20/2010,01/08/2010,,01/08/2009,"The primary endpoint of this trial is objective response (CR, PR) by RECIST criteria|Time to progression Progression free survival Overall survival Time to objective response Duration of objective response Occurrence and intensity of adverse events graded according to NCI CTCAE Version 3.0",http://ClinicalTrials.gov/show/NCT00431067,"United States, &nbsp; United Kingdom",1,0,1,NA
NCT00431964,Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Who Are Not Infected With P. Aeruginosa,Completed,No Results Available,Cystic Fibrosis,Drug: azithromycin 250 mg tablets|Drug: placebo tablets,CF Therapeutics Development Network Coordinating Center|Cystic Fibrosis Foundation,Both,Child|Adult,Phase IV,263,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AZ0004,02/02/2007,01/02/2007,01/11/2009,10/07/2010,01/10/2010,,01/07/2009,"Change in FEV1 from baseline to end of treatment|Safety, frequency of pulmonary exacerbations, changes in other measures of lung function, treatment emergent pathogens, weight, and serum inflammatory markers",http://ClinicalTrials.gov/show/NCT00431964,"United States, &nbsp; Canada",1,1,2,1
NCT00432276,Efficacy of SYR-322 and Pioglitazone in Subjects With Type 2 Diabetes Mellitus,Completed,No Results Available,Diabetes Mellitus,Drug: Alogliptin and pioglitazone and metformin|Drug: Pioglitazone and metformin,"Takeda Global Research & Development Center, Inc.",Both,Adult|Senior,Phase III,821,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-06-TL-322OPI-004|2006-006025-73|U1111-1112-3363,02/05/2007,01/12/2006,01/06/2009,04/08/2010,01/04/2010,,01/05/2009,Change from Baseline in Glycosylated Hemoglobin.|Glycosylated Hemoglobin|Fasting Plasma Glucose|Proinsulin|Insulin|Proinsulin/Insulin ratio|C-peptide|Serum Lipids|Nuclear magnetic resonance Lipid Fractionation|Free Fatty Acids|Apolipoprotein A-I|Apolipoprotein A-II|Apolipoprotein B|Apolipoprotein C-III|Plasminogen activator inhibitor-1|High-sensitivity C-reactive protein|Adiponectin|Body weight|Change from Baseline in calculated HOMA insulin resistance|Change from Baseline in calculated HOMA beta-cell function|Incidence of Marked Hyperglycemia (fasting plasma glucose greater than or equal to 200 mg/dL) (11.10 mmol/L).|Incidence of Rescue.|Incidence of Glycosylated Hemoglobin less than or equal to 6.5%|Incidence of Glycosylated Hemoglobin less than or equal to 7.0%|Incidence of Glycosylated Hemoglobin less than or equal to 7.5%|Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 0.5%|Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 1.0%|Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 1.5%|Incidence of Glycosylated Hemoglobin decrease from Baseline greater than or equal to 2.0%,http://ClinicalTrials.gov/show/NCT00432276,United States,1,0,2,NA
NCT00433745,Vaccination for Patients With High Risk Cancers of the Blood,Completed,No Results Available,Myelodysplastic Syndrome|Acute Myeloid Leukemia (AML)|Chronic Myeloid Leukemia (CML),Drug: WR 1 and PR 1 Peptide Vaccine,"National Heart, Lung, and Blood Institute (NHLBI)",Both,Adult|Senior,Phase II,4,NIH,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,070091|07-H-0091,02/09/2007,01/02/2007,01/11/2009,3/26/2010,01/11/2009,,01/11/2009,"The primary objectives will to evaluate the efficacy and toxicity associated with the immunotherapy approach of lymphodepletion, lymphocyte infusion, and WT1 vaccination in selected patients with hematological malignancies.|Secondary objectives will include evaluation of disease response by following the numbers of WT1 expressing cells in blood, hematological measurements (reduction in marrow blast cells, changes in blood counts), transfusion dependence, and time t...",http://ClinicalTrials.gov/show/NCT00433745,United States,1,0,1,NA
NCT00433836,Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure,Completed,No Results Available,Hypertension,Drug: Valsartan|Drug: Enalapril,Novartis Pharmaceuticals,Both,Child,Phase III,300,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",CVAL489K2302,02/08/2007,01/02/2007,01/03/2009,10/23/2009,01/10/2009,,01/02/2009,"Reduction of mean sitting systolic blood pressure (MSSBP)|Reduction of mean sitting diastolic blood pressure (MSDBP)|Decrease in MSSBP to < 95th percentile for age, gender and height|Change in mean ambulatory systolic blood pressure and mean ambulatory diastolic blood pressure over 24 hours in subset of patients|Safety and tolerability of valsartan compared to enalapril",http://ClinicalTrials.gov/show/NCT00433836,"United States, &nbsp; Belgium, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Italy, &nbsp; Poland, &nbsp; Slovakia, &nbsp; Sweden, &nbsp; Turkey",1,1,2,0
NCT00434473,IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome,Completed,No Results Available,Sickle Cell Disease|Vaso-occlusive Crisis|Acute Chest Syndrome,Drug: A-001|Other: Placebo,Anthera Pharmaceuticals,Both,Child|Adult|Senior,Phase II,60,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",AN-SCD1121,02/09/2007,01/12/2006,01/12/2009,4/28/2010,01/04/2010,,01/08/2009,"To determine the safety and tolerability of different doses of A 001 therapy when administered as a 2-day continuous infusion to sickle cell disease (SCD) patients at-risk for the acute chest syndrome (ACS).|To determine the pharmacokinetic profile of A-001 in SCD patients|To confirm the ability of A-001 infusion to suppress serum sPLA2 activity in SCD patients with elevated serum sPLA2|To determine the efficacy of A-001 infusion in preventing ACS in SCD patients with the combination of vaso-occlusive crisis (VOC), fever, and elevated serum sPLA2",http://ClinicalTrials.gov/show/NCT00434473,United States,1,0,2,NA
NCT00434876,The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence,Completed,No Results Available,Alcoholism|Sleep Initiation and Maintenance Disorders,Drug: Quetiapine XR|Drug: Placebo.,Department of Veterans Affairs,Both,Adult,Phase III,24,U.S. Fed,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",101206,02/12/2007,01/08/2007,01/12/2009,02/08/2010,01/02/2010,,01/11/2009,"Sleep Efficiency (from an in-laboratory polysomnogram)|Objective sleep-wake recordings using actigraphy.|Pittsburgh Sleep Quality Index, Insomnia Severity Index and Epworth Sleepiness Scale.|Time Line Followback, Penn Alcohol craving scale.|PHQ-9, Beck's Anxiety Rating Scale",http://ClinicalTrials.gov/show/NCT00434876,United States,1,1,2,1
NCT00435162,Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure,Completed,No Results Available,Hypertension,Drug: Valsartan,Novartis Pharmaceuticals,Both,Child,Phase III,75,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",CVAL489K2303,2/13/2007,01/03/2007,01/01/2009,02/06/2010,01/02/2010,,01/01/2009,"Change in mean sitting systolic blood pressure (MSSBP)|safety and tolerability of valsartan measured by frequency of adverse events, laboratory values, pulse, standing blood pressure, body weight|Change in mean sitting systolic blood pressure (MSSBP) at end of placebo-controlled withdrawal period|Change in mean sitting diastolic blood pressure (MSDBP)|Change in mean sitting diastolic blood pressure (MSDBP) at end of placebo-controlled withdrawal period",http://ClinicalTrials.gov/show/NCT00435162,"United States, &nbsp; Belgium, &nbsp; Brazil, &nbsp; France, &nbsp; Hungary, &nbsp; India, &nbsp; Italy, &nbsp; Poland, &nbsp; South Africa, &nbsp; Sweden, &nbsp; Turkey",1,1,1,0
NCT00435253,US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study,Completed,No Results Available,Pulmonary Emphysema,Biological: BLVR Treatment,Aeris Therapeutics,Both,Adult|Senior,Phase II,20,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,01-C06-003,02/07/2007,01/02/2007,01/06/2009,1/14/2010,01/01/2010,,01/06/2009,Reduction in gas trapping|SAEs - Safety of treatment and the procedure|Improvement in vital capacity|Improvement in expiratory flow|Improvement in inspiratory flow|Improvement in dyspnea symptoms (breathlessness)|Improvement in exercise capacity|Improvement in respiratory quality of life,http://ClinicalTrials.gov/show/NCT00435253,United States,0,NA,1,NA
NCT00435916,Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma,Completed,No Results Available,"Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin",Drug: SGN-40,"Seattle Genetics, Inc.|Genentech",Both,Adult|Senior,Phase II,35,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SG040-0004,2/14/2007,01/12/2006,NA,09/08/2009,01/09/2009,,01/01/2009,"Objective response as assessed by CT and PET scans and revised response criteria for malignant lymphoma.|Progression-free survival, disease-free survival, and overall survival.|Adverse events, laboratory values, and anti-drug antibody immune responses.|PK profile.",http://ClinicalTrials.gov/show/NCT00435916,United States,1,0,1,NA
NCT00436475,Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes,Completed,No Results Available,Glucose Intolerance|Type 2 Diabetes Mellitus|Metabolic Syndrome,"Drug: Vitamin D3 2,000 IU orally once daily|Drug: Calcium Carbonate 400 mg orally twice daily|Drug: Vitamin D3-Placebo|Drug: Calcium-Placebo","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Office of Dietary Supplements (ODS)|Tufts Medical Center",Both,Adult|Senior,Phase I|Phase II,112,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DK76092 (completed)|DK76092,2/16/2007,01/09/2007,01/11/2009,6/13/2010,01/06/2010,CaDDM,01/11/2009,"Insulin sensitivity, Insulin secretion and Disposition Index|glucose tolerance (fasting, after OGTT), systemic inflammation, lipoprotein profile, blood pressure, body weight and body composition|Genetic studies on Vitamin D related genes and risk of type 2 diabetes and cardiometabolic outcomes|To collect and archive biological specimens (serum, plasma, DNA) so that they can be used for testing of new hypotheses either within the parent stud or through future ancillary studies.",http://ClinicalTrials.gov/show/NCT00436475,United States,1,1,4,0
NCT00436553,Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization,Completed,No Results Available,Macular Degeneration|Choroidal Neovascularization,"Drug: Verteporfin for injection, Ranibizumab injection|Drug: ranibizumab",Novartis,Both,Adult|Senior,Phase II|Phase III,321,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CBPD952A2308,2/16/2007,01/02/2007,NA,05/10/2010,01/05/2010,,01/10/2009,"Change from baseline in Best-Corrected Visual Acuity (BCVA) (letters) at Month 12 and Treatment-free interval of at least 3 months duration until Month 12|Retreatment pattern of combination therapy until Month 12/24 based on the time to first retreatment, the number of retreatment, and the proportion of patients with a treatment-free interval of at least 3 months duration until Month 24|Safety of combination therapy and monotherapy over 24 months|Changes in Best Corrected Visual Acuity from baseline over 24 months|Angiographic and optical coherence tomography (OCT) outcomes from baseline over 24 months|Onset of effect assessed by change from baseline in BCVA at Months 1, 2 and 3",http://ClinicalTrials.gov/show/NCT00436553,"United States, &nbsp; Canada",1,1,2,1
NCT00437021,MVA Post-Event: Administration Timing and Boost Study,Completed,No Results Available,Variola Major (Smallpox),Biological: Dryvax?ó|Biological: IMVAMUNE?ó|Drug: Placebo (subcutaneous)|Drug: Placebo (scarification),National Institute of Allergy and Infectious Diseases (NIAID),Both,Adult,Phase I|Phase II,206,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",06-0012|N01AI80003C|POX-MVA-009,2/16/2007,01/04/2007,01/04/2009,1/13/2011,01/03/2010,,01/04/2009,"Safety: adverse events and reactogenicity to the vaccine.|Determine whether the Geometric Mean Titer (GMT) of neutralizing antibody, among subjects receiving 2 doses of IMVAMUNE?ó (Days 0 and 7, Group A) is noninferior to that among subjects receiving 2 doses of IMVAMUNE?ó (Days 0 and 28, Group B).|Using enzyme linked immunosorbent assay results, determine whether the GMT among subjects receiving a 2 dose regimen of IMVAMUNE?ó (Days 0 and 7, Group A) is noninferior to that among subjects receiving 2 doses of IMVAMUNE?ó (Days 0 and 28, Group B).",http://ClinicalTrials.gov/show/NCT00437021,United States,0,NA,4,NA
NCT00437268,A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Patients With Colorectal Cancer,Completed,No Results Available,Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumor,Drug: enzastaurin|Drug: irinotecan|Drug: cetuximab,Eli Lilly and Company,Both,Adult|Senior,Phase II,26,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,10538|H6Q-MC-S018,2/16/2007,01/03/2007,01/05/2009,4/16/2010,01/04/2010,,01/05/2009,Progression-free survival (PFS) rate|Tumor response rate|Duration of response|Overall survival|Safety and adverse events,http://ClinicalTrials.gov/show/NCT00437268,United States,1,0,3,NA
NCT00438815,Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks,Completed,Has Results,Hereditary Angioedema,Biological: C1 esterase inhibitor [human] (C1INH-nf),ViroPharma,Both,Child|Adult|Senior,Phase III,113,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LEVP2006-1,2/21/2007,01/09/2006,01/03/2009,6/16/2010,01/06/2010,CHANGE 2,01/03/2009,Number of Hereditary Angioedema (HAE) Attacks Treated With C1INH-nf|Percent of HAE Attacks With Substantial Relief of the Defining Symptom|Time to Beginning of Substantial Relief of the Defining Symptom|Time to Beginning of Substantial Relief of the Defining Symptom for Subjects Who Received Multiple Treatments|Antigenic C1 Inhibitor (C1INH) Serum Levels|Functional C1INH Serum Levels|Complement C4 Serum Levels,http://ClinicalTrials.gov/show/NCT00438815,United States,0,NA,1,NA
NCT00439725,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,Completed,No Results Available,Venous Thromboembolism,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Placebo","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Both,Adult|Senior,Phase III,1193,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",11899|EudraCT No: 2006-004494-96,2/23/2007,01/02/2007,01/09/2009,11/18/2010,01/11/2010,,01/08/2009,"Symptomatic recurrent VTE, i.e., the composite of recurrent DVT or fatal or non-fatal PE|Time-to-first major bleeding|Clinically relevant bleeding|All death and other vascular events",http://ClinicalTrials.gov/show/NCT00439725,"United States, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; China, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Hong Kong, &nbsp; Hungary, &nbsp; India, &nbsp; Indonesia, &nbsp; Israel, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Malaysia, &nbsp; Netherlands, &nbsp; New Zealand, &nbsp; Norway, &nbsp; Philippines, &nbsp; Poland, &nbsp; Singapore, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; Taiwan, &nbsp; Thailand, &nbsp; United Kingdom",1,0,2,NA
NCT00440050,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",Completed,Has Results,Alzheimer's Disease,Drug: DHA (Docosahexaenoic Acid)|Drug: Placebo,Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)|Martek Biosciences Corporation,Both,Adult|Senior,Phase III,402,Other|NIH|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IA0099|1RC2AG036535|ADC-027-DHA,2/22/2007,01/02/2007,01/05/2009,8/27/2010,01/08/2010,DHA,01/05/2009,Rate of Change on the ADAS-Cog 11.|Rate of Change on CDR-SOB|ADCS-ADL|Neuropsychiatric Inventory (NPI),http://ClinicalTrials.gov/show/NCT00440050,United States,1,0,2,NA
NCT00441558,A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).,Completed,No Results Available,"Sexual Dysfunctions, Psychological",Drug: Flibanserin,Boehringer Ingelheim Pharmaceuticals,Female,Adult,Phase III,1767,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment,511.84,2/28/2007,01/02/2007,NA,8/20/2009,01/08/2009,,01/08/2009,"The frequency of adverse events (side effects).|Clinically significant changes to physical exam, pelvic exam, vital signs, ECG, labs, eye exams, and overall patient status. Additionally, patients must complete questionnaires related to sexual health, depression and suicidal thoughts.",http://ClinicalTrials.gov/show/NCT00441558,"United States, &nbsp; Canada",1,0,1,NA
NCT00442039,Lithium for the Treatment of Pediatric Mania,Completed,No Results Available,Bipolar I Disorder Without Psychotic Symptoms,Drug: Lithium Carbonate,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Both,Child,Phase II,61,NIH,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NICHD-2005-07-01|DUNS No. 07-775-8407,2/27/2007,01/12/2006,01/09/2009,05/12/2010,01/05/2009,,01/04/2009,"To describe evidence-based dosing strategies for lithium in children and adolescents|To characterize the pharmacokinetics/biodisposition of lithium in pediatric patients|To examine the effectiveness and safety of lithium as a maintenance treatment for children and adolescents with bipolar I disorder|To examine the long-term and short-term safety and tolerability of lithium in pediatric bipolar disorder|To describe and compare the pharmacokinetic profile and systemic exposure of lithium after single and multiple doses in children and adolescents|To evaluate the influence of intrinsic factors (e.g. age, gender, race, renal function, height (measured by stadiometer) and weight) on lithium exposure|To describe lithium exposure in the pediatric population in comparison to what is known in adults|To examine the relationship between the systemic exposure and effectiveness and toxicity|To examine the long-term safety and tolerability of combination therapy, lithium plus other psychotropic agents, in pediatric bipolar disorder|To critically assess the efficacy of lithium for prophylaxis against recurrence of mood episodes in children and adolescents|In those patients who discontinue treatment with lithium and experience a mood relapse, to determine the duration of lithium treatment necessary before re-stabilization is achieved",http://ClinicalTrials.gov/show/NCT00442039,United States,1,1,1,0
NCT00442767,Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Pramlintide acetate,"Baylor College of Medicine|Amylin Pharmaceuticals, Inc.",Both,Child|Adult,Phase IV,8,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,H-18629|GCRC protocol #:0954,03/01/2007,01/02/2007,01/02/2009,11/30/2010,01/11/2010,,01/02/2009,Blood glucose level|Insulin levels|Glucagon levels,http://ClinicalTrials.gov/show/NCT00442767,United States,1,1,1,1
NCT00443079,A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH),Completed,No Results Available,Fatty Liver,Drug: IdB 1016 (Siliphos),"University of California, San Diego|American College of Gastroenterology",Both,Adult|Senior,Phase II,10,Other,Interventional,Allocation: Non-Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,51117,03/02/2007,01/03/2007,01/12/2009,6/24/2010,01/06/2008,,01/12/2009,"Safety, as determined by laboratory and clinical assessment, during and after treatment|Tolerability, as determined by clinical assessment of side effects, during and after treatment|Efficacy, determined by serial measurement of serum aminotransferase levels before, during, and after treatment",http://ClinicalTrials.gov/show/NCT00443079,United States,1,0,1,NA
NCT00444145,Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?,Completed,No Results Available,Larynx Disease|Gastroesophageal Reflux,Drug: Lansoprazole Tablet|Procedure: Esophageal and Laryngeal Biopsies,Vanderbilt University,Both,Adult|Senior,Phase IV,30,Other,Interventional,Allocation: Non-Randomized|Control: Active Control|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,61244,03/05/2007,01/03/2007,01/12/2009,11/12/2010,01/11/2010,biopsy II,01/03/2009,Dilation of intracellular spaces 3 months after therapy,http://ClinicalTrials.gov/show/NCT00444145,United States,1,1,2,0
NCT00444457,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Completed,Has Results,"Vaccines, Pneumococcal",Biological: 13-valent Pneumococcal Conjugate Vaccine|Biological: 7vPnC,Wyeth,Both,Child,Phase III,1712,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",6096A1-3005,03/05/2007,01/05/2007,01/06/2009,11/09/2010,01/11/2010,,01/06/2009,Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series|Percentage of Participants Achieving Predefined Antibody Level ??­0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series|Percentage of Participants Achieving Predefined Antibody Level ??­1:8 for Poliovirus in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series|Percentage of Participants Achieving Predefined Antibody Level ??­10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series|Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ??­0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Infant Series|Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ??­0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose|Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ??­1.00 Mcg/mL in the Combined 13vPnC Group 1 Month After the Infant Series|Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ??­1.00 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose|Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose,http://ClinicalTrials.gov/show/NCT00444457,United States,0,NA,2,NA
NCT00444912,The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD),Completed,Has Results,Non-Hodgkin Lymphoma|Hodgkin Disease,Drug: G-CSF plus plerixafor|Drug: G-CSF plus plerixafor|Biological: rituximab,Genzyme,Both,Adult|Senior,Phase II,30,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AMD31002113,03/07/2007,01/02/2006,01/06/2009,08/10/2010,01/06/2010,,01/06/2009,Summary of Adverse Events (AEs)|Median Cumulative Number of CD34+ Cells Collected During Apheresis|Median Fold Increase in the Number of CD34+ Cells After Plerixafor Administration|Median Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg|Median Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg|Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment|Median Number of Days to Platelet (PLT) Engraftment|Median Number of Days to Lymphocyte Engraftment|Median Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant|Median Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant|The Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day|Number of Participants With Durable Engraftment 12 Months After Transplantation,http://ClinicalTrials.gov/show/NCT00444912,United States,1,1,3,0
NCT00445549,"Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Completed,No Results Available,Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms,Drug: Zactima (Vandetanib)(ZD6474),National Cancer Institute (NCI),Female,Adult|Senior,Phase II,12,NIH,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,070061|07-C-0061,03/07/2007,01/01/2007,01/10/2009,01/11/2011,01/07/2010,,01/10/2009,"Clinical outcome (complete response, partial response, or disease stabilization lasting 6 months or longer)|Biochemical modulation of activated (phosphorylated) vascular endothelial growth factor receptor 2, epidermal growth factor receptor, extracellular signal-regulated kinase, and AKT|Toxicity|Quality of life|Progression-free survival",http://ClinicalTrials.gov/show/NCT00445549,United States,1,0,1,NA
NCT00445588,Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme,Completed,No Results Available,Brain and Central Nervous System Tumors,Drug: erlotinib hydrochloride|Drug: sorafenib tosylate|Genetic: gene expression analysis|Genetic: mutation analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: mass spectrometry|Other: pharmacological study|Procedure: biopsy,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,56,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000531731|NABTT-0502,03/07/2007,01/01/2007,NA,8/27/2009,01/10/2008,,01/08/2009,Overall survival|Six-month progression-free survival|Tumor response rate|Toxicity as measured by CTCAE v 3.0|Pharmacokinetics of erlotinib hydrochloride and sorafenib tosylate|Relationship between tumor and blood biomarkers and clinical outcome,http://ClinicalTrials.gov/show/NCT00445588,United States,1,1,9,0
NCT00446550,A Study of Oral AT2101 in Treatment-naive Patients With Gaucher Disease,Completed,No Results Available,"Gaucher Disease, Type 1",Drug: AT2101,Amicus Therapeutics,Both,Adult|Senior,Phase II,16,Industry,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,GAU-CL-202,03/09/2007,01/12/2007,01/08/2009,09/10/2009,01/09/2009,,01/08/2009,The primary objective of this study is to evaluate the safety and tolerability of AT2101.|The secondary objective of the study is to evaluate the pharmacodynamic effects of AT2101.,http://ClinicalTrials.gov/show/NCT00446550,"United States, &nbsp; Germany, &nbsp; Israel, &nbsp; South Africa, &nbsp; United Kingdom",1,0,1,NA
NCT00446849,Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC),Completed,Has Results,Ulcerative Colitis,Drug: MMX Mesalamine,Shire Pharmaceutical Development,Both,Adult|Senior,Phase IV,290,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SPD476-404,03/12/2007,01/05/2007,01/07/2009,08/03/2010,01/08/2010,,01/07/2009,Clinical Recurrence of Ulcerative Colitis (UC) During the Maintenance Phase at 6 Months|Clinical Recurrence of UC During the Maintenance Phase at 12 Months|Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 6 Months|Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 12 Months|Quiescent UC During the Maintenance Phase at 12 Months|Endoscopic Remission of UC During the Maintenance Phase at 12 Months,http://ClinicalTrials.gov/show/NCT00446849,United States,1,1,1,1
NCT00446966,Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery,Completed,No Results Available,Atrial Fibrillation,Drug: Omega Three Polyunsaturated fatty acids,University of Iowa|GlaxoSmithKline,Both,Adult|Senior,Phase IV,260,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",1733860001,03/12/2007,01/02/2007,01/01/2010,05/10/2010,01/02/2007,FISH,01/12/2009,The primary endpoint is the development of postoperative atrial fibrillation or flutter after bypass surgery.|Time to post-operative atrial fibrillation.,http://ClinicalTrials.gov/show/NCT00446966,United States,1,1,1,0
NCT00447187,Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk,Completed,No Results Available,Corneal Diseases|Cornea Transplant,Drug: LX201,"Lux Biosciences, Inc.",Both,Adult|Senior,Phase III,175,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",LX201-01,03/12/2007,01/03/2007,01/09/2009,11/03/2009,01/11/2009,,01/09/2009,immunological rejection|graft loss|vision|quality of life,http://ClinicalTrials.gov/show/NCT00447187,"United States, &nbsp; Germany",1,0,1,NA
NCT00447694,Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment,Completed,No Results Available,Beta-Thalassemia|Iron Overload,Drug: Deferasirox,Novartis,Both,Child|Adult|Senior,Phase II,30,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CICL670AUS04,3/13/2007,01/02/2006,01/11/2009,11/18/2009,01/11/2009,,01/11/2009,"Cardiac Iron in B thalassemia patients|Safety and tolerabilty of deferasirox|Changes in liver iron concentration (LIC)|Changes in ventricular ejection fraction|Ferritin, NTBI (LPI and DCI)& iron metabolism parameters|Compliance with deferasirox",http://ClinicalTrials.gov/show/NCT00447694,United States,1,1,1,1
NCT00448149,Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer,Completed,No Results Available,"Carcinoma, Renal Cell",Drug: RAD001|Drug: Sorafenib,The Methodist Hospital System|Novartis Pharmaceuticals,Both,Adult|Senior,Phase I|Phase II,55,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RCC-06-102|1006-0152,3/15/2007,01/12/2006,NA,11/03/2009,01/01/2009,,01/06/2009,Phase I: To establish the maximally tolerated dose (MTD) and safety profile of RAD001 in combination with Nexavar?ó in patients with metastatic renal cell carcinoma (MRCC).|Phase II: Study the anti-tumor effects of RAD001 plus Nexavar?ó|Phase II: Response rate|Duration of tumor response|Progression free survival|Overall survival|Study the safety of RAD001 plus Nexavar?ó given at MTD.,http://ClinicalTrials.gov/show/NCT00448149,United States,1,1,2,1
NCT00448552,Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer,Completed,No Results Available,Head and Neck Cancer,Drug: capecitabine|Drug: oxaliplatin,University of Miami Sylvester Comprehensive Cancer Center,Both,Adult|Senior,Phase II,30,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,EPROST-20030243|SCCC-2003050|WIRB-20060071,3/15/2007,01/02/2004,01/06/2009,04/07/2010,01/01/2010,,01/06/2009,Objective response rate (complete response and partial response)|Toxicity as measured by NCI CTC|Survival,http://ClinicalTrials.gov/show/NCT00448552,United States,1,1,2,0
NCT00449748,Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis,Completed,No Results Available,Systemic Mastocytosis,Drug: RAD001,M.D. Anderson Cancer Center|Novartis Pharmaceuticals,Both,Adult|Senior,Phase II,10,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2006-0759,3/19/2007,01/04/2007,01/10/2009,10/23/2009,01/10/2009,,01/10/2009,Patients with Improvement in Objective Response over 30%,http://ClinicalTrials.gov/show/NCT00449748,United States,1,1,1,1
NCT00449904,Phase III ALTU-135 Safety Trial,Completed,No Results Available,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Drug: ALTU-135,Alnara Pharmaceuticals,Both,Child|Adult|Senior,Phase III,215,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,767,3/19/2007,01/06/2007,01/06/2009,12/13/2010,01/12/2010,DIGEST,01/05/2009,To evaluate the long-term safety and tolerability of ALTU-135 treatment in patients with Cystic Fibrosis-related exocrine pancreatic insufficiency.,http://ClinicalTrials.gov/show/NCT00449904,United States,1,0,1,NA
NCT00450112,Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee,Completed,No Results Available,Osteoarthritis of the Knee,Drug: Gel-200,Seikagaku Corporation,Both,Adult|Senior,Phase III,240,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Gel/1132,3/20/2007,01/03/2007,01/06/2009,6/28/2010,01/06/2010,,01/06/2009,"Occurrence of systemic and local adverse events following a single or repeat intra-articular injection of Gel-200|Safety: Examination of the knee, Laboratory tests|Effectiveness: WOMAC VAS scores (Pain subscore, Stiffness subscore, Physical Function subscore, Total WOMAC score), OMERACT-OARSI Response, SF-36, subject and physician global evaluations, acetaminophen consumption",http://ClinicalTrials.gov/show/NCT00450112,United States,1,0,1,NA
NCT00451048,Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,Completed,No Results Available,Leukemia|Myelodysplastic Syndromes,Drug: sunitinib malate,"University Health Network, Toronto|National Cancer Institute (NCI)",Both,Adult|Senior,Phase II,32,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000535656|PMH-PHL-063,3/20/2007,01/02/2007,NA,10/27/2010,01/10/2010,,01/05/2009,"Overall response rate (complete response, partial response, or hematologic improvement) defined by the International Working Group Criteria|Duration of response|Overall survival and progression-free survival at 6 months and 1 year|Time to progression at 6 months and 1 year|Toxicity and safety",http://ClinicalTrials.gov/show/NCT00451048,"United States, &nbsp; Canada",1,1,1,1
NCT00451152,Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma,Completed,No Results Available,Open-Angle Glaucoma,Drug: Anecortave Acetate,Alcon Research,Both,Adult|Senior,Phase II,81,Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,C-06-19,3/21/2007,01/03/2007,NA,09/10/2009,01/09/2009,,01/08/2009,Mean IOP|Percentage of patients declared treatment failures,http://ClinicalTrials.gov/show/NCT00451152,United States,1,0,1,NA
NCT00452348,A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg Twice Daily In Symptomatic Patients With Asthma,Completed,Has Results,Asthma,Drug: Fluticasone propionate 250 mcg BID|Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID,GlaxoSmithKline,Both,Child|Adult|Senior,Phase IV,628,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADA109057,3/26/2007,01/05/2007,01/05/2009,03/04/2010,01/03/2010,,01/05/2009,Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52|Mean Change From Baseline in AM PEF Over Weeks 1-52|Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52|Rate of Asthma Attacks Per Participant Per Year,http://ClinicalTrials.gov/show/NCT00452348,"United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Canada, &nbsp; Philippines",1,1,2,0
NCT00452699,A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg BID In Symptomatic Subjects With Asthma,Completed,Has Results,Asthma,Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Drug: Fluticasone propionate 250 mcg BID,GlaxoSmithKline,Both,Child|Adult|Senior,Phase IV,621,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADA109055|Fluticasone Propionate/salmete,3/26/2007,01/05/2007,01/05/2009,03/04/2010,01/03/2010,,01/05/2009,Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52|Mean Change From Baseline in AM PEF Over Weeks 1-52|Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52|Rate of Asthma Attacks Per Participant Per Year,http://ClinicalTrials.gov/show/NCT00452699,"United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Canada, &nbsp; Philippines",1,1,2,1
NCT00452920,"Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer",Completed,No Results Available,Cervical Cancer,Drug: docetaxel|Radiation: cesium Cs 137|Radiation: radiation therapy,University of Miami Sylvester Comprehensive Cancer Center,Female,Adult|Senior,Phase I|Phase II,72,Other,Interventional,Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment,EPROST-20020358|SCCC-2002058|WIRB-20050719,3/27/2007,01/09/2003,01/06/2009,01/11/2010,01/01/2010,,01/06/2009,Recommended phase II dose (Phase I)|Progression-free survival (Phase II)|Response (Phase II)|Toxicity (Phase II),http://ClinicalTrials.gov/show/NCT00452920,United States,1,1,3,0
NCT00453180,A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders,Completed,No Results Available,"Autistic Disorder|Asperger Syndrome|Child Development Disorders, Pervasive",Drug: N-acetylcysteine|Drug: Placebo,Indiana University School of Medicine|National Alliance for Autism Research,Both,Child,Phase II,32,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",0611-10,3/27/2007,01/03/2007,01/11/2009,8/23/2010,01/08/2010,,01/08/2009,"Clinical Global Impression - Severity done at Screen, Baseline, and at the end of week 12 of treatment|Clinical Global Impression - Improvement done at the end of weeks 4, 8, and 12 of treatment|Aberrant Behavior Checklist done at Baseline and end of weeks 4, 8, and 12|Social Responsiveness Scale done at Baseline and end of weeks 4, 8, and 12|Pervasive Developmental Disorder Behavior Index done at Baseline and end of week 12|Vineland Adaptive Behavior Scales done at Baseline and end of week 12",http://ClinicalTrials.gov/show/NCT00453180,United States,1,1,2,0
NCT00454116,"A Phase II, Double Blind Study of 2 Doses of ZACTIMA?ºÑ(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients",Completed,No Results Available,Colorectal Cancer,Drug: Vandetanib|Drug: FOLFIRI,AstraZeneca,Both,Adult|Senior,Phase II,110,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D4200C00048,3/28/2007,01/01/2008,01/11/2009,5/19/2010,01/05/2010,,01/03/2009,,http://ClinicalTrials.gov/show/NCT00454116,"United States, &nbsp; Argentina, &nbsp; Korea, Republic of, &nbsp; Norway, &nbsp; Spain, &nbsp; United Kingdom",1,1,2,0
NCT00454181,Treatment of Oral Warts in HIV+ Patients,Completed,Has Results,Papillomatosis|HIV Infections,Drug: Interferon-alpha|Other: placebo,"Amarillo Biosciences, Inc.",Both,Adult|Senior,Phase II,59,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",03HUHI19,3/29/2007,01/02/2007,01/10/2009,1/13/2011,01/01/2011,,01/09/2009,Change in Total Oral Mucosal Area Covered by Warts.|Total Surface Area of the Lips Covered by Warts|Subject Questionnaire Regarding Changes in Warts|Subject Questionnaire Regarding Global Oral Changes|Investigator Assessment Regarding Changes in Warts|Investigator Assessment Regarding Global Oral Changes.,http://ClinicalTrials.gov/show/NCT00454181,United States,1,0,2,NA
NCT00455039,INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients,Completed,No Results Available,Breast Cancer,Drug: GW572016,University of New Mexico,Female,Child|Adult|Senior,Phase I|Phase II,55,Other,Interventional,Allocation: Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,INST 0514C,3/30/2007,01/07/2005,01/10/2009,6/23/2010,01/10/2009,,01/10/2009,The primary end point of this study is clinical efficacy of GW572016 in treatment na??ve patients with locally advanced breast cancer.|The secondary end points would be the biologic correlative of relevant biomarkers.,http://ClinicalTrials.gov/show/NCT00455039,United States,1,0,1,NA
NCT00455533,Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: Ixabepilone|Drug: Paclitaxel|Drug: Cyclophosphamide|Drug: Doxorubicin,Bristol-Myers Squibb,Female,Adult|Senior,Phase II,294,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CA163-100|EUDRACT 2006-003047-24,04/02/2007,01/10/2007,01/12/2009,01/06/2011,01/06/2010,,01/12/2009,Estimate the pathologic complete response (pCR) rate in the two arms|Estimate pCR rate in a biomarker predefined population|Estimate the sensitivity and specificity for each of the predictive models|Explore other gene expression and protein expression that may be predictive of pCR in the two arms|Estimate the clinical objective response rates in the two arms|Determine the rate of breast conservation surgery achieved by subjects in each treatment arm|Evaluate the safety of AC followed by ixabepilone in subjects with early stage breast cancer|Determine the combined pCR and minimum residual cancer burden 1 rates in the two arms,http://ClinicalTrials.gov/show/NCT00455533,"United States, &nbsp; Argentina, &nbsp; Austria, &nbsp; France, &nbsp; Germany, &nbsp; India, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Peru, &nbsp; Philippines, &nbsp; Russian Federation, &nbsp; Singapore, &nbsp; Spain, &nbsp; Taiwan, &nbsp; United Kingdom",1,1,4,0
NCT00456300,Role of Exenatide in Type 1 Diabetes,Completed,No Results Available,Type 1 Diabetes,Drug: Exenatide,Baylor College of Medicine|National Institutes of Health (NIH),Both,Child|Adult,Phase IV,17,Other|NIH,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",H-16488,04/03/2007,01/03/2007,01/03/2009,11/30/2010,01/11/2010,,01/03/2009,Area under the curve for glucose,http://ClinicalTrials.gov/show/NCT00456300,United States,1,1,1,0
NCT00457119,"Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients Not Treated Previously With Systemic Therapy",Completed,No Results Available,Non Small Cell Lung Cancer,Drug: RAD001,Novartis Pharmaceuticals,Both,Adult|Senior,Phase I|Phase II,52,Industry,Interventional,Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CRAD001C2114,04/04/2007,01/02/2007,NA,02/04/2010,01/02/2010,,01/11/2009,Establish the feasible doses/regimens of RAD001 in combination with chemotherapy. Primary endpoint is the End-of-cycle DLT rate|Relative dose intensity (RDI) of Carboplatin + Paclitaxel (step 1)|Relative dose intensity (RDI) of Carboplatin + Paclitaxel + bevacizumab (step 2)|PK parameters derived from PK profiles of treatment drugs alone and in combination|Best overall response - measured by CT/MRI scan every 6-8 week,http://ClinicalTrials.gov/show/NCT00457119,"United States, &nbsp; Australia, &nbsp; Germany",1,1,1,0
NCT00458705,"Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma",Completed,No Results Available,Multiple Myeloma and Plasma Cell Neoplasm,Drug: bortezomib|Drug: dexamethasone|Drug: pegylated liposomal doxorubicin hydrochloride|Drug: thalidomide,Memorial Sloan-Kettering Cancer Center,Both,Adult|Senior,Phase II,44,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000537583|MSKCC-06067,04/09/2007,01/11/2006,NA,12/29/2009,01/07/2009,,01/12/2009,Disease response|Toxicity,http://ClinicalTrials.gov/show/NCT00458705,United States,1,0,4,NA
NCT00460928,Preventive IVIG Therapy for Congenital Heart Block,Completed,No Results Available,Congenital Heart Block|Neonatal Lupus|Autoantibody-Associated Heart Block,Drug: intravenous immune globulin (IVIG),New York University School of Medicine|Alliance for Lupus Research,Female,Adult,Phase II|Phase III,54,Other,Interventional,Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,H-07-045,4/13/2007,01/04/2007,01/06/2009,6/23/2009,01/06/2009,PITCH,01/06/2009,"2nd or 3rd degree heart block|Prolonged PR interval (>0.150 sec)|Sign of myocardial injury, w/o change in heart rate/rhythm|Echocardiographic density consistent with EFE|Fetal death|Rash consistent w neonatal lupus|Gestational age at birth|Birth weight|Abnormal fluid collection",http://ClinicalTrials.gov/show/NCT00460928,United States,1,0,1,NA
NCT00461006,A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: aleglitazar|Drug: Actos,Hoffmann-La Roche,Both,Adult|Senior,Phase II,176,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",BC20653,4/16/2007,,01/04/2009,5/13/2009,01/05/2009,,01/04/2009,"Relative change from baseline in glomerular filtration rate|Relative change from baseline in ERPF and UACR|Absolute change in HbAlc, FPG and FPI.|AEs, laboratory parameters.",http://ClinicalTrials.gov/show/NCT00461006,"United States, &nbsp; Mexico, &nbsp; Puerto Rico, &nbsp; Russian Federation, &nbsp; Ukraine",1,0,2,NA
NCT00462488,Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ,Completed,No Results Available,Urinary Bladder Cancer|Bladder Cancer|Bladder Neoplasms|Bladder Tumors,Drug: Vicinium,Viventia Biotech,Both,Adult|Senior,Phase II,46,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,VB4-845-02-IIA,4/17/2007,01/03/2007,01/10/2009,12/02/2009,01/12/2009,,01/10/2009,"Treatment Schedule A: 12-Week Efficacy, Treatment Schedule B: 13-Week Efficacy",http://ClinicalTrials.gov/show/NCT00462488,"United States, &nbsp; Canada",1,0,1,NA
NCT00462709,Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks,Completed,Has Results,Hereditary Angioedema,Biological: C1 esterase inhibitor [human] (C1INH-nf),ViroPharma,Both,Child|Adult|Senior,Phase III,146,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,LEVP2006-4,4/17/2007,01/06/2006,01/03/2009,05/07/2010,01/05/2010,CHANGE 3,01/03/2009,Frequency of All HAE Attacks,http://ClinicalTrials.gov/show/NCT00462709,United States,0,NA,1,NA
NCT00463047,Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain,Completed,Has Results,Chronic Pain,Drug: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone,Cephalon,Both,Adult|Senior,Phase III,323,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",C25608/3055/BP/MN,02/08/2007,01/07/2007,01/02/2009,11/16/2010,01/11/2010,,01/02/2009,Pain Intensity Difference (PID15) At 15 Minutes|Pain Intensity Difference (PID 5) at 5 Minutes|Pain Intensity Difference (PID 10) at 10 Minutes|Pain Intensity Difference (PID 30) at 30 Minutes|Pain Intensity Difference (PID 45) at 45 Minutes|Pain Intensity Difference (PID 60) at 60 Minutes|Percentage Change in Pain Intensity Difference (% PID) at 5 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (%PID) at 10 Minutes|Percentage Change in Pain Intensity Difference (%PID) at 15 Minutes|Percentage Change in Pain Intensity Difference (%PID) at 30 Minutes|Percentage Change in Pain Intensity Difference (% PID) at 45 Minutes|Percentage Change in Pain Intensity Difference (%PID) at 60 Minutes|Sum of Pain Intensity Difference at 30 Minutes Post-treatment (SPID30)|Sum of Pain Intensity Difference at 60 Minutes Post-treatment (SPID60)|Pain Relief (PR) Score at 5 Minutes|Pain Relief Score (PR) at 10 Minutes|Pain Relief Score (PR) at 15 Minutes|Pain Relief Score (PR) at 30 Minutes|Pain Relief Score (PR) at 45 Minutes|Pain Relief Score (PR) at 60 Minutes|Total Pain Relief (TOTPAR60) at 60 Minutes|Percent Total Pain Relief at 60 Minutes Posttreatment (%TOTPAR)|Time to Any Pain Relief (APR) by Treatment - <= 5 Minutes|Time to Any Pain Relief (APR) by Treatment <=10 Minutes|Time to Any Pain Relief (APR) by Treatment <=15 Minutes|Time to Any Pain Relief (APR) by Treatment <=30 Minutes|Time to Any Pain Relief (APR) by Treatment <=45 Minutes|Time to Any Pain Relief (APR) by Treatment <=60 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment - <= 5 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=10 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=15 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=30 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=45 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=60 Minutes|Standard Rescue Medication Usage|Medication Performance Assessment 30 Minutes After-treatment|Medication Performance Assessment 60 Minutes After-treatment|Breakthrough Pain Preference Questionnaire|Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at the End of the First Double-blind Treatment Period (Visit 5)|Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at the End of the Second Double-blind Treatment Period (Visit 6)|Pain Flare Treatment Satisfaction (PFTS) Questionnaire - Question 21 at Endpoint (End of Second Double-blind Treatment Period or Last Observation After Start of Treatment Period),http://ClinicalTrials.gov/show/NCT00463047,United States,1,0,1,NA
NCT00463242,"A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)",Completed,No Results Available,Major Depressive Disorder,Drug: agomelatine|Drug: paroxetine|Drug: placebo,Novartis,Both,Adult|Senior,Phase III,501,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CAGO178A2303,4/19/2007,01/03/2007,NA,11/08/2010,01/11/2010,,01/06/2009,"Change from Baseline to Week 8 on the total score Hamilton Depression Rating Scale|To demonstrate less sexual dysfunction in patients with MDD receiving agomelatine compared to paroxetine, as measured by the change from baseline to Week 8 on the total score of the Arizona Sexual Experience Scale (ASEX).|Proportion of patients who demonstrate clinical improvement where improvement is defined by a score of 1 or 2 on the Clinical Global Impression Improvement (CGI-I) scale at Week 8.|Proportion of patients with MDD who achieve remission,|Change from baseline to Week 8 on the total score and Anxiety subscale of the Hospital Anxiety and Depression Scale (HAD).",http://ClinicalTrials.gov/show/NCT00463242,"United States, &nbsp; Puerto Rico",1,0,3,NA
NCT00464178,A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma,Completed,No Results Available,Multiple Myeloma,Drug: bevacizumab,Hackensack University Medical Center|Genentech,Both,Adult|Senior,Phase II,30,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AV3502s|Protocol no. AVF3502s|WIRB no. 20070359,4/19/2007,01/04/2007,01/02/2009,10/20/2010,01/10/2010,,01/02/2009,Time to Tumor Progression (TTP)|TTP is calculated at the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Blad?¢ et al (Appendix F). If disease progression is based on increasing monoclonal parap|Overall Survival (OS)|Overall survival is calculated at the time of the screening evaluation to death from any cause.,http://ClinicalTrials.gov/show/NCT00464178,United States,1,1,1,1
NCT00465452,Impact of Switching to Continuous Release Dopamine Agonists,Completed,No Results Available,Parkinson Disease,Drug: Continuous Release Dopamine Agonists,University of Toledo Health Science Campus,Both,Adult|Senior,Phase III,15,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MUO-04,4/24/2007,01/01/2007,01/03/2009,3/18/2009,01/03/2009,,01/03/2009,"Equal or improved motor scores as measured by the Unified Parkinson's Disease Rating Scale (UPDRS), parts 3 (motor performance) and 4 (disability).|A significant improvement in somnolence as measured by the Epworth Sleepiness Scale (ESS).|A significant stabilization or improvement in the cognitive/mood battery of the Mini-Mental Status Exam (MMSE), the Clock Drawing Test (CDT), the Patient Health Questionnaire (PHQ-9) and the Neuropsychiatric Inventory Questionnaire (NPI-Q).|An improvement in peripheral edema, as measured by quantitative assessment of ankle and calf edema.|Increased patient satisfaction/preference (Patient Satisfaction Questionnaire - PS) scores.|Improvement in quality of life (Parkinson's Disease Questionnaire - PDQ-39).",http://ClinicalTrials.gov/show/NCT00465452,United States,1,1,1,0
NCT00465647,An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain,Completed,No Results Available,Acute Pain,Drug: Hydromorphone HCl,Purdue Pharma LP,Both,Child,Phase IV,116,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HMP4009,4/24/2007,01/04/2007,01/04/2010,05/06/2010,01/05/2010,,01/05/2009,"Population Pharmacokinetic/Pharmacodynamic (PK/PD) analysis|Faces Pain Scale-Revised (FPS-R)|Visual Analog Scale (VAS)|The Faces, Legs, Activity, Cry, Consolability (FLACC) Scale",http://ClinicalTrials.gov/show/NCT00465647,United States,1,1,1,0
NCT00466440,A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients,Completed,No Results Available,Prostate Cancer,Drug: enzastaurin|Drug: placebo|Drug: docetaxel|Drug: prednisone,Eli Lilly and Company,Male,Adult|Senior,Phase II,101,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11311|H6Q-MC-S032,4/25/2007,01/06/2007,01/06/2010,11/23/2010,01/11/2010,,01/08/2009,To determine response rate of enzastaurin given with chemotherapy in prostate cancer patients when they have taken enzastaurin for a maximum of 3 years|To assess rate of PSA level decline of greater than or equal to 30%|Progression free survival|Adverse events and safety|To characterize the pharmacokinetics of enzastaurin|Assess tumor biomarkers,http://ClinicalTrials.gov/show/NCT00466440,"United States, &nbsp; Germany, &nbsp; Italy",1,0,4,NA
NCT00467259,Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women,Completed,No Results Available,Hypoactive Sexual Desire Disorder,Drug: Testosterone Transdermal System|Drug: Placebo patch,Warner Chilcott,Female,Adult|Senior,Phase III,1271,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2007004,4/27/2007,01/04/2007,01/01/2009,3/22/2010,01/03/2010,,01/01/2009,To estimate the incidence of endometrial hyperplasia associated with 300 mcg/day testosterone transdermal system therapy in naturally postmenopausal women with hypoactive sexual desire disorder who are not using concomitant estrogen.,http://ClinicalTrials.gov/show/NCT00467259,United States,1,1,2,0
NCT00467402,"Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder",Completed,No Results Available,Major Depressive Disorder,Drug: agomelatine|Drug: placebo,Novartis,Both,Adult|Senior,Phase III,644,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CAGO178A2304,4/27/2007,01/04/2007,NA,05/10/2010,01/05/2010,,01/09/2009,"Time to relapse, where relapse is defined by the occurrence of any one of the following:|Hamilton Depression Rating Scale total score ??­16 at two consecutive visits;|hospitalization due to depression;|suicide attempt or suicide;|discontinuation due to lack of efficacy according to Investigator judgment.|Proportion of patients who demonstrate clinical improvement at the end of the double-blind continuation phase, where improvement is defined by a score of 1 or 2 on the Clinical Global Impression Improvement (CGI-I) scale.|Proportion of patients experiencing relapse during the double-blind continuation phase.|Proportion of patients who achieve remission at the end of the double-blind continuation phase, where remission is defined by a total score of ???7 on the HAM-D.|Change from randomization to the end of the double-blind continuation phase, on the Hospital Anxiety and Depression (HAD) total score and subscale scores.",http://ClinicalTrials.gov/show/NCT00467402,United States,1,0,2,NA
NCT00467519,Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age,Completed,Has Results,Tetanus|Diphtheria|Pertussis,Biological: Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|Biological: DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed),Sanofi-Aventis,Both,Child,Phase III,1045,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",TD517,4/27/2007,01/04/2007,01/12/2009,11/04/2010,01/11/2010,,01/11/2009,Percentage of Participants Who Achieved Seroprotection at Baseline and 30 Days Post-vaccination for Diphtheria and Tetanus at ??­ 0.1 IU/mL Level|Percentage of Participants Who Achieved Serothreshold at Baseline and 30 Days Post Vaccination for Diphtheria and Tetanus at Level ??­ 1.0 IU/mL|Percentage of Participants Who Demostrated Booster Response at 30 Days Post-Vaccination for Pertussis|Percentage of Participants Who Demostrated Booster Response at 30 Days Post-Vaccination for Diphtheria and Tetanus|Geometric Mean Titers (GMTs) at Baseline and 30 Days Post Vaccination for Pertussis,http://ClinicalTrials.gov/show/NCT00467519,"United States, &nbsp; Canada",0,NA,2,NA
NCT00467857,Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora Contamination,Completed,No Results Available,Skin Flora Contamination,Device: cyanoacrylate based microbial sealant|Other: Standard preoperative skin preparation,Kimberly-Clark Corporation,Both,Adult|Senior,Phase IV,310,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,IS 100-06-0001,4/27/2007,01/04/2007,01/03/2009,04/02/2009,01/01/2009,,01/03/2009,Qualitative reduction in skin flora at the end of surgery compared to the intact skin flora at the start of the surgery between two treatment groups.|Compare quantitative reduction in microbial count of skin flora at the end of surgery to intact skin at the beginning of surgery between two treatment groups.|Comparison of quantitative microbial counts at end of surgery between two treatment groups.|Comparison of qualitative reduction in skin flora immediately post incision to intact skin flora at beginning of surgery between two treatment groups.|Comparison of quantitative reduction in microbial count of skin flora immediately post-incision to intact skin flora at beginning of surgery between two treatment groups.|Comparison of quantitative microbial count of skin flora immediately post-incision between two treatment groups.|Evaluation of proportion of subjects with SSIs between two treatment groups.|Evaluation of other factors related to SSIs.,http://ClinicalTrials.gov/show/NCT00467857,"United States, &nbsp; Brazil, &nbsp; Chile, &nbsp; Germany, &nbsp; Singapore",0,NA,2,NA
NCT00467870,Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men,Completed,No Results Available,Hypogonadism|Primary Hypogonadism|Secondary Hypogonadism,Drug: Testosterone Undecanoate,Endo Pharmaceuticals Solutions Inc.,Male,Adult|Senior,Phase III,500,Industry,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,IP157-001,4/27/2007,01/03/2006,01/07/2009,9/21/2010,01/09/2010,TU,01/07/2009,"To evaluate the pharmacokinetics of TU|To compare serum levels of DHT, E2, and SHBG to simultaneous levels of serum total testosterone at steady state",http://ClinicalTrials.gov/show/NCT00467870,United States,1,0,1,NA
NCT00467922,An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy,Completed,No Results Available,Crohn's Disease|Ulcerative Colitis|Rectal Cancer|Colon Cancer|Colon Polyps|Rectal Polyps|Diverticulitis,Drug: Hextend|Drug: Lactated Ringers,"Spectrum Health Hospitals|Deltex Medical, Inc.",Both,Adult|Senior,Phase III,69,Other|Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",2007-109|2007-109,4/27/2007,01/05/2007,01/10/2009,10/20/2009,01/10/2009,,01/09/2009,"Determine the relative effects of a standard, colloid or crystalloid based strategy for hand-assisted laparoscopic colectomy surgery on decreasing length of stay|1. Determine the effects of the three fluid management strategies on post-operative fluid requirements in colorectal surgery. on the incidence and severity of post-operative complications. on return of gastrointestinal function.",http://ClinicalTrials.gov/show/NCT00467922,United States,1,0,2,NA
NCT00468143,A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall,Completed,No Results Available,Attention Deficit Hyperactivity Disorder,Drug: Adderall ?ó and Adderall XR ?ó,New York University School of Medicine,Both,Adult,Phase IV,49,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,IR v XR,4/30/2007,01/08/2007,01/01/2009,9/22/2009,01/09/2009,,01/01/2009,Medication Event Monitoring System (MEMS?ó). Dosage adherence (MEMSd) is the number of bottle openings divided by number of doses prescribed.|Medication Event Monitoring System (MEMS?ó). Regimen adherence (MEMSr) is a percentage of the number of days in which the complete dose regimen was taken as prescribed.|Medication Event Monitoring System (MEMS?ó). Time adherence (MEMSt) is the percentage of doses taken within an interval compared to the total number of dosing intervals.|Dichotomous Measure of Nonadherence|Pill count|self report,http://ClinicalTrials.gov/show/NCT00468143,United States,1,1,1,1
NCT00468273,"A Clinical Study of the PK, Efficacy and Safety of Omr-IgG-am IGIV in Subjects With Primary Immune Deficiency Diseases",Completed,No Results Available,Immunologic Deficiency Syndromes,Drug: Intravenous Immune Globulin,FFF Enterprises,Both,Child|Adult|Senior,Phase III,57,Industry,Interventional,Allocation: Non-Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,GAM-PID-03-US,05/01/2007,01/11/2006,01/08/2009,07/06/2010,01/07/2010,,01/05/2009,"Incidence of acute serious bacterial infections|IgG pharmacokinetics|Incidence of adverse events that occur during or within 1 hour, 24 hours and 72 hours following infusion|The number of hospitalizations and days of hospitalization per subject per year for PID related infections|The incidence of infections other than acute serious bacterial infections|The number of days lost from work/school/usual activities|The number of days of antibiotic therapy (prophylactic and treatment)|Pharmacokinetic parameters of IgG subclasses and specific antibodies will be determined in at least 20 patients: AUC0-t, Cmax, Tmax, t1/2, Vd and elimination rate constants.|Trough levels of IgG subclasses and specific antibodies will be estimated for each subject in the pharmacokinetic study at defined intervals.|The number of patients whose trough IgG levels fall below the target of 500 mg/dL at any time will be recorded.|All adverse events that occur during the study regardless of the investigator's assessment of the relationship to the investigational product.|Laboratory assessments on blood and urine samples including direct antiglobulin (Coomb's) tests.|Markers of blood borne virus infections at baseline and up to 3 months after the last infusion i.e. HIV (serology), HCV (serology and NAT), HBV (HbsAg).",http://ClinicalTrials.gov/show/NCT00468273,"United States, &nbsp; Canada",1,0,1,NA
NCT00468728,PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),Completed,No Results Available,Clostridium Infections|Diarrhea,Drug: PAR-101/OPT-80|Drug: Vancomycin,Optimer Pharmaceuticals,Both,Child|Adult|Senior,Phase III,536,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",101.1.C.004|101.1.C.004,05/01/2007,01/04/2007,01/12/2009,8/30/2010,01/08/2010,,01/11/2009,Cure rate at end of therapy|Recurrence,http://ClinicalTrials.gov/show/NCT00468728,"United States, &nbsp; Belgium, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",1,0,2,NA
NCT00469235,Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars,Completed,No Results Available,Keloid,Drug: Avotermin,Renovo,Both,Adult|Senior,Phase I|Phase II,20,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RN1001-0064,05/03/2007,01/06/2007,01/05/2009,9/15/2009,01/09/2009,,01/03/2009,Frequency of adverse events|Keloid reoccurrence,http://ClinicalTrials.gov/show/NCT00469235,United States,1,0,1,NA
NCT00469508,Modafinil vs Placebo for the Treatment of Methamphetamine Dependence,Completed,No Results Available,Methamphetamine Dependence,Drug: Modafinil|Drug: Placebo,National Institute on Drug Abuse (NIDA),Both,Adult|Senior,Phase II,73,NIH,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",P50 DA018185-03|P50 DA018185-03|DPMCDA,05/03/2007,01/04/2007,01/01/2009,09/03/2009,01/09/2009,Modafinil,01/01/2009,Urine toxicology|Beck Depression Inventory|Clinical Global Impressions|Brief Symptom Inventory,http://ClinicalTrials.gov/show/NCT00469508,United States,1,1,2,1
NCT00470535,Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Drug: erlotinib hydrochloride|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis,Roswell Park Cancer Institute,Both,Adult|Senior,Phase II,17,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000543406|RPCI-I-87106,05/03/2007,01/01/2007,01/09/2010,9/28/2010,01/09/2010,,01/01/2009,"Progression-free survival|Clinical response (complete and partial response) as measured by RECIST criteria|Median overall survival|Change in quality of life (QOL) as measured by EORTC PAN26 every 3 weeks during study therapy and after completion of study therapy|Correlation of smoking status with overall survival|Correlation of response, QOL, and survival with EGFR, E-cadherin, P-cadherin, vimentin, cytokeratin, ki67, and fibronectin and with other prognostic variables, such as age and tumor grade",http://ClinicalTrials.gov/show/NCT00470535,United States,1,1,3,1
NCT00472797,Rebif New Formulation (RNF) Quality of Life (QOL) Study,Completed,Has Results,Relapsing Multiple Sclerosis,Drug: Rebif New Formulation Non Titrated|Drug: Rebif New Formulation Titrated,EMD Serono,Both,Adult,Phase III,232,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care,27955,05/10/2007,01/04/2007,01/11/2009,8/17/2010,01/08/2010,RebiQoL,01/02/2009,Percent Change in Global Side Effects (GSE) on Multiple Sclerosis Treatment Concerns Quesionnaire (MSTCQ)|Total Score for Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)|Change in Score From Baseline to Week 12 for All Domains Other Than Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)|Total Score on Short-Form McGill Pain Questionnaire (SF-MPQ): Change in Baseline to Wk 12|Tolerability in Pain Using Visual Analog Scale (VAS)|Tolerability - Redness at Injection Site,http://ClinicalTrials.gov/show/NCT00472797,United States,1,0,2,NA
NCT00473551,Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies,Completed,No Results Available,Leukemia|Lymphoma|Myeloma,Drug: Rituximab|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Mesna|Radiation: Radiation Treatment|Procedure: Stem Cell Transplantation (SCT)|Drug: Sirolimus|Procedure: Anti-third Party Cytolytic T-lymphocytes (CTL),M.D. Anderson Cancer Center,Both,Adult|Senior,Phase I|Phase II,4,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2005-0682,05/11/2007,01/05/2007,01/11/2009,12/07/2009,01/12/2009,,01/11/2009,Maximally Tolerated Dose of antithird party cytolytic T-lymphocytes (CTLs),http://ClinicalTrials.gov/show/NCT00473551,United States,1,1,8,0
NCT00474058,Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine,Completed,Has Results,Parkinson's Disease,Drug: Rotigotine|Other: Placebo,"UCB, Inc.",Both,Adult|Senior,Phase III,287,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SP889|EudraCT No.: 2006-006752-35,5/14/2007,01/05/2007,01/03/2009,11/24/2010,01/11/2010,RECOVER,01/03/2009,"Change in Early Morning UPDRS Part III Score|Change in Parkinson's Disease Sleep Scale (PDSS)|Change in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS)|Change in Number of Nocturias",http://ClinicalTrials.gov/show/NCT00474058,"United States, &nbsp; Australia, &nbsp; Austria, &nbsp; Finland, &nbsp; Germany, &nbsp; Hungary, &nbsp; Italy, &nbsp; New Zealand, &nbsp; Poland, &nbsp; South Africa, &nbsp; Spain, &nbsp; United Kingdom",1,1,2,1
NCT00474630,A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Type 2 Diabetics,Completed,No Results Available,"Obesity|Diabetes Mellitus, Type 2",Drug: Naltrexone SR/Bupropion SR|Other: Placebo,"Orexigen Therapeutics, Inc",Both,Adult|Senior,Phase III,525,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NB-304,5/15/2007,01/05/2007,01/05/2009,1/22/2010,01/01/2010,,01/05/2009,Change from baseline in percentage of total body weight lost and percentage of subjects who achieve a weight decrease of ??­ 5%|Proportion of subjects who lose at least 10% of baseline body weight and who achieve a HbA1c value < 7%; Change in HbA1c; Effects on selected obesity-associated risk factors,http://ClinicalTrials.gov/show/NCT00474630,United States,1,1,2,0
NCT00474695,Study Evaluating Genotypes Using Lucentis,Completed,No Results Available,Age-Related Maculopathy,Drug: Lucentis,University of Utah|Genentech,Both,Adult|Senior,Phase IV,65,Other|Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,21441|SEAGUL,5/15/2007,01/05/2007,01/12/2009,10/15/2010,01/10/2010,SEAGUL,01/06/2009,To determine the VEGF and HTRA1 genotypes associated with improvement in visual acuity|Determine VEGF and HTRA1 genotypes associated with change or no change in visual acuity,http://ClinicalTrials.gov/show/NCT00474695,United States,1,1,1,1
NCT00474916,Neuropathic Pain in Patients With Cancer,Completed,No Results Available,Neuropathic Pain,Drug: KRN5500|Drug: Placebo,DARA Therapeutics,Both,Adult|Senior,Phase II,19,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DTCL100,5/15/2007,01/06/2006,01/04/2009,8/13/2010,01/08/2010,,01/03/2009,"Average pain intensity over the previous 24 hours as measured by a numeric rating scale (NRS) ranging from 0 to 10 where 0 represents \no pain\"" and 10 represents the \""worst possible pain.\""|Physical Examination",http://ClinicalTrials.gov/show/NCT00474916,"United States, &nbsp; Puerto Rico",1,0,2,NA
NCT00475865,Pilot Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis,Completed,No Results Available,Multiple Sclerosis,Drug: teriflunomide (HMR1726)|Drug: Placebo,Sanofi-Aventis,Both,Adult,Phase II,120,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PDY6046|EUDRACT : 2006-004893-29|HMR1726D-2004|LTS6047,5/18/2007,01/05/2007,01/10/2009,12/18/2009,01/12/2009,,01/10/2009,"Tolerability and safety data based on adverse event reports, physical examinations, laboratory evaluations, electrocardiograms and abdominal ultrasound of the pancreas.|Total number of gadolinium enhancing T1-lesions per MRI (Magnetic Resonance Imaging) scan, Percentage change from baseline in burden of disease (based on T2-lesions per MRI), Annualized relapse rate.",http://ClinicalTrials.gov/show/NCT00475865,"United States, &nbsp; Austria, &nbsp; Canada, &nbsp; Germany, &nbsp; Italy, &nbsp; United Kingdom",1,0,2,NA
NCT00475878,SSRI and Buprenorphine,Completed,No Results Available,Opiate Dependence|Depression,Drug: escitalopram|Drug: placebo,Butler Hospital,Both,Adult|Senior,Phase III,147,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",DA022207|0807-002,5/18/2007,01/12/2006,01/09/2009,9/30/2009,01/08/2006,,01/09/2009,buprenorphine adherence|mood symptoms,http://ClinicalTrials.gov/show/NCT00475878,United States,1,1,2,0
NCT00476645,Fulvestrant in Hormone Refractory Prostate Cancer,Completed,No Results Available,Prostatic Neoplasms|Prostate Cancer|Prostate Cancer Localized Disease|Prostate Cancer Metastatic Disease,Drug: Fulvestrant,Stanford University|AstraZeneca,Male,Adult|Senior,Phase II,20,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PROS0010|96025|PROS0010,5/18/2007,01/09/2006,01/12/2009,7/23/2010,01/07/2010,,01/09/2009,"Efficacy, defined as the first evidence of a total serum PSA decline of >50% from baseline maintained for at least 28 days and confirmed with two consecutive measurements taken two weeks apart|Time to progression, defined as the time from first administration of study drug to the first observation of disease progression|Disease progression, defined as an increase of >25% over the baseline PSA on two consecutive measurements two weeks apart, need for palliative therapy, or a decline in at least 20% in KPS|Time to sustained biochemical response, defined as the time from first administration of drug to first evidence of sustained response|Duration of sustained response, defined as time from PSA decrease of >50% from baseline to the first evidence of disease progression",http://ClinicalTrials.gov/show/NCT00476645,United States,1,1,1,1
NCT00477087,Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer,Completed,No Results Available,Prostatic Neoplasms,Drug: Mitoxantrone|Drug: GM-CSF,Stanford University|Bayer,Male,Adult|Senior,Phase II,20,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PROS0017|96817|PROS0017,5/18/2007,01/07/2006,01/07/2010,09/10/2010,01/09/2010,,01/01/2009,"Time to Progression - 1st study drug dose to observation of disease progression (increase >25% over baseline PSA on 2 consecutive measurements 2 weeks apart, need for palliative therapy, formation/progression of new bone lesions, or decline of >20% KPS)|PSA response, defined as the first evidence of a total serum PSA decline of >50% from baseline maintained for at least 28 days and confirmed with two consecutive measurements taken two weeks apart|Time to sustained biochemical response, defined as the time from first administration of drug to first evidence of sustained response|Duration of sustained response, defined as time from PSA decrease of >50% from baseline to the first evidence of disease progression",http://ClinicalTrials.gov/show/NCT00477087,United States,1,1,2,0
NCT00477334,Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients,Completed,No Results Available,Genital Herpes,Drug: Famciclovir|Drug: Placebo,Novartis,Both,Adult|Senior,Phase IV,463,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CFAM810A2310,5/22/2007,01/06/2007,NA,03/12/2010,01/03/2010,,01/03/2009,Time to healing of non-aborted genital herpes lesions|Safety as assessed by adverse events and laboratory abnormalities,http://ClinicalTrials.gov/show/NCT00477334,"United States, &nbsp; South Africa",1,1,2,1
NCT00477633,Study of Safety and Efficacy of an Oral Contraceptive,Completed,No Results Available,Contraception,Drug: Norethindrone/ethinyl estradiol|Drug: norethindrone / ethinyl estradiol,Warner Chilcott,Female,Adult,Phase III,1702,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,PR-00207,5/22/2007,01/06/2007,01/02/2009,05/06/2009,01/05/2009,,01/01/2009,"Pregnancy rate among women 18-35 years old, expressed in terms of the Pearl Index defined as the number of pregnancies per 100 women-years of treatment|Descriptive parameters of bleeding/spotting, safety and tolerability.",http://ClinicalTrials.gov/show/NCT00477633,United States,1,1,2,0
NCT00477672,A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Completed,No Results Available,Parkinson's Disease Psychosis,Drug: pimavanserin tartrate (ACP-103)|Drug: ACP-103|Drug: Placebo,ACADIA Pharmaceuticals Inc.,Both,Adult|Senior,Phase III,240,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ACP-103-012,5/22/2007,01/06/2007,NA,08/04/2010,01/08/2010,,01/06/2009,Antipsychotic efficacy will be assessed using the scale for the assessment of Positive Symptoms (SAPS),http://ClinicalTrials.gov/show/NCT00477672,"United States, &nbsp; Bulgaria, &nbsp; France, &nbsp; India, &nbsp; Russian Federation, &nbsp; Ukraine, &nbsp; United Kingdom",1,0,3,NA
NCT00478205,Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease,Completed,No Results Available,Alzheimer's Disease,Drug: Aricept (donepezil SR 23 mg)|Drug: Aricept (donepezil IR 10 mg),Eisai Inc.|Eisai Limited,Both,Adult|Senior,Phase III,1200,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",E2020-G000-326,5/22/2007,01/06/2007,NA,4/25/2010,01/04/2010,,01/06/2009,"Co-primary parameters: Severe Impairment Battery (SIB); Clinician's Interview-Based Impression of Change (Plus version) (CIBIC); Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL).|Secondary parameters: Mini-Mental State Examination (MMSE), ADCS-ADL, or CIBIC+, depending on region.|Exploratory parameters: Quality of Life in Alzheimer's Disease (QoL-AD), EuroQol-5 Dimensions (EQ-5D), Screen for Caregiver Burden (SCB), Treatment Expectation Scale (TES), Treatment Outcome Scale (TOS), and Goal Attainment Scale (GAtS).|Vital signs, physical and neurological examinations, laboratory screens of blood and urine, and 12-lead electrocardiogram.",http://ClinicalTrials.gov/show/NCT00478205,United States,1,1,2,1
NCT00478556,Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT,Completed,Has Results,Healthy,Drug: Omnipaque|Drug: Gastroview,University of Alabama at Birmingham|GE Healthcare,Both,Adult|Senior,Phase IV,300,Other|Industry,Interventional,"Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Diagnostic",F070208011|Omnipaque vs Gastroview Oral,5/24/2007,01/08/2007,01/03/2009,5/19/2010,01/05/2010,,01/03/2009,Preferred Contrast Agent|Bowel Opacification Score,http://ClinicalTrials.gov/show/NCT00478556,United States,1,1,2,1
NCT00478647,Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase,Completed,Has Results,"Gaucher Disease, Type 1",Biological: GA-GCB (velaglucerase alfa),"Shire Human Genetic Therapies, Inc.",Both,Child|Adult|Senior,Phase II|Phase III,40,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TKT034,5/23/2007,01/07/2007,01/08/2009,9/20/2010,01/09/2010,,01/07/2009,Patients Which Experienced at Least One Adverse Event|Change From Baseline to Week 53 in Hemoglobin Concentration|Percent Change From Baseline to Week 53 in Platelet Count|Percent Change From Baseline to Week 51 in Normalized Liver Volume|Percent Change From Baseline to Week 51 in Normalized Spleen Volume,http://ClinicalTrials.gov/show/NCT00478647,"United States, &nbsp; Israel, &nbsp; Poland, &nbsp; Spain, &nbsp; United Kingdom",0,NA,1,1
NCT00478673,Post-Approval Study of the NexStent Carotid Stent System and the FilterWire EZ Embolic Protection System: SONOMA,Completed,No Results Available,Extracranial Carotid Artery Stenosis,Device: NexStent Carotid Stent System (Monorail Delivery System)|Device: FilterWire EZ?ºÑ Embolic Protection System,Boston Scientific Corporation,Both,Adult|Senior,Phase IV,298,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,S2042|SONOMA,5/24/2007,01/05/2007,01/07/2009,09/03/2009,01/09/2009,SONOMA,01/07/2009,30-day rate of major adverse events (MAE); 12-month composite rate of major adverse events (MAE) and ipsilateral stroke events that occur within 31-365 days for all subjects.,http://ClinicalTrials.gov/show/NCT00478673,United States,0,NA,2,NA
NCT00479687,SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder,Completed,No Results Available,Glenohumeral Osteoarthritis of the Shoulder,Device: SUPARTZ|Device: Saline,"Smith & Nephew, Inc.|Seikagaku Corporation",Both,Adult|Senior,Phase III,300,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SHO-0106,5/24/2007,01/05/2007,01/10/2009,10/27/2010,01/10/2010,,01/10/2009,Improvement in shoulder pain compared to subjects treated with placebo|Characteristic effects of pain improvement over a period of 26 weeks.,http://ClinicalTrials.gov/show/NCT00479687,United States,0,NA,2,NA
NCT00480324,"Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants",Completed,Has Results,Gastroenteritis Caused by Rotavirus|Rotavirus Vaccines,Biological: Rotarix|Biological: Placebo,GlaxoSmithKline,Both,Child,Phase III,765,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",107625,5/29/2007,01/06/2007,01/11/2009,10/21/2010,01/10/2010,,01/11/2009,Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains|Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains|Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type|Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types|Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains|Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains|Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration|Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies|Number of Subjects Reporting Solicited Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AEs)|Number of Subjects Reporting Serious Adverse Events (SAEs),http://ClinicalTrials.gov/show/NCT00480324,"United States, &nbsp; Japan, &nbsp; Sweden",0,NA,2,NA
NCT00480441,Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal,Completed,No Results Available,Marijuana Dependence,Drug: Dronabinol|Behavioral: BRENDA therapy|Drug: Placebo,National Institute on Drug Abuse (NIDA),Both,Adult,Phase II,61,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",5-P60-DA-005186-19,5/30/2007,01/08/2006,01/07/2009,6/29/2010,01/06/2010,,01/06/2009,Cannabis dependent patients will be able to tolerate dronabinol.|Dronabinol will attenuate cannabis withdrawal.|The quantitative THC and self-report measurements will decrease over the time of study.|Cannabis dependent patients will complete neurocognitive assessments with dronabinol improving performance in certain spheres of function.|Cannabis dependent patients will demonstrate physiological changes in response to cue-induced craving which will be attenuated by dronabinol treatment.|Select group of cannabis dependent patients will complete fMRI scans with demonstrable dronabinol related changes in brain activation.|Structural and perfusion brain differences will be correlated with performance on neurocognitive tasks,http://ClinicalTrials.gov/show/NCT00480441,United States,1,1,3,1
NCT00481624,Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia,Completed,No Results Available,Advanced Lung Cancer|Chemotherapy Induced Anemia,Drug: Epoetin Alfa plus Iron,James Graham Brown Cancer Center,Both,Adult|Senior,Phase II,25,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,7.021,06/01/2007,01/05/2007,01/11/2009,01/11/2010,01/01/2010,Procrit,01/11/2009,"Achieve hemoglobin responses > 2g/dl in at least 70% of patients|Descriptive evaluation of adverse effects of parenteral iron and epoetin alfa 120,000 units given every three weeks",http://ClinicalTrials.gov/show/NCT00481624,United States,1,1,1,1
NCT00482911,"Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma",Completed,No Results Available,Intraocular Melanoma|Malignant Conjunctival Neoplasm,Drug: cyclophosphamide|Drug: lenalidomide|Drug: sunitinib malate,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,50,NIH,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Masking: Open Label|Primary Purpose: Treatment,CDR0000546695|NCI-07-C-0134,06/04/2007,01/04/2007,NA,4/21/2009,01/10/2008,,01/04/2009,Response rate (complete and partial response)|Toxicity|Progression-free survival|Overall survival,http://ClinicalTrials.gov/show/NCT00482911,United States,1,1,3,0
NCT00483301,"A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma",Completed,No Results Available,Malignant Melanoma,Drug: Sorafenib (BAY 43-9006)|Drug: ABI-007(Abraxane),"Mt. Sinai Medical Center, Miami|Abraxis BioScience, LLC.|Bayer",Both,Adult|Senior,Phase II,43,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MEL0205,5/30/2007,01/05/2007,01/08/2009,9/17/2009,01/09/2009,,01/08/2009,,http://ClinicalTrials.gov/show/NCT00483301,United States,1,1,2,0
NCT00483379,Dose and Dose Interval Study of Alglucosidase Alfa,Completed,No Results Available,Pompe Disease|Glycogen Storage Disease Type II (GSD-II)|Glycogenesis 2 Acid Maltase Deficiency,Biological: alglucosidase alfa,Genzyme,Both,Child|Adult|Senior,Phase IV,13,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AGLU03306,06/06/2007,01/05/2007,01/07/2010,12/25/2010,01/12/2010,,01/12/2009,Evaluate the safety and efficacy of alternate alglucosidase alfa dosing regimens|Evaluate difference in efficacy in 2 dosing arms|Evaluate effect of increases in alglucosidase alfa dose or dose frequency on cardiac pathophysiology|Evaluate effect of increases in alglucosidase alfa dose or dose frequency on respiratory function|Evaluate effect of increases in alglucosidase alfa dose or dose frequency on proximal and distal muscle strength|Evaluate effect of increases in alglucosidase alfa dose or dose frequency on gross motor function|Evaluate effect of increases in alglucosidase alfa dose or dose frequency on functional status and health-related quality of life,http://ClinicalTrials.gov/show/NCT00483379,"United States, &nbsp; Australia, &nbsp; Canada",0,NA,1,1
NCT00483574,Study of the Safety of Menactra?ó Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers,Completed,No Results Available,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Biological: Menactra?ó: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|Biological: Routine pediatric vaccines,Sanofi-Aventis,Both,Child,Phase III,1378,Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,MTA48,06/06/2007,01/05/2007,01/04/2009,3/31/2010,01/03/2010,,01/01/2009,To provide information concerning the safety of Menactra after vaccination.,http://ClinicalTrials.gov/show/NCT00483574,"United States, &nbsp; Chile",0,NA,2,NA
NCT00484198,"Randomized, Double-Blind Active Comparator-Controlled Study of Rivoglitazone in Type 2 Diabetes Mellitus",Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: pioglitazone|Drug: placebo|Drug: rivoglitazone HCl|Drug: rivoglitazone HCl,Daiichi Sankyo Inc.,Both,Adult|Senior,Phase III,1820,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CS0011-A-U301,06/07/2007,01/04/2007,01/02/2009,02/01/2010,01/02/2010,,01/02/2009,Glycemic control - HbA1c|Glycemic control - FPG Responder rates - A1C Effects on lipid parameters,http://ClinicalTrials.gov/show/NCT00484198,"United States, &nbsp; Argentina, &nbsp; Austria, &nbsp; Chile, &nbsp; Czech Republic, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Latvia, &nbsp; Mexico, &nbsp; Peru, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Serbia, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Ukraine, &nbsp; United Kingdom",1,0,4,NA
NCT00485134,Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection,Completed,No Results Available,Shigellosis,Biological: Invaplex 50 Vaccine,Department of Defense|U.S. Army Office of the Surgeon General,Both,Adult,Phase I|Phase II,NA,U.S. Fed,Interventional,Allocation: Randomized|Control: Dose Comparison|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention,NMRC.2006.0007|A-14057|WRAIR 1328,06/11/2007,01/05/2007,01/07/2009,12/01/2010,01/12/2010,,01/07/2009,,http://ClinicalTrials.gov/show/NCT00485134,United States,0,NA,1,NA
NCT00485693,Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty,Completed,No Results Available,Postoperative Pain,Drug: Bupivacaine HCl|Drug: SKY0402,"Pacira Pharmaceuticals, Inc",Both,Adult|Senior,Phase II,138,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",SKY0402C208,06/11/2007,01/06/2007,01/08/2009,09/01/2010,01/09/2010,TKA,01/08/2009,"AUC of the NRS pain scores from 0 through 72 hours|AUC of the NRS pain scores from 0 through intervening timepoints 24, 36, 48, and 60 hours",http://ClinicalTrials.gov/show/NCT00485693,United States,1,0,2,NA
NCT00486044,Evaluating Simvastatin's Potential Role in Therapy,Completed,No Results Available,Alzheimer Disease,Drug: Simvastatin|Drug: Placebo,"University of Wisconsin, Madison|National Institute on Aging (NIA)|Paul Beeson Faculty Scholars Program|The John A. Hartford Foundation|The Atlantic Philanthropies|Starr Foundation|American Federation for Aging Research|Merck",Both,Adult|Senior,Phase II,100,Other|NIH|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IA0116|1K23AG026752-01,06/12/2007,01/02/2005,01/06/2009,9/27/2010,01/09/2010,ESPRIT,01/06/2009,"Changes in cerebrospinal fluid beta-amyloid levels|Changes in biomarkers of CNS cholesterol metabolism, inflammatory markers, and cerebral perfusion|Changes in cognitive function",http://ClinicalTrials.gov/show/NCT00486044,United States,1,1,2,1
NCT00488059,AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients.,Completed,No Results Available,HIV Infections,Drug: enfuvirtide [Fuzeon]|Drug: Optimized ARV background|Drug: Integrase inhibitor|Drug: enfuvirtide [Fuzeon],Hoffmann-La Roche|Trimeris,Both,Adult|Senior,Phase IV,30,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ML20837,6/18/2007,,01/02/2009,5/13/2009,01/05/2009,,01/02/2009,"Number and percentage of patients with HIV RNA <50 copies/mL|Mean change in HIV RNA and CD4 from baseline; number and percentage of patients with HIV RNA <=50 copies/mL and <400 copies/mL; number and percentage of patients with >=1 log decline in HIV RNA from baseline. SAEs, ISRs, laboratory parameters.",http://ClinicalTrials.gov/show/NCT00488059,"United States, &nbsp; Puerto Rico",1,1,4,0
NCT00488345,"Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age",Completed,No Results Available,"Bacterial Infections|Intra-abdominal Infection|Pneumonia, Bacterial|Skin Diseases, Bacterial|Skin Diseases, Infectious",Drug: Tygacil,Wyeth,Both,Child,Phase II,59,Industry,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,3074K4-2207,6/18/2007,01/12/2007,01/09/2009,9/22/2009,01/09/2009,,01/09/2009,"Six samples. Serum Tigecycline concentrations to determine individual PK parameters using noncompartmental methods including Cmax, tmax, AUC and clearance. Population PK methods to investigate the impact of covariates: age, weight and height|Tolerability and safety: Vital signs, adverse events, laboratory. Interim safety data reviews planned to validate escalation to the next dose cohort.Clinical response: cure, failure, or indeterminate.",http://ClinicalTrials.gov/show/NCT00488345,"United States, &nbsp; Belgium, &nbsp; Mexico, &nbsp; South Africa, &nbsp; Taiwan, &nbsp; Ukraine",1,1,1,1
NCT00488514,Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents,Completed,Has Results,Migraine Disorders,Drug: Combination Tablet of Treximet (sumatriptan/naproxen sodium),GlaxoSmithKline,Both,Child,Phase III,656,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TXA107977,6/18/2007,01/07/2007,01/08/2009,11/04/2010,01/11/2010,,01/08/2009,"Number of Participants With the Indicated Drug-related Adverse Events|Number of Participants With Any Adverse Event Categorized by Severity|Number of Participants With Any Adverse Event Categorized Over Time|Number of Participants With Any Adverse Event Categorized by Participant Age|Number of Participants With Any Adverse Event Categorized by Participant Race|Number of Participants With Any Adverse Event Categorized by Participant Gender|Number of Participants With Any Adverse Event That Occurred Within 3 or 5 Days of the First Dose of the Combination Tablet|Number of Tablets Taken, After Which at Least One Adverse Event Occurred Within 3 or 5 Days of Dosing With That Combination Tablet|Number of Participants With Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine, Potassium, and Blood Urea Nitrogen (BUN) Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit|Number of Participants With Hematocrit and Hemoglobin Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit|Mean Height for All Study Participants at the Indicated Time Points|Mean Weight for All Study Participants at the Indicated Time Points|Mean Body Mass Index (BMI) for All Study Participants at the Indicated Time Points|Mean Blood Pressure for All Study Participants at the Indicated Time Points|Mean Heart Rate for All Study Participants at the Indicated Time Points|Number of Participants With Abnormal Electrocardiogram Findings at Screening and at the Final Visit as Assessed by the Investigator|Number of Treated Migraine Attacks|Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 24 Hours of Dosing With the Combination Tablet|Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 4 Hours of Dosing With a Combination Tablet|Number of Treated Attacks Classified as Migraine Pain-Free Within 4 Hours That Were Also Pain Free Within 2 Hours of Dosing With the Combination Tablet|Average Number of Headaches, Migraine Attacks, and Treated Migraine Attacks Per Month|Number of Total Migraines Headaches and Migraines Treated With the Combination Tablet|Number of Migraine Attacks Rated With the Indicated Pain Severity|Number of Treated Migraine Attacks With Photophobia, Phonophobia, Nausea, Neck Pain, Sinus Pain, and Vomiting|Mean Change From Baseline in the Migraine Specific Quality of Life (QOL) Questionnaire for Adolescents (MSQ-A) Score at Months 3, 6, 9, and 12|Number of Participants Categorized by Response to Each of the 3 Global Satisification Questions From the Patient Perception Migraine Questionnaire-Revised (PPMQ-R) at the Screening Visit|Number of Participants Categorized by Response to Each of the 3 Global Satisification Questions From the Patient Perception Migraine Questionaire-Revised (PPMQ-R) at Month 12",http://ClinicalTrials.gov/show/NCT00488514,United States,1,1,1,1
NCT00489489,Pilot Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis,Completed,No Results Available,Multiple Sclerosis,Drug: teriflunomide (HMR1726)|Drug: placebo,Sanofi-Aventis,Both,Adult,Phase II,116,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",PDY6045|2006-003134-14|HMR1726D-2003,6/20/2007,01/06/2007,01/06/2009,10/27/2010,01/09/2010,,01/02/2009,Number of patients with adverse events|Number of patients with clinically significant abnormalities|Total number of gadolinium enhancing T1-lesions per Magnetic Resonance Imaging (MRI) scan|Burden of disease|Annualized relapse rate (number of relapses per subject-year),http://ClinicalTrials.gov/show/NCT00489489,"United States, &nbsp; Canada, &nbsp; Germany, &nbsp; Italy, &nbsp; Spain",1,0,2,NA
NCT00490022,DHT-3-Effect of Dihydrotestosterone (DHT) on Prostate Tissue,Completed,No Results Available,Healthy,Drug: Dihydrotestosterone (DHT) gel (0.7%)|Drug: Placebo gel,University of Washington|National Institute on Aging (NIA)|ASCEND Therapeutics,Male,Adult,Phase I|Phase II,43,Other|NIH|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",31866-A|AGO27238-01 A1,6/20/2007,01/06/2007,01/01/2009,07/09/2009,01/07/2009,DHT-3,01/01/2009,Prostate tissue hormone levels at 28 days of treatment|Prostate epithelial cell gene and protein expression,http://ClinicalTrials.gov/show/NCT00490022,United States,1,0,2,NA
NCT00490542,Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State,Completed,No Results Available,Bipolar Disorder|Bipolar Depression|Depression,Drug: ziprasidone (Geodon)|Drug: placebo,Tufts Medical Center|Pfizer,Both,Adult,Phase II,100,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",GA128000,6/20/2007,01/12/2006,01/08/2009,11/13/2009,01/11/2009,,01/08/2009,To determine if ziprasidone is effective for the depressive mixed state in bipolar and unipolar depression.,http://ClinicalTrials.gov/show/NCT00490542,United States,1,1,2,0
NCT00490776,Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma,Completed,No Results Available,Cutaneous T-Cell Lymphoma,Drug: LBH589,Novartis Pharmaceuticals,Both,Adult|Senior,Phase II|Phase III,9,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CLBH589B2212,6/21/2007,01/06/2007,NA,2/16/2010,01/02/2010,,01/09/2009,"To determine the overall response rate of patients treated with LBH589 by using the modified Severity-Weighted Assessment Tool to assess skin disease and the evaluation of disease in the viscera, lymph nodes, and blood (circulation SS cells)|To determine the response rate using the Physicians Global Assessment of Clinical Condition(PGA)of patients with resistant CTCL|To determine the response rate using Modified Severity Weighted Assessment (mSWAT) skin score of patients with resistant CTCL|Responses in index lesions by lesion measurements with photographic supporting documentation|Overall response rate of patients with resistant CTCL treated with oral LBH589 by using the modified Physician's Global Assessment (PGA) to assess skin disease and the evaluation of disease in the viscera, lymph nodes and blood (circulating SS cells).|Duration of response",http://ClinicalTrials.gov/show/NCT00490776,United States,1,0,1,NA
NCT00492141,Aerosol L9-NC and Temozolomide in Ewing's Sarcoma,Completed,No Results Available,Ewing's Sarcoma,Drug: Temozolomide|Drug: L9-NC,M.D. Anderson Cancer Center,Both,Child|Adult|Senior,Phase I|Phase II,10,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2005-0889,6/26/2007,01/06/2006,01/09/2009,10/07/2009,01/10/2009,,01/09/2009,To learn if liposomal 9-nitro-20(S)-camptothecin (L9-NC) given alone and given in combination with Temodar (temozolomide) can help to control Ewing's sarcoma or another type of cancer that has spread to the lungs.,http://ClinicalTrials.gov/show/NCT00492141,United States,1,0,2,NA
NCT00492284,Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL),Completed,Has Results,Choroidal Neovascularization|Macular Degeneration,Drug: verteporfin|Drug: verteporfin|Drug: ranibizumab|Drug: dexamethasone,QLT Inc,Both,Adult|Senior,Phase II,162,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,BPD OCR 022,6/25/2007,01/07/2007,01/05/2010,6/22/2010,01/06/2010,RADICAL,01/05/2009,Mean Number of Retreatments (Day 0 Excluded)|Mean Change From Baseline in Study Eye Best-corrected VA Score (ETDRS Chart)|Percentage of Subjects With >=15 Letters of Visual Acuity Gained From Baseline|Percentage of Subjects With >=0 Letter Gain of Visual Acuity From Baseline|Percentage of Subjects With >=15 Letters of Visual Acuity Lost From Baseline|Mean Change From Baseline in Central Retinal Thickness|Mean Change From Baseline in Lesion Size,http://ClinicalTrials.gov/show/NCT00492284,"United States, &nbsp; Canada",1,1,4,0
NCT00493051,Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities,Completed,No Results Available,Diabetic Foot,Biological: GAM501|Biological: Placebo|Other: Standard of care,Tissue Repair Company|Cardium Therapeutics,Both,Adult|Senior,Phase II,124,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SWHI-03,6/25/2007,01/11/2007,01/12/2009,02/08/2010,01/02/2010,MATRIX,01/12/2009,Effect of GAM501 on the incidence of complete ulcer closure|Time to complete ulcer closure|The absolute change and percent change in ulcer area|The durability of ulcer closure|Ulcer healing trajectories will be assessed by plots of percentage of ulcer closure versus time|Safety and tolerance,http://ClinicalTrials.gov/show/NCT00493051,United States,0,NA,3,NA
NCT00493987,The Role of 5-alpha Reductase in Mediating Testosterone Actions,Completed,No Results Available,Healthy,Drug: Testosterone Enanthate|Drug: Dutasteride,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Male,Adult,Phase IV,184,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R01HD043348|R01HD043348,6/28/2007,01/11/2002,01/03/2010,05/12/2010,01/01/2009,5aR,01/12/2009,"Change from baseline in fat-free mass, measured by DEXA scanning|Body composition by Deuterium dilution method|Maximal voluntary strength in the leg press and chest press exercises.|Upper and lower extremity muscle power|Muscle volume by MRI scan|Prostate volume by MRI Scan|International Index of Erectile Function|Men's Sexual Health Questionnaire|Davidson Sexual Encounter Profile|Nocturnal penile tumescence and penile rigidity measures|Prostate specific antigen|Hematocrit|Fasting lipid profile / atherogenic markers",http://ClinicalTrials.gov/show/NCT00493987,United States,1,1,2,1
NCT00494234,Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-Positive Advanced Breast Cancer,Completed,No Results Available,Breast Neoplasms,Drug: KU-0059436 (AZD2281)(PARP inhibitor),AstraZeneca|KuDOS Pharmaceuticals Limited,Female,Adult|Senior,Phase II,54,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,KU36-44|D0810C00008,6/27/2007,01/06/2007,01/02/2009,5/14/2009,01/05/2009,ICEBERG 1,01/02/2009,Objective tumour response rate|Clinical benefit rate|Safety and tolerability profile,http://ClinicalTrials.gov/show/NCT00494234,"United States, &nbsp; Australia, &nbsp; Germany, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",1,0,1,NA
NCT00494442,Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-Positive Advanced Ovarian Cancer,Completed,No Results Available,Ovarian Neoplasm,Drug: KU-0059436 (AZD2281)(PARP inhibitor),AstraZeneca|KuDOS Pharmaceuticals Limited,Female,Adult|Senior,Phase II,57,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,KU36-58|D0810C00009,6/27/2007,01/06/2007,01/03/2009,5/14/2009,01/05/2009,ICEBERG 2,01/03/2009,Objective tumour response rate|Clinical benefit rate|Safety and tolerability,http://ClinicalTrials.gov/show/NCT00494442,"United States, &nbsp; Australia, &nbsp; Germany, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",1,0,1,NA
NCT00495495,Healozone Study to Evaluate the Safety and Efficacy of the Use of Ozone for Management of Dental Caries,Completed,Has Results,Dental Caries,Device: Ozone treatment|Device: Placebo treatment,Indiana University School of Dentistry|Tufts University|State University of New York at Buffalo,Both,Child|Adult,Phase II|Phase III,394,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention",07-D-187|IDE G50008|Clinical Trials. gov,07/01/2007,01/02/2007,01/12/2009,01/05/2011,01/01/2011,,01/05/2009,ICDAS Severity Value|Change in Caries Lesion Activity|Progression of Radiographic Scores at 12 Months|Laser Fluorescence Progression-12 Month (Increase From <=20 to >=30)|Laser Fluorescence Progression-12 Month (Increase at Least 10),http://ClinicalTrials.gov/show/NCT00495495,United States,0,NA,2,NA
NCT00498550,Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual,Completed,No Results Available,Schizophrenia|Dual Diagnosis|Schizoaffective Disorder|Psychotic Disorder|Cannabis Abuse,Drug: Clozapine|Drug: Treatment as usual,"National Institute on Drug Abuse (NIDA)|Dartmouth-Hitchcock Medical Center|University of Missouri, Kansas City|VA Medical Center-West Los Angeles|University of South Carolina",Both,Adult,Phase IV,35,NIH|Other|U.S. Fed,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,R01 DA013196|DPMCDA,07/06/2007,01/10/2000,01/03/2009,4/15/2009,01/04/2009,,01/03/2009,Days of cannabis use as measured by the Timeline Followback|To begin to investigate the process by which Clozapine produces its affects on cannabis use through the study of negative symptoms using the Scale for the Assessment of Negative Symptoms.,http://ClinicalTrials.gov/show/NCT00498550,United States,1,1,2,1
NCT00498628,Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency,Completed,No Results Available,Alcoholism|Alcohol Abuse,Drug: Quetiapine fumarate|Other: Placebo,National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Department of Veterans Affairs|National Institute on Drug Abuse (NIDA)|AstraZeneca,Both,Adult,Phase II,224,NIH|U.S. Fed|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",NIAAA_DTRR-2007-LITTEN-01,07/06/2007,01/12/2007,01/11/2009,02/02/2010,01/02/2010,,01/08/2009,Percentage of Days of Heavy Drinking,http://ClinicalTrials.gov/show/NCT00498628,United States,1,1,2,1
NCT00499577,"Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma",Completed,No Results Available,Multiple Myeloma and Plasma Cell Neoplasm,Biological: CMV pp65 peptide|Biological: hTERT I540/R572Y/D988Y multipeptide vaccine|Biological: pneumococcal polyvalent vaccine|Biological: survivin Sur1M2 peptide vaccine,University of Maryland Greenebaum Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase I|Phase II,56,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000552988|MSGCC-0610-GCC|UPCC-0610-GCC,07/10/2007,01/12/2006,NA,11/03/2010,01/08/2009,,01/02/2009,Toxicity at 21 and 28 days post-transplant|T-cell responses against the hTERT vaccine as measured by tetramer assays at 100 days post-transplant|Paraprotein levels in the blood or urine and serum free light chain analyses at 60 days and at 6 months post-transplant|Cytotoxic T-cell responses against autologous myeloma cell at day 100 post-transplant via chromium-51 release or flow-based assays|Maximum clinical response|1 and 2-year event-free survival|Overall survival rates|CD4 and CD8 T-cell responses against cytomegalovirus (CMV) at days 60 and 100 post-transplantation by CFSE dye dilution assays|Composite binding antibody responses at days 60 and day 100 post-transplant by ELISA,http://ClinicalTrials.gov/show/NCT00499577,United States,0,NA,4,NA
NCT00499889,"Imatinib Mesylate, Busulfan, Fludarabine, and ATG for CML Patients",Completed,No Results Available,Leukemia,Drug: Imatinib Mesylate|Drug: Fludarabine|Drug: Busulfan|Drug: ATG,M.D. Anderson Cancer Center|National Cancer Institute (NCI),Both,Child|Adult|Senior,Phase II,42,Other|NIH,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ID02-901,07/10/2007,01/02/2003,01/11/2009,7/26/2010,01/07/2010,,01/11/2009,Number of Patients with Molecular Complete Remission at 1 year,http://ClinicalTrials.gov/show/NCT00499889,United States,1,1,4,1
NCT00500266,Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects,Completed,No Results Available,Pneumococcal Infections,Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC),Wyeth,Both,Senior,Phase III,1053,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,6115A1-3000,07/09/2007,01/05/2008,01/05/2009,03/02/2010,01/06/2009,,01/04/2009,Safety,http://ClinicalTrials.gov/show/NCT00500266,"United States, &nbsp; Germany, &nbsp; Sweden",0,NA,1,NA
NCT00500318,A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe COPD,Completed,No Results Available,"Pulmonary Disease, Chronic Obstructive",Drug: Aclidinium Bromide,"Forest Laboratories|Laboratorios Almirall, SA",Both,Adult|Senior,Phase III,NA,Industry|Other,Interventional,Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double-Blind,LAS-MD-CL26,07/10/2007,01/07/2007,NA,3/30/2009,01/03/2009,,01/03/2009,"Endurance time (ET) at 75% Wmax|Trough Forced Expiratory Volume in 1 second (FEV1), Inspiratory Capacity (IC), Functional Residual Capacity (FRC), IC/Total Lung Capacity (TLC) ratio, Safety",http://ClinicalTrials.gov/show/NCT00500318,United States,1,0,1,NA
NCT00500578,Intermittent Use of Aerosolized Ribavirin for Treatment of RSV,Completed,Has Results,Hematological Malignancies,Drug: Ribavirin|Drug: Ribavirin,M.D. Anderson Cancer Center|ICN Pharmaceuticals,Both,Child|Adult|Senior,Phase IV,51,Other|Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ID03-0010,07/10/2007,01/02/2003,01/01/2009,10/18/2010,01/10/2010,,01/01/2009,Occurrences of Pneumonia,http://ClinicalTrials.gov/show/NCT00500578,United States,1,1,2,1
NCT00501293,Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Methylphenidate Transdermal System,Shire Pharmaceutical Development,Both,Child,Phase III,163,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SPD485-410,07/12/2007,01/08/2007,01/02/2009,01/03/2011,01/01/2011,,01/02/2009,Systolic Blood Pressure|Diastolic Blood Pressure|Pulse Rate|Electrocardiogram Results (QTcF Interval)|Post Sleep Questionnaire (PSQ) Quality of Sleep|Weight|Dermal Reactions|Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Scores at 6 Months|Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) at 6 Months|Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores|Number of Participants With Improvement on Parent Global Assessment (PGA) Scores.|Change From Baseline in Youth Quality of Life-research Version (YQOL-R) Total Score at 6 Months,http://ClinicalTrials.gov/show/NCT00501293,United States,1,1,1,1
NCT00501540,Lithium for Low-Grade Neuroendocrine Tumors,Completed,No Results Available,Neuroendocrine Tumors,Drug: Lithium Carbonate,"University of Wisconsin, Madison|National Institutes of Health (NIH)",Both,Adult|Senior,Phase II,15,Other|NIH,Interventional,Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CO07203|R21CA117117-01A2,7/13/2007,01/07/2007,01/06/2009,10/15/2010,01/10/2010,,01/06/2009,tumor response rate of patients with low-grade neuroendocrine tumors treated with lithium,http://ClinicalTrials.gov/show/NCT00501540,United States,1,1,1,0
NCT00501592,Study of INT-747 in Patients With Diabetes and Presumed NAFLD,Completed,No Results Available,"Diabetes Mellitus, Type II|Fatty Liver",Drug: INT-747,Intercept Pharmaceuticals,Both,Adult|Senior,Phase II,45,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",747-203,7/13/2007,01/07/2007,01/04/2009,04/07/2009,01/04/2009,,01/02/2009,The primary objective of assessing changes in insulin resistance and glucose homeostasis will be attained by performing a euglycemic clamp procedure at baseline (Day 0) and at the end of 6 weeks of treatment (Day 43).,http://ClinicalTrials.gov/show/NCT00501592,United States,1,0,1,NA
NCT00501644,Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer,Completed,Has Results,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cavity Cancer,Drug: Carboplatin|Drug: GM-CSF (Sargramostim)|Drug: Interferon Gamma,"M.D. Anderson Cancer Center|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Bristol-Myers Squibb|InterMune",Female,Child|Adult|Senior,Phase II,59,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ID02-231,07/12/2007,01/01/2003,01/01/2009,12/23/2010,01/12/2010,,01/01/2009,Number of Patients With Response,http://ClinicalTrials.gov/show/NCT00501644,United States,1,1,3,0
NCT00502216,Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers,Completed,Has Results,Smoking|Nicotine Dependence,Drug: Naltrexone|Drug: Varenicline,Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institute on Drug Abuse (NIDA),Both,Adult|Senior,Phase I|Phase II,40,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",NIAAA_TOL-AA15632|P50AA015632|NIH Grant P50-AA15632|NIH Grant K12-DA00167,7/13/2007,01/07/2007,01/06/2009,8/30/2010,01/08/2010,,01/06/2009,Weight Gain in Treatment Completers|Weight Gain in Participants Who Are Continuously Abstinent for the Last 4 Weeks of Treatment|Tolerability of the Combination of 25 mg Naltrexone and 2 mg Varenicline,http://ClinicalTrials.gov/show/NCT00502216,United States,1,1,2,0
NCT00502515,Dose-effect of SSR180575 in Diabetic Neuropathy,Completed,No Results Available,Diabetic Neuropathies,Drug: SSR180575|Drug: Placebo,Sanofi-Aventis,Both,Adult,Phase II,309,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PDY5807,7/16/2007,01/07/2007,01/02/2009,1/19/2010,01/01/2010,,01/02/2009,"Rate of epidermal nerve fiber regeneration|Efficacy: change between baseline and 24 weeks of peripheral neuropathy assessed with nerve conduction studies, clinical evaluation, Total Neuropathy Score|Safety: physical examination, clinical laboratories, adverse event reporting",http://ClinicalTrials.gov/show/NCT00502515,United States,1,0,2,NA
NCT00503685,Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Patients With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFr Therapy,Completed,No Results Available,Colorectal Cancer,Biological: IMC-A12|Biological: cetuximab,ImClone LLC,Both,Adult|Senior,Phase II,65,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,13936|CP02-0657|CP13-0605,7/17/2007,01/06/2007,01/12/2009,10/12/2010,01/10/2010,,01/02/2009,"Objective response rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)|Duration of stable disease (SD)|Duration of Overall response|Summary Listing of Participants Reporting Treatment-Emergent Adverse Events (AEs)|Summary Listing of Participants Reporting Treatment-Emergent Severe Adverse Events (SAEs)|Maximum concentration (Cmax)|Minimum concentration (Cmin)|Area under Serum Concentration (AUC)|Potential associations between KRAS mutations and response rate (cetuximab)|Evaluate tumors for expression of Type I IGF receptors (IGF-IR), IGF binding proteins (IGFBP2, IGFBP3), and related signaling molecules, and potential association|Evaluate tumors for expression of Type I IGF receptors (IGF-IR), IGF binding proteins (IGFBP2, IGFBP3), and related signaling molecules, and assess potential association",http://ClinicalTrials.gov/show/NCT00503685,United States,0,NA,2,NA
NCT00504140,Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma,Completed,No Results Available,Osteosarcoma,Drug: Etoposide|Drug: Interferon Alpha,M.D. Anderson Cancer Center|Schering-Plough,Both,Child|Adult|Senior,Phase II,30,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,P96-221,7/17/2007,01/11/1996,01/03/2009,8/18/2009,01/08/2009,,01/03/2009,Efficacy of combining IFN with etoposide for the treatment of relapsed osteosarcoma.,http://ClinicalTrials.gov/show/NCT00504140,United States,1,1,2,0
NCT00504166,Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women,Completed,No Results Available,Osteopenia|Osteoporosis,Drug: alendronate,"University of California, San Francisco|Merck",Female,Adult,Phase IV,44,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",M250,7/17/2007,01/02/2006,01/04/2009,4/16/2009,01/01/2007,,01/03/2009,"Mean percent change from baseline in apparent trabecular number at the distal radius at 24 months of treatment with alendronate, 70 mg once a week as compared to placebo.",http://ClinicalTrials.gov/show/NCT00504166,United States,1,1,1,1
NCT00505076,Treatment Study for Cognitive Deficits in Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: MK-0777|Drug: MK-0777|Drug: placebo,"University of California, Los Angeles|University of Maryland|Washington University School of Medicine|Massachusetts General Hospital|Nathan Kline Institute for Psychiatric Research|Columbia University|Duke University|Beth Israel Deaconess Medical Center",Both,Adult,Phase II,90,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",TURNS02|HHSN 278200441003C,7/19/2007,01/07/2007,01/09/2009,1/13/2010,01/01/2010,TURNS,01/09/2009,Primary: MCCB: MATRICS Consensus Cognitive Battery|Secondary: UPSA: UCSD Performance-Based Skills Assessment; SCoRS: Schizophrenia Cognition Rating Scale,http://ClinicalTrials.gov/show/NCT00505076,United States,1,0,3,NA
NCT00505765,A Multicenter Study of NAP (AL-108) in Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: AL-108|Drug: AL-108|Drug: placebo|Drug: placebo,"University of California, Los Angeles|University of Maryland|Washington University School of Medicine|Massachusetts General Hospital|Nathan Kline Institute for Psychiatric Research|Columbia University|Duke University|Beth Israel Deaconess Medical Center",Both,Adult,Phase II,60,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",TURNS03|HHSN 278200441003C,7/20/2007,01/07/2007,01/04/2009,1/13/2010,01/01/2010,AL-108,01/04/2009,Primary: MCCB: MATRICS Consensus Cognitive Battery|Secondary: UPSA: UCSD Performance-Based Skills Assessment; SCoRS: Schizophrenia Cognition Rating Scale,http://ClinicalTrials.gov/show/NCT00505765,United States,1,0,4,NA
NCT00505921,Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma,Completed,No Results Available,Lymphoma,Drug: Campath-1H,M.D. Anderson Cancer Center|Bayer,Both,Child|Adult|Senior,Phase II,28,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ID02-645,7/20/2007,01/03/2003,01/11/2009,7/26/2010,01/07/2010,,01/11/2009,Full disease staging,http://ClinicalTrials.gov/show/NCT00505921,United States,1,1,1,1
NCT00506441,"A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia",Completed,No Results Available,Chronic Kidney Disease|Dialysis|Hyperphosphatemia,"Drug: MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE?ó)|Drug: Placebo",Mitsubishi Tanabe Pharma Corporation,Both,Adult|Senior,Phase III,245,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCI-196-A05,7/24/2007,01/09/2007,01/09/2009,6/27/2010,01/06/2010,,01/09/2009,The change in serum phosphorus levels for MCI-196 and placebo|Change from baseline in serum phosphorus|Change from baseline in PTH|Change from baseline in Calcium|Change from baseline in Calcium x phosphorus ion product|Change from baseline in Total cholesterol|Change from baseline in LDL cholesterol|Change from baseline in HDL cholesterol|Change from baseline in VLDL cholesterol|Change from baseline in Triglyceride|Incidence of adverse events,http://ClinicalTrials.gov/show/NCT00506441,"United States, &nbsp; Puerto Rico",1,0,2,NA
NCT00506792,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis",Completed,No Results Available,Cystic Fibrosis,Drug: QAU145|Drug: Placebo,Novartis,Both,Adult,Phase II,9,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CQAU145A2201,7/22/2007,01/07/2007,NA,4/30/2009,01/04/2009,,01/04/2009,"Pharmacodynamic response to single intranasal doses of QAU145 in cystic fibrosis patients using nasal potential difference measurements up to 6 hours post-dose.|Safety and tolerability of single ascending doses assessed by nasal examinations, adverse events, medications, and a nasal symptom questionnaire. Pharmacokinetics up to 6 hours post-dose",http://ClinicalTrials.gov/show/NCT00506792,United States,1,0,2,NA
NCT00506922,Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT,Completed,No Results Available,Leukemia|Lymphoma,Drug: Pentostatin|Drug: Tacrolimus|Drug: Methotrexate,M.D. Anderson Cancer Center|SuperGen,Both,Child|Adult|Senior,Phase I|Phase II,150,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ID00-132,7/20/2007,01/09/2000,01/11/2009,4/26/2010,01/04/2010,,01/11/2009,Number of Patients without GVHD at 100 days,http://ClinicalTrials.gov/show/NCT00506922,United States,1,1,3,0
NCT00510224,Sandostatin for Patients With Androgen Independent Prostate Cancer,Completed,No Results Available,Prostate Cancer,Drug: Sandostatin,"University of California, San Francisco|Novartis",Male,Child|Adult|Senior,Phase II,27,Other|Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UCSF055514,7/30/2007,01/07/2007,01/08/2009,09/03/2009,01/09/2009,,01/08/2009,To evaluate changes in prostate specific antigen (PSA) in patients with androgen independent prostate cancer who are treated with Sandostatin LAR.|To evaluate the effects of Sandostatin LAR on circulating levels of IGF-1 and IGF-Binding Protein 1. To evaluate the safety of Sandostatin. To evaluate the pre versus post treatment mitogenic effects.,http://ClinicalTrials.gov/show/NCT00510224,United States,1,1,1,1
NCT00510276,Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Atomoxetine hydrochloride|Drug: Placebo,Eli Lilly and Company,Both,Adult,Phase IV,445,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10803|B4Z-US-LYDZ,7/30/2007,01/08/2007,01/02/2009,04/07/2010,01/04/2010,,01/02/2009,Mean Change in the Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptom Score From Baseline to 12 Week Endpoint|Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Total Score|Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Relationship Subscale|Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Life Productivity Subscale|Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Psychological Health Subscale|Mean Change From Baseline to 12-Week Endpoint on the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life-29 (AAQOL-29) Life Outlook Subscale|Mean Change From Baseline to 12 Week Endpoint in Clinical Global Impression-ADHD- Severity (CGI-ADHD-S)|Mean Change From Baseline to 12 Week Endpoint in CAARS Self Report (CAARS-S:SV) Total Score|Endpoint Scores in Patient Global Impression - Improvement (PGI-I)|Mean Change From Baseline to 12 Week Endpoint on the Montgomery Asberg Depression Rating Scale (MADRS)|Mean Change From Baseline to 12 Week Endpoint on the Beck Anxiety Inventory (BAI)|Correlation of Mean Changes From Baseline to 12 Week on the Adult ADHD Quality of Life-29 Total Score and of Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated:Screening Version Total Score|Mean Change From Baseline to 12 Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Alcohol|Mean Change From Baseline to 12-Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Caffeine|Mean Change From Baseline to 12-Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Drugs|Mean Change From Baseline to 12-Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Nicotine|Mean Change From Baseline to 12 Week Endpoint on the Habits Timeline Followback (TLFB) Incidence for Use of Marijuana|Mean Change From Baseline to 12 Week Endpoint on the Fagerstrom Test for Nicotine Dependence (FTND)|Mean Change From Baseline to 12 Week Endpoint on the Social Adaptation Self-Evaluation Scale (SASS)|Mean Change From Baseline to 12-Week Endpoint on the Driving Behavior Survey Self-Report|Mean Change From Baseline to 12-Week Endpoint on the Driving Behavior Survey-Other Report|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Behavioral Regulation Section Score|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Emotional Control Section Score|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - GEC Section Score|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Inconsistency Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Infrequency Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Inhibit Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Initiate Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Metacognition Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Negativity Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Organization of Materials Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Plan/Organize Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - SHIFT Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Self Monitor Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Task Monitor Section|Mean Change From Baseline to 12-Week Endpoint on the Behavior Rating Inventory of Executive Function-Adult Version Self Report (BRIEF-A) - Working Memory Section|Mean Change From Baseline to 12-Week Endpoint on the Epworth Sleepiness Scale (ESS)|Responders by Baseline Smoking Status|Strong Responders by Baseline Smoking Status,http://ClinicalTrials.gov/show/NCT00510276,"United States, &nbsp; Puerto Rico",1,1,2,1
NCT00511706,Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-VEGF Treatment in Patients With Age-Related Macular Degeneration,Completed,No Results Available,Choroidal Neovascularization|Age-Related Maculopathy,Drug: Dexamethasone and ranibizumab|Other: Sham injection and ranibizumab,Allergan,Both,Adult|Senior,Phase II,243,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment",206207-016,08/02/2007,01/11/2007,01/03/2009,4/15/2010,01/04/2010,,01/03/2009,Time to retreat with ranibizumab|Visual Acuity|Central Retinal Thickness (OCT)|Lesion size (FA)|Quality of Life questionnaires,http://ClinicalTrials.gov/show/NCT00511706,"United States, &nbsp; Australia, &nbsp; Israel",1,1,2,0
NCT00511836,"ALK21-018: Effects of Medisorb?ó Naltrexone (VIVITROL?ó) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults",Completed,Has Results,Alcohol Dependence,Drug: VIVITROL 380 mg|Drug: Placebo,Alkermes,Both,Adult,Phase IV,31,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALK21-018,08/02/2007,01/07/2007,01/10/2009,12/09/2010,01/12/2010,,01/06/2009,Change From Baseline in Blood Oxygen-level-dependent (BOLD) Signal Activation Values Detected in the Reward Circuitry of the Brain in Alcohol-dependent Subjects After Presentation of Alcohol-related Cues.|Change From Baseline in BOLD Signal Activation Values for the Inferior Frontal Gyrus|Change From Baseline in BOLD Signal Activation Values in the Reward Circuitry|Change From Baseline in Obsessive-Compulsive Drinking Scale (OCDS) Score in Alcohol-dependent Subjects|Change From Baseline in Daily Craving Score in Alcohol-dependent Subjects (Actiwatch Data),http://ClinicalTrials.gov/show/NCT00511836,United States,1,1,2,1
NCT00512083,Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia,Completed,No Results Available,"Leukemia, Myeloid",Drug: AS1411,Antisoma Research,Both,Adult|Senior,Phase II,70,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AS1411-C-201,08/06/2007,01/07/2007,NA,9/24/2009,01/09/2009,,01/04/2009,The prorportion of patients achieving a completel response (CR) after the first cycle of treatment in each treatment group,http://ClinicalTrials.gov/show/NCT00512083,"United States, &nbsp; New Zealand",1,0,1,NA
NCT00512135,Safety and Efficacy of NT 201 in the Treatment of Glabellar Frown Lines,Completed,No Results Available,Glabellar Lines,"Drug: Injection of: NT 201, a Botulinum neurotoxin type A, free of complexing proteins",Merz Pharmaceuticals GmbH,Both,Adult|Senior,Phase III,796,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MRZ 60201-0609/1,08/06/2007,01/06/2007,NA,1/21/2010,01/01/2010,,01/12/2009,- Safety endpoints - Investigator's assessment - Patient's assessment,http://ClinicalTrials.gov/show/NCT00512135,"United States, &nbsp; Canada, &nbsp; Germany",1,1,1,1
NCT00513019,Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation,Completed,No Results Available,Neurotic Excoriation|Pathologic Skin Picking|Psychogenic Excoriation|Dermatillomania,Drug: Lamictal (lamotrigine)|Drug: Placebo,University of Minnesota - Clinical and Translational Science Institute,Both,Adult,Phase II,35,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",0703M03384,08/07/2007,01/08/2007,01/09/2009,3/23/2010,01/03/2010,,01/08/2009,The Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS) will be the primary outcome measure,http://ClinicalTrials.gov/show/NCT00513019,United States,1,1,2,1
NCT00513214,Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus,Completed,No Results Available,Type 2 Diabetes,Drug: XOMA 052|Drug: Placebo,XOMA (US) LLC,Both,Adult|Senior,Phase I|Phase II,72,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",X052073,08/07/2007,01/07/2007,01/02/2010,03/12/2010,01/03/2010,,01/06/2009,"Safety assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and treatment-emergent adverse events.|Pharmacokinetic assessments from serum samples collected at time points specified in the protocol.|Assessment of inflammatory markers CRP and ESR collected at time points specified in the protocol.|Glucose Control assessed by the collection of HbA1c, fructosamine, and fasting plasma glucose (FPG) at time points specified in the protocol.",http://ClinicalTrials.gov/show/NCT00513214,United States,1,0,2,NA
NCT00513305,"Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide, Compared With Low-Dose Cytarabine Alone, for the Treatment of Elderly Patients With Acute Myeloid Leukemia",Completed,No Results Available,Acute Myeloid Leukemia,Drug: Arsenic Trioxide and Low-Dose Cytarabine|Drug: low-dose cytarabine (LDAC) plus arsenic trioxide,Cephalon,Both,Adult|Senior,Phase III,67,Industry,Interventional,Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,C18477/3059/AM/US-CA,08/06/2007,01/10/2007,01/12/2009,4/23/2010,01/04/2010,,01/07/2009,The primary objective is to determine whether low dose cytarabine (LDAC) in combination with arsenic trioxide is more effective than low dose cytarabine alone in achieving complete remission (CR) in elderly patients.|Evaluate the safety of treatment with LDAC in combination with arsenic trioxide,http://ClinicalTrials.gov/show/NCT00513305,"United States, &nbsp; Canada",1,1,2,0
NCT00514371,A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma,Completed,No Results Available,Multiple Myeloma,Drug: tanespimycin and bortezomib,Bristol-Myers Squibb,Both,Adult|Senior,Phase II|Phase III,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CA200-003|KAG-302,08/08/2007,01/08/2007,01/02/2009,9/15/2010,01/11/2009,TIME-2,01/02/2009,Objective Response Rate|Response rate between treatment arms and time-to-event endpoints.,http://ClinicalTrials.gov/show/NCT00514371,United States,1,0,1,NA
NCT00515086,Study of Everolimus in Patients With Recurrent Glioblastoma Multiforme,Completed,No Results Available,Glioblastoma Multiforme,Drug: everolimus,Novartis Pharmaceuticals,Both,Adult|Senior,Phase II,41,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CRAD001C2410,08/10/2007,01/10/2006,NA,6/21/2010,01/06/2010,,01/12/2009,Arm 1: To explore the biological effectiveness of 2 doses of RAD001 measured by inhibition of S6 phosphokinase in GBM tumor cells.|Arm 2: To determine the efficacy of RAD001 in patients with recurrent GBM as measured by the objective response rate.|Arm 1: To determine blood and brain tissue levels of RAD001|Arm 1: To measure time to progression after salvage surgery while receiving treatment with a fixed dose of daily RAD001|Arm 1: To define the safety profile of daily RAD001 administration in patients with recurrent GBM.|Arm 2: To correlate response with biomarkers for the PTEN and EGFR pathways|Arm 2: To determine the progression free survival at 3 months post-treatment in patients with recurrent GBM receiving RAD001.,http://ClinicalTrials.gov/show/NCT00515086,United States,1,1,1,1
NCT00515177,Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study,Completed,No Results Available,Chronic Insomnia|Primary Insomnia,Behavioral: Mindfulness-Based Stress Reduction|Drug: eszopiclone,"University of Minnesota - Clinical and Translational Science Institute|Hennepin County Medical Center, Minneapolis",Both,Adult,Phase II|Phase III,40,Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,0705M09301,08/10/2007,01/08/2007,01/06/2009,11/01/2010,01/11/2010,MVP#1,01/06/2009,Pittsburgh Sleep Quality Index (PSQI)|Insomnia Severity Index|Actigraphy|State-Trait Anxiety Inventory (STAI)|Center for Epidemiological Studies Depression Scale (CES-D)|Medical Outcome Study Short Form (SF-12),http://ClinicalTrials.gov/show/NCT00515177,United States,1,1,2,1
NCT00515320,Study of Fluoxetine in Autism,Completed,No Results Available,Autistic Disorder,Drug: Fluoxetine|Drug: Placebo,Neuropharm|Autism Speaks,Both,Child,Phase III,158,Industry|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NPL-2008-4-AUTUS-004,08/10/2007,01/08/2007,01/01/2009,2/23/2009,01/02/2009,SOFIA,01/01/2009,"The percentage change from baseline to the endpoint visit for the CYBOCS-PDD score.|The time and dose related course of therapeutic effects|The inter-relationship between these effects in the context of global clinical changes.|The indirect effects on patient caregivers of the dose regime in these subjects compared to placebo during treatment.|Safety measures will be physical examination, vital signs, EKG/ECG & clinical laboratory tests.",http://ClinicalTrials.gov/show/NCT00515320,United States,1,1,2,1
NCT00515788,DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis,Completed,No Results Available,Neoplastic Meningitis,Drug: DepoCyt|Drug: Temozolomide,"M.D. Anderson Cancer Center|Enzon Pharmaceuticals, Inc.|Schering-Plough",Both,Adult|Senior,Phase I|Phase II,11,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2005-0135,8/13/2007,01/02/2006,01/06/2009,6/30/2009,01/06/2009,,01/06/2009,Maximum Tolerated Dose,http://ClinicalTrials.gov/show/NCT00515788,United States,1,1,2,1
NCT00517933,Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis,Completed,No Results Available,"Pulmonary Fibrosis|Hypertension, Pulmonary",Drug: Sildenafil Citrate|Other: Placebo,"National Heart, Lung, and Blood Institute (NHLBI)|Pfizer",Both,Adult|Senior,Phase III,180,NIH|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",507|5 U10 HL080413-01,8/15/2007,01/08/2007,01/10/2009,2/19/2010,01/02/2010,STEP-IPF,01/05/2009,"Change in 6-minute walk distance (defined as greater than or equal to 20% improvement or less than 20% improvement)|Change in dyspnea|Change in oxygen desaturation measures (time, distance, recovery time) during 6-minute walk test|Change in forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO)|Change in quality of life|Change in 6-minute walk distance",http://ClinicalTrials.gov/show/NCT00517933,United States,1,1,2,1
NCT00518089,A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis,Completed,No Results Available,Bacterial Conjunctivitis,Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops,Allergan,Both,Child|Adult|Senior,Phase III,859,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",198782-005,8/16/2007,01/02/2008,01/01/2009,11/30/2009,01/11/2009,,01/01/2009,Proportion of patients with clearing of conjunctival hyperemia and conjunctival discharge|Microbiological cure|Clinical improvement of ocular signs|Clinical improvement of ocular symptoms,http://ClinicalTrials.gov/show/NCT00518089,"United States, &nbsp; India",1,1,2,0
NCT00518713,Clobazam in Patients With Lennox-Gastaut Syndrome,Completed,No Results Available,"Epilepsy|Epilepsy, Generalized|Seizures",Drug: Clobazam|Drug: Clobazam|Drug: Clobazam|Drug: Placebo,Lundbeck Inc.,Both,Child|Adult,Phase III,238,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",13110A|OV1012,8/20/2007,01/08/2007,01/04/2010,5/27/2010,01/05/2010,,01/12/2009,"Percent reduction in number of drop seizures (average per week) from the 4-week baseline period compared to the 12-week maintenance period.|Percent reduction in number of drop seizures (average per week) from the 4-week baseline period compared to the first 8 weeks of the maintenance period.|Percent reduction in number of drop seizures (average per week) from the 4-week baseline period compared to the first 4 weeks of the 12-week maintenance period.|Percent reduction in number of drop seizures (average per week) from the 4-week baseline period compared to the middle 4 weeks of the 12-week maintenance period.|Percent reduction in number of drop seizures (average per week) from the 4-week baseline period compared to the last 4 weeks of the 12-week maintenance period.|Percent of patients considered treatment responders defined as those with a >=25%, >=50%, >=75%, 100% reduction in drop seizures (average per week) from the 4-week baseline period compared to the 12-week maintenance period.|Percent of patients considered treatment responders defined as those with a >=25%, >=50%, >=75%, 100% reduction in drop seizures (average per week) from the 4-week baseline period compared to the first 8 weeks of the maintenance period.|Tolerance will be assessed in study responders who have a mean of >=50% improvement in reduction of drop seizures over any 4-week consecutive period during the first 8 weeks of maintenance treatment compared to mean number of drop seizures at baseline.|Investigator global evaluations of the patient's overall change in symptoms.|Parent/caregiver global evaluations of the patient's overall change in symptoms.",http://ClinicalTrials.gov/show/NCT00518713,"United States, &nbsp; Australia, &nbsp; Belarus, &nbsp; India, &nbsp; Lithuania, &nbsp; Serbia",1,0,4,NA
NCT00518986,Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Comorbid Major Depressive Disorder or Dysthymic Disorder,Completed,No Results Available,Sleep Disorders|Obstructive Sleep Apnea|Major Depressive Disorder|Dysthymic Disorder,Drug: armodafinil|Drug: placebo,Cephalon,Both,Adult,Phase IV,250,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",C10953/4024/ES/US,8/17/2007,01/10/2007,01/03/2009,05/08/2009,01/05/2009,,01/03/2009,MWT mean sleep latency assessed at week 12 (or last postbaseline observation) and CGI-C ratings assessed at week 12 (or last postbaseline observation).|ESS assessed at week 12 (or last postbaseline observation).,http://ClinicalTrials.gov/show/NCT00518986,United States,1,1,2,1
NCT00519818,Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia,Completed,No Results Available,Congenital Adrenal Hyperplasia|21-Hydroxylase Deficiency|Adrenogenital Syndrome,Drug: Chronocort for the treatment of CAH,Diurnal Limited|National Institutes of Health Clinical Center (CC),Both,Child|Adult,Phase I|Phase II,20,Industry|NIH,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,070211|07-CH-0211,8/22/2007,01/08/2007,01/05/2009,10/06/2010,01/10/2010,,01/05/2009,"Chronocort vs. Cortef cortisol concentrations (max, min, AUC).|Changes in adrenal hormone concentrations, changes in fatigue, changes in weight.",http://ClinicalTrials.gov/show/NCT00519818,United States,1,0,1,NA
NCT00520572,"A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)",Completed,Has Results,Rheumatoid Arthritis,Drug: AZD9056|Drug: Etanercept|Drug: Placebo,AstraZeneca,Both,Adult|Senior,Phase II,385,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",D1520C00001,8/22/2007,01/08/2007,01/03/2009,12/02/2010,01/12/2010,,01/03/2009,American College of Rheumatology 20 Response (ACR20) at 6 Months|American College of Rheumatology 50 Response (ACR50) at 6 Months|American College of Rheumatology 70 Response (ACR70) at 6 Months|Disease Activity Score (Based on 28 Joint Count) (DAS28) at 6 Months.|Health Assessment Questionnaire - Disability Index (HAQ-DI) at 6 Months.,http://ClinicalTrials.gov/show/NCT00520572,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Belgium, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; France, &nbsp; Mexico, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Slovakia",1,0,3,NA
NCT00521339,"Phase 2, Open-label Study to Evaluate Apremilast Recalcitrant (Not Responded to Therapy) Plaque-type Psoriasis",Completed,No Results Available,Psoriasis,Drug: apremilast,Celgene Corporation,Both,Adult|Senior,Phase II,31,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CC-10004-PSOR-004,8/24/2007,01/08/2007,01/05/2009,8/24/2010,01/08/2010,,01/04/2009,"To evaluate the safety and tolerability of CC-10004, twice per day (BID) for 84 days in subjects with recalcitrant plaque-type psoriasis.|To evaluate the pharmacodynamic(PD)effects of CC-10004 in plaque-type; characterize PK effects and evaluate clinical efficacy;and determine the effect on quality of life;",http://ClinicalTrials.gov/show/NCT00521339,United States,1,0,1,NA
NCT00522145,Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: XL647,"Symphony Evolution, Inc.",Both,Adult|Senior,Phase II,41,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,XL647-203,8/27/2007,01/05/2007,01/02/2010,2/18/2010,01/02/2010,,01/10/2009,"Determine the best confirmed response rate|Safety and tolerability of XL647 administered daily|Progression-free survival, duration of response, and overall survival|Further characterize the pharmacokinetic (PK) parameters",http://ClinicalTrials.gov/show/NCT00522145,United States,1,0,1,NA
NCT00522275,Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures,Completed,Has Results,Partial Epilepsies,Drug: lacosamide,"UCB, Inc.",Both,Child|Adult|Senior,Phase III,308,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SP756,8/27/2007,01/10/2004,01/10/2009,11/23/2010,01/11/2010,,01/10/2009,Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (Maximum 6 Years)|Number of Subjects Prematurely Discontinuing Due to a Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (Maximum 6 Years)|Number of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (Maximum 6 Years)|Median Percentage Change From Baseline in 28-day Seizure Frequency During the Treatment Period (Maximum 6 Years)|Percentage of at Least 50% Responders During the Treatment Period (Maximum 6 Years),http://ClinicalTrials.gov/show/NCT00522275,United States,1,1,1,1
NCT00522873,Endometrial Safety Study,Completed,No Results Available,Postmenopause,Drug: SH K 04739 B|Drug: SH K 04739 E,"Bayer|Laboratorium f??r Klinische Forschung|Diagnostic Cytology Laboratory|University of California, San Francisco",Female,Adult,Phase III,662,Industry|Other,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",91508|EudraCT No. 2006-006199-39|310523,8/29/2007,01/08/2007,01/08/2009,9/21/2010,01/09/2010,,01/08/2009,The proportion of subjects with an assessment of endometrial hyperplasia or worse during or after one year of treatment.|The incidence of amenorrhea (no bleeding or spotting) during months 1-3 and 10-12 of treatment.,http://ClinicalTrials.gov/show/NCT00522873,"United States, &nbsp; Argentina, &nbsp; Austria, &nbsp; Brazil, &nbsp; Denmark, &nbsp; Italy, &nbsp; Mexico, &nbsp; Russian Federation",1,0,2,NA
NCT00525174,Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children,Completed,No Results Available,Amblyopia,Device: Bangerter filters|Device: Patching|Procedure: Near activities,Jaeb Center for Health Research|National Eye Institute (NEI),Both,Child,Phase III,186,Other|NIH,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NEI-136|2U10EY011751,8/31/2007,01/11/2007,01/01/2009,3/23/2010,01/08/2009,ATS10,01/01/2009,Amblyopic and sound eye visual acuity|Time course of visual improvement with Bangerter filter treatment|Compare patient quality of life between patients treated with patching vs Bangerter filters|Determine in the Bangerter filter group whether the degree of blurring of sound eye visual acuity relative to the amblyopic eye visual acuity predicts improvement in acuity|Determine in the Bangerter filter group whether fixation preference is predictive of improvement in visual acuity,http://ClinicalTrials.gov/show/NCT00525174,United States,0,NA,3,NA
NCT00525421,A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus,Completed,No Results Available,Oral Lichen Planus,Drug: Curcuminoids|Drug: Placebo,"University of California, San Francisco",Both,Adult|Senior,Phase II,26,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H1113-30233-01,09/04/2007,01/09/2007,01/02/2009,03/02/2009,01/02/2009,,01/02/2009,"Change in symptoms of oral lichen planus|Change in clinical signs, occurrence of side-effects, change in serum C-reactive protein and serum interleukin-6 levels",http://ClinicalTrials.gov/show/NCT00525421,United States,1,0,2,NA
NCT00526630,Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease,Completed,No Results Available,Parkinson's Disease|Gait Impairment,Drug: Methylphenidate (MPD)|Drug: Placebo,University of Cincinnati|Michael J. Fox Foundation for Parkinson's Research,Both,Adult|Senior,Phase IV,20,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-06-19-07,09/05/2007,01/12/2007,01/10/2009,10/27/2009,01/10/2009,,01/10/2009,"The primary outcome measures will be the change in the gait composite score between the MPD and Placebo groups, at week 12 after completion of each study arm, immediately before and at the end of the cross-over period.|Secondary outcome measures include changes in gait diary (number of freezing episodes and falls), static posturography, FOGQ (total score), MADRS, EQ-5D, and the ESS between days 1 and 56, that is, at the end of week 12 for each study arm.",http://ClinicalTrials.gov/show/NCT00526630,United States,1,1,2,1
NCT00527904,"A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)",Completed,Has Results,Gastric Ulcer,Drug: PN400 (VIMOVO)|Drug: PN 400 (VIMOVO),POZEN,Both,Adult|Senior,Phase III,239,Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PN400-304,09/10/2007,01/03/2007,01/03/2009,8/27/2010,01/08/2010,,01/03/2009,Number of Subjects Monitored for Long-term Safety of PN 400,http://ClinicalTrials.gov/show/NCT00527904,United States,1,1,2,1
NCT00528372,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,Completed,No Results Available,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin|Drug: Dapagliflozin matching Placebo|Drug: Metformin|Drug: Metformin (as needed for rescue based on protocol specific criteria),Bristol-Myers Squibb|AstraZeneca,Both,Adult|Senior,Phase III,560,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",MB102-013,09/11/2007,01/09/2007,01/07/2010,12/15/2010,01/12/2010,,01/02/2009,"Change from baseline in hemoglobin A1C|Change from baseline in fasting plasma glucose for each dose of dapagliflozin vs placebo|Proportion of subjects achieving a therapeutic glycemic response, defined as AIC < 7.0%|Change from baseline in total body weight|Change from baseline in fasting plasma glucose",http://ClinicalTrials.gov/show/NCT00528372,"United States, &nbsp; Canada, &nbsp; Mexico, &nbsp; Russian Federation",1,0,9,NA
NCT00528411,"A Study of the Onset and Offset of Antiplatelet Effects Comparing AZD6140, Clopidogrel, and Placebo With Aspirin",Completed,No Results Available,Coronary Artery Disease,Drug: AZD6140|Drug: Clopidogrel|Drug: aspirin,AstraZeneca,Both,Adult|Senior,Phase II,112,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D5130C00048,09/10/2007,01/10/2007,01/03/2009,4/17/2009,01/04/2009,,01/03/2009,To determine the onset and offset of antiplatelet effect of AZD6140 compared to clopidogrel by evaluation of the % IPA by LTA and by evaluation of the difference in slope of IPA effect curve by LTA|To evaluate the PK/PD relationship of AZD6140 and its active metabolite; to determine the effect on platelet aggregation of AZD6140 compared to clopidogrel; to assess the overall safety and tolerability of AZD6140 compared to clopidogrel and placebo,http://ClinicalTrials.gov/show/NCT00528411,"United States, &nbsp; United Kingdom",1,0,3,NA
NCT00528970,A Study Evaluating IV MOA-728 for the Treatment of POI In Subjects After Ventral Hernia Repair,Completed,No Results Available,Ileus,Drug: MOA-728|Other: placebo,"Wyeth|Progenics Pharmaceuticals, Inc.",Both,Adult|Senior,Phase III,500,Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double-Blind|Primary Purpose: Treatment,3200L2-301,09/11/2007,01/08/2007,01/02/2009,02/05/2010,01/07/2009,,01/02/2009,Primary: The effect of the interventional treatment will be measured by the time to bowel movement.,http://ClinicalTrials.gov/show/NCT00528970,"United States, &nbsp; Australia, &nbsp; Belgium, &nbsp; Canada, &nbsp; Germany, &nbsp; Hungary, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Netherlands, &nbsp; Poland, &nbsp; South Africa",1,1,2,1
NCT00528996,An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.,Completed,No Results Available,"Pulmonary Disease, Chronic Obstructive",Drug: BEA 2180 BR|Drug: tiotropium,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase II,2080,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,1205.14|2007-007946-42,09/12/2007,01/09/2007,NA,7/16/2010,01/07/2010,,01/05/2009,"The primary endpoint in this study is trough FEV1 response after 24 weeks.|Trough FEV1 response after 1, 2, 4, 8, 12, and 18 weeks",http://ClinicalTrials.gov/show/NCT00528996,"United States, &nbsp; Canada, &nbsp; Germany, &nbsp; Hungary, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Taiwan",1,0,2,NA
NCT00531427,Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee,Completed,Has Results,Chronic Pain|Osteoarthritis of the Knee,Drug: Buprenorphine|Drug: Placebo,Purdue Pharma LP,Both,Adult|Senior,Phase III,567,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",BUP3025,9/17/2007,01/09/2007,01/11/2009,8/24/2010,01/08/2010,,01/04/2009,"\Average Pain Over the Last 24 Hours\"" Score of the Study Knee at Week 12 of the Double Blind Phase.|Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Used From Week 2 to 12 of the Double-blind Phase.|Sleep Disturbance Subscale of the MOS-Sleep Scale at Weeks 4",http://ClinicalTrials.gov/show/NCT00531427,United States,1,1,2,0
NCT00531622,An Eight-Week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder,Completed,No Results Available,Major Depressive Disorder,Drug: saredutant (SR48968)|Drug: escitalopram|Drug: placebo,Sanofi-Aventis,Both,Adult,Phase III,615,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC10290|EudraCT 2007-003159-36,9/18/2007,01/09/2007,01/01/2009,2/13/2009,01/02/2009,,01/01/2009,Change from baseline in Hamilton Depression Rating Scale total score|Change from baseline in the Changes in Sexual Functioning Questionnaire total score|Change from baseline in the Clinical Global Impression severity of illness score,http://ClinicalTrials.gov/show/NCT00531622,"United States, &nbsp; Argentina, &nbsp; Finland, &nbsp; France, &nbsp; Mexico, &nbsp; Sweden",1,0,3,NA
NCT00532233,Clinical Study With QAX576 in Patients With Idiopathic Pulmonary Fibrosis,Completed,No Results Available,Idiopathic Pulmonary Fibrosis,Drug: QAX576,Novartis,Both,Adult|Senior,Phase II,31,Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,CQAX576A2202,9/19/2007,01/10/2007,NA,8/27/2010,01/08/2010,,01/06/2009,-To investigate the possibility that some IPF patients experience increased IL-13 production. Blood samples to be collected pre-dose and weekly after dosing. -To investigate the hypothesis that QAX576 will neutralize IL-13 in patients with IPF|-To evaluat,http://ClinicalTrials.gov/show/NCT00532233,United States,1,0,1,NA
NCT00532779,A Study of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Obese Subjects,Completed,No Results Available,Obesity,Drug: naltrexone SR/bupropion SR,"Orexigen Therapeutics, Inc",Both,Adult,Phase III,1650,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NB-301,9/19/2007,01/09/2007,01/05/2009,02/04/2010,01/02/2010,,01/05/2009,"Co-primary outcome measures are the percentage of total body weight lost and the percentage of subjects who achieve a weight decrease of ??­ 5%.|Proportion of subjects achieving ??­10% weight loss; Waist circumference; Fasting triglyceride, HDL cholesterol, insulin and glucose",http://ClinicalTrials.gov/show/NCT00532779,United States,1,1,1,0
NCT00533429,Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Patients With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy,Completed,No Results Available,Non-small Cell Lung Cancer,Drug: enzastaurin|Drug: pemetrexed|Drug: carboplatin|Drug: bevacizumab|Drug: Placebo,Eli Lilly and Company|Genentech,Both,Adult|Senior,Phase II,40,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",11398|H6Q-MC-S034,9/19/2007,01/10/2007,01/02/2009,2/16/2010,01/02/2010,,01/02/2009,Progression-free survival|Response rate|Overall survival|Time to progressive disease|Duration of response|Pharmacology toxicity,http://ClinicalTrials.gov/show/NCT00533429,United States,1,0,5,NA
NCT00536120,The Effects of TYSABRI Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis,Completed,No Results Available,Multiple Sclerosis,Biological: TYSABRI (natalizumab),Biogen Idec,Both,Adult,Phase IV,60,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label,101MS404,9/25/2007,01/01/2008,01/01/2010,01/06/2011,01/01/2011,,01/10/2009,Difference proportion of tetanus responders at Day 28|Difference in proportion of KLH responders at Day 28|Change from baseline Lymphocyte Subset at Month 3|Change from baseline Lymphocyte subset at Month 6,http://ClinicalTrials.gov/show/NCT00536120,United States,0,NA,1,1
NCT00537303,Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: insulin detemir|Drug: insulin aspart|Drug: insulin aspart,Novo Nordisk,Both,Adult|Senior,Phase IV,296,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NN304-1833|2007-000123-18,9/28/2007,01/10/2007,01/03/2009,10/14/2010,01/10/2010,,01/03/2009,Glycosylated Haemoglobin A1c (HbA1c)|Glycosylated Haemoglobin A1c (HbA1c)|Hypoglycaemic Episodes|Biochemistry: Serum Alanine Aminotransferase|Haematology: Haemoglobin Measured in Blood|Cardiovascular Risk Marker: High-sensitivity C-reactive Peptide,http://ClinicalTrials.gov/show/NCT00537303,"United States, &nbsp; Denmark, &nbsp; Finland, &nbsp; Former Serbia and Montenegro, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Russian Federation, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",1,1,3,0
NCT00537680,"Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia",Completed,No Results Available,Friedreich's Ataxia,Drug: Idebenone|Drug: Idebenone|Drug: Placebo,Santhera Pharmaceuticals,Both,Child,Phase III,70,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SNT-III-002,09/07/2007,01/12/2007,01/04/2009,5/28/2009,01/05/2009,IONIA,01/04/2009,ICARS|FARS|ADL of FARS|FACT,http://ClinicalTrials.gov/show/NCT00537680,United States,1,0,3,NA
NCT00537745,Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders,Completed,No Results Available,Alcohol Consumption,Drug: Vivitrol (Medication Therapy)|Other: Individual Compliance Enhancement (Medication Management Therapy),Pacific Institute for Research and Evaluation|Cephalon,Both,Adult|Senior,Phase IV,14,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,C18816/6075/DP/US|0328.01.01,9/28/2007,01/04/2007,01/05/2009,05/06/2009,01/05/2009,,01/05/2009,Evidence of attempts to drive after drinking,http://ClinicalTrials.gov/show/NCT00537745,United States,1,1,2,1
NCT00538291,Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment,Completed,No Results Available,Colorectal Cancer,Biological: cetuximab|Drug: capecitabine|Genetic: gene expression analysis|Genetic: microarray analysis|Genetic: polymorphism analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: immunohistochemistry staining method,City of Hope Medical Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,13,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000567432|P30CA033572|CHNMC-05033,10/01/2007,01/08/2005,NA,12/22/2009,01/12/2009,,01/02/2009,Response rate|Overall survival|Progression-free survival|Duration of overall survival (median and 1-year rate)|Progression-free survival (median)|Safety|Tolerance to therapy,http://ClinicalTrials.gov/show/NCT00538291,United States,1,1,7,1
NCT00538434,Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years,Completed,No Results Available,Eosinophilic Esophagitis,Biological: Reslizumab|Other: Saline,Ception Therapeutics,Both,Child|Adult,Phase II|Phase III,226,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Res-05-0002,10/01/2007,01/02/2008,01/10/2009,02/02/2010,01/01/2010,,01/10/2009,esophageal eosinophil counts (co-primary)|EE Global Assessment (co-primary)|EE Predominant Symptom Assessment|Child Health Questionnaire,http://ClinicalTrials.gov/show/NCT00538434,"United States, &nbsp; Canada",0,NA,2,NA
NCT00538980,Dasatinib in Polycythemia Vera,Completed,No Results Available,Polycythemia Vera,Drug: Dasatinib,Weill Medical College of Cornell University|Bristol-Myers Squibb,Both,Adult|Senior,Phase II,24,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA180-104|0701008940,10/02/2007,01/04/2007,NA,10/20/2009,01/10/2009,,01/10/2009,"To evaluate the effect of dasatinib on the platelet count and the stabilization of hematocrit when restored by phlebotomy to normal range (HCT <45% for men, <42% for women).|To determine change in performance status and development of side effects and complications in patients treated under this protocol.|To determine changes in marrow cellularity, reticulin and fibrous content.|To determine change in cytogenetics if initially abnormal.|To determine if quantitative change in JAK2 expression occurs as measured by quantitative pyrosequencing.",http://ClinicalTrials.gov/show/NCT00538980,United States,1,1,1,0
NCT00542425,Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis,Completed,Has Results,Osteoporosis,Drug: teriparatide|Drug: Placebo|Drug: BA058 20 ??g|Drug: BA058 40 ??g|Drug: BA058 80 ??g,Radius Health,Female,Adult|Senior,Phase II,222,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",BA058-05-002,10/10/2007,01/04/2007,01/06/2009,6/30/2010,01/06/2010,,01/06/2009,"Change in Marker of Bone Metabolism, PINP|Change in Bone Mineral Density, Total Spine.|Change in Bone Mineral Density, Femoral Neck.|Change in Bone Mineral Density, Total Hip.|Change in Bone Mineral Density, Total Spine.",http://ClinicalTrials.gov/show/NCT00542425,United States,1,0,5,NA
NCT00543101,Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors,Completed,Has Results,HIV Infections,Drug: Darunavir (DRV/r)|Drug: continue on current dual boosted PI,Community Research Initiative of New England,Both,Adult|Senior,Phase IV,24,Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,07-142,10/11/2007,01/10/2007,01/01/2009,12/06/2010,01/07/2010,DVD,01/01/2009,"The Percentage of Participants With Successful Virologic Suppression|Economic Impact of a Substitution of Dual Boosted PIs With DRV/r|Lipid Fraction Results, Mean of the Change From Baseline to Week 24.|Treatment Satisfaction (+3, Much More Satisfied Now to -3, Much Less Satisfied Now)",http://ClinicalTrials.gov/show/NCT00543101,United States,1,1,2,0
NCT00543270,Powerlink Bifurcated Stent Graft Long-Term Follow-up Study,Completed,No Results Available,Abdominal Aortic Aneurysm,Device: Powerlink infrarenal bifurcated stent graft delivery system|Procedure: Open Surgery,Endologix,Both,Adult|Senior,Phase II|Phase III,231,Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,TP00-005/CP04-001,10/10/2007,01/10/2005,01/11/2009,2/22/2010,01/02/2010,,01/11/2009,"Safety: Major adverse events. Effectiveness: Stent graft patency, aneurysm exclusion, aneurysm related mortality, and all-cause mortality.",http://ClinicalTrials.gov/show/NCT00543270,United States,0,NA,2,NA
NCT00543374,Extended Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease,Completed,No Results Available,Crohn's Disease,Drug: adult human mesenchymal stem cells|Drug: adult human mesenchymal stem cells,Osiris Therapeutics,Both,Adult|Senior,Phase III,200,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Osiris 610,10/11/2007,01/10/2007,01/07/2009,7/23/2010,01/07/2010,,01/07/2009,Duration of clinical benefit|Re-induction of clinical benefit|Improvement in quality of life,http://ClinicalTrials.gov/show/NCT00543374,"United States, &nbsp; Canada",1,0,2,NA
NCT00543400,Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE),Completed,No Results Available,Coronary Artery Disease (CAD)|Percutaneous Coronary Intervention (PCI),Drug: M118|Drug: Unfractionated Heparin,"Momenta Pharmaceuticals, Inc.",Both,Adult|Senior,Phase II,503,Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,MOM-M118-006|M118-006a Substudy,10/11/2007,01/09/2007,01/05/2009,9/30/2009,01/09/2009,EMINENCE,01/04/2009,"Clinical events defined as the composite of 30-day death, MI, repeat revascularization, catheter thrombus, stroke, thrombocytopenia, bailout use of glycoprotein IIb/IIIa inhibitors and bleeding.",http://ClinicalTrials.gov/show/NCT00543400,"United States, &nbsp; Canada",1,0,2,NA
NCT00546078,Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America,Completed,Has Results,Human Papillomavirus (HPV) Infection|Papillomavirus Vaccines,Biological: Cervarix?ºÑ,GlaxoSmithKline,Female,Child|Adult,Phase II,116,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,109628,10/17/2007,01/01/2008,01/11/2009,12/02/2010,01/12/2010,,01/11/2009,"Number of Subjects With Anti-human Papilloma Virus-16 (Anti-HPV-16) and Anti-HPV-18 Antibody Titers Greater Than or Equal to Pre-defined Cut-off Values|Anti-HPV-16 and Anti-HPV-18 Antibody Titers|Number of Subjects With Anti-HPV-16 and Anti-HPV-18 Greater Than or Equal to Pre-defined Cut-off Values|Anti-HPV-16 and Anti-HPV-18 Antibody Titers|Number of Subjects With Antibody Titers Against Other Oncogenic HPV Types (HPV-31 & HPV-45) Greater Than or Equal to 59 EL.U/mL|Anti-HPV-31 and Anti-HPV-45 Antibody Titers|Number of Subjects With Cluster of Differentiation 4 (CD4) T Cell-mediated Immune Responses Specific to Defined Oncogenic HPV Types|Number of Subjects With Cluster of Differentiation 8 (CD8) T Cell-mediated Immune Responses Specific to Defined Oncogenic HPV Types|Number of Subjects With B Cell-mediated Immune Responses Specific to Defined Oncogenic HPV Types|Number of Subjects Seropositive for Anti-HPV-16 and Anti-HPV-18 Antibodies in Cervico-vaginal Secretion Samples|Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Cervico-vaginal Secretion Samples|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Outcome of Any Reported Pregnancies|Number of Subjects With New Onset of Chronic Diseases (NOCDs), New Onset of Autoimmune Diseases (NOADs) and Medically Significant Conditions (MSCs)|Number of Subjects Reporting Serious Adverse Events (SAEs)",http://ClinicalTrials.gov/show/NCT00546078,"United States, &nbsp; Canada",0,NA,1,NA
NCT00546429,DePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial,Completed,Has Results,Femoral Fracture (Proximal),Device: Intramedullary nailing,DePuy Orthopaedics,Both,Adult|Senior,Phase IV,62,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,4077,10/17/2007,01/09/2006,01/09/2009,12/09/2010,01/12/2010,ATN,01/09/2009,Success in Terms of the Merle D'Aubigne Score|Lower Extremity Measure (LEM)|Medical Imaging|Six Item Screener and Ambulatory Status|SF-12|Merle d'Aubigne and Postel,http://ClinicalTrials.gov/show/NCT00546429,United States,0,NA,1,NA
NCT00546585,"Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults",Completed,No Results Available,Influenza,Biological: Influenza A/H7N7 Vaccine|Drug: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),Both,Adult,Phase I|Phase II,126,NIH,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",07-0023|N01AI30039C,10/18/2007,01/03/2008,01/02/2009,1/13/2011,01/01/2010,,01/02/2009,"Adverse event (AE) or serious adverse event (SAE) information (solicited in-clinic and via memory aids, concomitant medications, and periodic targeted physical assessment).|Geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing antibody titers in each group and serum hemagglutination inhibition (HAI) antibody titers in each group.|Proportion of subjects in each dose group achieving a serum neutralizing antibody titer of greater than or equal to 40 against the influenza A/H7N7 virus.",http://ClinicalTrials.gov/show/NCT00546585,United States,0,NA,2,NA
NCT00546637,"Fesoterodine \add-on\"" Male Overactive Bladder Study""",Completed,Has Results,Overactive Bladder Syndrome,Drug: Fesoterodine|Drug: Placebo,Pfizer,Male,Adult|Senior,Phase III,947,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A0221009,10/18/2007,01/11/2007,01/02/2009,10/22/2010,01/10/2010,,01/02/2009,"Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12|Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 4|Percentage Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12|Percentage Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12|Percentage Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12|Percentage Change From Baseline in UUI Episodes Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Severe Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12|Percentage Change From Baseline in Severe Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Nocturnal Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12|Percentage Change From Baseline in Nocturnal Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12|Numerical Change From Baseline in Urinary Sensation Scale (USS) Sum Rating Per 24 Hours at Week 4 and 12|Change From Baseline in International Prostate Symptom Score (IPSS) Total Score (Sum Question 1 [Q1] to Q7) Per 24 Hours at Week 4 and 12|Change From Baseline in IPSS Storage Domain (Sum Q2, Q4, and Q7) Per 24 Hours at Week 4 and 12|Change From Baseline in IPSS Voiding Domain (Sum Q1, Q3, Q5, and Q6) Per 24 Hours at Week 4 and 12|Change From Baseline in IPSS Quality of Life (QoL) Score (Q8) Per 24 Hours at Week 4 and 12|Change From Baseline in IPSS Individual Item Scores (Q1, Q2, Q3, Q4, Q5, Q6, and Q7) Per 24 Hours at Week 4|Change From Baseline in IPSS Individual Item Scores (Q1, Q2,Q3, Q4, Q5, Q6, and Q7) Per 24 Hours at Week 12|Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) Per 24 Hours at Week 4|Number of Participants With Change From Baseline in PPBC Per 24 Hours at Week 12|Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) Per 24 Hours at Week 4|Number of Participants With Change From Baseline in Change From Baseline in UPS Per 24 Hours at Week 12.|Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Per 24 Hours at Week 4 and 12|Change From Baseline in Total Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12|Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Concern Domain)|Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Coping Domain)|Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Sleep Domain)|Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Social Interaction Domain)|Change From Baseline in Post Void Residual (PVR) Urine Volume Per 24 Hours at Week 4, 8 and 12|Change From Baseline in Maximum Urinary Flow Rate (QMAX) Per 24 Hours at Week 12|Number of Participants Reporting Urinary Retention Requiring Catheterization (All Causalities)|Number of Participants Experiencing Adverse Events Related to Increased Voiding Difficulty (All Causalities)",http://ClinicalTrials.gov/show/NCT00546637,"United States, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Colombia, &nbsp; Germany, &nbsp; Greece, &nbsp; India, &nbsp; Korea, Republic of, &nbsp; Malaysia, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Philippines, &nbsp; Poland, &nbsp; Singapore, &nbsp; Slovakia, &nbsp; Spain, &nbsp; Sweden, &nbsp; Thailand",1,1,2,0
NCT00546871,"Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in PID Subjects",Completed,No Results Available,Primary Immunodeficiency (PID),"Drug: Immune Globulin Intravenous (Human), 10%",Baxter Healthcare Corporation,Both,Child|Adult|Senior,Phase II|Phase III,45,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,160601,10/18/2007,01/10/2007,01/09/2009,7/27/2010,01/07/2010,,01/07/2009,"Subjects aged 12 years or older: Bioavailability of IgG after administration of IGIV, 10%, either IV, SC or SC at an adapted dose, as measured by area under the curve IgG concentration versus time curve (AUC) per week.|Subjects aged >2 to <12 years: Bioavailability of IgG after administration of IGIV, 10%, either IV, SC or SC at an adapted dose, as measured by trough levels of IgG.",http://ClinicalTrials.gov/show/NCT00546871,United States,1,0,1,NA
NCT00547534,"Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma",Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: bortezomib|Drug: bendamustine|Drug: rituximab,"University of Rochester|Millennium Pharmaceuticals, Inc.|Cephalon",Both,Adult|Senior,Phase II,30,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ULYM07054,10/18/2007,01/10/2007,01/10/2009,01/08/2010,01/01/2010,,01/06/2009,To determine the progression-free survival following treatment with the BVR combination in patients with relapsed or refractory indolent and mantle cell non-Hodgkin lymphoma.|??Ñ Determine safety and toxicity of BVR combination in patients with relapsed or refractory indolent and mantle cell NHL ??Ñ Determine ORR following BVR combination therapy in patients with relapsed or refractory indolent or mantle cell NHL,http://ClinicalTrials.gov/show/NCT00547534,United States,1,1,3,1
NCT00547976,PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis,Completed,No Results Available,Atherosclerosis|Healthy,Drug: [C-11]PBR28,National Institute of Mental Health (NIMH),Both,Adult|Senior,Phase I|Phase II,5,NIH,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic,080006|08-M-0006,10/20/2007,01/10/2007,01/08/2009,05/11/2010,01/05/2010,,01/08/2009,Binding of [11C]PBR28 at peripheral benzodiazepine receptor|PET [F-18]FDG uptake,http://ClinicalTrials.gov/show/NCT00547976,United States,1,0,1,NA
NCT00548249,Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With ESRD Receiving Chronic Hemodialysis,Completed,No Results Available,End-Stage Renal Disease,Drug: Soluble Ferric Pyrophosphate,"Rockwell Medical Technologies, Inc.",Both,Adult|Senior,Phase II,131,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",RMTI-SFP-2,10/19/2007,01/09/2007,01/01/2010,6/21/2010,01/06/2010,,01/10/2009,"Efficacy of an SFP-containing dialysate solution in maintaining physiological iron levels during chronic HD, as measured by the percent of subjects whose hgb decreases by a total of 1.0 g/dL (or more) from baseline on each of two successive measurements.|Safety of an SFP-containing dialysate solution, measured by AEs, physical examination, vital signs, ECGs, lab measures (complete blood count, coagulation, blood chemistries including liver function tests),Transferrin Saturation,UIBC, and ferritin levels.|Efficacy of SFP as measured by time in days for hgb to decrease by a total of > = 1.0 g/dL from baseline on each of two successive measurements in each treatment group. The mean change from baseline in hgb will also be compared across treatment groups.|Efficacy of SFP administration in dialysate solution as measured by reticulocyte hemoglobin values every four weeks, and at the end of the subject's treatment.|The incidence of infection episodes requiring antibiotic or anti-fungal therapy in each treatment group.|Estimate the amount of SFP transferred from the dialysate to the blood during a dialysis session.|Incidence rate of subjects with a rise in hemoglobin to 12.6 g/dL or more on two separate occasions measured one week apart.",http://ClinicalTrials.gov/show/NCT00548249,"United States, &nbsp; Canada",1,0,1,NA
NCT00548587,Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome,Completed,No Results Available,Acute Coronary Syndrome,Drug: E5555|Drug: E5555|Drug: E5555|Drug: Placebo,Eisai Inc.,Both,Adult|Senior,Phase II,600,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",E5555-G000-202,10/22/2007,01/10/2007,01/08/2009,09/02/2009,01/09/2009,,01/04/2009,Safety and tolerability|Incidence of Major Adverse Cardiovascular Events; Platelet Aggregation Inhibition; Holter Monitoring. Exploratory Outcome Measure: effects on endovascular inflammatory processes,http://ClinicalTrials.gov/show/NCT00548587,"United States, &nbsp; United Kingdom",1,0,4,NA
NCT00548691,Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients,Completed,No Results Available,Anemia,Drug: Ferric Carboxymaltose,Luitpold Pharmaceuticals,Both,Adult|Senior,Phase III,NA,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,1VIT07018,10/22/2007,01/10/2007,01/04/2009,06/05/2009,01/06/2009,,01/04/2009,Safety and Tolerability,http://ClinicalTrials.gov/show/NCT00548691,United States,1,0,1,NA
NCT00548860,Study to Investigate the Safety of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients,Completed,No Results Available,Anemia,Drug: Ferric Carboxymaltose,Luitpold Pharmaceuticals,Female,Child|Adult|Senior,Phase III,NA,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,1VIT07017,10/22/2007,01/10/2007,01/04/2009,06/05/2009,01/06/2009,,01/04/2009,safety and tolerability,http://ClinicalTrials.gov/show/NCT00548860,United States,1,0,1,NA
NCT00549042,Study to Test the Effectiveness of Controlled-Release OROS?ó Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain,Completed,No Results Available,Chronic Low Back Pain,"Drug: Drug: OROS?ó hydromorphone at 4, 8, 16, and 32 mg tablets will be used to provide doses of 12-64mg.",Neuromed Pharmaceuticals,Both,Adult|Senior,Phase III,450,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NMT 1077-301,10/23/2007,01/09/2007,01/01/2009,03/12/2009,01/03/2009,,01/01/2009,"The primary efficacy variable is the mean change from baseline to week 12 (or last visit) average pain intensity of double-blind treatment phase based on the weekly pain intensity scores obtained from patient diary entry, as compared to placebo.|Additional analyses on pain intensity.",http://ClinicalTrials.gov/show/NCT00549042,United States,1,0,1,NA
NCT00549549,Celebrex In Acute Gouty Arthritis Study,Completed,No Results Available,"Arthritis, Gouty",Drug: Indomethacin|Drug: Celecoxib|Drug: Celecoxib|Drug: Celecoxib,Pfizer,Both,Adult|Senior,Phase III,402,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3191219,10/24/2007,01/02/2008,01/12/2009,1/21/2010,01/01/2010,,01/12/2009,"The primary endpoint of the study will be the Change from Baseline to Day 2 (24-hour recall of pain experienced during Day 2 assessed on the morning of Day 3) in the Patient's Assessment of Pain Intensity in the index joint.|Time weighted average change from Baseline in the Patient's Assessment of Pain Intensity over 8 (TWA-8), 12 (TWA-12) and 24 (TWA-24) hours post first dose of study medication on Day 1|Incidence of at least a 30% and 50% reduction from Baseline in the Patient's Assessment of Pain Intensity on Day 2 (24-hour recall of pain experienced during Day 2 assessed on the morning of Day 3)|Change from Baseline to in the Patient's Assessment of Pain Intensity (24-hour recall of pain experienced during prior day as assessed on the next morning for each day), and average change in this measure over Days 2-5 and Days 2-8|Incidence of withdrawal due to lack of efficacy on Day 1 and over Days 1-8|Patient's Global Evaluation of Study Medication score on Day 8 and Day 14|Physician's Assessment of the Index Joint on : change from Baseline to each post-baseline assessment for \tenderness\"" and \""swelling\""",http://ClinicalTrials.gov/show/NCT00549549,"United States, &nbsp; Canada, &nbsp; Colombia, &nbsp; Costa Rica, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Peru, &nbsp; Philippines, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Taiwan, &nbsp; Thailand",1,1,4,0
NCT00549640,Testing Methylphenidate for Smoking Abstinence,Completed,Has Results,Smoking,Drug: Methylphenidate|Drug: Placebo,"Mayo Clinic|Ortho-McNeil Janssen Scientific Affairs, LLC",Both,Adult,Phase II,80,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",06-005407|06-006284,10/24/2007,01/01/2008,01/05/2009,11/29/2010,01/11/2010,,01/01/2009,Number of Subjects Biochemically Confirmed to be Abstinent From Smoking at End of Treatment.|Number of Subjects Biochemically Confirmed to be Abstinent From Smoking at End of Study|The Change in the Average Nicotine Withdrawal Symptom Score From Baseline to 14 Days Post Target Quit Date.,http://ClinicalTrials.gov/show/NCT00549640,United States,1,1,2,0
NCT00549939,Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction,Completed,No Results Available,Neurogenic Urinary Bladder,Drug: Alfuzosin|Drug: Placebo,Sanofi-Aventis,Both,Child,Phase III,172,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC5722|2004-002397-38,10/25/2007,01/10/2007,01/12/2009,12/17/2010,01/12/2010,ALFACHIN,01/03/2009,Number of patients with detrusor Leak Point Pressure (LPP) < 40 cm H2O|Baseline and 12-week detrusor Leak Point Pressure (LPP)|Absolute change in detrusor Leak Point Pressure (LPP)|Relative change in detrusor Leak Point Pressure (LPP)|Baseline and 12-week detrusor compliance|Relative change in detrusor compliance|Symptomatic Urinary Tract Infection (UTI) Episodes|Symptomatic Urinary Tract Infection (UTI) Episodes,http://ClinicalTrials.gov/show/NCT00549939,"United States, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Estonia, &nbsp; France, &nbsp; Germany, &nbsp; India, &nbsp; Malaysia, &nbsp; Philippines, &nbsp; Poland, &nbsp; Portugal, &nbsp; Russian Federation, &nbsp; Serbia, &nbsp; Singapore, &nbsp; Slovakia, &nbsp; Spain, &nbsp; Taiwan, &nbsp; Turkey",1,1,2,0
NCT00550342,Rituximab Treatment of Focal Segmental Glomerulosclerosis,Completed,No Results Available,Focal Segmental Glomerulosclerosis (FSGS),Drug: rituximab,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Genentech,Both,Child|Adult,Phase II,10,NIH|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,R21 DK77329 (completed)|1 R21 DK077329-01A1,10/26/2007,01/01/2008,01/12/2009,09/02/2010,01/09/2010,,01/12/2009,The primary endpoint will be resolution of proteinuria defined as a Up/C ratio of <0.2.|Number of subjects who achieve partial remission defined at a fall of 50% or more in the Up/C ratio from the pre-treatment baseline|Number of subjects who develop a recurrence or increase of proteinuria on samples obtained at least 4 weeks apart|Effect of treatment on PF levels|Safety as measured by infections and drug infusion reactions.,http://ClinicalTrials.gov/show/NCT00550342,United States,1,1,1,1
NCT00550446,A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis,Completed,No Results Available,"Arthritis, Rheumatoid","Drug: Adalimumab|Drug: CP-690-550|Drug: CP-690-550|Drug: CP-690-550|Drug: CP-690,550|Drug: CP-690,550|Drug: Placebo",Pfizer,Both,Adult|Senior,Phase II,350,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3921035,10/25/2007,01/09/2007,01/01/2009,10/07/2009,01/10/2009,,01/01/2009,"American College of Rheumatology 20 (ACR 20) responder rate at the Week 12 visit.|Incidence and severity of adverse events after switch from adalimumab to CP- 690,550 compared to CP-690,550 alone|Categorical summary of absolute vital signs and vital signs changes compared to baseline by subject|The ACR 20 Responder rate (in addition to week 12)|ACR 50 Responder rate|ACR 90 Responder rate|Area under the ACR n curve|Actual and change from baseline in FACS lymphocyte biomarkers.|Mean change from baseline in vital signs (blood pressure, heart rate, and oral or tympanic temperature) measurements|Actual and change from baseline in the FACIT Fatigue Scale|Actual and change from baseline in the Medical Outcomes Study (MOS) Sleep Scale|Actual and change from baseline in serum IgG, IgM and IgA levels|Actual and change from baseline in disease activity, assessed as the|ACR 70 Responder rate|Actual and change from baseline in the SF 36 Health Questionnaire|Actual and change from baseline in the EuroQol EQ 5D|Actual and change from baseline of the 7 individual components of the ACR 20, 50, 70, and 90 response criteria|Actual and change from baseline in the Health Assessment Questionnaire (HAQ DI)|Incidence and severity of adverse events|Incidence and severity of clinical laboratory abnormalities",http://ClinicalTrials.gov/show/NCT00550446,"United States, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Chile, &nbsp; Croatia, &nbsp; Czech Republic, &nbsp; Germany, &nbsp; Greece, &nbsp; Hungary, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Romania, &nbsp; Slovakia, &nbsp; Ukraine",1,0,7,NA
NCT00550459,"Effects of Titrated Oral Tolvaptan 15, 30, or 60 mg QD on Cognitive and Neurological Function in Elderly Hyponatremic Patients",Completed,No Results Available,Hyponatremia,Drug: Tolvaptan,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.",Both,Adult|Senior,Phase III,57,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",156-04-246|INSIGHT,10/25/2007,01/08/2007,01/03/2009,2/24/2010,01/09/2009,INSIGHT,01/02/2009,"Change from baseline in the variable of the sum of z-scores of individual cognitive variables under the domains of Reaction Time, Psychomotor Speed, and Processing Speed at Day 22|Safety endpoint: Adverse events, vital signs, ECGs, Clinical laboratory test.|Change from baseline: in the individual neurocognitive domains included in the primary endpoint (reaction time, psychomotor speed, and processing speed), in the overall Neurocognitive Composite Score, in Postural Stability, in serum sodium concentrations",http://ClinicalTrials.gov/show/NCT00550459,United States,1,1,1,1
NCT00551135,Surgical Pain After Inguinal Hernia Repair (SPAIHR),Completed,Has Results,"Pain, Postoperative|Hernia, Inguinal",Drug: Pregabalin|Drug: placebo|Drug: Pregabalin|Drug: Pregabalin,Pfizer,Male,Child|Adult|Senior,Phase III,425,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",A0081171,10/26/2007,01/01/2008,01/09/2009,06/08/2010,01/06/2010,,01/06/2009,"Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery|Numeric Rating Scale (NRS): Current Pain With Movement - Sitting|Numeric Rating Scale (NRS): Current Pain With Movement - Walking|Numeric Rating Scale (NRS): Current Pain With Movement - Coughing|Numeric Rating Scale (NRS): Current Pain With Movement - Area Under the Curve (AUC) for Sitting, Walking, and Coughing|Numerical Rating Scale (NRS): Current Pain at Rest|Numeric Rating Scale (NRS): Current Pain at Rest - Area Under the Curve (AUC)|Numeric Rating Scale (NRS): Average Pain|Time From End of Surgery to First Rescue Medication|Time From End of Surgery to Reach a Total Score of at Least 9 on the Post-Anesthetic Discharge Scoring System (PADS)|Time From End of Surgery to Discharge From Post-Anesthesia Care Unit (PACU)|Daily Sleep Interference Rating Scale (DSIRS) Score|Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery|Amount of Non-opioid Rescue Medication (Naproxen and Antiemetic Medications) Used During the Study|Total Clinically Meaningful Event (CME) Score and Cumulative Total Distinct CME Score Using the Opioid-Related Symptom Distress Scale (OR-SDS)|Participants With Clinically Meaningful Events (CMEs) for Individual Symptoms Using the Opioid-Related Symptom Distress Scale (OR-SDS)|Subject Global Evaluation of Study Medication (GESM)|Participants With Wound Healing Complications|Participants With Physician Contacts Post-discharge|Baseline and Change From Baseline in Anxiety Visual Analog Scale (VAS) Score|Baseline and Change From Baseline in EuroQol (EQ-5D) Health State Profile Score|Change From Baseline in Pain Catastrophizing Scale (PCS) Total Score and Subscales|Relationship Between Baseline and Postoperative Pain Catastrophizing Scale (PCS) Score and Severity of Acute Pain and to Response to Therapy|Baseline and Change From Baseline in Short Form Acute Health Survey 12-Item Version (SF-12v2) Physical Component Summary Score (PCSS) and Mental Component Summary Score (MCSS)|Participants With Chronic Postoperative Pain|Chronic Postoperative Pain: Pain Severity Index Score and Pain Interference Index Score on the Modified Brief Pain Inventory-Short Form (mBPI-sf)|Chronic Postoperative Pain: Total Score and Subscale Scores Using the Neuropathic Pain Symptom Inventory (NPSI)",http://ClinicalTrials.gov/show/NCT00551135,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; India, &nbsp; Spain, &nbsp; Sweden",1,1,4,0
NCT00551616,Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception,Completed,No Results Available,Contraception,Drug: CDB-2914|Drug: Levonorgestrel,HRA Pharma,Female,Child|Adult|Senior,Phase III,2321,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,2914-004,10/30/2007,01/04/2007,01/04/2009,6/16/2010,01/06/2010,,01/04/2009,Pregnancy rate|Prevented fraction (number of prevented pregnancies divided by number of expected pregnancies)|Menstrual bleeding patterns|Frequencies of subjects with treatment emergent adverse events,http://ClinicalTrials.gov/show/NCT00551616,"United States, &nbsp; Ireland, &nbsp; United Kingdom",1,0,2,NA
NCT00552058,Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease,Completed,Has Results,Crohn Disease,"Biological: certolizumab pegol (CDP870, CZP)|Other: Placebo","UCB, Inc.",Both,Adult|Senior,Phase III,439,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C87085|2007-001913-41,10/18/2007,01/03/2008,01/11/2009,12/01/2010,01/12/2010,,01/10/2009,Percentage of Subjects in Clinical Remission at Week 6|Percentage of Subjects Achieving a Clinical Response at Week 6|Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 6|Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 6|Change in Harvey Bradshaw Index (HBI) Score From Week 0 to Week 6|Percentage of Subjects in Clinical Remission at Week 2|Percentage of Subjects in Clinical Remission at Week 4|Percentage of Subjects Achieving a Clinical Response at Week 2|Percentage of Subjects Achieving a Clinical Response at Week 4|Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 2|Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 4|Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 2|Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 4|Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6|Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6|Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6|Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6,http://ClinicalTrials.gov/show/NCT00552058,"United States, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Canada, &nbsp; Chile, &nbsp; Czech Republic, &nbsp; Estonia, &nbsp; Finland, &nbsp; Germany, &nbsp; Hungary, &nbsp; Israel, &nbsp; Italy, &nbsp; Latvia, &nbsp; New Zealand, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Ukraine",0,NA,2,NA
NCT00552188,Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event,Completed,No Results Available,Acute Coronary Syndrome,Drug: VIA-2291|Drug: Placebo,"VIA Pharmaceuticals|Massachusetts General Hospital|Mount Sinai School of Medicine|University of Massachusetts, Worcester|Winthrop University Hospital|Montreal Heart Institute",Both,Adult|Senior,Phase II,52,Industry|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VIA-2291-03,10/31/2007,01/10/2007,01/11/2009,12/15/2009,01/12/2009,,01/10/2009,Change from baseline in plaque imaging|Change from baseline in plaque imaging,http://ClinicalTrials.gov/show/NCT00552188,United States,1,0,2,NA
NCT00552565,Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D),Completed,No Results Available,Irritable Bowel Syndrome With Diarrhea,Drug: Rezular 15mg|Drug: Placebo|Drug: Rezular|Drug: Rezular,"AGI Therapeutics, Inc.",Both,Adult|Senior,Phase III,711,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ARDIS-1,10/31/2007,01/09/2007,01/06/2009,06/10/2009,01/06/2009,ARDIS-1,01/06/2009,Adequate Relief,http://ClinicalTrials.gov/show/NCT00552565,United States,1,0,4,NA
NCT00553631,Study of Gene-Activated?ó Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease,Completed,Has Results,"Gaucher Disease, Type 1",Biological: velaglucerase alfa|Biological: imiglucerase,"Shire Human Genetic Therapies, Inc.",Both,Child|Adult|Senior,Phase III,34,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HGT-GCB-039,11/01/2007,01/01/2008,01/06/2009,12/03/2010,01/12/2010,,01/05/2009,Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group.|Change From Baseline to Month 9 in Platelet Counts for Each Treatment Group.|Change From Baseline to Month 9 in Normalized Liver Volume (Percent (%) Body Weight) for Each Treatment Group.|Change From Baseline to Month 9 in Normalized Spleen Volume (Percent (%) Body Weight) for Each Treatment Group.|Change From Baseline to Month 9 in Plasma Chitotriosidase for Each Treatment Group.|Change From Baseline to Month 9 in Plasma Chemokine (C-C Motif) Ligand 18 (CCL18) for Each Treatment Group.|Number of Patients Who Developed Antibody for Each Treatment Group.|Time to Response- Comparison of GA-GCB and Imiglucerase on the Earliest Time to Respond as Assesed Via Hemoglobin Concentration,http://ClinicalTrials.gov/show/NCT00553631,"United States, &nbsp; Argentina, &nbsp; India, &nbsp; Israel, &nbsp; Paraguay, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Tunisia, &nbsp; United Kingdom",0,NA,2,1
NCT00553787,Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions,Completed,No Results Available,Obesity|Type 2 Diabetes,Drug: VI-0521|Drug: VI-0521|Drug: VI-0521,"VIVUS, Inc.|Medpace, Inc.",Both,Adult|Senior,Phase III,2487,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VIVUS OB-303,11/03/2007,01/11/2007,01/06/2009,11/30/2009,01/11/2009,,01/06/2009,Demonstrate an improvement over placebo in mean percent loss of baseline body weight and percent of subjects with at least 5% weight loss|Demonstrate improvements in HgbA1c and other obesity-associated comorbidities|Demonstrate an improvement over placebo in absolute weight loss and reduction in waist circumference|Demonstrate an improvement in quality of life,http://ClinicalTrials.gov/show/NCT00553787,United States,1,0,3,NA
NCT00554216,Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults,Completed,No Results Available,Obesity,Drug: VI-0521|Drug: VI-0521|Drug: Placebo matched phentermine/topiramate CR,"VIVUS, Inc.|Medpace, Inc.",Both,Adult|Senior,Phase III,1267,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VIVUS OB-302,11/03/2007,01/11/2007,01/05/2009,11/30/2009,01/11/2009,,01/05/2009,"Demonstrate an improvement over placebo in mean percent loss of baseline body weight, and percent of subjects with at least a 5% weight loss.|Demonstrate improvements in obesity-associated comorbidities|Demonstrate an improvement over placebo in absolute weight loss and reduction in waist circumference|Demonstrate an improvement in quality of life",http://ClinicalTrials.gov/show/NCT00554216,United States,1,0,3,NA
NCT00554606,"Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis",Completed,No Results Available,Rheumatoid Arthritis,Drug: ACZ885,Novartis,Both,Adult|Senior,Phase II,115,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CACZ885A2211,11/05/2007,01/10/2007,NA,11/19/2009,01/11/2009,,01/08/2009,"??Ñ Adverse events and infections ??Ñ Vital signs and body measurements, hematology, blood chemistry, and urinalysis ??Ñ Physical examination ??Ñ Antinuclear antibody (ANA) assessment ??Ñ Electrocardiogram (ECG) evaluation|??Ñ Response to treatment according to ACR20, ACR50, ACR70, and ACR90 and SDAI and DAS28. ??Ñ Effect on ACR components. ??Ñ Long-term immunogenicity. ??Ñ Long-term pharmacokinetics of ACZ885. ??Ñ Long term maintenance of health-related quality of life",http://ClinicalTrials.gov/show/NCT00554606,"United States, &nbsp; Belgium, &nbsp; Germany, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Switzerland, &nbsp; Turkey",1,1,1,0
NCT00556478,"Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation",Completed,No Results Available,Premature Ejaculation,"Drug: PSD502, contains a mixture of lidocaine and prilocaine|Drug: PSD502 Placebo","Plethora Solutions Ltd|Shionogi Pharma, Inc.",Male,Adult|Senior,Phase II|Phase III,256,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PSD502-PE-002,11/09/2007,01/10/2007,01/10/2009,7/14/2010,01/07/2010,PSD502-PE-002,01/10/2009,To evaluate efficacy of treatment with PSD502 compared with placebo in subjects with PE as measured by: ??Ñ changes in mean IELT from baseline to during 3 month double-blind treatment ??Ñ changes in all 3 IPE domains from baseline to month 3|Proportion of subjects with short mean IELT during double-blind treatment; Change in mean IELT from Baseline; Subject & Partner PEP scores; Evaluation of safety and tolerability measured by Adverse Event data,http://ClinicalTrials.gov/show/NCT00556478,United States,1,0,2,NA
NCT00556998,A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents,Completed,No Results Available,Pharmacokinetics,Drug: Voriconazole,Pfizer,Both,Child,Phase I|Phase II,26,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,A1501081,11/09/2007,01/06/2008,01/12/2009,08/02/2010,01/08/2010,,01/12/2009,Pharmacokinetic parameters of voriconazole in adolescents compared to historical adult data.|Safety and tolerability of voriconazole in adolescents,http://ClinicalTrials.gov/show/NCT00556998,United States,1,1,1,1
NCT00557037,A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer,Completed,No Results Available,Prostate Cancer,Drug: Phenoxodiol,"Marshall Edwards, Inc",Male,Adult|Senior,Phase II,60,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Yale 0703002467,11/08/2007,01/11/2007,01/11/2009,04/06/2010,01/04/2010,,01/11/2009,The proportion of patients that have a 50% post-therapy PSA decline at 12 weeks in patients with: a)Chemotherapy na??ve androgen independent disease (Group A) b)Rising PSA after radical prostatectomy or radiotherapy that are androgen dependent (Group B)|To determine the proportion of patients treated with Phenoxodiol that has measurable disease regression at 12 weeks in patients with chemotherapy na??ve androgen independent disease.,http://ClinicalTrials.gov/show/NCT00557037,United States,1,0,1,NA
NCT00557973,A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury,Completed,No Results Available,Muscle Spasticity,"Drug: XP19986, 10 mg BID|Drug: XP19986, 20 mg BID|Drug: XP19986, 30 mg BID","XenoPort, Inc.",Both,Adult,Phase II,37,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",XP-B-065,11/12/2007,01/12/2007,01/04/2009,09/10/2010,01/09/2010,,01/04/2009,Assessment of muscle tone|Severity and pain associated with muscle spasms; muscle strength and tendon reflexes; sleep symptoms,http://ClinicalTrials.gov/show/NCT00557973,United States,1,0,3,NA
NCT00558467,Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria,Completed,Has Results,Tourette Syndrome,Drug: pramipexole IR|Drug: Placebo,Boehringer Ingelheim Pharmaceuticals,Both,Child,Phase II,63,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,248.644,11/14/2007,01/01/2008,NA,10/04/2010,01/10/2010,,01/06/2009,Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale|Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 1|Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 2|Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 3|Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 4|Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 6|Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 1|Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 2|Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 3|Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 4|Clinical Global Impressions - Improvement at 1 Week|Clinical Global Impressions - Improvement at Week 2|Clinical Global Impressions - Improvement at Week 3|Clinical Global Impressions - Improvement at Week 4|Clinical Global Impressions - Improvement at Week 6|Clinical Global Impressions - Severity of Illness at Week 1|Clinical Global Impressions - Severity of Illness at Week 2|Clinical Global Impressions - Severity of Illness at Week 3|Clinical Global Impressions - Severity of Illness at Week 4|Clinical Global Impressions - Severity of Illness at Week 6|Patient Global Impression at Week 1|Patient Global Impression at Week 2|Patient Global Impression at Week 3|Patient Global Impression at Week 4|Patient Global Impression at Week 6,http://ClinicalTrials.gov/show/NCT00558467,"United States, &nbsp; Germany",1,1,2,1
NCT00558844,Multidose Safety and Tolerability Study of (Arikace?ºÑ) for Inhalation In Cystic Fibrosis Patients,Completed,No Results Available,Cystic Fibrosis,Drug: Arikace?ºÑ,Insmed,Both,Child|Adult|Senior,Phase I|Phase II,40,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TR02-106,11/13/2007,01/06/2007,01/06/2009,7/14/2009,01/07/2009,,01/06/2009,"To evaluate the safety and tolerability of 28 days of daily dosing of nebulized Arikace?ºÑ, liposomal amikacin for inhalation.|To access pharmacokinetics (PK) of Arikace?ºÑ in serum and urine, and evaluate sputum amikacin levels|To evaluate change in Pulmonary function|To evaluate change in density of Pseudomonas aeruginosa in sputum|To evaluate time to and duration of systemic anti-Pseudomonal rescue therapy|To evaluate change in CFQ-R measurements|Exploratory evaluation of a Cystic Fibrosis Symptom Diary (CFSD)|Exploratory evaluation of durability of clinical benefit",http://ClinicalTrials.gov/show/NCT00558844,United States,1,1,1,1
NCT00559052,An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI),Completed,No Results Available,Exocrine Pancreatic Insufficiency,Drug: VIOKASE 16,Axcan Pharma|AAIPharma|Mayo Clinical Services|City Hospital Laboratory Birmingham,Both,Adult|Senior,Phase II,22,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Diagnostic,VIO16IP07-01,11/14/2007,01/03/2008,01/02/2009,02/09/2010,01/02/2010,,01/02/2009,Evaluation of the Intraduodenal Lipase activity following single dose administration of VIOKASE16 tablets in EPI after a liquid meal.|Evaluation of the Intraduodenal protease and amylase activities following administration of VIOKASE16 tablets in EPI after a liquid meal.,http://ClinicalTrials.gov/show/NCT00559052,United States,1,0,1,NA
NCT00559364,Safety and Efficacy Study of VIOKASE 16 for the Correction of Steatorrhea,Completed,No Results Available,Exocrine Pancreatic Insufficiency|Chronic Pancreatitis,Drug: VIOKASE 16|Drug: Placebo,Axcan Pharma|i3 Statprobe|Quintiles|Mayo Clinical Trial Services|Laboratoire Marcel Merieux|City Hospital Laboratory Birmingham,Both,Adult|Senior,Phase III,60,Industry|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",VIO16EPI07-01,11/14/2007,01/11/2007,01/08/2009,05/04/2010,01/05/2010,,01/08/2009,Efficacy of VIOKASE 16 for the correction of steatorrhea (malabsorption of dietary fats). The efficacy will be based on a comparison of the Coefficient of Fecal Fat Absorption (CFA%) between VIOKASE 16 and placebo.|Effect of VIOKASE 16 on stool frequency and stool characteristics. Evaluate the safety of VIOKASE 16 used for the correction of steatorrhea using laboratory analyses and adverse events.,http://ClinicalTrials.gov/show/NCT00559364,"United States, &nbsp; Canada, &nbsp; Poland, &nbsp; Slovakia",1,0,2,NA
NCT00559871,Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease,Completed,No Results Available,Parkinson's Disease,Drug: fipamezole,Juvantia Pharma Ltd|Santhera Pharmaceuticals,Both,Adult|Senior,Phase II,180,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SNT-II-004,11/15/2007,01/10/2007,01/05/2009,06/02/2009,01/06/2009,Fjord,01/05/2009,"To compare the efficacy of 3 different doses of fipamezole with that of placebo on dyskinesia as assessed by a dyskinesia assessment scale.|To compare efficacy of 3 different doses of fipamezole with that of placebo on the mean daily 'Off' time, as recorded in the patient diary.",http://ClinicalTrials.gov/show/NCT00559871,"United States, &nbsp; India",1,0,1,NA
NCT00560417,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Lispro Protamine Suspension|Drug: Insulin Glargine,Eli Lilly and Company,Both,Adult|Senior,Phase III,339,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,11647|F3Z-US-IOPB,11/15/2007,01/11/2007,01/12/2009,01/12/2011,01/01/2011,,01/12/2009,"Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])|Actual Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)|Change From Baseline in Hemoglobin A1C at 24 Weeks and Endpoint (LOCF)|Percentage of Participants With Hemoglobin A1C Less Than 7.0% and Hemoglobin A1C Less Than or Equal to 6.5%|7-Point Self-Monitored Blood Glucose (SMBG) Profiles at Baseline and Endpoint (LOCF)|Glycemic Variability at Baseline and Endpoint (LOCF)|Incidence of Self-reported Hypoglycemic Episodes (All, Non-Nocturnal, Nocturnal, and Severe)|Rate of All, Non-Nocturnal, and Nocturnal Self-Reported Hypoglycemic Episodes (Adjusted for One Year)|Actual Body Weight at Baseline and Endpoint (LOCF)|Change From Baseline in Body Weight at Endpoint (LOCF)|Total Daily Insulin Dose at Endpoint (LOCF)",http://ClinicalTrials.gov/show/NCT00560417,"United States, &nbsp; Puerto Rico",1,1,2,0
NCT00560703,Treatment of Patients With Blepharitis and Facial Rosacea,Completed,No Results Available,Blepharitis|Meibomianitis|Dry Eye,"Drug: COL-101 (doxycycline, USP) capsules|Drug: placebo",Galderma,Both,Adult|Senior,Phase II,70,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COL-101-BLEPH-201,11/16/2007,01/11/2007,01/07/2009,12/02/2010,01/12/2010,,01/05/2009,Change in Ocular Surface Disease Index Change in bulbar conjunctival hyperemia|Change in Schirmer tear test at each study visit Change in tear break-up time at each study visit Change in meibum character/fluidity at each study visit Change in meibomian gland inspissation at each study visit,http://ClinicalTrials.gov/show/NCT00560703,United States,1,0,2,NA
NCT00562185,Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer,Completed,No Results Available,Ovarian Cancer,Drug: carboplatin|Drug: doxorubicin hydrochloride,Simmons Cancer Center,Female,Adult|Senior,Phase I|Phase II,61,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000574034|SCCC-04E07|SCCC-062007-043|ORTHO-SCCC-04E07,11/20/2007,01/05/2008,NA,3/19/2009,01/03/2009,,01/03/2009,Acute toxicity|Maximum tolerated dose of intraperitoneal carboplatin when given in combination with IV doxorubicin hydrochloride (phase I)|Primary efficacy and safety (phase II),http://ClinicalTrials.gov/show/NCT00562185,United States,1,1,2,0
NCT00564226,SSR240600C Treatment in Women With Overactive Bladder,Completed,No Results Available,Overactive Bladder,Drug: SSR240600C|Drug: tolterodine|Drug: placebo,Sanofi-Aventis,Female,Adult|Senior,Phase II,345,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",DRI6271|EudraCT 2007-004126-24,11/26/2007,01/11/2007,01/02/2009,9/22/2009,01/09/2009,BILADY,01/02/2009,"Change from baseline in the number of micturitions per 24 hours|Changes from baseline in number of urge urinary incontinence episodes, in number of urgency episodes, in number of nocturia episodes, in volume of urine per void|Safety of SSR240600|Quality of life",http://ClinicalTrials.gov/show/NCT00564226,"United States, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; France, &nbsp; Germany, &nbsp; Netherlands, &nbsp; Portugal",1,0,3,NA
NCT00564395,Detemir: Role in Type 1 Diabetes,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: insulin detemir,Baylor College of Medicine,Both,Child|Adult,Phase IV,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,H-16541,11/27/2007,01/08/2007,01/05/2010,8/23/2010,01/10/2009,,01/12/2009,Blood sugars patterns,http://ClinicalTrials.gov/show/NCT00564395,United States,1,1,1,1
NCT00565058,Combination of GTI 2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML),Completed,No Results Available,Acute Myeloid Leukemia,Biological: GTI-2040,Lorus Therapeutics|Ohio State University,Both,Adult,Phase II,60,Industry|Other,Interventional,Allocation: Randomized|Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2040AML201,11/27/2007,01/08/2007,01/02/2010,02/11/2010,01/02/2010,,01/09/2009,To determine the overall response rate of GTI-2040 combined with HiDAC in refractory or relapsed AML|To determine the influence of GTI-2040 treatment on pharmacologic activity in leukemic cells. To assess the activity and toxicity profile of the early and delayed GTI-2040 treatment,http://ClinicalTrials.gov/show/NCT00565058,United States,0,NA,1,NA
NCT00566540,"Cisplatin, Paclitaxel, Radiation Therapy, and Surgery in Treating Patients With Advanced Cancer of the Oral Cavity, Oropharynx, or Hypopharynx That Can Be Removed by Surgery",Completed,No Results Available,Head and Neck Cancer,Drug: cisplatin|Drug: paclitaxel|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: intensity-modulated radiation therapy|Radiation: intraoperative radiation therapy,Arthur G. James Cancer Hospital & Richard J. Solove Research Institute|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,50,Other|NIH,Interventional,Allocation: Non-Randomized|Primary Purpose: Treatment,CDR0000576461|OSU-06026|OSU-2007C0056,11/30/2007,01/12/2007,NA,02/06/2010,01/06/2009,,01/01/2009,Feasibility of treatment|Disease-free interval and failure sites|Correlation of molecular markers with treatment outcome|Correlation of quality of life with treatment outcome|Frequency and severity of toxicities|Treatment completion,http://ClinicalTrials.gov/show/NCT00566540,United States,1,1,8,0
NCT00566722,Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy,Completed,Has Results,Psoriasis,Biological: adalimumab,Abbott,Both,Adult|Senior,Phase III,152,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,M10-238,12/01/2007,01/01/2008,01/04/2009,6/17/2010,01/06/2010,,01/04/2009,"Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16|Number of Participants Achieving a PGA of Clear (0) at Week 16|Number of Participants Achieving at Least 1 Grade of Improvement in PGA at Week 16 Compared to Screening|Number of Participants Achieving 0 or 1 on Patient's Global Assessment at Weeks 2, 4, and 8|Dermatology Life Quality Index (DLQI) Total Score|Number of Participants Achieving DLQI Total Score of 0 at Week 4 and Week 16|Psoriasis-related Pruritus Assessment|Visual Analog Scale (VAS) for Pain Involving Psoriatic Plaques and/or Psoriatic Arthritis|Percent Work Time Missed Due to Psoriasis|Percent Overall Work Impairment Due to Psoriasis|Percent Impairment While Working Due to Psoriasis|Percent Activity Impairment Due to Psoriasis|Sleep Problems Index II",http://ClinicalTrials.gov/show/NCT00566722,"United States, &nbsp; Canada",0,NA,1,1
NCT00567008,Chantix for Treating Cocaine Dependence,Completed,No Results Available,Cocaine Dependence,Drug: varenicline|Drug: placebo,National Institute on Drug Abuse (NIDA),Both,Adult,Phase II,37,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",806565|NIDA P60DA0005186,12/03/2007,01/12/2007,01/09/2009,7/29/2010,01/06/2010,,01/09/2009,"Evidence of abstinence from cocaine as indicated by qualitative urinalysis for benzoylecgonine.|Evidence of more cocaine non-use days during the medication treatment and decreases in cocaine craving, demonstrated by scores on self-report measures of cocaine craving.",http://ClinicalTrials.gov/show/NCT00567008,United States,1,1,2,1
NCT00567164,Efficacy and Safety of Two Extended Regimens (Yaz Flex) in Comparison With the Conventional Regimen of YAZ,Completed,No Results Available,"Contraception|Ovulation Inhibition|Contraceptives, Oral","Drug: Yaz (SH T00186D)|Drug: SH T00186D|Drug: SH T00189D, SH T470PD + Placebo",Bayer,Female,Adult,Phase III,1885,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,91698|311642,12/03/2007,01/10/2007,01/11/2009,12/08/2010,01/12/2010,,01/10/2009,"Number of observed unintended pregnancies (evaluated using the Pearl Index)|Number of bleeding and spotting days|Number of intracyclic bleeding days, including and excluding spotting",http://ClinicalTrials.gov/show/NCT00567164,United States,1,0,3,NA
NCT00567229,Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma,Completed,No Results Available,Multiple Myeloma and Plasma Cell Neoplasm,Biological: rituximab|Drug: lenalidomide|Genetic: microarray analysis|Other: flow cytometry|Other: laboratory biomarker analysis,Memorial Sloan-Kettering Cancer Center|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,41,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000576698|MSKCC-07070,12/01/2007,01/11/2007,NA,03/07/2009,01/12/2008,,01/02/2009,"Final response rate after 4 courses of treatment|Pre- and post-treatment analyses of peripheral blood and bone marrow lymphocyte subsets, NK cell phenotype, and ex vivo antibody-dependent cellular cytotoxicity",http://ClinicalTrials.gov/show/NCT00567229,United States,1,1,5,0
NCT00567255,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Obesity,Completed,No Results Available,Obesity,Drug: naltrexone SR/bupropion SR,"Orexigen Therapeutics, Inc",Both,Adult,Phase III,1500,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NB-303,11/30/2007,01/11/2007,01/05/2009,1/22/2010,01/01/2010,,01/05/2009,"Co-primary outcome measures are the percentage of total body weight lost and the percentage of subjects who achieve a weight decrease of greater than or equal to 5%|Proportion of subjects achieving a weight loss of ??­10%; Waist circumference; Fasting triglyceride,insulin, blood glucose and HDL cholesterol; HOMA-IR:IW QOL-Lite score; SF-36; IDS-SR score; hs-CRP; systolic and diastolic blood pressure",http://ClinicalTrials.gov/show/NCT00567255,United States,1,1,1,0
NCT00567710,"A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study",Completed,No Results Available,Schizophrenia,Drug: BL - 1020|Drug: BL - 1020|Drug: Placebo|Drug: Risperidone,"BioLineRx, Ltd.",Both,Adult,Phase II,360,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BL - 1020 IIb|BL - 1020 IIb,12/04/2007,01/07/2008,01/09/2009,6/27/2010,01/06/2010,,01/07/2009,to evaluate the safety and tolerability of two dose ranges|to evaluate the efficacy of two dose ranges,http://ClinicalTrials.gov/show/NCT00567710,United States,1,0,4,NA
NCT00568087,N-acetylcysteine in Alcohol Dependence,Completed,No Results Available,Alcoholism,Drug: N-acetylcysteine|Drug: Placebo,Minneapolis Veterans Affairs Medical Center|Minnesota Veterans Research Institute,Both,Adult,Phase I|Phase II,60,U.S. Fed|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Protocol #3852-B,12/04/2007,01/12/2007,01/08/2009,9/24/2009,01/09/2009,,01/08/2009,Alcohol consumption|Liver function tests,http://ClinicalTrials.gov/show/NCT00568087,United States,1,1,2,0
NCT00568594,Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD),Completed,No Results Available,Coronary Heart Disease,Drug: APL180|Drug: Placebo,Novartis,Both,Adult|Senior,Phase I|Phase II,176,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science",CAPL180A2201,12/05/2007,01/11/2007,NA,10/02/2009,01/10/2009,,01/09/2009,"Safety and tolerability, pharmacokinetics and effects on biomarkers of HDL function of APL180 after a single and 7-daily infusions in healthy volunteers (HV) and in patients with coronary heart disease (CHD)|Pharmacokinetic/pharmacodynamic relationship after a single and 7 daily infusions in CHD patients",http://ClinicalTrials.gov/show/NCT00568594,"United States, &nbsp; Belgium, &nbsp; Denmark, &nbsp; Israel, &nbsp; Netherlands, &nbsp; South Africa, &nbsp; United Kingdom",1,0,2,NA
NCT00568646,Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Drug: MKC-1,EntreMed,Both,Adult|Senior,Phase II,33,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MKC-105,12/04/2007,01/11/2007,01/05/2009,05/04/2009,01/05/2009,,01/04/2009,Objective tumor response rate based on tumor measurements according to the RECIST,http://ClinicalTrials.gov/show/NCT00568646,United States,1,0,1,NA
NCT00568919,Armodafinil for Fibromyalgia Fatigue,Completed,No Results Available,Fibromyalgia|Fatigue,Drug: armodafinil|Drug: Placebo,State University of New York - Upstate Medical University|Martin Morell MD Arthritis Associates,Both,Adult,Phase III,60,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",ArmoFibro-001a|001,12/04/2007,01/09/2007,01/06/2009,6/29/2009,01/06/2009,,01/06/2009,"Brief Fatigue Inventory|Fatigue Severity SCale, Fibromylagia Impact Questionairre, Sheehan Disability SCale",http://ClinicalTrials.gov/show/NCT00568919,United States,1,1,2,1
NCT00569010,Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory AML or High Risk MDS,Completed,No Results Available,Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Leukemia,Drug: Azacitidine|Drug: Ara-C,M.D. Anderson Cancer Center|Celgene Corporation,Both,Adult|Senior,Phase I|Phase II,36,Other|Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2005-0291,12/05/2007,01/12/2005,01/10/2009,10/23/2009,01/10/2009,,01/10/2009,Dose limiting toxicity of the combination of azacitidine and Ara-C(ie. recommended Phase II dose)|Clinical Activity,http://ClinicalTrials.gov/show/NCT00569010,United States,1,1,2,1
NCT00569270,Dynamic Hyperinflation and Tiotropium,Completed,No Results Available,COPD,Drug: tiotropium|Drug: placebo|Drug: tiotropium,"Gelb, Arthur F., M.D.|Boehringer Ingelheim Pharmaceuticals|Pfizer",Both,Adult|Senior,Phase IV,40,Other|Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20061693|IIS Boehringer-Ingelheim|IIS Pfizer,12/06/2007,01/10/2006,01/03/2009,6/19/2009,01/06/2009,,01/02/2009,"Measurement of inspiratory capacity|measurement of spirometry, lung volumes, airway resistance",http://ClinicalTrials.gov/show/NCT00569270,"United States, &nbsp; Canada",1,1,3,1
NCT00570089,Microvascular Coronary Disease In Women: Impact Of Ranolazine,Completed,No Results Available,Myocardial Ischemia,Drug: Ranolazine|Drug: Placebo,Cedars-Sinai Medical Center|CV Therapeutics,Female,Child|Adult|Senior,Phase II,20,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",IRB 10465,12/07/2007,01/04/2007,01/12/2009,3/23/2010,01/03/2010,,01/12/2009,"CMRs (CMR 1 and CMR 2) end of the 4th week of treatment 1 and treatment 2 respectively, 4 hours after the morning dose of study drug|Questionnaires will be completed (SAQ, WISE angina frequency, DASI and SF-36)",http://ClinicalTrials.gov/show/NCT00570089,United States,1,1,2,1
NCT00570141,OASIS Wound Matrix (Oasis) Mechanism of Action,Completed,Has Results,Diabetic Foot Ulcers (DFU)|Venous Stasis Ulcers (VSU),Device: OASIS Wound Matrix,Healthpoint,Both,Adult|Senior,Phase IV,13,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label,9310-002-004,12/06/2007,01/10/2007,01/04/2010,08/12/2010,01/08/2010,,01/04/2009,"Decrease in Wound Area From Baseline After 12 Weeks of Treatment or Until Wound Closure, Whichever Occurred First.|Percent Wounds Closed",http://ClinicalTrials.gov/show/NCT00570141,United States,0,NA,1,NA
NCT00570336,Study of CTS-1027 in Hepatitis C Patients,Completed,No Results Available,Chronic Hepatitis C Virus Infection,Drug: CTS-1027|Other: Placebo,Conatus Pharmaceuticals Inc.|FGK Clinical Research GmbH,Both,Adult|Senior,Phase II,87,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CTS-1027-01,12/06/2007,01/12/2007,01/07/2009,9/14/2010,01/09/2010,,01/07/2009,Number of adverse events at each dose level|Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels at each dose|Peak and trough levels of CTS-1027 in plasma,http://ClinicalTrials.gov/show/NCT00570336,United States,1,0,2,NA
NCT00570635,A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib,Completed,No Results Available,Gastrointestinal Stromal Tumors|Gastrointestinal Neoplasms,Drug: XL820|Drug: XL820,Exelixis,Both,Adult|Senior,Phase II,60,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,XL820-201,12/07/2007,01/12/2007,01/05/2009,08/09/2010,01/08/2010,,01/05/2009,"Clinical benefit, defined as either confirmed complete response, confirmed partial response, or evidence of stable disease lasting ??­16 weeks, in subjects with advanced GIST resistant to/intolerant of imatinib and/or sunitinib|Safety and tolerability of XL820|Progression-free survival, duration of response, and overall survival|Further characterize the pharmacokinetic and pharmacodynamic parameters of XL820 in subjects with advanced GIST",http://ClinicalTrials.gov/show/NCT00570635,United States,1,0,2,NA
NCT00570739,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",Completed,Has Results,Type 2 Diabetes Mellitus|Hypercholesterolemia|Pre-diabetes,Drug: Metformin HCl and Colesevelam Placebo|Drug: Metformin HCl tablets and Colesevelam tablets|Drug: Colesevelam placebo|Drug: Colesevelam,Daiichi Sankyo Inc.,Both,Adult|Senior,Phase III,502,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","WEL-411|IND 68,466",12/10/2007,01/11/2007,01/05/2009,7/19/2010,01/07/2010,,01/04/2009,"Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-na??ve, Diabetic Subjects.|Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-na??ve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks.|Fasting Plasma Glucose When Given to Drug-na??ve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Fasting Insulin When Given to Drug-na??ve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Fasting C-Peptide Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|30 Minute Post-Meal Glucose Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|1 Hour Post-Meal Glucose Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|2 Hour Post-Meal Glucose Levels to in Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|2 Hour Post-Meal Insulin Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|2 Hour Post-Meal C-Peptide Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|The Percent Change of Low Density Lipoprotein Cholesterol (LDL-C) When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Non-High Density Lipoprotein (Non-HDL) Levels When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of High Density Lipoprotein Cholesterol(HDL-C) When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Total Cholesterol (TC) When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Triglycerides (TG)When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Apolipoprotein A-1 (Apo A-1) When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Apolipoprotein B (Apo B)When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change of Apolipoprotein C3 (Apo C3)When Given to Drug-na??ve, Diabetic Subjects From Baseline to 8, and 16 Weeks|Change in the Levels of Various Lipoprotein Particles When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Size of Various Lipoprotein Particles When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Calculated Total Triglycerides When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Calculated Very Low Density Lipoprotein Triglycerides When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Change in the Calculated High Density Lipoprotein Cholesterol When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Percent of Subjects Achieving HbA1c Goal of <7.0% at Weeks 4, 8, 12, and 16 if Baseline HbA1c Was > or = to 7.0% When Given to Drug-na??ve, Diabetics|Percent of Subject Achieving HbA1c Goal of <6.5% at Weeks 4, 8, 12, and 16 When Given to Drug-na??ve, Diabetic Subjects|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <100 mg/dL at Weeks 8, 16 When Given to Drug-na??ve, Diabetic Subjects|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol Goal of <70 mg/dL at Weeks 8, 16 When Given as to Drug-na??ve, Diabetics|Change in Body Weight When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Change in Waist-to-Hip Ratio When Given to Drug-Naive Diabetic Subjects From Baseline to 16 Weeks|Change in Plasma Glucose Area Under the Curve (0 to 120 Minutes) From the Baseline Glucose Tolerance Test (GTT) to the 16 Week GTT|Percent Change of Various Calculated Lipid Parameters When Given as Initial Therapy to Drug-na??ve, Diabetic From Baseline to 16 Weeks Subjects|Percent of Subjects Achieving 2-Hr. Post Meal Glucose Goal of <180 mg/dL When Given to Drug-na??ve, Diabetic Subjects From Baseline to Week 16|Percent of Subjects Achieving Hs-C-Reactive Protein Goal of <2.0 mg/L When Given to Drug-na??ve, Diabetic Subjects From Baseline to 16 Weeks|Percent Change in Low Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Non-High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Total Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Apolipoprotein A-1 in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Apolipoprotein B in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Apolipoprotein CIII in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Triglycerides in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks|Percent Change in Hs-C-Reactive Protein in Pre-Diabetic Subjects From Baseline to 16 Weeks|Level of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks|Particle Size of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Various Calculated Lipid Parameters in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Change of HbA1c in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Percent Change of Fasting Plasma Glucose in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Percent Change of Fasting Insulin in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks|Change of Fasting C-peptide Levels in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Glucose Levels 30 Minutes Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Glucose Levels 1 Hour Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Glucose Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of Insulin Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change of C-Peptide Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <100 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects|Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <70 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects|Change in Body Weight in Pre-Diabetic Subjects From Baseline to 16 Weeks|Change in Waist-to-Hip Ratio in Pre-Diabetic Subjects From Baseline to 16 Weeks|Area Under the Curve for Plasma Glucose From 0 to 120 Minutes During the Oral Glucose Tolerance Tests in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Achievement of <140 mg/dL Plasma Glucose 2 Hours Post the Oral Glucose Tolerance Test in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was >or= to 140 mg/dL From Baseline to 16 Weeks|Percent Achievement of <110 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 110 mg/dL From Baseline to 4, 8, 12, and 16 Weeks|Percent Achievement of <100 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 100 mg/dL From Baseline to 4, 8, 12 and 16 Weeks|Percent Achievement of <140 mg/dL Plasma Glucose Post 2 Hour Glucose Tolerance Test and Fasting Plasma Glucose <110 mg/dL in Pre-Diabetic Subjects From Baseline to 16 Weeks|Percent Achievement of Hs-C-Reactive Protein <2.0 mg/L in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 2.0 mg/L From Baseline to 16 Weeks|Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose >or= to 126 mg/dL or Plasma Glucose >or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks",http://ClinicalTrials.gov/show/NCT00570739,"United States, &nbsp; Colombia, &nbsp; India, &nbsp; Mexico",1,1,4,0
NCT00570986,A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis,Completed,No Results Available,Plaque Psoriasis,Drug: Placebo|Biological: ABT-874|Biological: ABT-874,Abbott,Both,Adult|Senior,Phase III,1465,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M06-890,12/07/2007,01/12/2007,NA,11/02/2010,01/09/2010,,01/06/2009,PGA|PASI|PGA|DLQI|NAPSI|PASI|Safety parameters,http://ClinicalTrials.gov/show/NCT00570986,"United States, &nbsp; Canada",1,0,3,NA
NCT00571896,The Use of SennaS for Prevention of Post-Operative Constipation After Urogynecologic Surgery,Completed,No Results Available,Constipation,Drug: Senna+ docusate|Drug: placebo,Hartford Hospital,Female,Adult|Senior,Phase II|Phase III,72,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PATE002472HE,12/10/2007,01/01/2008,01/06/2009,07/01/2009,01/07/2009,,01/06/2009,1. Time to first bowel movement after surgery. 2. Need for magnesium citrate or enemas in the immediate post-operative period.|Straining and pain with bowel movements in the immediate post-operative period,http://ClinicalTrials.gov/show/NCT00571896,United States,1,1,2,1
NCT00572455,Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.,Completed,No Results Available,Primary Open Angle Glaucoma|Ocular Hypertension,Drug: PF-04217329--High Dose|Drug: PF-04217329--Low Dose|Drug: PF-04217329--Medium Dose|Drug: Xalatan|Drug: vehicle|Drug: High Dose PF-04217329 and Xalatan|Drug: Low Dose PF-04217329 and Xalatan|Drug: Medium Dose PF-04217329 and Xalatan,Pfizer,Both,Adult|Senior,Phase II,318,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",A0191001,12/11/2007,01/12/2007,01/06/2009,01/03/2011,01/01/2011,,01/06/2009,Mean diurnal IOP (intraocular pressure) change from baseline in the study eye at the Day 14 Visit (Stage 1)|Evaluation of ocular and systemic safety assessments throughout the study period (Stage 1)|Mean diurnal IOP (intraocular pressure) change from baseline in the study eye at the Day 28 Visit (Stage 2)|Proportion of patients reaching a target IOP across study visits.|Mean IOP value and its change from baseline in the study eye across study visits.|Evaluation of ocular and systemic safety assessments throughout the study period (Stage 2)|Proportion of patients reaching a target IOP across study visits (Stage 2)|Mean IOP value and its change from baseline in the study eye across study visits.,http://ClinicalTrials.gov/show/NCT00572455,United States,1,0,8,NA
NCT00572936,Circadian Rhythms of Aqueous Humor Dynamics in Humans,Completed,No Results Available,Glaucoma,Drug: prostaglandin,University of Nebraska|Pfizer,Both,Adult|Senior,Phase II,30,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",405-05-FB,12/07/2007,01/11/2005,01/11/2009,1/29/2010,01/01/2010,,01/11/2009,"Observed patterns of normal, healthy eyes during daytime and nighttime hours.",http://ClinicalTrials.gov/show/NCT00572936,United States,1,1,1,1
NCT00573170,TREXIMET?ó Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults,Completed,Has Results,"Migraine Disorders|Migraine, Acute",Drug: TREXIMET?ó|Drug: Butalbital-containing Combination Medications (BCM)|Drug: placebo,GlaxoSmithKline,Both,Adult,Phase III,375,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",TRX109011/TRX109013,12/12/2007,01/02/2008,01/08/2009,11/30/2010,01/11/2010,,01/08/2009,"Number of Participants With a Sustained Pain-free (SPF) Response From 2 to 24 Hours Post-dose|Number of Participants With a Pain-free Response From 2 to 48 Hours Post-dose|Number of Participants Using Rescue Medication Within 48 Hours Post Dose|Mean Time to First Use of Rescue Medication for the First Attack Treated With Study Medication (Attack 1)|Mean Time to First Use of Rescue Medication for the Second Attack Treated With Study Medication (Attack 2)|Mean Time to First Use of Rescue Medication for the Third Attack Treated With Study Medication (Attack 3)|Number of Participants With a Migraine-free Response 2-48 Hours After Dosing|Number of Participants With Pain-freedom and Relief of Nausea at 2, 4, 6, 8, 24 and 48 Post-dose Time Points|Number of Participants With Pain-freedom and Relief of Photophobia at 2, 4, 6, 8, 24 and 48 Post-dose Time Points|Number of Participants With Pain-freedom and Relief of Phonophobia at 2, 4, 6, 8, 24 and 48 Post-dose Time Points|Number of Participants With Pain-freedom and Relief of Vomiting at 2, 4, 6, 8, 24 and 48 Hours Post-dose|Number of Participants With Relief From Sinus/Facial Pain at 2, 4, 6, 8, 24 and 48 Hours After Dosing in Those Who Also Had the Symptom at Dosing|Number of Participants With Relief From Neck Pain at 2, 4, 6, 8, 24 and 48 Hours After Dosing Who Also Had the Symptom at Baseline|Number of Participants With Pain Relief at 2, 4, 6, 8, 24 and 48 Hours After Dosing Moderate or Severe Baseline Pain|Number of Participants Who Reported a Complete Symptom-Free Response at 2, 4, 6, 8, 24 and 48 Hours After Dosing|Mean Performance Index (PI) Scores at Time of Dosing and at 2, 4, 6, 8, 24 and 48 Hours After Dosing|Mean Stanford Sleepiness (SS) Scale Scores at Time of Dosing and at 2, 4, 6, 8, 24 and 48 Hours After Dosing|Efficacy Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Treating a Migraine|Functionality Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication|Ease-of-Use Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication|Bothersomeness-of-side Effect Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication|Total PPMQ-R Score as Measured With the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication|Numbers of Participants Able to \Engage in Normal Activities Not Impaired\"" at Time of Dosing and 2",http://ClinicalTrials.gov/show/NCT00573170,United States,1,1,3,0
NCT00573313,Effects of SAMe in Patients With Alcoholic Liver Disease,Completed,No Results Available,"Liver Disease, Alcoholic",Drug: S-adenosylmethionine|Drug: placebo,"University of California, Davis|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Abbott|Joint Clinical Research Center|University of Colorado, Denver|University of California, Los Angeles",Both,Adult,Phase III,94,Other|NIH|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NIAAA_HAL-014562|R01AA014562,12/12/2007,01/09/2005,01/09/2009,9/30/2010,01/09/2010,,01/06/2009,Liver Histopathology|Liver biochemistry,http://ClinicalTrials.gov/show/NCT00573313,United States,1,0,2,NA
NCT00573443,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,Completed,No Results Available,Pseudobulbar Affect (PBA),Drug: AVP-923,Avanir Pharmaceuticals|Kendle International,Both,Adult|Senior,Phase III,326,Industry|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-AVR-123,12/13/2007,01/12/2007,01/09/2009,10/03/2010,01/10/2010,STAR,01/06/2009,The primary efficacy endpoint is the number of laughing and/or crying episodes as recorded in the patient diary.|The main secondary endpoint is the mean change in CNS-LS score.,http://ClinicalTrials.gov/show/NCT00573443,"United States, &nbsp; Argentina, &nbsp; Brazil",1,0,1,NA
NCT00574171,Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma,Completed,No Results Available,Metastatic Colorectal Cancer,Drug: lapatinib|Drug: Capecitabine,"University of Wisconsin, Madison|GlaxoSmithKline",Both,Adult|Senior,Phase II,29,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CO07201 (LAP109859),12/13/2007,01/09/2007,01/08/2009,10/15/2010,01/10/2010,,01/08/2009,response to therapy|toxicity and tolerability of the lapatinib/capecitabine combination in this patient population,http://ClinicalTrials.gov/show/NCT00574171,United States,1,1,2,1
NCT00574197,Enteric-coated Mycophenolate Sodium (Myfortic?ó) in Heart Transplant Recipients,Completed,No Results Available,Gastrointestinal Symptoms|Heart Transplantation,Drug: Mycophenolate Sodium,Cedars-Sinai Medical Center|Novartis Pharmaceuticals,Both,Adult|Senior,Phase IV,11,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,9810,12/13/2007,01/06/2006,01/12/2009,7/21/2010,01/08/2009,,01/12/2009,"Side-effects using the GSRS (Gastrointestinal Symptoms Rating Scale), GI complications and GI adverse events|Incidence of biopsy proven acute rejection, graft loss, and death",http://ClinicalTrials.gov/show/NCT00574197,United States,1,0,1,NA
NCT00575224,"Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9",Completed,No Results Available,Chronic Hepatitis C|Asian Americans|Novel Genotypes|Treatment,Drug: Pegylated interferon and ribavirin,Pacific Health Foundation|Hoffmann-La Roche,Both,Adult|Senior,Phase IV,60,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PEG-183|IRB Protocol #20041038|IRB Study #1059635,12/15/2007,01/10/2004,01/09/2009,11/23/2009,01/11/2009,,01/09/2009,Sustained virologic response,http://ClinicalTrials.gov/show/NCT00575224,United States,1,1,1,1
NCT00577512,UARK 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE,Completed,No Results Available,Multiple Myeloma,Drug: DTPACE,University of Arkansas,Both,Adult|Senior,Phase II,4,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2006-32,12/18/2007,01/04/2007,01/04/2009,05/12/2009,01/05/2009,,01/04/2009,"To find out how many subjects treated with high dose DTPACE and Etoposide. (HD DTPACE) on this protocol will have a complete response or near complete response that lasts for 6 months or longer.|In subjects achieving a response, to find out how long the response will last.",http://ClinicalTrials.gov/show/NCT00577512,United States,1,0,1,NA
NCT00577668,"A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)",Completed,No Results Available,Multiple Myeloma,"Drug: Melphalan, Velcade, Thalidomide, Dexamethasone",University of Arkansas,Both,Adult|Senior,Phase II,75,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,2007-01,12/18/2007,01/04/2007,01/04/2009,10/20/2009,01/04/2009,,01/04/2009,"To find out if using the VTD regimen, along with higher doses melphalan, in subjects who have relapsed or progressed after previous transplant(s), can be given safely to subjects who have failed previous transplant(s).",http://ClinicalTrials.gov/show/NCT00577668,United States,1,1,1,0
NCT00578175,Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad?ó in Children 12-14 Months of Age,Completed,Has Results,"Measles-Mumps-Rubella-Varicella Vaccine|Diseases Caused by Measles, Mumps, Rubella and Varicella Viruses.",Biological: Priorix-Tetra?ºÑ (MMRV vaccine 208136)|Biological: ProQuad?ó|Biological: Havrix?ó|Biological: Prevnar?ó,GlaxoSmithKline,Both,Child,Phase II,1851,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention",110058,12/20/2007,01/11/2007,01/02/2009,12/02/2010,01/12/2010,,01/02/2009,"Number of Subjects With Seroresponse for Antibodies to Varicella Virus (VZV)|Concentration of Antibodies to Varicella Virus (VZV)|Number of Subjects With Seroresponse for Antibodies to Mumps Virus|Number of Subjects With Seroresponse for Antibodies to Measles Virus|Number of Subjects With Seroresponse for Antibodies to Rubella Virus|Concentration of Antibodies to Hepatitis A Virus (HAV)|Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F|Antibody Titers to Mumps Virus|Concentration of Antibodies to Measles Virus|Concentration of Antibodies to Rubella Virus|Number of Subjects With Vaccine Response to Havrix?ó|Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value|Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value|Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value|Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Fever ??­ 38.0??C/100.4??F and > 39.5??C/103.1??F During the 15-day Follow up Period After Vaccination|Number of Subjects Reporting Fever ??­ 38.0??C/100.4??F and > 39.5??C/103.1??F During the 43-day Follow-up Period After Vaccination|Number of Subjects Reporting Investigator-confirmed Measles/Rubella-like Rash|Number of Subjects Reporting Investigator-confirmed Varicella-like Rash|Number of Subjects Reporting Investigator-confirmed Parotid/Salivary Gland Swelling|Number of Subjects Reporting Unsolicited Adverse Events and Medically-attended Adverse Events (Excluding Rash and Parotid/Salivary Gland Swelling)|Number of Subjects Reporting New Onset Chronic Illnesses and Conditions Prompting Emergency Room Visits|Number of Subjects Reporting Serious Adverse Events",http://ClinicalTrials.gov/show/NCT00578175,United States,0,NA,4,NA
NCT00578279,EUS-CPN in Unresectable Pancreatic Cancer: a Pilot Study,Completed,No Results Available,Pancreatic Cancer,Drug: dehydrated alcohol,Indiana University,Both,Adult|Senior,Phase IV,20,Other,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment",0702-25|IRB # 0702-25|Clarian Values Grant: vfr-262,12/19/2007,01/03/2007,01/06/2009,9/15/2010,01/06/2010,,01/06/2009,Increased amounts of alcohol used in EUS-CPN is more efficacious in improving pain relief in patients with locally advanced or unresectable pancreatic adenocarcinoma.|Increased amounts of alcohol used in EUS-CPN is safe in improving pain relief in patients with locally advanced or unresectable pancreatic adenocarcinoma.|Effective pain relief obtained from EUS-CPN will be related to better QOL,http://ClinicalTrials.gov/show/NCT00578279,United States,1,1,1,0
NCT00578552,Gabapentin for Smoking Cessation,Completed,Has Results,Cigarette Smoking|Tobacco Use,Drug: Placebo|Drug: Gabapentin - 1800 mg/day|Drug: Gabapentin - 2700 mg/day,Mayo Clinic,Both,Adult,Phase II,80,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment",06-005262|07-000700,12/19/2007,01/10/2007,01/05/2009,12/01/2010,01/12/2010,,01/02/2009,Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco,http://ClinicalTrials.gov/show/NCT00578552,United States,1,1,3,0
NCT00578617,Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial,Completed,No Results Available,Atrial Fibrillation|Arrhythmia|Stroke Prevention|Mortality,Drug: Pharmacologic Therapy Rate and/or Rhythm Control|Device: NAVI-STAR Thermo-cool (Left Atrial Catheter Ablation),Mayo Clinic|Duke University|St. Jude Medical,Both,Adult|Senior,Phase III,60,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,06-003867|RO1-HL089907,12/14/2007,01/09/2006,01/06/2010,11/10/2010,01/11/2010,CABANA,01/02/2009,"Percutaneous left atrial catheter ablation for the purpose of eliminating AF is superior to current state-of-the-art therapy with either rate or rhythm control drugs for reducing total mortality in patients with untreated or under-treated AF.|A composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest.|Medical costs and resource utilization and cost effectiveness|Composite adverse events|Determine the impact of age, AF type, symptom state, and presence of underlying disease on these outcomes and establish the importance of AF elimination in this population of patients.|Quality of Life",http://ClinicalTrials.gov/show/NCT00578617,United States,0,NA,2,NA
NCT00578773,A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea,Completed,No Results Available,Acute Otitis Media,Drug: AL-15469A|Drug: AL-38905,Alcon Research,Both,Child,Phase III,300,Industry,Interventional,Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,C-05-38,12/19/2007,01/11/2007,01/01/2009,05/07/2009,01/05/2009,,01/01/2009,Time to cessation of otorrhea as recorded by the parent or guardian via a patient diary|Clinical cures at each visit|Absence of otorrhea at each visit,http://ClinicalTrials.gov/show/NCT00578773,United States,1,0,2,NA
NCT00579189,Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes,Completed,No Results Available,Acute Otitis Media With Tympanostomy Tubes,Drug: AL-15469A / AL-38905,Alcon Research,Both,Child,Phase III,660,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C-05-36,12/19/2007,01/01/2006,01/01/2009,05/07/2009,01/05/2009,,01/01/2009,Time to cessation of otorrhea as recorded by the parent or guardian via a patient diary|Clinical cure rate|Microbiological outcome|Treatment failures,http://ClinicalTrials.gov/show/NCT00579189,United States,1,0,1,NA
NCT00580073,Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum,Completed,No Results Available,Rectal Cancer,Drug: FOLFOX4|Drug: Cetuximab,"University of Wisconsin, Madison|Sanofi-Aventis|Bristol-Myers Squibb|ImClone LLC",Both,Adult|Senior,Phase II,6,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2007-0197 (CO06207),12/17/2007,01/12/2007,01/11/2009,10/15/2010,01/10/2010,,01/11/2009,response to therapy,http://ClinicalTrials.gov/show/NCT00580073,United States,1,1,2,0
NCT00582933,"Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor",Completed,No Results Available,Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma|Allogeneic Marrow Transplant,"Drug: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|Drug: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|Drug: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF",Memorial Sloan-Kettering Cancer Center,Both,Child|Adult,Phase II,96,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,01-055|CA23766,12/21/2007,01/05/2001,01/04/2009,07/09/2009,01/07/2009,,01/04/2009,"To establish 1-the incidence and quality of engraftment and hematopoietic reconstitution, 2- the early transplant-related severe morbidity and mortality and 3-the incidence and severity of GvHD.|To establish initial estimates of 1-the incidence of overall survival and disease-free survival at 2 years and 2- the quality of immune reconstitution following transplantation.",http://ClinicalTrials.gov/show/NCT00582933,United States,1,1,3,0
NCT00584701,Pharmacogenomics in Autism Treatment,Completed,No Results Available,Autism,Drug: risperidone,"University of California, San Francisco|Janssen, LP|National Institute of Mental Health (NIMH)",Both,Child|Adult,Phase II|Phase III,54,Other|Industry|NIH,Interventional,Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,200715817-1|R21MH080026,12/22/2007,01/01/2008,01/05/2009,11/18/2010,01/11/2010,PG,01/05/2009,ABC and CGI|ABC,http://ClinicalTrials.gov/show/NCT00584701,United States,1,1,1,1
NCT00584974,"A Safety, Efficacy and Tolerability Study of SEP-225289",Completed,No Results Available,"Depressive Disorder, Major",Drug: SEP-225289|Drug: SEP-225289|Drug: Venlafaxine|Drug: placebo,Sunovion,Both,Adult,Phase II,523,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",360-029,12/21/2007,01/12/2007,01/05/2009,11/01/2010,01/11/2010,,01/05/2009,"To assess the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder (MDD)|To examine the response to SEP-225289 in MDD subjects meeting DSM_IV criteria for atypical and melancholic features",http://ClinicalTrials.gov/show/NCT00584974,United States,1,0,4,NA
NCT00585039,Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED),Completed,No Results Available,Asthma,Drug: xopenex,Phoenix Children's Hospital,Both,Child,Phase IV,300,Other,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SRC176,12/20/2007,01/09/2005,01/03/2009,9/17/2009,01/02/2009,Xopenex,01/03/2009,FEV1|Plasma R and S isomer levels|clinical asthma scores,http://ClinicalTrials.gov/show/NCT00585039,United States,1,1,1,0
NCT00585715,Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening,Completed,No Results Available,Cellulite,Device: 1064 nm Nd:YAG laser,"University of California, Irvine|Candela Corporation",Both,Adult|Senior,Phase I|Phase II,25,Other|Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2006-5138|No. 062905,12/26/2007,01/10/2006,01/01/2010,6/23/2010,01/01/2010,IH062905,01/12/2009,Celluite skin tightening|Safety and efficacy of laser with and without cooling,http://ClinicalTrials.gov/show/NCT00585715,United States,0,NA,1,NA
NCT00586209,L-Glutamine Therapy for Sickle Cell Anemia,Completed,No Results Available,Sickle Cell Anemia|Thalassemia,Drug: L-Glutamine|Drug: Placebo,"Los Angeles Biomedical Research Institute|Emmaus Medical, Inc.",Both,Adult|Senior,Phase II,50,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",10511-01RY,12/21/2007,01/01/2003,01/11/2009,12/02/2010,01/12/2010,,01/01/2009,Number of occurrences of painful sickle cell crises|Frequency of hospitalizations for sickle cell pain|Frequency of emergency room visits for sickle cell pain|Number of days patients' usual daily activities are interrupted due to sickle cell pain|Subjective exercise tolerance,http://ClinicalTrials.gov/show/NCT00586209,United States,1,1,2,0
NCT00586573,Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS,Completed,No Results Available,ADHD|ADHD NOS,Drug: memantine hydrochloride,Massachusetts General Hospital,Both,Adult,Phase IV,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2007-P-000067,12/28/2007,01/03/2007,01/10/2009,6/21/2010,01/06/2010,,01/10/2009,DSM-IV ADHD Rating Scale|BRIEF-A|CANTAB,http://ClinicalTrials.gov/show/NCT00586573,United States,1,1,1,1
NCT00586846,Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma,Completed,No Results Available,Osteosarcoma,Drug: Cisplatin|Drug: Doxorubicin|Drug: Methotrexate,Memorial Sloan-Kettering Cancer Center,Both,Child|Adult|Senior,Phase II,40,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,03-074,12/21/2007,01/07/2003,01/02/2009,02/12/2009,01/02/2009,,01/02/2009,Determine the safety and feasibility of administration of pamidronate with conventional chemotherapy for osteosarcoma.,http://ClinicalTrials.gov/show/NCT00586846,United States,1,1,3,0
NCT00586898,Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle,Completed,No Results Available,Prostate|Cancer|Hormonal Cycling,Drug: GnRH|Drug: Ketoconazole|Drug: Bicalutamide|Drug: Testosterone transdermal gel|Drug: Estrogen transdermal patch,Memorial Sloan-Kettering Cancer Center,Male,Adult|Senior,Phase II,36,Other,Interventional,Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,01-085,12/21/2007,01/07/2001,01/03/2009,07/09/2009,01/07/2009,,01/03/2009,To determine the response to rapid hormonal cycling in patients with non-castrate prostate cancer.,http://ClinicalTrials.gov/show/NCT00586898,United States,1,1,5,1
NCT00588341,Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection,Completed,No Results Available,Melanoma|Skin Cancer|Cancer,Drug: Temozolomide,Memorial Sloan-Kettering Cancer Center|Schering-Plough,Both,Adult|Senior,Phase II,24,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,05-076,12/26/2007,01/09/2005,01/03/2009,3/18/2009,01/03/2009,,01/03/2009,Overall objective response rate (CR and PR)|Correlation of oligonucleotide array pattern and of methylation of the MGMT promoter and MGMT expression level with response to treatment; of volumetric tumor measurements with standard response criteria and with final pathological findings; Toxicity,http://ClinicalTrials.gov/show/NCT00588341,United States,1,1,1,0
NCT00590031,Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.,Completed,No Results Available,Esophageal Carcinoma,Drug: Cisplatin|Drug: Irinotecan|Radiation: External Beam Radiation Therapy,Memorial Sloan-Kettering Cancer Center,Both,Adult|Senior,Phase II,61,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,02-045|IND 65889,12/26/2007,01/11/2002,01/12/2009,12/23/2009,01/12/2009,,01/12/2009,"Determine pathologic complete response rate for subjects on study|Evaluate toxicity and tolerability including surgical morbidity and mortality|Determine overall survival, disease free survival, and pattern of failure.|Assess parameters of quality of life using the Dysphagia scale, and FACT-E questionnaires",http://ClinicalTrials.gov/show/NCT00590031,United States,1,1,3,0
NCT00590590,Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort,Completed,No Results Available,Vulvodynia,Drug: Lidocaine/Diphenhydramine|Drug: lidocaine|Drug: placebo,KV Pharmaceutical Company,Female,Adult,Phase II,140,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LDC-201-601-669020,12/26/2007,01/10/2007,01/07/2009,7/21/2009,01/07/2009,,01/06/2009,The primary outcome measure of the study will be measurement of a woman's ability to have vaginal intercourse.|Important secondary outcome measures include change in discomfort.,http://ClinicalTrials.gov/show/NCT00590590,"United States, &nbsp; Canada",1,0,3,NA
NCT00590863,Combining Medications to Enhance Depression Outcomes,Completed,No Results Available,Major Depressive Disorder,"Drug: One of the following: bupropion, escitalopram, mirtazapine, or venlafaxine|Drug: Two of the following: bupropion, escitalopram, mirtazapine or venlafaxine",National Institute of Mental Health (NIMH),Both,Adult|Senior,Phase IV,665,NIH,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,N01 MH090003-02|DSIR AT,12/26/2007,01/03/2008,01/09/2009,2/19/2010,01/04/2009,CO-MED,01/09/2009,"Remission rates in patients with chronic and/or recurrent major depression.|Anxiety, social functioning, quality of life, cognitive and physical well being, treatment emergent psychiatric symptoms, and side-effect burden",http://ClinicalTrials.gov/show/NCT00590863,United States,1,1,2,0
NCT00591227,Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: insulins aspart and detemir,Rush University Medical Center|Novo Nordisk,Both,Adult|Senior,Phase IV,176,Other|Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,7070902,12/27/2007,01/05/2008,01/07/2009,9/27/2010,01/09/2010,,01/07/2009,length of stay in the hospital|average blood glucose during the hospital admission|frequency of hypoglycemia|efficacy of blood glucose lowering during the emergency room stay|frequency of hypoglycemia during emergency room therapy with insulin,http://ClinicalTrials.gov/show/NCT00591227,United States,1,1,1,0
NCT00591253,Efficacy and Safety of Azilsartan Medoxomil in African American Subjects With Essential Hypertension,Completed,No Results Available,Essential Hypertension,Drug: Azilsartan medoxomil|Drug: Azilsartan medoxomil|Drug: Placebo,"Takeda Global Research & Development Center, Inc.",Both,Adult|Senior,Phase III,413,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-06-TL-491-011|U1111-1113-8925,12/27/2007,01/10/2007,01/04/2009,7/14/2010,01/07/2010,,01/04/2009,"Change from baseline to Week 6 in the 24-hour mean systolic blood pressure by ambulatory blood pressure monitor.|Change from baseline to Week 6 in trough clinic sitting systolic blood pressure.|Change from baseline to Week 6 in the 24-hour mean diastolic blood pressure by ambulatory blood pressure monitor.|Change from baseline to Week 6 in trough clinic sitting diastolic blood pressure.|Change from baseline for daytime mean (6am to 10pm) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for daytime mean (6am to 10pm) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) diastolic blood pressure by ambulatory blood pressure monitor|Proportion of subjects who achieve a Clinic Diastolic Blood Pressure Response, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg|Proportion of subjects who achieve a Clinic Systolic Blood Pressure Response, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg|Proportion of subjects who achieve both a clinic Diastolic and Systolic Blood Pressure Response",http://ClinicalTrials.gov/show/NCT00591253,"United States, &nbsp; Puerto Rico",1,0,3,NA
NCT00591266,"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Subjects With Essential Hypertension",Completed,No Results Available,Essential Hypertension,Drug: Azilsartan Medoxomil|Drug: Azilsartan Medoxomil|Drug: Amlodipine,"Takeda Global Research & Development Center, Inc.",Both,Adult|Senior,Phase III,566,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-05-TL-491-010|U1111-1113-9132,12/27/2007,01/10/2007,01/04/2009,04/09/2010,01/04/2010,,01/03/2009,"Change from baseline to Week 6 in the 24-hour mean systolic blood pressure by ambulatory blood pressure monitor.|Change from baseline to Week 6 in trough clinic sitting systolic blood pressure.|Change from baseline to Week 6 in the 24-hour mean diastolic blood pressure by ambulatory blood pressure monitor.|Change from baseline to Week 6 in trough clinic sitting diastolic blood pressure.|Change from baseline for daytime mean (6am to 10pm) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for daytime mean (6am to 10pm) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) diastolic blood pressure by ambulatory blood pressure monitor|Proportion of subjects who achieve a Clinic Diastolic Blood Pressure Response, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg|Proportion of subjects who achieve a Clinic Systolic Blood Pressure Response, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg|Proportion of subjects who achieve both a Clinic Diastolic Blood Pressure < 90 mm Hg and/or reduction of ??­ 10 mm Hg from Baseline and a Systolic Blood Pressure < 140 mm Hg and/or reduction of ??­ 20 mm Hg from Baseline.",http://ClinicalTrials.gov/show/NCT00591266,United States,1,0,3,NA
NCT00591578,Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Subjects With Essential Hypertension,Completed,No Results Available,Essential Hypertension,Drug: Azilsartan Medoxomil|Drug: Azilsartan Medoxomil|Drug: Valsartan,"Takeda Global Research & Development Center, Inc.",Both,Adult|Senior,Phase III,984,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAK-491_301|U1111-1113-9238,12/27/2007,01/12/2007,01/03/2010,3/25/2010,01/03/2010,,01/09/2009,Change from Baseline in the 24-hour mean Systolic Blood Pressure by ambulatory blood pressure monitor.|Change from Baseline in trough sitting clinic Systolic Blood Pressure|Change from Baseline for 24-hour mean Diastolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline in trough sitting clinic Diastolic Blood Pressure|Change from Baseline for daytime mean (6am to 10pm) Systolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for daytime mean (6am to 10pm) Diastolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for nighttime mean (12am to 6am) Systolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for nighttime mean (12am to 6am) Diastolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for 0-12-hr mean Systolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for 0-12-hr mean Diastolic Blood Pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) Systolic Blood Pressure by ambulatory blood pressure monitor|Change from Baseline for trough mean (22-24-hr) Diastolic Blood Pressure by ambulatory blood pressure monitor|Percentage of subjects who achieve a clinic Diastolic Blood Pressure < 90 mm Hg and/or reduction of ??­10 mm Hg from baseline|Percentage of subjects who achieve a clinic Systolic Blood Pressure < 140 mm Hg and/or reduction of ??­20 mm Hg from baseline|Proportion of subjects who achieve both clinic Diastolic and Systolic Blood Pressure Response,http://ClinicalTrials.gov/show/NCT00591578,"United States, &nbsp; Chile, &nbsp; Mexico, &nbsp; Peru",1,0,3,NA
NCT00591773,Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Subjects With Essential Hypertension,Completed,No Results Available,Essential Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and chlorthalidone|Drug: Chlorthalidone,"Takeda Global Research & Development Center, Inc.",Both,Adult|Senior,Phase III,551,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-05-TL-491-009|U1111-1113-9040,12/27/2007,01/09/2007,01/03/2009,7/14/2010,01/07/2010,,01/03/2009,"Change from baseline to Week 6 in the 24-hour mean systolic blood pressure by ambulatory blood pressure monitor.|Change from baseline to Week 6 in trough clinic sitting systolic blood pressure.|Change from baseline to Week 6 in the 24-hour mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline to Week 6 in trough clinic sitting diastolic blood pressure.|Change from baseline for daytime mean (6am to 10pm) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for daytime mean (6am to 10pm) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) diastolic blood pressure by ambulatory blood pressure monitor|Proportion of subjects who achieve a Clinic Diastolic Blood Pressure Response, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg|Proportion of subjects who achieve a Clinic Systolic Blood Pressure Response, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg|Proportion of subjects who achieve both a clinic Diastolic and Systolic Blood Pressure Response",http://ClinicalTrials.gov/show/NCT00591773,United States,1,0,3,NA
NCT00592488,Acetyl-L-Carnitine in the Treatment of Septic Shock,Completed,No Results Available,Septic Shock,Drug: Acetyl-L-Carnitine,Vanderbilt University,Both,Adult|Senior,Phase I|Phase II,16,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",50730,01/02/2008,01/08/2006,01/09/2009,1/13/2010,01/01/2010,ALC,01/08/2009,mean arterial blood pressure|vasopressor dose|serum lactate,http://ClinicalTrials.gov/show/NCT00592488,United States,1,0,1,NA
NCT00592553,Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (DMD/BMD),Completed,No Results Available,Duchenne Muscular Dystrophy|Becker Muscular Dystrophy,Drug: PTC124|Drug: PTC124|Drug: PTC124,PTC Therapeutics,Male,Child|Adult|Senior,Phase II|Phase III,165,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PTC124-GD-007-DMD,01/01/2008,01/02/2008,01/12/2009,03/03/2010,01/03/2010,,01/12/2009,To determine the effect of PTC124 on ambulation in subjects with nonsense-mutation-mediated DMD/BMD (as assessed by changes in the distance walked during a 6-minute walk test)|Activity in the community setting|Proximal muscle function|Muscle strength|Muscle fragility|Biceps muscle dystrophin expression|Quality of Life|Cognitive ability|Cardiac function|Frequency of accidental falls during ambulation|Treatment satisfaction|Safety|Compliance with treatment|PTC124 pharmacokinetics,http://ClinicalTrials.gov/show/NCT00592553,"United States, &nbsp; Australia, &nbsp; Belgium, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Israel, &nbsp; Italy, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",1,0,3,NA
NCT00592839,"Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women",Completed,Has Results,Nocturnal Vasomotor Symptoms,Drug: SCE-B|Drug: Placebo,Duramed Research,Female,Adult,Phase IV,157,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",DR-ENJ-401,12/20/2007,01/12/2007,01/02/2009,3/16/2010,01/03/2010,,01/02/2009,Mean Change in Average Frequency of Awakenings Due to Sleep-time Hot Flashes|Mean Change in Individual Sleep Parameters on a Three-point Scale|Mean Change in Stanford Sleepiness Scale|Mean Change in Biochemical Markers of Bone Metabolism (N-telopeptide).|Mean Change in Biochemical Markers of Bone Metabolism (Osteocalcin)|Mean Change in Biochemical Markers of Bone Metabolism (Sex Hormone Binding Globulin).,http://ClinicalTrials.gov/show/NCT00592839,United States,1,1,2,1
NCT00593112,Proton Magnetic Spectroscopy in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) Before and After Treatment With OROS Methylphenidate,Completed,No Results Available,ADHD,Drug: OROS methylphenidate|Other: No intervention,Massachusetts General Hospital,Both,Child|Adult,Phase IV,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,2005-P-002180,12/28/2007,01/11/2006,01/05/2009,6/21/2010,01/06/2010,,01/05/2009,H MRS Scan results,http://ClinicalTrials.gov/show/NCT00593112,United States,1,1,2,1
NCT00593567,Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer,Completed,No Results Available,Diabetic Foot Ulcer,Drug: gentamicin-collagen sponge|Drug: Levofloxacin,Innocoll Technologies|Premier Research Group plc,Both,Adult|Senior,Phase II,70,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,INN-TOP-001,01/04/2008,01/12/2007,01/05/2009,7/22/2010,01/07/2010,,01/05/2009,"Percent of patients with a clinical outcome of \clinical cure\"" in each treatment group|Percent of patients with a clinical outcome of \""clinical cure\"" in each treatment group|Percent of patients with pathogen eradication in each treatment group|Reduction (absolute and percent decrease",http://ClinicalTrials.gov/show/NCT00593567,United States,1,0,2,NA
NCT00594256,Sodium Oxybate in Schizophrenia With Insomnia,Completed,No Results Available,Schizophrenia|Insomnia Associated to Schizophrenia,Drug: Sodium Oxybate,Nathan Kline Institute for Psychiatric Research|Jazz Pharmaceuticals,Both,Adult,Phase II,8,Other|Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,07I/C36-0,01/03/2008,01/05/2008,01/04/2009,11/30/2009,01/11/2009,,01/04/2009,Pittsburgh Sleep Quality Index|Epworth Sleepiness Scale|Positive and Negative Syndrome Scale (PANSS)|MATRICS+ neurocognitive battery|Polysomnographic Measures,http://ClinicalTrials.gov/show/NCT00594256,United States,1,1,1,1
NCT00595413,Study of Atacicept in Anti-TNF??-na??ve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate,Completed,No Results Available,Rheumatoid Arthritis,Drug: Atacicept|Drug: Atacicept|Other: Placebo|Biological: Humira,EMD Serono,Both,Adult|Senior,Phase II,311,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",27905|2007-002536-29,01/07/2008,01/09/2007,01/08/2009,12/07/2010,01/12/2010,,01/05/2009,The proportion of subjects achieving an ACR20 response at Week 26.,http://ClinicalTrials.gov/show/NCT00595413,United States,1,0,4,NA
NCT00595426,A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery,Completed,No Results Available,"Arthroplasty, Replacement, Knee",Drug: YM150|Drug: Warfarin,Astellas Pharma Inc,Both,Adult|Senior,Phase II,685,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",150-CL-033,01/07/2008,01/05/2008,01/05/2009,5/26/2010,01/05/2010,PEARL,01/05/2009,"The incidence of total venous thromboembolisms (VTE).|The incidence of bleeding events classified as major by the Adjudication Committee|Evaluation of efficacy variables including: Proximal VTE, Distal VTE, Confirmed symptomatic VTE, death due to any cause|Incidence of the bleeding types: major, clinically relevant nonmajor, minor",http://ClinicalTrials.gov/show/NCT00595426,"United States, &nbsp; Canada",1,0,2,NA
NCT00595543,Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%,Completed,No Results Available,Acute Pseudophakic Cystoid Macular Edema,Drug: Bromfenac|Drug: Ketorolac|Drug: Diclofenac,"Bp Consulting, Inc",Both,Adult|Senior,Phase IV,166,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,5349,01/07/2008,01/01/2008,01/03/2009,3/17/2009,01/03/2009,,01/03/2009,Acute Pseudophakic Cystoid Macular Edema|Visual Acuity,http://ClinicalTrials.gov/show/NCT00595543,United States,1,1,3,0
NCT00595556,Zonisamide vs. Placebo in the Treatment of Alcohol Dependence,Completed,Has Results,Alcoholism|Alcohol Abuse|Alcohol Dependence,Drug: zonisamide|Drug: Placebo,University of Connecticut Health Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Center for Research Resources (NCRR),Both,Adult,Phase IV,40,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",06-113-1|P50 AA03510|M01RR006192,01/06/2008,01/07/2006,01/05/2009,9/28/2010,01/09/2010,,01/05/2009,"Change in Number of Heavy Drinking Days (i.e., 5 or More Drinks Per Day for Men, and 4 or More Per Day for Women)Per Week, by Week|Weekly Rate of Change in Abstinent Days|Change in Number of Drinks Per Week by Week|Change in the Urge to Drink Alcohol as Measured by the Alcohol Urge Questionnaire (AUQ)|Change in Gamma-glutamyl Transferase (GGT) Concentration",http://ClinicalTrials.gov/show/NCT00595556,United States,1,1,2,1
NCT00595946,Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone,Completed,No Results Available,Opioid-Induced Bowel Dysfunction,Drug: Lubiprostone|Drug: Placebo,"Sucampo Pharmaceuticals, Inc.|Takeda Pharmaceutical Company Limited",Both,Adult|Senior,Phase III,420,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OBD0631,01/04/2008,01/08/2007,01/03/2009,12/10/2009,01/12/2009,OPAL,01/03/2009,"Change from baseline in SBM frequency|Change from baseline in SBM frequency|First post-dose SBM (percentage of patients)|Responder rate|Mean changes from baseline in straining, stool consistency, constipation severity, abdominal bloating, abdominal discomfort, and bowel habit regularity|Treatment effectiveness",http://ClinicalTrials.gov/show/NCT00595946,"United States, &nbsp; Canada",1,1,2,1
NCT00596687,Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery,Completed,No Results Available,Type 2 Diabetes|Inpatient Hyperglycemia,Drug: Insulin glargine and insulin glulisine|Drug: Regular insulin,Emory University|Sanofi-Aventis,Both,Adult|Senior,Phase IV,282,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,e5062|e5062,01/08/2008,01/12/2007,01/12/2009,04/09/2010,01/04/2010,RABBIT 2-SX,01/12/2009,"To determine differences in glycemic control as measured by mean daily blood glucose concentration between insulin glargine once daily plus supplemental glulisine insulin versus sliding scale regular insulin in surgical patients with type 2 diabetes.|To determine differences between treatment arms in: # of hypoglycemic events, # of episodes of severe hyperglycemia, LOS,rate of post-op complications, and/or need for ICU admission",http://ClinicalTrials.gov/show/NCT00596687,United States,1,1,2,1
NCT00596934,Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH),Completed,No Results Available,"Fatty Liver Disease, Nonalcoholic",Drug: metreleptin,University of Michigan|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Male,Adult,Phase II,10,Other|NIH,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,R03 DK74488|R03DK074488|Protocol 2145 (MCRU)|Amylin Protocol 20050119|DRDA 643938K3,01/08/2008,01/02/2006,01/03/2009,03/01/2010,01/03/2010,,01/03/2009,Liver histopathology|Body weight|Liver fat by MRI and MR spectroscopy|Liver function tests|Fasting lipids|Fasting glucose|Insulin sensitivity,http://ClinicalTrials.gov/show/NCT00596934,United States,1,0,1,NA
NCT00597428,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone,Completed,No Results Available,Opioid-Induced Bowel Dysfunction,Drug: Lubiprostone|Drug: Placebo,"Sucampo Pharmaceuticals, Inc.|Takeda Pharmaceutical Company Limited",Both,Adult|Senior,Phase III,420,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OBD0632,01/09/2008,01/08/2007,01/03/2009,12/10/2009,01/12/2009,OPAL,01/03/2009,"Change from baseline in SBM frequency|Change from baseline in SBM frequency|First post-dose SBM (percentage of patients)|Responder rate|Mean changes from baseline in straining, stool consistency, constipation severity, abdominal bloating, abdominal discomfort, and bowel habit regularity|Treatment effectiveness",http://ClinicalTrials.gov/show/NCT00597428,"United States, &nbsp; Canada",1,1,2,1
NCT00597584,Hematide?ºÑ Injection for Anemia in Chronic Hemodialysis (HD) Patients,Completed,No Results Available,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Drug: Hematide?ºÑ|Drug: Epoetin,Affymax,Both,Adult|Senior,Phase III,823,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AFX01-14,01/10/2008,01/10/2007,01/01/2010,10/07/2010,01/10/2010,EMERALD 2,01/07/2009,Mean change in Hgb between baseline and the Evaluation Period|Proportion of patients who received red blood cell (RBC) transfusions during the Titration and Evaluation Periods.|Proportion of patients whose mean Hgb level during the Evaluation Period is within the target range of 10.0 - 12.0 g/dL.,http://ClinicalTrials.gov/show/NCT00597584,"United States, &nbsp; Bulgaria, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Poland, &nbsp; Romania, &nbsp; Spain, &nbsp; United Kingdom",1,0,2,NA
NCT00597753,Hematide?ºÑ Injection for Anemia in Chronic Hemodialysis (HD) Patients,Completed,No Results Available,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Drug: Hematide?ºÑ|Drug: Epoetin Alfa,Affymax,Both,Adult|Senior,Phase III,803,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AFX01-12,01/10/2008,01/09/2007,01/01/2010,10/07/2010,01/10/2010,EMERALD 1,01/07/2009,Mean change in Hgb between baseline and the Evaluation Period|Proportion of patients who receive red blood cell (RBC) transfusions during the Titration and Evaluation Periods.|Proportion of patients whose mean Hgb level during the Evaluation Period is within the target range of 10.0 - 12.0 g/dL.,http://ClinicalTrials.gov/show/NCT00597753,United States,1,0,2,NA
NCT00597818,Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury,Completed,No Results Available,NSAID-induced Gastroduodenal Injury|Ulcers|Rheumatoid Arthritis|Osteoarthritis,Drug: Cobiprostone|Drug: Placebo,"Sucampo Pharmaceuticals, Inc.",Both,Adult|Senior,Phase II,120,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SU0621,01/10/2008,01/08/2007,01/05/2009,06/02/2010,01/06/2010,,01/04/2009,"Incidence of gastric ulcers|Proportion of patients developing duodenal and gastroduodenal ulcers|Proportion of patients developing gastric, duodenal, and gastroduodenal ulcers|Change in number of ulcers by patient|Change in number of erosions by patient|Size of ulcers/erosions|Time-to-onset of ulcer/erosion development|Lanza assessment of gastroduodenal injury|Analysis of dyspepsia/dyspeptic symptoms",http://ClinicalTrials.gov/show/NCT00597818,United States,1,0,2,NA
NCT00598273,Safety & Efficacy of Hematide?ºÑ for the Correction of Anemia in Patients With Chronic Renal Failure,Completed,No Results Available,Chronic Renal Failure|Anemia,Drug: Hematide?ºÑ|Drug: Hematide?ºÑ|Drug: Darbepoetin Alfa,Affymax,Both,Adult|Senior,Phase III,490,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AFX01-11,01/10/2008,01/10/2007,01/12/2009,10/07/2010,01/10/2010,PEARL 1,01/12/2009,Mean change in Hgb between baseline and the Evaluation Period.|Proportion of patients who received RBC transfusions during the Correction and Evaluation Periods.|Proportion of patients achieving Hgb response during the Correction and Evaluation Periods.,http://ClinicalTrials.gov/show/NCT00598273,"United States, &nbsp; Puerto Rico",1,0,3,NA
NCT00598442,Safety and Efficacy of Hematide?ºÑ for the Correction of Anemia in Patients With Chronic Renal Failure (PEARL 2),Completed,No Results Available,Chronic Renal Failure|Anemia,Drug: Hematide?ºÑ|Drug: Darbepoetin Alfa,Affymax,Both,Adult|Senior,Phase III,493,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AFX01-13,01/10/2008,01/12/2007,01/12/2009,10/07/2010,01/10/2010,PEARL 2,01/12/2009,Mean change in Hgb between baseline and the Evaluation Period.|Proportion of patients who received RBC transfusions during the Correction and Evaluation Periods.|Proportion of patients achieving Hgb response during the Correction and Evaluation Periods.,http://ClinicalTrials.gov/show/NCT00598442,"United States, &nbsp; Bulgaria, &nbsp; Czech Republic, &nbsp; Germany, &nbsp; Hungary, &nbsp; Italy, &nbsp; Poland, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Spain, &nbsp; United Kingdom",1,0,2,NA
NCT00598689,GenTeal in Perioperative Treatment of LASIK Patients,Completed,No Results Available,Refractive Surgical Procedures,Drug: 0.3% hypromellose|Other: No Artificial Tears|Drug: 0.3% hypromellose,Medical College of Georgia,Both,Adult,Phase IV,80,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,07/09/1952,01/10/2008,01/10/2007,01/10/2009,9/23/2010,01/09/2010,,01/10/2009,"Assess whether preoperative GenTeal Gel enhances epithelial healing after LASIK surgery within the first post-operative week, compared to control (no preoperative lubricant).|Assess whether preoperative GenTeal Gel alleviates post operative pain in LASIK surgery patients compared to control (no preoperative lubricant).",http://ClinicalTrials.gov/show/NCT00598689,United States,1,0,3,NA
NCT00598975,"A Phase 2a/2b Multicenter, Open-Label Study to Evaluate NKTR 102 (PEG-Irinotecan) in Combination With Cetuximab Versus Irinotecan in Combination With Cetuximab in Second Line Colorectal Cancer Patients",Completed,No Results Available,Tumor|Colorectal Cancer,Drug: NKTR-102 + Cetuximab,Nektar Therapeutics,Both,Adult|Senior,Phase II,18,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,07-PIR-02,01/11/2008,01/01/2008,NA,11/11/2009,01/11/2009,,01/05/2009,"Establish the recommended Phase 2a dose (RPTD) of the combination of NKTR-102 and cetuximab|Safety, pharmacokinetics, and tumor response of NKTR-102 in combination with cetuximab.",http://ClinicalTrials.gov/show/NCT00598975,United States,1,0,1,NA
NCT00600119,"A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)",Completed,No Results Available,Opioid Induced Constipation (OIC),Drug: placebo|Drug: NKTR-118,Nektar Therapeutics,Both,Adult|Senior,Phase II,224,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",07-IN-NX003,01/11/2008,01/12/2007,01/04/2009,06/09/2009,01/06/2009,,01/03/2009,"Increase in number of spontaneous bowel movements from baseline|Dose-response, safety, tolerability, pharmacokinetics, other symptoms of OBD assessed using the Patient Assessment of Constipation Symptoms (PAC-SYM), QOL, measurements, and maintenance of opioid analgesic effect",http://ClinicalTrials.gov/show/NCT00600119,United States,1,0,2,NA
NCT00600184,Clinic-Based AMES Treatment of Stroke,Completed,No Results Available,Stroke|Cerebrovascular Accident,Device: The AMES device,AMES Technology|Oregon Health and Science University,Both,Adult|Senior,Phase I|Phase II,2,Industry|Other,Interventional,Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CT002|IRB00004005,12/31/2007,01/01/2008,01/11/2009,12/15/2009,01/12/2009,AMES,01/11/2009,Fugl-Meyer Assessment of the Lower Extremity|Gait Assessment|Stroke Impact Scale|Spasticity (Modified Ashworth) Scale|Biodex Isokinetic Strength Measurements|Strength Test|Joint Position Test|Passive Motion Test,http://ClinicalTrials.gov/show/NCT00600184,United States,0,NA,1,NA
NCT00600743,Effect of a CCK-1R Agonist on Food Intake in Humans,Completed,No Results Available,Bulimia Nervosa|Normal Subjects Eating to Satiation|Normal Subjects Overeating,Drug: GSKI181771X (CCK-1R agonist)|Drug: GSKI181771X (CCK-1R agonist),St. Luke's-Roosevelt Hospital Center|GlaxoSmithKline,Female,Adult,Phase II,40,Other|Industry,Interventional,"Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science",07-101,1/14/2008,01/01/2008,01/02/2009,03/03/2010,01/03/2010,GSK,01/02/2009,Significant reduction in food intake by drug compared to placebo|Significant increase in satiation after drug compared to placebo,http://ClinicalTrials.gov/show/NCT00600743,United States,1,0,2,NA
NCT00600925,A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection,Completed,No Results Available,Colorectal Surgery|Surgical Wound Infection,Drug: gentamicin-collagen sponge dipped in saline,Innocoll Technologies|Duke University|Premier Research Group plc,Both,Adult|Senior,Phase III,600,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention",INN-SWI-002,1/14/2008,01/01/2008,01/09/2010,10/18/2010,01/07/2010,,01/03/2009,"Primarily, efficacy will be evaluated by a comparison between the 2 study groups of the incidence of surgical wound infections (involving the laparotomy incision) that occur within the period from surgery through postop day 60.|The effect of the gentamicin-collagen sponge on the proportion of patients with surgically treated surgical wound infections adjudicated by an independent blinded committee|The effect of the gentamicin-collagen sponge on the proportion of patients with deep incisional surgical wound infection based on CDC criteria adjudicated by an independent blinded committee.|The effect of the gentamicin-collagen sponge on the proportion of patients with superficial incisional surgical wound infection based on CDC criteria adjudicated by an independent blinded committee.|The effect of the gentamicin-collagen sponge on type of pathogen/bacteriology|The effect of the gentamicin-collagen sponge on the ASEPSIS score|The effect of the gentamicin-collagen sponge on length of hospital stay postoperatively.|The effect of the gentamicin-collagen sponge on rehospitalization for surgical wound infection.|The effect of the gentamicin-collagen sponge on the total hospitalization related costs.|Serum gentamicin levels in subjects receiving gentamicin-collagen sponge.|Serum gentamicin levels in subjects receiving reapplication of gentamicin-collagen sponge in cases of early reoperation.|Subject self-reported assessment of pain and wound healing based on a structured wound healing questionnaire.|Change in serum creatinine from baseline to peak.|Incidence of reported serious and nonserious AEs, including, but not limited to, development of renal failure, ileus, anastomitic leakage, and small-bowel obstruction.|All-cause mortality|Emergency Room and/or surgical office visits secondary to wound complaints.|The amount of pain medications administered",http://ClinicalTrials.gov/show/NCT00600925,United States,1,0,1,NA
NCT00601107,A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Patients With Moderate to Severe Psoriasis,Completed,No Results Available,Moderate to Severe Chronic Plaque Psoriasis,Drug: doxercalciferol|Drug: doxercalciferol|Drug: doxercalciferol|Drug: placebo,Genzyme,Both,Adult|Senior,Phase II,136,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HECTPS02507,1/15/2008,01/04/2008,01/06/2009,05/04/2010,01/05/2010,,01/02/2009,Achievement of at least a 50% reduction in PASI score (PASI 50)|Achievement of PASI 50|Achievement of a static PGA score of clear (0) or almost clear (1),http://ClinicalTrials.gov/show/NCT00601107,United States,1,1,4,1
NCT00601172,A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.,Completed,No Results Available,"Nausea and Vomiting|Nausea and Vomiting, Chemotherapy-Induced",Drug: Casopitant|Drug: Dexamethasone and Ondansetron|Drug: Placebo,GlaxoSmithKline,Both,Adult|Senior,Phase III,710,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care",NKV110721|NKV110721,1/15/2008,01/03/2008,01/04/2009,10/14/2010,01/10/2010,,01/04/2009,"Complete response (no vomiting and no use of rescue medication) assessed via subject diary completed during cycle 1, that records vomiting and the use of rescue medication.|Complete response during cycle 2.|The proportion of subjects who achieve a complete response in the acute and delayed phases of Cycle 1.|Assessed in the overall, acute and delayed phases of Cycle 1:|Maximum nausea score, assessed by a Visual Analogue Scale (VAS). ??Ñ The proportion of subjects who receive rescue medication. ??Ñ The proportion of subjects who vomit/retch.|The proportion of subjects reporting significant nausea, defined as a maximum nausea score ??­ 25 mm on the VAS. ??Ñ The proportion of subjects reporting nausea, defined as a maximum nausea score ??­ 5 mm on the VAS.|The proportion of subjects achieving complete protection, defined as complete responders who had no significant nausea.|The proportion of subjects achieving total control, defined as complete responders who had no nausea. ??Ñ Time to first anti-emetic rescue medication. ??Ñ Time to first emetic event.|Time to event is defined as the time elapsed from the start of the oxaliplatin infusion to the first event.|If a subject withdraws prematurely or dies during the first 120 hours, then the time of withdrawal or death will be considered to be their time to first event, and will be censored.|Health Outcomes Endpoints assessed in Cycle 1: ??Ñ The impact on subjects' daily life activities in the overall phase, as assessed by the FLIE questionnaire.|Severity of nausea in the overall, acute, and delayed phases assessed by a categorical scale.|PK Endpoints assessed in Cycle 1 (subset of subjects only)|Single-dose pharmacokinetic parameters: AUC(0-???), AUC(0-t), Cmax, tmax, t1/2 for casopitant and metabolites GSK525060, GSK517142 and GSK631832; and CL and Vdss for casopitant only.",http://ClinicalTrials.gov/show/NCT00601172,"United States, &nbsp; Belgium, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; Germany, &nbsp; Hungary, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Russian Federation, &nbsp; Slovakia",1,0,3,NA
NCT00601250,Efficacy and Safety of B I1356 vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: BI 1356|Drug: Placebo,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase III,702,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,1218.17|EudraCT No.: 2007-002457-24,1/15/2008,01/01/2008,NA,5/28/2009,01/05/2009,,01/05/2009,"The primary endpoint in this study is the change from baseline in HbA1c (HbA1c after 24 weeks of treatment).|change from baseline in HbA1c, change from baseline in FPG, Change from baseline in Postprandial glucose",http://ClinicalTrials.gov/show/NCT00601250,"United States, &nbsp; Czech Republic, &nbsp; Finland, &nbsp; Greece, &nbsp; India, &nbsp; Israel, &nbsp; Mexico, &nbsp; New Zealand, &nbsp; Russian Federation, &nbsp; Sweden",1,0,2,NA
NCT00601484,An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis,Completed,No Results Available,"Cystitis, Interstitial",Drug: PF-04383119|Drug: Placebo,Pfizer,Both,Adult|Senior,Phase II,65,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",A4091010,1/15/2008,01/03/2008,01/04/2009,01/04/2011,01/01/2011,,01/04/2009,"Change in average daily pain|Change in O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) score|Change in Pelvic Pain and Urgency/Frequency (PUF) symptom score|Change in O'Leary-Sant Interstitial Cystitis Problem Index (ICPI) score|Global response assessment|Patient-reported treatment impact assessment|Treatment failures|Biomarkers|Safety endpoints|Pharmacokinetic measures|Change in average daily pain|Change in micturition variables including frequency, nocturnal frequency, incontinence episode frequency, mean volume voided per micturition, mean interstitial cystitis pain severity, urinary urgency episodes, average sleep disturbance score,....",http://ClinicalTrials.gov/show/NCT00601484,United States,1,0,2,NA
NCT00602420,Naproxen in Preventing Bone Pain Caused by Pegfilgrastim in Patients With Non-Hematologic Cancer Undergoing Chemotherapy,Completed,No Results Available,"Musculoskeletal Complications|Pain|Unspecified Adult Solid Tumor, Protocol Specific",Drug: naproxen|Other: placebo,University of Rochester|National Cancer Institute (NCI),Both,Adult|Senior,Phase III,322,Other|NIH,Interventional,Allocation: Randomized|Control: Placebo Control|Masking: Double-Blind|Primary Purpose: Supportive Care,CDR0000584341|U10CA037420|URCC-07079,1/22/2008,01/06/2008,01/05/2010,11/08/2010,01/11/2010,,01/06/2009,Severity and duration of bone pain from baseline through day 5 (day 1 being the day pegfilgrastim is administered) as measured by a daily diary|Potential risk factors for the development of pegfilgrastim-induced bone pain|Potential clinical predictors for response or failure to respond to treatment|Presence or severity of symptoms prior to study enrollment and at study outcome as measured by the Symptom Inventory|Toxicity,http://ClinicalTrials.gov/show/NCT00602420,United States,1,1,2,0
NCT00603239,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide|Drug: placebo,"Amylin Pharmaceuticals, Inc.|Eli Lilly and Company",Both,Adult|Senior,Phase III,165,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",H8O-MC-GWCG,1/17/2008,01/01/2008,01/07/2009,09/02/2010,01/09/2010,,01/07/2009,Change in Glycosylated Hemoglobin (HbA1c)|Percentage of Patients Achieving HbA1c <= 7%|Percentage of Patients Achieving HbA1c <= 6.5%|Change in Fasting Serum Glucose (FSG)|Change in Body Weight|Change in Waist Circumference|Change in Beta-cell Function|Change in Insulin Sensitivity.|Number of Subjects Who Experienced an Episode of Minor Hypoglycemia|Change in Impact of Weight on Quality of Life (IWQOL)-Lite Score|Change in Euroqol - 5 Domain Quality of Life (EQ-5D) Score,http://ClinicalTrials.gov/show/NCT00603239,"United States, &nbsp; Canada, &nbsp; Mexico, &nbsp; Romania, &nbsp; South Africa",1,1,2,1
NCT00603902,BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management,Completed,No Results Available,Obesity,Drug: lorcaserin|Drug: lorcaserin|Drug: placebo,Arena Pharmaceuticals,Both,Adult,Phase III,3000,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",APD356-011,1/16/2008,01/01/2008,01/08/2009,10/07/2009,01/10/2009,,01/07/2009,"Proportion (%) of patients achieving > or = 5% weight reduction at Week 52.|Change in body weight (kg) from Baseline to Week 52.|Change in waist and hip measurements from Baseline to Week 52.|Change in blood pressure (systolic and diastolic) from Baseline to Week 52.|Change in lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) from Baseline to Week 52.|Change in Quality of Life measures from Baseline to Week 52.",http://ClinicalTrials.gov/show/NCT00603902,United States,1,0,3,NA
NCT00604019,Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock,Completed,No Results Available,Septic Shock,Drug: Dopamine|Drug: Norepinephrine,Rush University Medical Center,Both,Adult|Senior,Phase III,262,Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ORA-02102801,01/03/2008,01/03/2003,01/08/2009,9/23/2010,01/09/2010,,01/08/2009,"Efficacy - dead or alive at 28 days|Safety, arrythmia - yes or no for each group",http://ClinicalTrials.gov/show/NCT00604019,United States,1,1,2,0
NCT00604591,Effects of Tolcapone on Frontotemporal Dementia,Completed,No Results Available,Frontotemporal Lobar Degeneration,Drug: Tolcapone,National Institute of Neurological Disorders and Stroke (NINDS),Both,Adult|Senior,Phase II,9,NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",080045|08-N-0045,1/19/2008,01/01/2008,01/10/2009,8/25/2010,01/09/2009,,01/10/2009,Reaction time on the most difficult N-back condition that the patients can succesfully perform.|A difference in the normalized BOLD signal intensity between subjects on placebo vs. tolcapone.,http://ClinicalTrials.gov/show/NCT00604591,United States,1,1,1,1
NCT00605553,Study to Evaluate SYN115 in Parkinson's Disease,Completed,No Results Available,Parkinson's Disease,Drug: Placebo|Drug: SYN115,"Synosia Therapeutics, Inc.",Both,Adult|Senior,Phase II,30,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SYN115-CL01,1/15/2008,01/04/2008,NA,12/03/2009,01/12/2009,,01/05/2009,"This is an exploratory study to evaluate effects of SYN115 in patients with PD, as determined by clinical and fMRI evaluation. The results of this initial study will help determine the range to be used in subsequent studies.|Pittsburgh side effect scale|VAS for overall well being, dizziness/light-headedness, nausea/vomiting, mood anxiety|Measurement of motor symptoms of Parkinson's disease and tapping speed",http://ClinicalTrials.gov/show/NCT00605553,United States,1,0,2,NA
NCT00605735,PoC in Rheumatoid Arthritis With Methotrexate,Completed,No Results Available,"Rheumatoid Arthritis, NOS",Drug: BMS-582949|Drug: Placebo,Bristol-Myers Squibb,Both,Adult|Senior,Phase II,121,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",IM119-015,1/18/2008,01/03/2008,01/09/2009,01/06/2011,01/10/2009,,01/08/2009,"The primary endpoint is the proportion of subjects achieving an ACR 20 at Week 12|Proportion of subjects achieving an ACR 20|Proportion of subjects schieving and ACR 50|Proportion of subjects schieving and ACR 70|Percent change from baseline to each scheduled visit in DAS28 score|Percent change from baseline to each scheduled visit in ACR scores|Proportion of subjects schieving a 20% change in assessment of pain, disease activity and fatigue|Percent change from baseline to each scheduled visit in HAQ score",http://ClinicalTrials.gov/show/NCT00605735,"United States, &nbsp; Argentina, &nbsp; Czech Republic, &nbsp; France, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Spain, &nbsp; Taiwan",1,0,2,NA
NCT00606489,Efficacy and Safety Study of Caldolor in Hospitalized Adult and Pediatric Burn Patients,Completed,No Results Available,Burns,Drug: Caldolor|Drug: Placebo,Cumberland Pharmaceuticals,Both,Child|Adult|Senior,Phase III,60,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CPI-CL-010,1/22/2008,01/11/2007,01/05/2009,04/08/2010,01/04/2010,,01/05/2009,To evaluate the efficacy of Caldolor compared to placebo when administered every 6 hours for 24 hours on reducing fever,http://ClinicalTrials.gov/show/NCT00606489,"United States, &nbsp; India",1,1,2,1
NCT00607087,Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin glulisine|Drug: Insulin lispro|Drug: Insulin aspart,Sanofi-Aventis,Both,Adult|Senior,Phase IV,289,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,APIDR_C_02083|2007-003579-38,1/23/2008,01/01/2008,01/06/2009,8/26/2010,01/08/2010,PUMP,01/06/2009,"Percentage of Patients With at Least One Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion|Monthly Rate of Unexplained Hyperglycemia and/ or Confirmed Infusion Set Occlusion|Percentage of Patients With at Least One Unexplained Hyperglycemia|Monthly Rate of Unexplained Hyperglycemia|Percentage of Patients With at Least One Confirmed Infusion Set Occlusion|Monthly Rate of Confirmed Infusion Set Occlusion|Percentage of Patients With at Least One Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis|Monthly Rate of Episode of Significant Ketosis and/ or Risk Level for Impending Diabetic Ketoacidosis|Rate of Symptomatic Hypoglycemia With a Plasma Glucose (PG) ??? 70 mg/dL Per Patient-year|Rate of Severe Symptomatic Hypoglycemia Per Patient-year|Rate of Nocturnal Symptomatic Hypoglycemia With a Plasma Glucose (PG) ???70 mg/dL Per Patient-year|Patients With at Least One Site Infection, Site Inflammation/Erythema, Pruritus or Isolated Pain at Injection Site|Time Interval Between Infusion Set Changes: All Changes|Time Interval Between Infusion Set Changes in Routine|Glycosylated Hemoglobin: HbA1c|Total Daily Basal Insulin Infusion|Total Daily Bolus Insulin Dose",http://ClinicalTrials.gov/show/NCT00607087,"United States, &nbsp; Australia, &nbsp; Austria, &nbsp; France, &nbsp; Hungary, &nbsp; Israel, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Netherlands, &nbsp; Spain, &nbsp; Sweden, &nbsp; United Kingdom",1,1,3,1
NCT00607373,Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia,Completed,No Results Available,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Drug: ISIS 301012 (mipomersen sodium)|Drug: Placebo,Genzyme|Isis Pharmaceuticals,Both,Child|Adult|Senior,Phase III,51,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",301012-CS5|2005-003449-15,1/22/2008,01/09/2007,01/04/2009,10/02/2010,01/10/2010,RADICHOL 1,01/03/2009,"To evaluate the LDL-C lowering efficacy of ISIS 301012 (mipomersen) in subjects with homozygous familial hypercholesterolemia on lipid-lowering therapy|To evaluate the incremental apoB-lowering efficacy of ISIS 301012 (mipomersen)|To assess the incremental total cholesterol-lowering efficacy of ISIS 301012 (mipomersen)|To assess the incremental non-HDL-C-lowering efficacy of ISIS 301012 (mipomersen)|To evaluate the incremental effects of ISIS 301012 (mipomersen) on triglycerides, VLDL-C, HDL-C, apoA-1, Lp(a), lipoprotein subclasses, and hsCRP",http://ClinicalTrials.gov/show/NCT00607373,"United States, &nbsp; Brazil, &nbsp; Canada, &nbsp; Singapore, &nbsp; South Africa, &nbsp; Taiwan, &nbsp; United Kingdom",1,0,2,NA
NCT00607789,"A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder",Completed,No Results Available,Binge Eating|Depression,Drug: duloxetine|Drug: placebo,University of Cincinnati,Both,Adult,Phase IV,40,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",Nelson #2,1/23/2008,01/10/2006,01/10/2009,10/09/2009,01/10/2009,,01/10/2009,"The specific aim of this study is to assess the efficacy, tolerability, and safety of duloxetine compared with placebo in outpatients with binge eating disorder and a comorbid depressive disorder.",http://ClinicalTrials.gov/show/NCT00607789,United States,1,1,2,0
NCT00608894,LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis,Completed,No Results Available,Autoimmune Hepatitis,Drug: LCP-Tacro (tacrolimus)|Drug: Azathioprine,LifeCycle Pharma A/S,Both,Adult|Senior,Phase II,60,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LCP-Tacro Study 2016,1/23/2008,01/12/2007,01/07/2009,10/21/2009,01/10/2009,,01/02/2009,"Percent of patients that achieve biochemical remission of (AIH) at Month 6 during treatment with LCP-Tacro + prednisone or azathioprine + prednisone. Biochemical remission is defined as ALT, total bilirubin and gamma globulin within normal limits.|Percent of patients who achieve biochemical remission by Month 3 during treatment with LCP-Tacro + prednisone or azathioprine + prednisone.|Percents of patients in each treatment group classified as either in remission, having an incomplete response, a treatment failure, or a case of relapse. Each patient will be classified as being one of the four states at Month 6.",http://ClinicalTrials.gov/show/NCT00608894,"United States, &nbsp; Canada",1,1,2,0
NCT00609011,Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma,Completed,No Results Available,Metastatic Melanoma,Drug: MPC-6827 + Temozolomide,Myrexis Inc.,Both,Adult|Senior,Phase I|Phase II,22,Industry,Interventional,Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MPC-6827-07-005,1/23/2008,01/03/2008,01/08/2009,8/19/2010,01/08/2010,,01/08/2009,Safety and Tolerability; Maximum Tolerated Dose|Pharmacokinetics|Antitumor Activity,http://ClinicalTrials.gov/show/NCT00609011,United States,1,0,1,NA
NCT00609167,"Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma",Completed,Has Results,Multiple Myeloma and Plasma Cell Neoplasm,Drug: bortezomib|Drug: cyclophosphamide|Drug: dexamethasone,Mayo Clinic|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,63,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000583225|P30CA015083|MC0686|06-002613|NCI-2010-02147,1/31/2008,01/12/2006,01/11/2010,12/14/2010,01/12/2010,,01/01/2009,"Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment|Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants Who Responded to Treatment (Complete Response,CR; Near Complete Response, nCR; Very Good Partial Response, VGPR; or Partial Response, PR) After 4 Cycles|Duration of Response|Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 8 Cycles|Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 12 Cycles|Number of Participants With Severe Adverse Events|Participants Who Successfully Completed Collection of Peripheral Blood Stem Cells for Transplant",http://ClinicalTrials.gov/show/NCT00609167,"United States, &nbsp; Canada",1,1,3,0
NCT00611026,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.,Completed,Has Results,Overactive Bladder,Drug: Tolterodine ER|Drug: Placebo|Drug: Fesoterodine,Pfizer,Both,Adult|Senior,Phase III,2417,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",A0221046,1/28/2008,01/02/2008,01/10/2009,12/13/2010,01/12/2010,,01/10/2009,Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12|Change From Baseline in Mean Voided Volume Per Micturition|Change From Baseline in Mean Number of Micturitions Per 24 Hours|Percent Change From Baseline of Micturitions Per 24 Hours|Change From Baseline in Mean Number of Nocturnal Micturitions Per 24 Hours|Percent Change From Baseline of Nocturnal Micturitions Per 24 Hours|Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 1 and Week 4|Percent Change From Baseline of UUI Episodes Per 24 Hours|Change From Baseline in Mean Number of Urgency Urinary Episodes Per 24 Hours (Urinary Sensation Scale ??­3 in the Diary)|Percent Change From Baseline in Mean Number of Urgency Urinary Episodes Per 24 Hours (Urinary Sensation Scale ??­3 in the Diary)|Change From Baseline in Mean Number of Severe Urgency Episodes Per 24 Hours|Percent Change From Baseline of Severe Urgency Episodes Per 24 Hours|Change From Baseline in Mean Urinary Sensation Scale (USS) Rating Per Micturition Per 24 Hours.|Change From Baseline in Frequency-Urgency Sum (FUS) Per 24 Hours (Synonymous With USS Sum in the Study Protocol)|Diary Dry Rate: Percentage of Participants With no Urgency Urinary Incontinence (UUI) in the 3-day Bladder Diary|Change From Baseline in Patient Perception of Bladder Condition (PPBC)|Change From Baseline in Urgency Perception Scale (UPS). UPS Formerly Known as Patient Perception of Urgency Scale (PPUS) in the Protocol.|Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Symptom Bother Score at Week 12|Change From Baseline in Overactive Bladder Questionnaire (OAB-q): Health Related Quality of Life (HRQL) at Week 12,http://ClinicalTrials.gov/show/NCT00611026,"United States, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Colombia, &nbsp; Costa Rica, &nbsp; Estonia, &nbsp; Germany, &nbsp; Greece, &nbsp; Hungary, &nbsp; India, &nbsp; Ireland, &nbsp; Korea, Republic of, &nbsp; Latvia, &nbsp; Lithuania, &nbsp; Malaysia, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Singapore, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Ukraine",1,1,3,0
NCT00612014,Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis,Completed,No Results Available,Gastroparesis|Diabetes Mellitus,Drug: 5% dextrose in water|Drug: TZP-101|Drug: TZP-101|Drug: TZP-101|Drug: TZP-101|Drug: TZP-101,"Tranzyme, Inc.",Both,Adult|Senior,Phase II,78,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",TZP-101-CL-G004|2007-003279-38,1/28/2008,01/10/2007,01/03/2009,09/09/2010,01/09/2010,,01/02/2009,Change from baseline in the mean Gastroparesis Cardinal Symptom Index score (24 hour recall version) across the four days of dosing. Baseline is the average of the scores collected across the 4 days just prior to admission for dosing.|Cumulative GSA score after each dosing event and after all dosing events,http://ClinicalTrials.gov/show/NCT00612014,"United States, &nbsp; Denmark, &nbsp; India, &nbsp; Norway, &nbsp; Sweden, &nbsp; United Kingdom",1,0,6,NA
NCT00612105,Safety/Efficacy Study of Retigabine vs. Placebo in PHN,Completed,No Results Available,Postherpetic Neuralgia,Drug: Retigabine|Drug: Placebo,Valeant Pharmaceuticals North America,Both,Adult|Senior,Phase II,187,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VRX-RET-E22-NP201|VRX-RET-E22-NP201,1/25/2008,01/10/2007,01/12/2009,01/07/2010,01/01/2010,,01/05/2009,Primary endpoint will be the change from baseline in average pain score over the last 7 days of the Maintenance Phase.,http://ClinicalTrials.gov/show/NCT00612105,"United States, &nbsp; South Africa",1,0,2,NA
NCT00612170,"A 14-Week, Multi-Center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.",Completed,No Results Available,Fibromyalgia,"Drug: [S,S]-Reboxetine|Drug: Placebo|Drug: [S,S]-Reboxetine|Drug: [S,S]-Reboxetine",Pfizer,Both,Adult|Senior,Phase III,1129,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",A6061043|A6061043,1/29/2008,01/12/2007,01/05/2009,07/09/2009,01/07/2009,,01/05/2009,Change from baseline in the endpoint mean pain score|Fibromyalgia Impact Questionnaire|Change from baseline in the endpoint mean sleep interference score|Patient Global Impression of Change|Multidimensional Assessment of Fatigue|Hospital Anxiety and Depression Scale|Short Form 36|Sheehan Disability Score|Pain Visual Analogue Scale,http://ClinicalTrials.gov/show/NCT00612170,"United States, &nbsp; Canada",1,0,4,NA
NCT00612456,"A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD",Completed,No Results Available,Macular Degeneration,Drug: Pazopanib,GlaxoSmithKline,Both,Adult|Senior,Phase II,70,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",MD7108240,1/29/2008,01/02/2008,01/01/2009,4/22/2010,01/04/2010,,01/01/2009,"central retinal thickness measured by OCT, an imaging technique|Clinical lab tests, ECG, vital signs, eye exam, visual acuity|Retinal morphology, neovascular size, and lesion size and characteristics|Plasma pharmacokinetics|Safety endpoints include complete ophthalmic examination, vital signs (heart rate and blood pressure), cardiac monitoring (electrocardiogram), clinical laboratory tests, clinical monitoring and adverse event reporting.|Change in visual acuity (number of letters read on standardized ETDRS charts).|Change in retinal morphology (i.e. CNV, intraretinal cysts, intraretinal fluid, subretinal fluid, and retinal pigment epithelial detachment) as determined by OCT.|Change in neovascular size, lesion size and characteristics (fibrosis, atrophy, blood) as measured by fluorescein angiography and fundus photography.|Cmax, tmax, and AUC(0-24) of plasma pazopanib, if data are sufficient.",http://ClinicalTrials.gov/show/NCT00612456,"United States, &nbsp; Australia, &nbsp; Belgium, &nbsp; Italy",1,1,1,1
NCT00612664,"Phase II, 2nd Line Melanoma - RAND Monotherapy",Completed,No Results Available,Melanoma,Drug: Anti-CD137 (4-1BB) (BMS-663513),Bristol-Myers Squibb,Both,Adult|Senior,Phase II,158,Industry,Interventional,Allocation: Randomized|Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CA186-006,1/30/2008,01/03/2008,01/10/2009,01/06/2011,01/01/2010,,01/10/2009,"Radiographic imaging, photographic and clinical evaluation will be used for tumor assessment to determine 6-month progression-free survival rate|Safety profiles|Disease response rate|Disease control rate|1-year survival|Pharmacokinetics|Pharmacodynamics|Biomarkers",http://ClinicalTrials.gov/show/NCT00612664,"United States, &nbsp; Canada, &nbsp; Denmark, &nbsp; France, &nbsp; Germany, &nbsp; Italy",1,0,1,NA
NCT00614445,The Efficacy Of Diclectin?ó For Nausea And Vomiting Of Pregnancy,Completed,No Results Available,Nausea and Vomiting of Pregnancy,Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|Drug: Placebo,Duchesnay Inc.|Premier Research Group plc,Female,Adult|Senior,Phase III,280,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",DIC-301,1/29/2008,01/01/2008,01/12/2009,02/03/2010,01/02/2010,,01/07/2009,The change in the Pregnancy Unique Quantification of Emesis (PUQE) score from baseline between Diclectin?ó and placebo.,http://ClinicalTrials.gov/show/NCT00614445,United States,1,1,2,1
NCT00614939,Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,Both,Adult|Senior,Phase III,572,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",D1680C00007|EudraCT number 2007-004951-12,1/31/2008,01/01/2008,01/03/2010,06/07/2010,01/06/2010,,01/06/2009,Absolute Change From Baseline in Glucosylated Haemoglobin A1c (HbA1c) (%) Level to Week 12|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) (mg/dL) to Week 12 - Moderate Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) (mg/dL) to Week 12 - Severe Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (mg/dL) - End-Stage Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) (mmol/L) to Week 12 - Moderate Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (mmol/L) - Severe Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (mmol/L) - End-Stage Renal Impairment Subgroup,http://ClinicalTrials.gov/show/NCT00614939,"United States, &nbsp; Belarus, &nbsp; Bulgaria, &nbsp; Croatia, &nbsp; Czech Republic, &nbsp; Estonia, &nbsp; Germany, &nbsp; Hungary, &nbsp; Latvia, &nbsp; Lithuania, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Ukraine",1,1,2,1
NCT00615017,AZD9773 Dose Escalation Study,Completed,No Results Available,Severe Sepsis,Drug: AZD9773 (CytoFab),AstraZeneca,Both,Adult|Senior,Phase II,74,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",D0620C00004,1/31/2008,01/01/2008,01/07/2009,3/23/2010,01/03/2010,,01/07/2009,"The primary purpose of the study is to evaluate the safety profile of AZD9773 as evidenced by adverse events, serious adverse events, laboratory safety assessments, vital signs, 12-lead ECG and physical examination.|Additional outcome variables include general assessment of sepsis care, PK, and PD.",http://ClinicalTrials.gov/show/NCT00615017,United States,1,0,1,NA
NCT00615199,"A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease",Completed,No Results Available,Crohn's Disease,"Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550",Pfizer,Both,Adult|Senior,Phase II,150,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A3921043,1/14/2008,01/12/2007,01/10/2009,11/23/2009,01/11/2009,,01/10/2009,Clinical response defined by a decrease in the Crohn's disease activity index (CDAI) score of at least 70 points from baseline|Percentage of subjects achieving clinical remission defined as a reduction of CDAI score below 150|Clinical response defined by a decrease in the CDAI score of at least 100 points from baseline|Clinical response defined by a decrease in the CDAI score of at least 70 points from baseline,http://ClinicalTrials.gov/show/NCT00615199,"United States, &nbsp; Belgium, &nbsp; Czech Republic, &nbsp; France, &nbsp; Hungary, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; United Kingdom",1,0,3,NA
NCT00615251,A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization,Completed,No Results Available,Infertility,Drug: DR-2011|Drug: Crinone 8%,Duramed Research,Female,Adult,Phase III,1300,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,DR-PGN-302,02/04/2008,01/02/2008,01/08/2009,01/08/2010,01/01/2010,,01/08/2009,"Clinical pregnancy rate at 8 weeks and 12 weeks of pregnancy|Secondary outcome measures will include: live birth rate, cycle cancellation rate, rate of spontaneous abortion, rate of biochemical pregnancy, rate of ectopic pregnancy|Adverse events",http://ClinicalTrials.gov/show/NCT00615251,United States,1,0,2,NA
NCT00615433,Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: Lurasidone|Drug: Lurasidone|Drug: Olanzapine|Drug: Sugar Pill,Dainippon Sumitomo Pharma America,Both,Adult|Senior,Phase III,478,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",D1050231,02/01/2008,01/01/2008,01/03/2010,3/15/2010,01/03/2010,,01/12/2009,Change in total PANSS score from baseline to the end of the double blind treatment period.|CGI-S from baseline to the end of the double-blind treatment.,http://ClinicalTrials.gov/show/NCT00615433,"United States, &nbsp; Colombia, &nbsp; India, &nbsp; Lithuania, &nbsp; Philippines",1,1,4,0
NCT00615693,"Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis",Completed,No Results Available,Uveitis|Posterior Uveitis|Panuveitis,Drug: AEB071,Novartis,Both,Adult|Senior,Phase II,13,Industry,Interventional,Control: Historical Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CAEB071A2211,02/01/2008,01/07/2008,NA,7/19/2010,01/07/2010,,01/10/2009,Safety and tolerability of AEB071|Change in the degree of inflammation in the study eye|Change in the visual acuity of the study eye|Change in macular edema in the study eye,http://ClinicalTrials.gov/show/NCT00615693,United States,1,0,1,NA
NCT00615966,Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients,Completed,No Results Available,Kidney Transplantation,Drug: Diannexin|Drug: Placebo|Drug: Diannexin,Alavita Pharmaceuticals Inc|CTI Clinical Trial and Consulting Services,Both,Adult|Senior,Phase I|Phase II,58,Industry|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",DAV-CL002,02/01/2008,01/02/2008,01/02/2010,8/13/2010,01/08/2010,,01/01/2009,"Safety assessments -- physical examinations, vital signs, clinical safety laboratory tests, ECGs, immunogenicity testing, adverse events|Population pharmacokinetics",http://ClinicalTrials.gov/show/NCT00615966,United States,1,0,3,NA
NCT00616330,Vaginal Infection Study,Completed,No Results Available,Vulvovaginitis|Vaginitis,Drug: clindamycin phosphate/butoconazole nitrate|Drug: clindamycin phosphate|Drug: butoconazole nitrate,KV Pharmaceutical Company,Female,Child|Adult|Senior,Phase III,1443,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CBC-302-602-622467,02/04/2008,01/01/2008,01/12/2009,05/03/2010,01/05/2010,,01/12/2009,The primary outcome measure of the study will be clinical symptom resolution.|Secondary outcome measures will include laboratory assessments of presence or absence of vaginal infection.,http://ClinicalTrials.gov/show/NCT00616330,"United States, &nbsp; India, &nbsp; Puerto Rico, &nbsp; Russian Federation",1,1,3,0
NCT00616421,Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children,Completed,No Results Available,Meningococcal Infections,Biological: Novartis MenACWY Conjugate Vaccine|Biological: Novartis MenACWY Conjugate Vaccine|Biological: Licensed meningococcal ACWY vaccine,Novartis|Novartis Vaccines and Diagnostics,Both,Child,Phase III,2907,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",V59P20|11278,1/31/2008,01/03/2008,01/10/2009,11/30/2010,01/11/2010,,01/04/2009,"Percentage of Participants With At Least a 4-fold Rise in Meningococcal Antibody Titer after 1 dose of MenACWY or Licensed Vaccine in 2-5-year-old children|Percentage of Participants With At Least a 4-fold Rise in Meningococcal Antibody Titer after 1 dose of MenACWY or Licensed Vaccines in 6-10-year-old children|Percentage of Subjects With At Least a 4-Fold Rise in Meningococcal Antibody Titer, hSBA Titer of >= 1:4, hSBA Titer of >=1:8 in Healthy 2-5-year-old children|Percentage of Subjects With At Least a 4-Fold Rise in Meningococcal Antibody Titer, hSBA >=1:4, hSBA >=1:8, in 2-10-year-old children",http://ClinicalTrials.gov/show/NCT00616421,"United States, &nbsp; Canada",0,NA,3,NA
NCT00616564,Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma,Completed,No Results Available,Malignant Melanoma,Drug: GM-CSF,"Mt. Sinai Medical Center, Miami|Bayer|Chiron Corporation",Both,Child|Adult|Senior,Phase II,35,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MEL0105,02/04/2008,01/02/2006,01/09/2009,9/17/2009,01/09/2009,,01/09/2009,,http://ClinicalTrials.gov/show/NCT00616564,United States,1,1,1,1
NCT00617097,Paracervical Block in First Trimester Surgical Abortions,Completed,No Results Available,"Pain|Abortion, Induced",Drug: lidocaine|Drug: ketorolac and lidocaine,Johns Hopkins University|Oregon Health and Science University,Female,Adult,Phase II|Phase III,50,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NA_00013075|SFP1-1,12/28/2007,01/01/2008,01/06/2009,06/08/2009,01/06/2009,,01/05/2009,The mean difference in distance (in millimeters) on a 100-mm Visual Analogue Scale (VAS) taken during specific time intervals throughout termination procedure.,http://ClinicalTrials.gov/show/NCT00617097,United States,1,1,2,0
NCT00617344,Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US,Completed,No Results Available,Dengue Fever|Dengue Hemorrhagic Fever|Dengue Virus,Biological: ChimeriVax?ºÑ Tetravalent Dengue Vaccine|Biological: ChimeriVax?ºÑ Tetravalent Dengue Vaccine|Biological: ChimeriVax?ºÑ Tetravalent Dengue Vaccine,Sanofi-Aventis,Both,Adult,Phase II,260,Industry,Interventional,"Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CYD12,02/06/2008,01/04/2008,01/02/2010,5/18/2010,01/05/2010,,01/12/2009,Neutralizing antibody titers to each of four dengue virus serotypes in 2 groups of subjects after the second vaccination|Safety: Adverse events in the first 28 days after each injection and SAEs during the entire trial. Immunogenicity: Neutralizing antibody titers to each of the dengue virus serotypes for each vaccine at baseline and 30 days after vaccinations,http://ClinicalTrials.gov/show/NCT00617344,United States,0,NA,3,NA
NCT00617461,A Clinical Study Of XP13512/GSK1838262 In Subjects With Neuropathic Pain From Post-Herpetic Neuralgia (PHN) Who Have Had An Inadequate Response To Gabapentin Treatment,Completed,No Results Available,"Neuralgia, Postherpetic|Pain Associated With Post-Herpetic Neuralgia",Drug: XP13512/GSK1838262,GlaxoSmithKline,Both,Adult|Senior,Phase II,96,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",110527,02/06/2008,01/03/2008,01/07/2009,9/17/2010,01/09/2010,,01/07/2009,"the mean daily average pain intensity score for the last week of each treatment period based on an 11-point PI-NRS (0 = \no pain\"" and 10 = \""pain as bad as you can imagine\"").|24-hour",http://ClinicalTrials.gov/show/NCT00617461,"United States, &nbsp; Germany",1,0,1,NA
NCT00617994,"Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis",Completed,No Results Available,Plaque Psoriasis,Drug: INCB018424,Incyte Corporation,Both,Adult,Phase II,25,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,INCB 18424-202,1/21/2008,01/08/2007,01/05/2009,6/28/2010,01/06/2010,,01/04/2009,"Safety and tolerability will be assessed by signs and symptoms of adverse experiences, measuring VS and ECGs, clinical laboratory blood and urine samples. The PK endpoints are planned to determine the INCB018424 plasma concentrations.|Pharmacodynamics and preliminary efficacy",http://ClinicalTrials.gov/show/NCT00617994,United States,1,0,1,NA
NCT00619476,A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN),Completed,No Results Available,Neuropathic Pain Associated With Post-Herpetic Neuralgia,Drug: XP13512/GSK1838262,GlaxoSmithKline,Both,Adult|Senior,Phase II,376,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",110748,02/07/2008,01/02/2008,01/07/2009,2/18/2010,01/02/2010,,01/07/2009,"The change from baseline to end of treatment with respect to the mean 24-hour average pain intensity score based on an 11-point PI-NRS (0 = \no pain\"" and10 = \""pain as bad as you can imagine\"").|24-hour",http://ClinicalTrials.gov/show/NCT00619476,"United States, &nbsp; Canada",1,0,1,NA
NCT00619619,Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients With Major Depressive Disorder,Completed,No Results Available,Depression|Major Depressive Disorder,Drug: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR),Wyeth,Both,Child,Phase I|Phase II,64,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label,3151A6-2000,1/28/2008,01/01/2008,01/12/2009,06/11/2010,01/06/2010,,01/12/2009,1) safety and tolerability of single ascending doses of DVS SR in children and adolescents with MDD and 2) characterization of PK profile of single ascending doses of DVS SR in children and adolescents with MDD|1) characterization of pop PK in children and adolescents with MDD 2) exploratory efficacy evaluation of DVS SR in children and adolescents with MDD. CDRS-R total score will be summarized by mean change from baseline at each time point using LOCF data,http://ClinicalTrials.gov/show/NCT00619619,United States,1,1,1,0
NCT00620022,The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,Completed,No Results Available,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol 300 ??g delivered via SDDPI|Drug: Placebo to indacaterol delivered via SDDPI,Novartis,Both,Adult|Senior,Phase III,90,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CQAB149B2311,02/08/2008,01/04/2008,NA,12/16/2009,01/12/2009,,01/05/2009,Exercise endurance time after 3 weeks of treatment.|Trough inspiratory capacity after 3 weeks of treatment,http://ClinicalTrials.gov/show/NCT00620022,"United States, &nbsp; Belgium, &nbsp; Canada, &nbsp; Denmark, &nbsp; Italy, &nbsp; Spain",1,0,2,NA
NCT00620061,Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone,Completed,No Results Available,Opioid-Induced Bowel Dysfunction,Drug: Lubiprostone,"Sucampo Pharmaceuticals, Inc.|Takeda Pharmaceutical Company Limited",Both,Adult|Senior,Phase III,440,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,OBD06S1,02/11/2008,01/11/2007,01/09/2009,12/10/2009,01/12/2009,,01/09/2009,"Evaluation of overall safety, including AEs; clinical laboratory evaluations; vital signs; 12-lead resting electrocardiograms; and physical examination results.|Change from baseline in spontaneous bowel movement (SBM) and bowel movement (BM) frequency|Frequency of SBMs and BMs|Responder rates|Mean change from baseline in straining associated with SBMs; stool consistency of SBMs; constipation severity; treatment effectiveness; abdominal bloating; abdominal discomfort; and bowel habit regularity.",http://ClinicalTrials.gov/show/NCT00620061,United States,1,1,1,1
NCT00620451,"Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate (AT-1001) in Active Celiac Disease",Completed,No Results Available,Celiac Disease,Drug: larazotide acetate (AT-1001)|Drug: larazotide acetate (AT-1001)|Drug: placebo,Alba Therapeutics,Both,Adult|Senior,Phase II,105,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AT1001-011,02/07/2008,01/02/2008,01/12/2009,1/18/2010,01/01/2010,,01/07/2009,Villous Height to Crypt Depth (Vh:Cd) ratio|To assess the safety and tolerability of larazotide acetate (AT-1001),http://ClinicalTrials.gov/show/NCT00620451,"United States, &nbsp; Canada, &nbsp; Spain",1,0,3,NA
NCT00620893,"Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).",Completed,No Results Available,Dry Eye Syndromes,Drug: PEG- 400 based artificial tear|Drug: Systane,"Bp Consulting, Inc",Both,Adult|Senior,Phase IV,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",5339,02/11/2008,01/02/2008,01/05/2009,9/17/2009,01/09/2009,,01/05/2009,dry eye signs|refractive regression,http://ClinicalTrials.gov/show/NCT00620893,United States,1,0,2,NA
NCT00621192,Pharmacokinetic and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections,Completed,No Results Available,Necrotizing Enterocolitis|Intra-abdominal Infection,Drug: meropenem|Drug: meropenem|Drug: meropenem,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Both,Child,Phase I|Phase II,200,NIH,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HHSN267200700051C|HHSN267200700051C,2/20/2008,01/06/2008,01/10/2009,05/12/2010,01/05/2009,Meropenem PK,01/10/2009,Pharmacokinetics|seizure frequency,http://ClinicalTrials.gov/show/NCT00621192,United States,1,1,3,1
NCT00621517,Bupropion and Restless Legs Syndrome,Completed,No Results Available,Restless Legs Syndrome,Drug: Bupropion|Drug: Placebo,East Tennessee State University,Both,Adult|Senior,Phase II|Phase III,70,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ETSU-07-061f,02/12/2008,01/02/2008,01/07/2009,10/01/2009,01/10/2009,,01/07/2009,"Change in International Restless Legs Syndrome Study Group severity scale|Clinical Global Impression - Improvement Scale|Ordinal Scale(i.e., 1-8)of symptom severity",http://ClinicalTrials.gov/show/NCT00621517,United States,1,1,2,1
NCT00621842,Lamotrigine for Symptoms of Geriatric Bipolar Depression,Completed,No Results Available,"Bipolar Disorder|Depression, Bipolar",Drug: Lamotrigine regular tablet formulation|Drug: Lamotrigine novel formulation,University Hospitals of Cleveland|GlaxoSmithKline,Both,Adult|Senior,Phase III,60,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,"L0971|GSK110720|IND 78,081",02/12/2008,01/01/2008,01/12/2009,1/26/2010,01/01/2010,Geri-BD SAD,01/12/2009,"Assessment of change in depressive symptoms from baseline on the Montgomery Asberg Depression Rating Scale (MADRS)|Assessment of adverse effects with standardized rating scales and Udvalg fur Kliniske Undersogelser (UKU)|Change in depressive symptoms from baseline using the Hamilton Depression Rating Scale (GRID-HAM-D)|Change in manic symptoms from baseline using the Young Mania Rating Scale (YMRS)|Change from baseline in overall clinical diagnosis using the CGI-BP|Change in or appearance of extrapyramidal symptoms from baseline using the SAS, BAS, and AIMS scales.|Change in body weight from baseline|Spontaneous reports of adverse effects",http://ClinicalTrials.gov/show/NCT00621842,United States,1,1,2,0
NCT00621855,RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome,Completed,No Results Available,Coronary Disease,Drug: Dabigatran etexilate|Drug: Placebo,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase II,1878,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,1160.67|RE-DEEM EUDRACT2007-004301-99,2/13/2008,01/03/2008,NA,10/12/2009,01/10/2009,,01/10/2009,The composite of major and clinically relevant minor bleeding events during six months of treatment|Indicators of efficacy and composite of cardiovascular death or all cause death with: non fatal MI and non haemorrhagic stroke during six months of treatment.,http://ClinicalTrials.gov/show/NCT00621855,"United States, &nbsp; Belgium, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Finland, &nbsp; France, &nbsp; Georgia, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Ireland, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Sweden, &nbsp; Ukraine, &nbsp; United Kingdom",1,1,2,1
NCT00621985,Dexamethasone Treatment of Congenital Adrenal Hyperplasia,Completed,No Results Available,"Adrenal Hyperplasia, Congenital",Drug: dexamethasone,Children's Hospital Boston,Both,Child,Phase II,5,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,08/01/2025,02/11/2008,01/02/2008,01/06/2009,08/03/2009,01/08/2009,,01/06/2009,Area under the curve of 17 hydroxyprogesterone as measured via frequent lab draws in a 24 hour period.|Area under the curve of ACTH and Androstenedione as measured via frequent lab draws during a 24 hour period,http://ClinicalTrials.gov/show/NCT00621985,United States,1,1,1,0
NCT00622193,Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: anamorelin HCl|Drug: anamorelin HCl|Drug: placebo,"Helsinn Therapeutics (U.S.), Inc",Both,Adult|Senior,Phase II,228,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ST-ANAM-207,02/12/2008,01/03/2008,01/12/2009,4/20/2010,01/04/2010,,01/12/2009,Hand grip strength and body weight|Quality of Life and Biomarker,http://ClinicalTrials.gov/show/NCT00622193,"United States, &nbsp; India",1,0,3,NA
NCT00622739,Ziprasidone in Pediatric Bipolar Disorder,Completed,No Results Available,Bipolar Disorder,Drug: Ziprasidone|Drug: Ziprasidone,University of Texas Southwestern Medical Center|Stanley Medical Research Institute|Pfizer|Children's Medical Center Dallas,Both,Child,Phase IV,45,Other|Industry,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SaxenaZiprasidone,2/13/2008,01/02/2007,01/11/2009,01/11/2010,01/10/2008,,01/09/2009,Young Mania Rating Scale (YMRS)|Clinical Global Impressions (CGI) Scale|SAFTEE (Side effects rating scale)|AIMS (Abnormal Involuntary Movement Scale)|Children's Depression Rating Scale,http://ClinicalTrials.gov/show/NCT00622739,United States,1,1,2,1
NCT00624351,Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease,Completed,No Results Available,Systemic Lupus Erythematosus,Biological: Epratuzumab|Other: Placebo,"UCB, Inc.",Both,Adult|Senior,Phase II,227,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SL0007|EudraCT Number: 2007-002566-35,2/15/2008,01/01/2008,01/08/2009,11/22/2010,01/11/2010,,01/08/2009,"Efficacy as measured by the responder rate according to a combined response index evaluated at week 12 (visit 10) incorporating BILAG assessment, SLEDAI, a physician's global assessment and treatment failure status.|The combined response index analysis described for the primary endpoint.|The combined response index including an additional criteria involving the SF-36 response.|Number and percent of patients with BILAG improvement.|Change from baseline in total BILAG score.|Change from baseline in SLEDAI.|Change from baseline in physician and patient global assessments.|Percentage of patients achieving SF-36 response from baseline.|EQ-5D results at weeks 12.|Time to first sustained BILAG response|Time to enhanced BILAG response.|Proportion of patients meeting treatment failure.|Endpoints relating to use of steroids over treatment period.|Safety outcome measures include adverse events (including infusion reactions), vital signs and clinical safety laboratory assessments.|Immunogenicity as measured from baseline by human anti-human antibodies (HAHA)|Assessment of changes from baseline in levels of circulating B and T cells",http://ClinicalTrials.gov/show/NCT00624351,"United States, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Hong Kong, &nbsp; Hungary, &nbsp; India, &nbsp; Lithuania, &nbsp; Poland, &nbsp; Spain, &nbsp; Ukraine, &nbsp; United Kingdom",0,NA,2,NA
NCT00624416,Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas,Completed,No Results Available,Lipoma,Drug: Isoproterenol;Prednisolone,Pennington Biomedical Research Center|Lipothera,Both,Adult,Phase I|Phase II,10,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PBRC27015,2/15/2008,01/10/2007,01/03/2009,11/25/2009,01/11/2009,,01/03/2009,Lipoma volume at the end of the treatment period compared to baseline.,http://ClinicalTrials.gov/show/NCT00624416,United States,1,1,1,0
NCT00624442,A Study of CK-1827452 Infusion in Stable Heart Failure,Completed,Has Results,Heart Failure,Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: Placebo|Drug: Placebo|Drug: CK-1827452|Drug: Placebo|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452,Cytokinetics,Both,Adult|Senior,Phase II,45,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CY 1121,12/21/2007,01/04/2007,01/02/2009,7/16/2010,01/07/2010,,01/02/2009,Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations|Change From Baseline of Fractional Shortening at Various CK-1827452 Plasma Concentrations|Pharmacokinetics of CK-1827452 Injection in Stable Heart Failure Patients,http://ClinicalTrials.gov/show/NCT00624442,"United States, &nbsp; Georgia, &nbsp; Russian Federation, &nbsp; United Kingdom",1,0,16,NA
NCT00624559,The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure,Completed,No Results Available,Healthy,Drug: celecoxib (Celebrex)|Drug: placebo,University of Delaware|Christiana Care Health Services,Both,Adult,Phase IV,32,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Basic Science",HS 08-054,2/15/2008,01/02/2008,01/01/2009,3/30/2009,01/03/2009,,01/01/2009,Blood Pressure|Urinary sodium excretion,http://ClinicalTrials.gov/show/NCT00624559,United States,1,1,2,1
NCT00624845,"Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy",Completed,No Results Available,Postoperative Pain,Drug: OMS103HP|Drug: Vehicle,Omeros Corporation,Both,Adult|Senior,Phase II|Phase III,200,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C07-004,2/19/2008,01/12/2007,01/05/2009,4/28/2010,01/04/2010,C07-004,01/05/2009,The primary efficacy endpoint is the mean VAS at 24 hours postoperatively.,http://ClinicalTrials.gov/show/NCT00624845,United States,1,0,2,NA
NCT00624858,A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression,Completed,No Results Available,Depression,Drug: naltrexone SR 32 mg/ bupropion SR 360 mg daily,"Orexigen Therapeutics, Inc",Both,Adult,Phase II,25,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NB-402,2/19/2008,01/01/2008,01/07/2009,07/10/2009,01/07/2009,,01/07/2009,To assess the change in depressive symptoms as measured by Montgomery-Asberg Depression Rating Scale (MADRS) total score at 12 weeks|To assess the percentage change from baseline in total body weight at 12 and 24 weeks.,http://ClinicalTrials.gov/show/NCT00624858,United States,1,1,1,0
NCT00625573,Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01),Completed,No Results Available,Colorectal Cancer,Drug: Abraxane,"Mt. Sinai Medical Center, Miami|Abraxis BioScience, LLC.",Both,Adult|Senior,Phase II,29,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,COL-01,2/19/2008,01/09/2007,01/03/2009,9/17/2009,01/09/2009,ABX067,01/02/2009,"To evaluate the efficacy by means of response rate of Abraxane and capecitabine in combination, in the treatment of patients with colorectal cancer in the 2nd or 3rd line metastatic setting following failure of irinotecan or oxaliplatin based therapy|To evaluate overall survival, time to progression, response duration, time to response and safety of this combination",http://ClinicalTrials.gov/show/NCT00625573,United States,1,1,1,1
NCT00626236,Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems,Completed,No Results Available,Attention Deficit Disorder With Hyperactivity|Conduct Disorder,Drug: SPN-810,"Supernus Pharmaceuticals, Inc.",Both,Child,Phase II,72,Industry,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,810P201,2/20/2008,01/09/2008,01/10/2009,1/14/2010,01/01/2010,,01/09/2009,"safety scales (Simpson-Angus, Barnes Akathisia, AIMS)|Nisonger Child Behavior Rating Form - TIQ",http://ClinicalTrials.gov/show/NCT00626236,United States,1,0,1,NA
NCT00626431,A Study of Leuprolide to Treat Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Leuprolide acetate - Formulation A|Drug: Leuprolide acetate - Formulation B,Abbott,Male,Adult|Senior,Phase III,310,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,L-PC07-169,2/20/2008,01/02/2008,01/09/2009,10/07/2010,01/10/2010,,01/08/2009,"Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary Endpoint.|Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation B: ITT Population for the Primary Endpoint|Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation A: ITT Population|Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation B: ITT Population|Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation A: ITT Population|Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation B: ITT Population|Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation A: ITT Population|Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation B: ITT Population|Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation A: ITT Population|Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation B: ITT Population",http://ClinicalTrials.gov/show/NCT00626431,United States,1,1,2,1
NCT00626795,"Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)",Completed,No Results Available,Impetigo|Secondarily Infected Traumatic Lesions,Drug: TD1414 2% cream|Drug: TD1414 2% cream|Drug: Bactroban?ó (mupirocin) 2% cream,LEO Pharma,Both,Child|Adult|Senior,Phase II,682,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,TD1414-C21,2/21/2008,01/02/2008,01/06/2009,03/05/2010,01/03/2010,,01/03/2009,Clinical cure at end of treatment according to investigator's assessment|Clinical cure at follow-up according to investigator's assessment. Clinical cure at end of treatment and follow-up according to investigator's assessment. Bacteriological cure at end of treatment and follow-up.,http://ClinicalTrials.gov/show/NCT00626795,"United States, &nbsp; South Africa",1,0,3,NA
NCT00626886,"Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy",Completed,No Results Available,Herniorrhaphy|Postoperative Pain|Inguinal Hernia,Drug: Bupivacaine Collagen Sponge|Drug: placebo collagen sponge,Innocoll Technologies|Premier Research Group plc,Male,Adult|Senior,Phase II,53,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",INN-CB-003,2/20/2008,01/01/2008,01/01/2009,3/19/2009,01/03/2009,,01/01/2009,"Total use of opioid rescue analgesia|Total use of opioid rescue analgesia|Total use of opioid rescue analgesia|Pain intensity on the VAS at rest and after aggravated movement (cough)|Pain intensity rating on a 4-point Likert scale at rest and after aggravated movement (cough)|Pain relief rating on a 5-point Likert scale at rest and after aggravated movement (cough)|Patient's global evaluation of the study treatment on a 5 point Likert scale|Time to first use of opioid rescue analgesia|Pharmacokinetic parameters|Treatment emergent adverse events|Vital signs (heart rate, respiratory rate, systolic and diastolic blood pressure and body temperature)",http://ClinicalTrials.gov/show/NCT00626886,United States,1,0,2,NA
NCT00627016,A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn,Completed,Has Results,Gastroesophageal Reflux,Drug: Dexlansoprazole|Drug: Placebo,"Takeda Global Research & Development Center, Inc.",Both,Adult,Phase III,305,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",T-GD07-170|U1111-1113-9537,2/21/2008,01/03/2008,01/03/2009,5/21/2010,01/05/2010,,01/03/2009,Median Percentage of Nights Without Heartburn Over 4 Weeks as Assessed by Daily Diary.|Percent of Subjects With Relief of Night Time Heartburn Over the Last 7 Days of Treatment as Assessed by Daily Diary.|Percentage of Participants With Relief of Gastro-Esophageal Reflux Disease (GERD) Associated Sleep Disturbances Over the Last 7 Days of Treatment as Assessed by Daily Diary.,http://ClinicalTrials.gov/show/NCT00627016,United States,1,1,2,1
NCT00628095,"Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate",Completed,No Results Available,"Arthritis, Rheumatoid","Drug: CE-224,535|Drug: Placebo",Pfizer,Both,Adult|Senior,Phase II|Phase III,100,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A6341009,2/25/2008,01/03/2008,01/02/2009,10/07/2009,01/10/2009,,01/02/2009,ACR 20|DAS 28(3) crp|pharmacokinetics|adverse events|ACR 50 and 70|components of ACR responses,http://ClinicalTrials.gov/show/NCT00628095,"United States, &nbsp; Chile, &nbsp; Czech Republic, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Poland, &nbsp; Spain",1,0,2,NA
NCT00628433,"Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis",Completed,No Results Available,Ulcerative Colitis,Drug: Placebo|Drug: HE3286,"Harbor BioSciences, Inc",Both,Adult,Phase I|Phase II,36,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HE3286-0301,2/25/2008,01/02/2008,01/05/2009,6/15/2009,01/06/2009,,01/05/2009,safety and pharmacokinetics|assess activity on the signs and symptoms of active mild-to-moderate ulcerative colitis,http://ClinicalTrials.gov/show/NCT00628433,United States,1,0,2,NA
NCT00629122,Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation,Completed,No Results Available,"Kidney Failure, Chronic",Drug: Tacrolimus/Clotrimazole Troche|Drug: Tacrolimus/Nystatin Suspension,Weill Medical College of Cornell University,Both,Adult|Senior,Phase IV,20,Other,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Health Services Research,710009492,02/12/2008,01/02/2008,01/12/2009,11/04/2010,01/11/2010,,01/12/2009,"Pharmacokinetic evaluation (absorption, distribution, elimination, area under the curve) between sublingual and oral administration routes.|Impact of drug interaction between tacrolimus and clotrimazole troche vs. nystatin suspension. Evaluate genotype polymorphisms that influence CYP3A4, CYP3A5, and p-glycoprotein expression to determine impact on sublingual and oral tacrolimus delivery.",http://ClinicalTrials.gov/show/NCT00629122,United States,1,1,2,0
NCT00629551,An Eight-Week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder,Completed,No Results Available,"Depressive Disorder, Major",Drug: saredutant (SR48968)|Drug: paroxetine|Drug: placebo,Sanofi-Aventis,Both,Adult,Phase III,820,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC10438|EudraCT 2007-003863-31,2/26/2008,01/02/2008,01/02/2009,3/19/2009,01/03/2009,COMPASS,01/02/2009,Change from baseline in Hamilton Depression Rating Scale total score|Change from baseline in the Changes in Sexual Functioning Questionnaire total score|Change from baseline in the Clinical Global Impression severity of illness score,http://ClinicalTrials.gov/show/NCT00629551,"United States, &nbsp; Chile, &nbsp; Estonia, &nbsp; Germany, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Russian Federation, &nbsp; South Africa",1,0,3,NA
NCT00630227,Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study,Completed,No Results Available,Homogeneous Emphysema,Biological: Biologic Lung Volume Reduction,Aeris Therapeutics,Both,Adult|Senior,Phase II,33,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,01-C07-002,2/27/2008,01/02/2008,01/12/2009,1/14/2010,01/01/2010,,01/12/2009,reduction in gas trapping|improvement in exercise capacity|improvement in expiratory flow|improvement in vital capacity|improvement in dyspnea sysmptoms|improvemnet in respiratory quality of life|serious adverse events,http://ClinicalTrials.gov/show/NCT00630227,United States,0,NA,1,NA
NCT00630656,Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis,Completed,No Results Available,Severe Sepsis,Drug: Talactoferrin alfa|Drug: Placebo,Agennix,Both,Adult|Senior,Phase II,190,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",LF-0801|NIH grant 1R44GM077816-01A2,2/28/2008,01/04/2008,01/02/2010,8/25/2010,01/08/2010,,01/08/2009,All-cause mortality|All-cause mortality|All-cause mortality,http://ClinicalTrials.gov/show/NCT00630656,"United States, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Spain",1,0,2,NA
NCT00630825,A Study of Dose Titration of LY2189265 in Overweight Patients With Type 2 Diabetes Mellitus,Completed,No Results Available,Diabetes Mellitus Type 2,Drug: Placebo|Drug: LY2189265|Drug: LY2189265|Drug: LY2189265,Eli Lilly and Company,Both,Adult|Senior,Phase II,266,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",12068|H9X-MC-GBCJ,2/28/2008,01/04/2008,01/01/2009,12/09/2009,01/12/2009,EGO,01/01/2009,"Evaluate once weekly injections of LY2189265 (adjusted and non-adjusted doses) compared to placebo on blood glucose as measured by HbA1C change from baseline in overweight patients with Type 2 Diabetes Mellitus|Fasting blood glucose|Meal test glucose excursion (change in blood glucose to test meal)|Self-monitoring of blood glucose (SMBG) 8-point profile|Body weight and waist circumference|B-cell function and insulin sensitivity as estimated by the updated Homeostasis Model Assessment tool (HOMA2)|Percentage of Patients achieving an HbA1C of < 7% and <, equal to 6.5%|Evaluate safety/tolerability of LY2189265 compared to placebo; Evaluate symptoms of nausea,vomiting,diarrhea,dyspepsia measured by Visual Analog Scale and Gastroparesis Cardinal Symptom Index questionnaire; Evaluate hypoglycemia, hyperglycemia,lipids|To characterize the pharmacokinetics (PK) of LY2189265 and the relationship between LY2189265 exposure and safety measures.|To measure and evaluate patient perception of medication effectiveness using the Perceptions about Medications - Diabetes (PAM-D-S) questionnaire.|To test the psychometric properties of the PAM-D-S and to validate its use for future clinical trials.",http://ClinicalTrials.gov/show/NCT00630825,"United States, &nbsp; Puerto Rico",1,0,4,NA
NCT00630864,The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis,Completed,No Results Available,Transthyretin-associated Amyloidosis With Polyneuropathy,Drug: Fx-1006A,FoldRx Pharmaceuticals,Both,Adult|Senior,Phase II,24,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Fx1A-201,2/27/2008,01/06/2008,01/02/2010,2/23/2010,01/02/2010,,01/03/2009,TTR stabilization|Incidence of patients experiencing treatment-emergent adverse events|Incidence of patients experiencing treatment-emergent >/= Grade 3 adverse events|Incidence of patients with treatment-emergent echocardiography findings considered by the Investigator to be clinically significant|Incidence of patients with treatment-emergent electrocardiogram (ECG) findings considered by the Investigator to be clinically significant|Incidence of patients with treatment-emergent Holter monitoring findings considered by the Investigator to be clinically significant|Incidence of patients discontinuing from the study because of clinical or laboratory adverse events|Change from Baseline in the Neuropathy Impairment Score (NIS) and NIS-Lower Limb (LL) scores|Response to treatment (change from Baseline in the NIS-LL of < 2)|Change from Baseline in the total quality of life and five individual domain scores of the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN)|Change from Baseline in nerve conduction studies (NCS)|Change from Baseline in heart rate response to deep breathing (HRDB)|Change from Baseline in modified body mass index (mBMI)|Change from Baseline in overall quality of life and individual domains of the SF-36|Change from Baseline in echocardiography parameters|Change from Baseline in NT-pro-BNP and troponin I levels|Change from Baseline in Karnofsky score,http://ClinicalTrials.gov/show/NCT00630864,"United States, &nbsp; France, &nbsp; Germany, &nbsp; Italy",1,0,1,NA
NCT00631007,"A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: INT131 besylate|Drug: Pioglitazone HCl|Drug: Placebo,"InteKrin Therapeutics, Inc.",Both,Adult|Senior,Phase II,367,Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",INT131-007,2/27/2008,01/02/2008,01/09/2009,8/18/2010,01/08/2010,,01/08/2009,Change From Baseline in Hemoglobin A1c (HBA1c) at Week 24 With Last Observation Carried Forward|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 With Last Observation Carried Forward.,http://ClinicalTrials.gov/show/NCT00631007,"United States, &nbsp; Mexico",1,0,3,NA
NCT00631319,A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic OA Pain,Completed,No Results Available,Chronic Pain,Drug: OROS HYDROMORPHONE,Neuromed Pharmaceuticals,Both,Adult|Senior,Phase III,400,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NMT 1077-302,2/28/2008,01/02/2008,01/06/2009,8/26/2010,01/08/2010,OA Pain,01/04/2009,Mean change from baseline to week 12 (or last visit) of the average PI of the DB treatment based on weekly avrg. PI scores from the patient diary.,http://ClinicalTrials.gov/show/NCT00631319,United States,1,1,1,0
NCT00631917,A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension,Completed,No Results Available,Hypertension,Drug: Aliskiren|Drug: Ramipril,Novartis,Both,Adult|Senior,Phase IV,774,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CSPP100A2404,03/03/2008,01/02/2008,NA,7/15/2010,01/07/2010,,01/11/2009,"Occurrence of colonic pathology as defined by the composite endpoint (hyperplastic polyps, inflammatory polyps, adenomatous polyps or carcinomas) after one year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen|To assess mucosal hyperplasia, dysplasia, and severity of inflammation in rectal and cecal mucosal biopsy specimens obtained at baseline and following one-year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen|To assess the occurrence of the individual components of the composite endpoint following one-year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen.|To assess the number of each component of the composite endpoint following one-year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen.|To evaluate the overall gastrointestinal tolerability following one-year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen.",http://ClinicalTrials.gov/show/NCT00631917,"United States, &nbsp; Argentina, &nbsp; Colombia, &nbsp; France, &nbsp; Germany, &nbsp; India, &nbsp; Spain",1,1,2,0
NCT00633217,Advair HFA For Chronic Obstructive Pulmonary Disease(COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|Drug: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg,GlaxoSmithKline,Both,Adult|Senior,Phase IV,247,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",111117,2/19/2008,01/03/2008,01/02/2009,12/07/2009,01/12/2009,,01/02/2009,Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug|Mean Change From Baseline in AM Pre-dose FEV1|Mean Change From Baseline in Peak Expiratory Flow,http://ClinicalTrials.gov/show/NCT00633217,United States,1,1,2,0
NCT00633880,Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),Completed,No Results Available,Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Drug: Placebo|Drug: Droxidopa,Chelsea Therapeutics|Chiltern International Inc.,Both,Adult|Senior,Phase III,118,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Droxidopa NOH302,03/05/2008,01/01/2008,01/09/2009,7/30/2010,01/07/2010,302NOH,01/08/2009,"To evaluate the efficacy of droxidopa in patients with symptomatic NOH as measured by the relative change in mean score of Item 1 of the (OHSA) 14 days following randomization to continued therapy with droxidopa or placebo.|Evaluate efficacy of droxidopa as measured by changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements 3 minutes post standing;|Evaluate efficacy of droxidopa by global assessment evaluations using the clinician-recorded and patient-recorded Clinical Global Impressions-Severity (CGI-S) and Clinical Global Impressions-Improvement (CGI-I) scales;|Evaluate efficacy of droxidopa by symptom and activity measurements using the composite scores of OHSA, OHDAS (the two subcomponents of the Orthostatic Hypotension Questionnaire (OHQ))|Evaluate the safety of droxidopa based on the occurence of treatment-emergent adverse events and specific evaluation of blood pressure, heart rate, ECG, and laboratory findings across the study",http://ClinicalTrials.gov/show/NCT00633880,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; New Zealand",1,0,2,NA
NCT00634283,Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects,Completed,No Results Available,Depression,Drug: venlafaxine,"University of California, Los Angeles",Both,Adult|Senior,Phase IV,7,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver)",07-10-051|07-10-051,03/06/2008,01/02/2008,01/02/2009,08/06/2009,01/08/2009,,01/02/2009,"Whether short-term antidepressant exposure results in long-term changes in resting brain function, as measured using QEEG cordance.",http://ClinicalTrials.gov/show/NCT00634283,United States,1,1,1,1
NCT00635154,Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma,Completed,Has Results,Multiple Myeloma and Plasma Cell Neoplasm,Biological: Anakinra (IL-1Ra)|Drug: Dexamethasone acetate,Mayo Clinic|National Cancer Institute (NCI),Both,Adult|Senior,Phase II,55,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000583300|P30CA015083|MC0282|1316-02,03/12/2008,01/12/2002,01/11/2010,12/17/2010,01/12/2010,,01/12/2009,"Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months of Treatment With Anakinra Alone|Number of Patients With Response to Treatment With Dexamethasone and Anakinra|Number of Patients Who Are Progression-free and Alive at 6 Months|Number of Patients With Severe Non-hematological Adverse Events in Patients Receiving Anakinra Alone or in Combination With Dexamethasone.|Progression Free Survival (PFS) in Patients Treated With Anakinra Alone or in Combination With Dexamethasone|Number of Patients With Severe Non-hematological Adverse Events in Participants Receiving Anakinra in Combination With Dexamethasone|Duration of Response",http://ClinicalTrials.gov/show/NCT00635154,United States,1,1,2,0
NCT00635206,Investigation of a Novel Positive Pressure Therapy to Rescue Patients Failing to Tolerate CPAP During an Initial Encounter,Completed,No Results Available,Obstructive Sleep Apnea,Device: BiPap auto with Fi Flex|Device: Standard CPAP,Clayton Sleep Insititute,Both,Adult|Senior,Phase III,51,Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",BIPAP Rescue|ABF-2007-MCT-03,03/06/2008,01/09/2007,01/05/2009,7/13/2009,01/07/2009,BIPAP,01/05/2009,"proportion of participants compliant (at least four hours of use per night for all nights) in the Auto Bilevel group compared to the CPAP group after 90 days of treatment during the investigation.|ASdherence to BiPAP?ó Auto with Bi-Flex?ó therapy compared to CPAP therapy will include: compliance, AHI, HRV, FOSQ, Visual Analog Scale for mask comfort & satisfaction, ESS, PVT, Attitudes toward use, Actigraphy & sleep diary, FSS, & DFS",http://ClinicalTrials.gov/show/NCT00635206,United States,0,NA,2,NA
NCT00635622,Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis,Completed,No Results Available,Bacterial Vaginosis,Drug: LACTIN-V|Drug: Placebo control substance,"Osel, Inc.|University of California, San Francisco",Female,Adult,Phase II,40,Industry|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",LV-006,03/10/2008,01/04/2008,01/01/2009,07/09/2009,01/03/2009,,01/01/2009,"To evaluate the vaginal colonization efficiency of L. crispatus CTV-05 after vaginal administration of LACTIN-V at 2 x 10^9 cfu/dose (600 mg) daily for 5 days followed by weekly applications over 2 additional weeks|To evaluate the safety of L. crispatus, LACTIN-V in otherwise healthy pre-menopausal women with BV, immediately after standardized antibiotic treatment with 0.75% topical metronidazole|To evaluate the tolerability and acceptability of LACTIN-V as a powder in a pre-filled applicator|To evaluate and compare vaginal flora by Gram stain before and after receipt of LACTIN-V or placebo.|To identify and compare bacteria colonizing the vagina at screening in women with bacterial vaginosis and after antibiotic and probiotic treatment.|To measure and compare the 4 week cure rate of BV after receipt of MetroGel in women who receive LACTIN-V or placebo.|To measure the rate of vaginal colonization by Candida sp. and symptomatic vaginal candidiasis after receiving LACTIN-V or placebo",http://ClinicalTrials.gov/show/NCT00635622,United States,1,1,2,0
NCT00635934,A-MAV?ºÑ Anterior Motion Segment Replacement,Completed,No Results Available,Spinal Diseases,Device: A-MAV?ºÑ disc,Medtronic Spinal and Biologics,Both,Adult|Senior,Phase III,53,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,G040135,03/07/2008,01/12/2005,01/05/2010,01/05/2011,01/01/2011,,01/10/2009,Overall Success= Oswestry Disability Index success; Maintenance or improvement in neurological status; No serious AE classified as implant or implant/surgical procedure associated; No additional surgical procedure classified as a failure|Disc height; SF-36; Back Pain Status; Leg Pain Status; Patient Satisfaction; Patient Global Perceived Effect; Other Measurements-Radiographic; Return to Work; Doctor's Perception of Results,http://ClinicalTrials.gov/show/NCT00635934,United States,0,NA,1,NA
NCT00636636,Safety and Efficacy of Gabapentin in Postherpetic Neuralgia,Completed,No Results Available,"Neuralgia,Postherpetic",Drug: Gabapentin Extended Release tablets,Depomed,Both,Adult|Senior,Phase III,450,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",81-0062,2/21/2008,01/03/2008,01/09/2009,11/02/2009,01/11/2009,,01/08/2009,The primary study objective is to assess the relative efficacy of G-ER versus placebo in reducing the average daily pain score from the baseline week to the final week of the efficacy treatment period (Treatment Week 10) in patients with PHN|Daily pain scores will be measured using an electronic diary.|Secondary objectives include assessment of changes from baseline in average daily sleep interference scores,http://ClinicalTrials.gov/show/NCT00636636,"United States, &nbsp; Argentina, &nbsp; Russian Federation",1,1,1,0
NCT00636740,"Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients",Completed,No Results Available,Hormone-Refractory Prostate Cancer,Drug: Zoledronic Acid 20mg Tablets|Drug: Zoledronic Acid|Drug: Zoledronic Acid 20mg Tablets,"Merrion Pharmaceuticals, LLC",Male,Adult|Senior,Phase II,30,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MER-101-03,03/07/2008,01/02/2008,01/02/2009,2/19/2009,01/02/2009,,01/02/2009,Effects on 4 markers of bone metabolism|Brief Pain Inventory,http://ClinicalTrials.gov/show/NCT00636740,"United States, &nbsp; Estonia, &nbsp; Latvia",1,1,3,1
NCT00638014,Rapid Sternal Closure System (TALON),Completed,No Results Available,Sternal Wound Infection|Mediastinitis,Device: Rapid Sternal Closure System,"Duke University|KLS Martin, L.P.",Both,Adult|Senior,Phase IV,200,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention,PRO00006260,03/12/2008,01/03/2008,01/07/2009,5/24/2010,01/05/2010,TALON,01/07/2009,The primary objective is to establish if the Rapid Sternal Closure System improves early postoperative recovery as manifested by decreased pain and improved pulmonary function.|Evaluation of Rapid Sternal Closure System with regard to sternal wound infection and sternal instability/non-union as outlined in the protocol.,http://ClinicalTrials.gov/show/NCT00638014,United States,0,NA,1,NA
NCT00638365,Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa,Completed,No Results Available,Cystic Fibrosis,Biological: KB001|Other: Placebo,KaloBios Pharmaceuticals,Both,Child|Adult|Senior,Phase I|Phase II,48,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KB001-03,03/12/2008,01/03/2008,01/04/2009,7/29/2009,01/07/2009,,01/03/2009,The safety and tolerability of a single-dose of KB001.|To measure to the pharmacodynamic effects of a single-dose of KB001 as determined by lung microbial ecology and lung function.,http://ClinicalTrials.gov/show/NCT00638365,United States,0,NA,2,NA
NCT00638378,Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer,Completed,No Results Available,Metastatic Prostate Cancer,Drug: INCB018424,Incyte Corporation,Male,Adult|Senior,Phase II,41,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,INCB 18424-254,03/12/2008,01/02/2008,01/01/2009,6/17/2010,01/06/2010,,01/01/2009,"PSA50 response rate of oral INCB018424 as monotherapy in the treatment of metastatic, androgen-independent prostate cancer and safety and tolerability of oral INCB018424 in patients with metastatic prostate cancer|Median time to progression in patients with metastatic androgen-independent prostate cancer and response rate according to RECIST criteria in patients with measurable metastatic prostate cancer who are treated with INCB018424.",http://ClinicalTrials.gov/show/NCT00638378,United States,1,0,1,NA
NCT00638456,Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis,Completed,No Results Available,Eosinophilic Esophagitis,Drug: Budesonide plus Prevacid|Drug: placebo plus Prevacid,"University of California, San Diego|Meritage Pharma, Inc.",Both,Child|Adult|Senior,Phase II,33,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VPI-106-01,03/12/2008,01/02/2008,01/09/2009,09/09/2009,01/09/2009,,01/09/2009,Histologic resolution of esophageal eosinophilia on repeat endoscopy.|Endoscopic resolution of esophagitis and improvement in EE symptom score as assessed by a pediatric EE questionnaire.|Open Label Budesonide given and measured through endoscopic resolution of esophagitis and improvement in EE symptoms,http://ClinicalTrials.gov/show/NCT00638456,United States,1,1,2,0
NCT00639860,Clinical and Histological Evaluation of OSSIX-Plus Resorbable Collagen Membranes for Alveolar Ridge Preservation Following Exodontia,Completed,No Results Available,Tooth Extractions,Device: OSSIX-Plus,University of Michigan|Johnson & Johnson|OraPharma,Both,Adult|Senior,Phase I|Phase II,10,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2008-01,3/14/2008,01/03/2008,01/03/2009,5/20/2009,01/05/2009,OSSIX,01/03/2009,"bone gain or loss in millimeters, radiographic bone changes, and percentage of new bone formation in the alveolar bone core biopsies|soft tissue wound healing",http://ClinicalTrials.gov/show/NCT00639860,United States,0,NA,1,NA
NCT00640250,Clinical Evaluation of T.R.U.E. TEST?ó Panel 3.2 Allergens: Dose Response,Completed,No Results Available,Contact Dermatitis,Biological: T.R.U.E. TEST?ó Skin Patch Test: Dose Response Allergens,Allerderm,Both,Adult|Senior,Phase II,48,Industry,Interventional,Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,Mekos 07 2P3.2 201|2007-007130-19|WIRB Pr. No.: 20072233,03/03/2008,01/04/2008,01/09/2009,5/13/2010,01/05/2010,,01/03/2009,"Determination of optimal test concentration for Disperse Blue 106 and Bronopol as the lowest concentration eliciting either +1 or +2 positive reactions in 70-90% of sensitive subjects.|Frequency of irritation, late/persistent reactions, tape reactions, subject-reported itching or burning, and adverse events for each allergen and concentration.",http://ClinicalTrials.gov/show/NCT00640250,"United States, &nbsp; Denmark",0,NA,1,NA
NCT00640614,Clinical Evaluation of T.R.U.E. TEST?ó : Safety and Efficacy,Completed,No Results Available,Contact Dermatitis,Biological: T.R.U.E. TEST?ó Skin Patch Test: Dose Response Allergens,Allerderm,Both,Adult|Senior,Phase III,235,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,Mekos 07 7P3.2 301|2008-000168-18|WIRB Pr. No.: 20080089,03/03/2008,01/04/2008,01/10/2009,5/13/2010,01/05/2010,,01/08/2009,"The performance of each allergen will be evaluated based on: Calculating concordance/discordance between T.R.U.E. Test Panel 3.2 allergens and their corresponding petrolatum or aqueous-based allergens and calculated sensitivity and specificity.|Evaluations will be based on: Frequency and characterization of late and/or persistent reactions, tape-induced irritation, incomplete panel adhesion, and subject-reported sensations of itching or burning and the frequency of adverse events.",http://ClinicalTrials.gov/show/NCT00640614,"United States, &nbsp; Denmark",0,NA,1,NA
NCT00640926,Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia,Completed,Has Results,Community-Acquired Pneumonia (CAP),Drug: Radezolid|Drug: Radezolid|Drug: Radezolid,"Rib-X Pharmaceuticals, Inc.",Both,Adult,Phase II,158,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",RX-1741-201,3/18/2008,01/10/2007,01/04/2009,02/11/2010,01/02/2010,,01/03/2009,Clinical Cure in the Clinically Evaluable (CE) Population at Test of Cure (TOC),http://ClinicalTrials.gov/show/NCT00640926,"United States, &nbsp; Canada, &nbsp; Russian Federation",1,0,3,NA
NCT00641329,CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD,Completed,No Results Available,ADHD,Drug: CLONICEL (clonidine HCl sustained release)|Drug: Placebo,"Addrenex Pharmaceuticals, Inc.",Both,Child,Phase III,198,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLON-302,3/19/2008,01/02/2008,01/02/2009,04/08/2010,01/03/2009,,01/02/2009,"ADHDRS-IV Total Score|Treatment Emergent Adverse Events, Laboratory Tests, Vital Signs, and ECGs",http://ClinicalTrials.gov/show/NCT00641329,United States,1,0,2,NA
NCT00642174,Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3),Completed,Has Results,Diabetes Mellitus|Coronary Artery Disease,Drug: prasugrel|Drug: Clopidogrel,Eli Lilly and Company|Daiichi Sankyo Inc.,Both,Adult|Senior,Phase II,35,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11241|H7T-MC-TACA,3/21/2008,01/04/2008,01/01/2009,2/19/2010,01/02/2010,OPTIMUS-3,01/01/2009,Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow?ºÑ P2Y12 Assay|Inhibition of Platelet Aggregation at 1- and 24-Hours After Loading Dose (LD) and 24-Hours After Last Maintenance Dose (LMD) Assessed by Accumetrics VerifyNow?ºÑ P2Y12 Assay|Maximum Platelet Aggregation (MPA) as Assessed by Light Transmittance Aggregometry (LTA)|Platelet Reactivity Index (PRI)|Inhibition of Platelet Function as Measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate,http://ClinicalTrials.gov/show/NCT00642174,United States,1,1,2,0
NCT00642642,Safety and Efficacy Study of Isolagen Therapy in the Treatment of Severe Facial Acne Scarring,Completed,No Results Available,Acne Scarring of the Face,Biological: Autologous Human Fibroblasts (Isolagen TherapyTM)|Biological: Placebo,"Isolagen Technologies, Inc.",Both,Adult,Phase II|Phase III,120,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IT-A-008,3/19/2008,01/11/2007,NA,10/22/2009,01/10/2009,,01/03/2009,"Change from baseline of Investigator assessment of acne scarring severity|Change from baseline of subject assessment of appearance|Adverse Events, vital signs and physical examination|Change from baseline of subject and Investigator assessments of scarring",http://ClinicalTrials.gov/show/NCT00642642,United States,0,NA,2,NA
NCT00642811,A Study of the Antiplatelet Effects Comparing AZD6140 With Clopidogrel Responder and Non-Responders,Completed,No Results Available,Stable Coronary Artery Disease,Drug: AZD6140|Drug: Clopidogrel|Drug: Aspirin,AstraZeneca,Both,Adult|Senior,Phase II,80,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D5130C00030,3/19/2008,01/05/2008,01/03/2009,4/23/2009,01/04/2009,RESPOND,01/03/2009,"To assess the effect of AZD6140 on inhibition of platelet aggregation compared with clopidogrel in patients previously identified as non-responsive to clopidogrel.|To compare inhibition of platelet aggregation (IPA), platelet aggregation and biomarker expression in clopidogrel responsive patients when directly switched from clopidogrel to AZD6140, in addition, also when switching from AZD6140 to Clopidogrel|To assess the overall safety and tolerability of AZD6140 compared to clopidogrel and placebo",http://ClinicalTrials.gov/show/NCT00642811,"United States, &nbsp; Canada, &nbsp; Denmark, &nbsp; United Kingdom",1,0,3,NA
NCT00643383,A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain,Completed,No Results Available,Acute Low Back Pain,Drug: Combination drug (Acetaminophen + Tramadol)|Drug: Placebo,Labopharm Inc.,Both,Adult|Senior,Phase III,250,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,06CCL3-001,3/20/2008,01/03/2008,01/02/2009,01/12/2010,01/01/2010,,01/01/2009,Pain Intensity change from Baseline|Overall satisfaction with the study medication|Safety evaluation,http://ClinicalTrials.gov/show/NCT00643383,"United States, &nbsp; Canada",1,1,2,0
NCT00643760,A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN),Completed,No Results Available,"Neuropathic Pain From Peripheral Diabetic Neuropathy|Neuropathy, Diabetic",Drug: XP13512/GSK1838262,GlaxoSmithKline,Both,Adult|Senior,Phase II,421,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",110448,2/19/2008,01/03/2008,01/02/2009,11/04/2010,01/11/2010,,01/02/2009,Change from baseline to end of treatment with respect to the mean 24-hour average pain intensity score based on an 11-point PI-NRS|24-hour average pain intensity score.|Percent of subjects achieving various levels of reduction in 24 hour average pain intensity score (derived from primary endpoint)|Time to onset of sustained improvement in the 24-hour average pain intensity score (sustained improvement is defined as a reduction of ??­ 2 points from baseline for ??­ 2 consecutive days).|Day-time average pain intensity score recorded in the evening before bedtime. Day-time is defined as the time between rising in the morning and going to bed at night.|Night-time average pain intensity score recorded in the morning upon awakening. Night-time is defined as the time between going to bed at night and rising in the morning.|Current pain intensity score recorded in the morning upon awakening and in the evening before bedtime.|Day-time worst pain intensity score recorded in the evening before bedtime. Day-time is defined as the time between rising in the morning and going to bed at night.|Night-time worst pain intensity score recorded in the morning upon awakening. Night-time is defined as the time between going to bed at night and rising in the morning.|Sleep interference score recorded in the morning upon awakening. The sleep interference score is the subject's assessment of sleep interference due to pain.|Pain quality (completed in physician's office)|Patient global impression of change (completed in physician's office)|Pre and post 50 foot (15 meter) walk. The pain intensity before and after walking 50 feet.|Rescue analgesic use recorded in the evening before bedtime|Physical functioning (completed in physician's office)|Quality of life (completed in physician's office)|Emotional functioning (completed in physician's office)|Clinician global impression of change (completed in physician's office),http://ClinicalTrials.gov/show/NCT00643760,United States,1,0,1,NA
NCT00643851,An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets,Completed,No Results Available,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Metformin XR,Bristol-Myers Squibb|AstraZeneca,Both,Adult|Senior,Phase III,600,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",MB102-021,3/20/2008,01/06/2008,01/08/2009,09/10/2010,01/08/2010,,01/08/2009,"Change from baseline in hemoglobin A1C|Change from baseline in fasting plasma glucose achieved with Dapagliflozin in Combination with Metformin compared to Dapagliflozin Monotherapy and compared to Metformin Monotherapy|Proportion of subjects achieving a therapeutic glycemic response, defined as A1C < 7.0%|Change from baseline in total body weight|Change from baseline in A1C (A1C category ??­9.0%)|Change from baseline in total body weight (baseline BMI category ??­27 kg/m2)",http://ClinicalTrials.gov/show/NCT00643851,"United States, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Philippines, &nbsp; Puerto Rico, &nbsp; Russian Federation, &nbsp; Ukraine",1,0,2,NA
NCT00644358,A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD),Completed,No Results Available,Major Depressive Disorder,Drug: vilazodone,"PGxHealth, LLC",Both,Adult|Senior,Phase III,616,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CLDA-07-DP-04,3/20/2008,01/12/2007,01/05/2009,8/24/2010,01/08/2010,,01/05/2009,"adverse events (AEs), laboratory parameters, physical examinations, vital signs, weight, ECGs, the CSFQ, ophthalmologic exams, the Columbia-Suicide Severity Rating Scale (C-SSRS).|The study will collect information on effectiveness of vilazodone therapy over the course of the treatment period using MADRS, CGI severity of illness and CGI improvement scales.",http://ClinicalTrials.gov/show/NCT00644358,United States,1,0,1,NA
NCT00645177,Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer,Completed,No Results Available,Metastatic Breast Cancer,Drug: ABT-869|Drug: paclitaxel|Drug: Placebo for ABT-869,Abbott|Genentech,Female,Adult|Senior,Phase II,10,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",M10-265|EudraCT 2007-005949-38,3/24/2008,01/07/2008,NA,11/02/2010,01/09/2010,,01/12/2009,Progression-free survival|Overall survival,http://ClinicalTrials.gov/show/NCT00645177,"United States, &nbsp; Mexico",1,0,3,NA
NCT00645671,Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery,Completed,Has Results,Ocular Inflammation,Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment|Drug: Vehicle of Loteprednol Etabonate Ophthalmic Ointment,"Bausch & Lomb, Inc.",Both,Adult|Senior,Phase III,400,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",525,3/13/2008,01/03/2008,01/03/2009,09/01/2010,01/06/2010,,01/03/2009,Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.|Grade 0 for Pain|Subjects With Complete Resolution of Anterior Chamber Cells and Flare. At Each Follow-up Visit.|Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare,http://ClinicalTrials.gov/show/NCT00645671,United States,1,1,2,1
NCT00645840,Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Anakinra,University of Texas Southwestern Medical Center|Children's Medical Center Foundation,Both,Child|Adult,Phase I|Phase II,15,Other,Interventional,Control: Historical Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UTSW 112007-037,3/25/2008,01/03/2008,01/09/2009,6/28/2010,01/06/2010,,01/09/2009,Change in EGR2 expression in PBMCs upon treatment with anakinra in subjects with newly diagnosed type 1 diabetes|Effect size on preservation of C-peptide secretory capacity,http://ClinicalTrials.gov/show/NCT00645840,United States,1,1,1,1
NCT00646204,Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease,Completed,No Results Available,Parkinson's Disease,Drug: Memantine|Drug: placebo,Baylor College of Medicine|Forest Laboratories,Both,Adult|Senior,Phase IV,40,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",H-18912,12/28/2007,01/04/2006,01/03/2009,4/30/2009,01/04/2009,,01/02/2009,"This is an exploratory study. The primary efficacy point will be global impressions.|Analyses will be computed for the categorical dependent variables (DV): spirograph, pouring, subjective ADL, observed tremor, global assessment by examiner, global assessment by patient, and subjective assessment by patient scores.",http://ClinicalTrials.gov/show/NCT00646204,United States,1,1,2,1
NCT00646906,Mechanisms of Action of Acetaminophen,Completed,No Results Available,Myocardial Infarction|Arthritis,Drug: Aspirin first|Drug: Aspirin last,University of Pennsylvania,Both,Adult,Phase IV,12,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",708270|0898,3/26/2008,01/05/2004,01/03/2009,10/14/2009,01/10/2009,,01/03/2009,"Serum thromboxane B2 concentration|Arachidonic acid induced platelet aggregation|Urinary 11-dehydro thromboxane B2 concentration|Urinary 2,3 dinor-6 keto PGF1?? concentration|Urinary 8,12-iso-iPF2??-VI concentration",http://ClinicalTrials.gov/show/NCT00646906,United States,1,1,2,0
NCT00647270,"Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing",Completed,Has Results,Rheumatoid Arthritis,Drug: adalimumab|Drug: Placebo|Drug: adalimumab,Abbott,Both,Adult|Senior,Phase III,420,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M10-261,3/27/2008,01/12/2007,01/04/2009,11/04/2010,01/09/2010,,01/04/2009,The Number of Responders According to the American College of Rheumatology (ACR) 20 Response Criteria at Week 12 Involving the Comparison of Adalimumab 80 mg Monthly Dose Versus Placebo and Adalimumab 40 mg Every Other Week (Eow)|Within Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)|Within Group Mean Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])|Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)|Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF]),http://ClinicalTrials.gov/show/NCT00647270,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Germany, &nbsp; Puerto Rico, &nbsp; United Kingdom",1,1,3,1
NCT00647296,Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS),Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: KNS-760704,Knopp Neurosciences,Both,Adult|Senior,Phase II,102,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KNS-760704-CL201,3/26/2008,01/03/2008,01/10/2009,11/06/2009,01/11/2009,CL201,01/09/2009,To evaluate the safety and tolerability of oral administration of 3 dosage levels of KNS-760704 compared to placebo for 12 weeks in patients with ALS (Part 1)|To evaluate the long-term safety and tolerability of oral administration of 2 dosage levels of KNS 760704 in ALS patients (Part 2)|To evaluate the effects of KNS-760704 on measures of clinical function|To evaluate the reliability and clinical predictive value of upright and supine vital capacity|To evaluate the effects of KNS-760704 on selected protein levels in blood and cerebrospinal fluid,http://ClinicalTrials.gov/show/NCT00647296,United States,1,0,1,NA
NCT00648167,A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD),Completed,No Results Available,Hyperphosphatemia|End-Stage Renal Disease,Drug: ferric citrate,Keryx Biopharmaceuticals,Both,Adult|Senior,Phase II,24,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,KRX-0502-201,3/27/2008,01/03/2008,01/01/2009,01/05/2009,01/01/2009,,01/01/2009,This study is exploratory in nature and is intended to assess the tolerability and safety of Zerenex.|Serum phosphorus levels will be monitored prior to study drug titration.,http://ClinicalTrials.gov/show/NCT00648167,United States,1,1,1,1
NCT00648895,A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients,Completed,Has Results,Hypertension,Drug: Nebivolol|Drug: Metoprolol ER (TM),Forest Laboratories,Both,Adult|Senior,Phase III,12,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NEB-MD-08,3/28/2008,01/11/2007,NA,8/30/2010,01/08/2010,,01/07/2009,Percentage Change From Baseline to End of Treatment for the Difference Between the Post-ischemia and Pre-ischemia Forearm Vascular Resistance (FVR).,http://ClinicalTrials.gov/show/NCT00648895,United States,1,1,2,1
NCT00649389,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Completed,Has Results,Hypertension,Drug: Olmesartan medoxomil|Drug: Amlodipine|Drug: Hydrochlorothiazide,Daiichi Sankyo Inc.,Both,Adult|Senior,Phase III,2500,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CS8635-A-U301,3/28/2008,01/05/2008,01/12/2009,8/31/2010,01/08/2010,,01/04/2009,"Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).|Percentage of Subjects Who Reached Blood Pressure Goal (<140/90 mmHg; <130/80 mmHg for Subjects With Diabetes, Chronic Renal Disease, or Chronic Cardiovascular Disease)by 12 Weeks|Change in Mean 24-hour Ambulatory Blood Pressure From Baseline to Week 12 or Early Termination|Change in Seated Systolic Blood Pressure From Baseline to Week 12",http://ClinicalTrials.gov/show/NCT00649389,"United States, &nbsp; Puerto Rico",1,1,3,0
NCT00650078,Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra?ó) Therapy in Patients With Active Rheumatoid Arthritis,Completed,No Results Available,Rheumatoid Arthritis,Drug: MR tablet formulation of prednisone|Drug: Placebo,Nitec Pharma AG,Both,Adult|Senior,Phase III,294,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NP01-007|EudraCT-Number: 2007-003508-36,3/28/2008,01/03/2008,01/07/2009,7/17/2009,01/07/2009,CAPRA-2,01/07/2009,ACR 20 response rate|Relative reduction of morning stiffness,http://ClinicalTrials.gov/show/NCT00650078,"United States, &nbsp; Canada, &nbsp; Germany, &nbsp; Hungary, &nbsp; Poland, &nbsp; United Kingdom",1,0,2,NA
NCT00650104,Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164,Completed,Has Results,Parkinson's Disease,Drug: Ropinirole XL (formerly CR),GlaxoSmithKline,Both,Adult|Senior,Phase III,76,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,101468/196,3/27/2008,01/05/2002,01/03/2009,4/22/2010,01/04/2010,,01/03/2009,Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population)|Number of Participants With the Indicated Number of Adverse Events (AEs)|Unified Parkinson's Disease Rating Scale (UPDRS) Total Activities of Daily Living Score (Responder Population)|Unified Parkinson's Disease Rating Scale (UPDRS) Total Activities of Daily Living Scores (Maintained Responder Population)|Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (ITT Population)|Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (Reponder Population)|Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (Maintained Responder Population)|Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (ITT Population)|Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (Responder Population)|Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (Maintained Responder Population),http://ClinicalTrials.gov/show/NCT00650104,"United States, &nbsp; Belgium, &nbsp; France, &nbsp; Netherlands, &nbsp; Norway",1,1,1,1
NCT00650702,Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Completed,No Results Available,Glaucoma|Ocular Hypertension,Drug: Latanoprost-PPDS|Drug: Latanoprost-PPDS|Drug: Latanoprost-PPDS,"QLT Plug Delivery, Inc.",Both,Adult|Senior,Phase II,60,Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PPL GLAU 02,3/27/2008,01/03/2008,01/02/2009,5/19/2009,01/05/2009,CORE,01/02/2009,IOP change from baseline,http://ClinicalTrials.gov/show/NCT00650702,United States,1,0,3,NA
NCT00650767,"Orally Active, Small Molecule Inhibitor of MEK1 and MEK2 in Patients With Active Rheumatoid Arthritis",Completed,No Results Available,Rheumatoid Arthritis,Drug: ARRY-438162|Other: Placebo,Array BioPharma,Both,Adult|Senior,Phase II,200,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ARRAY-162-201,3/31/2008,01/03/2008,01/07/2009,12/09/2009,01/12/2009,,01/07/2009,"To compare the efficacy of 3 dose levels of ARRY-438162 (10 mg BID, 40 mg QD, and 20 mg BID) versus placebo, administered over 12 weeks for the treatment of the signs and symptoms of patients with Rheumatoid Arthritis on stable doses of methotrexate.|To determine the American College of Rheumatology 20% (ACR20) best response rate at week 12 of patients treated with any well-tolerated dose.|To evaluate the safety and tolerability of ARRY-438162 in patients with active Rheumatoid Arthritis on stable doses of methotrexate (> 10 mg <25 mg) for > 6 weeks.|To evaluate the pharmacokinetic profiles of multiple doses of ARRY-438162 administered for 12 weeks to patients with active Rheumatoid Arthritis on stable doses of methotrexate.|To evaluate the dose-and concentration- response of ARRY-438162 against measures of disease activity through 12 weeks of treatment",http://ClinicalTrials.gov/show/NCT00650767,"United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Hungary, &nbsp; Peru, &nbsp; Poland, &nbsp; Romania",1,0,2,NA
NCT00651820,Effect of Collagenase on Healing and Scarring,Completed,No Results Available,Healthy,Drug: Collagenase Santyl|Drug: Vehicle,Healthpoint,Both,Adult,Phase IV,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",017 101 09 001,3/20/2008,01/04/2008,01/03/2010,06/04/2010,01/06/2010,,01/11/2009,complete wound closure,http://ClinicalTrials.gov/show/NCT00651820,United States,1,1,2,1
NCT00652314,Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel?ó Versus Gelfoam-Thrombin,Completed,No Results Available,Surgical Intervention Hemostasis|Comparison of Surgical Hemostats,Device: Thrombi-Gel,"Vascular Solutions, Inc|King Pharmaceuticals",Both,Adult|Senior,Phase IV,75,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care,0307|The CONTROL Study,3/28/2008,01/03/2008,01/10/2009,12/21/2009,01/12/2009,Control,01/10/2009,The primary objective of this investigation is to gather information to support the effectiveness of Thrombi-Gel as compared to a gelatin sponge (Gelfoam) plus thrombin as an adjunct to hemostasis in multi-specialty surgical settings.|Effectiveness: Device success (defined as the percentage of first bleeding site applications for which hemostasis was obtained within 6 minutes of study device application without the need for adjunctive treatment)|Effectiveness: Hemostatic handling characteristics (surgeon's questionnaire)|Safety: Incidence rate of device-related adverse events|Safety: Immunological testing for factor Va antibodies and coagulation parameters,http://ClinicalTrials.gov/show/NCT00652314,United States,0,NA,1,NA
NCT00653133,Multicenter Continuous Peripheral Nerve Block Surveillance Study,Completed,No Results Available,Postoperative Pain,Device: Ultrasound imaging plus ON-Q Cbloc|Device: Peripheral nerve stimulator plus ON-Q Cbloc,I-Flow,Both,Adult|Senior,Phase IV,3400,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,iflocpnb2007,3/28/2008,01/05/2007,01/03/2009,9/27/2009,01/09/2009,cpnb,01/03/2009,complications of peripheral nerve block,http://ClinicalTrials.gov/show/NCT00653133,United States,0,NA,2,NA
NCT00654030,Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer,Completed,No Results Available,Non-small Cell Lung Cancer,Drug: 1650-G Vaccine,University of Kentucky|Kentucky Lung Cancer Research Program,Both,Adult|Senior,Phase II,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CTN-0505|UKIRB 06-0716-F3R|ULIRB 065.07|CIRB 1079747,04/02/2008,01/10/2006,01/11/2009,1/15/2010,01/01/2010,,01/11/2009,Primary Outcome Measure: Immunological Response,http://ClinicalTrials.gov/show/NCT00654030,United States,1,0,1,NA
NCT00654745,"18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics",Completed,Has Results,Type 2 Diabetes|Hypertension,Drug: Amlodipine|Drug: amlodipine / olmesartan medoxomil combination|Drug: Hydrochlorothiazide,Daiichi Sankyo Inc.,Both,Adult|Senior,Phase IV,207,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CS-8663-403,04/04/2008,01/05/2008,01/06/2009,07/09/2010,01/07/2010,,01/04/2009,"Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment|Change From Week 0 (Baseline) in Mean ABPM Diastolic Blood Pressure (DBP) After 12 Weeks of Active Treatment|Change From Week 0 (Baseline) in Mean ABPM SBP After 12 Weeks of Active Treatment|Change in Mean Seated Systolic Blood Pressure (SeSBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks|Change in Mean Seated Diastolic Blood Pressure (SeDBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks|Number of Participants Achieving Mean 24-hour Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Mean Daytime Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Mean Nighttime Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Mean Last 6 Hour Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Mean Last 4 Hour Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Mean Last 2 Hour Ambulatory Blood Pressure Thresholds at Week 12|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 3|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 6|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 9|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 12|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 15|Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 18|Number of Participants Achieving Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Daytime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Nighttime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Last 6 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Last 4 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions|Number of Participants Achieving Mean Last 2 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 3|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 6|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 9|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 12|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 15|Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 18",http://ClinicalTrials.gov/show/NCT00654745,United States,1,1,3,0
NCT00654953,"Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-dependent Humans",Completed,No Results Available,Cocaine Dependence|Depressive Symptoms,Drug: sertraline|Drug: Placebo|Drug: gabapentin,National Institute on Drug Abuse (NIDA),Both,Adult,Phase II,105,NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P50-DA018197|P50-DA018197|DPMCDA,04/04/2008,01/01/2006,01/05/2009,12/15/2010,01/12/2010,,01/05/2009,Urine toxicology results for cocaine/metabolite or other illicit drugs|scores on Ham-D,http://ClinicalTrials.gov/show/NCT00654953,United States,1,1,3,0
NCT00655057,Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression,Completed,No Results Available,Depression,Drug: S-citalopram|Behavioral: Cognitive behavioral therapy (CBT)|Procedure: TRODAT-1 single photon emission computed tomographic (SPECT) imaging,National Institute of Mental Health (NIMH),Both,Adult,Phase II|Phase III,66,NIH,Interventional,Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Open Label,R34 MH070753|DATR A3-NSS,04/07/2008,01/10/2005,01/12/2009,4/23/2010,01/03/2009,,01/08/2009,Change in dopamine transporter binding,http://ClinicalTrials.gov/show/NCT00655057,United States,1,1,3,0
NCT00655551,Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures,Completed,Has Results,Partial Epilepsies|Partial Onset Seizures,Drug: lacosamide|Drug: lacosamide|Drug: lacosamide,"UCB, Inc.",Both,Child|Adult,Phase III,100,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SP925,3/26/2008,01/04/2008,01/09/2009,11/15/2010,01/11/2010,,01/09/2009,Number of Subjects With at Least One Adverse Event During the Treatment Period (up to 7 Days)|Number of Subjects Who Withdrew From the Trial Due to an Adverse Event|Number of Subjects With at Least One Adverse Event With an Onset Within 4 Hours of Start of Infusion,http://ClinicalTrials.gov/show/NCT00655551,United States,1,1,3,1
NCT00655629,"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",Completed,No Results Available,Erectile Dysfunction,Drug: Vardenafil ODT (BAY 38-9456)|Drug: Placebo,Bayer|GlaxoSmithKline|Schering-Plough,Male,Adult|Senior,Phase III,339,Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,12094,04/04/2008,01/04/2008,01/02/2009,02/08/2010,01/02/2010,,01/02/2009,"Positive change in IIEF-EF domain scores. Statistically significant simultaneous change from baseline for both SEP-2, and SEP-3|Percentage of subjects achieving \back to normal\"" erectile function (IIEF-EF > / = 26) at visit 4 (week 12) or LOCF;|All diary questions other than SEP 2 and 3 concerning erectile function administered over the entire treatment period;|Treatment Satisfaction Scale (TSS) to be administered at the randomization visit and the final visit (or at Premature Discontinuation).|A Global Assessment Question (GAQ) concerning the overall effect on erectile function to be administered at the final visit only.|Safety laboratory examinations",http://ClinicalTrials.gov/show/NCT00655629,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Mexico",1,1,2,1
NCT00656357,Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers,Completed,No Results Available,Cocaine Dependence,Drug: SYN117|Drug: SYN117,"Synosia Therapeutics, Inc.|National Institute on Drug Abuse (NIDA)",Both,Adult,Phase I|Phase II,20,Industry|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SYN117-CL01,04/04/2008,01/06/2008,NA,12/03/2009,01/12/2009,,01/05/2009,"Determine the safety of treatment with SYN117 in cocaine-dependent volunteers by measuring hemodynamic and subjective effects of administration of ascending doses of cocaine(10mg, 20mg, 40mg)and placebo during treatment with ascending doses of SYN117.|Determine tolerability by measuring adverse events|Determine subjective effects produced by self administration of cocaine or placebo|Determine the effect of SYN117 of the pharmacokinetics of IV cocaine|Determine if any baseline measures of impulsivity or drug use severity predict efficacy of SYN117 in reducing subjective effects of cocaine",http://ClinicalTrials.gov/show/NCT00656357,United States,1,0,2,NA
NCT00656890,A Study of MDX-1100 in Subjects With Active Ulcerative Colitis,Completed,No Results Available,Ulcerative Colitis,Biological: sterile saline for injection|Biological: MDX-1100,Bristol-Myers Squibb,Both,Adult|Senior,Phase II,110,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",MDX1100-06|IM129-004,04/04/2008,01/04/2008,01/09/2009,4/22/2010,01/04/2010,MDX1100-06,01/09/2009,Change in Mayo score at Day 57 compared with Screening|the remission rate,http://ClinicalTrials.gov/show/NCT00656890,"United States, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; Hungary, &nbsp; Latvia, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Ukraine",0,NA,2,NA
NCT00657046,Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension,Completed,No Results Available,Intradialytic Hypotension,Drug: Droxidopa 400 mg|Drug: Droxidopa 600 mg|Drug: Placebo,Chelsea Therapeutics,Both,Adult|Senior,Phase II,75,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Droxidopa IDH201,04/08/2008,01/12/2007,01/01/2009,7/30/2010,01/07/2010,IDH201,01/01/2009,"Determine the efficacy of droxidopa in the treatment of intradialytic hypotension as measured by the change between baseline (visits 2-7) and treatment (visits 14-19) in average mean arterial blood pressure during hemodialysis|Evaluate the efficacy of droxidopa in the treatment of intradialytic hypotension as measured by the change between baseline (visits 2-7) and treatment (visits 14-19) in average mean nadir systolic and diastolic blood pressures during hemodialysis;|Evaluate the efficacy of droxidopa as measured by the number of hypotension-induced interventions during hemodialysis (HD) sessions;|Evaluate the effect of droxidopa on hypotension-induced symptoms measured during hemodialysis|Evaluate the effect of droxidopa on daily symptoms associated with hemodialysis|Evaluate the effect of droxidopa on fatigue using the Multidimensional Fatigue Inventory (MFI-20)|Evaluate the dose-response relationship for droxidopa between the doses of 400 mg and 600 mg in the treatment of intradialytic hypotension|Evaluate the safety of droxidopa based on the occurrence of treatment-emergent adverse events (AE) and specific evaluation of blood pressure, heart rate, ECG, and laboratory findings across the study.",http://ClinicalTrials.gov/show/NCT00657046,United States,1,0,3,NA
NCT00657150,Dabigatran Etexilate Compared With Enoxaparin in Prevention of VTE Following Total Hip Arthroplasty,Completed,Has Results,Venous Thromboembolism,Drug: Dabigatran etexilate|Drug: Enoxaparin,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase III,2055,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention,1160.64,3/27/2008,01/03/2008,NA,11/18/2010,01/10/2010,,01/09/2009,Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period|Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period|Proximal Deep Vein Thrombosis During Treatment Period|Total Deep Vein Thrombosis During Treatment Period|Symptomatic Deep Vein Thrombosis During Treatment Period|Pulmonary Embolism During Treatment Period|Death During Treatment Period|Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period|Major Bleeding Events During Treatment Period,http://ClinicalTrials.gov/show/NCT00657150,"United States, &nbsp; Australia, &nbsp; Austria, &nbsp; Belgium, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Finland, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Italy, &nbsp; Netherlands, &nbsp; New Zealand, &nbsp; Norway, &nbsp; Poland, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden",1,1,2,0
NCT00657553,Pre-Emptive Strike With Bortezomib in Multiple Myeloma Patients,Completed,No Results Available,Multiple Myeloma,Drug: Bortezomib,University of Arkansas,Both,Adult|Senior,Phase III,10,Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,100241,04/09/2008,01/02/2008,01/01/2009,05/12/2009,01/05/2009,2007-77,01/01/2009,The amount of patients on Bortezomib that have maintained event-free survival will be compared to the patients on observation.|To determine if there is any increase in the amount of positive response when given Bortezomib alone.|To determine if Bortezomib will cause the reduction in MRI-defined focal lesions.|To evaluate whether Bortezomib will induce bone formation.,http://ClinicalTrials.gov/show/NCT00657553,United States,1,1,1,1
NCT00658086,Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV),Completed,No Results Available,Respiratory Syncytial Virus Infections,Drug: ALN-RSV01|Drug: normal saline,Alnylam Pharmaceuticals,Both,Adult|Senior,Phase II,24,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALN-RSV01-106,04/09/2008,01/04/2008,01/06/2009,6/15/2009,01/06/2009,,01/04/2009,Assess safety and tolerability of aerosolized ALN-RSV01 versus placebo in lung transplant patients infected with RSV|Evaluate effects of ALN-RSV01 on clinical and virologic endpoints,http://ClinicalTrials.gov/show/NCT00658086,"United States, &nbsp; Australia",1,0,2,NA
NCT00658476,Omega-3 Fatty Acids for Treatment of Depression in Adolescents,Completed,No Results Available,Depression,Dietary Supplement: Fish Oil|Behavioral: Cognitive Behavior Therapy|Drug: Placebo,Cedars-Sinai Medical Center|National Alliance for Research on Schizophrenia and Depression,Both,Child|Adult,Phase III,40,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",9407,04/08/2008,01/11/2006,01/04/2009,11/19/2009,01/11/2009,PUFA,01/04/2009,Child Depression Inventory - CDI|Ham-D,http://ClinicalTrials.gov/show/NCT00658476,United States,1,1,3,0
NCT00658528,Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD),Completed,No Results Available,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole sodium|Drug: Esomeprazole,Eisai Inc.,Both,Adult|Senior,Phase III,1060,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",E3810-G000-301,04/09/2008,01/02/2008,01/01/2010,03/10/2010,01/03/2010,,01/09/2009,"Upper GI endoscopy (EGD), symptoms based on subject's daily diary and Investigator's assessment.|Adverse events, Electrocardiograms (ECGs), laboratory evaluations (hematology, blood chemistry, urinalysis, serum gastrin), physical examinations, vital signs.",http://ClinicalTrials.gov/show/NCT00658528,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Chile, &nbsp; Croatia, &nbsp; Estonia, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Latvia",1,1,2,0
NCT00658567,A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Completed,No Results Available,Parkinson's Disease Psychosis,Drug: Pimavanserin tartrate (ACP-103)|Drug: Pimavanserin tartrate (ACP-103)|Drug: Pimavanserin tartrate (ACP-103),ACADIA Pharmaceuticals Inc.,Both,Adult|Senior,Phase III,240,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ACP-103-014,04/10/2008,01/03/2008,NA,08/04/2010,01/08/2010,,01/12/2009,Antipsychotic efficacy will be assessed using the scale for the assessment of Positive Symptoms (SAPS),http://ClinicalTrials.gov/show/NCT00658567,"United States, &nbsp; Austria, &nbsp; Belgium, &nbsp; Italy, &nbsp; Poland, &nbsp; Portugal, &nbsp; Serbia, &nbsp; Spain, &nbsp; Sweden",1,0,3,NA
NCT00658632,Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD),Completed,No Results Available,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole sodium|Drug: Esomeprazole,Eisai Inc.,Both,Adult|Senior,Phase III,1320,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",E3810-G000-303,04/09/2008,01/02/2008,01/09/2009,03/10/2010,01/03/2010,,01/04/2009,"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and investigator's assessment.|Adverse events, electrocardiograms (ECGs), lab evaluations (hematology, blood chemistry, urinalysis, serum gastrin), physical exams, vital signs.",http://ClinicalTrials.gov/show/NCT00658632,United States,1,1,2,0
NCT00658723,The Fibrin Patch Soft Tissue Study,Completed,No Results Available,Hemostasis,Drug: Fibrin Pad|Device: SURGICEL?ºÑ,"Ethicon, Inc.|OMRIX Biopharmaceuticals",Both,Adult|Senior,Phase II,141,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,400-07-002,04/11/2008,01/03/2008,01/05/2009,8/30/2010,01/08/2010,,01/04/2009,Proportion of subjects achieving hemostatic success|Proportion of subjects achieving hemostatic success|Incidence of treatment failures|Incidence of adverse events that are potentially related to bleeding|Incidence of adverse events that are potentially related to thrombotic events|Incidence of adverse events potentially related to transfusion exposure|Incidence of re-treatment|Incidence of adverse events,http://ClinicalTrials.gov/show/NCT00658723,United States,1,0,2,NA
NCT00658775,"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)",Completed,No Results Available,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole sodium|Drug: Esomeprazole,Eisai Inc.,Both,Adult|Senior,Phase III,1060,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",E3810-G000-302,04/09/2008,01/02/2008,01/01/2010,3/16/2010,01/03/2010,,01/09/2009,"Upper GI esophagogastroduodenoscopy (EGD), symptoms based on subject's daily diary and Investigator's assessment.|Adverse events, electrocardiograms (ECGs), lab evaluations (hematology, blood chemistry, urinalysis, serum gastrin), physical exams, vital signs.",http://ClinicalTrials.gov/show/NCT00658775,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Chile, &nbsp; Croatia, &nbsp; Estonia, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Latvia, &nbsp; Lithuania",1,1,2,0
NCT00658788,"Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis",Completed,No Results Available,Psoriasis,Drug: clobetasol propionate spray 0.05%|Drug: calcitriol ointment,"Galderma Laboratories, L.P.",Both,Adult|Senior,Phase III,305,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,US10085,03/04/2008,01/03/2008,01/01/2009,8/31/2009,01/08/2009,,01/01/2009,"Percent of Subjects with an improvement from baseline in Overall Disease Severity score|Efficacy - Percent of Subjects with an improvement from baseline in Overall Disease Severity score|Efficacy - Overall Disease Severity, Global Improvement Score, Signs of Psoriasis, Percent change from baseline in Body Surface Area|Efficacy - Koo-Menter Psoriasis Qualify of Life Questionnaire; Subject Satisfaction Survey|Safety - Tolerability, adverse events",http://ClinicalTrials.gov/show/NCT00658788,United States,1,0,2,NA
NCT00659646,The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers,Completed,No Results Available,Diabetic Foot Ulcer,Drug: gentamicin-collagen sponge and levofloxacin|Drug: Levofloxacin only,Innocoll Technologies|Premier Research Group plc,Both,Adult|Senior,Phase II,56,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,INN-TOP-003,04/11/2008,01/04/2008,01/02/2010,7/22/2010,01/07/2010,,01/05/2009,"The percent of patients with a clinical outcome of \clinical cure\"" in each treatment group at Visit 3|The percent of patients with a positive clinical response at each time point|The percent of patients with a \""clinical cure\""|The percent of patients with pathogen eradication|Absolute change in total wound surface area in each treatment group|Time to clinical cure|Time to positive clinical response|Time on parenteral antimicrobial therapy|Visual Analog Scale (VAS) for pain assessment|Lipsky wound score|Treatment emergent adverse events""",http://ClinicalTrials.gov/show/NCT00659646,United States,1,0,2,NA
NCT00660010,Study of Lupron Depot In The Treatment of Central Precocious Puberty,Completed,Has Results,"Puberty, Precocious",Drug: Lupron (leuprolide acetate),Abbott,Both,Child,Phase III,55,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,M90-516,4/15/2008,01/01/1991,01/04/2009,11/18/2010,01/09/2010,,01/04/2009,Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics Acccording to Tanner Staging (Breast Development in Females)|Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics Acccording to Tanner Staging (Genital Development in Males)|Mean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations|Mean Stimulated Estradiol Concentrations in Females|Mean Stimulated Testosterone Concentrations in Males|Mean Ratio of Bone Age to Chronological Age,http://ClinicalTrials.gov/show/NCT00660010,United States,1,1,1,1
NCT00660309,A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: aliskiren|Drug: irbesartan,Novartis,Both,Adult|Senior,Phase IV,45,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label,CSPP100A2329,04/11/2008,01/04/2008,NA,4/26/2010,01/04/2010,,01/12/2009,"Renal blood flow and glomerular filtration rate at baseline, after 1 and 14 days of treatment with aliskiren or irbesartan and after a single dose of captopril (an angiotensin converting enzyme inhibitor and positive control)|Retinal blood flow at baseline, after 14 days of treatment with aliskiren or irbesartan, after a singe dose of captopril Plasma levels of renin system biomarkers (renin, pro-renin, angiotensin 1, angiotensin 2, angiotensinogen, and aldosterone)",http://ClinicalTrials.gov/show/NCT00660309,United States,1,1,2,0
NCT00661479,An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa,Completed,No Results Available,Retinitis Pigmentosa,Drug: Brimonidine Tartrate|Drug: Brimonidine Tartrate|Drug: Brimonidine Tartrate|Drug: Brimonidine Tartrate,Allergan,Both,Adult|Senior,Phase I|Phase II,25,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,190342-028D,10/29/2007,01/07/2008,01/06/2010,09/08/2010,01/09/2010,,01/12/2009,Change in Visual Acuity|Contrast sensitivity|Patient questionnaires,http://ClinicalTrials.gov/show/NCT00661479,"United States, &nbsp; France, &nbsp; Germany, &nbsp; Portugal",1,1,4,0
NCT00661609,A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer,Completed,Has Results,Bladder Cancer|Transitional Cell Bladder Cancer|Urethra Cancer|Ureter Cancer|Renal Pelvis Cancer,Drug: AZD4877,AstraZeneca,Both,Adult|Senior,Phase II,54,Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,D2782C00010,4/16/2008,01/05/2008,01/12/2009,12/13/2010,01/12/2010,,01/05/2009,Objective Response Rate (ORR) as Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST)|Disease Control Rate (DCR)|Duration of Objective Tumor Response (OTR)|Progression Free Survival (PFS)|Overall Survival (OS),http://ClinicalTrials.gov/show/NCT00661609,"United States, &nbsp; Canada, &nbsp; Germany, &nbsp; Spain, &nbsp; United Kingdom",1,0,1,NA
NCT00661895,Black Education and Treatment of Hypertension (BEAT HTN),Completed,No Results Available,Hypertension,Drug: Hydrochlorothiazide|Drug: Lisinopril|Drug: Lisinopril and Hydrochlorothiazide|Drug: Nifedipine XL|Drug: Metoprolol tartrate|Drug: Atenolol|Drug: Valsartan|Drug: Doxazosin|Drug: Clonidine|Drug: Hydralazine|Drug: Metoprolol succinate|Drug: Amlodipine,Creighton University,Both,Adult|Senior,Phase IV,160,Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,05-13859|05-13589,12/28/2007,01/08/2005,01/11/2009,11/27/2009,01/11/2009,BEAT,01/08/2009,The primary study endpoint will be the percentage of subjects achieving blood pressure goals (< 140/90 mmHg for non-diabetic subjects and < 130/80 mmHg in diabetic subjects) in the usual care and intervention subject groups|New onset diabetes mellitus,http://ClinicalTrials.gov/show/NCT00661895,United States,1,1,12,0
NCT00662532,Antibiotic Study for Dental Implants,Completed,Has Results,Periodontitis,Drug: Minocycline HCl,Johnson & Johnson Consumer & Personal Products Worldwide,Both,Adult|Senior,Phase III,44,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment",OP-P-5265-1,4/17/2008,01/04/2008,01/04/2009,7/22/2010,01/07/2010,,01/04/2009,Overall PD Reduction|Initial PD Reduction|BOP Percent Reduction From Baseline,http://ClinicalTrials.gov/show/NCT00662532,United States,1,1,1,0
NCT00662909,Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 in Patients With Symptoms of Overactive Bladder,Completed,No Results Available,"Urinary Bladder, Overactive",Drug: YM178|Drug: Placebo,Astellas Pharma Inc,Both,Adult|Senior,Phase III,2190,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",178-CL-047,4/17/2008,01/04/2008,01/04/2009,4/15/2010,01/04/2010,ARIES,01/04/2009,Change from baseline to end of treatment in mean number of micturitions per 24 hours|Change from baseline to end of treatment in mean number of incontinence episode per 24 hours|Change from baseline in mean volume voided per micturition|Change from baseline in mean number of urgency incontinence episodes per 24 hours|Change from baseline in mean number of urgency episodes (grade 3 and/or 4) per 24 hours,http://ClinicalTrials.gov/show/NCT00662909,"United States, &nbsp; Canada",1,0,2,NA
NCT00663117,The Effects of Naltrexone on Active Crohn's Disease,Completed,No Results Available,Inflammation|Crohn's Disease,Drug: Naltrexone|Drug: Placebo,Penn State University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|The Broad Foundation,Both,Adult|Senior,Phase II,40,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DK073614 l|NIH 1 R03DK073614 l|IBD-0180R,4/18/2008,01/09/2006,01/10/2009,3/30/2010,01/12/2009,LDN,01/10/2009,Effects of naltrexone on inflammation of the bowel based upon the following: CDAI scores (Crohn's disease activity index) scores; C-Reactive Protein and ESR; Endoscopic appearance on colonoscopy; Histology biopsies|Quality of life: based upon 2 QOL surveys|Effects of naltrexone on remission of Crohn's disease,http://ClinicalTrials.gov/show/NCT00663117,United States,1,1,2,0
NCT00663169,Efficacy and Safety of a Single Dose of ACZ885 in Hospitalized Patients With Acute Gout,Completed,No Results Available,"Arthritis, Gouty",Biological: ACZ885|Biological: ACZ885,Novartis,Both,Adult|Senior,Phase II,6,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CACZ885A2212,4/18/2008,01/04/2008,NA,9/21/2010,01/09/2010,,01/10/2009,"Self-assessed response to treatment at 72 hours post-dose.|non-inferiority of a single dose of ACZ885 compared to the active comparator during treatment period|safety, tolerability and immunogenicity following administration of ACZ885 to patients with acute gout during treatment period|time to walk independently and time to recurrence of the symptoms of acute gout (if applicable) during treatment period|change in C-reactive protein (CRP) and serum amyloid A protein (SAA) from baseline to last visit|pharmacokinetics (PK) of ACZ885 during treatment period|change in pain following ACZ885 administration via a 0-100 mm Visual Analog Scale during treatment period",http://ClinicalTrials.gov/show/NCT00663169,"United States, &nbsp; Switzerland, &nbsp; United Kingdom",0,NA,2,1
NCT00663208,A Multiple Ascending Dose Study of BMS-790052 in Hepatitis C Virus (HCV) Infected Subjects,Completed,No Results Available,Chronic Hepatitis C,Drug: BMS-790052|Drug: Placebo,Bristol-Myers Squibb,Both,Adult,Phase II,30,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",AI444-004,4/18/2008,01/05/2008,01/06/2009,12/02/2010,01/12/2010,,01/06/2009,Pharmacodynamic Measures: Antiviral activity will be assessed by the magnitude and rate of change in plasma HCV RNA levels from baseline|PD-PK Relationship Measures: Assess relationship between antiviral activity and measures of exposure to BMS-790052|Safety Outcome Measures|Pharmacokinetic Measures,http://ClinicalTrials.gov/show/NCT00663208,"United States, &nbsp; Puerto Rico",1,0,2,NA
NCT00663403,Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD),Completed,Has Results,Critically Ill|Hemodialysis,Drug: Daptomycin,University of Michigan|Cubist Pharmaceuticals,Both,Adult|Senior,Phase IV,8,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label,063940|HUM00005646,4/18/2008,01/02/2007,01/04/2009,8/27/2010,01/05/2009,,01/04/2009,Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis|Daptomycin Dose Actually Administered|Observed Daptomycin Peak Serum Concentration|Daptomycin Volume of Distribution at Steady State|Daptomycin Total Body Clearance|Daptomycin Half-life|Daptomycin Free Fraction,http://ClinicalTrials.gov/show/NCT00663403,United States,1,1,1,0
NCT00664625,A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects,Completed,No Results Available,Chronic Hepatitis C,Drug: BMS-791325|Drug: Placebo,Bristol-Myers Squibb,Both,Adult,Phase I|Phase II,24,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",AI443-002,4/18/2008,01/05/2008,01/06/2009,01/06/2011,01/12/2009,,01/06/2009,Safety Outcome Measures|Pharmacokinetic Measures|Pharmacodynamic Measures,http://ClinicalTrials.gov/show/NCT00664625,"United States, &nbsp; Argentina",1,0,2,NA
NCT00665145,Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Diabetic Polyneuropathy",Drug: SB-509|Drug: SB-509|Drug: Placebo|Drug: SB-509,Sangamo Biosciences,Both,Adult|Senior,Phase II,23,Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,SB-509-0703,4/21/2008,01/01/2008,01/10/2009,2/25/2010,01/02/2010,,01/10/2009,Stem cells circulating in peripheral blood|Safety and Efficacy of SB-509,http://ClinicalTrials.gov/show/NCT00665145,United States,1,0,4,NA
NCT00665626,Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3),Completed,No Results Available,Rheumatoid Arthritis,Drug: Fostamatinib disodium (R935788),Rigel Pharmaceuticals,Both,Adult|Senior,Phase II,195,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C-935788-011,4/22/2008,01/05/2008,01/06/2009,6/17/2009,01/06/2009,Taski-3,01/06/2009,"The primary objective of this study is to assess the efficacy of R788 100 mg PO bid compared with placebo, as determined by ACR20 responder rates at Month 3.|To assess the response rate of R788 100 mg PO bid as determined by ACR50, ACR70, ACRn, DAS28-CRP, and DAS28-ESR at Month 3|To assess the rapidity of onset of clinical effect of R788 100 mg PO bid compared with placebo as determined by ACR20 response rates at Weeks 1 and 2|To assess the radiologic response of R788 100 mg PO bid compared with placebo as determined by Magnetic Resonance Imaging (MRI) using the modified RAMRIS scoring system of hands and wrists at baseline and Month 3|To assess and compare the safety profiles of R788 100 mg PO bid dose with placebo for effects on liver function tests, clinically significant reduction in peripheral neutrophil counts, G-I side effects and other adverse effects as they may appear.",http://ClinicalTrials.gov/show/NCT00665626,"United States, &nbsp; Belgium, &nbsp; Colombia, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Peru",1,0,1,NA
NCT00665925,Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis,Completed,No Results Available,Rheumatoid Arthritis,Drug: Fostamatinib disodium (R935788),Rigel Pharmaceuticals,Both,Adult|Senior,Phase II,420,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C-935788-010,4/22/2008,01/05/2008,01/06/2009,9/15/2009,01/09/2009,Taski-2,01/06/2009,"confirm the efficacy of R788 100 mg PO bid as determined by ACR20 responder rates at 6 months.|compare response rates for R788 100 mg PO bid and R788 150 mg PO qd as determined by ACR20, ACR50, ACR70, ACRn, DAS28-CRP and DAS28-ESR response rates over 6 months|To assess the rapidity of onset of clinical effect among the R788 100 mg PO bid, R788 150 mg PO qd, and placebo groups as determined by ACR20 response rates at Weeks 1 and 2|To compare changes for R788 100 mg PO bid and R788 150 mg PO qd in the FACIT-fatigue and SF-36 from baseline to 6 months|To assess and compare the safety profiles for R788 100 mg bid and R788 150 mg qd compared with placebo for effects on liver function tests, clinically significant reductions in peripheral neutrophil counts, G-I side effects and other adverse effect",http://ClinicalTrials.gov/show/NCT00665925,"United States, &nbsp; Bulgaria, &nbsp; Colombia, &nbsp; Israel, &nbsp; Mexico, &nbsp; Poland, &nbsp; Romania",1,0,1,NA
NCT00666536,"The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy",Completed,Has Results,Hypertension,Drug: valsartan and amlodipine|Drug: valsartan and amlodipine,Novartis,Both,Adult|Senior,Phase IV,728,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",CVAA489AUS02,4/23/2008,01/03/2008,NA,11/17/2010,01/11/2010,EXTRA,01/01/2009,"Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 4 Weeks|Proportion of Patients Achieving Blood Pressure Goal (<140/90 mmHg)|Change in Mean Sitting Diastolic Blood Pressure (MSDBP) After 4 Weeks|Change in MSSBP After 2, 8 and 12 Weeks|Change in MSDBP After 2, 8 and 12 Weeks|Proportion of Patients Achieving BP Goal of MSSBP < 140mmHg",http://ClinicalTrials.gov/show/NCT00666536,United States,1,1,2,0
NCT00666757,A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression,Completed,Has Results,Depression,Drug: duloxetine|Drug: fluoxetine|Drug: citalopram|Drug: paroxetine|Drug: sertraline,Eli Lilly and Company|Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase IV,750,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,11715|F1J-US-HMFT,4/23/2008,01/05/2008,01/03/2009,05/12/2010,01/05/2010,TRY FIRST,01/02/2009,"Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint]|Change From Baseline in QIDS-SR Total Score at 12-Week Endpoint (Mood Measure)|Probability of Remission [17-item Hamilton Depression Rating Scale (HAMD-17) (Mood Measure) Less Than or Equal to 7 at 12-Week Endpoint]|Probability of Response [QIDS-SR Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]|Probability of Response [HAMD-17 Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]|Change From Baseline in HAMD-17 Total Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Maier Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Bech Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Retardation Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in HAMD-17 Sleep Subscale Score at 12-Week Endpoint (Mood Measure)|Change From Baseline in Brief Pain Inventory (BPI) Average 24-hour Pain Score, in Particpants With a Baseline BPI Average 24-hour Pain Score of 3 or Greater, at 12-Week Endpoint (Pain Measure)|Change From Baseline in BPI Average 24 Hour Pain Score at 12-Week Endpoint (Pain Measure)|Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score at 12-Week Endpoint (Functional Outcome Measure)|Change From Baseline in SDS Work/School Item Score at 12-Week Endpoint (Functional Outcome Measure)|Change From Baseline in Sheehan Disability Scale (SDS) Family/Home Item Score at Week-12 Endpoint (Functional Outcome Measure)|Change From Baseline in SDS Social Item Score at 12-Week Endpoint (Functional Outcome Measure)|Change From Baseline in Systolic Blood Pressure at Week-12 Endpoint|Change From Baseline in Diastolic Blood Pressure at Week-12 Endpoint|Change From Baseline in Pulse Rate at Week-12 Endpoint|Change From Baseline in Weight at Week-12 Endpoint",http://ClinicalTrials.gov/show/NCT00666757,United States,1,1,5,0
NCT00666900,A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris,Completed,No Results Available,Acne Vulgaris,Drug: Low Strength IDP-107|Drug: High Strength IDP-107|Drug: Placebo Comparator,Dow Pharmaceutical Sciences,Both,Child|Adult|Senior,Phase II,366,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",DPSI-IDP-107-P2-01,4/23/2008,01/01/2008,01/09/2009,9/15/2010,01/09/2010,,01/03/2009,Change from baseline in the number of inflammatory lesions|Improvement from baseline in global severity|Change from baseline in the number of non-inflammatory lesions,http://ClinicalTrials.gov/show/NCT00666900,United States,1,0,3,NA
NCT00667719,A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension,Completed,No Results Available,Essential Hypertension,Drug: aliskiren /amlodipine/hydrochlorothiazide,Novartis,Both,Adult|Senior,Phase III,564,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CSAH100A2301,4/24/2008,01/06/2008,NA,03/12/2010,01/03/2010,,01/10/2009,To assess the long term safety of the combination of aliskiren /amlodipine / hydrochlorothiazide in patients with essential hypertension over 28 weeks to 54 weeks of treatment.|To assess the long-term blood pressure lowering (msDBP and msSBP) efficacy of the combination of aliskiren / amlodipine / hydrochlorothiazide in patients with essential hypertension|To evaluate the proportion of patients achieving the blood pressure control target of < 140/90 mmHg at the end of the study.,http://ClinicalTrials.gov/show/NCT00667719,"United States, &nbsp; Belgium, &nbsp; Egypt, &nbsp; Germany, &nbsp; Poland, &nbsp; Slovakia, &nbsp; Spain, &nbsp; Turkey",1,1,1,0
NCT00667732,"How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics",Completed,No Results Available,Type 2 Diabetes,Drug: exenatide|Drug: placebo,"Oregon Health and Science University|Amylin Pharmaceuticals, Inc.|Eli Lilly and Company",Both,Adult|Senior,Phase IV,75,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","IND 75,235",4/24/2008,01/03/2007,01/04/2010,8/17/2010,01/08/2010,MEXELIN,01/10/2009,"The hemoglobin A1c test, which measures the blood glucose level over a 2-month period, will be looking at glucose control.|The hemoglobin A1c test, which measures the blood glucose level over a 2-month period, will be looking at glucose control.|The hemoglobin A1c test, which measures the blood glucose level over a 2-month period, will be looking at glucose control.|Participants' changes in weight will also be closely examined, since one of the primary objectives of this study was to look at the effect of this regimen of drugs to control blood sugar levels as well as weight.|Participants' changes in weight will also be closely examined, since one of the primary objectives of this study was to look at the effect of this regimen of|Participants' changes in weight will also be closely examined, since one of the primary objectives of this study was to look at the effect of this regimen of",http://ClinicalTrials.gov/show/NCT00667732,United States,1,1,2,1
NCT00667992,Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma,Completed,No Results Available,Asthma,Drug: Budesonide HFA|Drug: Budesonide CFC,AstraZeneca,Both,Adult,Phase IV,60,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,D5252C00008,4/23/2008,01/04/2008,01/05/2009,11/12/2009,01/11/2009,,01/05/2009,"Change from pooled baseline (i.e., post run-in or washout periods) in methacholine airway responsiveness measured as the provocative concentration of methacholine (PC20) that causes a 20% drop in FEV1 for each treatment|Change from pooled baseline in PEF, FEV1 and Forced Expiratory Flow (FEF25-75) for each treatment|Change from pooled baseline in exhaled NO for each treatment|Asthma symptom scores (day, night and total) and rescue use consumption (day, night and total) for each treatment.|Change in pooled baseline for morning PEF",http://ClinicalTrials.gov/show/NCT00667992,"United States, &nbsp; United Kingdom",1,1,2,0
NCT00668525,Escitalopram in Adult Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Escitalopram|Drug: Placebo|Drug: Escitalopram,Forest Laboratories,Both,Adult,Phase III,877,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SCT-MD-49,4/28/2008,01/04/2008,NA,05/07/2010,01/05/2010,,01/02/2009,Change From Baseline in Total Montgomery Asberg Depression Rating Scale (MADRS) at 8 Weeks.|Change From Baseline in Hamiltion Rating Scale for Depression (HAM-D) at Week 8,http://ClinicalTrials.gov/show/NCT00668525,United States,1,1,3,0
NCT00668746,Long-term Safety of Minocycline in Patients With Gum Disease,Completed,Has Results,Periodontitis,Drug: Minocycline HCl microspheres,Johnson & Johnson Consumer & Personal Products Worldwide,Both,Adult|Senior,Phase IV,35,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment",OP-P-5756-1,4/24/2008,01/12/2007,01/02/2009,04/01/2010,01/04/2010,,01/02/2009,Change in Percent of Minocycline-Resistant Bacteria Using Bacterial Culture|Micocycline-Resistance From Plaque Samples|Micocycline-Resistance From Saliva Sample,http://ClinicalTrials.gov/show/NCT00668746,United States,1,0,1,NA
NCT00670267,Oral Nadolol for the Treatment of Adults With Mild Asthma,Completed,No Results Available,Asthma,Drug: nadolol,"Inverseon, Inc.|University of Houston|Sandler Program for Asthma Research|Baylor College of Medicine",Both,Adult,Phase I|Phase II,10,Industry|Other,Interventional,Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SAND1002,4/29/2008,01/01/2007,01/06/2009,02/02/2010,01/02/2010,,01/05/2009,safety|Airway hyper-responsiveness,http://ClinicalTrials.gov/show/NCT00670267,United States,1,1,1,0
NCT00670306,Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH),Completed,Has Results,Benign Prostatic Hyperplasia (BPH),Drug: Cetrorelix Pamoate,AEterna Zentaris,Male,Adult|Senior,Phase III,528,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AEZS-102-Z041,4/22/2008,01/03/2008,01/08/2009,12/15/2010,01/12/2010,AEZS-102-Z041,01/08/2009,IPSS Change From Baseline,http://ClinicalTrials.gov/show/NCT00670306,"United States, &nbsp; Canada",1,1,1,0
NCT00671073,Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,No Results Available,"Pulmonary Disease, Chronic Obstructive",Drug: Oglemilast|Drug: Placebo|Drug: Oglemilast|Drug: Oglemilast,Forest Laboratories,Both,Adult|Senior,Phase II,400,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",GRC-MD-50,4/29/2008,01/04/2008,NA,5/27/2009,01/05/2009,,01/05/2009,Pre-bronchodilator morning (trough) forced expiratory volume in 1 second (FEV1)|Pre-bronchodilator forced vital capacity (FVC),http://ClinicalTrials.gov/show/NCT00671073,United States,1,0,4,NA
NCT00671502,A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,Completed,No Results Available,Lower Back Pain,Drug: Carisoprodol|Drug: Carisoprodol SR|Drug: Placebo,Meda Pharmaceuticals,Both,Adult|Senior,Phase III,840,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP510,05/01/2008,01/04/2008,01/02/2009,4/30/2009,01/04/2009,,01/02/2009,Subject rating of pain on a 100-point visual analog scale (VAS)|Subject functional assessment based on the Roland-Morris Disability Questionnaire (RMDQ)|Adverse events assessments,http://ClinicalTrials.gov/show/NCT00671502,United States,1,0,3,NA
NCT00671580,"Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection",Completed,No Results Available,Skin Infections,Drug: PZ-601|Drug: PZ-601|Drug: Standard of Care,"Protez Pharmaceuticals, Inc.",Both,Adult|Senior,Phase II,99,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,PZ-601-02,05/01/2008,01/05/2008,01/02/2009,06/02/2009,01/06/2009,,01/02/2009,"The primary efficacy parameter is the proportion of patients experiencing clinical response based on improvement or resolution of clinical signs and symptoms of infection in the Clinically Evaluable population at the Test of Cure visit.|Clinical Response in the Clinically Evaluable (CE) population at the End of Treatment (EOT) visit|Clinical Response in the Intent-to-Treat (ITT), Microbiological ITT (mITT), and Microbiologically Evaluable (ME) populations at the Test of Cure (TOC) visit|Clinical Response in the Intent-to-Treat (ITT), Microbiological ITT (mITT), and Microbiologically Evaluable (ME) populations at the End of Treatment (EOT) visit|By-pathogen and by-patient Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the Test of Cure (TOC) visit|By-pathogen and by-patient Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the End of Treatment (EOT) visit|Overall combined Clinical and Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the Test of Cure (TOC) visit|Overall combined Clinical and Microbiological Response in the Microbiological ITT (mITT) and Microbiologically Evaluable (ME) populations at the End of Therapy (EOT) visit",http://ClinicalTrials.gov/show/NCT00671580,United States,1,0,3,NA
NCT00671879,Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,Completed,No Results Available,Lower Back Pain,Drug: Carisoprodol SR 700 mg|Drug: Carisoprodol SR 500 mg|Drug: Placebo,Meda Pharmaceuticals,Both,Adult|Senior,Phase III,840,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP511,05/01/2008,01/04/2008,01/03/2009,4/30/2009,01/04/2009,,01/03/2009,Subject rating of pain on a 100-point visual analog scale|Subject functional assessment based on the Roland-Morris Disability Questionnaire (RMDQ)|Adverse events assessment,http://ClinicalTrials.gov/show/NCT00671879,United States,1,0,3,NA
NCT00671918,Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma,Completed,No Results Available,Breast Cancer|Melanoma,Drug: Lymphoseek,Neoprobe Corporation,Both,Adult|Senior,Phase III,238,Industry,Interventional,Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NEO3-05,4/30/2008,01/04/2008,01/07/2009,8/24/2009,01/08/2009,,01/06/2009,The primary objective of efficacy is the concordance between Lymphoseek and vital blue dye in the in-vivo detection of the excised lymph node(s) as confirmed by pathology.|The secondary objective is the assessment of the resected lymph node(s) to confirm the presence/absence of tumor metastases.,http://ClinicalTrials.gov/show/NCT00671918,"United States, &nbsp; Israel",1,0,1,NA
NCT00672074,Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus,Completed,No Results Available,Ileus,Drug: Ipamorelin|Drug: placebo,"Helsinn Therapeutics (U.S.), Inc",Both,Adult|Senior,Phase II,117,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ST-IPAM-201,05/02/2008,01/04/2008,01/12/2009,09/01/2010,01/09/2010,,01/12/2009,Recovery of GI function,http://ClinicalTrials.gov/show/NCT00672074,United States,1,0,2,NA
NCT00672243,Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme,Completed,No Results Available,Glioblastoma|Gliosarcoma,"Drug: Erlotinib, Sirolimus",Duke University|Genentech|OSI Pharmaceuticals,Both,Adult|Senior,Phase II,20,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,345,1/29/2008,01/04/2007,01/12/2009,01/09/2011,01/01/2011,,01/04/2009,"6 month progression-free survival.|a.Median PFS, radiographic response & overall survival b.Correlation of clinical response & pathological findings of EGFR expression, amplification, PTEN gene copy number & EGFR-vIII expression|Gr 3 or greater, treatment related, non-hematologic toxicities",http://ClinicalTrials.gov/show/NCT00672243,United States,1,1,1,1
NCT00673075,The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease,Completed,Has Results,Hypertension|Coronary Artery Disease,Drug: Nebivolol|Drug: Carvedilol,Forest Laboratories,Both,Adult|Senior,Phase IV,39,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NEB-MD-06,4/29/2008,01/05/2008,NA,09/02/2010,01/09/2010,,01/09/2009,Peripheral Diastolic Blood Pressure (DBP)|Peripheral Systolic Blood Pressure (SBP)|Proportion of Patients With Peripheral SBP <140 mm Hg and DBP <90 mm Hg at Week 18|Left Ventricular Ejection Fraction (LVEF) (%) at Week 18,http://ClinicalTrials.gov/show/NCT00673075,United States,1,1,2,1
NCT00673452,A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: duloxetine hydrochloride|Drug: placebo,Eli Lilly and Company|Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase IV,530,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12220|F1J-US-HMGB,05/05/2008,01/06/2008,01/07/2009,5/28/2010,01/05/2010,,01/04/2009,"Patient's Global Impressions of Improvement (PGI-I) at Week 12|Change From Baseline in Brief Pain Inventory (BPI) (Modified Short Form) at 12 Week Endpoint|Change From Baseline in Multidimensional Fatigue Inventory (MFI) at 12 Week Endpoint|Change From Baseline in Beck Depression Inventory-II (BDI-II) at 12 Week Endpoint|Change From Baseline in Clinical Global Impressions of Severity (CGI-S) at 12 Week Endpoint|Change From Baseline in Beck Anxiety Inventory (BAI) at 12 Week Endpoint|Change From Baseline in 36-Item Short-form Health Survey (SF-36) at 12 Weeks|Change From Baseline in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score at 12 Week Endpoint|Change From Baseline in the Mood, Anxiety, Pain, Sleep, and Stiffness Likert Scale at 12 Week Endpoint|Number of Responders: 30% Improvement in Brief Pain Inventory Average Pain at 12 Week Endpoint|Number of Responders: 50% Improvement in Brief Pain Inventory Average Pain Score at 12 Week Endpoint|Change From Baseline in Blood Pressure at 12 Week Endpoint|Change From Baseline in Heart Rate at 12 Week Endpoint|Number of Patients With Columbia Suicide Severity Rating Scale (CSSR-S) Events (Behaviors, Ideations, Acts)|Change From Baseline in Weight at 12 Week Endpoint",http://ClinicalTrials.gov/show/NCT00673452,"United States, &nbsp; Puerto Rico",1,1,2,1
NCT00673881,ABT-355 Reverse Cholesterol Transport (RCT) Study,Completed,No Results Available,Dyslipidemia,Drug: ABT-335,Radiant Research,Both,Adult|Senior,Phase I|Phase II,25,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ABT-335-001,05/05/2008,01/03/2008,01/05/2009,10/08/2009,01/10/2009,,01/05/2009,"The outcome will measure the rate of appearance (Ra) of plasma cholesterol (cholesterol efflux (mg/kg/hr), cholesterol excretion (%/day), RCT efflux (mg/kg/day) and de novo cholesterol synthesis (%).",http://ClinicalTrials.gov/show/NCT00673881,United States,1,1,1,1
NCT00674739,Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts,Completed,No Results Available,Genital Warts,Drug: Imiquimod A|Drug: Imiquimod B|Drug: Placebo,"Graceway Pharmaceuticals, LLC",Both,Child|Adult|Senior,Phase III,450,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GW01-0801,05/07/2008,01/05/2008,01/07/2009,1/26/2010,01/01/2010,,01/07/2009,"The primary efficacy endpoint is the proportion of subjects achieving complete clearance of all warts (baseline and new) at the EOS.|Safety variables include adverse reactions (AEs), local skin reactions (LSRs), and number and duration of rest periods during the Treatment Period.",http://ClinicalTrials.gov/show/NCT00674739,United States,1,1,3,0
NCT00675103,Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients,Completed,No Results Available,Treatment Failure Gout,Drug: pegloticase 8 mg i.v.,Savient Pharmaceuticals,Both,Adult|Senior,Phase III,18,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,C0409,05/06/2008,01/05/2008,01/04/2009,03/02/2010,01/03/2010,,01/01/2009,"evaluate the safety profile of pegloticase in this patient population|clinical effect on quality of life, functional improvement,swollen and tender joints, and tophus burden",http://ClinicalTrials.gov/show/NCT00675103,United States,1,1,1,0
NCT00676403,Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients,Completed,Has Results,Restless Legs Syndrome,Drug: placebo|Drug: Pregabalin|Drug: Pregabalin|Drug: Pregabalin|Drug: Pregabalin|Drug: Pregabalin,Pfizer,Both,Adult,Phase II,137,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",A0081183,05/08/2008,01/04/2008,01/01/2009,6/28/2010,01/06/2010,,01/01/2009,Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6|Number of Subjects Responding to Treatment as Assessed by the Clinical Global Impression - Improvement Scale (CGI-I)|Number of Subjects With Categorical Scores on the Clinical Global Impression - Severity Scale (CGI-S)|Subjective Sleep Questionnaire (SSQ): Latency Subscale; Observed Change From Baseline|Subjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline|Subjective Sleep Questionnaire: Number of Awakenings Subscale; Observed Change From Baseline|Subjective Sleep Questionnaire: Total Wake Time After Sleep Onset Subscale; Observed Change From Baseline|Subjective Sleep Questionnaire: Quality of Sleep Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Disturbance Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Snoring Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Awaken Short of Breath or With Headache Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Somnolence Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Quantity Subscale; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): 6-Item Sleep Problems Index; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): 9-Item Sleep Problems Index; Observed Change From Baseline|Medical Outcomes Study - Sleep Scale (MOSS-SS): Optimal Sleep; Observed Cases Summarized by Week|Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6|Medical Outcomes Study Short Form 36 (SF-36): Change From Baseline to Week 6|Medical Outcomes Study Short Form 36 (SF-36); Number of Subjects With Self-Evaluated Change in Health Status Scores,http://ClinicalTrials.gov/show/NCT00676403,"United States, &nbsp; Austria, &nbsp; Germany, &nbsp; Spain",1,1,6,1
NCT00676832,Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis,Completed,No Results Available,"Colitis, Ulcerative",Drug: Placebo|Drug: COLAL-PRED,Prometheus Laboratories,Both,Adult|Senior,Phase II,190,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",08CP01,05/09/2008,01/05/2008,01/10/2009,9/27/2010,01/09/2010,,01/10/2009,"The proportion of patients with Complete Response at Week 4 defined as a decrease from baseline in the DAI score by ??­ 30% or ??­ 3 points, and with a decrease in the rectal bleeding subscore of ??­ 1 or an absolute rectal bleeding sub-score of 0 or 1.|The proportion of patients in Clinical Remission defined as a DAI score of ??? 2 points, with no-individual DAI sub-score > 1 at Week 4. Patients in remission by this definition will have a rectal bleeding DAI sub-score of either 0 or 1.",http://ClinicalTrials.gov/show/NCT00676832,United States,1,0,2,NA
NCT00677365,"Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients",Completed,No Results Available,Cystic Fibrosis,Drug: MP-376 (Levofloxacin solution for Inhalation)|Drug: Placebo,Mpex Pharmaceuticals,Both,Child|Adult|Senior,Phase II,151,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Mpex-204,05/12/2008,01/06/2008,01/06/2009,8/17/2009,01/05/2009,,01/06/2009,"Change in P. aeruginosa density from baseline to end of treatment|Changes in respiratory and other domains of CFQ-R from baseline to end of treatment|Time to administration of other anti-pseudomonal antimicrobials|Evaluate changes in FEV1 and FVC from baseline to end of treatment|Changes in bacterial load and susceptability patterns of isolated organisms from baseline to end of treatment|Evaluate the safety and tolerability of three dosage regimens of MP-376 administered over 28 days, compared to placebo",http://ClinicalTrials.gov/show/NCT00677365,"United States, &nbsp; Germany, &nbsp; Netherlands",1,0,2,NA
NCT00677807,"Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",Completed,No Results Available,COPD,Drug: Indacaterol 150 ??g o.d.|Drug: Indacaterol 300 ??g o.d.|Drug: Placebo o.d.,Novartis,Both,Adult|Senior,Phase III,415,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CQAB149B2335SE|2008-000663-42,5/13/2008,01/05/2008,01/03/2009,2/22/2010,01/02/2010,,01/03/2009,Safety profile of two doses of indacaterol compared to placebo over 52 weeks of treatment|Quality of life assessment with St George's Respiratory Questionnaire (SGRQ),http://ClinicalTrials.gov/show/NCT00677807,"United States, &nbsp; Argentina, &nbsp; Canada, &nbsp; Germany, &nbsp; India, &nbsp; Italy, &nbsp; Spain, &nbsp; Sweden, &nbsp; Turkey",1,0,3,NA
NCT00678210,"Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",Completed,No Results Available,Psoriasis,"Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: Placebo",Pfizer,Both,Adult|Senior,Phase II,197,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",A3921047,5/13/2008,01/07/2008,01/08/2009,9/14/2009,01/09/2009,,01/08/2009,"Proportion of subjects achieving a PASI 75 response (ie, at least a 75% reduction in PASI relative to baseline) at Week 12.|Proportion of subjects achieving a PASI 75 response|Proportion of subjects achieving a PASI 50 response (ie, at least a 50% reduction in PASI relative to baseline)|Proportion of subjects achieving a PASI 90 response (ie, at least a 90% reduction in PASI relative to baseline)|Actual and change from baseline in PASI (Psoriasis Area and Severity Index) and PASI component scores|Proportion of subjects with a Physician's Global Assessment (PGA) of \clear\"" or \""almost clear\""""",http://ClinicalTrials.gov/show/NCT00678210,"United States, &nbsp; Canada",1,0,4,NA
NCT00678379,Pediatric Tonsillectomy Pain Reduction Study,Completed,No Results Available,Postoperative Pain,Drug: lidocaine + bupivacaine|Drug: normal saline|Drug: lidocaine + bupivacaine + clonidine,Vanderbilt University,Both,Child,Phase III,120,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",80127,05/08/2008,01/04/2008,01/11/2009,12/10/2009,01/12/2009,,01/11/2009,Total number of post-operative doses of analgesics.|Mean number of pain medication doses per day.|Total time until discharge from hospital.|Mean visual analog scale pain number.|Type of diet patient is able to tolerate.,http://ClinicalTrials.gov/show/NCT00678379,United States,1,1,3,0
NCT00678561,"Topical CP-690,550 For Chronic Plaque Psoriasis",Completed,No Results Available,Psoriasis,"Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: Placebo Vehicle|Drug: Placebo Vehicle",Pfizer,Both,Adult|Senior,Phase II,81,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",A3921038,5/13/2008,01/10/2008,01/07/2009,11/12/2010,01/11/2010,,01/07/2009,target plaque severity score|local toleration|safety laboratory assays|blood levels of drug|physician's global assessment of target lesion,http://ClinicalTrials.gov/show/NCT00678561,"United States, &nbsp; Canada",1,0,8,NA
NCT00678691,"An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue",Completed,No Results Available,"Fibromyalgia, Primary",Drug: armodafinil|Drug: placebo,State University of New York - Upstate Medical University,Both,Adult,Phase IV,60,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",ArmoFibro-001,5/13/2008,01/08/2007,01/12/2009,08/04/2010,01/08/2010,,01/06/2009,Brief Fatigue Inventory,http://ClinicalTrials.gov/show/NCT00678691,United States,1,1,2,1
NCT00680069,H5N1 (Clade 2) Vaccination of Adults and Elderly,Completed,No Results Available,Influenza,Biological: Inactivated Influenza A/H5N1/Indonesia/05/05 (clade 2),National Institute of Allergy and Infectious Diseases (NIAID),Both,Adult|Senior,Phase I|Phase II,517,NIH,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",07-0022|N01AI80008C,5/15/2008,01/11/2008,01/11/2009,1/13/2011,01/11/2009,,01/05/2009,"Immune responses approximately 28 days after one dose of an H5N1 clade 2 vaccine.|Immunologic outcomes include antibodies generated against strains other than A/Indonesia/05/05.|Safety outcomes include frequencies and severities of adverse events (AEs) in the high- and low-dose groups in aggregate, and in other strata previously identified.",http://ClinicalTrials.gov/show/NCT00680069,United States,0,NA,1,NA
NCT00683423,BMS-741672 for Diabetic Neuropathic Pain,Completed,No Results Available,Neuropathic Pain,Drug: BMS-741672|Drug: Placebo,Bristol-Myers Squibb,Both,Adult|Senior,Phase II,50,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",MB114-006,5/21/2008,01/07/2008,01/02/2009,01/06/2011,01/07/2009,,01/01/2009,"Reduction in weekly average pain score for BMS drug vs. placebo, computed from diary scores|Other glycemic, vascular, and mechanism-based biomarkers will be measured",http://ClinicalTrials.gov/show/NCT00683423,United States,1,0,2,NA
NCT00683462,An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD),Completed,No Results Available,ADHD,Drug: Placebo|Drug: AZD3480|Drug: AZD3480,AstraZeneca|Targacept Inc.,Both,Adult,Phase II,24,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TC-1734-226-CRD-005,5/21/2008,01/05/2008,01/07/2009,10/29/2009,01/10/2009,,01/07/2009,The Total Symptoms Scale Score (of ADHD) of the Connors Adult ADHD Rating Scale-Investigator Rating (CAARS-INV).|Clinical Global Impressions Scales (NIMH 1985)|CDR computerized cognitive battery|CNRU computerized cognitive battery,http://ClinicalTrials.gov/show/NCT00683462,United States,1,0,3,NA
NCT00683592,"Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)",Completed,Has Results,Major Depressive Disorder,Drug: vilazodone|Drug: placebo,"PGxHealth, LLC",Both,Adult|Senior,Phase III,481,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLDA-07-DP-02,5/21/2008,01/03/2008,01/03/2009,10/05/2010,01/10/2010,,01/02/2009,Change From Baseline to Week 8 in the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score.|Change From Baseline to Week 8 in the HAM-D 17 (17-Item Hamilton Rating Scale for Depression) Total Score|The CGI-I (Clinician's Global Impression of Improvement) Score at Week 8|Change From Baseline to Week 8 in the HAM-A ( Hamilton Anxiety Rating Scale) Total Score|MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate at Week 8|MADRS (Montgomery-Asberg Depression Rating Scale) Remission Rate at Week 8,http://ClinicalTrials.gov/show/NCT00683592,United States,1,0,2,NA
NCT00683657,Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo,Bristol-Myers Squibb|AstraZeneca,Both,Adult|Senior,Phase III,93,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CV181-066|Eudract-2008-000976-26,5/21/2008,01/07/2008,01/02/2009,11/30/2010,01/11/2010,,01/02/2009,Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4|Change From Baseline in 4-Hour Mean Weighted Postprandial Plasma Glucose at Week 4|Change From Baseline in 2-Hour Postprandial Plasma Glucose After the Evening Meal at Week 4|Change From Baseline in Mean Daily Glucose at Week 4|Change From Baseline in 2-Day Average Fasting Plasma Glucose (FPG) at Week 4,http://ClinicalTrials.gov/show/NCT00683657,"United States, &nbsp; Argentina, &nbsp; Israel, &nbsp; Italy, &nbsp; Mexico, &nbsp; Philippines, &nbsp; Puerto Rico, &nbsp; Sweden",1,1,2,1
NCT00683852,"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",Completed,No Results Available,Major Depressive Disorder,Drug: Aripiprazole|Drug: Aripiprazole|Drug: Placebo,Massachusetts General Hospital|Bristol-Myers Squibb,Both,Adult,Phase III,224,Other|Industry,Interventional,"Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BMS - 2008A053242,5/22/2008,01/07/2008,01/09/2009,08/11/2010,01/08/2010,,01/09/2009,The primary outcome will be the difference in rate of response (decrease in MADRS total score of at least 50%) between patients treated with adjunctive aripiprazole 2 mg and adjunctive placebo using the sequential parallel comparison design.|To document the safety and tolerability of low doses of aripiprazole augmentation,http://ClinicalTrials.gov/show/NCT00683852,United States,1,1,3,1
NCT00684177,Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL),Completed,Has Results,"Secondarily-infected Abrasions|Secondarily-infected Lacerations|Secondarily-infected Sutured Wounds|Secondarily-infected Traumatic Lesions|Skin Diseases, Bacterial","Drug: Retapamulin Ointment, 1%|Drug: Placebo ointment",GlaxoSmithKline,Both,Child|Adult|Senior,Phase III,508,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",TOC110977,5/22/2008,01/05/2008,01/10/2009,01/06/2011,01/01/2011,,01/10/2009,Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Primary Efficacy Population|Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Intent-to-Treat Bacteriology (ITTB) Subset of the Primary Efficacy Population|Number of Participants With Microbiological Success and Failure at Follow-up (7-9 Days Post Therapy)|Number of Participants With the Indicated Clinical Outcome at End of Therapy (2-4 Days Post Therapy)|Number of Baseline Pathogens With the Indicated Microbiological Outcome at End of Therapy (2-4 Days Post Therapy)|Number of Participants With Therapeutic Success and Failure at Follow-up (7-9 Days Post Therapy),http://ClinicalTrials.gov/show/NCT00684177,"United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; India, &nbsp; South Africa",1,1,2,1
NCT00684918,Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML),Completed,No Results Available,AML,Drug: Obatoclax,Gemin X,Both,Senior,Phase II,18,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,GEM016,5/23/2008,01/04/2008,01/12/2009,9/13/2010,01/09/2010,,01/08/2009,Determine the rate of morphologic CR after treatment in the obatoclax single-agent therapy in older patients with previously untreated AML.,http://ClinicalTrials.gov/show/NCT00684918,"United States, &nbsp; Canada",1,0,1,NA
NCT00685698,Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections,Completed,No Results Available,Diabetic Foot Infections,Drug: TG-873870 (Nemonoxacin),"TaiGen Biotechnology Co., Ltd.",Both,Adult|Senior,Phase II,40,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TG-873870-04,5/22/2008,01/06/2008,01/06/2009,1/18/2010,01/01/2010,,01/04/2009,Clinical Success|Safety Evaluation|Microbiological Success Rate|PK and PD Evaluation,http://ClinicalTrials.gov/show/NCT00685698,"United States, &nbsp; South Africa, &nbsp; Taiwan, &nbsp; Thailand",1,0,1,NA
NCT00686088,"An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy",Completed,No Results Available,Locally Recurrent Prostate Cancer,Drug: PRX302,Protox Therapeutics,Male,Adult|Senior,Phase II,30,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PRX302-1-02,5/26/2008,01/02/2008,01/09/2009,10/27/2009,01/09/2009,,01/09/2009,"PSA levels, PSA doubling time, PSA velocity and tumor burden assessment by biopsy compared to screening.|Safety and tolerability of PRX302.",http://ClinicalTrials.gov/show/NCT00686088,United States,1,0,1,NA
NCT00686712,Insulin Glargine at Bedtime or in AM Versus NPH,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin glargine|Drug: Insulin glargine|Drug: NPH insulin,Charles Drew University of Medicine and Science|National Institutes of Health (NIH),Both,Adult|Senior,Phase IV,108,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,03-02-524|U54RR014616,5/27/2008,01/02/2003,01/08/2009,9/15/2010,01/09/2010,,01/08/2009,Hemoglobin A1c Change From Baseline|Frequency of Glucose Readings < 130 mg/dL|Frequency of Total Hypoglycemic Reactions|Frequency of Severe Hypoglycemic Reactions|Body Mass Index Change From Baseline|Total Daily Insulin Dose|Any Adverse Event Other Than Hypoglycemia,http://ClinicalTrials.gov/show/NCT00686712,United States,1,1,3,0
NCT00686868,Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients,Completed,No Results Available,Rheumatoid Arthritis,Drug: ofatumumab|Other: placebo,GlaxoSmithKline,Both,Adult|Senior,Phase II,35,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,OFA110867,5/28/2008,01/06/2008,01/11/2009,3/31/2010,01/03/2010,,01/11/2009,"Safety and tolerability as described by the incidence and severity of adverse events [AEs], clinical laboratory parameters and vital signs.|Requirement for the use of pre-medication, including the timing, type and dose required.|Pharmacodynamics (B-cell depletion and re-population) as measured by CD-19 peripheral blood B- lymphocyte count via routine fluorescent activated cell sorting (FACS) analysis.|PK/PD parameters including estimation of time to re-population of CD-19 peripheral blood B-cells to above LLQ (and/or <95% depletion) following single subcutaneous dose of Ofatumumab.|Immunogenicity as measured by the incidence, titre and type of human anti-human antibody (HAHA) immune response.|Other pharmacodynamic/biomarkers of disease activity and immune status may include high sensitivity C-reactive protein (hsCRP), Erythrocyte Sedimentation Rate (ESR), B-Lymphocyte Stimulator (BLyS/BAFF), B-Lymphocyte Chemokine (BLC), IL-6,|Immunoglobulins (IgA, IgG, IgM), Complement (CH50, C3, C4), IgM Rheumatoid Factor (IgM-RF), IgA-RF and IgG-RF, anti-cyclic citrullinated peptide antibody (aCCP),|serum amyloid A (SAA), CD-3+, CD-4+ and CD-8+ lymphocytes or other biomarkers, as data permit.|Pharmacodynamics (B-cell depletion and re-population) as measured by CD-19 peripheral blood B- lymphocyte count via routine FACS analysis.Other Secondary Endpoints",http://ClinicalTrials.gov/show/NCT00686868,"United States, &nbsp; Australia, &nbsp; Belgium, &nbsp; Italy, &nbsp; New Zealand, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Spain",1,1,2,1
NCT00686998,Phase IIA Study in Patients With Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: AZD2624|Drug: Olanzapine|Drug: Placebo,AstraZeneca,Both,Adult,Phase II,110,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",D0970C00004,5/28/2008,01/05/2008,01/05/2009,8/18/2009,01/08/2009,,01/05/2009,Change in PANSS total score|Safety and Tolerability of AZD2624 vs Placebo|Pharmacokinetic evaluation,http://ClinicalTrials.gov/show/NCT00686998,United States,1,0,3,NA
NCT00687453,Insulin Glargine Versus Twice-Daily NPH,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin glargine at bedtime instead of NPH|Drug: NPH twice-daily,Charles Drew University of Medicine and Science|National Institutes of Health (NIH),Both,Adult|Senior,Phase IV,27,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,03-02-519|U54RR014616,5/27/2008,01/02/2003,01/08/2009,9/15/2010,01/09/2010,,01/08/2009,Hemoglobin A1c Change From Baseline|Frequency of Pre-supper Glucose Readings 120 mg/dL or Less|Frequency of Total Hypoglycemic Reactions|Frequency of Severe Hypoglycemic Reactions|Body Mass Index Change From Baseline|Total Daily Insulin Dose|Any Adverse Event Other Than Hypoglycemia,http://ClinicalTrials.gov/show/NCT00687453,United States,1,1,2,0
NCT00687557,Study of TAS-108 in Postmenopausal Patients With Locally Advanced Breast Carcinoma Following Standard First or Second Line Endocrine Therapy,Completed,No Results Available,Metastatic Breast Cancer,Drug: TAS-108,"Taiho Pharma USA, Inc.|Quintiles",Female,Adult|Senior,Phase II,180,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",TAS108-0004,5/28/2008,01/10/2003,01/06/2009,6/30/2009,01/06/2009,,01/06/2009,"The primary efficacy endpoints for this study are the response rate of the tumor, namely CR and PR, and clinical benefit, namely CR, PR, or SD for 24 weeks.|To evaluate the safety of TAS-108 administered on this schedule|To investigate the comparative concentrations of TAS-108 and its metabolites in tumor tissue and blood at steady-state|To determine the time to progression of TAS-108 administered on this schedule|To investigate selective biomarker activity related to TAS-108 including ER??, progesterone receptor (PgR), phosphorylated ER?? (S118 and S167), estrogen receptor subtype (ER??), and coactivator of ER-mediated gene transcription (AIB1)",http://ClinicalTrials.gov/show/NCT00687557,"United States, &nbsp; Russian Federation",1,0,1,NA
NCT00687635,Efficacy and Safety Study of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment,Completed,No Results Available,Attention Impairment,Drug: Donepezil hydrochloride|Drug: Placebo,Eisai Inc.|Eisai Limited,Both,Child,Phase III,300,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",E2020-G000-334,5/28/2008,01/08/2008,01/09/2009,9/22/2009,01/09/2009,,01/06/2009,"Change in the TOVA-CPT (Test of Variables in Attention - Continuous Performance Test) reaction time variability measure (administered to subjects).|Paired Assoc. Learning Test, Woodcock Johnson Decision Speed Test, Woodcock Johnson Mathematics Fluency; Go/No-Go Task (for subjects); Conners' Parent Rating Scale-Revised (S); Behavioral Rating Inventory of Executive Functioning (parent/legal guardian).",http://ClinicalTrials.gov/show/NCT00687635,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Canada, &nbsp; Chile, &nbsp; France, &nbsp; Germany, &nbsp; Netherlands, &nbsp; Spain, &nbsp; United Kingdom",1,1,2,1
NCT00687830,Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.,Completed,No Results Available,Colon Cancer,Drug: Polythylene Glycol|Drug: Polythylene Glycol|Drug: Polyethylene glycol|Drug: Polyethylene glycol,Cleveland Clinic Florida,Both,Child|Adult|Senior,Phase III,192,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Caregiver)|Primary Purpose: Treatment,CCFL-8964,5/28/2008,01/02/2008,01/11/2009,1/27/2010,01/01/2009,CCF,01/07/2009,Bowel cleansing effect as measured by the Ottawa scale: Evening v Morning|Patient satisfaction with the bowel prep: Evening v Morning,http://ClinicalTrials.gov/show/NCT00687830,United States,1,1,4,0
NCT00687908,Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance,Completed,Has Results,Acne,Drug: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Drug: Vehicle Gel,Galderma,Both,Child|Adult,Phase III,243,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RD.03.SPR.29075,5/28/2008,01/11/2008,01/07/2009,9/30/2010,01/09/2010,ACCESS II,01/07/2009,Maintenance Success for Total Lesions at Week 24|Maintenance Success for Inflamatory Lesions at Week 24|Maintenance Success for Non-inflammatory Lesions at Week 24|Investigator Global Assessment (IGA) Maintenance Success at Week 24|Percent of Subjects With Adverse Events,http://ClinicalTrials.gov/show/NCT00687908,"United States, &nbsp; Canada, &nbsp; Puerto Rico",1,1,2,0
NCT00688064,Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris,Completed,Has Results,Severe Acne Vulgaris,Drug: Adapalene BPO Gel associated with Doxycyline Hyclate|Drug: Vehicle Gel associated with Doxycycline Hyclate,Galderma,Both,Child|Adult,Phase III,459,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RD.03.SPR.29074,5/28/2008,01/08/2008,01/02/2009,3/31/2010,01/03/2010,ACCESS I,01/02/2009,Percent Change From Baseline in Total Lesion Counts at Week 12.|Percent Change From Baseline in Inflammatory Lesion Counts at Week 12.|Percent Change From Baseline in Non-inflammatory Lesion Counts at Week 12|Success Rate on the Investigator's Global Assessment|Percent of Subjects With Adverse Events,http://ClinicalTrials.gov/show/NCT00688064,"United States, &nbsp; Canada, &nbsp; Puerto Rico",1,0,2,NA
NCT00688376,Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment,Completed,No Results Available,Attention Impairment,Drug: Donepezil hydrochloride|Drug: Placebo,Eisai Inc.|Eisai Limited,Both,Child,Phase III,300,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",E2020-G000-333,5/28/2008,01/08/2008,01/09/2009,9/22/2009,01/09/2009,,01/06/2009,"Change in the TOVA-CPT (Test of Variables in Attention - Continuous Performance Test) reaction time variability measure (administered to subjects).|Paired Assoc. Learning Test, Woodcock Johnson Decision Speed Test, Woodcock Johnson Mathematics Fluency; Go/No-Go Task (for subjects); Conners' Parent Rating Scale-Revised (S); Behavioral Rating Inventory of Executive Functioning (parent/legal guardian).",http://ClinicalTrials.gov/show/NCT00688376,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Canada, &nbsp; Chile, &nbsp; France, &nbsp; Germany, &nbsp; Netherlands, &nbsp; Spain, &nbsp; United Kingdom",1,1,2,1
NCT00688701,GLP-1 Agonist AVE0010 in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: LIXISENATIDE (AVE0010)|Drug: Placebo,Sanofi-Aventis,Both,Adult|Senior,Phase III,361,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC6018|EudraCT 2007-005887-29,05/07/2008,01/05/2008,01/12/2009,11/26/2010,01/11/2010,GETGOAL-MONO,01/12/2009,Absolute change from baseline in HbA1c|Change from baseline in body weight|Change from baseline in fasting plasma glucose|Change from baseline in 2-hours post-prandial plasma glucose,http://ClinicalTrials.gov/show/NCT00688701,"United States, &nbsp; Belgium, &nbsp; India, &nbsp; Israel, &nbsp; Japan, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Tunisia",1,0,2,NA
NCT00688909,Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: letrozole,Novartis Pharmaceuticals,Female,Adult|Senior,Phase IV,260,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,CFEM345DUS59,5/29/2008,01/03/2008,01/10/2009,11/18/2009,01/11/2009,REAL,01/10/2009,"Proportion of patients discontinuing due to grade 2 or higher arthralgia-myalgia.|Time to discontinuation due to grade 2 or higher arthralgia- myalgia.|Proportion of patients discontinuing, irrespective of cause.",http://ClinicalTrials.gov/show/NCT00688909,United States,1,1,1,1
NCT00689117,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,Completed,Has Results,Acne Vulgaris|Acne,Drug: CT Gel|Drug: Clindamycin Gel (clindamycin )|Drug: Tretinoin Gel (tretinoin)|Drug: Vehicle Gel,"Stiefel, a GSK Company",Both,Child|Adult|Senior,Phase III,1649,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",114681|W0265-03,5/24/2008,01/04/2008,01/05/2009,12/17/2010,01/12/2010,,01/04/2009,"Absolute Change From Baseline in Lesion Counts (Total, Inflammatory, and Non-inflammatory) at Week 12 (End of Study)|The Percentage of Participants Who Had a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12|Percent Change From Baseline in Lesion Counts (Inflammatory, Non-inflammatory, and Total) at Week 12|The Percentage of Participants With a Subjects Global Assessment Score of 0 or 1 at Week 12|The Percentage of Participants Who Had ISGA Scores of 0 or 1 at Week 12",http://ClinicalTrials.gov/show/NCT00689117,"United States, &nbsp; Belize, &nbsp; Canada",1,1,4,0
NCT00689260,Easypod United States User Trial,Completed,Has Results,Growth Hormone Deficiency,Device: easypod|Device: easypod,EMD Serono,Both,Child|Adult,Phase IV,42,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Subject),28358,5/22/2008,01/03/2008,01/10/2009,10/29/2010,01/10/2010,,01/05/2009,Percent rhGH Injections Missed During the Treatment Period (Based on the Easypod?ºÑ Injection Log)|Subjects Perception of Easypod Ease of Use Compared to Two Other rhGH Pen Injection Devices|Subject Perceptions of Easypod: Storage Convenience Compared to Two Other rhGH Pen Injection Devices.|Subject Perceptions of Easypod: Preference to Use Easypod Over Two Other rhGH Pen Injection Devices.,http://ClinicalTrials.gov/show/NCT00689260,United States,0,NA,2,NA
NCT00689299,Phase 2 Study in Adults Sensitized to Cat,Completed,No Results Available,Allergy to Cat Hair,Biological: SLIT,"Antigen Laboratories, Inc.",Both,Adult,Phase II,167,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALI002-08,5/30/2008,01/10/2008,01/06/2009,10/14/2009,01/10/2009,,01/05/2009,Average of Total Symptom Scores,http://ClinicalTrials.gov/show/NCT00689299,United States,0,NA,1,NA
NCT00690716,The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines,Completed,No Results Available,Migraine,Drug: Nasal CO2|Drug: Inactive Placebo,"Capnia, Inc.",Both,Adult,Phase II,292,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",C112,06/03/2008,01/08/2008,01/06/2009,8/18/2010,01/09/2009,,01/06/2009,The proportion of patients who are pain-free,http://ClinicalTrials.gov/show/NCT00690716,United States,1,0,2,NA
NCT00690794,Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension,Completed,No Results Available,Open-Angle Glaucoma|Ocular Hypertension,"Drug: Travatan 0.004%, BAC Free",Alcon Research,Both,Adult|Senior,Phase III,700,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",C-08-03,06/03/2008,01/07/2008,NA,07/06/2009,01/07/2009,,01/06/2009,Ocular Surface Disease index questionnaire at 3 months|Corneal fluorescein staining at 3 months,http://ClinicalTrials.gov/show/NCT00690794,United States,1,1,1,1
NCT00690807,A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis,Completed,No Results Available,Atopic Dermatitis,Drug: PH-10,Provectus Pharmaceuticals,Both,Adult|Senior,Phase II,30,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PH-10-AD-21,06/03/2008,01/06/2008,01/09/2009,9/24/2009,01/09/2009,,01/08/2009,The primary efficacy endpoint is \Treatment Success,http://ClinicalTrials.gov/show/NCT00690807,United States,1,0,1,NA
NCT00691483,Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date,Completed,Has Results,Smoking Cessation,Drug: placebo|Drug: varenicline,Pfizer,Both,Adult|Senior,Phase IV,659,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",A3051095,06/03/2008,01/09/2008,01/12/2009,11/19/2010,01/11/2010,,01/09/2009,Percentage of Participants With 4-week Continuous Abstinence (CA)|Percentage of Participants With Continuous Abstinence (CA) From Smoking Weeks 9-24|Percentage of Participants With Long Term Quit Through Week 24|Percentage of Participants With 7-day Point Prevalence of Nonsmoking (Smoking Cessation)|Percentage of Participants With 4-week Point Prevalence of Nonsmoking,http://ClinicalTrials.gov/show/NCT00691483,"United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Canada, &nbsp; China, &nbsp; Czech Republic, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Taiwan, &nbsp; United Kingdom",1,1,2,1
NCT00691665,Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial,Completed,Has Results,Seasonal Allergic Rhinitis,"Drug: Olopatadine HCL Nasal Spray, 0.6%|Drug: Fluticasone Propionate Nasal Spray, 50 mcg",Alcon Research,Both,Child|Adult|Senior,Phase IV,130,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",SMA-08-06,06/03/2008,01/05/2008,NA,3/23/2010,01/03/2010,,01/01/2009,Mean Percent Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline|Mean Percent Change in Instantaneous Total Nasal Symptom Score (iTNSS) From Baseline|Mean Percent Change in Reflective Total Ocular Symptom Scores (rTOSS) From Baseline|Mean Percent Change in Instantaneous Total Ocular Symptom Scores (iTOSS) From Baseline,http://ClinicalTrials.gov/show/NCT00691665,United States,1,1,2,0
NCT00691717,Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension,Completed,No Results Available,Open-Angle Glaucoma|Ocular Hypertension,Drug: Anecortave Acetate|Drug: Placebo,Alcon Research,Both,Adult|Senior,Phase II|Phase III,400,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",C-07-36,06/03/2008,01/06/2008,NA,9/30/2009,01/09/2009,,01/09/2009,Mean IOP|Percent of patient with a therapeutic benefit.,http://ClinicalTrials.gov/show/NCT00691717,United States,1,0,2,NA
NCT00691964,Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis,Completed,No Results Available,Plaque Psoriasis,Biological: ABT-874|Biological: etanercept|Drug: placebo,Abbott|Paragon Biomedical,Both,Adult|Senior,Phase III,347,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",M10-114,06/04/2008,01/06/2008,NA,11/01/2010,01/09/2010,,01/03/2009,Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12,http://ClinicalTrials.gov/show/NCT00691964,United States,1,0,3,NA
NCT00692445,TC-5214 as add-on the Treatment of Major Depressive Disorder,Completed,No Results Available,Major Depressive Disorder|Depression,Drug: TC-5214|Drug: Placebo,Targacept Inc.,Both,Adult|Senior,Phase II,574,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TC-5214-23-CRD-001,06/04/2008,01/06/2008,01/07/2009,7/28/2009,01/07/2009,,01/05/2009,"Mean change between TC-5214 and placebo from DB baseline (Week 8) of the HAMD-17 score, at Week 16.|Safety and Pharmacokinetic Endpoints",http://ClinicalTrials.gov/show/NCT00692445,"United States, &nbsp; India",1,1,2,0
NCT00693056,Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED),Completed,No Results Available,Erectile Dysfunction (ED),Drug: Placebo|Drug: RX-10100 5mg|Drug: RX-10100 10mg|Drug: RX-10100 15mg,"Rexahn Pharmaceuticals, Inc.",Male,Adult,Phase II,40,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",RX-10100-P2A-001,06/04/2008,01/06/2008,01/05/2009,05/04/2009,01/05/2009,,01/03/2009,"Scores on IIEF-EF Questionnaires and on SEP Questions II and III|Scores on other domains of IIEF, other questions on Subject Diaries, RigiScan measurement, and ED-QoL questionnaires",http://ClinicalTrials.gov/show/NCT00693056,United States,1,0,4,NA
NCT00694135,Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis,Completed,No Results Available,"Uveitis, Anterior",Drug: EGP-437 1.6 mA-min at 0.4 with EyeGate?ó II System|Drug: EGP-437 4.8 mA-min at 1.2 mA with EyeGate?ó II System|Drug: EGP-437 10.0 mA-min at 2.5 mA with EyeGate?ó II System|Drug: EGP-437 14.0 mA-min at 3.5 mA with EyeGate?ó II System,"Eyegate Pharmaceuticals, Inc.",Both,Child|Adult|Senior,Phase II,40,Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EGP-437-001,06/05/2008,01/06/2008,01/08/2009,8/27/2010,01/08/2010,,01/07/2009,Proportion of subjects with an ACC score of zero at Days 14 and 28|Time to ACC score of zero|Proportion of subjects with a reduction of one full ACC score or more from baseline at Day 28|Change from baseline in ACC score at Day 28|Treatment emergent adverse events,http://ClinicalTrials.gov/show/NCT00694135,"United States, &nbsp; India",1,0,4,NA
NCT00694707,Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: Placebo|Drug: RGH-188|Drug: RGH-188|Drug: RGH-188|Drug: Risperidone,Forest Laboratories|Gedeon Richter Ltd.,Both,Adult,Phase II,732,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",RGH-MD-16,06/06/2008,01/06/2008,01/08/2009,5/25/2010,01/05/2010,,01/08/2009,PANSS total score|Clinical Global Impression - Severity,http://ClinicalTrials.gov/show/NCT00694707,"United States, &nbsp; India, &nbsp; Malaysia, &nbsp; Russian Federation, &nbsp; Ukraine",1,0,5,NA
NCT00694928,Vaginal Infection Study 2,Completed,No Results Available,Vaginal Infection,Drug: clindamycin phosphate/butoconazole nitrate|Drug: butoconazole nitrate,KV Pharmaceutical Company,Female,Child|Adult|Senior,Phase III,843,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CBC-303-603-622467,06/09/2008,01/05/2008,01/11/2009,11/30/2009,01/11/2009,,01/11/2009,The primary outcome measure of the study will be clinical symptom resolution|Secondary outcome measures will include laboratory assessments of presence or absence of vaginal infection.,http://ClinicalTrials.gov/show/NCT00694928,"United States, &nbsp; India, &nbsp; Russian Federation",1,1,2,0
NCT00695565,Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy,Completed,No Results Available,Painful Diabetic Neuropathy,Drug: placebo|Drug: topical clonidine (ARC-4558),Arcion Therapeutics Inc,Both,Adult|Senior,Phase II,170,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CLO-027,06/10/2008,01/05/2008,01/12/2009,1/22/2010,01/01/2010,,01/12/2009,mean change from Baseline in NPRS score|mean change from Baseline in NPRS score at each week|Percentage of subjects who experience at least 30% or at least 50% reduction in pain intensity from Baseline to each week of treatment,http://ClinicalTrials.gov/show/NCT00695565,United States,1,0,2,NA
NCT00696020,Combination of Orally Inhaled BI1744Cl/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD),Completed,No Results Available,"Pulmonary Disease, Chronic Obstructive",Drug: BI1744/Tiotropium bromide|Drug: Tiotropium bromide,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase II,360,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,1237.4|EudraCT No: 2007-005087-26,06/10/2008,01/06/2008,NA,03/03/2009,01/03/2009,,01/02/2009,The primary efficacy variable will be forced expiratory volume in one second (FEV1). The primary endpoint is the trough FEV1 response [L] after four weeks of treatment.|FEV1 and FVC responses at different timepoints Weekly mean predose morning and evening PEF Weekly mean number of occations of rescue therapy used per day Patient's Global Rating scale Adverse events Laboratory and Vital signs,http://ClinicalTrials.gov/show/NCT00696020,"United States, &nbsp; Canada, &nbsp; Germany",1,0,2,NA
NCT00696384,A Safety and Tolerability Study of Azilsartan Medoxomil in Subjects With Essential Hypertension,Completed,No Results Available,Essential Hypertension,Drug: Azilsartan medoxomil|Drug: Placebo,"Takeda Global Research & Development Center, Inc.",Both,Adult|Senior,Phase III,418,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-06-TL-491-016|U1111-1113-9088,06/10/2008,01/06/2007,01/04/2009,7/14/2010,01/07/2010,,01/04/2009,Change from Baseline in sitting clinic diastolic blood pressure.|Change from Baseline in sitting clinic systolic blood pressure.,http://ClinicalTrials.gov/show/NCT00696384,"United States, &nbsp; Argentina, &nbsp; Mexico",1,0,2,NA
NCT00696436,An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Subjects With Essential Hypertension.,Completed,No Results Available,Essential Hypertension,Drug: Azilsartan medoxomil|Drug: Azilsartan medoxomil|Drug: Valsartan|Drug: Olmesartan|Drug: Placebo,"Takeda Global Research & Development Center, Inc.",Both,Adult|Senior,Phase III,1291,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",01-06-TL-491-019|U1111-1113-9161,06/10/2008,01/04/2008,01/08/2009,7/14/2010,01/07/2010,,01/08/2009,"Change from baseline in the 24-hour mean systolic blood pressure by ambulatory blood pressure monitoring.|Change from baseline in trough sitting systolic blood pressure taken in the clinic|Change from baseline for 24-hour mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline in trough sitting diastolic blood pressure taken in the clinic|Change from baseline for daytime mean (6am to 10pm) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for daytime mean (6am to 10pm) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for nighttime mean (12am to 6am) diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for 0-12-hr mean diastolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) systolic blood pressure by ambulatory blood pressure monitor|Change from baseline for trough mean (22-24-hr) diastolic blood pressure by ambulatory blood pressure monitor|Proportion of subjects who achieve a Clinic Diastolic Blood Pressure Response, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg|Proportion of subjects who achieve a Clinic Systolic Blood Pressure Response, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg|Proportion of subjects who achieve both clinic Diastolic and Systolic Blood Pressure Response",http://ClinicalTrials.gov/show/NCT00696436,"United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Mexico, &nbsp; Peru, &nbsp; Puerto Rico",1,0,5,NA
NCT00696475,Diazoxide Choline in Hypertriglyceridemia,Completed,No Results Available,Hypertriglyceridemia,Drug: Diazoxide choline|Drug: Diazoxide choline|Drug: Diazoxide choline|Drug: Placebo,"Essentialis, Inc.|Medpace, Inc.",Both,Adult|Senior,Phase II,80,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PC007,06/10/2008,01/06/2008,01/03/2009,11/04/2010,01/11/2010,,01/01/2009,"To assess the effect on triglycerides of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects|To assess the effect on other lipid parameters (LDL, HDL, VLDL, and non-HDL cholesterol), insulin, glucose and weight of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects|To assess the safety and tolerability of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects",http://ClinicalTrials.gov/show/NCT00696475,United States,1,0,4,NA
NCT00697099,Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery,Completed,No Results Available,Venous Thromboembolism,Drug: Semuloparin sodium (AVE5026)|Drug: Enoxaparin|Drug: Placebo,Sanofi-Aventis,Both,Adult|Senior,Phase III,2326,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",EFC10342|2007-007944-80,06/12/2008,01/06/2008,01/06/2009,12/20/2010,01/12/2010,SAVE-HIP1,01/05/2009,"Occurence of the composite endpoint of any VTE confirmed by a blinded Central Independent Adjudication Committee (CIAC) and deaths from any cause|Occurence of the composite endpoint of any proximal Deep Vein Thrombosis (DVT), symptomatic distal DVT, nonfatal Pulmonary Embolism (PE), and all cause deaths|Number of patients with major bleedings and clinically relevant non-major bleedings as confirmed by the CIAC",http://ClinicalTrials.gov/show/NCT00697099,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Belarus, &nbsp; Canada, &nbsp; Chile, &nbsp; Colombia, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Estonia, &nbsp; Finland, &nbsp; Germany, &nbsp; Greece, &nbsp; India, &nbsp; Italy, &nbsp; Mexico, &nbsp; Norway, &nbsp; Peru, &nbsp; Philippines, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Taiwan, &nbsp; Thailand, &nbsp; Turkey, &nbsp; Ukraine",1,0,3,NA
NCT00698230,Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics,Completed,No Results Available,Type 2 Diabetes,Drug: INCB013739|Drug: Placebo,Incyte Corporation,Both,Adult|Senior,Phase II,300,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",INCB 13739-202,6/13/2008,01/05/2008,01/05/2009,6/17/2010,01/06/2010,,01/04/2009,Change from baseline in hemoglobin A1c (HbA1c) and safety and tolerability data.|Change from baseline in fasting plasma glucose (FPG) and proportion of subjects meeting HbA1c goal.,http://ClinicalTrials.gov/show/NCT00698230,"United States, &nbsp; Puerto Rico",1,0,2,NA
NCT00698646,Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.,Completed,Has Results,Hypertension,Drug: Valsartan + HCTZ|Drug: Valsartan|Drug: HCTZ,Novartis Pharmaceuticals,Both,Senior,Phase IV,384,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",CVAH631BUS08,6/13/2008,01/04/2008,01/06/2009,11/16/2010,01/11/2010,,01/06/2009,"Change in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP)|Change in Office Cuff Mean Sitting Diastolic Blood Pressure (MSDBP)|Change in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8, 12 and 16|Proportion of Subjects Achieving Blood Pressure (BP) Control (Defined as BP < 140/90 mmHg)|Proportion of Patients Achieving BP Goal (MSSBP < 140 mmHg)|Time to Achieving the First Treatment Success (Defined as the Time of the First Achievement of the Target Blood Pressure Goal [MSSBP/MSDBP <140/90 mmHg])",http://ClinicalTrials.gov/show/NCT00698646,United States,1,1,3,0
NCT00698724,"Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care",Completed,No Results Available,Cataracts,"Drug: Xibrom, and Optive|Drug: Xibrom and Pred Forte","Bp Consulting, Inc",Both,Adult|Senior,Phase IV,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,5359,6/13/2008,01/06/2008,01/06/2009,06/08/2009,01/06/2009,,01/06/2009,OCT|Visual Acuity,http://ClinicalTrials.gov/show/NCT00698724,United States,1,0,2,NA
NCT00698828,SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD),Completed,No Results Available,Cachexia,Drug: Placebo comparator|Drug: SUN11031,"Asubio Pharmaceuticals, Inc.",Both,Adult|Senior,Phase II,225,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",ASBI 307,05/01/2008,01/03/2008,01/10/2009,1/20/2010,01/01/2010,,01/09/2009,"The physical performance|Safety and tolerability data as measured by adverse events, electrocardiograms, physical exams, clinical laboratory tests, vital signs, and lung function|Evaluate the effect of SUN11031 on body composition data",http://ClinicalTrials.gov/show/NCT00698828,"United States, &nbsp; Argentina, &nbsp; Chile, &nbsp; Guatemala, &nbsp; Honduras, &nbsp; Romania",1,0,2,NA
NCT00698841,Study to Evaluate the Effect of Cetuximab on Corrected QT Interval Changes in Patients With Advanced Malignancies From Solid Tumors,Completed,No Results Available,"Advanced Cancer IV, NOS",Drug: cetuximab,Bristol-Myers Squibb|ImClone LLC,Both,Adult|Senior,Phase II,3,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA225-315,6/16/2008,01/02/2009,01/12/2009,7/26/2010,01/02/2010,,01/12/2009,Average maximum change from time-matched baseline in QTc interval in study population|To assess the safety and tolerability of cetuximab administration in the study population,http://ClinicalTrials.gov/show/NCT00698841,"United States, &nbsp; Puerto Rico",1,1,1,1
NCT00699153,Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery,Completed,Has Results,Ocular Inflammation,Drug: Loteprednol Etabonate|Drug: Vehicle of Ophthalmic Loteprednol Etabonate,"Bausch & Lomb, Inc.",Both,Adult|Senior,Phase III,400,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",526,6/13/2008,01/06/2008,01/06/2009,09/01/2010,01/09/2010,,01/05/2009,"Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0|Participants With Grade 0 (no) Pain|Participants With Complete Resolution of Anterior Chamber Cells and Flare, at Each Visit.|Mean Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare",http://ClinicalTrials.gov/show/NCT00699153,United States,1,1,2,1
NCT00699218,A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression,Completed,No Results Available,Mood Disorder|Bipolar Disorder|Major Depression|Depression,Device: Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.,"University of California, Davis|National Alliance for Research on Schizophrenia and Depression",Both,Adult,Phase I|Phase II,15,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,200715749-1,06/04/2008,01/05/2008,01/04/2010,6/25/2010,01/06/2010,TMS-BD,01/07/2009,Hamilton Rating Scale for Depression (HAM-D)|Inventory of Depressive Symptomatology,http://ClinicalTrials.gov/show/NCT00699218,United States,0,NA,1,NA
NCT00700622,Safety and Efficacy of Technosphere?ó Insulin Inhalation Powder and Lantus?ó Compared to Humalog?ó and Lantus?ó Over 16-Weeks,Completed,No Results Available,Diabetes Type 1,Drug: Technosphere Insulin|Drug: Lantus|Drug: Humalog,Mannkind Corporation,Both,Adult|Senior,Phase III,137,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MKC-TI-117,6/16/2008,01/05/2008,01/03/2010,08/03/2010,01/08/2010,,01/11/2009,"efficacy endpoint is the change from Visit 5 to Visit 14 in A1c|Proportion of subjects who achieve an A1c of less than or equal to 6.5%|Proportion of subjects who achieve an A1c of less than or equal to 7.0 %|Proportion of subjects who achieve an A1c of less than or equal to 7.0%, AND do not have any episodes of severe hypoglycemia|Area under the glucose concentration curve (AUC0-240 min), based on plasma glucose concentrations measured at -30, 0, 30, 60, 90, 105, 120, 180, and 240 min following the Meal Challenge(s)|Responder rate as measured by the number of subjects who attain 2-hour PPG levels of < 180 mg/dL (10.0 mmol/L), and < 140 mg/dL (7.8 mmol/L) following Meal Challenges|7-point blood glucose (BG) profiles at regular intervals|CGM parameters|Body weight|Subject treatment satisfaction",http://ClinicalTrials.gov/show/NCT00700622,"United States, &nbsp; Brazil",1,0,3,NA
NCT00700635,Dose Comparison Study of Menactra?ó in US Children,Completed,Has Results,Meningitis|Meningococcal Infection|Neisseria Meningitidis,Biological: Menactra?ó: Meningococcal Polysaccharide Diphtheria Conjugate|Biological: Menactra?ó: Meningococcal Polysaccharide Diphtheria Conjugate|Biological: Menactra?ó: Meningococcal Polysaccharide Diphtheria Conjugate,Sanofi-Aventis,Both,Child,Phase II,333,Industry,Interventional,Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,MTA61,05/07/2008,01/06/2008,01/10/2009,12/22/2010,01/12/2010,,01/05/2009,Percentage of Participants With Meningococcal Antibody Titers ??­ 8 After Each Vaccination|Percentage of Participants With Meningococcal Antibody Titers at ??­ 4 After Each Vaccination|Geometric Mean Titers (GMTs) of Meningococcal Antibodies After Each Menactra?ó Vaccination.|Percentage of Participants Reporting Solicited Injection Site and Solicited Systemic Reactions After Dose 1 Vaccination|Percentage of Participants Reporting Solicited Injection Site and Solicited Systemic Reactions After Dose 2 Vaccination,http://ClinicalTrials.gov/show/NCT00700635,United States,0,NA,3,NA
NCT00700713,Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra?ó Three Years Earlier in Study MTA26,Completed,No Results Available,Meningitis|Meningococcemia,Biological: Meningococcal polysaccharide diphtheria toxoid conjugate|Biological: Meningococcal polysaccharide diphtheria toxoid conjugate|Biological: Meningococcal polysaccharide diphtheria toxoid conjugate,Sanofi-Aventis,Both,Child,Phase II,181,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,MTA62,05/07/2008,01/06/2008,01/03/2009,09/02/2010,01/09/2010,,01/02/2009,To provide information concerning the immune response to Menactra?ó after booster vaccination.,http://ClinicalTrials.gov/show/NCT00700713,United States,0,NA,3,NA
NCT00700817,"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: sitagliptin|Drug: metformin|Drug: liraglutide,Novo Nordisk,Both,Adult|Senior,Phase III,665,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NN2211-1860|2007-003937-17,6/18/2008,01/06/2008,01/06/2010,08/04/2010,01/07/2010,,01/06/2009,"Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26|Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 26|Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 26|Mean Change From Baseline in Body Weight at Week 26|Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26|Mean Change From Baseline in Beta-cell Function at Week 26|Mean Change From Baseline in Total Cholesterol at Week 26|Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 26|Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 26|Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 26|Mean Change From Baseline in Triglycerides (TG) at Week 26|Mean Change From Baseline in Free Fatty Acids (FFA) at Week 26|Mean Change From Baseline in Apolipoprotein B at Week 26|Mean Change From Baseline in Highly Sensitive C-reactive Protein (hsCRP) at Week 26|Mean Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at Week 26.|Mean Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 26.|Mean Change From Baseline in Interleukin-6 (IL-6) at Week 26.|Mean Change From Baseline in Adiponectin at Week 26.|Mean Change From Baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 26.|Mean Change From Baseline in Von Willebrand Factor (vWf) at Week 26.|Mean Change From Baseline in Waist to Hip Ratio at Week 26.|Mean Change From Baseline in Waist Circumference at Week 26.|Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 26|Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 26|Mean Change From Baseline in Pulse at Week 26|Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 26|Hypoglyceamic Episodes, Weeks 0-26|Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-26|Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 52|Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 52|Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 52|Mean Change From Baseline in Body Weight at Week 52|Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52|Mean Change From Baseline in Beta-cell Function at Week 52|Mean Change From Baseline in Total Cholesterol at Week 52|Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 52|Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 52|Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 52|Mean Change From Baseline in Triglycerides (TG) at Week 52|Mean Change From Baseline in Free Fatty Acids (FFA) at Week 52|Mean Change From Baseline in Apolipoprotein B at Week 52|Mean Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at Week 52|Mean Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 52|Mean Change From Baseline in Interleukin-6 (IL-6) at Week 52|Mean Change From Baseline in Adiponectin at Week 52|Mean Change From Baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 52|Mean Change From Baseline in Von Willebrand Factor (vWf) at Week 52|Mean Change From Baseline in Waist Circumference at Week 52|Mean Change From Baseline in Waist to Hip Ratio at Week 52|Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 52|Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 52|Mean Change From Baseline in Pulse at Week 52|Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 52|Hypoglyceamic Episodes, Weeks 0-52|Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 78|Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 78|Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 78|Mean Change From Baseline in Body Weight at Week 78|Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 78|Mean Change From Baseline in Beta-cell Function at Week 78|Mean Change From Baseline in Total Cholesterol at Week 78|Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 78|Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 78|Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 78|Mean Change From Baseline in Triglycerides (TG) at Week 26|Mean Change From Baseline in Free Fatty Acids (FFA) at Week 78|Mean Change From Baseline in Apolipoprotein B at Week 78|Mean Change From Baseline in Waist Circumference at Week 78|Mean Change From Baseline in Waist to Hip Ratio at Week 78|Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 78|Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 78|Mean Change From Baseline in Pulse at Week 78|Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 78|Hypoglyceamic Episodes, Weeks 0-78",http://ClinicalTrials.gov/show/NCT00700817,"United States, &nbsp; Canada, &nbsp; Croatia, &nbsp; Former Serbia and Montenegro, &nbsp; Germany, &nbsp; Ireland, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Slovakia, &nbsp; Slovenia, &nbsp; Spain, &nbsp; United Kingdom",1,1,4,0
NCT00701116,Safety Study of Clenbuterol in Combination With Left Ventricular Assist Device to Treat Chronic Heart Failure,Completed,No Results Available,Heart Failure|Nonischemic Cardiomyopathy|Cardiac Disease,Drug: Clenbuterol,Ohio State University|Massachusetts General Hospital|Montefiore Medical Center|Northwestern University|Texas Heart Institute|University of Michigan|Washington Hospital Center,Both,Adult|Senior,Phase I|Phase II,40,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2007H0101,6/17/2008,01/03/2007,01/08/2009,9/22/2009,01/09/2009,HARPS,01/01/2009,To determine if the proportion of subjects treated with the HARPS protocol who Experience LVAD removal and subsequent freedom from mechanical circulatory support or heart transplantation for 1 year post-LVAD removal.|To asses the effect of the HARP regimen on LVAD explantation and the changes to the heart,http://ClinicalTrials.gov/show/NCT00701116,United States,1,0,1,NA
NCT00701727,Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study,Completed,No Results Available,Hypercholesterolemia,Drug: ezetimibe|Drug: Placebo,Radiant Research,Both,Adult|Senior,Phase IV,30,Other,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,Ezetimibe RCT-001,6/17/2008,01/06/2008,01/03/2009,10/08/2009,01/10/2009,,01/03/2009,fecal excretion of plasma-derived cholesterol|de novo cholesterol synthesis (DNC)|Cholesterol efflux rate (Ra cholesterol|RCT efflux|Fasting lipid levels,http://ClinicalTrials.gov/show/NCT00701727,United States,1,1,2,0
NCT00702325,Phase4/Symbicort Versus Pulmicort Flexhaler in African Americans,Completed,No Results Available,Asthma,Drug: Budesonide /formoterol fumarate|Drug: Budesonide,AstraZeneca,Both,Child|Adult|Senior,Phase IV,300,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D589BL00003,6/19/2008,01/06/2008,01/09/2009,11/11/2009,01/11/2009,Titan,01/09/2009,"change from baseline in the pre-dose forced expiratory volume in one second (FEV1) averaged over the double-blind treatment period|AM Peak Expiratory Flow (PEF)|PM Peak Expiratory Flow (PEF)|Spirometry Measures [forced vital capacity (FVC), forced expiratory flow (FEF)]",http://ClinicalTrials.gov/show/NCT00702325,United States,1,1,2,1
NCT00702650,A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations,Completed,Has Results,Hypogonadism,Drug: Testosterone MD-Lotion,Eli Lilly and Company,Male,Adult|Senior,Phase III,155,Industry,Interventional,Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,14272|MTE08|I5E-MC-TSAH,6/19/2008,01/06/2008,01/07/2009,01/05/2011,01/01/2011,,01/07/2009,Percentage of Participants With 24-Hour Average Concentration [Cavg(0-24h)] Total Testosterone Within Normal Range at Day 120|Percentage of Participants With Maximum Serum Concentration (Cmax) >1500 ng/dL|Percentage of Participants With Cmax Between 1800 and 2500 ng/dL|Percentage of Participants With Cmax >2500 ng/dL|Percentage of Participants With Minimum Concentration (Cmin) <300 ng/dL|Change From Baseline to Endpoint in Psychosexual Daily Questionnaire|Change From Baseline to Endpoint in the 36-Item Short-Form Health Survey (SF-36)|Change From Baseline to Endpoint in Fasting Insulin|Change From Baseline to Endpoint in Fasting Glucose|Change From Baseline to Endpoint in Prostate Specific Antigen (PSA)|Change From Baseline to Endpoint in Luetinizing Hormone (LH) and Follicle Stimulating Hormone (FSH)|Change From Baseline to Endpoint in Estradiol|Change From Baseline to Endpoint in Haemoglobin|Change From Baseline to Endpoint in Haematocrit|Change From Baseline to Endpoint in Draize Score,http://ClinicalTrials.gov/show/NCT00702650,"United States, &nbsp; Australia, &nbsp; France, &nbsp; Germany, &nbsp; Sweden, &nbsp; United Kingdom",1,0,1,NA
NCT00703053,H5N1 Priming and Boosting Strategies,Completed,Has Results,Influenza,Biological: A/Vietnam/1203/04|Biological: A/Indonesia/05/05,National Institute of Allergy and Infectious Diseases (NIAID),Both,Adult,Phase II,505,NIH,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",07-0019|N01AI80003C,6/19/2008,01/09/2008,01/11/2009,11/11/2010,01/09/2009,,01/07/2009,"Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen|Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen|Number of Subjects Achieving a 4-fold or Greater HAI Antibody Titer Increase Against A/Vietnam/04 Antigen|Number of Subjects Achieving a 4-fold or Greater HAI Antibody Titer Increase Against A/Indonesia/05 Antigen|Number of Subjects Achieving a HAI Antibody Titer of 1:40 or Greater Against A/Vietnam/04 Antigen|Number of Subjects Achieving a HAI Antibody Titer of 1:40 or Greater Against A/Indonesia/05 Antigen|Number of Serious Adverse Events|Number of Subjects Reporting Solicited Symptoms Within 7 Days of First Vaccination|Number of Subjects Reporting Solicited Symptoms Within 7 Days of Second Vaccination|Neutralizing Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen|Neutralizing Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen|Number of Subjects Achieving a 4-fold or Greater Neutralizing Antibody Titer Increase Against A/Vietnam/04 Antigen|Number of Subjects Achieving a 4-fold or Greater Neutralizing Antibody Titer Increase Against A/Indonesia/05 Antigen|Number of Subjects Achieving Neutralizing Antibody Titer of 1:40 or Greater Against A/Vietnam/04 Antigen|Number of Subjects Achieving Neutralizing Antibody Titer of 1:40 or Greater Against A/Indonesia/05 Antigen|Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 6 Months Post Last Vaccination|Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen at 6 Months Post Last Vaccination|Neutralizing Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 6 Months Post Last Vaccination|Neutralizing Geometric Mean Titer (GMT) Against A/Indonesia/05 Antigen at 6 Months Post Last Vaccination|Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen at 1, 2, 3 and 4 Weeks After 2 Doses",http://ClinicalTrials.gov/show/NCT00703053,United States,0,NA,2,NA
NCT00703573,Phase IIa Safety and Efficacy of S-777469 in Patients With Atopic Dermatitis,Completed,No Results Available,Atopic Dermatitis,Drug: S-777469|Drug: S-777469|Drug: Placebo,"Shionogi USA, Inc.",Both,Adult,Phase II,209,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0721D1424,6/20/2008,01/05/2008,01/12/2009,02/03/2010,01/02/2010,POC,01/05/2009,Physician Global Assessment (PGA)|Itch Numerical Rating Score (NRS)|Itch Behavioral Rating Score (BRS)|Eczema Area and Severity Index (EASI)|Digital Photography with IPR|Thymus Activation-Regulated Chemokine (TARC)|Skindex-16 Quality of Life Determination,http://ClinicalTrials.gov/show/NCT00703573,United States,1,0,3,NA
NCT00703937,Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia,Completed,No Results Available,Anemia,Drug: Ferric Carboxymaltose,Luitpold Pharmaceuticals,Both,Adult|Senior,Phase III,NA,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,1VIT08019,6/20/2008,01/06/2008,NA,8/30/2010,01/08/2010,,01/08/2009,Safety and Tolerability,http://ClinicalTrials.gov/show/NCT00703937,United States,1,0,1,NA
NCT00703963,Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care,Completed,No Results Available,INR Patient Self Testing.|Usual Care.,Device: INRatio monitor by Hemosense,Mayo Clinic|Sorin Group,Both,Adult|Senior,Phase IV,200,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Diagnostic",07-001398,06/10/2008,01/03/2007,01/03/2009,10/22/2010,01/10/2010,,01/03/2009,"To compare time in therapeutic range between patients that are self-testing, and patients that are being tested in the usual manner by their primary care provider.",http://ClinicalTrials.gov/show/NCT00703963,United States,0,NA,1,NA
NCT00704262,Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds,Completed,No Results Available,Psoriasis Vulgaris,Drug: Calcipotriol plus hydrocortisone (LEO 80190),LEO Pharma,Both,Adult|Senior,Phase II,33,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LEO 80190-O23,6/23/2008,01/05/2008,01/12/2009,12/14/2009,01/12/2009,,01/12/2009,Effect on the hypothalamic-pituitary-adrenal axis and effect on the calcium metabolism|Overall disease severity of the face and intertriginous areas according to the investigator??s global assessment of disease severity.,http://ClinicalTrials.gov/show/NCT00704262,"United States, &nbsp; Canada, &nbsp; Germany, &nbsp; United Kingdom",1,0,1,NA
NCT00704340,DuraSeal Sealant Post Market Study,Completed,Has Results,Elective Cranial Procedures With Dural Incision,Device: DuraSeal Dural Sealant System|Other: Standard of Care,Confluent Surgical|Covidien,Both,Adult|Senior,Phase IV,237,Industry,Interventional,Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,DRS-05-002,6/23/2008,01/09/2005,01/05/2009,7/27/2010,01/07/2010,,01/05/2009,"Percentage of Subjects With Surgical Wound Complications, Central Nervous System Events, and Neurosurgical Complications Related to Unplanned Intervention or Return to the Operating Room.|Percentage of Subjects With Post-operative Surgical Site Infections|Percentage of Subjects With a Cerebrospinal Fluid (CSF) Leak",http://ClinicalTrials.gov/show/NCT00704340,United States,0,NA,2,NA
NCT00704353,Safety and Tolerability of a Single Dose of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia,Completed,No Results Available,Anemia,Drug: Ferric Carboxymaltose|Drug: Ferrous Sulfate,Luitpold Pharmaceuticals,Both,Adult|Senior,Phase III,526,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,1VIT08021,6/20/2008,01/06/2008,NA,8/30/2010,01/08/2010,,01/07/2009,Safety and Tolerability,http://ClinicalTrials.gov/show/NCT00704353,United States,1,0,2,NA
NCT00704938,"Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer",Completed,No Results Available,"Kidney Cancer|Melanoma (Skin)|Unspecified Adult Solid Tumor, Protocol Specific",Biological: aldesleukin|Biological: anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Biological: autologous dendritic cell-adenovirus p53 vaccine|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate,National Cancer Institute (NCI),Both,Adult|Senior,Phase II,82,NIH,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Masking: Open Label|Primary Purpose: Treatment,CDR0000598419|NCI-08-C-0155|NCI-P07215,6/24/2008,01/06/2008,NA,09/04/2009,01/10/2008,,01/08/2009,Clinical tumor regression|In vivo survival of T-cell receptor (TCR) gene-engineered cells|Ability of a dendritic cell vaccine to restimulate TCR gene-engineered cells in vivo|Toxicity,http://ClinicalTrials.gov/show/NCT00704938,United States,1,1,6,0
NCT00705406,"A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza",Completed,No Results Available,"Acute, Uncomplicated Human Influenza",Drug: Peramivir|Drug: Placebo,BioCryst Pharmaceuticals,Both,Adult|Senior,Phase II,320,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",BCX1812-212,6/24/2008,01/07/2008,01/04/2009,05/08/2009,01/05/2009,,01/04/2009,To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.|To evaluate the safety and tolerability of peramivir administered intramuscularly.|To evaluate changes in influenza virus titer in nasopharyngeal samples (viral shedding) in response to treatment.,http://ClinicalTrials.gov/show/NCT00705406,"United States, &nbsp; Australia, &nbsp; New Zealand, &nbsp; South Africa",1,0,2,NA
NCT00705575,Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension,Completed,No Results Available,Hypertension,Drug: Aliskiren / HCTZ (300/25 mg)|Drug: Aliskiren,Novartis,Both,Adult|Senior,Phase III,688,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",CSPP100A2353,6/23/2008,01/06/2008,NA,1/19/2010,01/01/2010,ACQUIRE,01/04/2009,"Change from baseline in mean sitting systolic blood pressure (msSBP) after 12-weeks of treatment.|Change from baseline in msSBP (after 8 weeks of treatment) and in msDBP ( after 12 and 8 weeks of treatment)for aliskiren / HCTZ (300/25 mg) combination vs. aliskiren (300 mg) monotherapy|Change from baseline in msSBP and msDBP after 12 and 8 weeks of treatment with aliskiren / HCTZ (300/25 mg) combination|Change from baseline in msSBP and msDBP after 12 and 8 weeks of aliskiren (300 mg) monotherapy.|Proportion of patients achieving the target blood pressure (msSBP < 140 mmHg and msDBP < 90 mmHg, and msSBP < 130 mmHg and msDBP < 80 mmHg for diabetics), in both study arms, after 12 and 8 weeks of treatment.|Safety and tolerability of aliskiren / HCTZ (300/25 mg) combination compared to aliskiren (300 mg) monotherapy regimen in patients with Stage II hypertension.",http://ClinicalTrials.gov/show/NCT00705575,"United States, &nbsp; Argentina, &nbsp; Ecuador, &nbsp; Germany, &nbsp; Guatemala, &nbsp; Italy, &nbsp; Switzerland, &nbsp; Turkey",1,1,2,1
NCT00706719,To Evaluate Fertility in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone,Completed,Has Results,Infertility in Men|Secondary Hypogonadism,Drug: Androxal (enclomiphene citrate)|Drug: topical testosterone gel,Repros Therapeutics Inc.,Male,Adult,Phase II,17,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ZA-201,6/25/2008,01/06/2008,01/08/2009,9/21/2010,01/09/2010,,01/07/2009,Change in Sperm Concentration From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Sperm Concentration From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Sperm Concentration From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Sperm Count From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Sperm Count From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Sperm Count From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Semen Volume From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Semen Volume From Baseline in Men Treated With Androxal?ó Versus Testim|Change in Semen Volume From Baseline in Men Treated With Androxal?ó Versus Testim|Changes in Follicle Stimulating Hormone(FSH) and Leutinizing Hormone(LH) Levels From Baseline in Men Treated With Androxal?ó Versus Testim,http://ClinicalTrials.gov/show/NCT00706719,United States,1,0,2,NA
NCT00706849,Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Subjects With Coronary Artery Disease,Completed,No Results Available,Heterozygous Familial Hypercholesterolemia|Coronary Artery Disease,Drug: mipomersen sodium (ISIS 301012)|Drug: placebo,Genzyme|Isis Pharmaceuticals,Both,Adult|Senior,Phase III,124,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",301012-CS7,6/26/2008,01/08/2008,01/05/2010,10/02/2010,01/10/2010,RADICHOL II,01/12/2009,Percent reduction in low-density lipoprotein cholesterol (LDL-C) from Baseline at Week 28|Percent reduction in apolipoprotein B (apoB) from Baseline at Week 28|Percent reduction in total cholesterol from Baseline at Week 28|Percent reduction in non-high-density lipoprotein cholesterol (non-HDL-C) from Baseline at Week 28|Percent reduction in Lipoprotein (a) (Lp(a)) from Baseline at Week 28,http://ClinicalTrials.gov/show/NCT00706849,"United States, &nbsp; Canada",1,0,2,NA
NCT00708422,Ocular Surface Effects of Prostaglandin Analogues (PGAs),Completed,No Results Available,Glaucoma,Drug: Travoprost eye drop|Drug: Latanoprost,Alcon Research,Both,Adult|Senior,Phase IV,110,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|Primary Purpose: Treatment",SMA-08-07,6/30/2008,01/07/2008,NA,10/02/2009,01/10/2009,,01/08/2009,Measuring TBUT|Change in OSDI score,http://ClinicalTrials.gov/show/NCT00708422,United States,1,1,2,0
NCT00709098,Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension,Completed,No Results Available,Pulmonary Arterial Hypertension,Drug: iloprost|Drug: iloprost,Actelion,Both,Adult|Senior,Phase III,49,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AC-063A302,07/01/2008,01/06/2008,01/12/2009,4/30/2010,01/04/2010,PROWESS 15 Ext,01/11/2009,Treatment-emergent adverse events|Treatment-emergent serious adverse events|Adverse events leading to premature discontinuation of study drug|Treatment-emergent adverse events and serious adverse events leading to study drug discontinuation,http://ClinicalTrials.gov/show/NCT00709098,"United States, &nbsp; Austria, &nbsp; Germany",1,1,2,1
NCT00709371,Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity,Completed,No Results Available,Obesity,Drug: Zonisamide SR placebo plus bupropion SR placebo|Drug: Zonisamide SR placebo plus bupropion SR 360 mg/day|Drug: Zonisamide SR 120 mg/day plus bupropion SR placebo|Drug: Zonisamide SR 360 mg/day plus bupropion SR placebo|Drug: Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day|Drug: Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day,"Orexigen Therapeutics, Inc",Both,Adult,Phase II,600,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",ZB-202,6/29/2008,01/07/2008,01/07/2009,02/04/2010,01/02/2010,,01/04/2009,Percentage change in total body weight,http://ClinicalTrials.gov/show/NCT00709371,United States,1,1,6,0
NCT00709852,Safety and Efficacy of Gadobutrol 1.0 Molar (Gadovist?ó) in Patients for Central Nervous System (CNS) Imaging,Completed,No Results Available,Diagnostic Imaging|Central Nervous System Diseases,"Drug: Gadobutrol (Gadovist, BAY86-4875)|Drug: Gadoteridol (ProHance)",Bayer,Both,Adult|Senior,Phase III,402,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",91681|EudraCT: 2007-004746-33|310123,07/01/2008,01/06/2008,01/05/2009,11/18/2010,01/11/2010,,01/05/2009,"To demonstrate superiority of combined unenhanced and gadobutrol-enhanced magnetic resonance imaging (MRI).|To demonstrate noninferiority of combined unenhanced and gadobutrol-enhanced magnetic resonance imaging (MRI).|To demonstrate noninferiority of gadobutrol compared to gadoteridol for: degree of contrast enhancement, border delineation, internal morphology, total number of lesions|Demonstrate improvement of gadobutrol-enhanced MRI to unenhanced MRI and noninferiority to gadoteridol-enhanced MRI for: exact match of the MR diagnoses with the final clinical diagnosis|Assess the safety profile of gadobutrol compared to gadoteridol after intravenous (IV) administration",http://ClinicalTrials.gov/show/NCT00709852,"United States, &nbsp; Australia, &nbsp; Austria, &nbsp; Colombia, &nbsp; Germany, &nbsp; India, &nbsp; Japan, &nbsp; Switzerland",1,0,2,NA
NCT00709865,Phase 2b Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency,Completed,No Results Available,Congestive Heart Failure|Renal Insufficiency,Drug: tonapofylline|Drug: Placebo,Biogen Idec,Both,Adult|Senior,Phase II|Phase III,420,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",160HF301,07/01/2008,01/07/2008,01/12/2009,12/08/2009,01/12/2009,TRIDENT-1,01/10/2009,"Assess the safety andtolerability of intravenous tonapofylline, when added to standard therapy in subjects hospitalized with ADHF and renal insufficiency.",http://ClinicalTrials.gov/show/NCT00709865,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Brazil, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Czech Republic, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; India, &nbsp; Israel, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Sweden",1,0,2,NA
NCT00709956,Iloprost Power 15 in Pulmonary Arterial Hypertension,Completed,No Results Available,Pulmonary Arterial Hypertension,Drug: iloprost power 15 ( Ventavis(R))|Drug: placebo,Actelion,Both,Adult|Senior,Phase III,70,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AC-063A301,07/01/2008,01/06/2008,01/09/2009,8/17/2010,01/08/2010,PROWESS 15,01/08/2009,6-minute-walk distance after a single dose of iloprost power 15 or placebo|Borg dyspnea score after a single dose of iloprost power 15 or placebo,http://ClinicalTrials.gov/show/NCT00709956,"United States, &nbsp; Austria, &nbsp; Germany",1,1,2,1
NCT00710333,Safety of Juvista When Administered Following Excision of Ear Lobe Keloids,Completed,No Results Available,Keloid,Drug: Avotermin|Drug: placebo,Renovo,Both,Adult|Senior,Phase I|Phase II,10,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RN1001-0093,07/03/2008,01/07/2008,01/12/2009,03/08/2010,01/03/2010,RN1001-0093,01/10/2009,Frequency of Adverse events|Keliod recurrence,http://ClinicalTrials.gov/show/NCT00710333,United States,1,0,2,NA
NCT00710580,Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis,Completed,No Results Available,Moderate to Severe Plaque Psoriasis,Biological: ABT-874|Biological: etanercept|Drug: placebo,Abbott|Paragon Biomedical,Both,Adult|Senior,Phase III,350,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",M10-315,07/02/2008,01/07/2008,NA,11/01/2010,01/09/2010,,01/04/2009,Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12,http://ClinicalTrials.gov/show/NCT00710580,United States,1,0,3,NA
NCT00711516,Study to Evaluate the Effects of Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance in Adults With OSAHS Who Use nCPAP Therapy,Completed,No Results Available,Excessive Sleepiness,Drug: Armodafinil|Drug: Placebo,Cephalon,Both,Adult,Phase IV,40,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",C10953/4026/AP/US,07/08/2008,01/09/2008,01/10/2009,11/11/2009,01/11/2009,,01/09/2009,"fMRI activation volume in DLPFC (number of voxels meeting predefined threshold)|Response latency on the 2-back working memory test.|CANTAB, ESS, CGI-C, and MOS-CF6 assessments",http://ClinicalTrials.gov/show/NCT00711516,United States,1,1,2,0
NCT00712114,"Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis",Completed,No Results Available,Rheumatoid Arthritis,Drug: HE3286|Drug: HE3286|Drug: HE3286,"Harbor BioSciences, Inc",Both,Adult|Senior,Phase I|Phase II,18,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HE3286-0201,07/06/2008,01/07/2008,01/07/2009,05/11/2010,01/05/2010,,01/07/2009,Safety and pharmacokinetics|To assess the potential activity of HE3286 to decrease inflammation via evaluation of inflammatory cytokine activity.,http://ClinicalTrials.gov/show/NCT00712114,United States,1,0,3,NA
NCT00712166,"Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa",Completed,Has Results,Cystic Fibrosis|Lung Infection|Pseudomonas Aeruginosa,Drug: AZLI 75 mg three times daily (TID)|Drug: Placebo three times daily (TID),Gilead Sciences,Both,Child|Adult|Senior,Phase III,160,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GS-US-205-0117,07/07/2008,01/05/2008,01/08/2009,11/19/2010,01/11/2010,AIR-CF4,01/06/2009,Change From Baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS) Score at Day 28|Change From Baseline in CFQ-R RSS Score at Day 14|Change From Baseline in CFQ-R RSS Score at Day 42|Change From Baseline in CFQ-R Physical Functioning Domain Score|Number of Participants Using Additional (Nonprotocol-specified) Antipseudomonal Antibiotics During Study|Number of Participants Hospitalized During Study|Change From Baseline in Log10 Pseudomonas Aeruginosa (PA) Colony Forming Units (CFUs) in Sputum at Day 28|Relative Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted,http://ClinicalTrials.gov/show/NCT00712166,"United States, &nbsp; Australia, &nbsp; Canada",1,0,2,NA
NCT00712244,"DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus",Completed,Has Results,Cataract,Device: DisCoVisc|Device: DuoVisc|Device: Healon5|Device: Amvisc Plus,Alcon Research,Both,Adult|Senior,Phase IV,112,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,M07-014,07/07/2008,01/10/2007,NA,09/10/2010,01/09/2010,,01/04/2009,Corneal Endothelial Cell Loss|Percent Gain in Corneal Thickness.|Aqueous Signs - Corneal Edema|Aqueous Signs - Aqueous Flare|Aqueous Signs - Aqueous Cells|Intraocular Pressure (IOP)|Surgeon Survey - Anterior Chamber Dome Maintenance During Anterior Capsulotomy|Surgeon Surgey - Anterior Dome Maintenance During Phacoemulsification|Surgeon Surgey - Anterior Dome Maintenance During Intraocular Lens (IOL) Insertion,http://ClinicalTrials.gov/show/NCT00712244,United States,0,NA,4,NA
NCT00712543,A Preference Study Comparing Kristalose?ó and Liquid Lactulose,Completed,No Results Available,Constipation,Drug: lactulose (Kristalose?ó)|Drug: liquid lactulose,Cumberland Pharmaceuticals,Both,Adult|Senior,Phase IV,50,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,-1,07/08/2008,01/06/2009,01/09/2009,9/29/2009,01/09/2009,,01/09/2009,"To determine patient preference for the powder or liquid form of lactulose, as demonstrated by patients responses on a questionnaire.|To determine patient preference for the taste of the powder or liquid form of lactulose, as demonstrated by patients responses on a questionnaire.|To determine patient preference for the consistency of the powder or liquid form of lactulose, as demonstrated by patients responses on a questionnaire.|To determine patient preference for the portability of the powder or liquid form of lactulose, as demonstrated by patients responses on a questionnaire.",http://ClinicalTrials.gov/show/NCT00712543,United States,1,1,2,0
NCT00713609,Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne,Completed,No Results Available,Acne Vulgaris,Drug: Benzoyl peroxide/clindamycin gel + tazarotene cream|Drug: Benzoyl peroxide/clindamycin gel + vehicle cream|Drug: Benzoyl peroxide gel + tazarotene cream|Drug: Clindamycin gel + tazarotene cream|Drug: Vehicle gel+ tazarotene cream|Drug: Vehicle gel + vehicle cream,"Stiefel, a GSK Company",Both,Child|Adult,Phase II,591,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",W0259-201,07/07/2008,01/06/2008,01/03/2009,09/07/2010,01/09/2010,,01/03/2009,"The absolute change in lesion counts (total, inflammatory, noninflammatory) from baseline to week 12. The proportion of subjects who have a minimum 2-grade improvement in ISGA score from baseline to week 12.|The percent (%) change in lesion counts (total, inflammatory, noninflammatory) from baseline to week 12. The proportion of subjects who have an ISGA score of 0 or 1 at week 12.",http://ClinicalTrials.gov/show/NCT00713609,United States,1,1,6,0
NCT00716859,"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.",Completed,Has Results,Glaucoma,Drug: Timolol|Drug: latanoprost,Pfizer,Both,Child|Adult,Phase III,139,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A6111137,7/14/2008,01/07/2008,01/11/2009,11/01/2010,01/11/2010,,01/11/2009,"Reduction From Baseline in Mean IOP at Week 12, Last Observation Carried Forward (LOCF)|Reduction From Baseline in Mean IOP at Week 1|Reduction From Baseline in Mean IOP at Week 4|Reduction From Baseline in Mean IOP at Week 12 (Observed)|Mean IOP at Baseline|Mean IOP at Week 1|Mean IOP at Week 4|Mean IOP at Week 12|Percentage of Participants With Greater Than or Equal to (??­) 15% IOP Reduction From Baseline at Both Weeks 4 and 12|Percentage of Participants Discontinuing Therapy Due to a Drug-related Adverse Experience",http://ClinicalTrials.gov/show/NCT00716859,"United States, &nbsp; Belgium, &nbsp; Colombia, &nbsp; Czech Republic, &nbsp; France, &nbsp; Germany, &nbsp; India, &nbsp; Italy, &nbsp; Philippines, &nbsp; Poland, &nbsp; Portugal, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Serbia, &nbsp; Slovakia, &nbsp; Slovenia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Ukraine, &nbsp; United Kingdom",1,1,2,0
NCT00717522,Efficacy and Safety Study of CC-4047 to Treat Advanced Soft Tissue Sarcoma,Completed,No Results Available,Soft Tissue Sarcoma,Drug: CC-4047,Celgene Corporation,Both,Adult|Senior,Phase II,7,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CC-4047-STSAR-001,7/16/2008,01/05/2008,01/04/2009,9/18/2009,01/09/2009,,01/04/2009,"Safety (type, frequency, and severity of adverse events (AEs) and relationship of AEs to CC-4047)|Tumor response (Response Evaluation Criteria in Solid Tumors [RECIST])",http://ClinicalTrials.gov/show/NCT00717522,United States,1,0,1,NA
NCT00717769,"A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis",Completed,No Results Available,Atopic Dermatitis,Drug: SUN13834|Drug: Placebo,"Asubio Pharmaceuticals, Inc.",Both,Adult,Phase II,270,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ASBI 404,7/16/2008,01/07/2008,01/04/2009,5/21/2009,01/05/2009,,01/04/2009,"Eczema Area and Severity Index (EASI) Score measured throughout the study|Investigator's Global Assessment measured throughout the study|Pruritis score measured throughout the study|Insomnia evaluation measured throughout the study|Safety and tolerability data as measured by adverse events, electrocardiograms, serum biomarkers, clinical laboratory tests, and vital signs",http://ClinicalTrials.gov/show/NCT00717769,United States,1,0,2,NA
NCT00718081,"A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 in Patients Undergoing Major Abdominal Surgery",Completed,No Results Available,Major Upper or Lower Abdominal Surgery,Drug: Oral sufentanil|Drug: Placebo,"AcelRx Pharmaceuticals, Inc.",Both,Adult|Senior,Phase II,94,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ARX-C-005,7/16/2008,01/08/2008,01/03/2009,03/09/2009,01/07/2008,,01/03/2009,"To determine how effective different dosages of ARX-F01 is in the treatment of moderate to severe post-operative pain compared to placebo, as determined by the difference between pain intensity scores over the 12-hour study period.|To assess how effective ARX-F01 is for post-operative pain relief using categorical subject ratings as well as time to perceived pain relief and to meaningful pain relief.",http://ClinicalTrials.gov/show/NCT00718081,United States,1,0,2,NA
NCT00718224,Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery,Completed,No Results Available,Venous Thromboembolism,Drug: Semuloparin sodium (AVE5026)|Drug: Enoxaparin|Drug: Placebo,Sanofi-Aventis,Both,Adult|Senior,Phase III,1150,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",EFC10571|2007-007946-37,7/17/2008,01/07/2008,01/05/2009,12/20/2010,01/12/2010,SAVE-KNEE,01/04/2009,"Occurence of the composite endpoint of any VTE confirmed by a blinded Central Independent Adjudication Committee (CIAC) and deaths from any cause|Occurence of the composite endpoint of any proximal Deep Vein Thrombosis (DVT), symptomatic distal DVT, non-fatal Pulmonary Embolism (PE), and all cause deaths|Number of patients with major bleedings and clinically relevant non-major bleedings as confirmed by the CIAC",http://ClinicalTrials.gov/show/NCT00718224,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Belarus, &nbsp; Canada, &nbsp; Colombia, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Estonia, &nbsp; Greece, &nbsp; Lithuania, &nbsp; Mexico, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; South Africa, &nbsp; Ukraine",1,0,3,NA
NCT00719732,Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3,Completed,Has Results,Cataract,Device: ReSTOR,Alcon Research,Both,Adult|Senior,Phase IV,218,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,M07-001,7/21/2008,01/09/2007,01/05/2009,03/04/2010,01/03/2010,,01/05/2009,Uncorrected Visual Acuity (UCVA),http://ClinicalTrials.gov/show/NCT00719732,United States,0,NA,1,NA
NCT00720499,Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,No Results Available,"Pulmonary Disease, Chronic Obstructive",Drug: BI1744/Tiotropium bromide,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase II,141,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment,1237.9|EudtaCT No: 2008-000562-23,7/21/2008,01/07/2008,NA,03/05/2009,01/03/2009,,01/02/2009,The primary efficacy variable will be forced expiratory volume in one second (FEV1). The primary endpoint is the trough FEV1 response [L] after four weeks of treatment.|FEV1 and FVC responses at different timepoints Weekly mean predose morning and evening PEF Weekly mean number of occations of rescue therapy used per day Patient's Global Rating scale Adverse events Laboratory and Vital signs,http://ClinicalTrials.gov/show/NCT00720499,"United States, &nbsp; Belgium, &nbsp; Canada, &nbsp; Germany",1,0,1,NA
NCT00721695,Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.,Completed,No Results Available,Cataract Extraction,Drug: OMS302|Drug: OMS302-PE|Drug: Vehicle,Omeros Corporation,Both,Adult|Senior,Phase I|Phase II,60,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",C07-005,7/22/2008,01/05/2008,01/02/2009,4/28/2010,01/04/2010,,01/02/2009,Pupil diameter|Pain and other measures of ocular discomfort|Degree of inflammation in the anterior chamber|Ocular safety and changes in visual activity and intraocular pressure|General measures of safety,http://ClinicalTrials.gov/show/NCT00721695,United States,1,0,3,NA
NCT00721760,Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery,Completed,No Results Available,Venous Thromboembolism,Drug: Enoxaparin|Drug: Semuloparin sodium (AVE5026)|Drug: Placebo,Sanofi-Aventis,Both,Adult|Senior,Phase III,1003,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",EFC10343|2007-007945-11,7/22/2008,01/07/2008,01/10/2009,12/20/2010,01/12/2010,SAVE-HIP2,01/09/2009,"Occurence of the composite endpoint of any VTE confirmed by a blinded Central Independent Adjudication Committee (CIAC) and deaths from any cause|Occurence of the composite endpoint of any proximal Deep Vein Thrombosis (DVT), symptomatic distal DVT, nonfatal Pulmonary Embolism (PE), and all cause deaths|Number of patients with major bleedings and clinically relevant non-major bleedings as confirmed by the CIAC",http://ClinicalTrials.gov/show/NCT00721760,"United States, &nbsp; Argentina, &nbsp; Belarus, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Chile, &nbsp; China, &nbsp; Colombia, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Finland, &nbsp; Greece, &nbsp; India, &nbsp; Italy, &nbsp; Mexico, &nbsp; Peru, &nbsp; Poland, &nbsp; Portugal, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Sweden, &nbsp; Turkey, &nbsp; Ukraine",1,0,3,NA
NCT00722176,"Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020",Completed,No Results Available,Schizophrenia,Drug: BL-1020|Drug: BL-1020 10-30 mg|Drug: risperidone,"BioLineRx, Ltd.",Both,Adult,Phase II,220,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BL-1020 IIb (Extension),7/23/2008,01/06/2008,01/12/2009,6/27/2010,01/06/2010,,01/07/2009,"changes from baseline in vital signs, laboratory and ECG evaluations, physical/neurological examination, Extrapyramidal Symptom Rating Scale (ESRS), and incidence of adverse events (AEs) and adverse drop-outs (ADOs).|Comparisons between each of the BL-1020 treatment groups and the risperidone group",http://ClinicalTrials.gov/show/NCT00722176,United States,1,0,3,NA
NCT00722358,A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects,Completed,No Results Available,Chronic Hepatitis C,Drug: BMS-650032|Drug: Placebo,Bristol-Myers Squibb,Both,Adult,Phase II,15,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",AI447-004,7/23/2008,01/12/2008,01/12/2009,01/06/2011,01/06/2010,,01/12/2009,Antiviral activity will be assessed by the magnitude and rate of change in plasma HCV RNA levels from baseline. The primary endpoint for antiviral activity is decrease from baseline in plasma HCV RNA levels to Day 3/ or 5|PD-PK Relationship Measures: Asses relationship between antiviral activity and measures of exposure to BMS-650032|Safety Outcome Measures: Safety and tolerability assessments|Pharmacokinetic Measures: Pharmacokinetic assessments,http://ClinicalTrials.gov/show/NCT00722358,"United States, &nbsp; Puerto Rico",1,0,2,NA
NCT00722852,Study of Safety and Efficacy of Diractin?ó for the Treatment of Osteoarthritis (OA) of the Knee,Completed,No Results Available,Osteoarthritis of the Knee,Drug: ketoprofen in Diractin?ó|Drug: Placebo,IDEA AG,Both,Adult|Senior,Phase III,555,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CL-033-III-06,7/24/2008,01/06/2008,01/04/2009,10/02/2009,01/10/2009,,01/02/2009,pain subscale of the WOMAC|Patient global assessment of response to therapy|function subscale of the WOMAC,http://ClinicalTrials.gov/show/NCT00722852,United States,1,0,2,NA
NCT00724126,Rifaximin 3 Times/Day for Non-constipation IBS,Completed,No Results Available,Non-constipation Irritable Bowel Syndrome,Drug: Rifaximin|Drug: Placebo,Salix Pharmaceuticals,Both,Adult|Senior,Phase III,600,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RFIB3008,7/26/2008,01/07/2008,01/09/2009,12/21/2009,01/12/2009,TARGET 2,01/08/2009,Proportion of subjects achieving adequate relief of IBS symptoms,http://ClinicalTrials.gov/show/NCT00724126,United States,1,1,2,0
NCT00724412,Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye,Completed,No Results Available,Dry Eye,Drug: Systane|Drug: Optive,Alcon Research,Both,Adult|Senior,Phase IV,279,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SMA-07-15,7/25/2008,01/04/2008,NA,5/13/2009,01/05/2009,,01/02/2009,Tear Break-up time,http://ClinicalTrials.gov/show/NCT00724412,United States,1,0,2,NA
NCT00724815,The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine,Completed,No Results Available,Migraine Disorders,Drug: NP101|Drug: NP101 placebo,NuPathe Inc.,Both,Adult,Phase III,530,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",PROT-15-NP101-007,7/28/2008,01/07/2008,01/07/2009,7/30/2009,01/07/2009,NP101-007,01/07/2009,"The primary objective of this study is to assess the proportion of subjects who are headache pain free at two hours after patch activation.|To assess the proportion of subjects who are free from nausea, photophobia, phonophobia at two hours after patch activation.",http://ClinicalTrials.gov/show/NCT00724815,United States,1,0,2,NA
NCT00725712,Study of GSK1363089 in Metastatic Gastric Cancer,Completed,No Results Available,"Gastro Esophageal(GE)Junction Cancer|Neoplasms, Gastrointestinal Tract|Distal Esophageal Adenocarcinoma|Metastatic Gastric Carcinoma",Drug: GSK1363089 (formerly XL880),GlaxoSmithKline,Both,Adult|Senior,Phase II,74,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MET111643,7/29/2008,01/03/2007,01/11/2009,11/04/2010,01/11/2010,,01/11/2009,"Objective response rate (RECIST) of GSK1363089 on 2 different dosing regimens|Number of subjects with adverse events, and clinically significant changes in vital signs and laboratory values|Median progression free survival (PFS) of GSK1363089|Duration of Stable Disease of GSK1363089|Peak and trough concentrations of GSK1363089 in plasma samples|Disease stabilization rate of GSK 1363089|Median overall survival of GSK1363089|Plasma concentrations of soluble MET, HGF, soluble VEGFR2 and VEGFA",http://ClinicalTrials.gov/show/NCT00725712,United States,1,0,1,NA
NCT00725764,Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck,Completed,No Results Available,Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck,Drug: GSK1363089 (foretinib),GlaxoSmithKline,Both,Adult|Senior,Phase II,14,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MET111646,7/28/2008,01/08/2007,01/05/2009,3/25/2010,01/03/2010,,01/05/2009,"To determine the best confirmed response rate of GSK1363089 treatment in subjects with SCCHN|To assess the progression-free survival, duration of response, and overall survival in subjects with SCCHN treated with GSK1363089.|To further characterize the pharmacokinetic (PK) parameters of GSK1363089 in subjects with SCCHN",http://ClinicalTrials.gov/show/NCT00725764,United States,1,0,1,NA
NCT00726687,Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors,Completed,No Results Available,Advanced Solid Tumors,Drug: indibulin|Drug: capecitabine,ZIOPHARM,Both,Adult|Senior,Phase I|Phase II,30,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IBL1005,7/29/2008,01/06/2008,01/02/2009,10/12/2010,01/10/2010,,01/02/2009,toxicities|pharmacokinetics,http://ClinicalTrials.gov/show/NCT00726687,United States,1,0,2,NA
NCT00728910,Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study,Completed,No Results Available,Atherogenic Dyslipidemia,Drug: Lipitor|Drug: ABT335|Drug: Niaspan,University of Pennsylvania|Abbott,Both,Adult|Senior,Phase II,25,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Bio-availability Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,807965 CNTR|CTRC #1123,08/04/2008,01/06/2008,01/08/2009,12/14/2009,01/12/2009,CENTAUR,01/08/2009,"The apolipoprotein AI rate of catabolism and rate of production.|The incremental area under the curve for triglycerides and high-density lipoprotein cholesterol.|Other key outcomes include a. fasting cholesterol efflux, b. HDL cholesterol, apolipoprotein A-I, and enzymes that remodel HDL, c. atherogenic lipoproteins, and d. markers of energy metabolism and e. markers of inflammation.",http://ClinicalTrials.gov/show/NCT00728910,United States,1,0,3,NA
NCT00729326,Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: exenatide|Drug: sitagliptin|Drug: placebo|Drug: placebo,"Amylin Pharmaceuticals, Inc.|Eli Lilly and Company",Both,Adult|Senior,Phase IV,64,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",H8O-US-GWCV,08/04/2008,01/08/2008,01/10/2009,02/08/2010,01/08/2008,,01/10/2009,"Test the hypothesis that twice daily exenatide will result in a lower time-averaged glucose during a 24-hour period, compared with once daily oral sitagliptin, in patients with type 2 diabetes inadequately controlled on metformin or a TZD.|Compare exenatide and sitagliptin with respect to various pharmacodynamic measurements in subjects with type 2 diabetes mellitus.",http://ClinicalTrials.gov/show/NCT00729326,United States,1,1,4,1
NCT00729469,Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity,Completed,No Results Available,Atrophy|Vaginal Diseases,Drug: Ospemifene|Drug: Placebo,QuatRx Pharmaceuticals Company,Female,Adult|Senior,Phase III,750,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",15-50821,08/04/2008,01/07/2008,01/08/2009,02/02/2010,01/02/2010,,01/08/2009,Change from baseline to week 12 in percentage of parabasal cells in the maturation index of the vaginal smear|Change from baseline to week 12 in percentage of superficial cells in the maturation index of the vaginal smear|Change from baseline to week 12 in vaginal pH.|Change from baseline to week 12 in severity of the most bothersome symptom of vaginal dryness and vaginal pain associated with sexual activity.|Change from baseline in percentage of parabasal cells in the maturation index|Change from baseline in percentage of superficial cells in the maturation index|Change from baseline in vaginal pH|Change from baseline in severity of most bothersome symptom of vaginal dryness and vaginal pain associated with sexual activity,http://ClinicalTrials.gov/show/NCT00729469,United States,1,0,2,NA
NCT00730015,Trial of Linaclotide in Patients With Chronic Constipation,Completed,No Results Available,Chronic Constipation,Drug: Matching Placebo|Drug: Linaclotide,"Ironwood Pharmaceuticals, Inc.|Forest Laboratories",Both,Adult|Senior,Phase III,643,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MCP-103-303,08/05/2008,01/08/2008,01/10/2009,1/26/2010,01/01/2010,,01/08/2009,Complete Spontaneous Bowel Movement (CSBM) Overall Responder|Change from Baseline in 12-week CSBM Frequency|Change from Baseline in 12-week Spontaneous Bowel Movement (SBM) Frequency|Change from Baseline in 12-week Stool Consistency|Change from Baseline in 12-week Severity of Straining|Change from Baseline in 12-week Abdominal Discomfort|Change from Baseline in 12-week Bloating|Change from Baseline in 12-week Constipation Severity,http://ClinicalTrials.gov/show/NCT00730015,United States,1,0,2,NA
NCT00730691,Efficacy and Safety of Lu AA21004 in Treating Generalized Anxiety Disorder,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Lu AA21004|Drug: Lu AA21004|Drug: Lu AA21004|Drug: Placebo|Drug: Duloxetine,"Takeda Global Research & Development Center, Inc.|H. Lundbeck A/S",Both,Adult,Phase III,781,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",LuAA21004_308|U1111-1114-3966,08/06/2008,01/06/2008,01/02/2009,6/17/2010,01/06/2010,,01/02/2009,"The least squares mean change from Baseline in the Hamilton Anxiety Scale total score.|The least squares mean change from Baseline in the Hamilton Anxiety Scale total score at each week assessed.|Response rates at Week 8, with response defined as a ??­50% decrease in the Hamilton Anxiety Scale total score from Baseline.|Remission rates at Week 8, with remission defined as a Hamilton Anxiety Scale total score ???7.|The least squares mean change from Baseline in Clinical Global Impression Scale-Global Improvement.|The least squares mean change from Baseline in Clinical Global Impression Scale-Severity of Illness.|The least squares mean change from Baseline in Hospital Anxiety and Depression Scale.|Sheehan Disability Scale.|Healthcare resource utilization as assessed by the Health Economic Assessment Questionnaire.",http://ClinicalTrials.gov/show/NCT00730691,United States,1,0,5,NA
NCT00730964,A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.,Completed,No Results Available,Echocardiography,"Drug: Perflutren Protein-Type A Microspheres Injectable Suspension, USP",GE Healthcare,Both,Adult|Senior,Phase IV,1039,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label,GE-191-003,08/05/2008,01/05/2008,01/10/2009,02/04/2010,01/02/2010,OSSAR,01/10/2009,The frequency of serious adverse reactions (SAR's) among subjects who receive Optison during contrast enhanced echocardiography in routine clinical practice.|The frequency of overall serious adverse events (SAE's) among subjects who receive Optison during contrast enhanced echocardiography in routine clinical practice.,http://ClinicalTrials.gov/show/NCT00730964,United States,1,1,1,1
NCT00731055,Effects of Varenicline on Cigarette Self Administration,Completed,No Results Available,Nicotine Dependence,Drug: Varenicline,New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA),Both,Adult,Phase II,30,Other|NIH,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NIDA-17572-4|R01DA017572|DPMCDA,08/06/2008,01/02/2008,01/05/2009,12/08/2009,01/12/2009,,01/05/2009,Cigarette Choice.,http://ClinicalTrials.gov/show/NCT00731055,United States,1,1,1,1
NCT00731120,Efficacy and Safety of Lu AA21004 in Treating Generalized Anxiety Disorder,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Lu AA21004|Drug: Lu AA21004|Drug: Placebo,"Takeda Global Research & Development Center, Inc.|H. Lundbeck A/S",Both,Adult|Senior,Phase III,457,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",LuAA21004_309|U1111-1114-2380,08/06/2008,01/06/2008,01/02/2009,6/17/2010,01/06/2010,,01/01/2009,"The least squares mean change from Baseline in the Hamilton Anxiety Scale total score.|The least squares mean change from Baseline in Hamilton Anxiety Scale total score at each week assessed.|Response rates at Week 8, with response defined as a ??­50% decrease in the Hamilton Anxiety Scale total score from Baseline.|Remission rates at Week 8, with remission defined as a Hamilton Anxiety Scale total score ???7.|The least squares mean change from Baseline in Clinical Global Impression Scale-Global Improvement.|The least squares mean change from Baseline in Clinical Global Impression Scale-Severity of Illness.|The least squares mean change from Baseline in Hospital Anxiety and Depression anxiety subscale|Sheehan Disability Scale.|Medical Outcomes Study 36-Item Short-Form Health Survey.|Health care resource utilization as assessed by the Health Economic Assessment Questionnaire.",http://ClinicalTrials.gov/show/NCT00731120,United States,1,0,3,NA
NCT00731679,Rifaximin TID for Non-constipation Irritable Bowel Syndrome (IBS),Completed,No Results Available,Non-constipation Irritable Bowel Syndrome,Drug: Rifaximin|Drug: Placebo,Salix Pharmaceuticals,Both,Adult|Senior,Phase III,600,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RFIB3007,7/16/2008,01/07/2008,01/09/2009,12/21/2009,01/12/2009,TARGET 1,01/08/2009,Proportion of subjects achieving adequate of IBS symptoms.,http://ClinicalTrials.gov/show/NCT00731679,"United States, &nbsp; Canada",1,1,2,1
NCT00731939,Titan One Touch Release Inflatable Penile Prosthesis,Completed,No Results Available,Erectile Dysfunction,Device: Inflatable Penile Prosthesis,Coloplast A/S,Male,Adult|Senior,Phase IV,123,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DK057CC,08/07/2008,01/11/2007,01/04/2010,01/05/2011,01/01/2011,,01/10/2009,Assess the ease of deflation of the Titan OTR pump|Evaluate user acceptance of Titan OTR|Assess the ease of implant of the Titan OTR|Assess the ease of training for Titan OTR|Assess partner satisfaction (where applicable)|Summarize all device and procedure related adverse events,http://ClinicalTrials.gov/show/NCT00731939,"United States, &nbsp; Canada, &nbsp; France, &nbsp; United Kingdom",0,NA,1,NA
NCT00732030,Low Cylinder Toric,Completed,Has Results,Cataracts,Device: Toric IOL (SN60T3),Alcon Research,Both,Adult|Senior,Phase IV,26,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,M07-005,08/07/2008,01/06/2007,NA,3/25/2010,01/03/2010,,01/03/2009,Uncorrected Distance Visual Acuity|Best Corrected Distance Visual Acuity|Residual Refractive Cylinder|Patient Satisfaction Survey,http://ClinicalTrials.gov/show/NCT00732030,United States,0,NA,1,NA
NCT00733304,An Extension to Study MD7108240,Completed,No Results Available,Macular Degeneration,Drug: Pazopanib,GlaxoSmithKline,Both,Adult|Senior,Phase II,99,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",MD7111396,08/12/2008,01/06/2008,01/05/2009,10/14/2010,01/10/2010,,01/05/2009,"Safety and tolerability endpoints include ophthalmic examinations, vital signs (heart|Change in: visual acuity, central retinal thickness retinal morphology measured by OCT an imaging technique measured monthly, neovascular size lesion size, characteristics fibrosis atrophy blood measured fundus photography, fluorescein angiography|Change in visual acuity (number of letters read on standardized ETDRS charts).|Change from baseline in central retinal/lesion thickness and changed in retinal morphology as measured by optical coherence tomography|Change in enovascular size, lesion size and characteristics as measured by flourescein angiography and fundus photography.",http://ClinicalTrials.gov/show/NCT00733304,"United States, &nbsp; Australia, &nbsp; Italy",1,1,1,0
NCT00733902,Tanezumab in Osteoarthritis of the Knee,Completed,No Results Available,Arthritis|Osteoarthritis,Biological: tanezumab|Biological: tanezumab|Biological: tanezumab|Biological: Placebo,Pfizer,Both,Adult|Senior,Phase III,697,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",A4091011,08/11/2008,01/09/2008,01/11/2009,01/04/2011,01/01/2011,,01/09/2009,"WOMAC function|WOMAC pain|Patient Global Assessment of Osteoarthritis|Womac pain, physical function and stiffness at other timepoints|SF-36|Daily NRS scores|Safety (AEs, laboratory, ECGs, physical exam, vital signs)|Time to discontinuation",http://ClinicalTrials.gov/show/NCT00733902,United States,0,NA,4,NA
NCT00734071,An Efficacy and Safety Study of Lu AA21004 in Treating Generalized Anxiety Disorder,Completed,No Results Available,Generalized Anxiety Disorder,Drug: Lu AA21004|Drug: Placebo,"Takeda Global Research & Development Center, Inc.|H. Lundbeck A/S",Both,Adult|Senior,Phase III,309,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",LuAA21004_310|U1111-1114-4876,08/11/2008,01/06/2008,01/02/2009,6/17/2010,01/06/2010,,01/01/2009,"The least squares mean change from Baseline in the Hamilton Anxiety Scale total score after 8 weeks of treatment.|The least squares mean change from Baseline in Hamilton Anxiety Scale total score at each week assessed.|Response rates at Week 8, with response defined as a ??­50% decrease in the HAM-A total score from Baseline.|Remission rates at Week 8, with remission defined as a Hamilton Anxiety Scale total score ???7.|The least squares mean change from Baseline in Clinical Global Impression Scale-Severity of Illness and Hospital Anxiety and Depression anxiety subscale.|The least squares mean change from Baseline in Clinical Global Impression Scale-Global Improvement.|Sheehan Disability Scale.|Medical Outcomes Study 36-Item Short-Form Health Survey.|Health care resource utilization as assessed by the Health Economic Assessment Questionnaire",http://ClinicalTrials.gov/show/NCT00734071,United States,1,0,2,NA
NCT00734578,Efficacy and Safety of SPD503 in Combination With Psychostimulants,Completed,Has Results,ADHD,Drug: SPD503-AM|Drug: SPD503-PM|Drug: Placebo,Shire Pharmaceutical Development,Both,Child,Phase III,461,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SPD503-313,08/12/2008,01/09/2008,01/12/2009,12/06/2010,01/12/2010,,01/12/2009,Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 8 - Last Observation Carried Forward (LOCF)|Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 8 - LOCF|Assessment of Clinical Global Impression-Severity of Illness (CGI-S) at Week 8 - LOCF|Change From Baseline in Conners' Global Index - Parent (CGI-P) Total Score at Week 8 - LOCF: Morning Assessment (Before School)|Change From Baseline in Conners' Global Index - Parent (CGI-P) Total Score at Week 8 - LOCF: Evening Assessment (Before Bedtime)|Percentage of Participants With Improvement on Parent Global Assessment (PGA) at Week 8 - LOCF|Change From Baseline in the Oppositional Subscale of the Conners' Parent Rating Scale-Revised Long Form (CPRS-R:L) Score at Week 8 - LOCF|Change From Baseline in Before School Functioning Questionnaire (BSFQ) at Week 8 - LOCF|Post Sleep Questionnaire (PSQ) Quality of Sleep at Week 8 - LOCF,http://ClinicalTrials.gov/show/NCT00734578,United States,1,0,3,NA
NCT00734604,A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.,Completed,Has Results,Erectile Dysfunction,Drug: tadalafil once a day [T(OaD)]|Drug: sildenafil citrate as needed [S(PRN)]|Drug: tadalafil as needed [T(PRN)],Eli Lilly and Company,Male,Adult|Senior,Phase III,378,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,12313|H6D-CR-S024,08/12/2008,01/08/2008,01/09/2009,10/21/2010,01/10/2010,,01/09/2009,"Change From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)|Change From Baseline Between Tadalafil Once a Day (OaD) and Tadalafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)|Change From Baseline to Endpoint in the Spontaneity Domain of PAIRS|Change From Baseline to Endpoint in the Time Concerns Domain of PAIRS|Change From Baseline to Endpoint in the Erectile Function Domain of the International Index of Erectile Function (IIEF)|Change From Baseline to Endpoint in the Proportion of Days With at Least One Morning Erection|Change From Baseline to Endpoint in the Intercourse Satisfaction (IS) Domain of the IIEF|Change From Baseline to Endpoint in the Overall Satisfaction (OS) Domain of the IIEF|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Score at Endpoint|Number of Participants With at Least One Serious Adverse Event|Change From Baseline to Endpoint in the Self-Esteem And Relationship (SEAR) Questionnaire Transformed Total Score|Question 1 \I Felt as if I Did Not Have ED\"" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint|Question 2 \""I Felt in Control of my Sex Life\"" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint|Question 3 \""I Felt the Drug Was in Control of my Erections\"" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint|Question 4 \""I Felt Like a Whole Man\"" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint""",http://ClinicalTrials.gov/show/NCT00734604,"United States, &nbsp; Australia, &nbsp; Brazil, &nbsp; Germany, &nbsp; Italy, &nbsp; Mexico, &nbsp; Puerto Rico, &nbsp; Spain, &nbsp; United Kingdom",1,1,3,0
NCT00734929,Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy,Completed,No Results Available,Postoperative Nausea and Vomiting,Drug: Aprepitant + Dexamethasone|Drug: Ondansetron + Dexamethasone,Duke University|Merck,Both,Adult|Senior,Phase IV,110,Other|Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",1404,8/13/2008,01/09/2007,01/06/2009,10/06/2010,01/10/2010,,01/06/2009,cumulative incidence of emesis|Incidence of nausea|Incidence of nausea|Incidence if nausea|Incidence of vomiting|Incidence of vomiting|Use of rescue antiemetics|Use of rescue antiemetics|Use of rescue antiemetics|Complete response rate|Nausea scores|number of vomiting episodes|Time to first vomiting|Patient satisfaction,http://ClinicalTrials.gov/show/NCT00734929,United States,1,1,2,0
NCT00735007,12-week Study to Evaluate RebiSmart?ºÑ Suitability for Self Injection in Relapsing Multiple Sclerosis.,Completed,Has Results,Multiple Sclerosis,Drug: Rebif?ó New Formulation (RNF) using RebiSmartTM,EMD Serono,Both,Adult,Phase III,106,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,28733,08/12/2008,01/07/2008,NA,08/12/2010,01/08/2010,,01/01/2009,"The Number of Subjects Rating the Suitability of RebiSmart at the End of 12-week Treatment Period for Self-injecting Rebif?ó New Formulation (RNF).|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Items 13-16 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Items 13-16 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Items 13-16 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Site Reaction Score Items 17-20 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Site Reaction Score Items 17-20 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Site Reaction Score Items 17-20 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Global Side Effects Score Items 21-23 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Global Side Effects Score Items 21-23 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Global Side Effects Score Items 21-23 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Issues Score Item 34 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Issues Score Item 34 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Injection Issues Score Item 34 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Benefit Item 35 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Benefit Item 35 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Benefit Item 35 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Scale Item 37 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Scale Item 37 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Scale Item 37 at End Week 12|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Grade Item 38 at End Week 4|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Grade Item 38 at End Week 8|Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Pain Rating Grade Item 38 at End Week 12|The Incidence of Predefined Injection Site Reactions, MSTCQ Scores, Side Effects, McGill Pain Questionnaire, Visual Analog Scale, and Rating of Pain Regarding Injection Pain Following RNF Administration With RebiSmart at 12-week Treatment Period.",http://ClinicalTrials.gov/show/NCT00735007,"United States, &nbsp; Canada, &nbsp; Germany, &nbsp; Italy, &nbsp; Spain, &nbsp; Sweden",1,0,1,NA
NCT00735371,Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,ADHD,Drug: LDX 30 mg|Drug: LDX 50 mg|Drug: LDX 70 mg|Drug: Placebo,Shire Pharmaceutical Development,Both,Child,Phase III,314,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SPD489-305,08/12/2008,01/10/2008,01/04/2009,4/29/2010,01/04/2010,,01/04/2009,Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks|Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores|Youth Quality of Life-Research Version (YQOL-R) Total Score,http://ClinicalTrials.gov/show/NCT00735371,United States,1,1,4,1
NCT00735462,Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts,Completed,No Results Available,External Genital Warts|Perianal Warts|Condylomata Acuminata,Drug: imiquimod cream A|Drug: imiquimod cream B|Drug: placebo,"Graceway Pharmaceuticals, LLC",Both,Child|Adult|Senior,Phase III,450,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GW01-0805,8/14/2008,01/08/2008,01/07/2009,1/26/2010,01/01/2010,,01/07/2009,"The primary efficacy endpoint is the proportion of subjects achieving complete clearance of all warts (baseline and new) at the end of study.|Safety variables include adverse reactions (AEs), local skin reactions (LSRs), and number and duration of rest periods during the Treatment Period",http://ClinicalTrials.gov/show/NCT00735462,United States,1,1,3,0
NCT00735475,A Study to Determine the Immunogenicity and Safety of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine,Completed,No Results Available,Influenza,Biological: CSL Limited Influenza Virus Vaccine|Biological: US Licensed Influenza Virus Vaccine,CSL Limited,Both,Adult|Senior,Phase IV,1268,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention,CSLCT-USF-07-41,8/13/2008,01/10/2008,01/06/2009,11/05/2009,01/11/2009,,01/01/2009,"Geometric mean titer and seroconversion rate for each strain contained within the vaccines|Frequency, duration and intensity of local and systemic solicited symptoms, unsolicited adverse events, serious adverse events and new onset of chronic illnesses",http://ClinicalTrials.gov/show/NCT00735475,United States,0,NA,2,NA
NCT00735787,Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet,Completed,Has Results,Psoriasis,Biological: Placebo|Biological: Adalimumab,Abbott,Both,Adult|Senior,Phase IV,81,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",M10-405,8/13/2008,01/08/2008,01/09/2009,10/11/2010,01/10/2010,,01/09/2009,"Number of Subjects With Physician's Global Assessment of Psoriasis (PGA) of Clear or Almost Clear at Week 16|Mean Change From Baseline in Erythema, Scaling, Induration, and Fissuring (ESIF)|Mean Change From Baseline in ESIF for Palms|Mean Change From Baseline in ESIF for Soles|Number of Subjects With Moderate Improvement in ESIF From Baseline|Number of Subjects With Marked Improvement in ESIF From Baseline|Mean Change From Baseline in Nail Psoriasis Severity Index (NAPSI)|Number of Subjects With Physicians Global Assessment of Psoriasis (PGA) of Clear, Almost Clear, or Mild|Number of Subjects With PGA of Clear or Almost Clear|Number of Subjects With PGA of Clear|Number of Subjects With Psoriasis Area and Severity Index (PASI) 50|Number of Subjects With PASI 75|Number of Subjects With PASI 90|Number of Subjects With PASI 100|Mean Change From Baseline in Dermatology Life Quality Index (DLQI)|Number of Subjects Achieving a DLQI of 0|Mean Change From Baseline in Visual Analog Scale (VAS) for Psoriasis and Psoriatic Arthritis Pain|Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO)|Mean Change From Baseline in Patient Health Questionnaire (PHQ-9)|Number of Subjects With Difficulties According to PHQ-9",http://ClinicalTrials.gov/show/NCT00735787,"United States, &nbsp; Canada",0,NA,2,1
NCT00736372,A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer,Completed,No Results Available,Metastatic Cancer|Advanced Cancer,Drug: PX-12,Oncothyreon Inc.,Both,Adult|Senior,Phase I|Phase II,14,Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PX-12-004,8/13/2008,01/06/2008,01/08/2009,02/03/2010,01/02/2010,,01/08/2009,"To determine the MTD of PX-12 delivered as a 72-hour infusion over days 1, 2, and 3 of a 21-day cycle|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Evaluate the safety profile of PX-12|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Assess the pharmacodynamics of PX-12 using surrogate tissues obtained pre- and post-drug treatment|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Assess pharmacokinetic profiles of PX-12 in plasma samples|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Identify any antitumor activity of PX-12 in this patient population",http://ClinicalTrials.gov/show/NCT00736372,United States,1,0,1,NA
NCT00736879,Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo,Bristol-Myers Squibb|AstraZeneca,Both,Adult|Senior,Phase III,280,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",MB102-032,8/15/2008,01/09/2008,01/12/2009,01/06/2011,01/02/2010,,01/12/2009,"Change from baseline in hemoglobin A1C|Change from baseline in: total body weight; FPG; 2-hour post liquid meal glucose and waist circumference|Proportion of subjects achieving a therapeutic glycemic response, defined as AIC<7.0%",http://ClinicalTrials.gov/show/NCT00736879,"United States, &nbsp; Canada, &nbsp; India, &nbsp; Mexico, &nbsp; Puerto Rico, &nbsp; Russian Federation, &nbsp; South Africa",1,0,2,NA
NCT00737594,Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension,Completed,No Results Available,Portal Hypertension,Drug: Placebo|Drug: Cobiprostone|Drug: Cobiprostone,"Sucampo Pharmaceuticals, Inc.",Both,Adult|Senior,Phase II,9,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",SPH0721,8/15/2008,01/07/2008,01/03/2009,07/10/2009,01/07/2009,,01/02/2009,Change from baseline in hepatic venous pressure gradient (HVPG)|Acute changes from baseline in HVPG following administration of a single oral dose of cobiprostone|Change from baseline in total bilirubin|Change from baseline in ascites grade|Change from baseline in Child-Pugh score|Proportion of treatment responders|Change from baseline in quality of life,http://ClinicalTrials.gov/show/NCT00737594,United States,1,0,3,NA
NCT00739024,A Study of a Melatonin Receptor Agonist to Prevent Migraine,Completed,No Results Available,Migraine|Migraine With Aura|Migraine Without Aura,Drug: ramelteon,"Swedish Medical Center|Takeda Global Research & Development Center, Inc.",Both,Adult,Phase II,30,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",CRC 0690,8/19/2008,01/04/2008,01/09/2010,10/05/2010,01/10/2010,,01/04/2009,The primary efficacy variable is the percent reduction in the average monthly migraine/probable migraine frequency from the baseline period to the entire double-blind treatment phase of the study quantified by the number of attacks.,http://ClinicalTrials.gov/show/NCT00739024,United States,1,1,1,1
NCT00739349,NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye,Completed,No Results Available,Dry Eye,Drug: NOVA22007 ''Cyclosporine''|Drug: NOVA22007 ''Cyclosporine''|Drug: NOVA22007,Novagali Pharma,Both,Adult|Senior,Phase II,129,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NVG08B112,8/20/2008,01/08/2008,01/01/2009,7/15/2010,01/07/2010,,01/01/2009,Assess the safety and efficacy of two doses of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Emulsions,http://ClinicalTrials.gov/show/NCT00739349,United States,1,0,3,NA
NCT00739596,Blood Pressure Lowering of Aliskiren HCTZ Versus Amlodipine in Stage 2 Hypertension in African Americans,Completed,Has Results,Hypertension,Drug: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Drug: Amlodipine: 8 weeks,Novartis Pharmaceuticals,Both,Adult|Senior,Phase IV,332,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",CSPP100AUS03,8/21/2008,01/07/2008,01/03/2009,12/14/2010,01/12/2010,ATLAAST,01/03/2009,Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment|Change in Mean Sitting Diastolic Blood Pressure (MSDBP) After 8 Weeks of Treatment|Change in Mean Sitting Pulse Pressure (MSPP) After 8 Weeks of Treatment|Proportion of Responders After 8 Weeks of Treatment.|Proportion of Patients Achieving BP Control After 8 Weeks of Treatment,http://ClinicalTrials.gov/show/NCT00739596,United States,1,1,2,0
NCT00739908,A Study of CX157 (Tyrima) for the Treatment of Depression,Completed,No Results Available,Major Depressive Disorder,Drug: CX157|Drug: Placebo,CeNeRx BioPharma Inc.,Both,Adult,Phase II,272,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CX157-200,8/20/2008,01/09/2008,01/07/2009,7/28/2010,01/07/2010,CX157-200,01/07/2009,"The primary efficacy measure is the Montgomery-Asberg Depression Rating Scale (MADRS).|Efficacy measures: IDS-SR 30, HADS, CGI-I and CGI-S; Safety measures: PE, clinical laboratory evaluations, 12-lead ECG, AEs, vital signs, and suicidality assessment using the Columbia Suicide Severity Rating Scale (C-SSRS).",http://ClinicalTrials.gov/show/NCT00739908,United States,1,0,2,NA
NCT00739934,Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection,Completed,No Results Available,Candidiasis|Candidemia,Drug: Voriconazole,Pfizer,Both,Child,Phase II,40,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,A1501088,8/20/2008,01/12/2008,01/10/2009,08/09/2010,01/08/2010,,01/10/2009,"Steady-state pharmacokinetic parameters of voriconazole following oral administration: AUC12,ss, Cmax,ss and Tmax.|Steady-state pharmacokinetic parameters of voriconazole following IV administration: area under the curve over dosing interval at steady state (AUC12,ss), peak plasma concentration at steady state (Cmax,ss) and time to reach Cmax (Tmax).|Pharmacokinetic parameters of voriconazole following a single IV dose on Day 1: AUC12, Cmax and Tmax.|Trough concentrations (Cmin) of voriconazole following IV or oral administration.|Steady-state pharmacokinetic parameters of the N-oxide metabolite (UK-121, 265): AUC12,ss, Cmax,ss and Tmax for information disclosure.|To evaluate the safety and tolerability of voriconazole following an IV to oral switch regimen in immunocompromised children aged 2 to <12 years who are at high risk for systemic fungal infection.",http://ClinicalTrials.gov/show/NCT00739934,United States,1,1,1,1
NCT00739973,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Completed,No Results Available,Hypertension,Drug: Aliskiren|Drug: Aliskiren|Drug: Amlodipine|Drug: Amlodipine|Drug: Aliskiren/amlodipine|Drug: Aliskiren/amlodipine|Drug: Aliskiren/amlodipine|Drug: Aliskiren/amlodipine|Drug: Placebo,Novartis,Both,Adult|Senior,Phase III,1688,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",CSPA100A2305,8/20/2008,01/09/2008,NA,10/16/2009,01/10/2009,,01/05/2009,"Vital signs at every visit|Vital signs at every visit|Adverse events at every visit|24-hour blood pressure profile of in a subset of patients at Day 1 and Day 56 (end of study)|Biomarker assessments (PRA, PRC) at Day 1 and Day 56 in subset of patients.",http://ClinicalTrials.gov/show/NCT00739973,"United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Canada, &nbsp; Colombia, &nbsp; Denmark, &nbsp; Finland, &nbsp; Greece, &nbsp; Italy, &nbsp; Mexico, &nbsp; Panama, &nbsp; Peru, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Taiwan",1,1,9,1
NCT00740610,"Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)",Completed,No Results Available,Nonalcoholic Steatohepatitis,Drug: GS-9450|Drug: GS-9450|Drug: GS-9450|Drug: GS-9450|Drug: Placebo,Gilead Sciences,Both,Adult|Senior,Phase II,124,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GS-US-228-0101,8/21/2008,01/08/2008,01/09/2009,8/20/2010,01/01/2010,,01/08/2009,Safety and Tolerability|Plasma pharmacokinetic parameters of GS-9450 and metabolites|Change from baseline in ALT levels at Week 4,http://ClinicalTrials.gov/show/NCT00740610,"United States, &nbsp; France",1,0,5,NA
NCT00740779,Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.,Completed,No Results Available,Chronic Abacterial Prostatitis,Drug: Silodosin 8 mg|Drug: Placebo|Drug: Silodosin 4 mg,Watson Pharmaceuticals,Male,Adult|Senior,Phase II,153,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",SI08001,8/21/2008,01/09/2008,01/10/2009,10/30/2009,01/10/2009,,01/10/2009,National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) total score.|NIH-CPSI pain score|NIH-CPSI urinary symptoms score|Short Form Health Survey (SF-12),http://ClinicalTrials.gov/show/NCT00740779,United States,1,1,3,0
NCT00742183,"Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex?ó Ag Versus Silvadene?ó",Completed,Has Results,Second Degree Burn,Device: Mepilex|Device: Silvadene,Molnlycke Health Care AB,Both,Child|Adult|Senior,Phase IV,100,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research,PUMA 415,8/19/2008,01/08/2008,01/11/2009,10/11/2010,01/10/2010,,01/10/2009,Compare the Costs of Using the Interventions (Direct and Indirect),http://ClinicalTrials.gov/show/NCT00742183,United States,0,NA,2,NA
NCT00742391,A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations,Completed,No Results Available,Actinic Keratoses,Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel,Peplin,Both,Adult|Senior,Phase III,255,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",PEP005-014,8/25/2008,01/08/2008,01/02/2009,7/15/2010,01/07/2010,,01/02/2009,Efficacy (complete clearance of AKs)|Efficacy (partial clearance of AKs),http://ClinicalTrials.gov/show/NCT00742391,"United States, &nbsp; Australia",1,0,2,NA
NCT00742859,"Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin",Completed,No Results Available,Atrial Fibrillation,Drug: betrixaban|Drug: Warfarin,Portola Pharmaceuticals,Both,Adult|Senior,Phase II,508,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",08-015,8/26/2008,01/10/2008,01/11/2009,1/19/2010,01/01/2010,EXPLORE-Xa,01/08/2009,The primary endpoint will be the occurrence of major or clinically relevant non-major bleeding.,http://ClinicalTrials.gov/show/NCT00742859,"United States, &nbsp; Canada",1,0,2,NA
NCT00743002,A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: TT223|Drug: Placebo,Transition Therapeutics,Both,Adult|Senior,Phase II,80,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GIN-201,8/26/2008,01/08/2008,01/12/2009,3/29/2010,01/03/2010,,01/12/2009,"To evaluate the safety and tolerability of TT223 as a treatment for Type 2 diabetes at 1 mg, 2 mg and 3 mg.|To evaluate the efficacy of TT223 as a treatment for Type 2 diabetes by comparing the change in HbA1c value from baseline between the TT223 and placebo groups.|To evaluate the efficacy of TT223 on beta cell function by assessing additional outcome measures including fasting blood glucose levels, and meal tolerance testing.|To determine the pharmacokinetic (PK) parameter profile of TT223 in a subset of patients.",http://ClinicalTrials.gov/show/NCT00743002,United States,1,0,2,NA
NCT00743145,Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana,Completed,No Results Available,Marijuana Smoking,Drug: Naltrexone|Drug: Smoked marijuana,New York State Psychiatric Institute|Research Foundation for Mental Hygiene|National Institute on Drug Abuse (NIDA),Both,Adult,Phase II,48,Other|NIH,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind|Primary Purpose: Treatment,5693,8/26/2008,01/05/2008,01/09/2009,9/22/2009,01/09/2009,,01/07/2009,,http://ClinicalTrials.gov/show/NCT00743145,United States,1,1,2,0
NCT00743366,Effect of Quetiapine on Marijuana Withdrawal and Relapse,Completed,No Results Available,Marijuana Smoking,Drug: Marijuana|Drug: Quetiapine,New York State Psychiatric Institute|Research Foundation for Mental Hygiene|National Institute on Drug Abuse (NIDA),Both,Adult,Phase II,20,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Masking: Double-Blind|Primary Purpose: Treatment,5685,8/26/2008,01/08/2008,01/03/2009,9/22/2009,01/09/2009,,01/03/2009,Marijuana's direct effects|Marijuana withdrawal symptoms|Marijuana relapse,http://ClinicalTrials.gov/show/NCT00743366,United States,1,0,2,NA
NCT00744276,A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease,Completed,No Results Available,Fibrocystic Disease of Breast,Drug: danazol|Drug: Placebo,"FemmePharma Global Healthcare, Inc.",Female,Adult|Senior,Phase II,60,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FP1198-001,8/28/2008,01/01/2007,01/06/2009,5/25/2010,01/05/2010,FP1198-001,01/04/2009,Subject reported breast pain as measured using a visual analog scale on the subject daily diary|Physician assessment of breast nodularity at each treatment cycle visit,http://ClinicalTrials.gov/show/NCT00744276,United States,1,1,2,0
NCT00744848,Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy,Completed,No Results Available,Hemorrhoids,Drug: Bupivacaine HCl|Drug: SKY0402,"Pacira Pharmaceuticals, Inc",Both,Adult|Senior,Phase III,220,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Investigator)|Primary Purpose: Supportive Care",SIMPLE Hemorrhoidectomy 312,8/28/2008,01/08/2008,01/02/2009,8/27/2010,01/08/2010,,01/02/2009,Area under the curve (AUC) of NRS-R|AEs through Day 3 and SAEs through Day 30,http://ClinicalTrials.gov/show/NCT00744848,United States,1,0,2,NA
NCT00745290,A Phase 3 Study to Evaluate the Safety and Efficacy for Prolonged Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty,Completed,No Results Available,Total Knee Arthroplasty|Postoperative Pain,Drug: Bupivacaine HCl|Drug: SKY0402,"Pacira Pharmaceuticals, Inc",Both,Adult|Senior,Phase III,251,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",SIMPLE TKA 311,8/29/2008,01/08/2008,01/02/2009,8/27/2010,01/08/2010,TKA,01/01/2009,"Area under the curve (AUC) of pain scores with activity, using the NRS-A|Total postoperative consumption with and without supplemental opioid pain medication",http://ClinicalTrials.gov/show/NCT00745290,United States,1,0,2,NA
NCT00747162,Muscle Oxygenation and Skin Pigmentation,Completed,No Results Available,Muscle Oxygenation|Skin Pigmentation,Device: Measure of muscle oxygenation|Device: Skin pigmentation determination,Emory University,Both,Adult|Senior,Phase IV,500,Other,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,9004,8/27/2008,01/08/2008,01/01/2009,1/29/2009,01/01/2009,,01/01/2009,Measure from The INVOS cerebral oximeter and DermaSpectrometer,http://ClinicalTrials.gov/show/NCT00747162,United States,0,NA,2,NA
NCT00748098,Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in Restless Legs Syndrome (RLS) and Associated Sleep Disturbance,Completed,No Results Available,Restless Legs Syndrome (RLS),Drug: GSK1838262 Extended Release Tablets|Drug: Placebo,GlaxoSmithKline,Both,Adult|Senior,Phase III,136,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RXP110908,09/05/2008,01/10/2008,01/07/2009,08/12/2010,01/08/2010,,01/07/2009,"Change from baseline to end of each treatment period in Wake Time During Sleep (WTDS) measured by polysomnography|Change from baseline to end of each treatment period in Periodic Limb Movements associated with Arousal per hour (PLMAI) measured by polysomnography|Assess safety, tolerability, polysomnography efficacy measures, and patient reported outcomes.",http://ClinicalTrials.gov/show/NCT00748098,United States,1,0,2,NA
NCT00749190,BI 10773 add-on to Metformin in Patients With Type 2 Diabetes,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: BI 10773|Drug: placebo|Drug: sitagliptin,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase II,495,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,1245.10|EudraCT 2008-000641-54,09/08/2008,01/08/2008,NA,11/24/2009,01/11/2009,,01/10/2009,"The primary endpoint is the HbA1c change from baseline after 12 weeks of treatment.|Change in fasting plasma glucose Change in HbA1c over time The proportion of patients with HbA1c <=7.0%, HbA1c lowering >0.5% Change in fasting plasma insulin Change in HOMA indices Change in body weight Pharmacokinetics of BI 10773",http://ClinicalTrials.gov/show/NCT00749190,"United States, &nbsp; Argentina, &nbsp; Austria, &nbsp; Czech Republic, &nbsp; Estonia, &nbsp; Finland, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; Latvia, &nbsp; Norway, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; Spain, &nbsp; Ukraine",1,0,3,NA
NCT00749411,Safety and Tolerabilty of Repeat Dosing of GSK233705/GW642444 in COPD,Completed,No Results Available,Chronic Obstructive Pulmonary Disease (COPD)|Chronic Bronchitis|Emphysema,Drug: Placebo|Drug: GSK233705/GW642444,GlaxoSmithKline,Both,Adult|Senior,Phase II,61,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DB1111581,09/08/2008,01/11/2008,01/02/2009,02/05/2010,01/02/2010,,01/02/2009,Weight mean heart rate 0-4 hours post dose|adverse events|systolic and diastolic blood pressure|QTc measured by ECG|plasma glucose and serum potassium|Holter monitoring|Forced expiratory volume in one second (FEV1)|Pharmacodynamic assessments,http://ClinicalTrials.gov/show/NCT00749411,United States,1,0,2,NA
NCT00749944,"Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo",Completed,Has Results,Smoking Cessation,Drug: varenicline|Drug: placebo,Pfizer,Both,Adult|Senior,Phase IV,110,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",A3051115,09/09/2008,01/09/2008,01/08/2009,8/24/2010,01/08/2010,,01/07/2009,Change From Baseline in the Profile of Mood States (POMS): Total Mood Disturbance (TMD)|Change From Baseline in the Profile of Mood States (POMS): Tension-Anxiety Subscale|Change From Baseline in the Profile of Mood States (POMS): Depression-Dejection Subscale|Change From Baseline in the Profile of Mood States (POMS): Anger-Hostility Subscale|Change From Baseline in the Profile of Mood States (POMS): Vigor Subscale|Change From Baseline in the Profile of Mood States (POMS): Fatigue Subscale|Change From Baseline in the Profile of Mood States (POMS): Confusion Subscale|Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score|Change From Baseline in the Hamilton Anxiety Scale (HAM-A): Total Score|Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Aggression Total Score|Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score|Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score|Change From Baseline in the Social Dysfunction and Aggression Scale (SDAS): Total Score|Change From Baseline in the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Total Score|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Negative Affect Domain Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Insomnia Domain Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Urge to Smoke Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Restlessness Subscale|Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Increased Appetite Subscale|Number of Participants Exceeding Thresholds for the Profile of Mood States (POMS): Total Score|Number of Participants Exceeding Thresholds for the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score|Number of Participants Exceeding Thresholds for the Hamilton Anxiety Scale (HAM-A): Total Score|Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Agression Total Score|Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score|Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score|Number of Participants Exceeding Thresholds for the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score|Number of Participants Exceeding Thresholds for the Social Dysfunction and Aggression Scale (SDAS): Total Score|Number of Participants With Carbon Monoxide Confirmed Daily Smoking Cessation|Number of Participants With 7-day Point Prevalence of Abstinence (Smoking Cessation)|Change From Baseline in the Number of Cigarettes Smoked Per Day,http://ClinicalTrials.gov/show/NCT00749944,United States,1,1,2,1
NCT00750139,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis,Completed,No Results Available,Tinea Pedis|Athlete's Foot,Drug: NAFT-500|Drug: Placebo|Drug: topical allylamine cream|Drug: placebo,"Merz Pharmaceuticals, LLC",Both,Child|Adult|Senior,Phase III,709,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",MUS 90200-0736/1,09/08/2008,01/08/2008,01/12/2009,8/20/2010,01/08/2010,,01/08/2009,NAFT-500 cream to placebo at the 2 week time point post treatment with complete cure defined as negative mycology results from the central laboratory and negative signs and symptoms.|Treatment Effectiveness;Mycological Cure;Clinical Success;Clinical Cure;Physicians Global Evaluation;Subject Satisfaction Assessment,http://ClinicalTrials.gov/show/NCT00750139,United States,1,0,4,NA
NCT00750152,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris,Completed,No Results Available,Tinea Cruris|Jock Itch,Drug: NAFT-500|Drug: Placebo,"Merz Pharmaceuticals, LLC",Both,Child|Adult|Senior,Phase III,334,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",MRZ 90200/FI/3001,09/09/2008,01/09/2008,01/02/2010,8/20/2010,01/08/2010,,01/08/2009,"the percentage of subjects at the 2 week time point post treatment with complete cure defined as negative mycology results from the central laboratory (dermatophyte culture, KOH and Physicians Global Evaluation score of 1).|Mycological Cure;Clinical Cure;Clinical Success;Physicians Global Evaluation; Subject Satisfaction Assessment",http://ClinicalTrials.gov/show/NCT00750152,"United States, &nbsp; Puerto Rico",1,0,2,NA
NCT00750555,Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer,Completed,No Results Available,Head and Neck Cancer,Drug: Erlotinib,Geisinger Clinic|Genentech,Both,Adult|Senior,Phase II,42,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2008-0153|OSI4178S,09/09/2008,01/09/2008,01/12/2009,07/09/2010,01/07/2010,,01/12/2009,One year disease free|Overall Survival,http://ClinicalTrials.gov/show/NCT00750555,United States,1,1,1,1
NCT00750633,A Phase III Study of an Otic Formulation in Acute Otitis Externa,Completed,No Results Available,Acute Otitis Externa,Drug: AL-15469A/AL-38905|Drug: AL-15469A|Drug: AL-38905,Alcon Research,Both,Child|Adult|Senior,Phase III,1500,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",C-07-13,09/08/2008,01/06/2008,NA,1/27/2009,01/01/2009,,01/01/2009,Clinical cure|Microbiological success,http://ClinicalTrials.gov/show/NCT00750633,United States,1,0,3,NA
NCT00751777,Traveler's Diarrhea (TD) Automated Process,Completed,No Results Available,Prevention of Travelers' Diarrhea,Biological: heat-labile enterotoxin of E. coli (LT)|Biological: Placebo,"Intercell USA, Inc.",Both,Adult,Phase II,120,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ELT207,09/11/2008,01/09/2008,01/11/2009,08/12/2010,01/08/2010,,01/11/2009,Evaluation of immunogenicity of LT vaccine patch after first and second vaccination and comparison against placebo|Evaluation of safety of LT vaccine patch after first and second vaccination compared to placebo patch|Evaluation of residual LT in the patch and on the skin at the patch site post-wear|Evaluation of duration of LT-specific immune responses one-year after original treatment regimen in LT patch group,http://ClinicalTrials.gov/show/NCT00751777,United States,0,NA,2,NA
NCT00752219,Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections,Completed,No Results Available,Complicated Intra-Abdominal Infections,Drug: ceftazidime/NXL104 + metronidazole|Drug: meropenem,Novexel Inc,Both,Adult,Phase II,200,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NXL104/2002,09/11/2008,01/03/2009,01/12/2009,12/01/2009,01/12/2009,,01/11/2009,To estimate the efficacy of NXL104/ceftazidime with respect to the clinical response in baseline microbiologically evaluable patients with cIAI at the Test of Cure (TOC) visit|evaluate the safety and tolerability profile of NXL104/ceftazidime in the treatment of cIAI in adults,http://ClinicalTrials.gov/show/NCT00752219,"United States, &nbsp; Bulgaria, &nbsp; France, &nbsp; India, &nbsp; Lebanon, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation",1,0,2,NA
NCT00752505,"A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.",Completed,No Results Available,Fibromyalgia,Drug: Esreboxetine|Drug: Esreboxetine,Pfizer,Both,Adult,Phase II,89,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A6061061,09/12/2008,01/08/2008,01/06/2009,07/09/2009,01/07/2009,,01/06/2009,"Computer based psychometric tests|A questionnaire to evaluate the subjects cognitive status|A questionnaire to assess the subjects mood|A question to assess the subjects pain at visits|A daily diary to assess the subjects pain|A questionnaire to evaluate the impact the subject perceives fibromyalgia has on their cognitive ability|Two questionnaires to assess change in the subjects cognitive ability|Safety evaluations: medical history, physical and neurological exam, heart rate and blood pressure lying and standing, laboratory tests, electrical heart trace (ECG), adverse event collection, assessment of suicidal risk",http://ClinicalTrials.gov/show/NCT00752505,United States,1,0,2,NA
NCT00752609,Safety and Efficacy of Peginesatide Injection in Chronic Renal Failure Subjects.,Completed,No Results Available,Anemia,Drug: Peginesatide,"Takeda Global Research & Development Center, Inc.|Affymax",Both,Adult|Senior,Phase II,102,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AFX01_202|2008-003459-64|U1111-1114-1500,09/11/2008,01/10/2008,01/12/2009,06/02/2010,01/06/2010,,01/12/2009,Mean change in hemoglobin between baseline and the evaluation period.|Proportion of subjects who have mean Hemoglobin values within the target range of 10.0 to 12.0 g/dL during the evaluation period|Proportion of subjects with a change in Hemoglobin between Baseline and the evaluation period of less than or equal to ?? 1g/dL|Proportion of subjects who receive red blood cell transfusions.|Mean Hemoglobin during 4-week intervals|Proportion of subjects who maintain a target Hemoglobin of 10.0 to 12.0 g/dL during 4-week intervals.|Proportion of subjects requiring dose adjustments during the study,http://ClinicalTrials.gov/show/NCT00752609,United States,1,0,1,NA
NCT00755222,The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease,Completed,No Results Available,Peyronie's Disease,Biological: AA4500|Biological: Placebo,Auxilium Pharmaceuticals,Male,Adult|Senior,Phase II,120,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AUX-CC-801,9/16/2008,01/08/2008,01/12/2009,6/17/2010,01/06/2010,,01/12/2009,Total scores and change from baseline total scores for each of the four scales of the Peyronie's PRO questionnaire|Change from baseline and percent change from baseline in penile curvature,http://ClinicalTrials.gov/show/NCT00755222,United States,0,NA,2,NA
NCT00755274,Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone?ó,Completed,Has Results,Influenza|Orthomyxoviridae Infections,Biological: Influenza Virus Vaccine No Preservative: Pediatric Dose|Biological: Influenza Virus Vaccine No Preservative: Pediatric Dose,Sanofi-Aventis,Both,Child,Phase IV,32,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,GRC40,9/16/2008,01/09/2008,01/01/2009,03/10/2010,01/03/2010,,01/01/2009,Number of Participants With Solicited Local and Systemic Reactions After Fluzone?ó Vaccination 1|Number of Participants With Solicited Local and Systemic Reactions After Fluzone?ó Vaccination 2,http://ClinicalTrials.gov/show/NCT00755274,United States,0,NA,2,NA
NCT00755417,Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women,Completed,No Results Available,Hot Flashes,Drug: Gabapentin Extended Release tablets,Depomed,Female,Adult|Senior,Phase III,540,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",BREEZE 1|81-0058,9/17/2008,01/09/2008,01/10/2009,11/02/2009,01/11/2009,,01/08/2009,"Reduction of frequency and severity of hot flashes after 24 weeks of treatment with a stable dose relative to placebo, compared with the baseline week.",http://ClinicalTrials.gov/show/NCT00755417,United States,1,0,1,NA
NCT00758420,"Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Endovenous Microfoam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence",Completed,No Results Available,Varicose Veins,Drug: Varisolve (Polidocanol Endovenous Microfoam)|Drug: Agitated Saline,BTG Ltd.,Both,Adult,Phase II|Phase III,74,Other,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,VAP.VV013,9/22/2008,01/10/2008,01/09/2009,11/24/2009,01/11/2009,Pilot,01/08/2009,The absolute change from baseline score for the VEINES-Sym questionnaire (overall score) at 8 weeks,http://ClinicalTrials.gov/show/NCT00758420,United States,1,0,2,NA
NCT00758498,Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder,Completed,Has Results,Excessive Sleepiness,Drug: armodafinil|Drug: armodafinil|Drug: placebo,Cephalon,Both,Adult,Phase III,427,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C10953/3065/ES/MN,9/23/2008,01/09/2008,01/02/2009,06/11/2010,01/06/2010,,01/02/2009,Multiple Sleep Latency Test (MSLT)|Patient Global Impression of Severity (PGI-S)|Karolinska Sleepiness Scale (KSS)|Multiple Sleep Latency Test (MSLT)|Patient Global Impression of Severity (PGI-S),http://ClinicalTrials.gov/show/NCT00758498,United States,1,1,3,1
NCT00758524,"A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699, a New Experimental Antihypertensive Drug, in Patients With Essential Hypertension",Completed,No Results Available,Essential Hypertension,Drug: LCI699|Drug: Eplerenone|Drug: Placebo,Novartis Pharmaceuticals,Both,Adult|Senior,Phase II,526,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLCI699A2201,9/23/2008,01/09/2008,NA,2/22/2010,01/02/2010,,01/07/2009,Mean sitting diastolic blood pressure reduction|Efficacy of mean sitting systolic blood pressure,http://ClinicalTrials.gov/show/NCT00758524,United States,1,0,3,NA
NCT00758628,"Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.",Completed,No Results Available,Diabetic Macular Edema,Drug: Bromefenac|Drug: Blink,"Bp Consulting, Inc",Both,Adult|Senior,Phase IV,50,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",1,9/22/2008,01/08/2008,01/05/2009,09/03/2009,01/09/2009,,01/05/2009,"Macular/Foveal Thickness (on OCT) v/s Control Arm, compared to baseline evaluation.|Re-treatment rate and interval between successive sessions of ALT v/s Control Arm.",http://ClinicalTrials.gov/show/NCT00758628,United States,1,1,2,1
NCT00758758,Performance of the Hedrocel(R) Cervical Fusion Device,Completed,No Results Available,Symptomatic Cervical Disc Disease,Device: Anterior Cervical Discectomy and Fusion|Device: Anterior Cervical Discectomy and Fusion|Device: Anterior Cervical Discectomy and Fusion,"Zimmer, Inc.",Both,Adult|Senior,Phase III,231,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,IC 003-99,9/23/2008,01/12/2001,01/06/2009,06/11/2009,01/06/2009,,01/01/2009,"Overall Clinical Success (NDI, Fusion, Additional Surgical Procedures)|SF-36",http://ClinicalTrials.gov/show/NCT00758758,United States,0,NA,3,NA
NCT00758862,The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo,Completed,No Results Available,Secondarily Infected Traumatic Lesions (SITL)|Impetigo,Drug: 2% TD1414 Cream,LEO Pharma,Both,Adult,Phase II,20,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TD1414-C22,9/23/2008,01/12/2008,01/02/2009,08/11/2009,01/08/2009,,01/02/2009,To determine the pharmacokinetic profile of TD1414 after repeated topical administration of 2% TD1414 cream for the treatment of SITL or impetigo in adult patients|To determine the safety of 2% TD1414 cream in the treatment of SITL or impetigo in adult patients,http://ClinicalTrials.gov/show/NCT00758862,United States,1,0,1,NA
NCT00758953,Pain Associated With Endometriosis,Completed,No Results Available,Endometriosis,Drug: Danazol Once Weekly|Drug: Danazol Twice Weekly|Drug: Placebo Once Weekly|Drug: Placebo Twice Weekly,KV Pharmaceutical Company,Female,Adult,Phase II,66,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DZ2-201-601-725036,9/23/2008,01/02/2007,01/01/2009,01/11/2010,01/01/2010,,01/01/2009,Pain associated with endometriosis,http://ClinicalTrials.gov/show/NCT00758953,"United States, &nbsp; Canada, &nbsp; Russian Federation",1,1,4,0
NCT00759525,The Role of Mineralocorticoid Receptors in Vascular Function,Completed,No Results Available,Apparent Mineralocorticoid Excess (AME),Drug: Glycyrrhetic Acid|Drug: Placebo,Brigham and Women's Hospital,Both,Adult|Senior,Phase II|Phase III,20,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2001-P-001404,9/24/2008,01/02/2002,01/09/2009,10/16/2009,01/10/2009,,01/09/2009,To determine that inhibition of the enzyme 11-beta hydroxysteroid dehydrogenase (11-beta-HSD) will impair vascular smooth muscle function and endothelial function,http://ClinicalTrials.gov/show/NCT00759525,United States,1,1,2,0
NCT00759941,A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated IOP on a Prostaglandin,Completed,No Results Available,Glaucoma,Drug: AZOPT Solution|Drug: Placebo Eye Drops,Alcon Research,Both,Adult|Senior,Phase IV,90,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",SMA-07-08,9/24/2008,01/10/2007,NA,1/27/2010,01/01/2010,,01/07/2009,Intraocular Pressure|Safety,http://ClinicalTrials.gov/show/NCT00759941,United States,1,1,2,1
NCT00760097,Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression,Completed,No Results Available,Depression,Device: Transcranial direct stimulation,"University of California, Los Angeles",Both,Adult|Senior,Phase IV,18,Other,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic,aTDCS in MDD,9/24/2008,01/09/2007,01/05/2009,08/06/2009,01/08/2009,aTDCS,01/05/2009,"To test our hypotheses, assessments of cognition, mood, and brain activity will be performed on three occasions|ADVERSE EVENT REPORTS Subjects will be asked about adverse events at the end of each treatment session",http://ClinicalTrials.gov/show/NCT00760097,United States,0,NA,1,NA
NCT00760266,Blood Pressure Lowering of Aliskiren HCTZ Compared HCTZ in Stage 2 Systolic Hypertension in Older Population,Completed,No Results Available,Hypertension,Drug: Aliskiren HCTZ|Drug: HCTZ,Novartis,Both,Adult|Senior,Phase IV,432,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",CSPP100A2411,9/25/2008,01/09/2008,NA,05/05/2009,01/05/2009,ACTION,01/04/2009,Change in msSBP after 8 weeks of treatment|Change in msDBP after 8 weeks of treatment|Efficacy of regimens on msSBP and msDBP|Proportion of responders at week 4 and regimens at week 8|Proportion of patients achieving BP control at week 4 and regimens at week 8|Safety and tolerability of aliskiren HCTZ compared to HCTZ at week 4 and regimens at week 8,http://ClinicalTrials.gov/show/NCT00760266,United States,1,1,2,0
NCT00760578,A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Placebo|Drug: Pioglitazone|Drug: MSDC-0160 1|Drug: MSDC-0160 2,Metabolic Solutions Development Company,Both,Adult|Senior,Phase II,110,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSDC-C003,9/25/2008,01/09/2008,01/02/2009,05/11/2009,01/05/2009,,01/01/2009,Post Prandial Blood Glucose|Characterize pharmacokinetics and pharmacodynamics of MSDC-0160 and identify potential biomarkers,http://ClinicalTrials.gov/show/NCT00760578,United States,1,0,4,NA
NCT00761150,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP).,Completed,No Results Available,Chronic Low Back Pain,Drug: ABT-712|Drug: ABT-712 placebo,Abbott,Both,Adult|Senior,Phase III,310,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M10-385,9/25/2008,01/08/2008,NA,12/30/2010,01/12/2010,,01/03/2009,Visual Analog Scale (VAS) for pain intensity|Chronic Pain Sleep Inventory (CPSI),http://ClinicalTrials.gov/show/NCT00761150,United States,1,0,2,NA
NCT00761215,Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections,Completed,No Results Available,"Skin Diseases, Infectious|Skin Structure Infections",Drug: oral TR-701,"Trius Therapeutics, Inc.",Both,Adult|Senior,Phase II,180,Industry,Interventional,"Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TR701-104,9/25/2008,01/09/2008,01/05/2009,06/08/2009,01/06/2009,,01/05/2009,Clinical response at the early follow-up visit|Clinical outcome at the late follow-up visit|Microbiological response rates|Safety Profiles|Population pharmacokinetic profile of the study drug,http://ClinicalTrials.gov/show/NCT00761215,United States,1,0,1,NA
NCT00761319,Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health,Completed,No Results Available,Open-Angle Glaucoma|Ocular Hypertension,"Drug: Travoprost 0.004%, BAC-Free|Drug: Latanoprost 0.005%",Alcon Research,Both,Adult|Senior,Phase III,1100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C-08-47,9/25/2008,01/10/2008,01/09/2009,9/30/2009,01/09/2009,,01/09/2009,Ocular Surface Disease Index Questionnaire|Corneal fluorescein staining,http://ClinicalTrials.gov/show/NCT00761319,United States,1,1,2,1
NCT00761709,Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension,Completed,No Results Available,Open-Angle Glaucoma|Ocular Hypertension,"Drug: AL-39256|Drug: Latanoprost Ophthalmic Solution, 0.005%|Drug: Placebo (Vehicle Solution)",Alcon Research,Both,Adult|Senior,Phase II,90,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C-08-28,9/25/2008,01/01/2009,01/03/2009,3/23/2009,01/03/2009,,01/03/2009,Mean IOP from baseline,http://ClinicalTrials.gov/show/NCT00761709,United States,1,0,3,NA
NCT00762164,Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol,Completed,No Results Available,Hypercholesterolemia,Drug: Vytorin|Drug: Simvastatin,Bronx VA Medical Center,Both,Adult|Senior,Phase IV,34,U.S. Fed,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VA---19-07-01,9/29/2008,01/03/2007,01/05/2009,08/12/2009,01/08/2009,,01/04/2009,LDL cholesterol|Total cholesterol,http://ClinicalTrials.gov/show/NCT00762164,United States,1,1,2,0
NCT00762216,Rotational Stability of the AcrySof?ó Toric,Completed,Has Results,Cataract,Device: AcrySof?ó Toric intraocular lens,Alcon Research,Both,Adult|Senior,Phase IV,71,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RM-08-001,9/26/2008,01/05/2008,NA,05/10/2010,01/05/2010,,01/06/2009,Rotational Stability|Residual Refractive Cylinder,http://ClinicalTrials.gov/show/NCT00762216,United States,0,NA,1,NA
NCT00763321,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP).,Completed,No Results Available,Chronic Low Back Pain,Drug: ABT-712|Drug: ABT-712 placebo,Abbott,Both,Adult|Senior,Phase III,287,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M10-277,9/26/2008,01/08/2008,NA,12/30/2010,01/12/2010,,01/04/2009,Visual Analog Scale (VAS)for pain intensity|Chronic Pain Sleep Inventory (CPSI),http://ClinicalTrials.gov/show/NCT00763321,United States,1,0,2,NA
NCT00763555,Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis,Completed,No Results Available,Psoriasis,Drug: CD 2027|Drug: Vehicle (placebo),Galderma,Both,Adult|Senior,Phase II,88,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RD.06.SPR.18119,9/30/2008,01/09/2008,01/03/2009,12/02/2010,01/12/2010,,01/01/2009,Success rates at Week 8|Change in Global Severity Score from Baseline at Week 8,http://ClinicalTrials.gov/show/NCT00763555,"United States, &nbsp; Canada",1,0,2,NA
NCT00764790,Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children.,Completed,Has Results,Influenza|Influenza Vaccines,Biological: Fluarix|Biological: Fluzone,GlaxoSmithKline,Both,Child,Phase III,3317,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Caregiver, Outcomes Assessor)|Primary Purpose: Prevention",111751,10/01/2008,01/10/2008,01/03/2009,11/24/2010,01/11/2010,,01/03/2009,Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains|Number of Subjects Who Seroconverted|Number of Seroprotected Subjects|Seroconversion Factor|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)|Number of Subjects Reporting Rare Serious Events,http://ClinicalTrials.gov/show/NCT00764790,"United States, &nbsp; Hong Kong, &nbsp; Mexico, &nbsp; Taiwan, &nbsp; Thailand",0,NA,2,NA
NCT00765076,Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older,Completed,No Results Available,Influenza Infection,Biological: GSK Biologicals' Fluarix|Biological: GSK Biologicals' influenza vaccine GSK2186877A,GlaxoSmithKline,Both,Adult|Senior,Phase III,192,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",112147,10/01/2008,01/10/2008,01/11/2009,07/02/2010,01/07/2010,,01/11/2009,"The frequency of influenza-specific CD4 T-cells per 10E6 CD4+ T-cells identified after in vitro stimulation with pooled vaccine strains as producing at least two different markers (CD40L, IL-2, TNF-??, IFN-??) in the elderly vaccine groups|Frequency of influenza-specific CD4 T-cells per 10E6 CD4+ T-cells identified after in vitro stimulation with pooled vaccine strains and with each vaccine strain separately as producing at least two different markers in each vaccine group.|For pooled vaccine strains and for each vaccine strain separately, frequency of influenza-specific CD4 T-cells per 10E6 CD4+ T-cells defined on the expression profile of each of the immune markers plus another immune marker in each vaccine group.|Serum haemagglutination-inhibition (HI) antibody titers|Occurrence, intensity, duration of solicited local Adverse Events (AEs).|Occurrence, intensity, duration and relationship to vaccination of solicited general AEs.|Occurrence, intensity and relationship to vaccination of unsolicited AEs.|Occurrence, intensity and relationship to vaccination of AEs with a medically attended visit.|Occurrence and relationship to vaccination of serious AEs (SAEs) and AEs of specific interest including autoimmune diseases.",http://ClinicalTrials.gov/show/NCT00765076,"United States, &nbsp; Spain",0,NA,2,NA
NCT00765674,Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-Severe Hypertension,Completed,No Results Available,Hypertension,"Drug: Aliskiren 150/Amlodipine 5 mg, 300/10 mg|Drug: Aliskiren 150/Hydrochlorothiazide 12.5 mg, 300/25 mg|Drug: Amlodipine 150/Hydrochlorothiazide 12.5 mg, 10/25 mg|Drug: Aliskiren 150/Amlodipine 5/Hydrochlorothiazide 12.5 mg, 300/10/25 mg",Novartis,Both,Adult|Senior,Phase III,1160,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",CSAH100A2302,10/02/2008,01/09/2008,NA,03/12/2010,01/03/2010,,01/08/2009,Vital signs at every visit|Vital signs at every visit|Adverse events at every visit|24-hour ambulatory blood pressure measurement of a subset of patients at Day 1 and Day 56 (end of study)|Pharmacokinetics,http://ClinicalTrials.gov/show/NCT00765674,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Denmark, &nbsp; Germany, &nbsp; Israel, &nbsp; Italy, &nbsp; Latvia, &nbsp; Lithuania, &nbsp; Romania, &nbsp; Sweden, &nbsp; Turkey",1,1,4,0
NCT00765700,Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury,Completed,No Results Available,Sprain|Strain,Drug: ketoprofen|Drug: Placebo,Transdel Pharmaceuticals|Cato Research,Both,Adult|Senior,Phase III,364,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TDLP-110-101,10/01/2008,01/09/2008,01/09/2009,5/24/2010,01/05/2010,,01/08/2009,"Assess the efficacy of ketoprofen 10% cream in subjects with acute pain associated with mild to moderate acute soft tissue injury (acute sprain or strain) of upper and lower extremities on the day 3 visit.|Assess the safety, tolerability and other parameters of ketoprofen 10% cream in subjects with acute pain associated with mild to moderate acute soft tissue injury of upper and lower extremities.",http://ClinicalTrials.gov/show/NCT00765700,United States,1,0,2,NA
NCT00765804,Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye,Completed,No Results Available,Dry Eye Syndrome,Drug: EGP-437 with EyeGate?ó II System|Drug: Sodium citrate buffer solution with EyeGate?ó II System,"Eyegate Pharmaceuticals, Inc.",Both,Child|Adult|Senior,Phase II,89,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EGP-437-002,10/02/2008,01/10/2008,01/02/2009,8/27/2010,01/08/2010,,01/02/2009,Sign: Corneal fluorescein staining after CAE exposure at Visit 5|Symptom: Ocular discomfort during CAE exposure at Visit 5|Sign: Fluorescein staining at each visit over 3 weeks|Symptom: Ocular discomfort pre and post CAE,http://ClinicalTrials.gov/show/NCT00765804,United States,1,0,2,NA
NCT00765882,"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation",Completed,No Results Available,Chronic Constipation,Drug: Linaclotide 300 micrograms|Drug: Linaclotide 150 micrograms|Drug: Placebo,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",Both,Adult|Senior,Phase III,600,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LIN-MD-01,10/01/2008,01/09/2008,01/07/2009,1/20/2010,01/01/2010,,01/07/2009,Complete Spontaneous Bowel Movement (CSBM) Overall Responder|Change from Baseline in 12-week CSBM Frequency,http://ClinicalTrials.gov/show/NCT00765882,"United States, &nbsp; Canada",1,0,3,NA
NCT00766090,Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma,Completed,No Results Available,Asthma,Drug: GW685698X,GlaxoSmithKline,Both,Child|Adult|Senior,Phase II,190,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",112202,10/02/2008,01/10/2008,01/03/2009,02/05/2010,01/02/2010,,01/03/2009,safety and efficacy,http://ClinicalTrials.gov/show/NCT00766090,United States,1,0,1,NA
NCT00767806,A Study for Patient With Chronic Low Back Pain,Completed,Has Results,Chronic Low Back Pain,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Both,Adult|Senior,Phase III,401,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12360|F1J-MC-HMGC,10/03/2008,01/09/2008,01/07/2009,9/30/2010,01/09/2010,,01/07/2009,"Change From Baseline to 12 Weeks in Brief Pain Inventory 24-hour Average Pain Score|Change From Baseline to 12 Weeks on the Brief Pain Inventory - Severity (BPI-S) and Interference (BPI-I)|Change From Baseline to 12 Weeks in Weekly Mean of 24-hour Average Pain, Worst Pain, and Night Pain Rating|Number of Responders: 30 Percent (%) or Greater Reduction of the Brief Pain Inventory (BPI) Average Pain Severity Rating at 12 Week Endpoint|Number of Responders: 50 Percent (%) or Greater Reduction of the Brief Pain Inventory (BPI) Average Pain Severity Rating at 12 Week Endpoint|Number of Sustained Responders at 12 Week Endpoint|Number of Participants Reaching Each Threshold of of BPI Average Pain Score Reduction During the Study - Cumulative Distribution|Change From Baseline to 12 Weeks Endpoint in Clinical Global Impressions of Severity (CGI-S)|Patient's Global Impression of Improvement (PGI-I) at 12 Weeks|Change From Baseline to 12 Weeks in Roland Morris Disability Questionnaire|Change From Baseline to 12 Weeks in Profile of Mood States - Brief Form|Change From Baseline to 12 Weeks in 36-item Short-Form (SF-36) Health Survey|Change From Baseline to 12 Weeks in European Quality of Life Questionnaire - 5 Dimension|Change From Baseline to 12 Weeks in Work Productivity and Activity Impairment Instrument (WPAI)|Participants Who Discontinued From Baseline to 12 Weeks|Change From Baseline to 12 Weeks in Uric Acid|Change From Baseline to 12 Week Endpoint in Albumin|Change From Baseline to 12 Week Endpoint in Alkaline Phosphatase|Change From Baseline to 12 Week Endpoint in Alanine Aminotransferase|Change From Baseline to 12 Week Endpoint in Aspartate Aminotransferase|Change From Baseline to 12 Week Endpoint in Creatinine|Change From Baseline to 12 Week Endpoint in Total Protein|Change From Baseline to 12 Weeks in Blood Pressure|Change From Baseline to 12 Week Endpoint in Weight|Change From Baseline to 12 Week Endpoint in Pulse Rate|Number of Participants With Suicidal Ideation or Suicidal Behaviors According to the Columbia Suicide Severity Rating Scale",http://ClinicalTrials.gov/show/NCT00767806,"United States, &nbsp; Brazil, &nbsp; Germany, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Spain",1,1,2,1
NCT00768274,"Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol",Completed,No Results Available,Dyslipidemia|Atherosclerosis|Acute Coronary Syndrome|Cardiovascular Disease,Drug: RVX000222 (common name RVX-208),Resverlogix Corp,Both,Adult,Phase I|Phase II,72,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",RVX222-CS-003,10/07/2008,01/09/2008,NA,1/27/2010,01/01/2010,,01/08/2009,"Safety, pharmacokinetics and changes in lipid parameters from baseline and placebo.",http://ClinicalTrials.gov/show/NCT00768274,United States,1,0,1,NA
NCT00770029,"Efficacy and Safety of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines No. 2",Completed,No Results Available,Moderate to Severe Glabellar Frown Lines,Drug: Clostridium Botulinum neurotoxin type A|Drug: Placebo,Merz Pharmaceuticals GmbH,Both,Adult|Senior,Phase III,276,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",MRZ 60201 - 0724 / 1,10/08/2008,01/10/2008,NA,3/25/2010,01/01/2010,,01/03/2009,Investigator's rating on the Facial Wrinkle Scale and the patient's assessment on a 4-point scale|Percentage of responders by patient assessment on 4-point scale|Percentage of responders by investigator assessment on facial wrinkle scale,http://ClinicalTrials.gov/show/NCT00770029,"United States, &nbsp; Canada",1,1,2,1
NCT00770211,"Efficacy and Safety of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines",Completed,No Results Available,Moderate to Severe Glabellar Frown Lines,Drug: Clostridium Botulinum neurotoxin type A|Drug: Placebo,Merz Pharmaceuticals GmbH,Both,Adult|Senior,Phase III,271,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",MRZ 60201 - 0741 / 1,10/08/2008,01/10/2008,NA,3/25/2010,01/01/2010,,01/03/2009,Investigator's rating on the Facial Wrinkle Scale and the patient's assessment on a 4-point scale|Percentage of responders by patient assessment on 4-point scale|Percentage of responders by investigator assessment on facial wrinkle scale,http://ClinicalTrials.gov/show/NCT00770211,United States,1,1,2,1
NCT00770367,Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes,Completed,Has Results,Diabetes,Drug: Pioglitazone then Placebo|Drug: Placebo then Pioglitazone,"Medical University of South Carolina|Takeda Global Research & Development Center, Inc.",Both,Adult|Senior,Phase IV,36,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Takeda 07-060|18379,10/09/2008,01/10/2008,01/06/2010,10/21/2010,01/10/2010,,01/12/2009,Asymmetric Dimethylarginine (ADMA) Level|NOx f2-isoprostanes,http://ClinicalTrials.gov/show/NCT00770367,United States,1,1,2,1
NCT00770861,A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients,Completed,No Results Available,Hypertension,Drug: Nebivolol|Drug: Placebo,Forest Laboratories,Both,Adult|Senior,Phase IV,277,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NEB-MD-16,10/09/2008,01/09/2008,NA,03/09/2010,01/03/2010,,01/11/2009,Mean seated trough Diastolic Blood Pressure|Mean seated trough Systolic Blood Pressure,http://ClinicalTrials.gov/show/NCT00770861,"United States, &nbsp; Puerto Rico",1,1,2,1
NCT00771264,Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms,Completed,Has Results,Overactive Bladder,Device: Urgent PC Neuromodulation System,"Uroplasty, Inc",Both,Adult|Senior,Phase IV,220,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment",UPC082008,10/09/2008,01/09/2008,01/06/2009,8/26/2010,01/08/2010,SUmiT,01/06/2009,"The Global Response Assessment (GRA) for Overall Bladder Symptoms to Compare the Proportion of Subjects Reporting \Moderately\"" or \""Markedly Improved\"" Responses on the GRA After 12 Interventions of Randomized Therapy",http://ClinicalTrials.gov/show/NCT00771264,United States,0,NA,1,NA
NCT00771615,Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years,Completed,No Results Available,"Influenza Disease Caused by an Influenza A Virus With Pandemic Potential, Sub-type H5N1",Biological: GSK influenza virus H5N1 vaccine 1557484A,GlaxoSmithKline,Both,Adult,Phase II,469,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",111729,10/10/2008,01/10/2008,01/12/2009,07/02/2010,01/07/2010,,01/12/2009,"Vaccine-homologous virus antibody response measured by:Seroconversion rate (SCR), proportion of subjects with Hl titer >= 40, Geometric mean titer (GMT)|Vaccine-homologous virus antibody response measured by Seroconversion rate (SCR), proportion of subjects with HI titer >= 40, Geometric mean fold rise (GMFR)|The occurrence of all unsolicited adverse events.|The occurrence of SAEs and medically-attended events|Vaccine-heterologous virus antibody response measured by GMT, SCR, proportion of subjects with HI titer >= 40, GMFR|Homologous and drift variant H5N1 virus immune responses as assessed by reciprocal MN (microneutralization) titer GMT, reciprocal MN titer SCR, proportion of subjects with MN titers >= 40|The occurrence of specifically-solicited local and general safety signs and symptoms",http://ClinicalTrials.gov/show/NCT00771615,"United States, &nbsp; Canada",0,NA,1,NA
NCT00771914,The Effects of Omega-3 Fatty Acids on Aspirin Resistance,Completed,No Results Available,Aspirin Resistance,Drug: ethyl EPA + DHA,University of Rochester|GlaxoSmithKline|American College of Clinical Pharmacy|Cornell University,Both,Adult,Phase I|Phase II,26,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Study Protocol 112421,10/14/2008,01/11/2008,01/01/2009,2/18/2010,01/02/2010,,01/01/2009,Platelet Function Analyzer 100 and Thromboxane A2 as measures of platelet aggregation,http://ClinicalTrials.gov/show/NCT00771914,United States,1,1,1,0
NCT00772044,Randomized Study of Provent Versus Sham Device to Treat Obstructive Sleep Apnea,Completed,No Results Available,Obstructive Sleep Apnea Hypopnea|OSA|OSAH,Device: Provent Professional Sleep Apnea Therapy Device|Device: Sham Device,"Ventus Medical, Inc.",Both,Adult|Senior,Phase IV,250,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",C009,10/13/2008,01/11/2008,01/12/2009,3/31/2010,01/03/2010,AERO,01/09/2009,"Comparison of difference in AHI at one-week in-lab polysomnography between \device on\"" and \""device off\"" nights",http://ClinicalTrials.gov/show/NCT00772044,United States,0,NA,2,NA
NCT00772109,Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone?ó in Adults,Completed,No Results Available,Orthomyxoviridae Infection|Influenza|Myxovirus Infection,Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B,Sanofi-Aventis,Both,Adult,Phase III,4300,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",FID31,10/13/2008,01/10/2008,01/07/2009,3/31/2010,01/03/2010,,01/05/2009,Immunogenicity: To provide information concerning the immunogenicity of an investigational Fluzone vaccine.|Safety: To provide information concerning the safety of an investigational Fluzone vaccine.,http://ClinicalTrials.gov/show/NCT00772109,"United States, &nbsp; Puerto Rico",0,NA,4,NA
NCT00772525,Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis,Completed,No Results Available,Multiple Sclerosis|Optic Nerve|Neuritis,Drug: nerispirdine (HP184)|Drug: Placebo,Sanofi-Aventis,Both,Adult|Senior,Phase II,31,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",ACT10573,10/13/2008,01/09/2008,01/06/2009,12/18/2009,01/12/2009,,01/06/2009,Visual Evoked Potential (P100) - Latency|Contrast sensitivity score|ETDRS chart score|Visual Evoked Potentials (VEP) amplitude,http://ClinicalTrials.gov/show/NCT00772525,United States,1,0,2,NA
NCT00772577,Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ??­ 30) With Stage 2 Hypertension,Completed,No Results Available,Hypertension,Drug: Aliskiren Hydrochlorothiazide|Drug: Ramipril:,Novartis,Both,Adult|Senior,Phase IV,386,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CSPP100AUS07,10/10/2008,01/08/2008,NA,5/14/2009,01/05/2009,ATTAIN,01/05/2009,Change in from baseline in mean sitting systolic blood pressure (MSSBP) after|Change from baseline in mean sitting diastolic blood pressure (MSDBP)|Change from baseline in mean sitting pulse pressure|Proportion of responders (MSSBP <140 mmHg or a > 20 mmHg decrease from baseline in MSSBP)|Proportion of patients achieving BP control (BP <140/90 mmHg)|Safety and tolerability,http://ClinicalTrials.gov/show/NCT00772577,United States,1,1,2,0
NCT00772889,Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly,Completed,No Results Available,Influenza Infection,Biological: GSK Biologicals' Fluarix?ºÑ|Biological: Influenza vaccine GSK2186877A,GlaxoSmithKline,Both,Adult|Senior,Phase III,974,Industry,Interventional,"Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",111738,10/10/2008,01/10/2008,01/12/2009,07/02/2010,01/07/2010,,01/12/2009,"Occurrence, intensity and duration of solicited local symptoms|Occurrence, intensity, duration and relationship to vaccination of solicited general symptoms|Occurrence, intensity and relationship to vaccination of adverse events of specific interest including autoimmune diseases|Occurrence and relationship to vaccination of serious adverse events|Occurrence, intensity and relationship to vaccination of adverse events with medically attended visit|Occurrence, intensity and relationship to vaccination of adverse events of specific interest including autoimmune diseases|Occurrence and relationship to vaccination of serious adverse events|Haemagglutination-inhibition (HI) antibody titres",http://ClinicalTrials.gov/show/NCT00772889,"United States, &nbsp; Germany, &nbsp; Norway",0,NA,2,NA
NCT00773279,"Efficacy, Safety and Preference Study of a Comparator Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics",Completed,No Results Available,Diabetes Mellitus,Device: PDS290|Device: Novo Nordisk marketed insulin pen,Novo Nordisk,Both,Adult|Senior,Phase III,255,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,PDS290-1971,10/14/2008,01/09/2008,01/06/2009,11/09/2009,01/09/2009,,01/06/2009,HbA1c|Clinical technical complains|Compare the effectiveness of PDS290 vs a Novo Nordisk marketed insulin pen using questionnaires|Hypoglycaemic episodes|Adverse events and adverse device effects,http://ClinicalTrials.gov/show/NCT00773279,United States,0,NA,2,NA
NCT00773344,Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin,Completed,No Results Available,Solid Tumors|Breast Cancer,Drug: Tanespimycin,Bristol-Myers Squibb,Both,Adult|Senior,Phase I|Phase II,25,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA200-001|KAG 122,10/15/2008,01/12/2005,01/08/2009,12/06/2010,01/12/2010,,01/05/2009,"Objective tumor response rate (RECIST complete response, or partial response ) confirmed by CT and MRI as the preferred methods for tumor assessments and Chest x-ray is acceptable for pulmonary lesions|Kaplan-Meier estimates duration of response and time-to-event variables will be used (time to progression, progression-free survival, time to response, duration of response, time to treatment failure and overall survival)|Kaplan-Meier estimates duration of response and time-to-event variables will be used (time to progression, progression-free survival, time to response, duration of response, time to treatment failure and overall survival)|Kaplan-Meier estimates duration of response and time-to-event variables will be used (time to progression, progression-free survival, time to response, duration of response, time to treatment failure and overall survival)",http://ClinicalTrials.gov/show/NCT00773344,United States,1,0,1,NA
NCT00774761,A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease,Completed,No Results Available,Chronic Obstructive Pulmonary Disease,Drug: fluticasone propionate/formoterol fumarate|Drug: fluticasone propionate|Drug: formoterol fumarate,Dey,Both,Adult|Senior,Phase II,97,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",191-087,10/16/2008,01/11/2008,01/05/2009,9/22/2009,01/09/2009,,01/04/2009,Plasma AUC(0-t) after 1 week of dosing|FEV1,http://ClinicalTrials.gov/show/NCT00774761,United States,1,1,3,0
NCT00774800,Phase II PK Study With Humalog and Humulin R With and Without rHuPH20 in T1DM,Completed,No Results Available,Type 1 Diabetes Mellitus,"Drug: Humalog, Humulin R, rHuPH20",Halozyme Therapeutics,Both,Adult,Phase II,22,Industry,Interventional,Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,HZ2-08-05,10/15/2008,01/10/2008,01/03/2009,05/07/2009,01/05/2009,,01/03/2009,"Assess differences between PK and PD properties of two types of insulin (Humalog and Humulin R) when each product is injected SC with and without rHuPH20 following a liquid meal|Various other PK and PD endpoint measures|AEs, hematology, biochemistry, urinalyses, physical examinations, vital signs, ECGs, blood glucose, local tolerability at injection site, and antibody formation to insulin agents and to rHuPH20",http://ClinicalTrials.gov/show/NCT00774800,United States,1,0,1,NA
NCT00775138,A Study to Determine the Safety and Tolerability of Arikace?ºÑ Versus Placebo in Patients Who Have Bronchiectasis.,Completed,No Results Available,Bronchiectasis,Drug: Arikace 280 mg|Drug: Arikace 560 mg|Drug: Matching Placebo,Insmed,Both,Adult|Senior,Phase I|Phase II,60,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",TR02-107,10/15/2008,01/06/2008,01/05/2009,7/14/2009,01/07/2009,,01/05/2009,"Treatment emergent adverse events up to end of treatment|Treatment emergent marked laboratory abnormalities up to 28 days after study medication discontinuation|Treatment emergent pulmonary function test (PFT) abnormalities post-dose for acute tolerability assessment|Treatment emergent pulmonary function test (PFT) abnormalities up to end of treatment|Adverse events leading to permanent discontinuation of study medication|Serious adverse events up to 28 days after study medication discontinuation|To access pharmacokinetics (PK) of Arikace?ºÑ in serum and urine, and evaluate sputum amikacin levels|To evaluate change in Pulmonary function|To evaluate change in density of Pseudomonas aeruginosa in sputum|To evaluate time to and duration of systemic anti-Pseudomonal rescue therapy|To evaluate change in St. George's Respiratory Questionnaire measurements",http://ClinicalTrials.gov/show/NCT00775138,"United States, &nbsp; Bulgaria, &nbsp; Greece, &nbsp; Hungary, &nbsp; India, &nbsp; Poland, &nbsp; Serbia, &nbsp; Ukraine, &nbsp; United Kingdom",1,0,3,NA
NCT00775411,Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-VEGF in Subjects With Wet Age-Related Macular Degeneration,Completed,No Results Available,Choroidal Neovascularization|Age-Related Maculopathy,Drug: Dexamethasone as adjunctive therapy to Ranibizumab Injection,Allergan,Both,Adult|Senior,Phase II,40,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,206207-019,10/16/2008,01/11/2008,01/04/2010,9/24/2010,01/09/2010,,01/11/2009,Mean central retinal thickness by OCT|Best corrected visual acuity|Fluorescein leakage,http://ClinicalTrials.gov/show/NCT00775411,"United States, &nbsp; Australia, &nbsp; Philippines",1,1,1,0
NCT00775450,Influenza Vaccine Revaccination in Ambulatory Elderly Subjects,Completed,No Results Available,Influenza|Orthomyxovirus Infection|Myxovirus Infection,Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B|Biological: Influenza Virus Vaccine USP Trivalent Types A and B,Sanofi-Aventis,Both,Adult|Senior,Phase II,807,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,FID21,10/16/2008,01/10/2008,01/07/2009,3/31/2010,01/03/2010,,01/06/2009,Safety: To provide information concerning the safety after revaccination with influenza vaccine|Immunogenicity: To provide information concerning the immune response of Influenza vaccine,http://ClinicalTrials.gov/show/NCT00775450,United States,0,NA,5,NA
NCT00775528,Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis|Pancreatic Exocrine Insufficiency,Drug: Pancrelipase Delayed Release,Solvay Pharmaceuticals,Both,Child,Phase III,19,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,S245.3.128,10/17/2008,01/04/2009,01/06/2009,10/25/2010,01/10/2010,,01/06/2009,Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE)|Stool Fat (% Fat)|Fat Intake (g)|Total Calorie Intake (kcal),http://ClinicalTrials.gov/show/NCT00775528,United States,1,1,1,0
NCT00776919,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Completed,No Results Available,Acne Vulgaris,Drug: clindamycin / benzoyl peroxide gel|Drug: clindamycin gel|Drug: BPO gel|Drug: vehicle gel,"Stiefel, a GSK Company|Quintiles CRO|RHO CRO",Both,Child|Adult,Phase III,1319,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",W0261-301,10/21/2008,01/10/2008,01/10/2009,08/06/2010,01/08/2010,,01/09/2009,Acne lesion counts and Investigator's Static Global Assessment (ISGA).|Local tolerability and adverse events,http://ClinicalTrials.gov/show/NCT00776919,"United States, &nbsp; Belize, &nbsp; Canada",1,1,4,0
NCT00777023,Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.,Completed,No Results Available,Hot Flashes,Drug: Gabapentin,Depomed,Female,Adult|Senior,Phase III,540,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",BREEZE 2|81-0059,10/21/2008,01/10/2008,01/10/2009,11/02/2009,01/11/2009,,01/07/2009,"Reduction of frequency and severity of hot flashes after 12 weeks of treatment with a stable dose relative to placebo, compared with the baseline week.",http://ClinicalTrials.gov/show/NCT00777023,United States,1,0,1,NA
NCT00778700,A Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis,Completed,No Results Available,Plaque Psoriasis,Drug: INCB018424 Phosphate Cream|Drug: Placebo Cream,Incyte Corporation,Both,Adult|Senior,Phase II,200,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",INCB 18424-203,10/21/2008,01/10/2008,01/04/2009,6/17/2010,01/06/2010,,01/04/2009,To evaluate the safety and tolerability of 3 different strengths of INCB018424 cream formulation compared with placebo when applied once daily to patients with plaque psoriasis.|Change in total lesion score of all psoriatic lesions|To evaluate the pharmacokinetics of 3 different dose strengths of INCB018424 cream formulation when applied once daily to patients with plaque psoriasis.,http://ClinicalTrials.gov/show/NCT00778700,United States,1,0,2,NA
NCT00779519,Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss,Completed,No Results Available,Obesity,Drug: TTP435|Drug: Placebo,TransTech Pharma,Both,Adult,Phase II,100,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",TTP435-201,10/23/2008,01/02/2009,NA,8/25/2010,01/08/2010,,01/12/2009,Safety and tolerability of TTP435 when administered for 8 weeks to obese males and females|Change from Baseline Glucose Levels|Absolute Change in Body Weight|Absolute Change in Body Mass Index|Effects on Body Weight|Effect Subject-reported Satiety|Change from Baseline Insulin Levels|Change from Baseline Free Fatty Acid Levels|Change from Baseline Leptin Levels,http://ClinicalTrials.gov/show/NCT00779519,"United States, &nbsp; Canada",1,0,2,NA
NCT00782535,Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,No Results Available,Chronic Obstructive Pulmonary Disease,Drug: CHF 4226 pMDI|Drug: CHF 4226 pMDI|Drug: Placebo,Chiesi Pharmaceuticals Inc.,Both,Adult|Senior,Phase II,20,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CCD-0810-PR-0001,10/29/2008,01/12/2008,01/03/2009,8/18/2010,01/08/2010,,01/03/2009,FEV1|serum potassium|serum glucose|plasma concentrations of CHF 4226|urinary excretion of CHF 4226|FVC,http://ClinicalTrials.gov/show/NCT00782535,United States,1,0,3,NA
NCT00783289,A Phase 2a Study to Evaluate the Safety and Tolerability of MEDI-563 in Adults With Asthma,Completed,No Results Available,Asthma,Biological: MEDI-563|Other: Placebo,MedImmune LLC,Both,Adult|Senior,Phase II,24,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",MI-CP197,10/30/2008,01/11/2008,01/12/2009,7/20/2010,01/07/2010,MEDI-563,01/11/2009,Summarizing AEs and SAEs.|To assess the PK and IM of MEDI-563,http://ClinicalTrials.gov/show/NCT00783289,United States,0,NA,2,NA
NCT00784550,A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS 250/50mcg Plus SPIRIVA HANDIHALER Versus SPIRIVA HANDIHALER Plus Placebo DISKUS in Subjects With Chronic Obstructive Pulmonary Disease (COPD). SPIRIVA and HANDIHALER Are Trade Marks of Boehringer Ingelheim,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Tiotropium Bromide|Drug: FLuticasone Propionate/Salmeterol,GlaxoSmithKline,Both,Adult|Senior,Phase IV,342,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",111114,10/31/2008,01/12/2008,01/12/2009,01/06/2011,01/01/2011,ADC111114,01/12/2009,"Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Expiratory Volume in One Second (FEV1) at Endpoint|Mean Change From Baseline in 2 Hour Post-dose FEV1 at Endpoint|Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Vital Capacity (FVC) at Endpoint|Mean Change From Baseline in 2 Hour Post-dose FVC at Endpoint|Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-Dose Inspiratory Capacity (IC) at Endpoint|Mean Change From Baseline in Scores on the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) at Endpoint",http://ClinicalTrials.gov/show/NCT00784550,United States,1,1,2,1
NCT00784719,"A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.",Completed,No Results Available,Dry Eye Syndromes,"Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: Cyclosporine|Drug: CP-690,550 Vehicle",Pfizer,Both,Adult|Senior,Phase I|Phase II,412,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",A3921034|A3921034,11/03/2008,01/11/2008,01/10/2009,01/04/2010,01/01/2010,,01/10/2009,Incidence and severity of ocular adverse events|Incidence and severity of systemic adverse events|Tear break up time|Symptom questionnaire|Corneal staining|Conjunctival staining|Schirmer wetting,http://ClinicalTrials.gov/show/NCT00784719,United States,1,0,6,NA
NCT00784823,Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma,Completed,No Results Available,Multiple Myeloma,Drug: Bortezomib|Drug: Melphalan,Hackensack University Medical Center,Both,Adult|Senior,Phase I|Phase II,24,Other,Interventional,Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,06.05.109B,10/31/2008,01/01/2007,01/12/2009,11/15/2010,01/11/2010,Mel-Vel,01/12/2009,Maximum Tolerated Dose The maximum tolerated dose of bortezomib (MTD) will be defined as the dose level prior to that resulting in two out of six patients experiencing a DLT,http://ClinicalTrials.gov/show/NCT00784823,United States,1,1,2,1
NCT00785512,A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy,Completed,Has Results,Hypertension,Drug: Nebivolol|Drug: Placebo,Forest Laboratories,Both,Adult|Senior,Phase IV,207,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NEB-MD-17,11/03/2008,01/11/2008,NA,8/19/2010,01/08/2010,,01/08/2009,Trough Sitting Diastolic Blood Pressure|Trough Sitting Systolic Blood Pressure,http://ClinicalTrials.gov/show/NCT00785512,United States,1,1,2,1
NCT00786188,Eight-Week Efficacy & Safety Study of Mesafem in the Treatment of VMS Associated With Menopause,Completed,No Results Available,Hot Flashes,Drug: Mesafem|Drug: Sugar pill,Noven Therapeutics,Female,Adult|Senior,Phase II,103,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",N30-002,11/04/2008,01/11/2008,01/06/2009,12/30/2010,01/12/2010,,01/06/2009,Mean change in frequency of moderate to severe VMS from baseline to Week 4 and Week 8|Change from baseline in climacteric symptoms at Week 8.,http://ClinicalTrials.gov/show/NCT00786188,United States,1,0,2,NA
NCT00788541,A Dose-volume Study of a Treatment for Elevated IOP Due to Open-angle Glaucoma or Ocular Hypertension,Completed,No Results Available,Open-Angle Glaucoma|Ocular Hypertension,Drug: Anecortave Acetate|Drug: Vehicle|Drug: Vehicle|Drug: Anecortave Acetate|Drug: Anecortave Acetate|Drug: Anecortave Acetate,Alcon Research,Both,Adult|Senior,Phase II,300,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Prevention",C-08-049,11/07/2008,01/11/2008,NA,9/30/2009,01/09/2009,,01/09/2009,Mean Intraocular Pressure|Percent of patients who remain rescue-medication free,http://ClinicalTrials.gov/show/NCT00788541,United States,1,0,6,NA
NCT00788593,Randomized Double-Blind Placebo Crossover Study to Evaluate Safety/Efficacy of Two Doses in CP Patients With EPI,Completed,No Results Available,Chronic Pancreatitis|Exocrine Pancreatic Insufficiency,Drug: Placebo|Drug: EUR-1008 high dose|Drug: EUR-1008 low dose,Eurand S.p.A.,Both,Adult|Senior,Phase III,78,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",PR-002,11/10/2008,01/01/2008,01/03/2009,03/12/2009,01/03/2009,,01/03/2009,The primary analysis conducted on all patients who complete both the high dose and low dose. An additional analysis will be conducted to calculate the difference between the mean CFA after administration of doses after administration.|Calculation of the differences in CFA of patients on high dose EUR-1008 vs. CFA at placebo baseline and patients on low dose EUR-1008 vs. CFA at placebo baseline. Change in the CNA from baseline. Change in weight and BMI from baseline,http://ClinicalTrials.gov/show/NCT00788593,"United States, &nbsp; Italy, &nbsp; Ukraine",1,1,3,1
NCT00789191,Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: insulin detemir|Drug: sitagliptin|Drug: metformin|Drug: sulphonylurea,Novo Nordisk,Both,Adult|Senior,Phase III,222,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NN304-3511|2008-001050-40,11/10/2008,01/11/2008,01/08/2009,01/10/2011,01/01/2011,,01/08/2009,HbA1c (Glycosylated Haemoglobin A1c)|Number of Subjects Achieving HbA1c Less Than or Equal to 7.0%|Number of Subjects Achieving HbA1c Less Than or Equal to 7.0% Without Symptomatic Hypoglycaemia|Number of Subjects Achieving HbA1c Less Than or Equal to 6.5%|Number of Subjects Achieving HbA1c Less Than or Equal to 6.5% Without Symptomatic Hypoglycaemia|Change in BMI (Body Mass Index)|Change in Body Weight|FPG (Fasting Plasma Glucose)|Hypoglycemic Episodes|Hypoglycemic Episodes: Day Time|Hypoglycemic Episodes: Night Time|Self-measured 9-point Plasma Glucose Profile,http://ClinicalTrials.gov/show/NCT00789191,"United States, &nbsp; Canada, &nbsp; Finland, &nbsp; France, &nbsp; Hungary, &nbsp; Korea, Republic of, &nbsp; Slovakia, &nbsp; Turkey",1,1,4,0
NCT00789672,Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia,Completed,No Results Available,Amblyopia,Drug: levodopa/carbidopa|Device: patching|Drug: levodopa/carbidopa,Jaeb Center for Health Research|National Eye Institute (NEI),Both,Child,Phase II|Phase III,33,Other|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NEI-141|2U10EY011751,10/27/2008,01/01/2009,01/12/2009,2/26/2010,01/01/2010,ATS14,01/09/2009,Tolerability of levodopa by adverse events reported and symptom survey|Visual acuity,http://ClinicalTrials.gov/show/NCT00789672,United States,1,1,3,0
NCT00789724,Anakinra to Prevent Post-infarction Remodeling,Completed,Has Results,ST Segment Elevation Acute Myocardial Infarction,Drug: Anakinra|Drug: Placebo,Virginia Commonwealth University,Both,Adult|Senior,Phase III,10,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VCU-ART,11/11/2008,01/11/2008,01/08/2009,09/01/2010,01/09/2010,VCU-ART,01/08/2009,"Difference Between the Anakinra Arm and Placebo Arm in Change in End-systolic Volume Indices From Baseline to Follow up Exam 10-14 Weeks Later at Cardiac Magnetic Resonance Imaging.|Difference Between the 2 Arms in Change in End-diastolic Volume Indices and Ejection Fraction Values From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging|Difference Between the 2 Arms in Change in E/E' Ratios and Myocardial Performance (Tei) Indices From Baseline to Follow up Exam at Transthoracic Echo-color-Doppler Cardiac Exam|Difference Between the 2 Arms in the Percentage of Patients With Any of the Following : a) End-systolic or End-diastolic Volume Index Increase >10%; b) Ejection Fraction Decrease >10%; c) E/E'>15 at Follow up|Difference Between the 2 Arms in Change in Oxygen Uptake Kinetics From Baseline to Follow up Exam at Submaximal Cardiopulmonary Exercise Test|Difference Between the 2 Arms in Change in the Number of Circulating Endothelial Progenitor Cells From Baseline to Follow up Exam|Difference Between the 2 Arms in Change in Serum BNP Levels, C-reactive Protein, and Hemoglobin A1c% From Baseline to Follow up|Difference Between the 2 Arms in the Incidence of Significant Cardiac Arrhythmias in the Acute Phase|Difference Between the 2 Arms in the Number of Adverse Effects Including a) All Events; b) All Events Requiring Unblinding of the Treatment; c) All Events Requiring Early Termination of the Intervention",http://ClinicalTrials.gov/show/NCT00789724,United States,1,1,2,1
NCT00789880,Analysis of the Response of Subjects With Atopic Dermatitis to Oral Vitamin D3 by Measurement of Antimicrobial Peptide Expression in Skin and Saliva,Completed,No Results Available,Atopic Dermatitis,Drug: Vitamin D3|Drug: Placebo,"National Institute of Allergy and Infectious Diseases (NIAID)|Food and Drug Administration (FDA)|National Jewish Health|University of California, San Diego|Oregon Health and Science University",Both,Adult|Senior,Phase II,60,NIH|U.S. Fed|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DAIT ADVN CATH 03|Contract No. HHSN266200400029C,11/11/2008,01/12/2008,01/12/2009,2/23/2010,01/02/2010,,01/12/2009,"Difference in change in expression of AMP (hCAP18/LL-37, HBD3) from baseline to study day 21 in AD lesional skin biopsies compared to change in expression of AMP from baseline to study day 21 in AD non-lesional skin biopsies.|Expression of antimicrobial peptides (hCAP18/LL-37, HBD3) at baseline and study day 21 in AD subjects' lesional and non-lesional skin biopsies.|Expression of antimicrobial peptides (hCAP18/LL-37, HBD3) at baseline and study day 21 in non-AD subjects' skin biopsies.|Change in expression of systemic antimicrobial peptides (hCAP18/LL-37, HBD3) from baseline to study day 21 in AD and non-AD subjects' saliva.|Change in expression of TH2 cytokines IL-13 and IL-4 from baseline and study day 21 in AD subjects' lesional and non-lesional skin biopsies.|Change in expression of TH2 cytokines IL-13 and IL-4 from baseline and study day 21 in non-AD subjects' skin biopsies.|Change in expression of serum total IgE and RAST from baseline and study day 21 in AD and non-AD serum.|Change in EASI score from baseline and study day 21 in AD subjects.|The proportion of subjects in each arm who experience any Grade 3 or higher adverse events over the duration of follow-up in this trial.",http://ClinicalTrials.gov/show/NCT00789880,United States,1,1,2,0
NCT00790023,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis,Completed,No Results Available,Seasonal Allergic Rhinitis,Drug: 80 mcg Ciclesonide|Drug: 160 mcg Ciclesonide|Drug: Placebo,Sunovion,Both,Child|Adult|Senior,Phase III,660,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",060-622,11/11/2008,01/11/2008,01/02/2009,08/07/2009,01/08/2009,,01/02/2009,"Change from baseline in subject-reported AM and PM reflective TNSS averaged over the two-week treatment period|Change from baseline in subject-reported AM and PM instantaneous TNSS averaged over the two-week treatment period.|Change from baseline in subject-reported AM and PM reflective TOSS averaged over the two-week treatment period in subjects.|Change from baseline in subject-reported AM reflective TNSS, PM reflective TNSS, AM and PM reflective TNSS at each day, averaged over each week, and averaged over the two-week treatment period.|Change from baseline in subject-reported AM instantaneous TNSS, PM instantaneous TNSS, AM and PM instantaneous TNSS at each day, averaged over each week, and averaged over the two-week treatment period.|Change from baseline in subject-reported AM reflective TOSS, PM reflective TOSS, AM and PM reflective TOSS at each day, averaged over each week, and averaged over the two-week treatment period in subjects.|Change from baseline in subject-reported AM instantaneous TOSS, PM instantaneous TOSS, AM and PM instantaneous TOSS at each day, averaged over each week, and averaged over the two-week treatment period in subjects.|Change from baseline in subject-reported individual AM reflective NSS, individual PM reflective NSS, individual AM and PM reflective NSS at each day, averaged over each week, and averaged over the two-week treatment period.|Change from baseline in subject-reported individual AM reflective OSS, individual PM reflective OSS, individual AM and PM reflective OSS at each day, averaged over each week, and averaged over the two-week treatment period in subjects.|Change from baseline in subject-reported individual AM instantaneous OSS, individual PM instantaneous OSS, individual AM and PM instantaneous OSS at each day, averaged over each week, and averaged over the two-week treatment period in subjects.|Change from baseline in Rhinoconjunctivitis Quality of Life Questionnaire with Standardised Activities (RQLQ(S)) total and individual items at each day, averaged over each week, and averaged over the two-week treatment period in impaired patients.|Time to Onset of nasal improvement, defined as the first assessment at which instantaneous TNSS for active treatment demonstrates an improvement over placebo from baseline with one-sided p-value of ???0.025.|Time to Onset of ocular improvement, defined: first assessment where instantaneous TOSS for active treatment demonstrates an improvement over placebo from baseline in subjects with baseline TOSS ??­5.0|Time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between Ciclesonide HFA and placebo is at least 90% of the largest estimated difference.",http://ClinicalTrials.gov/show/NCT00790023,United States,1,1,3,0
NCT00790660,A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: ASP1941|Drug: Placebo,Astellas Pharma Inc,Both,Adult|Senior,Phase II,61,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",1941-CL-0016,11/11/2008,01/10/2008,01/02/2009,2/26/2010,01/02/2010,,01/02/2009,Evaluation of safety through clinical safety labs and adverse events|Evaluation of routine PK and PD parameters,http://ClinicalTrials.gov/show/NCT00790660,United States,1,0,2,NA
NCT00790751,Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED,Completed,No Results Available,Erectile Dysfunction,Drug: placebo|Drug: avanafil,"VIVUS, Inc.|Quintiles",Male,Adult|Senior,Phase III,646,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",TA-301,11/10/2008,01/11/2008,01/08/2009,11/09/2010,01/11/2010,REVIVE-G,01/08/2009,"The change in percent of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourse.|The change in percent of sexual attempts in which subjects are able to insert the penis into the partner's vagina.|The change in score on the erectile function (EF) domain of the IIEF questionnaire.|The change in response to individual questions and for other domains (orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction) from the IIEF|Responses to secondary subject diary questions|The response to the Global Assessment Question on treatment effect and the Future Use Question.",http://ClinicalTrials.gov/show/NCT00790751,United States,1,0,2,NA
NCT00791258,A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure,Completed,Has Results,Hypertension,Drug: amlodipine and olmesartan medoxomil tablets|Drug: hydrochlorothiazide tablets,Daiichi Sankyo Inc.|Integrium,Both,Adult|Senior,Phase IV,999,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CS8663-404,11/13/2008,01/11/2008,01/09/2009,9/30/2010,01/09/2010,BP CRUSH,01/08/2009,"The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks|The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks|The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks|Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks|Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks|Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks|Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks|Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks|Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks|Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks|Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values|Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values|Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks|Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks|Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks|Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks|Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks|Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks|Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks|Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks",http://ClinicalTrials.gov/show/NCT00791258,United States,1,1,2,0
NCT00792636,"A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period",Completed,Has Results,"Migraine With or Without Aura|Migraine Disorders|Migraine, Acute|Migraine Headaches",Drug: sumatriptan and naproxen sodium combination tablet|Drug: sumatriptan tablet|Drug: naproxen sodium tablet,GlaxoSmithKline,Both,Adult,Phase IV,407,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",110948,11/17/2008,01/11/2008,01/11/2009,11/11/2010,01/11/2010,,01/11/2009,"Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen|Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan and Naproxen|Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Sumatriptan|Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Naproxen|Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <4 Migraines Per Month, 4-6 Migraines Per Month, >=4 Migraines Per Month, and >6 Migrain|Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <1.3 Times Per Migraine, 1.3-1.7 Times Per Migraine, and >1.7 Times Per Migraine|Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, With <6, 6-10, >=6, 10-14, and >14 Doses Per Month|Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating With <30 Total Doses, 30-60 Total Doses, >=30, 60-90 Total Doses, and >90 Total Doses|Number of Participants With an Increase of >=5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements|Number of Participants With an Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements|Number of Participants With a Consecutive 2-day Average Systolic Blood Pressure of >=140 mmHg During the Study|Number of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of >=90 mmHg|Time to the First Day With an Average Systolic Blood Pressure Increase of >=5 mmHg From the Baseline Systolic Blood Pressure|Time to the First Day With an Average Diastolic Blood Pressure Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure|Number of Participants Withdrawn From the Study Due to Blood Pressure Changes",http://ClinicalTrials.gov/show/NCT00792636,United States,1,1,3,0
NCT00793819,A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia,Completed,No Results Available,Nocturia|Prostatic Hyperplasia,Drug: silodosin,Watson Pharmaceuticals,Male,Adult|Senior,Phase II,215,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",SI08005,11/17/2008,01/01/2009,01/10/2009,10/26/2009,01/10/2009,,01/10/2009,Change in nocturia episodes|Change in quality of life questionnaire responses,http://ClinicalTrials.gov/show/NCT00793819,United States,1,1,1,1
NCT00794976,Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral Epicondylitis,Completed,No Results Available,Lateral Epicondylitis|(Tennis Elbow),Drug: Dexamethasone Iontophoretic Patch (low dose)|Drug: Dexamethasone Iontophoretic Patch (high dose)|Drug: Dexamethasone Passive Patch|Drug: Placebo Patch,Travanti Pharma Inc.|ResearchPoint,Both,Adult|Senior,Phase II,200,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",1779,11/20/2008,01/10/2008,01/05/2009,5/19/2009,01/05/2009,,01/05/2009,Pain severity assessed by VAS (Visual Analog Scale)|Safety,http://ClinicalTrials.gov/show/NCT00794976,United States,1,0,4,NA
NCT00795769,Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant,Completed,No Results Available,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With T(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With T(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|De Novo Myelodysplastic Syndromes|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Poor Prognosis Metastatic Gestational Trophoblastic Tumor|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Neuroblastoma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage II Ovarian Epithelial Cancer|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Ovarian Epithelial Cancer|Stage III Small Lymphocytic Lymphoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Breast Cancer|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Ovarian Epithelial Cancer|Stage IV Small Lymphocytic Lymphoma",Drug: ondansetron|Other: survey administration|Procedure: management of therapy complications,Fred Hutchinson Cancer Research Center,Both,Adult|Senior,Phase II,50,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care,2247.00|NCI-2010-00325,11/20/2008,01/08/2008,NA,8/26/2010,01/08/2010,,01/09/2009,Reduction in rates of nausea or vomiting after ondansetron (compared to historical rates),http://ClinicalTrials.gov/show/NCT00795769,United States,1,1,3,1
NCT00795951,Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents,Completed,No Results Available,"Dermatitis, Contact",Biological: T.R.U.E. Test|Biological: TRUE TEST Diagnostic Patch Test,Allerderm,Both,Child|Adult,Phase IV,102,Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,MEKOS 07 29P1/2/3/401,11/20/2008,01/11/2008,01/11/2009,5/13/2010,01/05/2010,,01/10/2009,"Frequency and characterization of positive reactions per allergen.|Prevalence of late or persistent reactions, irritation, adhesion, subject-reported itching or burning, and adverse events",http://ClinicalTrials.gov/show/NCT00795951,United States,0,NA,2,NA
NCT00796289,Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females,Completed,No Results Available,Infertility,Drug: GnRH iontophoretic transdermal Lutrepatch|Drug: GnRH iontophoretic transdermal Lutrepatch|Drug: GnRH iontophoretic transdermal Lutrepatch|Drug: clomiphene citrate|Drug: placebo clomiphene citrate|Drug: placebo GnRH patch,Ferring Pharmaceuticals,Female,Adult,Phase II,350,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2008-03,11/20/2008,01/02/2009,01/01/2010,12/16/2010,01/12/2010,,01/12/2009,Ovulation rate|Pregnancy rate|Incidence of Ovarian Hyperstimulation Syndrome (OHSS)|Incidence of skin irritation,http://ClinicalTrials.gov/show/NCT00796289,United States,1,0,6,NA
NCT00796614,Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder,Completed,No Results Available,"Bladder, Neurogenic",Drug: tamsulosin hydrochloride|Drug: Placebo,Astellas Pharma Inc|Boehringer Ingelheim Pharmaceuticals,Both,Child,Phase II|Phase III,231,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",527.51,11/20/2008,01/09/2007,01/02/2009,5/26/2009,01/05/2009,,01/02/2009,"Response to treatment defined as patients who decrease their detrusor leak point pressure to a pre-set value|Change from baseline in detrusor leak point pressure|Improvement or stabilization of hydronephrosis and hydroureter|Assessment of physical examination, vital signs, orthostatic testing, ECG, laboratory values",http://ClinicalTrials.gov/show/NCT00796614,"United States, &nbsp; Belgium, &nbsp; Brazil, &nbsp; Germany, &nbsp; India, &nbsp; Italy, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Philippines, &nbsp; Russian Federation, &nbsp; South Africa, &nbsp; Spain, &nbsp; Ukraine",1,1,2,0
NCT00797108,A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization,Completed,No Results Available,"Pneumonia, Bacterial",Drug: sulopenem and PF-03709270|Drug: Sulopenem and PF-03709270|Drug: Ceftriaxone and amoxicillin/clavulanate,Pfizer,Both,Adult|Senior,Phase II,35,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A8811020,11/24/2008,01/01/2009,01/06/2009,9/21/2009,01/09/2009,,01/06/2009,"clinical response at the test of cure visit|clinical response at end of treatment and follow-up visit;|microbiological response at test of cure visit|change in Community acquired pneumonia symptom questionnaire.|Safety and tolerability will be measured by adverse event (AE) reporting including mortality, vital signs, physical examinations and safety laboratory results|Population pharmacokinetics|healthcare resource utilization",http://ClinicalTrials.gov/show/NCT00797108,"United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Korea, Republic of, &nbsp; Poland",1,0,3,NA
NCT00797316,Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension,Completed,Has Results,Hypertension,Drug: Aliskiren plus Hydrochlorothiazide|Drug: Aliskiren,Novartis,Both,Adult|Senior,Phase IV,532,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CSPP100A2410,11/24/2008,01/11/2008,01/12/2009,12/14/2010,01/12/2010,AIMS,01/12/2009,Change From Baseline in msSBP (Mean Sitting Systolic Blood Pressure) at Week 8|Reduction of msDBP at Week 8|Percent With BP Response at Week 8|Percent of Patients Achieving BP Control at Week 8|Change in Pulse Pressure at Week 8,http://ClinicalTrials.gov/show/NCT00797316,United States,1,1,2,0
NCT00797797,Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia,Completed,No Results Available,Fibromyalgia,Drug: pregabalin|Drug: milnacipran,Forest Laboratories,Both,Adult|Senior,Phase III,364,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MLN-MD-15,11/24/2008,01/11/2008,01/01/2010,4/29/2010,01/04/2010,,01/11/2009,PGIC responder rate at end of study|Change from baseline in VAS 1-week pain recall at end of study,http://ClinicalTrials.gov/show/NCT00797797,United States,1,1,2,1
NCT00797953,Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina,Completed,No Results Available,Angina Pectoris,Drug: T89,"Tasly Pharmaceuticals, Inc.",Both,Adult|Senior,Phase II,108,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",T89-005-0003-US,11/24/2008,01/02/2007,01/01/2010,1/13/2010,01/01/2010,T89 phase 2,01/12/2009,Total Exercise Duration (TED) change from screen baseline value in Exercise Tolerance Test (ETT) on Standard Bruce Protocol at trough drug levels at the end of the 4th and 8th week of treatment compared to placebo.|Frequency of weekly angina episodes,http://ClinicalTrials.gov/show/NCT00797953,United States,1,0,1,NA
NCT00798369,Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients,Completed,No Results Available,Acute Gout,Drug: ACZ885|Drug: ACZ885|Drug: ACZ885|Drug: ACZ885|Drug: ACZ885|Drug: Triamcinolone acetonide,Novartis,Both,Adult|Senior,Phase II,200,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CACZ885H2255|EudraCT 2008-004666-61,11/25/2008,01/11/2008,NA,9/23/2009,01/09/2009,,01/08/2009,The dose of ACZ885 for treatment of acute flares in gout patients that leads to the same efficacy as triamcinolone acetonide with respect to pain intensity on a 0-100 mm VAS|The change in pain intensity in the target joint following ACZ885 administration compared to triamcinolone acetonide on Visual Analog Scale and via a 5-point Likert scale|The efficacy of ACZ885 as compare to triamcinolone acetonide with regards to the patient`s global assessment of response to treatment|The efficacy of ACZ885 as compare to triamcinolone acetonide with regards to the time to 50% reduction of baseline pain intensity in the target joint|The efficacy of ACZ885 as compare to triamcinolone acetonide with regards to the high sensitivity C-reactive protein and serum amyloid protein levels|The efficacy of ACZ885 as compare to triamcinolone acetonide with regards to the amount of rescue medication taken,http://ClinicalTrials.gov/show/NCT00798369,"United States, &nbsp; Argentina, &nbsp; Belgium, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Switzerland, &nbsp; Turkey, &nbsp; United Kingdom",1,1,6,1
NCT00798577,Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment,Completed,Has Results,Bacterial Conjunctivitis,Drug: Vigamox Ophthalmic Solution|Drug: BSS placebo,Alcon Research|Topical Solutions Ltd.,Both,Child|Adult|Senior,Phase IV,24,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",SMA-08-03,11/25/2008,01/10/2008,01/02/2009,3/30/2010,01/03/2010,,01/02/2009,"Exploratory Outcomes From Digital Photography|Exploratory Evaluation of Changes in Ocular Signs and Symptoms|Microbiological Culture Evaluation/Eradication Percent - Enterobacter Faecalis and Candida Albicans|Microbiological Culture Evaluation/Eradication Percent - Eradication of All Other Isolates and Corynform-like|Microbiological Culture Evaluation/Eradication Percent - Staphylococcus Aureus, Steptococcus Pneumoniae, and Enterobacter Cloacae",http://ClinicalTrials.gov/show/NCT00798577,United States,1,1,2,1
NCT00798759,Examination of Ocular Surface Effects With Administration of Travatan Z and Xalatan,Completed,No Results Available,Open-Angle Glaucoma|Ocular Hypertension,Drug: Xalatan|Drug: Travatan Z,Alcon Research,Both,Adult|Senior,Phase IV,216,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",C-08-050,11/24/2008,01/12/2008,NA,10/28/2009,01/10/2009,,01/05/2009,Mean change from baseline (Day 0) in Tear Film Break-Up Time (TFBUT)|Mean change from baseline (Day 0) in corneal fluorescein staining score,http://ClinicalTrials.gov/show/NCT00798759,United States,1,1,2,1
NCT00799227,Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema,Completed,No Results Available,Diabetic Macular Edema|Vitrectomy,Drug: Dexamethasone,Allergan,Both,Adult|Senior,Phase II,40,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,206207-018,11/26/2008,01/01/2009,01/12/2009,9/24/2010,01/09/2010,,01/12/2009,Change from baseline in mean central retinal thickness by optical coherence tomography (OCT)|Proportion of patients with at least 10 letters of improvement from baseline in best corrected visual acuity (BCVA)|Change from baseline in fluorescein leakage assessed by fluorescein angiography (FA)|Change from baseline in the scales of the NEI-VFQ-25,http://ClinicalTrials.gov/show/NCT00799227,"United States, &nbsp; Australia",1,1,1,0
NCT00799552,Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye,Completed,No Results Available,Dry Eye Syndrome,Drug: RX-10045|Drug: Placebo,"Resolvyx Pharmaceuticals, Inc",Both,Adult|Senior,Phase II,232,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",08-004-03,11/26/2008,01/11/2008,01/06/2009,9/20/2010,01/09/2010,,01/05/2009,Corneal fluorescein staining and integrated subject diary data|Changes in dry eye signs and symptoms,http://ClinicalTrials.gov/show/NCT00799552,United States,1,0,2,NA
NCT00799604,Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery,Completed,No Results Available,Hypertension,Drug: Clevidipine butyrate injectable emulsion,The Medicines Company,Both,Adult|Senior,Phase II,40,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TMC-CLV-08-02,11/26/2008,01/11/2008,NA,10/27/2009,01/10/2009,SPRINT,01/10/2009,"The mean maximum absolute and percent change in systolic blood pressure from baseline within 15 minutes from the first bolus dose of clevidipine (pre-anesthesia).|The percentage of patients with systolic blood pressure ???85 mm Hg within 15 minutes from the first bolus dose of clevidipine (pre-anesthesia).|The median time to 5%, 10%, and 15% systolic blood pressure reduction from baseline within 15 minutes from the first bolus dose of clevidipine (pre-anesthesia).|The mean percent change in systolic blood pressure from baseline over time during the first 15 minutes following first bolus dose of clevidipine (pre-anesthesia).|The median time to 50% and, when available, 90% recovery from maximum systolic blood pressure effect following the first bolus dose of clevidipine (pre-anesthesia).|The area under the concentration versus time curve, maximum concentration, elimination half-life, clearance, volume of distribution, and elimination rate constant will be determined, if feasible, for each individual patient.|The following pharmacodynamic parameters will be determined, if feasible, for each individual patient following the first bolus dose of clevidipine: area under the effect-time curve, maximum effect, and time to maximum observed effect.|The relationship between change in systolic blood pressure from baseline and the blood concentration of clevidipine following the first bolus dose.|Incidence of adverse events and serious adverse events.|Change in heart rate.",http://ClinicalTrials.gov/show/NCT00799604,United States,1,1,1,1
NCT00800605,"Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection",Completed,No Results Available,Influenza,"Biological: Vero cell-derived, trivalent, seasonal influenza vaccine|Biological: Placebo: Phosphate-buffered saline",Baxter Healthcare Corporation,Both,Adult,Phase III,7252,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",720802,12/01/2008,01/12/2008,01/06/2009,10/28/2009,01/10/2009,,01/05/2009,To demonstrate the efficacy of an investigational Vero cell-derived influenza vaccine to prevent infection with an influenza virus that is antigenically similar to one of the three strains in the vaccine|Rate of subjects with seroconversion at Day 21 after vaccination,http://ClinicalTrials.gov/show/NCT00800605,United States,0,NA,2,NA
NCT00801684,A Study of TrIP Administered to Subjects With COPD,Completed,No Results Available,Chronic Obstructive Pulmonary Disease (COPD),Drug: Placebo|Drug: TrIP-B|Drug: TrIP-C|Drug: TrIP-D|Drug: TrIP-E,Alkermes,Both,Adult|Senior,Phase II,24,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALK27-001,12/02/2008,01/02/2009,01/07/2009,08/05/2009,01/08/2009,,01/04/2009,"Spirometry parameters, including peak FEV1, FEV1/FVC ratio, time to onset of response, and rescue medication use|Blood pressure and heart rate measurements|Maximum plasma concentration of TrIP|Area under the plasma concentration curve (AUC)",http://ClinicalTrials.gov/show/NCT00801684,United States,1,0,5,NA
NCT00802100,Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia,Completed,No Results Available,Schizophrenia,Drug: Olanzapine|Drug: Perphenazine|Drug: Aripiprazole|Behavioral: Behavioral Treatment|Drug: Metformin|Drug: Simvastatin|Drug: Benztropine,National Institute of Mental Health (NIMH),Both,Adult,Phase IV,60,NIH,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,N01 MH090001-02|N01MH90001|DSIR AT,12/03/2008,01/12/2008,01/10/2009,11/13/2009,01/11/2009,,01/09/2009,"Identification of appropriate clinical sites to mount the proposed clinical trial|Feasibility of randomizing a cohort of participants meeting the inclusion and exclusion criteria of the study|Feasibility of protocol implementation with a high level of protocol adherence and low participant attrition. The goal is for fewer than 25% of enrolled participants to be poorly adherent to the protocol interventions.|Antipsychotic efficacy, defined as completion of the trial without psychiatric hospitalization, clinician decision to discontinue treatment, or patient decision to discontinue treatment",http://ClinicalTrials.gov/show/NCT00802100,United States,1,1,7,0
NCT00802360,MENOPUR?ó Versus FOLLISTIM?ó,Completed,No Results Available,Infertility,Drug: Menopur?ó|Drug: Endometrin?ó|Drug: Follistim Pen?ó|Drug: Progesterone in oil,Ferring Pharmaceuticals,Female,Adult,Phase IV,173,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2008-04,12/03/2008,01/12/2008,01/01/2010,05/05/2010,01/05/2010,,01/11/2009,"Ongoing Pregnancy Rate|Number of Follicles|Number of oocytes retrieved|Fertilization rate|Embryo quality|Number of embryos frozen|Cycle cancellation rate|Implantation rate|Biochemical pregnancy rate|Clinical pregnancy rate|Adverse events, including ovarian hyperstimulation syndrome (OHSS)|Live birth rate",http://ClinicalTrials.gov/show/NCT00802360,United States,1,1,4,1
NCT00803556,"Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy",Completed,No Results Available,Solid Tumor|Breast Cancer,Drug: Alvespimycin|Drug: Trastuzumab|Drug: Paclitaxel,Bristol-Myers Squibb,Both,Adult|Senior,Phase I|Phase II,50,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CA201-001|KDG 132,12/04/2008,01/01/2006,01/08/2009,11/04/2009,01/11/2009,,01/08/2009,"No formal analysis of efficacy will occur. For patients with measurable disease, response will be assessed by RECIST criteria first after two cycles of therapy (8 weeks in patients having no delay in the schedule of administration)|Subsequent response evaluations will occur following every two cycles of treatment (8 weeks). All patients with responding tumors (CR or PR) must have the response confirmed 4 weeks after the first documentation of response, confirmed by CT|To evaluate the safety and cumulative toxicity of repeated dosing of KOS-1022 when administered in combination with trastuzumab or trastuzumab/paclitaxel|2. To determine the pharmacokinetics of KOS-1022 when delivered via weekly infusion when administered in combination with trastuzumab or trastuzumab/paclitaxel|To determine the effect of KOS-1022 on the expression of Hsp90-client proteins in peripheral blood lymphocytes|To describe any evidence of anti-tumor activity",http://ClinicalTrials.gov/show/NCT00803556,United States,1,0,3,NA
NCT00803686,"A Crossover Study of Oral Calcitonin Given at Night to Normal, Healthy, Postmenopausal Women",Completed,No Results Available,"Osteoporosis, Postmenopausal",Drug: Recombinant Salmon Calcitonin,Unigene Laboratories Inc.,Female,Adult|Senior,Phase II,12,Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,UGL-OR0803|Bio-Kinetic No.: 13808,12/04/2008,01/12/2008,01/01/2009,2/17/2009,01/02/2009,,01/01/2009,CTx-1,http://ClinicalTrials.gov/show/NCT00803686,United States,1,1,1,1
NCT00805025,Evaluation of the Quality of Life Questionnaire-Bronchiectasis in Patients With Bronchiectasis,Completed,No Results Available,Bronchiectasis,Drug: aztreonam for inhalation solution,Gilead Sciences,Both,Adult|Senior,Phase II,92,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GS-US-219-0102,12/05/2008,01/12/2008,01/12/2009,2/24/2010,01/02/2010,,01/10/2009,The primary objective is to determine the reliability and validity of the QOL-B.|The secondary objective is to evaluate the responsiveness of the QOL-B to perceived changes in respiratory symptoms.,http://ClinicalTrials.gov/show/NCT00805025,United States,1,0,1,NA
NCT00805350,Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties,Completed,No Results Available,Primary Insomnia,Drug: Eplivanserin (SR46349)|Drug: Placebo,Sanofi-Aventis,Both,Adult|Senior,Phase III,637,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC10844|EudraCT 2008-003791-22,12/04/2008,01/12/2008,01/06/2009,11/29/2010,01/11/2010,ECLIPSE,01/06/2009,"Change from baseline of mean PSG-WASO on N41/N42|Change from baseline of mean PSG-NAW on N41/N42|Other PSG sleep parameters: PSG-TST, PSG-SE (TST/Time in Bed), PSG-LPS; sleep architecture: percentage of time spent in each sleep stage (1, 2, 3-4/SWS, REM), shift to stage 1, shift to wake, stage 1 + WASO, [stages 3&4]/[stage 1 + WASO]).|Patient-reported sleep parameters measured on patient sleep questionnaire: pr-WASO, pr-NAW, pr-TST, QoS, RQoS.|Residual effects measured by psychometric tests DSST & RAVLT in the morning and evening following nights in sleep lab, and reported by patients on sleep questionnaires (morning sleepiness, ability to concentrate in the morning).",http://ClinicalTrials.gov/show/NCT00805350,"United States, &nbsp; Austria, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Hungary, &nbsp; Poland",1,0,2,NA
NCT00805441,A Study in the Treatment of Alcohol Dependence.,Completed,No Results Available,Alcohol Dependence,Drug: LY686017|Drug: Placebo,Eli Lilly and Company,Both,Adult,Phase II,190,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12422|H8R-MC-HJAQ,12/05/2008,01/12/2008,01/07/2009,5/27/2010,01/05/2010,,01/07/2009,Percent reduction in heavy drinking days.|Percent days abstinent per month.|Number of drinks per drinking day during a month.|Drinker inventory of Consequences (DrInC)|Alcohol Urge questionnaire - change from baseline.|Penn Alcohol Craving Scale - change from baseline.|Beck Depression Inventory II (BDI-II) - change from baseline.|Beck Anxiety Index - change from baseline.|Gamma-glutamyl transferase -change from baseline.|Plasma carbohydrate deficient transferring (CDT) - change from baseline.|Health outcomes (Short Form 12),http://ClinicalTrials.gov/show/NCT00805441,United States,1,0,2,NA
NCT00806260,A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.,Completed,No Results Available,Overweight|Obesity,Drug: VI-0521|Drug: Placebo|Other: Alcohol or fruit juice,"VIVUS, Inc.|MDS Pharma Services",Both,Adult,Phase II,80,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",OB-205,12/09/2008,01/12/2008,01/05/2009,11/20/2009,01/11/2009,,01/05/2009,"Measure of psychomotor function using speed and coordination on the CogScreen Pathfinder Number Test, assessed by reaction time for correct responses and coordination error, in subjects treated with VI-0521 compared to placebo.|Additional measures of psychomotor function supporting the primary endpoint including: Reaction time, attention, and information processing speed",http://ClinicalTrials.gov/show/NCT00806260,United States,1,0,3,NA
NCT00807001,"Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Na??ve Subjects",Completed,Has Results,Chronic Hepatitis C,Drug: IDX184,Idenix Pharmaceuticals,Both,Adult,Phase I|Phase II,41,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",IDX-08C-003,12/10/2008,01/12/2008,01/12/2009,10/08/2010,01/10/2010,,01/06/2009,Safety and Tolerability|Antiviral Activity. Change in Plasma HCV RNA,http://ClinicalTrials.gov/show/NCT00807001,"United States, &nbsp; Argentina, &nbsp; Austria, &nbsp; France, &nbsp; Poland",1,0,1,NA
NCT00807885,Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase,Completed,No Results Available,Dehydration,Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase|Drug: Lactated Ringer's solution and recombinant human hyaluronidase,Baxter Healthcare Corporation|Halozyme Therapeutics,Both,Adult,Phase IV,100,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,1838-007,12/10/2008,01/12/2008,01/01/2009,4/28/2010,01/04/2010,INFUSE-AT,01/01/2009,"Technical challenges (tube kinks, catheter dislodgement, catheter pull-out, infusion pump beeping, other pump failure, intervention to maintain infusion, other technical challenges) during infusion|Multiple ease-of-use measures|Safety and tolerability (catheter placement-associated pain, infusion site reactions, other adverse events)",http://ClinicalTrials.gov/show/NCT00807885,United States,1,1,9,1
NCT00807937,Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325,Completed,Has Results,Anxiety Disorders,Drug: AZD7325|Drug: AZD7325|Drug: Lorazepam|Drug: Placebo,AstraZeneca,Both,Adult,Phase II,369,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D1140C00014,12/12/2008,01/12/2008,01/05/2009,9/16/2010,01/09/2010,,01/05/2009,Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Change in Hospital Anxiety and Depression Scale for Anxiety (HADS-A) Total Score|Change in Psychic Anxiety Factor as Measured by HAM-A Psychic Cluster Score|Change in Somatic Symptoms as Measured by HAM-A Somatic Cluster Score|Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Percent Maximum Total Score,http://ClinicalTrials.gov/show/NCT00807937,United States,1,0,4,NA
NCT00808249,AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD),Completed,No Results Available,Anxiety Disorders,Drug: AZD7325|Drug: AZD7325|Drug: AZD7325|Drug: Placebo,AstraZeneca,Both,Adult,Phase II,725,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D1140C00006,12/12/2008,01/12/2008,01/05/2009,09/09/2009,01/09/2009,,01/05/2009,"To give evidence of an effect of AZD7325 versus placebo by change in the HAM-A total score from randomization to day 28.|To evaluate the efficacy of AZD7325 versus placebo by change in the HADS-A, HAM-A psychic cluster and HAM-A somatic cluster score from randomization to each assessment time point.|To assess the safety of the treatment with AZD7325 by incidence of AEs, vital signs, changes in laboratory evaluations etc.|To evaluate the effect of AZD7325 versus placebo on the health-related quality of life by assessment of change in SDS.",http://ClinicalTrials.gov/show/NCT00808249,United States,1,0,4,NA
NCT00809848,Safety and Efficacy of AGN 210699 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma,Completed,No Results Available,Ocular Hypertension|Glaucoma,Drug: AGN 210669 non-preserved ophthalmic solution|Drug: AGN 210669 non-preserved ophthalmic solution|Drug: AGN 210669 non-preserved ophthalmic solution|Drug: AGN 210669 vehicle ophthalmic solution|Drug: bimatoprost ophthalmic solution,Allergan,Both,Adult|Senior,Phase I|Phase II,150,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",210669-003,12/16/2008,01/02/2009,01/10/2009,09/08/2010,01/09/2010,,01/10/2009,IOP change from Baseline|Mean intraocular pressure,http://ClinicalTrials.gov/show/NCT00809848,United States,1,0,5,NA
NCT00809926,8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension,Completed,No Results Available,Stage 2 Hypertension,Drug: Valsartan/aliskiren|Drug: Valsartan,Novartis,Both,Adult|Senior,Phase IV,449,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment",CSPV100AUS01,12/16/2008,01/01/2009,NA,10/15/2009,01/10/2009,VANTAGE,01/07/2009,"Change in mean sitting systolic blood pressure (MSSBP)|Change in mean sitting diastolic blood pressure (MSDBP)|Percentage of patients achieving blood pressure control (defined as patients achieving a MSSBP <140 mmHg and MSDBP <90 mmHg)|Percentage of responders (defined as patients with MSSBP <140 mmHg or a decrease from baseline ??­20 mmHg)|Change from baseline in plasma renin activity (PRA) and plasma renin concentration (PRC)|Safety and tolerability of the valsartan and aliskiren combination (160/150 mg, 320/300 mg) compared to valsartan monotherapy (160 mg, 320 mg)",http://ClinicalTrials.gov/show/NCT00809926,United States,1,1,2,0
NCT00810108,Lopinavir/Ritonavir (Kaletra)PK,Completed,No Results Available,HIV/AIDS Treatment|HIV Infections,Drug: lopinavir/ritonavir (Kaletra?ó) tablets|Drug: lopinavir/ritonavir (Kaletra?ó) tablets,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|American Association of Colleges of Pharmacy,Female,Child,Phase IV,12,NIH|Other,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,10894,12/15/2008,01/06/2006,01/05/2009,01/09/2011,01/10/2010,,01/05/2009,Plasma Sampling (3 mL of blood)|Physical Exam|Clinical Assessment,http://ClinicalTrials.gov/show/NCT00810108,United States,1,1,2,1
NCT00810485,ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD),Completed,No Results Available,Gastroesophageal Reflux,Drug: ADX10059|Drug: ADX10059|Drug: ADX10059|Drug: ADX10059 Matching Placebo,Addex Pharma S.A.,Both,Adult|Senior,Phase II,320,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",ADX10059-205|2008-005105-18,12/17/2008,01/12/2008,NA,12/23/2009,01/12/2009,,01/12/2009,Number of GERD symptom free days in week 4 of study medication treatment|GERD symptoms|Sleep disturbance|Use of antacid medications|Global assessment of GERD|Safety and tolerability assessments,http://ClinicalTrials.gov/show/NCT00810485,"United States, &nbsp; France, &nbsp; Germany, &nbsp; Netherlands, &nbsp; Switzerland",1,0,4,NA
NCT00810979,Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia,Completed,No Results Available,Hyperlipidemia,Drug: SLx-4090|Drug: SLx-4090|Other: Placebo,Surface Logix,Both,Adult,Phase II,133,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",SLx-4090-08-06,12/17/2008,01/01/2009,01/09/2009,12/14/2009,01/03/2009,,01/09/2009,Reduction in LDL-C|Adverse events,http://ClinicalTrials.gov/show/NCT00810979,United States,1,0,3,NA
NCT00811499,Treatment With ARRY-371797 in Patients With Active Ankylosing Spondylitis,Completed,No Results Available,Ankylosing Spondylitis,Drug: ARRY-371797|Drug: Placebo,Array BioPharma,Both,Adult|Senior,Phase II,25,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ARRAY-797-201,12/17/2008,01/12/2008,01/09/2009,12/08/2009,01/12/2009,,01/09/2009,"Efficacy of ARRY-371797 as measured by ASAS 20 (Assessments in Ankylosing Spondylitis 20% Working Group response criterion)|Safety of ARRY-371797 as measured by adverse events, findings on physical examinations, laboratory abnormalities, change from baseline in vital sign measurements, and change from baseline in 12-lead ECG parameters|Efficacy as measured by ASAS 20, ASAS 40, ASAS 5/6, BASDAI, BASFI, BASMI, EASMI, SPARCC Enthesitis Index, Nocturnal Back Pain, Total Back Pain, Patient's Global Assessment of Disease Activity, SF-36 Health Questionnaire V2 Acute, and CRP|Pharmacokinetics as measured by plasma concentrations of ARRY-371797 and a metabolite|Pharmacodynamics as measured by circulating levels of exploratory biomarkers of disease activity, and sacroiliac (SI) and spinal SPARCC MRI scores",http://ClinicalTrials.gov/show/NCT00811499,"United States, &nbsp; Canada",1,0,2,NA
NCT00811603,Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery,Completed,No Results Available,Cesarean Section|Infection,Drug: Cefazolin (Timing of Antibiotic Prophylaxis),"MemorialCare|University of California, Irvine",Female,Adult|Senior,Phase III,50,Other,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",474-07,12/17/2008,01/08/2008,01/09/2009,9/17/2009,01/09/2009,,01/06/2009,"To assess the rates of maternal infectious morbidity with preoperative administration of antibiotics when compared to antibiotic prophylaxis given following umbilical cord clamping|To assess incidence of neonatal infectious morbidity (i.e. rates of sepsis work-up, confirmed sepsis, and length of hospital stay) between two study arms",http://ClinicalTrials.gov/show/NCT00811603,United States,1,1,1,0
NCT00812929,A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise,Completed,No Results Available,Asthma,Drug: Placebo|Drug: GSK2190915,GlaxoSmithKline,Both,Adult,Phase II,47,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",112025,12/18/2008,01/12/2008,01/06/2009,02/05/2010,01/02/2010,,01/06/2009,"Maximal percentage change from pre-exercise baseline FEV1 to the minimum FEV1 at 24 hours post dose.|Weighted Mean (WM) for FEV1 percentage change from baseline recorded.|Time to FEV1 recovery to within 5% of baseline following exercise challenge.|Proportion of subjects using a short acting beta-2 agonist (rescue medication).|Safety assessments: vital signs, ECG, safety laboratory parameters, adverse events.|Leukotriene biomarkers LTB4 and LTE4 in blood and urine samples, respectively.|Derived PK parameters for GSK2190915.|Maximal percentage change from pre-exercise baseline FEV1 to the minimum FEV1 at 2 and 9.5 hours post dose.",http://ClinicalTrials.gov/show/NCT00812929,United States,1,0,2,NA
NCT00812955,"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (\Bad Cholesterol\"") and Triglycerides""",Completed,No Results Available,Dyslipidemias|Hypercholesterolemia|Coronary Heart Disease|Hypertriglyceridemia,Drug: ABT-143|Drug: simvastatin,Abbott,Both,Adult|Senior,Phase III,474,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",M10-667,12/18/2008,01/11/2008,01/06/2009,9/13/2010,01/09/2010,,01/06/2009,"Percent change in LDL-C with ABT-143 20/135 mg versus simvastatin 40 mg|LDL-C|Percent change in LDL-C, with ABT-143 (10/135 mg) versus simvastatin 40 mg|Percent change in LDL-C with ABT-143 (5/135 mg) versus simvastatin 40 mg",http://ClinicalTrials.gov/show/NCT00812955,United States,1,0,2,NA
NCT00813098,Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome,Completed,Has Results,Irritable Bowel Syndrome,Drug: LX1031 High Dose|Drug: LX1031 Low Dose|Drug: Placebo,Lexicon Pharmaceuticals,Both,Adult|Senior,Phase II,155,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Protocol LX1031.1-201-IBS|LX1031.201,12/19/2008,01/12/2008,01/08/2010,11/04/2010,01/11/2010,,01/07/2009,Subjects Who Experienced Relief of IBS Pain and Discomfort at Week 4|Change From Baseline at Week 4 in Proportion of Days Per Week When Experiencing Urgency to Defecate|Change From Baseline at Week 4 in Stool Consistency Scores|Change From Baseline at Week 4 in Stool Frequency|Change From Baseline at Week 4 on the Severity of Bloating|Change From Baseline at Week 4 on the Global Improvement Score.,http://ClinicalTrials.gov/show/NCT00813098,United States,1,0,3,NA
NCT00813488,Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain,Completed,Has Results,Chronic Pain,Drug: Fentanyl Buccal Tablet|Drug: Immediate release oxycodone,Cephalon,Both,Adult|Senior,Phase III,213,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C25608/3056/BP/US,12/19/2008,01/12/2008,01/01/2010,1/15/2011,01/01/2011,,01/11/2009,Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15)|Pain Intensity Difference (PID) at 5 Minutes Post-treatment|Pain Intensity Difference (PID) at 10 Minutes Post-treatment|Pain Intensity Difference (PID) at 30 Minutes Post-treatment|Pain Intensity Difference (PID) at 45 Minutes Post-treatment|Pain Intensity Difference (PID) at 60 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 5 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 10 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 15 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 30 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 45 Minutes Post-treatment|Percentage Change in Pain Intensity Difference (% PID) at 60 Minutes Post-treatment|Sum of Pain Intensity Difference at 30 Minutes Post-treatment (SPID30)|Sum of Pain Intensity Difference at 60 Minutes Post-treatment (SPID60)|Pain Relief (PR) Score at 5 Minutes Post-treatment|Pain Relief Score at 10 Minutes Post-treatment|Pain Relief Score at 15 Minutes Post-treatment|Pain Relief Score at 30 Minutes Post-treatment|Pain Relief Score at 45 Minutes Post-treatment|Pain Relief Score at 60 Minutes Post-treatment|Total Pain Relief at 60 Minutes (TOTPAR60)|Percent Total Pain Relief at 60 Minutes Posttreatment (%TOTPAR)|Time to Any Pain Relief (APR) by Treatment - <= 5 Minutes|Time to Any Pain Relief (APR) by Treatment <=10 Minutes|Time to Any Pain Relief (APR) by Treatment <=15 Minutes|Time to Any Pain Relief (APR) by Treatment <=30 Minutes|Time to Any Pain Relief (APR) by Treatment <=45 Minutes|Time to Any Pain Relief (APR) by Treatment <=60 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment - <= 5 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=10 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=15 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=30 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=45 Minutes|Time to Meaningful Pain Relief (MPR) by Treatment <=60 Minutes|Use of Standard Rescue Medication|Medication Performance Assessment 30 Minutes Post-treatment|Medication Performance Assessment 60 Minutes Post-treatment|Breakthrough Pain Preference Questionnaire|Patient Global Impression of Change (PGIC) at Visit 7- 1 Month After Open Label Treatment|Patient Global Impression of Change (PGIC) at Visit 8- 2 Months After Open Label Treatment|Patient Global Impression of Change (PGIC) at Visit 9- 3 Months After Open Label Treatment|Patient Global Impression of Change (PGIC) Endpoint|Clinician Global Impression of Change at Visit 7- 1 Month After Open Label Treatment|Clinician Global Impression of Change (CGIC) at Visit 8- 2 Months After Open Label Treatment|Clinician Global Impression of Change (CGIC) at Visit 9- 3 Months After Open Label Treatment|Clinician Global Impression of Change (CGIC)Endpoint,http://ClinicalTrials.gov/show/NCT00813488,United States,1,0,2,NA
NCT00813735,Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder,Completed,No Results Available,Insomnia,Drug: Eszopiclone|Drug: Placebo|Drug: Escitalopram,Lehigh Center for Clinical Research|Sunovion,Both,Adult|Senior,Phase IV,60,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",ESRCO66,12/22/2008,01/09/2006,01/04/2009,10/08/2009,01/10/2009,,01/03/2009,"Change in total sleep time from baseline to final visit|change in sleep latency from baseline to final visit|Change in HAMD from baseline to final visit|Change in ISI from baseline to final visit|Change in CGI-S, CGI-I from baseline to final visit|labs (CBC,urinalysis,TSH,Chemprofile,drugscreen),height|vitals: BP,pulse,temperature,weight,assess AE's/SAE's",http://ClinicalTrials.gov/show/NCT00813735,United States,1,1,3,0
NCT00814944,A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model,Completed,No Results Available,Dry Eye,Drug: Sirolimus|Drug: Sirolimus|Drug: Sirolimus|Drug: Sirolimus,"Santen Inc.|MacuSight, Inc.",Both,Adult|Senior,Phase II,150,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DES-001,12/23/2008,01/04/2009,01/10/2009,7/22/2010,01/07/2010,,01/10/2009,"Mean corneal fluorescein staining (inferior region) after CAE exposure.|Mean ocular discomfort during CAE exposure.|Safety across treatment groups.|Additional evaluations of dry eye including fluorescein staining, lissamine green staining, conjunctival redness, tear film break-up time, blink rate, ocular protection index, Schirmer's Test, and corneal sensitivity.",http://ClinicalTrials.gov/show/NCT00814944,United States,1,1,4,1
NCT00816023,A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume,Completed,Has Results,"Bloodloss|Surgical Procedures, Operative",Drug: ecallantide|Drug: placebo,Cubist Pharmaceuticals,Both,Adult|Senior,Phase II,276,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ECAL-PCPB-08-02,12/29/2008,01/03/2009,01/01/2010,12/14/2010,01/12/2010,CONSERV-1,01/12/2009,Cumulative Volume of Packed Red Blood Cells Transfused at 12 Hours Post Surgery|Treatment-emergent Adverse Events,http://ClinicalTrials.gov/show/NCT00816023,"United States, &nbsp; Canada",1,1,2,0
NCT00817414,An Evaluation of the Effects of LCI699 on Cortisol in Patients With Hypertension,Completed,No Results Available,Hypertension,Drug: Placebo|Drug: LCI699,"Novartis|Great Lakes Drug Development, Inc.|Integrium",Both,Adult|Senior,Phase II,63,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CLCI699A2215|EudraCT 2008-007337-49,01/05/2009,01/12/2008,NA,2/22/2010,01/02/2010,,01/07/2009,To determine the maximum tolerated dose (MTD) of LCI699 with respect to effect on the ACTH-stimulated cortisol response following ACTH stimulation in hypertensive patients.|To characterize the LCI699 exposure-response relationship on cortisol levels following ACTH stimulation in hypertensive patients.|To characterize the pharmacokinetics of LCI699 in hypertensive patients|To assess the safety and tolerability of LCI699 in hypertensive patients|To explore the proportion of patients achieving a successful BP response and BP control in all treatment groups for 23-26 hour post dose (11-14 hour post dose for BID regimen) MSSBP and MSDBP,http://ClinicalTrials.gov/show/NCT00817414,"United States, &nbsp; Iceland",1,0,2,NA
NCT00817635,"A Study to Evaluate the Effects of LCI699 on Safety and Efficacy in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic",Completed,No Results Available,Hypertension,Drug: LCI699|Drug: Placebo|Drug: Eplerenone,"Novartis|Great Lakes Drug Development, Inc.|Integrium",Both,Adult|Senior,Phase II,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CLCI699A2216|EudraCT 2008-007338-23,01/05/2009,01/12/2008,NA,2/22/2010,01/02/2010,,01/12/2009,"Change in mean sitting systolic blood pressure (MSSBP) as measured by office blood pressure (OBP)|Change in mean sitting diastolic blood pressure (MSDBP) at 8 weeks as measured by OBP|Proportion of patients achieving a successful BP response and BP control (MSSBP and MSDBP), as measured by OBP|Dose/exposure BP response relationship of LCI699, as measured by OBP|Changes from baseline in mean 24 hours, mean daytime and mean nighttime SBP and DBP, as measured by ABPM|To evaluate safety and tolerability of LCI699",http://ClinicalTrials.gov/show/NCT00817635,"United States, &nbsp; Iceland",1,0,3,NA
NCT00817778,Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin,Completed,No Results Available,Type 2 Diabetes,Drug: AZD1656|Drug: Placebo,AstraZeneca,Both,Adult|Senior,Phase II,20,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,D1020C00019,01/05/2009,01/01/2009,01/07/2009,7/27/2009,01/07/2009,,01/07/2009,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG)|Pharmacokinetic variables (Area under the plasma conc vs. time curve (AUC), maximum plasma conc (Cmax), Plasma conc immediately before the next dose (Ctrough), time to reach maximum plasma conc, terminal elimination half-life and apparent oral clearance|Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide)",http://ClinicalTrials.gov/show/NCT00817778,United States,1,0,2,NA
NCT00817986,A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms,Completed,No Results Available,Back Spasms,"Drug: Arbaclofen placarbil, 20 mg BID|Drug: Placebo|Drug: Arbaclofen placarbil, 30 mg BID|Drug: Arbaclofen placarbil, 40 mg BID","XenoPort, Inc.",Both,Adult,Phase II,161,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",XP-B-083,01/06/2009,01/12/2008,01/07/2009,9/14/2010,01/09/2010,,01/07/2009,Incidence of treatment-emergent adverse events|Change in pain severity score using the VAS,http://ClinicalTrials.gov/show/NCT00817986,United States,1,0,4,NA
NCT00818116,Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL,Completed,Has Results,Cataracts,Device: AcrySof ReSTOR Aspheric IOL,Alcon Research,Both,Adult|Senior,Phase IV,34,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CH-08-001,01/06/2009,01/12/2008,NA,6/30/2010,01/06/2010,,01/07/2009,Uncorrected and Best Corrected Visual Acuities (Near and Distance),http://ClinicalTrials.gov/show/NCT00818116,United States,0,NA,1,NA
NCT00818337,Aspirin Responsiveness in Women at Risk for Cardiac Events,Completed,No Results Available,Heart Disease,Drug: Aspirin,Creighton University,Female,Adult|Senior,Phase IV,125,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,08-14888,01/06/2009,01/11/2008,01/06/2009,11/27/2009,01/11/2009,,01/06/2009,Primary outcome is percentage of women that are asa resistant,http://ClinicalTrials.gov/show/NCT00818337,United States,1,1,1,0
NCT00818454,4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma,Completed,Has Results,Asthma,Drug: Combivent CFC MDI|Drug: Albuterol HFA MDI|Drug: Respimat Combivent,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase II,226,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment,1012.57|57948,01/06/2009,01/12/2008,NA,11/23/2010,01/11/2010,,01/09/2009,FEV1 AUC0-6 Response (Crossover Part of the Study)|Peak FEV1 Response (Crossover Part of the Study)|Mini Asthma Quality of Life Questionnaire (Crossover Part of the Study)|Asthma Control Questionnaire (Crossover Part of the Study)|Puffs Study Medication Used During Day (Crossover Part of the Study)|Puffs Study Medication Used During Night (Crossover Part of the Study)|Puffs Open-label Albuterol Used During Day (Crossover Part of the Study)|Puffs Open-label Albuterol Used During Night (Crossover Part of the Study)|FEV1 AUC0-6 Response (Parallel Part of the Study)|Peak FEV1 Response,http://ClinicalTrials.gov/show/NCT00818454,United States,1,1,3,0
NCT00818493,Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty,Completed,No Results Available,Postoperative Pain,Drug: Q8003 (morphine sulfate and oxycodone hydrochloride)|Drug: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|Drug: Percocet (oxycodone and acetaminophen),QRxPharma Inc.,Both,Adult|Senior,Phase II,44,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Q8003-020,01/06/2009,01/02/2009,01/07/2009,8/30/2010,01/08/2010,,01/07/2009,Difference in pain intensity scores from baseline|Safety: adverse events,http://ClinicalTrials.gov/show/NCT00818493,United States,1,0,3,NA
NCT00818883,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Subjects With Moderate to Severe Hypertension,Completed,No Results Available,Essential Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and hydrochlorothiazide,"Takeda Global Research & Development Center, Inc.",Both,Adult|Senior,Phase III,609,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TAK-491CLD_306|U1111-1112-7119,01/07/2009,01/02/2009,01/11/2009,7/15/2010,01/07/2010,,01/11/2009,"Change from Baseline in trough, sitting, Clinic Systolic Blood Pressure|Change from Baseline in trough, sitting, Clinic Diastolic Blood Pressure|Change from Baseline in mean trough Systolic Blood Pressure (22 to 24 hours after dosing) per ambulatory blood pressure monitoring.|Change from Baseline in mean trough Diastolic Blood Pressure (22 to 24 hours after dosing) per ambulatory blood pressure monitoring.|Change from Baseline in 24-hour mean Systolic Blood Pressure per ambulatory blood pressure monitoring.|Change from Baseline in 24-hour mean Diastolic Blood Pressure per ambulatory blood pressure monitoring.|Change from Baseline in the mean daytime (6 AM to 10 PM) Systolic Blood Pressure per ambulatory blood pressure monitoring.|Change from Baseline in the mean daytime (6 AM to 10 PM) Diastolic Blood Pressure per ambulatory blood pressure monitoring.|Change from baseline in the mean nighttime (12 AM to 6 AM) Systolic Blood Pressure per ambulatory blood pressure monitoring.|Change from baseline in the mean nighttime (12 AM to 6 AM) Diastolic Blood Pressure per ambulatory blood pressure monitoring.|Change from baseline in the mean Systolic Blood Pressure at 0 to 12 hours after dosing per ambulatory blood pressure monitoring|Change from baseline in the mean Diastolic Blood Pressure at 0 to 12 hours after dosing per ambulatory blood pressure monitoring.|Proportion of subjects who reached their trough, sitting, clinic Systolic and Diastolic blood pressure targets, defined as <140/90 mm Hg without diabetes or chronic kidney disease or <130/80 mm Hg with diabetes or chronic kidney disease|Proportion of subjects who reached their trough, sitting, clinic Systolic blood pressure targets, defined as <140 mm Hg for subjects without diabetes or chronic kidney disease or <130 mm Hg for subjects with diabetes or chronic kidney disease|Proportion of subjects who reached their trough, sitting, clinic Diastolic blood pressure targets, defined as <90 mm Hg for subjects without diabetes or chronic kidney disease or <80 mm Hg for subjects with diabetes or chronic kidney disease",http://ClinicalTrials.gov/show/NCT00818883,"United States, &nbsp; Russian Federation",1,0,2,NA
NCT00820300,A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma,Completed,No Results Available,Glaucoma|Ocular Hypertension,Drug: Latanoprost-PPDS,"QLT Plug Delivery, Inc.",Both,Adult|Senior,Phase II,80,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PPL GLAU 03,01/08/2009,01/01/2009,01/12/2009,02/02/2010,01/02/2010,,01/12/2009,IOP change from baseline,http://ClinicalTrials.gov/show/NCT00820300,United States,1,0,1,NA
NCT00820950,A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis,Completed,No Results Available,Plaque Psoriasis,Drug: INCB018424 phosphate cream|Drug: Vehicle (placebo) cream,Incyte Corporation,Both,Adult|Senior,Phase II,29,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",INCB 18424-201,01/08/2009,01/05/2007,01/04/2009,6/17/2010,01/06/2010,,01/01/2009,"The safety, tolerability (assessed by local irritation, adverse experiences, vital signs, ECGs, and clinical labs) and pharmacokinetics (plasma concentrations) of INCB018424 cream formulations when applied once or twice daily to patients.|Efficacy endpoints will include: Change in target lesion scores including total score and each component analyzed separately. Change in target lesion area",http://ClinicalTrials.gov/show/NCT00820950,United States,1,0,2,NA
NCT00821002,A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS),Completed,No Results Available,Open-Angle Glaucoma|Ocular Hypertension,Drug: Latanoprost,"QLT Plug Delivery, Inc.|QLT Inc",Both,Adult|Senior,Phase II,30,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PPL GLAU 05,01/08/2009,01/01/2009,01/11/2009,11/27/2009,01/11/2009,,01/11/2009,Compare intraocular pressure and safety outcomes based on plug placement,http://ClinicalTrials.gov/show/NCT00821002,United States,1,0,1,NA
NCT00821093,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),Completed,No Results Available,Chronic Obstructive Pulmonary Disease (COPD),Drug: Indacaterol 150 ??g|Drug: Salmeterol 50 ??g,Novartis Pharmaceuticals,Both,Adult|Senior,Phase III,1084,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CQAB149B2349|2008-005146-23,01/09/2009,01/01/2009,NA,11/30/2009,01/11/2009,INSIST,01/10/2009,12 hr Area Under the Curve (AUC) forced expiratory volume in 1 second (FEV1)|Change from baseline to 24 hr post-dose of (trough) forced expiratory volume in 1 second (FEV1),http://ClinicalTrials.gov/show/NCT00821093,"United States, &nbsp; Czech Republic, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Slovakia, &nbsp; Spain, &nbsp; Turkey",1,0,2,NA
NCT00824460,Study of Phosphate Levels in Patients With Chronic Kidney Disease,Completed,No Results Available,Chronic Kidney Disease,Drug: PA21|Drug: Renagel,Vifor Inc.,Both,Adult|Senior,Phase II,252,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PA-CL-03A|75610,01/09/2009,01/12/2008,01/03/2010,04/12/2010,01/03/2010,PA21,01/10/2009,Change from baseline in serum-phosphate levels at the end of treatment.|Change from baseline in serum-phosphate levels at week 2|Change from baseline in serum-phosphate levels at week 4|Change from baseline in serum-phosphate levels at week 5,http://ClinicalTrials.gov/show/NCT00824460,"United States, &nbsp; Bulgaria, &nbsp; Croatia, &nbsp; Czech Republic, &nbsp; Germany, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Switzerland",1,0,2,NA
NCT00824473,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Placebo|Drug: 0.15% azelastine hydrochloride,Meda Pharmaceuticals,Both,Child|Adult|Senior,Phase III,506,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP443,1/14/2009,01/12/2008,01/02/2009,2/19/2010,01/02/2010,,01/02/2009,Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days|Mean Change From Baseline in Instantaneous Total Nasal Symptom Sscore (AM) for the Entire 14-day Study Period Compared to Placebo|Change From Baseline in Instantaneous Total Nasal Symptom Score for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)|Change From Baseline in 12-hour Reflective Total Ocular Symptom Score and Instantaneous Total Ocular Symptom Score for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)|Change From Baseline to Visit 4 in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Compared to Placebo in Subjects 18 Years of Age and Older|Change From Baseline on Direct Visual Nasal Exams to 14 Days,http://ClinicalTrials.gov/show/NCT00824473,United States,1,1,2,0
NCT00824720,Safety and Efficacy of a Glaucoma Drug Delivery System,Completed,Has Results,"Glaucoma, Open-Angle|Ocular Hypertension",Drug: bimatoprost|Drug: bimatoprost|Device: punctal plug,Vistakon Pharmaceuticals,Both,Adult|Senior,Phase II,55,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CR-1630,01/09/2009,01/12/2008,01/04/2009,4/15/2010,01/04/2010,,01/04/2009,Visual Acuity - Right Eye|Visual Acuity - Left Eye|Intraocular Pressure (IOP),http://ClinicalTrials.gov/show/NCT00824720,United States,1,0,3,NA
NCT00825500,Staccato Loxapine in Migraine (Out Patient),Completed,No Results Available,Migraine Headache,Drug: High dose|Drug: Low dose|Drug: Placebo,"Alexza Pharmaceuticals, Inc.",Both,Adult,Phase II,366,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",AMDC-104-202|24-October-2008,1/19/2009,01/01/2009,01/08/2009,8/28/2009,01/08/2009,,01/08/2009,"Pain-Relief|Pain free, Nausea, Photophobia, Phonophobia",http://ClinicalTrials.gov/show/NCT00825500,United States,1,1,3,1
NCT00827099,"UCB Transplant, Fludarabine, Melphalan, and ATG in Treating Patients With Hematologic Cancer",Completed,No Results Available,Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,Biological: anti-thymocyte globulin|Drug: fludarabine phosphate|Drug: melphalan|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation,"Northside Hospital, Inc.",Both,Adult,Phase II,5,Other,Interventional,Endpoint Classification: Safety Study|Masking: Open Label|Primary Purpose: Treatment,CDR0000632453|BMTGG-NSH-801,1/21/2009,01/06/2006,01/11/2009,03/10/2010,01/03/2010,,01/11/2009,Incidence of transplant-related mortality|Incidence of engraftment|Degree of donor-host chimerism|Incidence of acute and chronic graft-vs-host disease|Incidence of relapse|Survival,http://ClinicalTrials.gov/show/NCT00827099,United States,1,0,7,NA
NCT00827242,Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Placebo|Drug: tadalafil,Eli Lilly and Company,Male,Adult|Senior,Phase III,325,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",10893|H6D-MC-LVHJ,1/20/2009,01/01/2009,01/11/2009,10/19/2010,01/10/2010,,01/11/2009,"Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS)|Change From Baseline to 4 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index|Change From Baseline to 12 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index|Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore|Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore|Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Nocturia Question|Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index|Patient Global Impression of Improvement (PGI-I), Number of Participants in 7 Response Categories|Clinical Global Impression of Improvement (CGI-I), Number of Participants in 7 Response Categories|Change From Baseline to 1 Week, International Prostate Symptom Score (IPSS)|Change From Baseline to 4 Weeks, International Prostate Symptom Score (IPSS)|Change From Baseline to 12 Weeks, International Index of Erectile Function (IIEF)- Erectile Function (EF) Domain Scores|Change From Baseline to 12 Weeks, Peak Flow Rate (Qmax) by Uroflowmetry|Change From Baseline to 12 Weeks, Mean Flow Rate (Qmean) by Uroflowmetry|Change From Baseline to 12 Weeks, Voided Volume (Vcomp) by Uroflowmetry|Change From Baseline to 12 Weeks, Postvoid Residual (PVR) Volume",http://ClinicalTrials.gov/show/NCT00827242,"United States, &nbsp; Argentina, &nbsp; Germany, &nbsp; Italy, &nbsp; Mexico",1,1,2,1
NCT00828412,Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis,Completed,No Results Available,Atopic Dermatitis,Device: EpiCeram Skin Barrier Emulsion|Drug: Desonide Cream 0.05%,"Promius Pharma, LLC",Both,Child,Phase IV,100,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,EPC0801,1/21/2009,01/03/2009,01/08/2009,6/28/2010,01/06/2010,,01/08/2009,Change from baseline in three item severity score|Change from baseline in SCORAD|Pruritus severity score|Sleep disturbance score|Investigator global assessment|Quality of life index,http://ClinicalTrials.gov/show/NCT00828412,United States,1,1,2,0
NCT00828464,"Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis",Completed,Has Results,Hand Dermatosis,Drug: clobetasol propionate,"Stiefel, a GSK Company",Both,Adult|Senior,Phase IV,30,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,U0280-401,1/22/2009,01/10/2008,01/01/2009,09/07/2010,01/09/2010,,01/01/2009,Proportion of Subjects With at Least 1-grade Improvement From Baseline to Day 15 in Investigator's Static Global Assessment Score (ISGA) Score|Proportion of Subjects Who Achieve at Least a 1-grade Improvement Based on the ISGA at Day 8.|Change in Subject's Visual Analogue Assessment Scale|Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Finger Tips|Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Finger Tips|Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline - Fingers|Proportion of Subjects With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Fingers|Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Palm of Hands|Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Palm of Hands|Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Back of Hands|Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Back of Hands|Proportion of Subjects at Day 8 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Wrists|Proportion of Subjects at Day 15 With at Least 1-Grade Improvement In the Hand Eczema Severity Index Score (HESI) for All Symptoms Present at Baseline Wrists|Change in Subject's Visual Analogue Assessment Scale From Baseline to Day 15,http://ClinicalTrials.gov/show/NCT00828464,United States,1,1,1,1
NCT00828477,Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT),Completed,No Results Available,Intraocular Pressure,Drug: Xibrom|Drug: Nevanac,"Bp Consulting, Inc",Both,Adult|Senior,Phase IV,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,2009-0144,1/14/2009,01/01/2009,01/06/2009,06/08/2009,01/06/2009,,01/06/2009,Tolerability of study medication|Intraocular pressure changes|Visual Acuity,http://ClinicalTrials.gov/show/NCT00828477,United States,1,1,2,1
NCT00828568,A Therapeutic Equivalence Study of Two Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis,Completed,Has Results,Actinic Keratosis,Drug: Imiquimod 5% manufactured by Taro|Drug: Aldara - Imiquimod 5%|Drug: Imiquimod Vehicle manufactured by Taro,Taro Pharmaceuticals USA,Both,Adult|Senior,Phase III,425,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MIQ-0403,1/22/2009,01/06/2008,01/05/2009,11/30/2009,01/11/2009,,01/03/2009,Number of Participants With 100% Clearance of Actinic Keratosis Lesions: Comparison of Taro Imiquimod 5% and Aldara-Imiquimod 5%|Number of Participants in Intention-to-treat (ITT)Population With 100% Clearance of Actinic Keratosis (AK) Lesions Identified at Baseline|Patients Reporting at Least One Adverse Event,http://ClinicalTrials.gov/show/NCT00828568,United States,1,1,3,0
NCT00828711,"Misoprostol Vaginal Insert (MVI) 100, 150, 200 Mcg for Cervical Ripening and Induction of Labor",Completed,No Results Available,Cervical Ripening|Induction of Labor,Drug: MVI 100|Drug: MVI 150|Drug: MVI 200,Cytokine PharmaSciences,Female,Adult|Senior,Phase II,370,Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Miso-Obs-204,1/22/2009,01/04/2009,01/10/2009,12/03/2009,01/12/2009,,01/10/2009,Proportion of women delivering vaginally|Time to vaginal delivery|Adverse Events|Proportion of cesarean delivery|Cervical ripening using composite measure of success|Vaginal delivery|Use of oxytocin|pharmacokinetics,http://ClinicalTrials.gov/show/NCT00828711,United States,1,0,3,NA
NCT00828906,DuoTrav?ó Eye Drops As Replacement Therapy Program,Completed,No Results Available,Open-Angle Glaucoma|Ocular Hypertension,Drug: DuoTrav,Alcon Research,Both,Adult|Senior,Phase IV,2000,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DART-2,1/23/2009,01/02/2009,NA,03/11/2010,01/03/2010,,01/11/2009,Intra Ocular Pressure,http://ClinicalTrials.gov/show/NCT00828906,United States,1,0,1,NA
NCT00831051,Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients,Completed,No Results Available,Postoperative Pain,Drug: Q8003|Drug: Morphine sulfate|Drug: Oxycodone HCl|Drug: Q8003|Drug: Morphine sulfate|Drug: Oxycodone HCl 4mg,QRxPharma Inc.,Both,Adult|Senior,Phase II,197,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Q8003-021,1/27/2009,01/12/2008,01/02/2009,8/30/2010,01/08/2010,,01/01/2009,Difference in pain intensity scores from baseline|Safety: adverse events,http://ClinicalTrials.gov/show/NCT00831051,United States,1,0,6,NA
NCT00833495,Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation,Completed,No Results Available,Allergic Conjunctivitis,Drug: Prednisolone Acetate 0.12% (Pred Mild?ó)|Drug: FOV1101-00|Drug: Prednisolone Acetate 1% (Pred Forte?ó)|Drug: Placebo,Fovea Pharmaceuticals SA,Both,Adult|Senior,Phase II,90,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",08-003-27,1/30/2009,01/01/2009,01/03/2009,9/28/2010,01/09/2010,,01/03/2009,Ocular Allergic signs and symptoms Diary Scores|Various ocular and nasal allergic diary scores,http://ClinicalTrials.gov/show/NCT00833495,United States,1,0,4,NA
NCT00833638,A Study in Erectile Dysfunction,Completed,Has Results,Erectile Dysfunction,Drug: Placebo|Drug: Tadalafil,Eli Lilly and Company,Male,Adult|Senior,Phase IV,372,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",12719|H6D-US-LVHZ,1/30/2009,01/02/2009,01/06/2009,8/18/2010,01/08/2010,,01/06/2009,"Earliest Onset Day Measured by Cumulative Percentage of Participants With Yes Response to Sexual Encounter Profile Diary Question 3|Sexual Encounter Profile Diary Question Number 1, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses|Sexual Encounter Profile Diary Question Number 2, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses|Sexual Encounter Profile Diary Question Number 3, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses|Sexual Encounter Profile Diary Question Number 4, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses|Sexual Encounter Profile Diary Question Number 5, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses|Sexual Encounter Profile Diary Question 3, the Overall Distribution of Time to Onset by Yes Responses|Sexual Encounter Profile Diary Question 3, Daily Cumulative Percentage of Successful Intercourse Attempts|Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind and Open-label Periods for Participants Who Were Assigned to Placebo in the Double-blind Treatment Period|Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 2.5 mg in the Double-blind Treatment Period|Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 5 mg in the Double-blind Treatment Period|Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind Period and the Open-label Period for Participants Who Didn't Respond to Tadalafil 2.5 mg During Double-blind Period",http://ClinicalTrials.gov/show/NCT00833638,United States,1,1,2,1
NCT00835237,Evaluation of GlaxoSmithKline Biologicals' Boostrix?ó Vaccine in Comparison With Decavac?ºÑ Vaccine.,Completed,Has Results,Diphtheria|Pertussis|Diphtheria-Tetanus-acellular Pertussis Vaccines|Tetanus,Biological: Boostrix?ó|Biological: Decavac?ºÑ,GlaxoSmithKline,Both,Adult|Senior,Phase III,1332,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",111413,02/02/2009,01/02/2009,01/07/2009,12/02/2010,01/12/2010,,01/07/2009,"Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value|Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration|Anti-T and Anti-D Antibody Concentrations|Number of Subjects With Vaccine Response for Anti-T and Anti-D Antibodies Concentrations Above the Cut-off|Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off|Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off, Using Alternative Definitions.|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Number of Subjects Reporting Serious Adverse Events (SAE)",http://ClinicalTrials.gov/show/NCT00835237,United States,0,NA,2,NA
NCT00836485,"Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis",Completed,No Results Available,Allergic Conjunctivitis,Drug: Ketotifen 4.0% Patch|Drug: Placebo|Drug: Olopatadine 0.2%|Drug: Artificial tears,"Senju USA, Inc.",Both,Adult|Senior,Phase II,120,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",SNJ-ALK201/08-003-11,02/02/2009,01/02/2009,01/03/2009,5/15/2009,01/05/2009,,01/03/2009,"Ocular itching and bulbar conjunctival redness|Ocular: Ciliary, episcleral, and inferior palpebral conjunctival redness; chemosis; lid swelling; tearing; ocular mucous discharge|Nasal: Rhinorrhea; ear or palate pruritis; nasal pruritis; nasal congestion; and a composite score of all nasal symptoms",http://ClinicalTrials.gov/show/NCT00836485,United States,1,0,4,NA
NCT00837837,Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents,Completed,No Results Available,Allergic Reactions,Drug: Chlorpheniramine,Wyeth,Both,Child,Phase II,36,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CF-08-01,02/04/2009,01/12/2008,01/02/2009,02/04/2009,01/02/2009,,01/02/2009,"AUC and Cmax|Oral clearance (CL) and volume of distribution (Vd); time to reach Cmax (tmax), and apparent elimination constant (Kel) and half-life (t1/2).",http://ClinicalTrials.gov/show/NCT00837837,United States,1,1,1,0
NCT00838526,Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD),Completed,No Results Available,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole ER|Drug: Ranitidine,Eisai Inc.,Both,Adult|Senior,Phase III,240,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,E3810-G000-305|EudraCT No. 2007-007732-26,02/05/2009,01/08/2008,01/12/2009,3/17/2010,01/03/2010,,01/07/2009,"The primary outcome measure will include: esophagogastroduodenoscopy (EGD), Investigator's assessment of symptoms, quality of life as recorded by subjects and concomitant use of dispensed antacid.|Secondary outcome measures will include: adverse events, electrocardiograms (ECGs), laboratory evaluations (hematology, blood chemistry, urinalysis, gastrin), gastric biopsies, physical exam and vital signs.",http://ClinicalTrials.gov/show/NCT00838526,United States,1,1,2,0
NCT00838708,Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus,Completed,No Results Available,"Pruritus, Atopic Dermatitis",Drug: SRD174 Cream|Other: vehicle cream,Serentis Ltd.,Both,Adult|Senior,Phase II,62,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P174954201CD,02/05/2009,01/01/2009,01/08/2009,10/29/2009,01/10/2009,,01/07/2009,Measure of intensity and duration of itch episodes|Safety and local dermal tolerability,http://ClinicalTrials.gov/show/NCT00838708,United States,1,0,2,NA
NCT00839176,Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD),Completed,No Results Available,Major Depressive Disorder (MDD),Drug: RX-10100,"Rexahn Pharmaceuticals, Inc.",Both,Adult,Phase II,72,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",RX-10100-P2A-002,02/05/2009,01/01/2009,01/10/2009,12/04/2009,01/12/2009,,01/09/2009,"Change from baseline at 8 weeks on the Montgomery-Asberg Depression Rating Scale (MADRS)|Changes from baseline on the HAM-D|Changes from baseline on the QIDS-SR|CGI-I scale at the end of treatment,|Side effects during and immediately following the treatment period",http://ClinicalTrials.gov/show/NCT00839176,United States,1,0,1,NA
NCT00839306,Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD),Completed,No Results Available,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole ER|Drug: Ranitidine,Eisai Inc.,Both,Adult|Senior,Phase III,240,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",E3810-G000-306|EudraCT No. 2007-007733-39,02/05/2009,01/08/2008,01/01/2010,3/24/2010,01/03/2010,,01/08/2009,"The primary outcome measure will include: esophagogastroduodenoscopy (EGD), Investigator's assessment of symptoms, quality of life as recorded by subjects and concomitant use of dispensed antacid.|Secondary outcome measures will include: adverse events, electrocardiograms (ECGs), laboratory evaluations (hematology, blood chemistry, urinalysis, gastrin), gastric biopsies, physical exam and vital signs.",http://ClinicalTrials.gov/show/NCT00839306,United States,1,1,2,0
NCT00840268,A Study of Hydroxypropyl Guar Galactomannan 0.25% (HPGG) Versus Vehicle in Dry Eye Patients,Completed,No Results Available,Dry Eye,Drug: HPGG 0.25% or HPGG Vehicle,Alcon Research,Both,Adult|Senior,Phase II,427,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",C-08-34,02/06/2009,01/02/2009,NA,09/08/2009,01/09/2009,,01/08/2009,Mean change from baseline in sodium fluorescein corneal staining score|Mean change from baseline in Dry Eye Symptom Questionnaire score,http://ClinicalTrials.gov/show/NCT00840268,United States,1,0,1,NA
NCT00841919,Insulin Therapy in the Hospital Comparing Two Protocols,Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: Glargine insulin|Drug: NPH insulin and regular insulin|Drug: lispro insulin,John H. Stroger Hospital|Eli Lilly and Company,Both,Adult|Senior,Phase IV,60,Other|Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,BBJHS200901,02/09/2009,01/12/2006,01/06/2009,09/08/2009,01/09/2009,,01/03/2009,The rate of correct timing of insulin and food administration|Pre and post- prandial glucose levels|Length of hospital stay|Nursing staff satisfaction scores for evaluation of the two methods|Hypoglycemia rates.|High excursions of blood sugars (>300 mg/dl).,http://ClinicalTrials.gov/show/NCT00841919,United States,1,1,3,0
NCT00842751,Oral T-7 Oral Androgens in Man-7,Completed,No Results Available,Healthy Males,Drug: Acyline|Drug: Testosterone Undecanoate|Drug: Finasteride 0.5 mg|Drug: Finasteride 1 mg,University of Washington|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Male,Adult,Phase II,12,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,35724-W|1K23HD045386|5U54HD042454,02/10/2009,01/07/2009,01/12/2009,4/21/2010,01/04/2010,Oral T-7,01/11/2009,"To determine what dose of Finasteride, when combined with Oral TU, will yield an average serum testosterone over 24 hours in the eugonadal range while at the same time maintaining serum DHT concentrations within the normal range.",http://ClinicalTrials.gov/show/NCT00842751,United States,1,0,4,NA
NCT00845195,Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid,Completed,Has Results,Seasonal Allergic Rhinitis,"Drug: Olopatadine HCl Nasal Spray, 0.6%|Drug: Azelastine HCl Nasal Spray, 0.1%",Alcon Research,Both,Child|Adult|Senior,Phase IV,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",SMA-08-23,2/13/2009,01/03/2009,NA,4/22/2010,01/04/2010,,01/05/2009,Mean Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline|Mean Change in Reflective Total Ocular Symptom Scores (rTOSS) From Baseline|Mean Change in Instantaneous Total Nasal Symptom Scores (iTNSS) From Baseline|Mean Change in Instantaneous Total Ocular Symptom Scores (iTOSS) From Baseline,http://ClinicalTrials.gov/show/NCT00845195,United States,1,1,2,0
NCT00845299,Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma,Completed,No Results Available,Glaucoma|Ocular Hypertension,Drug: Latanoprost punctal plug|Drug: artificial tears preserved with Benzalkonium Chloride,"QLT Plug Delivery, Inc.",Both,Adult|Senior,Phase II,40,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PPL GLAU 04,2/16/2009,01/01/2009,01/12/2009,02/02/2010,01/02/2010,,01/12/2009,IOP change from baseline,http://ClinicalTrials.gov/show/NCT00845299,United States,1,0,2,NA
NCT00845923,Evaluation of Civamide Patch in Treatment of Postherpetic Neuralgia and Post-Incisional Neuralgia,Completed,No Results Available,Postherpetic Neuralgia,Drug: Civamide Patch,Winston Laboratories,Both,Adult|Senior,Phase I|Phase II,22,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,WL-1001-04-03,2/16/2009,01/03/2009,01/10/2009,10/16/2009,01/10/2009,,01/09/2009,Change in Average Daily Pain Score from the Baseline Period to the Average Daily Pain Score of the last week of the Treatment Period.|Average Daily Sleep Score,http://ClinicalTrials.gov/show/NCT00845923,"United States, &nbsp; Canada",1,0,1,NA
NCT00847730,Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negatvie Pressure Wound Therapy,Completed,No Results Available,Diabetic Foot Ulcers,Device: V.A.C. Negative Pressure Wound Therapy System,"KCI USA, Inc.",Both,Adult|Senior,Phase II,75,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care,VACDrsg 2008-37,2/17/2009,01/02/2009,01/09/2009,12/07/2009,01/12/2009,,01/06/2009,"Percentage of subjects with satisfactory performace, defined as a cumulative eas of use score >6 and a munimum score of >2 on each indiviual charecteristic|Percentage of subjects with a score of >2 on the patient comfort during wear assessment",http://ClinicalTrials.gov/show/NCT00847730,United States,0,NA,1,NA
NCT00847899,Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance,Completed,No Results Available,Hypertension|Impaired Glucose Tolerance,Drug: AR9281|Drug: AR9281|Drug: Placebo|Drug: Placebo,Arete Therapeutics,Both,Adult|Senior,Phase II,150,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",AR9281-CLN-003,2/17/2009,01/01/2009,01/11/2009,11/18/2009,01/11/2009,,01/10/2009,Systolic and Diastolic blood pressure|Glucose dynamics and insulin sensitivity,http://ClinicalTrials.gov/show/NCT00847899,United States,1,0,4,NA
NCT00848081,A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Tadalafil|Drug: Placebo,Eli Lilly and Company,Male,Adult|Senior,Phase III,318,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",11668|H6D-MC-LVHS,2/19/2009,01/03/2009,01/12/2009,8/16/2010,01/08/2010,,01/12/2009,Number of Men With Treatment-emergent Dizziness|Number of Participants With Positive Orthostatic Vital Signs Test; Shift From Any Pre-Randomization to Any Post-Randomization Visit|International Prostate Symptom Score (IPSS) Change From Baseline|Postvoid Residual Volume (PVR) Change From Baseline|Uroflowmetry (Qmax) Change From Baseline,http://ClinicalTrials.gov/show/NCT00848081,"United States, &nbsp; Puerto Rico",1,1,2,1
NCT00849290,Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442),Completed,Has Results,Metastatic Androgen Independent Prostate Cancer,Biological: APC8015F,Dendreon,Male,Adult|Senior,Phase II,113,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PB01,2/19/2009,01/04/2004,01/04/2009,10/08/2010,01/10/2010,,01/01/2009,Safety of APC8015F by Review of Reported Adverse Events|To Evaluate the Efficacy of APC8015F in Delaying Prostate Specific Antigen Doubling Time and on Overall Clinical Response,http://ClinicalTrials.gov/show/NCT00849290,"United States, &nbsp; Canada",0,NA,1,NA
NCT00851890,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",Completed,No Results Available,HCV Infection,Drug: ABT-333|Drug: Placebo|Drug: peginterferon alfa-2a|Drug: Ribavirin,Abbott,Both,Adult|Senior,Phase II,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)",M10-380,2/24/2009,01/04/2009,NA,10/19/2010,01/09/2010,,01/07/2009,"Analysis of pharmacokinetic variables and antiviral activity in treatment-na??ve HCV-infected subjects.|Analysis of safety measures including but not limited to tabulation of adverse events, physical exam, clinical lab results (include chemistry, hematology and urine) and vital signs.|Assess emergence of resistant virus in conjunction with kinetics of viral load decay and rebound in treatment-na??ve HCV-infected subjects.",http://ClinicalTrials.gov/show/NCT00851890,United States,1,0,4,NA
NCT00852137,"A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis",Completed,No Results Available,Actinic Keratosis,Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle Gel,Peplin,Both,Adult|Senior,Phase II,16,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",PEP005-017,2/22/2009,01/03/2009,01/06/2009,7/18/2010,01/07/2010,,01/06/2009,"Cmax for ingenol mebutate, PEP015 and PEP025 levels|Tmax for ingenol mebutate, PEP015 and PEP025 levels|AUC(0-24) for ingenol mebutate, PEP015 and PEP025 levels|Incidence rate of AEs, serious adverse events (SAEs) and AEs leading to discontinuation of study medication throughout the study|Complete clearance rate; and % reduction in AK lesions, in a 25 cm2 area within the selected treatment area|Incidence rate and grade of LSRs, pigmentation and scarring following study medication application",http://ClinicalTrials.gov/show/NCT00852137,United States,1,0,2,NA
NCT00852761,A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis,Completed,No Results Available,Plaque-Type Psoriasis,Drug: Clobetasol propionate formulation A|Drug: clobetasol propionate formulation B,"Stiefel, a GSK Company",Both,Adult|Senior,Phase IV,32,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,U0280-402,2/25/2009,01/01/2009,01/08/2009,8/19/2009,01/08/2009,,01/06/2009,Primary Outcome will be measured using the Psoriasis Grading Scale for Target Lesion from baseline to day 15 of the study|Proportion of subjects who achieve treatment success at day 7. Change in the psoriasis assessment from baseline to days 7 and 15. Proportion of subjects who achieve treatment success as evaluated by the subject from visit 1 to days 7 and 15,http://ClinicalTrials.gov/show/NCT00852761,United States,1,1,2,0
NCT00853242,"Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis",Completed,No Results Available,"Kidney Failure, Chronic","Drug: Genz-644470|Drug: Genz-644470|Drug: Genz-644470|Drug: Placebo|Drug: Sevelamer carbonate, Renvela|Drug: Sevelamer carbonate, Renvela|Drug: Sevelamer carbonate, Renvela",Genzyme,Both,Adult|Senior,Phase II,349,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",APB00108,2/27/2009,01/02/2009,01/09/2009,10/02/2010,01/10/2010,LEAP,01/09/2009,Change from baseline in serum phosphorus (Genz-644470 and placebo)|Evaluation of safety and tolerability|Change from baseline in serum phosphorus (Genz-644470 and sevelamer carbonate)|Change from baseline in serum calcium-phosphorus product|Change from baseline in serum lipids,http://ClinicalTrials.gov/show/NCT00853242,"United States, &nbsp; Puerto Rico",1,0,7,NA
NCT00854360,Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR,Completed,No Results Available,Seasonal Allergic Rhinitis|Hayfever,Drug: Beclomethasone dipropionate HFA Nasal Aerosol|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.",Both,Child|Adult|Senior,Phase II,480,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BDP-AR-201,03/02/2009,01/02/2009,01/05/2009,7/22/2009,01/07/2009,,01/05/2009,Average of the AM and PM patient-reported reflective Total Nasal Symptom Score (TNSS) over the two-week Treatment Period.|Average of AM and PM patient-reported instantaneous TNSS over the two week treatment period|AM patient-reported instantaneous TNSS over the two-week Treatment Period|Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at Endpoint in patients with impaired quality of life at Baseline as defined by a RQLQ score at the Randomization Visit (TV0) of 3.0 or greater|AM patient-reported 24-hour reflective ocular symptom score over the two-week Treatment Period in patients with adequate symptoms during the Run-in period|AM patient-reported 24-hour reflective non-nasal symptom score over the two-week Treatment Period in patients with adequate symptoms during the Run-in period,http://ClinicalTrials.gov/show/NCT00854360,United States,1,1,2,0
NCT00855595,Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea,Completed,No Results Available,Papulopustular Rosacea,Drug: azelaic acid gel plus 40 mg doxycycline|Drug: metronidazole plus doxycycline,Intendis GmbH,Both,Adult|Senior,Phase IV,200,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",1402604|Project number: 256-0024,03/03/2009,01/02/2009,01/10/2009,8/23/2010,01/08/2010,,01/04/2009,Change in inflammatory lesion count from baseline|Rapidity of improvement,http://ClinicalTrials.gov/show/NCT00855595,United States,1,0,2,NA
NCT00856193,A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,No Results Available,Chronic Obstructive Pulmonary Disease,Drug: Placebo|Drug: NVA237,Novartis,Both,Adult|Senior,Phase II|Phase III,33,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CNVA237A2207|2008-006849-28,03/04/2009,01/02/2009,NA,9/20/2010,01/09/2010,,01/05/2009,Measure: To investigate the bronchodilatory efficacy of 50 ??g NVA237 as measured by spirometry assessments|Measure: To investigate the peak bronchodilatory effect of NVA237 as measured by spirometry|Measure: To investigate the trough bronchodilatory effect at the end of the 24 hour assessment interval as measured by spirometry.|Measure: To investigate the bronchodilator effect on the first and second portion of the 24 hour assessment interval (0 hour - 12 hour and 12 hour - 24 hour after 14 days dosing) as measured by spirometry.|Measure: To investigate the bronchodilator effects of NVA237 on Day 7 as measured by spirometry.|Measure: To investigate the safety and tolerability of 50 ??g NVA237 in COPD patients,http://ClinicalTrials.gov/show/NCT00856193,"United States, &nbsp; Germany",1,0,2,NA
NCT00856843,BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects,Completed,Has Results,Colonoscopy,Drug: BLI800|Drug: Polyethylene glycol 3350 based bowel preparation,Braintree Laboratories,Both,Adult|Senior,Phase III,136,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,BLI800-303,03/05/2009,01/02/2009,NA,10/15/2010,01/10/2010,,01/05/2009,Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale|Assessment of Residual Stool - Cecum|Assessment of Residual Stool - Ascending Colon|Assessment of Residual Stool - Transverse Colon|Assessment of Residual Stool - Descending Colon|Assessment of Residual Stool - Sigmoid Colon/Rectum|Assessment of Residual Fluid - Cecum|Assessment of Residual Fluid - Ascending Colon|Assessment of Residual Fluid - Transverse Colon|Assessment of Residual Fluid - Descending Colon|Assessment of Residual Fluid - Sigmoid Colon/Rectum|Subject Symptom Scores|Mean Change in Serum Chemistry (mg/dL)|Mean Change in Serum Chemistry (mEq/L),http://ClinicalTrials.gov/show/NCT00856843,United States,1,0,2,NA
NCT00856908,Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes,Completed,No Results Available,Type II Diabetes,Drug: AZD1656|Drug: Placebo,AstraZeneca,Both,Adult|Senior,Phase II,20,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,D1020C00020,03/05/2009,01/02/2009,01/08/2009,12/06/2010,01/12/2010,,01/08/2009,"Safety variables (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG)|PK variables (Area under the plasma conc vs. time curve (AUC), max plasma conc (Cmax), Plasma conc immediately before the next dose (Ctrough), time to reach max plasma conc (tmax), terminal elimination half-life and apparent oral clearance (CL/F)|Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide)",http://ClinicalTrials.gov/show/NCT00856908,United States,1,0,2,NA
NCT00857272,F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects,Completed,Has Results,Colonoscopy,Drug: PEG electrolyte lavage solution + bisacodyl - reformulation|Drug: PEG electrolyte lavage solution + bisacodyl,Braintree Laboratories,Both,Adult|Senior,Phase IV,308,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,F38-27,03/05/2009,01/02/2009,NA,9/29/2010,01/09/2010,,01/05/2009,Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale,http://ClinicalTrials.gov/show/NCT00857272,United States,1,1,2,0
NCT00857454,A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations,Completed,Has Results,Hypogonadism,Drug: Testosterone MD-Lotion,Eli Lilly and Company,Male,Adult|Senior,Phase III,71,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,14273|MTE09|I5E-MC-TSAI,03/04/2009,01/10/2008,01/08/2009,12/15/2010,01/12/2010,,01/08/2009,Change From Baseline MTE08 to MTE09 Endpoint in Draize Score|Change From Baseline MTE08 to MTE09 Follow-up in Fasting Insulin|Change From Baseline MTE08 to MTE09 Follow-up in Fasting Glucose|Change From Baseline MTE08 to MTE09 Follow-up in Prostatic Specific Antigen (PSA)|Change From Baseline MTE08 to MTE09 Follow-up in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH)|Change From Baseline MTE08 to MTE09 Follow-up in Estradiol|Change From Baseline MTE08 to MTE09 Follow-up in Hemoglobin|Change From Baseline MTE08 to MTE09 Follow-up in Hematocrit,http://ClinicalTrials.gov/show/NCT00857454,United States,1,0,1,NA
NCT00857623,Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy,Completed,No Results Available,Pain|Diabetic Neuropathy,Drug: AZD2066|Drug: Placebo,AstraZeneca|anders.neijber@astrazeneca.com,Both,Adult|Senior,Phase II,334,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D0475C00009,2/27/2009,01/02/2009,01/08/2009,06/02/2010,01/06/2010,,01/08/2009,"Change in mean numerical rating scale (NRS) score from baseline to last 5 days of treatment|Patients with Patient Global Impression of Change (PGIC) socre of at least \much improved\"" (responder rate) at Day 28|Patients with >=30% reduction from baseline in NRS pain intensity score (responder rate) at Day 28|Patients with >=50% reduction from baseline in NRS pain intensity score (responder rate) at Day 28""",http://ClinicalTrials.gov/show/NCT00857623,United States,1,0,2,NA
NCT00857948,Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation,Completed,No Results Available,Pediculus Humanus Capitis (Head Lice),"Drug: ivermectin treatment conditioner|Drug: Placebo, vehicle control",Topaz Pharmaceuticals Inc,Both,Child|Adult|Senior,Phase II,78,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TOP003,03/06/2009,01/03/2009,01/04/2009,9/30/2010,01/09/2010,,01/04/2009,Presence or absence of live lice after final study drug application|Evaluation of safety based on reported adverse events.,http://ClinicalTrials.gov/show/NCT00857948,United States,1,1,2,1
NCT00858130,Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome,Completed,No Results Available,Post Thrombotic Syndrome|Deep Vein Thrombosis|Venous Stasis Syndrome|Venous Insufficiency Syndrome|Postphlebitic Syndrome,Device: VeinOPlus,"University of North Carolina, Chapel Hill|Clinical and Translational Research Center at UNC Hospitals|VeinoPlus USA",Both,Adult|Senior,Phase II|Phase III,12,Other,Interventional,Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Veinoplus08-2143,03/05/2009,01/03/2009,01/11/2009,01/07/2010,01/01/2010,VeinoPlus,01/11/2009,"Estimate the optimal electrical stimulation intensity level at which patients using the portable electrical muscle stimulator (VeinoPlus?ó) have the largest benefit for relief of symptoms.|Estimate whether use of the device was a \clinical success\"" as defined by the patient reporting benefit by the improvement of symptoms after having used the device",http://ClinicalTrials.gov/show/NCT00858130,United States,0,NA,1,NA
NCT00859313,"An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement",Completed,No Results Available,Unilateral Knee Replacement,Drug: Sublingual dosage of sufentanil,"AcelRx Pharmaceuticals, Inc.",Both,Adult|Senior,Phase II,32,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ARX-C-004,03/09/2009,01/04/2009,01/08/2009,08/12/2009,01/08/2009,,01/08/2009,"To evaluate the functionality of the NanoTab?ºÑ Delivery System for patient self-administration of ARX-F01 NanoTabs?ºÑ to the sublingual cavity.|To evaluate the safety, efficacy, and tolerability of the NanoTab?ºÑ Delivery System /ARX-F01.",http://ClinicalTrials.gov/show/NCT00859313,United States,1,0,1,NA
NCT00860262,Telmisartan and Amlodipine Fixed Dose Combination Trial for the Treatment of Severe Hypertension,Completed,Has Results,Hypertension,Drug: amlodipine|Drug: telmisartan|Drug: telmisartan and amlodipine,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase III,860,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,1235.20|2008-000873-40,03/11/2009,01/03/2009,NA,12/10/2010,01/12/2010,,01/12/2009,Change From Baseline in Trough Seated Systolic Blood Pressure at Week 8|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 8|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2|Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2|Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1|Patients Achieving Diastolic Blood Pressure Control at Week 1|Patients Achieving Diastolic Blood Pressure Control at Week 2|Patients Achieving Blood Pressure Control at Week 1|Patients Achieving Blood Pressure Control at Week 2|Patients Achieving Diastolic Blood Pressure Response at Week 1|Patients Achieving Diastolic Blood Pressure Response at Week 2|Patients Achieving Systolic Blood Pressure Response at Week 1|Patients Achieving Systolic Blood Pressure Response at Week 2|Patients Achieving Normal Blood Pressure Response at Week 1|Patients Achieving Normal Blood Pressure Response at Week 2|Patients Achieving Diastolic Blood Pressure Control at Week 4|Patients Achieving Diastolic Blood Pressure Control at Week 6|Patients Achieving Diastolic Blood Pressure Control at Week 8|Patients Achieving Blood Pressure Control at Week 4|Patients Achieving Blood Pressure Control at Week 6|Patients Achieving Blood Pressure Control at Week 8|Patients Achieving Diastolic Blood Pressure Response at Week 4|Patients Achieving Diastolic Blood Pressure Response at Week 6|Patients Achieving Diastolic Blood Pressure Response at Week 8|Patients Achieving Systolic Blood Pressure Response at Week 4|Patients Achieving Systolic Blood Pressure Response at Week 6|Patients Achieving Systolic Blood Pressure Response at Week 8|Patients Achieving Normal Blood Pressure Response at Week 4|Patients Achieving Normal Blood Pressure Response at Week 6|Patients Achieving Normal Blood Pressure Response at Week 8,http://ClinicalTrials.gov/show/NCT00860262,"United States, &nbsp; Bulgaria, &nbsp; Czech Republic, &nbsp; France, &nbsp; Hungary, &nbsp; Korea, Republic of, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; Spain, &nbsp; Ukraine",1,1,3,0
NCT00860951,P300 Brain Computer Interface Keyboard to Operate Assistive Technology,Completed,No Results Available,Healthy,Device: Brain Computer Interface Keyboard,University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Both,Adult|Senior,Phase I|Phase II,158,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research,H0002 - AT P300 Keyboard Study,03/11/2009,01/09/2008,01/05/2009,1/14/2010,01/01/2010,,01/05/2009,Accuracy of typing with BCI keyboard.,http://ClinicalTrials.gov/show/NCT00860951,United States,0,NA,1,NA
NCT00861185,Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma,Completed,No Results Available,Exercise Induced Asthma,Drug: senicapoc|Drug: Placebo,Icagen,Both,Adult,Phase II,69,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ICA-17043-18,03/12/2009,01/03/2009,01/09/2009,11/13/2009,01/11/2009,,01/07/2009,"The change from baseline in the maximal percentage decrease in forced expiratory volume in one second (FEV1) after exercise|- Area under the curve (AUC) for FEV1 after exercise challenge, - the length of time for recovery of FEV1 after exercise challenge, - changes in non-challenge pulmonary function tests, and an asthma control questionnaire.",http://ClinicalTrials.gov/show/NCT00861185,United States,1,0,2,NA
NCT00862641,A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Asthma|Coronary Artery Disease|Pulmonary Disease, Chronic Obstructive",Drug: Regadenoson|Drug: Placebo,Astellas Pharma Inc,Both,Adult|Senior,Phase IV,1009,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic",3606-CL-3001,3/15/2009,01/04/2009,01/10/2009,01/11/2011,01/01/2011,,01/10/2009,Percentage of Subjects Who Had a >15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline Assessment|Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration|Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration|Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Absolute Values|Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Percent Predicted|Change From Baseline to the 2 Hour Post-dose Assessment for Forced Vital Capacity (FVC)|Change From Baseline to the 2 Hour Post-dose Assessment for FEV1/ FVC Ratio|Change From Baseline to the 2 Hour Post-dose Assessment for Oxygen Saturation Measured by Pulse Oximetry|Percentage of Selected Respiratory Adverse Events,http://ClinicalTrials.gov/show/NCT00862641,United States,1,1,2,1
NCT00863551,Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial,Completed,No Results Available,Elderly|Pharmacokinetics|Overactive Bladder,Drug: Trospium Chloride,Allergan,Both,Adult|Senior,Phase IV,12,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MA-SXR-09-001|SMART Trial,3/16/2009,01/04/2009,01/08/2009,9/16/2010,01/09/2010,,01/08/2009,"Mean concentration of trospium in cerebral spinal fluid at day 10, hour 5|The proportion of study subjects with no clinically significant effect on neurocognitive function as measured by the Hopkins Verbal Learning test-Revised|The proportion of study subjects with no clinically significant effect on neurocognitive function as measured by the Brief Visuospatial Memory Test-Revised",http://ClinicalTrials.gov/show/NCT00863551,United States,1,1,1,1
NCT00863707,A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment,Completed,No Results Available,Kidney Diseases|Coronary Artery Disease,Drug: regadenoson|Drug: Placebo,Astellas Pharma Inc,Both,Adult|Senior,Phase IV,510,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic",3606-CL-3010,3/16/2009,01/04/2009,01/12/2009,01/04/2010,01/01/2010,,01/12/2009,Frequency of serious adverse events,http://ClinicalTrials.gov/show/NCT00863707,United States,1,1,2,1
NCT00864123,D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder,Completed,No Results Available,Obsessive-Compulsive Disorder,Behavioral: Cognitive-behavioral therapy|Drug: D-cycloserine,University of South Florida,Both,Child,Phase II,40,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MH076775|MH076775,3/17/2009,01/01/2008,01/11/2009,08/05/2010,01/08/2010,,01/11/2009,"Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS; Scahill et al., 1997). The CY-BOCS is a 10-item semi-structured measure of obsession and compulsion severity over the previous week. This measure will serve as the primary outcome index.|Clinical Global Impression - Severity (CGI-S; National Institute of Mental Health, 1985). The CGI-S is a 7-point clinician rating of severity of psychopathology.|Adverse Symptom Checklist (ASC; Goodman, 2005). This index assesses adverse side effects that have been associated with DCS, as well as other commonly used psychotropic agents (e.g., SRIs).",http://ClinicalTrials.gov/show/NCT00864123,United States,1,1,2,1
NCT00864682,Preventing Propofol-Associated Injection Pain,Completed,Has Results,Pain,Drug: Saline|Drug: Lidocaine / propofol admixture|Drug: lidocaine pretreatment,Benaroya Research Institute,Both,Adult|Senior,Phase IV,156,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",06091|373,3/16/2009,01/01/2008,01/04/2009,6/15/2009,01/06/2009,,01/03/2009,Verbal Pain Score|Complete Alleviation of Injection Pain|Satisfaction With Anesthetic Technique,http://ClinicalTrials.gov/show/NCT00864682,United States,1,1,3,0
NCT00865904,Study of VX-809 in Cystic Fibrosis Subjects With the ???F508-CFTR Gene Mutation,Completed,No Results Available,Cystic Fibrosis,Drug: VX-809|Drug: VX-809|Drug: VX-809|Drug: VX-809|Drug: VX-809 Placebo,Vertex Pharmaceuticals Incorporated,Both,Adult|Senior,Phase II,90,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",VX08-809-101,3/18/2009,01/03/2009,01/12/2009,01/07/2010,01/01/2010,,01/12/2009,"Safety and tolerability assessments based on adverse events, hematology, clinical chemistry, urinalysis, electrocardiograms (ECGs), vital signs, and physical examinations.|Pharmacodynamic assessments using spirometry (FVC, FEV1, and FEF25-75), sweat chloride, nasal potential difference (NPD), and the CF Questionnaire-Revised (CFQ-R), and evaluation of pharmacokinetic parameters.",http://ClinicalTrials.gov/show/NCT00865904,"United States, &nbsp; Belgium, &nbsp; Canada, &nbsp; Germany, &nbsp; Netherlands",1,0,5,NA
NCT00868439,Evaluation of RLY5016 in Heart Failure Patients,Completed,No Results Available,Hyperkalemia|Heart Failure,Drug: Spironolactone + RLY5016|Drug: Spironolactone + Placebo,"Relypsa, Inc.|Medpace, Inc.",Both,Adult|Senior,Phase II,105,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",RLY5016-202,3/23/2009,01/04/2009,NA,02/04/2010,01/02/2010,PEARL-HF,01/11/2009,Change from baseline in serum potassium|Safety and tolerability,http://ClinicalTrials.gov/show/NCT00868439,"United States, &nbsp; Czech Republic, &nbsp; Georgia, &nbsp; Germany, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Ukraine",1,0,2,NA
NCT00869063,"Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion",Completed,No Results Available,Acute Pain,Drug: Diclofenac Sodium Patch|Drug: Matching Placebo Patch,Cerimon Pharmaceuticals|PPD,Both,Child|Adult|Senior,Phase III,214,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DCF-005,3/24/2009,01/02/2009,01/09/2009,1/26/2010,01/01/2010,WIND,01/07/2009,Change in average pain during daily activity|Change in average pain during daily activity,http://ClinicalTrials.gov/show/NCT00869063,United States,1,1,2,0
NCT00869180,Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain,Completed,No Results Available,Acute Pain|Ankle Sprain,Drug: Diclofenac Sodium|Drug: Matching Placebo Patch,Cerimon Pharmaceuticals|PPD,Both,Child|Adult|Senior,Phase III,219,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DCF-004,3/24/2009,01/02/2009,01/08/2009,1/26/2010,01/01/2010,SUPPORT 2,01/06/2009,Change in average pain during daily activity at Day 3|Change in average pain during daily activity at Day 7,http://ClinicalTrials.gov/show/NCT00869180,United States,1,1,2,0
NCT00869336,Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot),Completed,No Results Available,Tinea Pedis,Drug: Luliconazole Cream 1% - 2 wks|Drug: Placebo Comparator -2 wks|Drug: Luliconazole Cream 1% - 4 wks|Drug: Placebo Comparator - 4 wks,Tinea Pharmaceuticals,Both,Child|Adult|Senior,Phase II,150,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TP-0801,3/25/2009,01/03/2009,01/09/2009,11/22/2010,01/11/2010,,01/09/2009,Proportion of subjects who achieve complete clearance at 2 weeks post treatment|Proportion of subjects who achieve effective treatment at 2 and 4 weeks post treatment,http://ClinicalTrials.gov/show/NCT00869336,United States,1,0,4,NA
NCT00869440,Dose-Finding Safety Study Evaluating CNS 7056 in Patients Undergoing Diagnostic Upper GI Endoscopy,Completed,No Results Available,Procedural Sedation|Endoscopy,Drug: CNS 7056|Drug: Midazolam,Paion UK Ltd.,Both,Adult,Phase II,102,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CNS 7056-003,3/25/2009,01/03/2009,01/09/2009,09/08/2010,01/09/2010,,01/09/2009,MOAA/S scores ???4 on three consecutive measurements after administration of study drug AND completion of the endoscopy procedure without requiring rescue sedative medication AND without requiring manual or mechanical ventilation|Time to fully alert (time to first of 3 consecutive MOAA/S scores of 5)|Time to ready for discharge (time to first of 3 consecutive Aldrete scores ??­9)|No requirement for rescue sedative medication|No manual or mechanical ventilation|MOAA/S score at specified time points|Drowsiness intensity rating on VAS at specified time points|HVLT-R Score|Brice Questionnaire,http://ClinicalTrials.gov/show/NCT00869440,United States,1,0,2,NA
NCT00869791,A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa,Completed,No Results Available,Parkinson's Disease,Drug: IPX066|Drug: CD-LD,"IMPAX Laboratories, Inc.",Both,Adult|Senior,Phase I|Phase II,27,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,IPX066-B08-11,3/24/2009,01/02/2009,01/08/2009,10/29/2010,01/10/2010,,01/06/2009,"Pharmacokinetics: CD and LD Cmax, Tmax, AUC, half-life|Safety (electrocardiogram, clinical laboratory tests, vital signs, AEs) and Pharmacodynamics (finger tapping, walking, UPDRS)",http://ClinicalTrials.gov/show/NCT00869791,United States,1,0,2,NA
NCT00870103,Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery,Completed,Has Results,Cataract,Drug: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops,Alcon Research,Both,Adult|Senior,Phase IV,64,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RM-08-05,9/26/2008,01/09/2008,NA,03/03/2010,01/03/2010,,01/02/2009,The Percentage of Patients With a Score of Zero for Anterior Chamber Cells.|The Percentage of Patients With no Ocular Pain,http://ClinicalTrials.gov/show/NCT00870103,United States,1,0,1,NA
NCT00871182,Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,No Results Available,Chronic Obstructive Pulmonary Disease,Drug: Inhaled PT001|Drug: Inhaled Placebo|Drug: tiotropium,"Pearl Therapeutics, Inc.",Both,Adult|Senior,Phase I|Phase II,33,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PT0010801,3/26/2009,01/03/2009,01/09/2009,10/05/2010,01/10/2010,,01/09/2009,Peak improvement in forced expiratory volume in one second (FEV1)|Time to onset of action (>10% improvement in FEV1 from baseline)|Time to peak FEV1|FEV1 area under the curve (AUC) from 0 to 24 hours|FEV1 AUC from 0 to 12 hours|Trough FEV1 at 12 and 24 hours|Peak Improvement in inspiratory capacity (IC),http://ClinicalTrials.gov/show/NCT00871182,United States,1,0,3,NA
NCT00871325,Effect of TU-100 on Gastrointestinal and Colonic Transit in Humans,Completed,No Results Available,Postoperative Ileus,Drug: TU-100,Tsumura USA,Both,Adult,Phase I|Phase II,60,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",TU100CPT1,3/26/2009,01/06/2009,01/01/2010,02/02/2010,01/02/2010,,01/12/2009,Gastric emptying of solid|Colonic geometric center at 24 hours|Ascending colon emptying|Colonic geometric center at 4 hours and 48 hours|Colonic filling at 6 hours|Stool frequency|Stool consistency,http://ClinicalTrials.gov/show/NCT00871325,United States,1,0,1,NA
NCT00871819,Optimized Programming in Spinal Cord Stimulation (SCS) System,Completed,No Results Available,Neuropathic Pain|Pain,Device: Precision Spinal Cord Stimulation,Boston Scientific Corporation,Both,Adult|Senior,Phase IV,20,Industry,Interventional,"Control: Dose Comparison|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Supportive Care",A2008,3/27/2009,01/03/2009,01/09/2009,12/17/2009,01/12/2009,OP,01/08/2009,Correlation between dorsal root paresthesia at maximum-comfortable stimulation level and anode-cathode separation distance|Location of dorsal root paresthesia under multipolar stimulation vs. traditional contact combinations,http://ClinicalTrials.gov/show/NCT00871819,United States,0,NA,1,NA
NCT00871936,A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes,Completed,No Results Available,Type 2 Diabetes,Drug: SLx-4090|Other: Placebo,Surface Logix,Both,Adult|Senior,Phase II,82,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",SLx-4090-09-07,3/26/2009,01/04/2009,01/10/2009,12/14/2009,01/08/2009,,01/10/2009,Reduction in HbA1c|Adverse Events,http://ClinicalTrials.gov/show/NCT00871936,United States,1,0,2,NA
NCT00871988,Nasolabial Fold Filler Study for People of Color,Completed,No Results Available,Bilateral Wrinkles in the Nasolabial Area,Drug: EVOLENCE,DeNova Research|Johnson & Johnson,Both,Adult|Senior,Phase IV,30,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DP101-US-04,3/27/2009,01/11/2008,01/11/2009,10/19/2010,01/10/2010,,01/11/2009,"To assess the safety EVOLENCE?ó in subjects with Fitzpatrick Skin Color Types IV, V, and VI seeking correction of facial wrinkles in accordance with the approved device labeling including for example correction of the nasolabial wrinkle /folds.|To assess the device effectiveness in skin types IV, V, and VI",http://ClinicalTrials.gov/show/NCT00871988,United States,1,0,1,NA
NCT00872534,Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers,Completed,No Results Available,Upper Gastrointestinal Mucosal Damage,Drug: acetylsalicylic acid,PLx Pharma,Both,Adult|Senior,Phase I|Phase II,164,Industry,Interventional,Allocation: Randomized|Control: Active Control|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Prevention,PL-ASA-002,03/10/2009,01/01/2009,01/07/2009,7/28/2009,01/05/2009,,01/07/2009,Incidence of subjects with gastroduodenal erosions and ulcers.|Incidence of subjects with ulcers (ulcers 3mm or greater in length with unequivocal depth).|Mean number of erosions in the duodenum and stomach.,http://ClinicalTrials.gov/show/NCT00872534,United States,1,0,1,NA
NCT00872885,Bunionectomy Trial With GRT6005,Completed,No Results Available,Post Operative Pain,Drug: GRT6005|Drug: Morphine|Drug: Placebo,Gr??nenthal GmbH,Both,Adult|Senior,Phase II,258,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",425965,3/24/2009,01/03/2009,01/10/2009,6/21/2010,01/06/2010,,01/08/2009,Sum of pain intensity 2-10 hours after Investigational medicinal product intake. Pain assessments|Amount of rescue medication|Adverse events|Time to first rescue medication|Patient Global Impression of Change,http://ClinicalTrials.gov/show/NCT00872885,United States,1,0,3,NA
NCT00874094,Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds,Completed,No Results Available,Nasolabial Folds,Biological: Autologous platelet rich fibrin matrix,The New York Eye & Ear Infirmary,Female,Adult|Senior,Phase I|Phase II,15,Other,Interventional,Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,8.01,04/01/2009,01/04/2008,01/07/2009,08/10/2009,01/06/2009,,01/06/2009,Improvement in nasolabial folds (laugh lines) from pre-treatment.,http://ClinicalTrials.gov/show/NCT00874094,United States,0,NA,1,NA
NCT00877799,Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery,Completed,No Results Available,Acute Pain|Post-operative Pain,Drug: CR845,"Cara Therapeutics, Inc.",Female,Adult,Phase II,114,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CR845-CLIN2001,04/06/2009,01/03/2009,01/01/2010,4/16/2010,01/04/2010,,01/12/2009,"Analgesic efficacy measured by patient's self reported pain level at rest after surgery (after single dose administration).|Time to onset of analgesic efficacy|Time specific and total level of pain relief|Duration of analgesia|Time specific pain intensity difference from baseline and total level of pain relief|Time and requirement for rescue medication including survival curve of patients requesting rescue medication|Patient satisfaction with study medication with the patient Global evaluation scale|Vital signs, clinical laboratory parameters, ECG|Incidence of adverse events (AEs)|Sedation as measured by Ramsay sedation scale|Anti-inflammatory effects (measured by quantification of serum TNF alpha and serum IL-6",http://ClinicalTrials.gov/show/NCT00877799,United States,1,0,1,NA
NCT00879034,"A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria",Completed,No Results Available,Progeria,Drug: Lonafarnib|Drug: Zoledronic Acid|Drug: Pravastatin,Children's Hospital Boston|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Schering-Plough,Both,Child|Adult|Senior,Phase II,5,Other|Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,09/02/1974,04/08/2009,01/03/2009,01/04/2009,4/20/2010,01/04/2010,,01/04/2009,"The primary objective of this study is to evaluate the feasibility of administering intravenous zoledronic acid, oral pravastatin and oral lonafarnib, to patients with Progeria for a minimum of 4 weeks|To describe any acute and chronic toxicities associated with treating progeria patients with the combination of zoledronic acid, pravastatin and lonafarnib|To investigate which clinical and laboratory studies are needed to monitor or alter therapy to prevent unacceptable toxicity|To assess the pharmacokinetics of lonafarnib in patients with progeria.|To assay for the inhibition of HDJ-2 farnesylation in Peripheral Blood Leukocytes (PBL)|To obtain baseline clinical and laboratory data so that longer-term measures of efficacy will be achievable if treatment continues beyond the 4-week feasibility study period.",http://ClinicalTrials.gov/show/NCT00879034,United States,1,0,3,NA
NCT00880100,Use of Ultrase MT12 in Young Cystic Fibrosis Children,Completed,No Results Available,Cystic Fibrosis|Pancreatic Insufficiency,Drug: Pancrelipase,Axcan Pharma,Both,Child,Phase III,54,Industry,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,UMT12CF08-01,04/09/2009,01/04/2009,01/11/2009,05/12/2010,01/05/2010,,01/11/2009,"Proportion of subjects with control of steatorrhea under Ultrase MT12.|Stool frequency,consistency and characteristics under Ultrase MT12. Abdominal complaints under Ultrase MT12. Tolerability of Ultrase MT12.",http://ClinicalTrials.gov/show/NCT00880100,United States,1,0,1,NA
NCT00881868,Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp,Completed,Has Results,Scalp Psoriasis,Drug: clobetasol propionate spray 0.05%|Drug: Vehicle spray,"Galderma Laboratories, L.P.",Both,Adult|Senior,Phase IV,81,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",US10118,4/13/2009,01/04/2009,01/12/2009,01/07/2011,01/01/2011,,01/12/2009,"Number of Participants Who Were a Success or Failure Based on the Global Severity Score (GSS) of Scalp Psoriasis From Baseline to End of Treatment (Week 4 or Week 2 if Clear)|Number of Participants in Each Category of the Scalp Psoriasis Individual Sign Scores (Scaling, Erythema and Plaque Elevation) at Baseline and Week 4|Number of Participants in Each Category of the Extent of Scalp Involvement Index at Baseline and Week 4|Number of Participants in Each Category of Pruritus at Baseline and Week 4",http://ClinicalTrials.gov/show/NCT00881868,United States,1,1,2,1
NCT00882557,A Study to Evaluate Daptomycin Given During Dialysis and After Dialysis,Completed,No Results Available,End-Stage Renal Disease|Hemodialysis,Drug: daptomycin|Drug: daptomycin,Cubist Pharmaceuticals,Both,Adult|Senior,Phase IV,12,Industry,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,DAP-RENID-08-06,4/15/2009,01/05/2009,01/07/2009,9/20/2010,01/09/2010,,01/07/2009,"Pharmacokinetic evaluation|Incidence of AEs, deaths, premature discontinuation due to an AE, clinical lab data, ECG results, Physical Exam Findings, and Concomitant medications and procedures.",http://ClinicalTrials.gov/show/NCT00882557,United States,1,1,2,1
NCT00882687,Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis,Completed,No Results Available,Allergic Conjunctivitis,Drug: SAR 1118|Other: Placebo,SARcode Corporation,Both,Adult|Senior,Phase II,60,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",1118-ACJ-100,4/15/2009,01/04/2009,01/05/2009,05/12/2009,01/05/2009,,01/05/2009,Ocular itching and conjunctival redness at defined timepoints.|Safety and tolerability in subjects with allergic conjunctivitis.,http://ClinicalTrials.gov/show/NCT00882687,United States,1,0,2,NA
NCT00883168,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,No Results Available,Seasonal Allergic Rhinitis,Drug: Placebo|Drug: azelastine hydrochloride|Drug: fluticasone propionate|Drug: azelastine hydrochloride/fluticasone propionate formulated product,Meda Pharmaceuticals,Both,Child|Adult|Senior,Phase III,1800,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP4006,4/16/2009,01/04/2009,01/07/2009,11/25/2009,01/11/2009,,01/07/2009,Change from baseline in 12 hour Reflective Total Nasal Symptom Score|Change from baseline in 12 hour Instantaneous Total Nasal Symptom Score|Onset of action|Change from baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)|Nasal Examinations,http://ClinicalTrials.gov/show/NCT00883168,United States,1,1,4,1
NCT00883311,A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis,Completed,No Results Available,Atopic Dermatitis,Device: BRT-FC-83C,"Biomed Research & Technologies, Inc.",Both,Adult,Phase II,32,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BRT-C09-C017,4/15/2009,01/01/2009,01/07/2009,8/29/2010,01/08/2010,,01/07/2009,Change in mean Atopic Dermatitis Severity Index (ADSI) in lesional skin at target site|Change in mean Trans Epidermal Water Loss (TEWL) in lesional skin at target site|Change in mean corneometer measurement in lesional skin at target site|Self assessment of efficacy of BRT-FC-83C on signs and symptoms of atopic dermatitis|Change in Investigator's Global Assessment (IGA) in lesional skin at target site,http://ClinicalTrials.gov/show/NCT00883311,United States,0,NA,1,NA
NCT00884234,Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines,Completed,No Results Available,Lateral Canthal Lines,Other: Vehicle Control|Drug: RT001 (Botulinum Toxin Type A Topical Gel),"Revance Therapeutics, Inc.",Both,Adult,Phase II,30,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",RT001-CL011LCL,4/17/2009,01/02/2009,01/06/2009,9/23/2010,01/09/2010,,01/04/2009,The number of subjects classified as exhibiting improvement via the Investigator Global Assessment from Baseline (Day 0) to End of Study (Week 6).|Incidence of treatment emergent AEs.,http://ClinicalTrials.gov/show/NCT00884234,United States,1,0,2,NA
NCT00884377,Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis,Completed,No Results Available,Cutaneous Leishmaniasis,Drug: Sodium stibogluconate (Pentostam)|Device: ThermoMed,U.S. Army Medical Research and Materiel Command|Walter Reed Army Medical Center,Both,Adult,Phase II,60,U.S. Fed,Interventional,Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,A-12364,4/17/2009,01/02/2004,01/03/2009,4/17/2009,01/04/2009,,01/01/2009,"The primary objective is to assess if local heat treatment with the ThermoMed device is equivalent in efficacy to 10 days of parenteral sodium stibogluconate|Determine efficacy of heat vs SSG for all lesions at 12 mos after treatment start.|Compare the toxicity profiles of heat versus parenteral SSG therapy|Evaluate the immune response to leishmania before, and on day 10 and 6 months following treatment|Establish the feasibility of a L. major species specific polymerase chain reaction as a rapid diagnostic device in the context of a treatment trial.",http://ClinicalTrials.gov/show/NCT00884377,United States,1,0,2,NA
NCT00888069,Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects,Completed,No Results Available,Chronic Kidney Disease|Secondary Hyperparathyroidism|Chronic Renal Insufficiency|Chronic Renal Failure,Drug: CTAP101|Drug: CTAP101|Drug: CTAP101,Cytochroma Inc.,Both,Adult|Senior,Phase I|Phase II,92,Industry,Interventional,Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CTAP101-CL-2004,4/23/2009,01/05/2009,01/12/2009,2/24/2010,01/02/2010,,01/11/2009,To assess the PK and bioavailability of CTAP101 in Stage 3 and 4 CKD subjects with vitamin D insufficiency and SHPT|To assess the safety and tolerability of CTAP101 capsules and injection|To assess the pharmacodynamics of single dose CTAP101 in Stage 3 and Stage 4 CKD subjects with vitamin D insufficiency and SHPT.,http://ClinicalTrials.gov/show/NCT00888069,United States,1,0,3,NA
NCT00888459,A Pilot Study Evaluating Nicotine Lozenges and Self Help,Completed,Has Results,Smokeless Tobacco Use,Drug: nicotine replacement therapy|Drug: placebo NRT,Mayo Clinic|Oregon Research Institute,Male,Adult|Senior,Phase II,60,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-008574|CA121165,4/24/2009,01/04/2008,01/05/2009,11/29/2010,01/11/2010,,01/04/2009,Number of Participants With Tobacco Abstinence,http://ClinicalTrials.gov/show/NCT00888459,United States,1,1,2,0
NCT00888914,Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines,Completed,No Results Available,Lateral Canthal Lines|Crow's Feet|Facial Wrinkles,Drug: RT001|Drug: RT001|Drug: RT001|Drug: RT001|Other: Vehicle Comparator,"Revance Therapeutics, Inc.",Both,Adult,Phase II,60,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",RT001-CL006LCL,4/24/2009,01/11/2008,01/02/2009,9/28/2010,01/09/2010,,01/01/2009,The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Smile from Baseline (Day 0) to End of Study (Day 28)|The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Rest from Baseline (Day 0) to End of Study (Day 28)|Incidence of treatment-emergent AEs,http://ClinicalTrials.gov/show/NCT00888914,United States,1,0,5,NA
NCT00888940,Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery,Completed,Has Results,"Bloodloss|Surgical Procedures, Operative",Drug: Ecallantide|Drug: Cyklokapron(R),Cubist Pharmaceuticals,Both,Adult|Senior,Phase II,243,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ECAL-CCPB-08-07,4/26/2009,01/06/2009,01/01/2010,12/14/2010,01/12/2010,CONSERV-2,01/12/2009,Cumulative Volume of Packed Red Blood Cells Transfused|Treatment-emergent Adverse Events.,http://ClinicalTrials.gov/show/NCT00888940,"United States, &nbsp; Germany, &nbsp; Poland",1,1,2,1
NCT00889252,"Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers",Completed,Has Results,Allergic Conjunctivitis,Device: contact lens with ketotifen|Device: contact lens,Vistakon Pharmaceuticals,Both,Child|Adult|Senior,Phase III,250,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CR-4539,4/24/2009,01/04/2009,NA,10/26/2010,01/10/2010,,01/07/2009,"Lid and Lid Margin Erythema, Change From Baseline|Lid and Lid Margin Swelling, Change From Baseline|Conjunctival Redness, Change From Baseline|Conjunctival Chemosis, Change From Baseline|Corneal Edema, Change From Baseline|Corneal Erosion, Change From Baseline|Corneal Endothelial, Change From Baseline|Lens Pathology, Change From Baseline|Flare in Anterior Chamber, Change From Baseline|Cells in Anterior Chamber, Change From Baseline|Corneal Staining - Nasal, Change From Baseline|Corneal Staining - Temporal, Change From Baseline|Corneal Staining - Inferior, Change From Baseline|Corneal Staining - Superior, Change From Baseline|Corneal Staining - Central, Change From Baseline|Intraocular Pressure - Change From Baseline|Dilated Ophthalmoscopy - Fundus, Change From Baseline|Dilated Ophthalmoscopy - Vitreous, Change From Baseline|Visual Acuity Assessment",http://ClinicalTrials.gov/show/NCT00889252,United States,0,NA,2,NA
NCT00889330,A Study of an Anti-allergy Eye-drop,Completed,No Results Available,Allergic Conjunctivitis,Drug: alcaftadine|Drug: Placebo,Vistakon Pharmaceuticals,Both,Child|Adult|Senior,Phase III,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",09-003-05,4/24/2009,01/04/2009,NA,06/01/2010,01/06/2010,,01/05/2009,Ocular Itching|Conjunctival Redness|ETDRS Visual Acuity|Slit Lamp Biomicroscopy|Undilated Fundoscopy|Ocular Symptoms|Nasal Symptoms,http://ClinicalTrials.gov/show/NCT00889330,United States,1,1,2,0
NCT00889473,Study of the Efficacy of AT1001 (Larazotide Acetate) to Treat Celiac Disease,Completed,No Results Available,Celiac Disease,Drug: Larazotide acetate (AT1001)|Drug: Placebo,Alba Therapeutics,Both,Adult|Senior,Phase II,42,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLIN1001-006 Part B,4/27/2009,01/04/2009,01/04/2010,08/12/2010,01/01/2010,,01/11/2009,Response to gluten|Anti-transglutaminase,http://ClinicalTrials.gov/show/NCT00889473,"United States, &nbsp; Canada",1,0,2,NA
NCT00889642,Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers,Completed,No Results Available,Local Anesthesia,Device: Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Device: Iontophoretic Drug Delivery System with Epinephrine,Dharma Therapeutics Inc.,Both,Adult|Senior,Phase II,90,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Dharma-NSCO3,4/27/2009,01/05/2009,01/06/2009,6/22/2009,01/06/2009,,01/05/2009,Following the iontophoresis treatment an IV will be inserted into the treatment area and the amount of pain will be assessed using the median visual analog pain scale (VAS).|Monitor the nature and frequency of adverse events associated with the iontophoretic device through observation during treatment.|Determining the duration of anesthesia through standard pin prick testing.,http://ClinicalTrials.gov/show/NCT00889642,United States,1,1,2,0
NCT00889915,Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study),Completed,No Results Available,Attention Deficit Disorder With Hyperactivity,Drug: Methylphenidate transdermal system|Drug: Lisdexamfetamine dimesylate|Drug: Osmotic-release oral system methylphenidate (OROS MPH)|Drug: Mixed amphetamine salts extended release,National Institute of Mental Health (NIMH),Both,Child,Phase IV,228,NIH,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,P30 MH066386-02|DSIR CTM 4571; Pro00014075,4/27/2009,01/04/2009,01/12/2009,02/05/2010,01/10/2009,,01/12/2009,Dichotomized Clinical Global Impression-Effectiveness (CGI-E) scale|Clinical Global Impressions-Improvement (CGI-I) scale|Clinical Global Improvements-Acceptability (CGI-A) scale,http://ClinicalTrials.gov/show/NCT00889915,United States,1,1,4,1
NCT00890682,Study of Postoperative Analgesia in Bunionectomy,Completed,No Results Available,Bunion|Hallux Valgus,Drug: SKY0402|Drug: NaCl,"Pacira Pharmaceuticals, Inc",Both,Adult|Senior,Phase III,193,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment",SKY0402C317,4/28/2009,01/04/2009,01/11/2009,8/31/2010,01/08/2010,,01/11/2009,The area under the curve (AUC0-24) of the numeric rating scale (NRS) pain intensity scores through 24 hours for subjects receiving SKY0402 vs. placebo,http://ClinicalTrials.gov/show/NCT00890682,United States,1,0,2,NA
NCT00890968,Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis,Completed,No Results Available,Hand Dermatoses,Drug: Triamcinolone Acetonide (TAC) DuraPeel|Drug: Placebo DuraPeel,ZARS Pharma Inc.,Both,Adult|Senior,Phase II,56,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",TAC-202,4/28/2009,01/04/2009,01/08/2009,11/16/2009,01/11/2009,TAC-202,01/06/2009,Response as assessed by Investigator Global Assessment (IGA)|Subject's Global Impression of Change (SGIC)|Individual Primary Parameters of Hand Dermatitis|Signs or symptoms of hand dermatitis|Subject's self-assessment of overall hand disease|Study medication assessment,http://ClinicalTrials.gov/show/NCT00890968,United States,1,0,2,NA
NCT00891462,Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Completed,No Results Available,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium bromide|Drug: Aclidinium bromide|Drug: Placebo,"Forest Laboratories|Almirall, S.A.",Both,Adult|Senior,Phase III,561,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LAS-MD-33|ACCORD COPD I,4/30/2009,01/04/2009,01/11/2009,2/23/2010,01/02/2010,,01/11/2009,Morning Pre-dose Forced Expiratory Volume in 1 Second|Peak Forced Expiratory Volume in 1 Second,http://ClinicalTrials.gov/show/NCT00891462,"United States, &nbsp; Canada",1,0,3,NA
NCT00891683,Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy,Completed,No Results Available,Diabetic Peripheral Neuropathy|Chronic Pain,Drug: AEG33773 oral dosing,Aegera Therapeutics,Both,Adult|Senior,Phase II,128,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AEG33773-201,4/30/2009,01/03/2009,01/02/2010,5/28/2010,01/05/2010,,01/12/2009,To evaluate the potential efficacy of AEG33773 in reducing chronic pain due to DPN|To evaluate a range of AEG33773 doses that provide efficacy|To determine a minimally effective dose of AEG33773|To determine a maximally tolerated dose of AEG33773|To evaluate the safety and tolerability of AEG33773|To explore AEG33773-dependent pharmacodynamic (PD) effects in blood of patients,http://ClinicalTrials.gov/show/NCT00891683,"United States, &nbsp; Bulgaria, &nbsp; Canada, &nbsp; Romania",1,0,1,NA
NCT00891774,Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI,Completed,No Results Available,Non Therapeutic Body Modification,Device: EVOLENCE?ó,Johnson & Johnson Consumer & Personal Products Worldwide,Both,Adult|Senior,Phase IV,172,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DP101 US-04,4/30/2009,01/12/2008,01/11/2009,12/31/2009,01/12/2009,,01/11/2009,"Local and systemic adverse events, including pigmentation changes and keloid formation|Reduction in wrinkle severity score|Investigator's satisfaction of the overall treatment|Subject's satisfaction of the overall treatment",http://ClinicalTrials.gov/show/NCT00891774,United States,0,NA,1,NA
NCT00891982,A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash,Completed,No Results Available,Acne Vulgaris,Drug: CTGel|Drug: Soap Free Cleanser and CTGel,"Stiefel, a GSK Company",Both,Child|Adult,Phase III,61,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,W0265-306,4/29/2009,01/04/2009,01/07/2009,9/13/2010,01/09/2010,,01/06/2009,Local tolerability - Skin Dryness|Local Tolerability - Skin scaling|Local tolerability - Erythema (redness)|Subject Assessment of Burning/Stinging and Itching,http://ClinicalTrials.gov/show/NCT00891982,United States,1,0,2,NA
NCT00892281,ORCA - Oracea?ó for Rosacea: A Community-based Assessment,Completed,Has Results,Rosacea,Drug: doxycycline (Oracea?ó) 40 mg modified release as monotherapy|Drug: doxycycline (Oracea?ó) 40 mg modified release as add-on therapy,"Galderma Laboratories, L.P.",Both,Adult|Senior,Phase IV,1421,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,US10120,4/30/2009,01/04/2009,01/10/2009,12/16/2010,01/12/2010,,01/10/2009,"Change in Investigator's Global Assessment (IGA) Score From Baseline to Endpoint|Change in Clinician's Erythema Assessment Scale (CEA) Score From Baseline to Endpoint|Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear)",http://ClinicalTrials.gov/show/NCT00892281,United States,1,1,2,1
NCT00894231,Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis,Completed,No Results Available,Perennial Allergic Rhinitis,Drug: levocetirizine (Xyzal)|Drug: placebo,"AAADRS Clinical Research Center|UCB, Inc.",Both,Child|Adult,Phase IV,30,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IIS071108,4/17/2009,01/01/2009,01/08/2009,09/03/2009,01/09/2009,,01/08/2009,"The change in objective measure of inflammation nasal NO after LC treatment.|The change in nasal eosinophils, QOL and diary scores after LC treatment.",http://ClinicalTrials.gov/show/NCT00894231,United States,1,1,2,1
NCT00894530,"The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period",Completed,No Results Available,Blepharitis,"Drug: Azithromycin ophthalmic solution, 1%|Drug: Placebo",Inspire Pharmaceuticals,Both,Adult|Senior,Phase II,314,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",044-102,05/05/2009,01/05/2009,01/12/2009,10/29/2010,01/10/2010,,01/12/2009,Eyelid margin erythema|Signs and symptoms of Blepharitis,http://ClinicalTrials.gov/show/NCT00894530,United States,1,1,2,0
NCT00894699,"A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab?ºÑ in Patients Undergoing an Elective Abdominal Liposuction Procedure",Completed,No Results Available,Sedation|Anxiety|Pain,Drug: Sublingual Sufentanil/Triazolam NanoTab?ºÑ (ARX-F03)|Drug: Placebo NanoTab?ºÑ,"AcelRx Pharmaceuticals, Inc.",Both,Adult,Phase II,40,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ARX-C-007,05/05/2009,01/06/2009,01/09/2009,10/06/2009,01/10/2009,,01/09/2009,The primary objective is to evaluate the efficacy of ARX-F03 administered once as a single treatment in providing mild sedation compared to placebo in the procedural setting.|A secondary objective is to evaluate the efficacy of ARX-F03 in providing a reduction in anxiety and in pain intensity compared to placebo in the procedural setting.,http://ClinicalTrials.gov/show/NCT00894699,United States,1,0,2,NA
NCT00895830,Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV),Completed,No Results Available,Postoperative Nausea and Vomiting,Drug: APD405|Drug: Placebo,Acacia Pharma Ltd,Both,Adult|Senior,Phase II,260,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",DP10002,05/07/2009,01/05/2009,01/11/2009,12/22/2009,01/12/2009,,01/11/2009,Post-operative nausea or vomiting,http://ClinicalTrials.gov/show/NCT00895830,"United States, &nbsp; France, &nbsp; Germany, &nbsp; Switzerland",1,0,2,NA
NCT00902200,A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP),Completed,No Results Available,Elevated Intraocular Pressure,Drug: AR-12286|Drug: AR-12286 vehicle,Aerie Pharmaceuticals,Both,Adult|Senior,Phase II,80,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AR-12286-CS201,5/13/2009,01/05/2009,01/09/2009,11/05/2009,01/11/2009,,01/09/2009,The primary efficacy endpoint will be mean diurnal IOP on each day at which diurnal IOP is measured at each timepoint.,http://ClinicalTrials.gov/show/NCT00902200,United States,1,0,2,NA
NCT00903448,Comparison of Prilosec Over-the-counter (OTC)?ó Versus Prevacid?ó for Gastric Acid Suppression,Completed,Has Results,Healthy,Drug: Prilosec OTC (omeprazole-magnesium)|Drug: Prevacid,Procter and Gamble,Both,Adult,Phase IV,40,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2009010,5/14/2009,01/04/2009,01/06/2009,12/22/2010,01/12/2010,,01/06/2009,Mean Percent Time That Gastric pH > 4.0 on Day 5,http://ClinicalTrials.gov/show/NCT00903448,United States,1,1,2,1
NCT00904670,NWP06 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD),Completed,No Results Available,Attention Deficit Hyperactivity Disorder,Drug: NWP06|Drug: Placebo,NextWave Pharmaceuticals,Both,Child,Phase III,45,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NWP06-ADD-100,5/18/2009,01/05/2009,01/08/2009,8/19/2009,01/08/2009,,01/08/2009,SKAMP|PERMP,http://ClinicalTrials.gov/show/NCT00904670,United States,1,0,2,NA
NCT00907101,Evaluate Effectiveness of Epiduo?ó Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes,Completed,No Results Available,P Acnes Colonization,Drug: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo?ó Gel),"Galderma Laboratories, L.P.",Both,Adult|Senior,Phase IV,30,Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,US10127,5/20/2009,01/06/2009,01/07/2009,8/14/2009,01/08/2009,,01/07/2009,Change from baseline in quantitative bacteriology measurements at week 4|Tolerability assessments,http://ClinicalTrials.gov/show/NCT00907101,United States,1,1,1,1
NCT00907257,A Study of Different Use Regimens Using Two Acne Treatments,Completed,No Results Available,Acne Vulgaris,Drug: benzoyl peroxide wash and tretinoin gel|Drug: benzoyl peroxide wash and tretinoin gel,Johnson & Johnson Consumer & Personal Products Worldwide,Both,Child|Adult|Senior,Phase IV,67,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,CA-P-6270,5/20/2009,01/02/2009,01/09/2009,11/30/2009,01/11/2009,,01/09/2009,Change from baseline in the total acne lesions count|Change from baseline and percent change from baseline in individual acne lesion counts|Measurement of success according to dichotomized IGA using criteria of improvement of 2 grades from baseline score or clear or almost clear grades (grades 0 or 1)|Change from baseline in Investigator's Global Assessment of Acne Severity (IGA) score,http://ClinicalTrials.gov/show/NCT00907257,United States,1,1,2,1
NCT00907335,A Study of Acne Treatment in Children Ages 9 to 11,Completed,No Results Available,Acne Vulgaris,Drug: Retin-A Micro 0.04% facial acne treatment|Drug: Vehicle control,Johnson & Johnson Consumer & Personal Products Worldwide,Both,Child,Phase II,110,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CA-P-6397,5/20/2009,01/02/2009,01/12/2009,1/14/2010,01/01/2010,,01/12/2009,Change from baseline in total non-inflammatory lesions.|Change from baseline and percent change from baseline in each lesion type|Change from baseline for each visit in Investigator's Global Assessment of Acne Severity (IGA #1 and IGA #2) score|Measurement of success according to dichotomized IGA scores (IGA #1 And IGA #2) using criteria of improvement of 2 grades from baseline score or clear or almost clear grades (grades 0 or 1)|Improvement from baseline in Investigator Global Assessment score (IGA # 3),http://ClinicalTrials.gov/show/NCT00907335,United States,1,1,2,1
NCT00907387,Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines,Completed,No Results Available,Lateral Canthal Lines,Drug: RT001|Drug: RT001|Other: Placebo,"Revance Therapeutics, Inc.",Both,Adult,Phase II|Phase III,72,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",RT001-CL010LCL,5/20/2009,01/04/2009,01/10/2009,9/28/2010,01/09/2010,,01/10/2009,The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Rest from Baseline (Day 0) to Day 28|Incidence of treatment-emergent adverse events,http://ClinicalTrials.gov/show/NCT00907387,United States,1,0,3,NA
NCT00911534,"Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)",Completed,No Results Available,Symptomatic Gastroesophageal Reflux Disease (sGERD),Drug: rabeprazole sodium|Drug: Placebo,Eisai Inc.,Both,Adult|Senior,Phase III,304,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",E3810-A001-307,5/29/2009,01/01/2009,01/10/2009,3/17/2010,01/03/2010,,01/07/2009,Time to achieve first 24-hour period without heartburn. Assessment based on subject daily symptom diary.|Percentage of subjects with complete heartburn relief; percentage of heartburn-free time period (daytime or nighttime); change from baseline in average daily severity score of GERD-related symptoms. Assessments based on subject daily symptom diary.,http://ClinicalTrials.gov/show/NCT00911534,United States,1,1,2,0
NCT00911586,Pharmacokinetic Study to Determine Time to Steady-state,Completed,No Results Available,Male Hypogonadism|Primary Hypogonadism|Secondary Hypogonadism,Drug: Testosterone undecanoate,"Clarus Therapeutics, Inc.",Male,Adult|Senior,Phase II,15,Industry,Interventional,Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CLAR-09009,5/29/2009,01/07/2009,01/01/2010,8/17/2010,01/08/2010,,01/09/2009,Confirmation of time to reach steady-state when oral testosterone undecanoate is administered twice daily.,http://ClinicalTrials.gov/show/NCT00911586,United States,1,0,1,NA
NCT00911612,Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in D-IBS?,Completed,No Results Available,Irritable Bowel Syndrome|Diarrhea,Drug: colesevelam,Mayo Clinic|National Institutes of Health (NIH),Both,Adult,Phase II,24,Other|NIH,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",08-007454|NIH (DK54681),5/29/2009,01/01/2009,01/05/2009,06/01/2009,01/05/2009,welchol,01/05/2009,"colonic transit, geometric center at 24 hours (GC 24)|ascending colon emptying T1/2|intestinal and colonic permeability in cumulative mannitol urine excretion at 0-2h and 2-24h collections|Colonic GC 48 h|Stool consistency",http://ClinicalTrials.gov/show/NCT00911612,United States,1,1,1,1
NCT00912301,Cheno Effect on Transit in Health and IBS-C,Completed,No Results Available,Constipation-predominant Irritable Bowel Syndrome,Drug: NaCDC,Mayo Clinic,Both,Adult,Phase II,120,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",08-001003|NIH DK 54681,5/29/2009,01/04/2009,01/12/2009,1/18/2010,01/01/2010,Chenotransit,01/11/2009,Colonic geometric center at 24 hours (GC24)|Colonic transit GC48 h|Ascending colon emptying T1/2|Stool consistency|Colonic Filling at 6 hours,http://ClinicalTrials.gov/show/NCT00912301,United States,1,0,1,NA
NCT00912873,Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks,Completed,No Results Available,Hip Arthroplasty|Hip Pain,Drug: ropivicaine (Psoas compartment block),"University of California, San Diego",Both,Adult|Senior,Phase IV,50,Other,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Outcomes Assessor)|Primary Purpose: Treatment",Hip Concentration Study,06/01/2009,01/05/2008,01/06/2009,1/13/2010,01/06/2009,,01/06/2009,"Quadriceps femoris muscle strength, by measuring the maximum voluntary isometric contraction (MVIC). The difference in MVIC on POD1 compared with the preoperative MVIC, expressed as a percentage of the preoperative MVIC.|Hip adductor strength, evaluated in sitting position using the same technique as described for the primary outcome measure.|Hip flexor strength, evaluated in the supine position using the same technique as described for the primary outcome measure.|Sensory level, evaluated in the seated position, the current through TES is increased from 0mV until the patient describes mild discomfort and the current is then recorded.|Ambulatory ability, evaluated using the 100-foot walk test and the six minute walk test. Afer patients walk 100 feet, they will continue to walk for six minutes and the total distance will be recorded.|Range of motion, evaluated using a standard goniometer for hip flexion within precaution limits.|Weight bearing, evaluated using a standard scale to demonstrate the correct amount of weight to place on an operative extremity.|Pain, evaluated using a verbal rating scale of 0-10, where 0=no pain and 10=worst imaginable pain.|Sample size estimation, as centered around our primary null hypothesis that differing the concentration but providing an equal total dose of ropivicaine has no impact on the percentage drop in quadriceps muscle strength.",http://ClinicalTrials.gov/show/NCT00912873,United States,1,0,1,NA
NCT00913627,Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain,Completed,No Results Available,Pain,Drug: ibuprofen|Drug: ibuprofen|Drug: naproxen|Drug: Placebo,Wyeth,Both,Child|Adult,Phase II,196,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,AK-09-07,5/29/2009,01/05/2009,01/08/2009,08/12/2009,01/08/2009,,01/08/2009,"SPID 0-12 (time weighted sum of pain intensity difference scores from 0-12 hrs) AND SPID 8-12 (time-weighted sum of pain intensity difference scores from 8-12 hrs)|Time to first perceptible relief confirmed by meaningful relief (onset) AND Time to treatment failure (time to first rescue medication or discontinuation due to lack of efficacy) AND Percentage of treatment failures by 8, 9, 10, 11 and 12 hours",http://ClinicalTrials.gov/show/NCT00913627,United States,1,1,4,0
NCT00915551,"A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)",Completed,No Results Available,Actinic Keratosis,Drug: PEP005 Gel|Drug: Vehicle Gel,Peplin,Both,Adult|Senior,Phase III,278,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",PEP005-025,06/04/2009,01/06/2009,01/09/2009,10/06/2010,01/10/2010,,01/09/2009,"Efficacy (complete and partial clearance of AK lesions)|Safety (Incidence of treatment related AEs, local skin reactions and pigmentation and scarring)",http://ClinicalTrials.gov/show/NCT00915551,"United States, &nbsp; Australia",1,0,2,NA
NCT00916006,"A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)",Completed,No Results Available,Actinic Keratosis,Drug: PEP005 Gel|Drug: Vehicle Gel,Peplin,Both,Adult|Senior,Phase III,269,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",PEP005-016,06/04/2009,01/06/2009,01/09/2009,10/06/2010,01/10/2010,,01/09/2009,"Efficacy (complete and partial clearance of AK lesions)|Safety (Incidence of treatment related AEs, local skin reactions and pigmentation and scarring)",http://ClinicalTrials.gov/show/NCT00916006,"United States, &nbsp; Australia",1,0,2,NA
NCT00916942,Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN),Completed,No Results Available,Postherpetic Neuralgia,Drug: capsaicin 8%|Drug: Lidocaine (2.5%)/Prilocaine (2.5%) Cream,NeurogesX,Both,Adult|Senior,Phase II,20,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,C123,06/08/2009,01/06/2009,01/07/2009,09/03/2009,01/09/2009,,01/06/2009,Duration of patch application|Mean change in NPRS scores from pre-treatment values to subsequent time points on the day of treatment,http://ClinicalTrials.gov/show/NCT00916942,United States,1,1,2,1
NCT00917020,The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis,Completed,No Results Available,Seasonal Allergic Rhinitis,Drug: Nasal CO2|Drug: Inactive Placebo Gas,"Capnia, Inc.",Both,Adult,Phase II,32,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C216,06/08/2009,01/07/2009,01/11/2009,12/01/2009,01/12/2009,,01/10/2009,To assess the efficacy of as-needed treatment with nasal carbon dioxide (CO2) in patients with seasonal allergic rhinitis (SAR).,http://ClinicalTrials.gov/show/NCT00917020,United States,1,0,2,NA
NCT00917111,The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis,Completed,No Results Available,Seasonal Allergic Rhinitis,Drug: Nasal CO2|Drug: Inactive Placebo Gas,"Capnia, Inc.",Both,Adult,Phase II,33,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C218,06/08/2009,01/07/2009,01/11/2009,12/02/2009,01/12/2009,,01/10/2009,To assess the efficacy of four times a day treatment with nasal carbon dioxide (CO2) in patients with seasonal allergic rhinitis (SAR).,http://ClinicalTrials.gov/show/NCT00917111,United States,1,0,2,NA
NCT00917306,"A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)",Completed,No Results Available,Actinic Keratosis,Drug: PEP005 Gel,Peplin,Both,Adult|Senior,Phase III,102,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PEP005-020,06/08/2009,01/06/2009,01/09/2009,10/06/2010,01/10/2010,,01/09/2009,"Safety (Incidence of treatment related AEs, local skin reactions and pigmentation and scarring)|Efficacy (complete and partial clearance of AK lesions)",http://ClinicalTrials.gov/show/NCT00917306,"United States, &nbsp; Australia",1,0,1,NA
NCT00918749,Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women,Completed,No Results Available,Healthy,Drug: risedronate IR tablet,Warner Chilcott,Female,Adult|Senior,Phase II,204,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2009003,06/10/2009,01/05/2009,01/10/2009,06/07/2010,01/07/2009,,01/10/2009,Serum type-1 collagen C-telopeptide (CTX) 75mg DR tablet compared with 150 mg IR tablet|Serum CTX 100 mg DR tablet compared with 150 mg IR tablet|Serum bone specific alkaline phosphatase (BAP) and urinary type-1 collagen N-telopeptide (NTX) of risedronate 150 mg IR tablet compared with 75 mg DR tablet ministered immediately after breakfast|Serum BAP and urinary NTX of risedronate 150 mg IR tablet compared with 100 mg DR tablet administered immediately after breakfast|Safety and tolerability of the 75 and 100 mg DR tablets|Relative bioavailability based on Ae (cumulative amount of risedronate recovered in urine) and A'e(% ) [percentage of dose recovered in urine] of the 75 & 100 mg DR tablets compared to 150 mg IR tablet,http://ClinicalTrials.gov/show/NCT00918749,United States,1,1,1,0
NCT00918866,A Study of Commercial DEFINITY?ó to Monitor the Effects of the Heart's Pulmonary Artery Pressure,Completed,No Results Available,Pulmonary Heart Disease,Drug: Definity,Lantheus Medical Imaging,Both,Adult|Senior,Phase IV,32,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,DMP 115-416,06/04/2009,01/07/2009,01/12/2009,11/10/2010,01/11/2010,,01/12/2009,Primary outcome is the evaluation of the effect of DEFINITY?ó on Pulmonary Artery Hemodynamics.,http://ClinicalTrials.gov/show/NCT00918866,United States,1,1,1,1
NCT00919191,Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face,Completed,Has Results,Acne Vulgaris,Drug: Tretinoin gel|Drug: Adapalene and Benzoyl peroxide,Johnson & Johnson Consumer & Personal Products Worldwide,Female,Adult,Phase IV,26,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,CA-P-6805,06/10/2009,01/04/2009,01/05/2009,03/09/2010,01/03/2010,,01/05/2009,Comparative Assessment of Facial Irritation and Cutaneous Effects.|Self Assessment of Burning/Stinging and Itching,http://ClinicalTrials.gov/show/NCT00919191,United States,1,1,2,1
NCT00919763,Efficacy and Safety Study of CD2027 Ointment 3 Mcg/g Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis,Completed,No Results Available,Atopic Dermatitis,Drug: CD 2027|Drug: CD 2027 Vehicle,Galderma,Both,Adult|Senior,Phase II,100,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RD.06.SPR.18158,06/09/2009,01/05/2009,01/11/2009,11/23/2010,01/11/2010,,01/10/2009,Total sum score (TSS)of target lesion|Percent change in TSS,http://ClinicalTrials.gov/show/NCT00919763,United States,1,0,2,NA
NCT00920426,Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929),Completed,No Results Available,"Infection, Human Immunodeficiency Virus",Drug: GSK1265744|Drug: Placebo,GlaxoSmithKline|Shionogi,Both,Adult,Phase II,9,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",112929,06/12/2009,01/06/2009,01/08/2009,9/23/2010,01/09/2010,,01/08/2009,"Change from plasma HIV-1 ribonucleic acid (RNA) to Day 1|GSK1265744 PK parameters following dose administration on Day 1 and 10: AUC(0-24), Cmax, tmax, concentration at 24 hrs post dose(C24), terminal half-life(t1/2), absorption lag time(tlag), and apparent clearance(CL/F)|GSK1265744 PK parameters following last repeat administration on Day 10:AUC(0-tau), predose concentration(C0), concentration at end of dosing interval(Ctau), minimum observed concentration during one dosing interval(Cmin), Cmax, tmax, t1/2, and CL/F|Safety and tolerability: adverse events (AEs)|Safety and tolerability: clinical laboratory results|Safety and tolerability: vital signs|Safety and tolerability: electrocardiogram (ECG) assessments|Change from baseline in plasma HIV-1 RNA|Change from baseline in plasma HIV-1 RNA to nadir (maximum change) over 11 days|Plasma HIV-1 RNA rate of decline (slope)|Proportion of subjects with HIV-1 RNA<400 copies/mL|Proportion of subjects with HIV-1 RNA<50 copies/mL|Change from baseline in CD4+ cell count to Day 11|Emergence of drug resistance mutations, if appropriate|GSK1265744 Day 10 AUC(0-tau), Cmax, and Ctau compared to Day 1 AUC(0-24), Cmax, and C24, respectively, to estimate accumulation ratios (R) for AUC, Cmax, and Ctau|Pre-morning dose concentrations (C0) on Day 2 through 10 to assess the achievement of steady state of GSK1265744 following repeat administration",http://ClinicalTrials.gov/show/NCT00920426,United States,1,0,2,NA
NCT00921947,Comparative Safety and Immunogenicity of 1.0 ??g Intramuscular (i.m.) and 2.0 ??g Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults,Completed,No Results Available,Influenza,Biological: VAX102,VaxInnate Corporation,Both,Adult,Phase I|Phase II,60,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Prevention,VAX102-09,6/15/2009,01/06/2009,01/08/2009,02/04/2010,01/02/2010,,01/07/2009,"To assess the safety, reactogenicity, tolerability, and adverse events (AEs) of the VAX102 vaccine in a two dose regimen (Day 0 and Day 28) at the 1.0 ??g dose level delivered i.m., or the 2.0 ??g dose level delivered s.c. in a healthy adult population.|To assess the anti-M2e serum antibody concentration after VAX102 vaccine in a two dose regimen (Day 0 and Day 28) at the 1.0 ??g dose level delivered i.m., or the 2.0 ??g dose level delivered s.c.",http://ClinicalTrials.gov/show/NCT00921947,United States,0,NA,1,NA
NCT00924612,Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation,Completed,No Results Available,Male Hypogonadism,Drug: Oral testosterone undecanoate (containing 300 mg of T),"Clarus Therapeutics, Inc.",Male,Adult,Phase II,16,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,CLAR-09008,6/17/2009,01/07/2009,01/07/2010,8/23/2010,01/08/2010,,01/09/2009,Serum testosterone Cmax|Serum testosterone Cavg|Serum testosterone Tmax|Serum testosterone AUC|Serum DHT Cmax|Serum DHT Cavg|Serum DHT Tmax|Serum DHT AUC|Serum testosterone undecanoate (TU) Cmax|Serum TU Tmax|Serum TU AUC,http://ClinicalTrials.gov/show/NCT00924612,"United States, &nbsp; Canada",1,0,1,NA
NCT00924729,Study of Ocular Penetration of Topically Administered Fluoroquinolones,Completed,Has Results,Cataract Extraction,Drug: Moxifloxacin 0.5% ophthalmic solution|Drug: Besifloxacin 0.6% ophthalmic suspension,Johns Hopkins University,Both,Adult|Senior,Phase IV,50,Other,Interventional,"Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)",NA_28692,06/05/2009,01/09/2009,01/11/2009,5/25/2010,01/11/2009,,01/10/2009,Aqueous Humor Concentration of Study Drug|Disk Diffusion Assay of Collected Aqueous Humor,http://ClinicalTrials.gov/show/NCT00924729,United States,1,1,2,1
NCT00924950,Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis,Completed,No Results Available,Plaque Psoriasis|Psoriasis Vulgaris,Drug: Taclonex Ointment and Hydrogel Patch|Drug: Taclonex Ointment,"University of California, San Francisco",Both,Adult|Senior,Phase IV,35,Other,Interventional,Allocation: Non-Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H5939-31328-02,6/17/2009,01/06/2009,01/12/2009,1/15/2010,01/01/2010,,01/12/2009,Difference in change between baseline and Week 4 modified PASI scores in targeted plaques treated with Taclonex under occlusive dressing versus Taclonex alone.|To determine the change in modified PASI scores between Week 4 and Week 6 during the follow-up period. This is to determine whether there is further improvement of psoriasis after the cessation of occlusion.,http://ClinicalTrials.gov/show/NCT00924950,United States,1,1,2,1
NCT00926367,Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications,Completed,No Results Available,Acne Vulgaris,Drug: topical antibiotic and benzoyl peroxide gel|Drug: benzoyl peroxide 2.5% and adapalene 0.1% gel,"Stiefel, a GSK Company",Both,Adult,Phase IV,52,Industry,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,C0000-405,6/21/2009,01/05/2009,01/07/2009,4/21/2010,01/04/2010,,01/06/2009,To determine and compare the tolerance and irritation potential of a topical antibiotic and benzoyl peroxide gel to benzoyl peroxide and adapalene gel using visual assessments by an independent blinded grader|Outcome Measure: To assess skin moisture and hydration and to assess subject tolerability through a skin assessment questionnaire,http://ClinicalTrials.gov/show/NCT00926367,United States,1,1,2,0
NCT00927758,Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair,Completed,No Results Available,Asthma,Drug: ADVAIR (fluticasone propionate/salmeterol),Sandoz Inc.,Both,Adult,Phase II,100,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CP-Sandoz-2009-PilotFP,6/23/2009,01/06/2009,01/12/2009,2/24/2010,01/11/2009,,01/12/2009,To examine the post-dose changes in eNO following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines,http://ClinicalTrials.gov/show/NCT00927758,United States,1,1,1,1
NCT00928421,"An Open-label, Single-dose Pilot Study to Evaluate Varisolve?ó (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins",Completed,No Results Available,Varicose Veins,Drug: Polidocanol Endovenous Microfoam 0.125%,BTG Ltd.,Both,Adult|Senior,Phase II,16,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,VAP.VV014,6/24/2009,01/06/2009,01/01/2010,09/08/2010,01/09/2010,,01/12/2009,Physician determined evaluation of PEM and EMA characteristics|Elimination of reflux through the SFJ.|Complete occlusion of the GSV,http://ClinicalTrials.gov/show/NCT00928421,United States,1,0,1,NA
NCT00928447,Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis,Completed,No Results Available,"Dermatitis, Allergic Contact",Drug: rHuPH20,Halozyme Therapeutics,Female,Adult,Phase II,22,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",HALO-114-201,6/25/2009,01/06/2009,01/10/2009,8/27/2010,01/08/2010,,01/09/2009,Determine the treatment effect of rHuPH20 or placebo control injection on the exposure to topical nickel allergen|Determine the time to onset and severity of the cutaneous reaction to nickel allergen after pre-treatment with rHuPH20 or placebo control|Assess the safety and tolerability of the rHuPH20 injection,http://ClinicalTrials.gov/show/NCT00928447,United States,1,1,1,1
NCT00928746,Actuation Indicator Trial in Patients With COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Device: Ipratropium bromide,Boehringer Ingelheim Pharmaceuticals,Both,Adult|Senior,Phase III,142,Industry,Interventional,Endpoint Classification: Efficacy Study|Primary Purpose: Treatment,244.2507,6/25/2009,01/06/2009,NA,9/28/2010,01/09/2010,,01/08/2009,Actuations Registered by the Actuation Indicator|Actuations Dispensed|Difference Between the Number of Actuations Registered by Actuation Indicator Versus Actuations Dispensed|Actuations Recorded on Patient Diary|Actuations Based on Advancing the Actuation Indicator|Actuations Registered by the Actuation Indicator and Read by Site Coordinator|Difference Between the Number of Actuations Recorded on Patient Diary Versus Actuations Dispensed|Difference Between the Number of Actuations Based on Advancing Actuation Indicator Versus Actuations Dispensed|Difference Between the Number of Actuations Registered by the Actuation Indicator and Read by Site Coordinator Versus Actuations Dispensed|Number of Participants Who Reported Problems With Use of Inhaler With Integrated Dose Counter According to Patient Handling Questionnaire|Number of Participants Who Reported Problems With Seeing Red Warning Indicating Inhaler Near End of Recommended Doses According to Patient Handling Questionnaire|Number of Participants Who Reported Problems With Inhaler and Dose Counter Performing as Expected Based on Instructions According to Patient Handling Questionnaire|Number of Participants Who Reported Satisfaction With Performance of the Dose Counter for Indicating Approximately How Many Doses Remain in Inhaler According to Patient Handling Questionnaire|Number of Participants Who Reported Satisfaction That the Dose Counter Worked Reliably According to Patient Handling Questionnaire|Number of Participants Who Reported Satisfaction With Ease of Use of the Dose Counter According to Patient Handling Questionnaire|Number of Participants Who Reported Satisfaction With Dose Counter in the Mouthpiece of the Inhaler According to Patient Handling Questionnaire|Number of Participants Having Any Additional Comments According to Patient Handling Questionnaire,http://ClinicalTrials.gov/show/NCT00928746,United States,0,NA,1,NA
NCT00931866,Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED),Completed,No Results Available,Acute Pain|Soft Tissue Injury,Drug: Diclofenac Sodium|Drug: Matching Placebo Patch,Cerimon Pharmaceuticals|PPD,Both,Adult|Senior,Phase III,407,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DCF-006,6/29/2009,01/04/2009,01/12/2009,08/12/2010,01/08/2010,,01/09/2009,Change in average pain during daily activity at Day 7|Change in average pain during daily activity at Day 14,http://ClinicalTrials.gov/show/NCT00931866,United States,1,1,2,0
NCT00933933,Evaluation of Diagnostic HIV Ag/Ab Combo Assay,Completed,Has Results,Human Immunodeficiency Viruses,Device: ARCHITECT HIV Ag/Ab Combo|Device: ARCHITECT HIV Ag/Ab Combo,Abbott Diagnostics Division,Both,Child|Adult|Senior,Phase III,635,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,7B5-02-06R01,07/02/2009,01/06/2009,01/11/2009,9/17/2010,01/09/2010,,01/10/2009,Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection|Architect HIV Combo Test Data for Clinical Sensitivity in HIV Positive Specimens|Architect HIV Combo Test Data for Specificity and Sensitivity in Pregnant Female Population|Architect HIV Combo Test Data for Specificity and Sensitivity in Pediatric Population (From 2 up to 21 Years of Age)|Architect HIV Combo Test Data for Reactivity of Architect HIV Combo in Increased HIV Risk Populations,http://ClinicalTrials.gov/show/NCT00933933,United States,0,NA,2,NA
NCT00934622,Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL,Completed,Has Results,Cataract,Device: AcrySof?ó ReSTOR?ó Aspheric IOL,Alcon Research,Both,Adult|Senior,Phase IV,76,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ALCONsur002.07,07/07/2009,01/11/2007,NA,05/05/2010,01/05/2010,,01/03/2009,Visual Acuity|Spectacle Independence,http://ClinicalTrials.gov/show/NCT00934622,United States,0,NA,1,NA
NCT00935311,Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction,Completed,No Results Available,Pain,Drug: Hydrocodone/Acetaminophen Extended Release|Drug: Hydrocodone/Acetaminophen|Drug: Placebo,Abbott,Both,Adult,Phase II,122,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",M11-063,6/29/2009,01/06/2009,NA,11/02/2010,01/09/2010,,01/08/2009,Sum of pain intensity difference|Pain relief|Rescue medication use|Adverse Events,http://ClinicalTrials.gov/show/NCT00935311,United States,1,0,3,NA
NCT00938951,Evaluate the Ability of Systane Ultra to Improve Subjective Symptoms of Ocular Irritation Post 60 Min. Athletic Performance.,Completed,No Results Available,Dry Eye Symptoms|Visual Performance,Drug: Systane?ó Ultra,Alcon Research,Both,Adult|Senior,Phase IV,60,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care,SMA-09-22,7/13/2009,01/06/2009,NA,02/08/2010,01/02/2010,,01/07/2009,Effectiveness of eye drop basd on athlete's opinion/experience during a one hour practice session,http://ClinicalTrials.gov/show/NCT00938951,United States,1,0,1,NA
NCT00941278,An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis,Completed,No Results Available,Psoriasis,Drug: PH-10 (0.001% Rose Bengal),Provectus Pharmaceuticals,Both,Adult|Senior,Phase II,30,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PH-10-PS-22,7/15/2009,01/07/2009,01/04/2010,07/02/2010,01/07/2010,,01/12/2009,The primary efficacy endpoint is \Treatment Success,http://ClinicalTrials.gov/show/NCT00941278,United States,1,0,1,NA
NCT00941304,Study of BEMA?ºÑ Buprenorphine in the Treatment of Dental Pain,Completed,No Results Available,Dental Pain,Drug: oxycodone|Drug: BEMA?ºÑ Buprenorphine|Drug: Placebo,BioDelivery Sciences International,Both,Adult,Phase II,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",BUP-201,7/15/2009,01/07/2009,01/11/2009,11/24/2009,01/11/2009,,01/10/2009,Sum of Pain Intensity Differences (SPID),http://ClinicalTrials.gov/show/NCT00941304,United States,1,1,3,0
NCT00942604,A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations,Completed,No Results Available,Actinic Keratoses,Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel,Peplin,Both,Adult|Senior,Phase III,203,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",PEP005-028,7/19/2009,01/07/2009,01/10/2009,10/06/2010,01/10/2010,,01/10/2009,Efficacy (complete clearance of AKs)|Efficacy (partial clearance of AKs),http://ClinicalTrials.gov/show/NCT00942604,United States,1,0,2,NA
NCT00945763,Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery,Completed,No Results Available,Dental Pain,Drug: N1539|Drug: placebo|Drug: N1539|Drug: N1539|Drug: ibuprofen,Elan Drug Delivery Inc,Both,Adult|Senior,Phase II,230,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",N1539-02,7/23/2009,01/07/2009,01/11/2009,8/19/2010,01/08/2010,,01/11/2009,Pain Intensity Difference at End of Study|Onset of action,http://ClinicalTrials.gov/show/NCT00945763,United States,1,0,5,NA
NCT00946777,Barrier Function Measurement in Dry Eye Patients After Using Systane Ultra for 30 Days,Completed,No Results Available,Dry Eye,Drug: Systane?ó Ultra,Alcon Research,Both,Adult|Senior,Phase IV,20,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SMA-09-04,7/24/2009,01/07/2009,NA,1/27/2010,01/01/2010,,01/09/2009,Percent change from baseline of corneal fluorescein|Adverse event occurence,http://ClinicalTrials.gov/show/NCT00946777,United States,1,0,1,NA
NCT00948428,"Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara?ºÑ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis",Completed,No Results Available,Actinic Keratoses,Drug: imiquimod|Drug: Aldara?ºÑ|Drug: Vehicle Cream,Actavis Mid-Atlantic LLC,Both,Adult|Senior,Phase III,462,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D94-3101-07,7/28/2009,01/05/2008,01/04/2009,8/13/2010,01/08/2010,,01/03/2009,"Primary - Proportion of subjects in each treatment group with Complete Clearance of AK lesions.|The Partial Clearance rates, defined as the proportion of subjects with at least a 75% reduction in the number of AK lesions counted at Baseline and the proportion of subjects with Complete Clearance of AK lesions.",http://ClinicalTrials.gov/show/NCT00948428,United States,1,1,3,0
NCT00952523,Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face,Completed,Has Results,Acne Vulgaris,Drug: Tretinoin Facial Gel|Drug: Adapalene/Benzoyl Peroxide Facial Gel,Johnson & Johnson Consumer & Personal Products Worldwide,Both,Adult,Phase IV,162,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,CA-P-7190,08/04/2009,01/07/2009,01/10/2009,04/08/2010,01/04/2010,,01/10/2009,Facial Irritation and Cutaneous Effects,http://ClinicalTrials.gov/show/NCT00952523,United States,1,1,2,1
NCT00953043,"Lubiprostone, Colonic Motility and Sensation",Completed,No Results Available,Healthy,Drug: lubiprostone,Mayo Clinic,Both,Adult,Phase IV,80,Other,Interventional,Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,07-001438,08/04/2009,,01/03/2009,02/05/2010,01/01/2010,,01/03/2009,"Colonic compliance|Fasting colonic tone|Postprandial colonic tone|Pain sensation ratings in response to colonic distensions|Gas sensation ratings in response to colonic distensions|Thresholds for colonic first, gas and pain sensation",http://ClinicalTrials.gov/show/NCT00953043,United States,1,1,1,1
NCT00954356,Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction,Completed,No Results Available,Dental Pain,Drug: XPF-001|Drug: placebo,Xenon Pharmaceuticals Inc.,Both,Adult,Phase II,60,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",XPF-001-201,7/22/2009,01/09/2009,01/12/2009,5/28/2010,01/05/2010,,01/11/2009,"Total pain relief at 6 hours post dose (TOTPAR 6)|Summed Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at defined timepoints post dose|Time to first perceptible and first meaningful relief|Time to rescue medication|Adverse Events, ECGs, vital sign and laboratory measurements",http://ClinicalTrials.gov/show/NCT00954356,United States,1,0,2,NA
NCT00955825,Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis,Completed,No Results Available,Grass Pollen-related Allergic Rhinoconjunctivitis,Biological: Grass pollen allergen extract|Drug: Placebo tablet,Stallergenes,Both,Adult,Phase III,473,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VO61.08 USA,08/03/2009,01/10/2008,01/08/2009,12/31/2009,01/12/2009,,01/08/2009,Average Combined Score (ACS): combined score will be calculated taking into account patient's daily RTSS ane RMS assuming equal weight for both scores. ACS will be calculated as the average of daily CS during the pollen period|Average Rhinoconjunctivitis Total Symptom Score (ARTSS): severity of the six rhinoconjunctivitis symptoms are evaluated daily and the daily total score recorded. ARTSS will be calculated as the average of all valid data during the pollen period.|Average Rescue Medication Score (ARMS): daily rescue medication use and corresponding score will be recorded. ARMS will be calculated as the average of all valid data during the pollen period|Proportion of Symptom-controlled Days (PSCD): Symptom-controlled days are days where RMS is equal to 0 and RTSS under a pre-defined threshold.|Average Adjusted Symptom Score (AASS): score taking account RTSS and rescue medication use. Symptom score will be adjusted according to the rescue medication use. AASS is calculated as the average of valid data during the pollen period.,http://ClinicalTrials.gov/show/NCT00955825,United States,1,0,2,NA
NCT00958126,A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA,Completed,No Results Available,Influenza,Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)|Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)|Biological: Placebo,CSL Limited,Both,Adult|Senior,Phase II,1313,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CSLCT-CAL-09-61,08/12/2009,01/08/2009,01/04/2010,5/17/2010,01/05/2010,,01/11/2009,"Immunogenicity|Frequency, duration and intensity of solicited adverse events|Frequency, duration and intensity of unsolicited adverse events|Incidence of serious adverse events, adverse events of special interest and new onset of chronic illness",http://ClinicalTrials.gov/show/NCT00958126,United States,0,NA,3,NA
NCT00958243,A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA,Completed,No Results Available,Influenza,Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)|Biological: CSL's 2009 H1N1 Influenza Vaccine (CSL425)|Biological: Placebo,CSL Limited,Both,Child,Phase II,473,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CSLCT-CAL-09-62,08/12/2009,01/08/2009,01/04/2010,5/17/2010,01/05/2010,,01/11/2009,"Immunogenicity|Frequency, duration and intensity of solicited adverse events|Frequency, duration and intensity of unsolicited adverse events|Incidence of serious adverse events, adverse events of special interest and new onset of chronic illness",http://ClinicalTrials.gov/show/NCT00958243,United States,0,NA,3,NA
NCT00959049,A Study to Determine the Immunogenicity and Safety of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population,Completed,No Results Available,Influenza,Biological: CSL's Influenza Virus Vaccine (Afluria)|Biological: Influenza Virus Vaccine (Fluzone),CSL Limited,Both,Child,Phase III,1474,Industry,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CSLCT-USF-07-36,08/12/2009,01/09/2009,01/05/2010,5/24/2010,01/05/2010,,01/12/2009,"Geometric mean titer and seroconversion rate for each strain contained within the vaccines|Frequency, duration and intensity of local and systemic solicited symptoms|Frequency, duration and intensity of unsolicited adverse events|Frequency, duration and intensity of serious adverse events|New onset of chronic illnesses",http://ClinicalTrials.gov/show/NCT00959049,United States,0,NA,2,NA
NCT00960622,Switch From Combivir to Truvada - Mitochondrial Effects,Completed,No Results Available,HIV|HIV Infections,Drug: Truvada vs Combivir,St. Luke's-Roosevelt Hospital Center|Gilead Sciences,Both,Adult|Senior,Phase IV,NA,Other|Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,TRU1,8/17/2009,01/08/2006,01/07/2009,9/28/2009,01/08/2009,TRU,01/07/2009,VO2 max,http://ClinicalTrials.gov/show/NCT00960622,United States,1,1,1,1
NCT00962065,Study of LX4211 in Subjects With Type 2 Diabetes Mellitus,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: LX4211 Low Dose|Drug: LX4211 High Dose|Drug: Placebo,Lexicon Pharmaceuticals,Both,Adult,Phase II,36,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LX4211.1-201-DM|LX4211.201,08/10/2009,01/08/2009,NA,1/20/2010,01/01/2010,,01/12/2009,"Safety and tolerability (physical examinations, monitoring of adverse events, clinical laboratory tests, vital signs measurements, and ECGs)|Efficacy (urinary glucose excretion, oral glucose tolerance testing, plasma glucose and fructosamine levels)",http://ClinicalTrials.gov/show/NCT00962065,United States,1,0,3,NA
NCT00964223,A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne,Completed,No Results Available,Acne Vulgaris,Drug: clindamycin and benzoyl peroxide gel (Duac?ó Topical Gel)|Drug: benzoyl peroxide and adapalene gel (EPIDUO?ºÑ Gel),"Stiefel, a GSK Company",Both,Adult|Senior,Phase IV,28,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,C0000-410,8/20/2009,01/07/2009,01/02/2010,4/21/2010,01/04/2010,,01/12/2009,"To compare the tolerability of clindamycin and benzoyl peroxide gel to benzoyl peroxide/adapalene gel in the treatment of facial acne during the first 2 weeks of treatment.|To evaluate efficacy, tolerability, safety and subject satisfaction of clindamycin and benzoyl peroxide gel in the treatment of acne vulgaris. To evaluate the influence of acne on subjects' quality of life.",http://ClinicalTrials.gov/show/NCT00964223,United States,1,1,2,1
NCT00964431,Phase 2 Study of Indomethacin Capsules to Treat Dental Pain,Completed,No Results Available,Analgesia,Drug: Celecoxib|Drug: Placebo|Drug: Indomethacin Test (lower dose)|Drug: Indomethacin Test (upper dose),"Iroko Pharmaceuticals, LLC",Both,Adult,Phase II,200,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IND2-08-03,8/24/2009,01/08/2009,01/12/2009,01/04/2010,01/01/2010,,01/12/2009,TOTPAR,http://ClinicalTrials.gov/show/NCT00964431,United States,1,1,4,0
NCT00964548,Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage,Completed,No Results Available,Cerebral Vasospasm After Subarachnoid Hemorrhage,Drug: Dantrolene|Drug: Dantrolene,"University of Massachusetts, Worcester|Massachusetts General Hospital",Both,Adult|Senior,Phase I|Phase II,15,Other,Interventional,Allocation: Non-Randomized|Control: Dose Comparison|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-13076,8/23/2009,01/07/2007,01/10/2009,11/11/2009,01/11/2009,,01/10/2009,"Hemodynamic parameters (compare before, during and 45 min after infusion) and Laboratory values (up to 24 hrs after infusion)|Transcranial Doppler peak systolic and mean flow velocities of vessel in vasospasm",http://ClinicalTrials.gov/show/NCT00964548,United States,1,1,2,0
NCT00966641,Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults,Completed,No Results Available,Healthy Volunteers,Drug: Naproxen|Drug: PL 3100,PLx Pharma|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),Both,Adult|Senior,Phase I|Phase II,28,Industry|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PL-NAP-001|NIH Grant 1R44AR056529-01,8/25/2009,01/08/2009,01/10/2009,05/10/2010,01/05/2010,,01/10/2009,Pharmacokinetic measures of plasma naproxen|Pharmacokinetic bioequivalence of PL 3100 and comparator naproxen,http://ClinicalTrials.gov/show/NCT00966641,United States,1,0,2,NA
NCT00968825,Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines,Completed,No Results Available,Lateral Canthal Lines|Crow's Feet|Facial Wrinkles,Drug: Botulinum Toxin Type A|Drug: Placebo,"Revance Therapeutics, Inc.",Both,Adult,Phase II,72,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",RT001-CL012LCL,8/27/2009,01/07/2009,01/10/2009,11/16/2009,01/11/2009,,01/10/2009,The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line Severity at Rest from Baseline (Day 0) to Week 4; incidence of treatment emergent AEs|The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line Severity at Rest and Smile from Baseline (Day 0) to Week 4 and Baseline (Day 0) to Week 6; incidence of treatment emergent AEs,http://ClinicalTrials.gov/show/NCT00968825,United States,1,0,2,NA
NCT00968942,Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines,Completed,No Results Available,Lateral Canthal Lines|Crow's Feet|Facial Wrinkles,Drug: Botulinum Toxin Type A|Drug: Placebo,"Revance Therapeutics, Inc.",Both,Adult,Phase II,36,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",RT001-CL015LCL,8/28/2009,01/08/2009,01/10/2009,11/16/2009,01/11/2009,,01/10/2009,"The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line-Rest Severity Scale of the LCA at Baseline compared to Week 8; incidence of treatment emergent AEs|The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line Severity at Smile and at Rest from Baseline to Weeks 2, 4, 6, 8; incidence of treatment emergent AEs",http://ClinicalTrials.gov/show/NCT00968942,United States,1,0,2,NA
NCT00973765,Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses,Completed,Has Results,Abscesses,Drug: bactrim|Drug: placebo,Wilford Hall Medical Center|Emergency Medicine Foundation,Both,Child|Adult|Senior,Phase III,212,U.S. Fed|Other,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",FWH20080055H_,09/08/2009,01/11/2007,01/08/2009,03/01/2010,01/09/2009,,01/08/2009,Treatment Failures at 7 Days,http://ClinicalTrials.gov/show/NCT00973765,United States,1,1,2,1
NCT00979615,Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis,Completed,No Results Available,Vasomotor Rhinitis,"Drug: Olopatadine HCL (Patanase) Nasal Spray, 0.6%|Drug: Azelastine HCl (Astelin) Nasal Spray, 137 mcg",Alcon Research,Both,Child|Adult|Senior,Phase IV,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SMA-09-03,9/17/2009,01/09/2009,NA,1/22/2010,01/01/2010,,01/11/2009,Total Nasal VMR Symptoms Score|Individual symptom severity scores,http://ClinicalTrials.gov/show/NCT00979615,United States,1,1,2,1
NCT00984022,Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage,Completed,Has Results,Abscess|Cellulitis,Device: Type of dressing - Iodoform|Device: Type of dressing - Aquacel,Maricopa Integrated Health System,Both,Adult,Phase II,92,Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2008-003,9/22/2009,01/03/2008,01/09/2009,10/27/2010,01/10/2010,,01/09/2009,Number of Participants Who Experienced a 30% or Greater Reduction in Surface Area of Abscess|Change in Patient Rating of Pain|Number of Participants Who Experienced a 30% or Greater Reduction in Surface Area of Cellulitis.,http://ClinicalTrials.gov/show/NCT00984022,United States,0,NA,2,NA
NCT00985439,Study of Diclofenac Capsules to Treat Dental Pain,Completed,No Results Available,Dental Pain,Drug: Diclofenac Test (lower dose)|Drug: Diclofenac Test (upper dose)|Drug: Celecoxib|Drug: Placebo,"Iroko Pharmaceuticals, LLC",Both,Adult,Phase II,200,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DIC2-08-03,9/25/2009,01/09/2009,01/12/2009,01/04/2010,01/01/2010,,01/12/2009,Total Pain Relief (TOTPAR),http://ClinicalTrials.gov/show/NCT00985439,United States,1,1,4,0
NCT00987272,Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects,Completed,No Results Available,Allergic Conjunctivitis,Drug: Olopatadine 0.2% + Olopatadine 0.2% vehicle|Drug: Olopatadine 0.1% + Olopatadine 0.1% Vehicle,Alcon Research,Both,Adult|Senior,Phase III,200,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C-09-044,9/28/2009,01/09/2009,NA,01/04/2010,01/01/2010,,01/11/2009,Ocular itching|Total redness|Ocular itching,http://ClinicalTrials.gov/show/NCT00987272,United States,1,1,2,1
NCT00987376,Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE Collaboration,Completed,No Results Available,Prostate Cancer,Device: Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy,Mayo Clinic|National Cancer Institute (NCI),Male,Adult|Senior,Phase I|Phase II,8,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,8-03|CA91956-02,12/20/2007,01/11/2003,01/09/2009,9/29/2009,01/09/2009,,01/09/2009,Test accuracy|Test comparative accuracy of PET and MRI,http://ClinicalTrials.gov/show/NCT00987376,United States,0,NA,1,NA
NCT00988143,A Study of Influenza Virus Vaccines in Children and Adults,Completed,No Results Available,Influenza,Biological: Quadrivalent Influenza Virus Vaccine|Biological: 2009-2010 Trivalent Influenza Virus Vaccine|Biological: 2008-2009 Trivalent Influenza Virus Vaccine,Sanofi-Aventis,Both,Child|Adult|Senior,Phase II,570,Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,GRC43|UTN: U1111-1111-5427,10/01/2009,01/10/2009,01/03/2010,01/03/2011,01/01/2011,,01/12/2009,To provide information concerning the immunogenicity Quadrivalent Influenza Vaccine|To provide information concerning the safety of the Quadrivalent Influenza Vaccine.,http://ClinicalTrials.gov/show/NCT00988143,United States,0,NA,3,NA
NCT00989014,Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea,Completed,No Results Available,Erythematotelangiectatic Rosacea,Drug: CD07805/47|Drug: CD07805/47|Drug: CD07805/47|Drug: CD07805/47 placebo,Galderma,Both,Adult|Senior,Phase II,122,Industry,Interventional,"Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RD.06.SPR.18144,9/30/2009,01/09/2009,01/12/2009,12/02/2010,01/12/2010,,01/11/2009,Clinician's Erythema Assessment|Patient's Self Assessment,http://ClinicalTrials.gov/show/NCT00989014,United States,1,0,4,NA
NCT00994162,Evaluation of the Use of EZCare??? in the Management of Acute and Chronic Wounds,Completed,No Results Available,Wounds,Device: EZCARE Negative Pressure Wound Therapy System,Smith & Nephew Wound Management Inc,Both,Adult|Senior,Phase IV,131,Industry,Interventional,Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CIME 012,10/09/2009,01/04/2008,01/07/2009,11/19/2009,01/11/2009,EZCARE-CIME,01/01/2009,The performance of EZCare??? in terms of wound progress towards closure in wounds deemed suitable for treatment with negative pressure wound therapy|General performance characteristics.|Wound pain over the treatment period including pain upon application and removal of the dressing and therapy.|Wound odor over the treatment period.|All adverse events and product complaints throughout the evaluation.,http://ClinicalTrials.gov/show/NCT00994162,United States,0,NA,1,NA
NCT00994422,Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects,Completed,No Results Available,Head Lice,Drug: Ivermectin cream|Drug: vehicle control,Topaz Pharmaceuticals Inc,Both,Child|Adult|Senior,Phase II,250,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TOP010,10/09/2009,01/10/2009,01/12/2009,11/30/2010,01/12/2009,,01/12/2009,The proportion within each treatment group of all subjects who are lice free (without live lice),http://ClinicalTrials.gov/show/NCT00994422,United States,1,1,2,0
NCT00995904,A Study Investigating the Tolerability and Pharmacokinetics of Submicron Budesonide in Children 4 Through 11 Years Old With a History of Mild-To-Moderate Stable Asthma,Completed,No Results Available,Asthma,Drug: submicron budesonide,"MAP Pharmaceuticals, Inc.",Both,Child,Phase II,24,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,MAP0020-CL-P201,10/06/2009,01/09/2009,01/11/2009,11/25/2009,01/11/2009,,01/11/2009,"Evaluate the pharmacokinetic profile of submicron budesonide resulting from inhalation aerosol delivery. The following pharmacokinetic parameters computed include Cmax, tmax, AUC0-last, AUC0-12, AUC1-inf, CL, kel, t ?¥, ??, and relative bioavailability.|Evaluate the safety and tolerability (adverse events) of a single dose of submicron budesonide via inhalation aerosol delivery.",http://ClinicalTrials.gov/show/NCT00995904,United States,1,0,1,NA
NCT00997321,Propofol Versus Ketamine for Moderate Procedural Sedation in the Emergency Department (ED),Completed,No Results Available,Sedation,Drug: propofol|Drug: Ketamine,Minneapolis Medical Research Foundation,Both,Adult|Senior,Phase IV,100,Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MMRF062661,10/12/2009,01/07/2007,01/10/2009,10/16/2009,01/10/2009,,01/10/2009,respiratory depression (sub-clinical and clinical signs)|time to return of baseline mental status|patient reported pain and recall of the procedure|depth of sedation,http://ClinicalTrials.gov/show/NCT00997321,United States,1,1,2,0
NCT01001806,"A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification",Completed,No Results Available,Cataracts,Drug: Ketorolac Tromethamine 0.45%|Drug: bromfenac 0.09%|Drug: nepafenac 0.1%,Bucci Laser Vision Institute|Allergan,Both,Adult|Senior,Phase IV,120,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,2009-0199,10/23/2009,01/10/2009,01/01/2010,8/16/2010,01/08/2010,,01/12/2009,Aqueous concentrations of drugs tested,http://ClinicalTrials.gov/show/NCT01001806,United States,1,1,3,1
NCT01003054,Autologous Transplantation for Chronic Myelogenous Leukemia,Completed,No Results Available,Chronic Myelogenous Leukemia,Drug: Busulfan|Drug: Cyclophosphamide|Drug: Imatinib Mesylate|Procedure: Autologous Stem Cell Transplantation,M.D. Anderson Cancer Center,Both,Child|Adult|Senior,Phase II,24,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ID02-672,10/26/2009,01/03/2005,01/10/2009,10/27/2009,01/10/2009,,01/10/2009,Number of patients with CML alive in cytogenetic remission at one year following treatment,http://ClinicalTrials.gov/show/NCT01003054,United States,1,1,4,0
NCT01004055,Efficacy Study of a Bioelectric Dressing to Treat Wounds Caused by Curettage and Electrodesiccation,Completed,No Results Available,Wound Healing|Wound Infection,Device: Procellera?ºÑ Antimicrobial Wound Dressing|Drug: ACTICOAT?ºÑ Antimicrobial Barrier Dressing|Drug: Mepilex?ó Ag Silver Foam Dressing,Vomaris Innovations,Both,Adult|Senior,Phase II,15,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,XSMP-011,10/27/2009,01/07/2008,01/10/2009,10/28/2009,01/10/2009,,01/08/2009,Wound healing over time|Comparing three FDA cleared products for pain reduction and incidence of infection,http://ClinicalTrials.gov/show/NCT01004055,United States,1,0,3,NA
NCT01005966,In Situ Caries Model of Fluoride Toothpastes,Completed,No Results Available,Caries,Drug: 675 ppmf toothpaste|Drug: Sodium Fluoride Toothpaste|Drug: Amine Fluoride Toothpaste|Drug: Sodium monofluorophosphate/Sodium Fluoride Toothpaste|Drug: Placebo,GlaxoSmithKline,Both,Adult|Senior,Phase III,57,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",T3508605,10/15/2009,01/11/2008,01/03/2009,10/29/2009,01/10/2009,,01/03/2009,To use an in situ caries model to compare fluoride toothpastes with respect to enamel remineralisation potential|To use an in situ caries model to compare fluoride toothpastes with respect to enamel fluoride uptake,http://ClinicalTrials.gov/show/NCT01005966,United States,1,0,5,NA
NCT01015638,Study to Compare the Tolerance of Clindamycin 1% and Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2% and BPO 2.5% Topical Acne Medications,Completed,No Results Available,Acne Vulgaris,Drug: clindamycin and benzoyl peroxide 5% gel|Drug: clindamycin phosphate and benzoyl peroxide 2.5% gel.,"Stiefel, a GSK Company",Both,Adult,Phase IV,36,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,C0000-409,11/17/2009,01/08/2009,01/09/2009,11/17/2009,01/11/2009,,01/09/2009,To determine and compare the tolerability and irritation potential of clindamycin and benzoyl peroxide 5%) and clindamycin phosphate and benzoyl peroxide 2.5% using visual assessments by an independent blinded grader.|To assess potential changes in the integrity of stratum corneum barrier and skin surface hydration and to assess subject tolerability through a skin assessment questionnaire and the Product Acceptability and Preference Questionnaire.,http://ClinicalTrials.gov/show/NCT01015638,United States,1,1,2,1
NCT01018095,Trichomonas Vaginalis Recurrence Among HIV+ Women,Completed,No Results Available,Trichomonas Infections|HIV Infections,Drug: Metronidazole,Tulane University Health Sciences Center|National Institute of Allergy and Infectious Diseases (NIAID),Female,Adult|Senior,Phase IV,270,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,543793|U19AI061972,11/20/2009,01/05/2005,01/08/2009,11/20/2009,01/11/2009,,01/07/2009,TV culture results|TV culture results,http://ClinicalTrials.gov/show/NCT01018095,United States,1,1,1,0
NCT01020331,Memantine Therapy in Amyotrophic Lateral Sclerosis,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Memantine,"Phoenix Neurological Associates, LTD|Forest Laboratories",Both,Adult|Senior,Phase II,20,Other|Industry,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Memantine in ALS,11/20/2009,01/06/2005,01/10/2009,11/23/2009,01/11/2009,TAME,01/07/2009,"Standardized assessment of ALS disease progression through the ALS Functional Rating Scale (ALSFRS) and compare the levels of Tau at baseline, 6 and 12 months|Change in muscle strength as measured by quantitative dynamometry (baseline vs 18 months)",http://ClinicalTrials.gov/show/NCT01020331,United States,1,1,1,0
NCT01027611,Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections,Completed,No Results Available,Pain,Drug: proparacaine HCL 0.5%|Drug: proparacaine HCL 0.5% + 4% lidocaine solution|Drug: 3.5% viscous lidocaine gel,Illinois Retina Associates,Both,Adult|Senior,Phase III,120,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,jsp-001,12/04/2009,01/10/2009,01/12/2009,05/03/2010,01/12/2009,,01/11/2009,"Injection experience \grade\""|Pain grades for lid speculum",http://ClinicalTrials.gov/show/NCT01027611,United States,1,1,3,0
NCT01031498,Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting,Completed,No Results Available,Acute Myelogenous Leukemia|Chemotherapy-Induced Nausea and Vomiting,Drug: Ondansetron|Drug: Palonosetron,M.D. Anderson Cancer Center|Eisai Inc.,Both,Adult|Senior,Phase II,150,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care,2005-0389,12/10/2009,01/09/2005,01/09/2009,12/11/2009,01/12/2009,,01/09/2009,Number of Emetic Episodes (with no use of rescue medication) During Chemotherapy Administration,http://ClinicalTrials.gov/show/NCT01031498,United States,1,1,2,1
NCT01035073,Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome,Completed,No Results Available,Major Depressive Disorder|Soft Tissue Discomfort Syndrome|Pain,Drug: Duloxetine,University of Pennsylvania|Eli Lilly and Company,Both,Adult|Senior,Phase IV,22,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,F1J-US-X018,12/17/2009,01/04/2006,01/05/2009,12/17/2009,01/12/2009,,01/05/2009,24-hour activity level|Functional Symptom Questionnaire,http://ClinicalTrials.gov/show/NCT01035073,United States,1,1,1,1
NCT01046682,Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults,Completed,No Results Available,HIV|Endothelial Dysfunction|Inflammation|Insulin Resistance,Drug: Salsalate,University Hospitals of Cleveland|Bristol-Myers Squibb,Both,Adult|Senior,Phase II,40,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,02/08/2002,01/11/2010,01/01/2009,01/07/2009,01/11/2010,01/01/2010,Salsalate,01/07/2009,"Flow mediated dilation of the brachial artery measured by ultrasound|Insulin resistance, measured by fasting glucose and insulin",http://ClinicalTrials.gov/show/NCT01046682,United States,1,0,1,NA
NCT01048242,Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375),Completed,No Results Available,Insomnia|Obstructive Sleep Apnea,Drug: rozerem|Drug: Placebo,"University of Pennsylvania|Takeda Global Research & Development Center, Inc.",Both,Adult|Senior,Phase III,29,Other|Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",804640,4/15/2009,01/07/2006,01/03/2009,01/11/2010,01/01/2010,,01/03/2009,Sleep onset latency,http://ClinicalTrials.gov/show/NCT01048242,United States,1,1,2,1
NCT01053247,Study of 0416 Ointment in the Treatment of Atopic Dermatitis,Completed,No Results Available,Atopic Dermatitis,Drug: 0416|Drug: Vehicle of 0416 test product|Drug: tacrolimus ointment 0.1%,Nycomed US Inc.,Both,Adult|Senior,Phase III,793,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",416,12/09/2009,01/01/2008,01/08/2009,1/20/2010,01/01/2010,,01/08/2009,"Incidence of success based on the investigator's global evaluation at the end of treatment|The mean change from baseline in the total individual clinical signs and symptoms per body region, the mean change from baseline in pruritus and mean change from baseline in the percentage total body surface affected (%BSA).",http://ClinicalTrials.gov/show/NCT01053247,United States,1,0,3,NA
NCT01070394,Effectiveness and Duration of Effect of Open Treatment in Adult Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate- LDX (Vyvanse),Completed,No Results Available,Attention Deficit Hyperactivity Disorder,Drug: Lisdexamfetamine Dimesylate-LDX,New York University School of Medicine|Shire Pharmaceutical Development,Both,Adult,Phase IV,NA,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,909,2/16/2010,01/10/2007,01/07/2009,2/17/2010,01/02/2010,,01/07/2009,,http://ClinicalTrials.gov/show/NCT01070394,United States,1,1,1,1
NCT01075256,Dose Response of a Tubule Occlusion Agent,Completed,No Results Available,Dental Pain,Drug: Monographed toothpaste|Device: Occlusion Product 2|Device: Placebo|Other: Occlusion Product 1,GlaxoSmithKline,Both,Adult,Phase IV,195,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,Z3690607,2/23/2010,01/12/2008,01/03/2009,2/23/2010,01/02/2010,,01/03/2009,Change from baseline Evaporative Sensitivity Pain Response on a visual analogue scale (VAS) at week 2|Change from baseline Thermal Sensitivity Pain Response (VAS) at week 2|Oral tolerance adverse events,http://ClinicalTrials.gov/show/NCT01075256,United States,1,0,4,NA
NCT01078259,Antimicrobial Response to Oral Vitamin D3 in Patients With Psoriasis,Completed,No Results Available,Atopic Dermatitis|Psoriasis,Drug: Vitamin D3|Drug: Placebo,"National Institute of Allergy and Infectious Diseases (NIAID)|Food and Drug Administration (FDA)|University of California, San Diego",Both,Adult|Senior,Phase II,46,NIH|U.S. Fed|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DAIT ADVN CATH 03-01,2/26/2010,01/12/2008,01/12/2009,2/26/2010,01/02/2010,,01/12/2009,"Difference between the change in expression of AMP (hCAP18/LL-37, HBD3) from baseline to study day 21 in psoriatic subjects' lesional skin biopsies and the change in expression of AMP from baseline to study day 21 in their non-lesional skin biopsies.|Expression of antimicrobial peptides (hCAP18/LL-37, HBD3) at baseline and study day 21 in psoriatic subjects' saliva and lesional and non-lesional skin biopsies.|Bacterial colony counts (colony forming units) at baseline and study day 21 in AD, non-AD, and psoriatic subjects.|Change in bacterial colony counts (colony forming units) from baseline to study day 21 in AD, non-AD, and psoriatic subjects.|Expression of antimicrobial peptides (hCAP18/LL-37, HBD3) at baseline and study day 21 in psoriatic subjects' lesional and non-lesional skin tape strips.|Change in expression of TH2 cytokines IL-13 and IL-4 from baseline and study day 21 in psoriatic subjects' lesional and non-lesional skin biopsies.|Change in expression of serum total IgE and RAST from baseline and study day 21 in psoriatic subjects' serum.|Change in PASI score from baseline and study day 21 in psoriatic subjects.|Profile of bacteria present in lesional and non-lesional skin swabs at baseline and study day 21 in AD, non-AD, and psoriatic subjects.",http://ClinicalTrials.gov/show/NCT01078259,United States,1,1,2,0
NCT01080677,Caffeine/Propranolol Acute Migraine,Completed,No Results Available,Migraine Disorders,Drug: caffeine propranolol combination,Stanford University,Both,Adult,Phase II,60,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SU-02112010-4963|7011,03/02/2010,01/01/2007,01/12/2009,03/02/2010,01/03/2010,,01/09/2009,"Pain-relief at 2 hrs post first administration of caffeine/propranolol (defined as a decrease in headache pain intensity from severe or moderate headache pain at baseline to mild or no pain at 2 hrs)|Pain free at 2 hrs post first administration of caffeine/propranolol|Relief of associated symptoms such as nausea, and photophobia and phonophobia at 2 hours|Safety and tolerability|Subject treatment satisfaction|Lack of need for rescue medication",http://ClinicalTrials.gov/show/NCT01080677,United States,1,0,1,NA
NCT01087801,A Study of Synthetic Human Secretin (ChiRhoStim?ó) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers,Completed,No Results Available,Pancreatic Disease,Drug: ChiRhoStim|Drug: Placebo,"ChiRhoClin, Inc.",Both,Adult|Senior,Phase III,55,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Diagnostic",2006-05,3/15/2010,01/10/2007,01/12/2009,3/15/2010,01/03/2010,CRC2006-05,01/11/2009,Endoscopic Sample,http://ClinicalTrials.gov/show/NCT01087801,United States,1,1,2,1
NCT01090323,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and the Effects on Liver Iron Concentration of Repeated Doses of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis",Completed,No Results Available,Transfusional Hemosiderosis in Sickle Cell Disease,Drug: ICL670,Novartis Pharmaceuticals,Both,Child|Adult|Senior,Phase II,185,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CICL670A0109E1|EudraCT no. 2004-000597-31,3/15/2010,01/07/2004,NA,3/19/2010,01/03/2010,,01/07/2009,"To evaluate the long-term safety and tolerability profile of ICL670 in sickle cell disease patients with transfusional iron overload requiring chelation therapy|To allow patients treated with either ICL670 or deferoxamine (DFO) satisfactorily completing the week 52 assessment of the core protocol ICL670A0109 to continue iron chelation therapy with ICL670|Change in serum ferritin over time in response to therapy with ICL670|To determine liver iron concentration (LIC) by MRI in a subset of patients (Although it was specified as a secondary objective in the protocol, MRI data were not collected in the extension phase of the trial).|Determinations relative to iron metabolism (serum ferritin, total iron, transferrin and transferrin saturation)",http://ClinicalTrials.gov/show/NCT01090323,"United States, &nbsp; Canada, &nbsp; France, &nbsp; Italy, &nbsp; United Kingdom",1,1,1,0
NCT01093131,Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy,Completed,No Results Available,Contrast Induced Nephropathy,Other: Oral hydration|Drug: Oral sodium bicarbonate|Other: Intravenous Hydration|Drug: Intravenous sodium bicarbonate,The Western Pennsylvania Hospital|Western Pennsylvania Allegheny Health System,Both,Adult|Senior,Phase IV,91,Other,Interventional,Allocation: Randomized|Control: Historical Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Prevention,04-11-097-DT / WPCI 2009-28,2/25/2010,01/02/2005,01/02/2010,6/22/2010,01/06/2010,HYDRATE,01/09/2009,Contrast Induced Nephropathy|Length of Hospital Stay|In-Hospital Mortality|Aspiration|Hypotension,http://ClinicalTrials.gov/show/NCT01093131,United States,1,1,4,0
NCT01097070,A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days,Completed,No Results Available,HIV-1 Infection,Drug: Bevirimat,Myrexis Inc.,Both,Adult|Senior,Phase II,35,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Bevirimat Study 206,3/23/2010,01/11/2008,01/01/2009,3/30/2010,01/03/2010,,01/01/2009,"Measure bevirimat blood plasma concentrations to calculate the pharmacokinetic parameters of AUC, Cmax, Cmin, and half-life when bevirimat is administered as 2 x 100 mg tablets BID, 3 X 100 mg tablets QD, 4 X 100 mg tablets QD for 15 days|Measure bevirimat blood plasma concentrations following the administration of bevirimat 2 X 100 mg, 3 x 100 mg, or 4 x 100 mg tablets after a standardized meal. The pharmacokinetic parameters of AUC, Cmax, Cmin, and half-life will be calculated.",http://ClinicalTrials.gov/show/NCT01097070,United States,1,0,1,NA
NCT01107574,Fibromyalgia Treatment Trial With Gabapentin and Osteopathic Manipulative Medicine,Completed,No Results Available,Fibromyalgia,Drug: Gabapentin|Procedure: Osteopathic Manipulative Medicine|Other: Gabapentin and Osteopathic Manipulative Medicine,"Good Samaritan Regional Medical Center, Oregon",Both,Adult,Phase III,41,Other,Interventional,"Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",04/01/2004,4/19/2010,01/04/2004,01/04/2010,4/20/2010,01/04/2010,FTTGO,01/12/2009,Outcomes of Efficacy and Tolerability by measure of scored visual tools|Number of Participants with Adverse Events as a Measure of Safety and Tolerability,http://ClinicalTrials.gov/show/NCT01107574,United States,1,1,3,1
NCT01127880,Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax,Completed,No Results Available,Hemopneumothorax|Pneumothorax,Drug: Ancef or Clindamycin|Drug: Placebo,"St. Luke's Hospital, Pennsylvania",Both,Child|Adult|Senior,Phase II|Phase III,50,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",SLHN 2005-34,5/19/2010,01/07/2005,01/12/2009,5/20/2010,01/02/2009,,01/12/2009,efficacy of prophylactic antibiotics in reduction of empyema|Incidence of Pneumonia and/or development of resistant microorganisms,http://ClinicalTrials.gov/show/NCT01127880,United States,1,1,2,0
NCT01130454,A Study for Evaluating the SCIO Biofeedback Device's Ability to Increase Body Wellness After One 45-minute Session,Completed,No Results Available,Stress,Device: Universal Electrophysiological Biofeedback Treatment|Device: Universal Electrophysiological Biofeedback Treatment,Maitreya Kft.,Both,Adult,Phase II,151,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",CT-103-01,05/10/2010,01/09/2009,01/04/2010,11/24/2010,01/11/2010,,01/11/2009,VARHOPE Score|Energy Index Factor|Strength Test|Anaerobic Oxygenation Test|Low Back Flexibility|Side to Side Flexibility|Neck Flexibility|Memory Test|pH Test|Quality of Life Questionnaire,http://ClinicalTrials.gov/show/NCT01130454,"United States, &nbsp; France, &nbsp; Germany, &nbsp; Romania",0,NA,2,NA
NCT01131312,Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS),Completed,No Results Available,Cervical Intraepithelial Neoplasia|Cervical Smears|HPV DNA Probes,Device: HPV Test,National Cancer Institute (NCI),Female,Adult|Senior,Phase III,5060,NIH,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,999908076|08-C-N076,5/25/2010,01/02/2008,01/02/2009,12/08/2010,01/11/2010,,01/02/2009,Cumulative detection of pathology QC histologically confirmed CIN3 (cervical precancer) over the 2 years of the trial.|Cumulative detection of clinical center histologically confirmed CIN2 and above (high grade lesion) over the 2 years of the trial.,http://ClinicalTrials.gov/show/NCT01131312,United States,0,NA,1,NA
NCT01139450,Study of 0417 Ointment in the Treatment of Atopic Dermatitis,Completed,No Results Available,Atopic Dermatitis,Drug: 0417|Drug: Vehicle of 0417 test product|Drug: Tacrolimus Ointment 0.03%,Nycomed US Inc.,Both,Child|Adult|Senior,Phase III,900,Industry,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",417,06/07/2010,01/01/2008,01/08/2009,06/07/2010,01/06/2010,,01/08/2009,Incidence of success based on the investigator's global evaluation at the end of treatment|The mean change from baseline in the total individual clinical signs and symptoms per body region|The mean change from baseline in pruritus|The mean change from baseline in the percentage total body surface affected (%BSA),http://ClinicalTrials.gov/show/NCT01139450,United States,1,0,3,NA
NCT01151579,Effect of Nebulized Bronchodilators on Heart Rate,Completed,No Results Available,"COPD|CABG Surgery|Sepsis|Shock|Ventilators, Mechanical",Drug: Levalbuterol|Drug: Albuterol,Genesys Regional Medical Center,Both,Adult|Senior,Phase IV,70,Other,Interventional,Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Single Blind (Subject)|Primary Purpose: Supportive Care,ME 07-0011,6/24/2010,01/12/2008,01/11/2009,7/14/2010,01/05/2010,,01/11/2009,Average difference in Heart rate between pre and post breathing treatments|Arrhythmias|Total number arrhythmias,http://ClinicalTrials.gov/show/NCT01151579,United States,1,1,2,0
NCT01180296,Oral Progesterone for Prevention of Preterm Birth,Completed,No Results Available,Preterm Birth,Drug: oral micronized progesterone|Drug: Identical Placebo tablet,Fetal Medicine Foundation,Female,Adult,Phase III,33,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",MVH-MP-Pilot-RCT,08/10/2010,01/11/2006,01/01/2009,08/11/2010,01/08/2010,,01/01/2009,Rate of recurrent preterm birth|Serum Progesterone Levels,http://ClinicalTrials.gov/show/NCT01180296,United States,1,0,2,NA
NCT01187498,Behavioral Treatment of Overactive Bladder in Men,Completed,No Results Available,Overactive Bladder,"Behavioral: Behavioral training|Drug: Oxybutynin chloride, extended release",Department of Veterans Affairs,Male,Adult|Senior,Phase III,143,U.S. Fed,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,B3083R,8/20/2010,01/01/2005,01/10/2009,8/20/2010,01/08/2010,MOTIVE,01/10/2009,24-hour voiding frequency|Urgency severity|Urge incontinence|Nocturia frequency|Patient satisfaction|Patient perception of improvement|American Urological Association (AUA) Symptom Index|Incontinence Impact Questionnaire|Patient global rating of bothersome symptoms|Patient global rating of activity restriction|Patient report of symptom distress|Patient desire for alternate treatment,http://ClinicalTrials.gov/show/NCT01187498,United States,1,1,2,0
NCT01199926,Effect of Vitamin D Supplementation on Muscle Mass and Function,Completed,No Results Available,Vitamin D|Exercise|Muscles|Inflammation,Dietary Supplement: cholecalciferol|Drug: Placebo,Purdue University|Gatorade Sports Science Institute,Both,Adult,Phase IV,34,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Prevention",GSSI-VitD (0801006402),09/09/2010,01/08/2008,01/02/2010,09/10/2010,01/09/2010,,01/07/2009,"Muscle function, glucose tolerance, and inflammation",http://ClinicalTrials.gov/show/NCT01199926,United States,1,1,2,0
NCT01202955,Pilot Study of Tolcapone in Smokers,Completed,No Results Available,Nicotine Dependence,Drug: Tolcapone|Drug: Placebo,University of Pennsylvania,Both,Adult,Phase II,16,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Treatment",808250,8/19/2010,01/07/2008,01/06/2009,9/15/2010,01/08/2010,,01/05/2009,"To assess the feasibility and safety of administering the Catechol-O-Methyl-Transferase (COMT) inhibitor, tolcapone, to smokers|To obtain preliminary data on the effects of tolcapone on abstinence-induced neurocognitive deficits in abstinent smokers with differing COMT genotypes.",http://ClinicalTrials.gov/show/NCT01202955,United States,1,1,2,1
NCT01210599,A Pilot Trial of IV Pamidronate for Low Back Pain,Completed,No Results Available,Chronic Low Back Pain,Drug: Pamidronate,"Pappagallo, Marco, M.D.",Both,Adult|Senior,Phase I|Phase II,44,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",06-0782,9/27/2010,01/04/2004,01/10/2009,10/12/2010,01/09/2010,,01/10/2009,,http://ClinicalTrials.gov/show/NCT01210599,United States,1,1,1,0
NCT01221974,"Use of Essure?ó Micro-inserts in Women With Hydrosalpinx Prior to In Vitro Fertilization: A Prospective, Multicenter, International Feasibility Study",Completed,No Results Available,Women Who Suffer From Hydrosalpinx That is Causing Infertility and Whom Want a Safer Way of Treamtent,Device: Essure Micro Insert,Reproductive Science Center|Shady Grove Fertility,Female,Adult,Phase I|Phase II,NA,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment,IVF1,10/04/2010,01/07/2008,NA,10/15/2010,01/10/2010,,01/07/2009,,http://ClinicalTrials.gov/show/NCT01221974,United States,0,NA,1,NA
NCT01229449,Ibuprofen/Acetaminophen Versus Nurofen Plus?ó and Panadeine?ó Extra Dental Pain Study,Completed,No Results Available,Post-operative Pain,Drug: Ibuprofen/acetaminophen|Drug: Ibuprofen/acetaminophen (higher dose)|Drug: Nurofen Plus?ó|Drug: Panadeine?ó Extra|Drug: Placebo,Reckitt Benckiser Inc.|Worldwide Clinical Trials Ltd.|Premier Research Group plc|ACM Laboratories|Aptuit Inc.|Clearcut Clinical Consulting,Both,Child|Adult|Senior,Phase III,678,Industry|Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NL0811,10/26/2010,01/01/2009,01/09/2009,10/26/2010,01/10/2010,,01/09/2009,SPRID (the sum of the pain intensity difference (PID) and the pain relief (PR) score)|SPID (Sum of Pain Intensity Difference)|SPRID|TOTPAR (Total Pain Relief),http://ClinicalTrials.gov/show/NCT01229449,United States,1,1,5,0
NCT01234207,Clinical Assessment of a Customized Free-form Progressive Addition Lens Spectacle,Completed,No Results Available,Presbyopia,"Device: Standard, non-free-form, non-customized PAL spectacles|Device: Individually customized free-form surfaced PAL spectacles","University of California, Berkeley|Funding by Carl Zeiss Vision, Inc., Germany",Both,Adult|Senior,Phase III,95,Other,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CZV_PAL1,11/03/2010,01/02/2009,01/10/2009,11/03/2010,01/11/2010,CZV_PAL1,01/10/2009,"Visual Acuity, high and low contrast, distance and near charts|30-degree off-axis visual acuity, high and low contrast, distance chart|Horizontal extent of undistorted vision at reading distance|Questionnaire Battery",http://ClinicalTrials.gov/show/NCT01234207,United States,0,NA,2,NA
NCT01235923,Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants,Completed,No Results Available,Preterm Infants,Drug: Epoetin Alfa,University of New Mexico|National Center for Research Resources (NCRR),Both,Child,Phase II,20,Other|NIH,Interventional,"Allocation: Randomized|Control: Active Control|Endpoint Classification: Bio-equivalence Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",05-380|M01RR000997,11/04/2010,01/04/2006,01/12/2009,11/05/2010,01/10/2010,,01/03/2009,reticulocyte count,http://ClinicalTrials.gov/show/NCT01235923,United States,1,1,1,1
NCT01238822,Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD),Completed,No Results Available,Attention Deficit Hyperactivity Disorder,Drug: Low Dose|Drug: placebo|Drug: Medium Dosage|Drug: methylphenidate,"Children's Hospital Medical Center, Cincinnati",Both,Child,Phase IV,89,Other,Interventional,"Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research",R01MH074770,11/09/2010,01/06/2006,01/06/2009,11/10/2010,01/11/2010,,01/06/2009,ADHD symptoms|Side effects,http://ClinicalTrials.gov/show/NCT01238822,United States,1,1,4,1
NCT01254045,Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome,Completed,No Results Available,Fragile X Syndrome,Drug: Oxytocin,Stanford University,Male,Child|Adult,Phase II,12,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SU-11182010-7215|8618,12/02/2010,01/02/2007,01/01/2010,12/14/2010,01/12/2010,,01/11/2009,Eye contact|Social Responsiveness Scale,http://ClinicalTrials.gov/show/NCT01254045,United States,1,1,1,0
